<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27929004</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>540</Volume><Issue>7632</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Gamma frequency entrainment attenuates amyloid load and modifies microglia.</ArticleTitle><Pagination><StartPage>230</StartPage><EndPage>235</EndPage><MedlinePgn>230-235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature20587</ELocationID><Abstract><AbstractText>Changes in gamma oscillations (20-50&#x2009;Hz) have been observed in several neurological disorders. However, the relationship between gamma oscillations and cellular pathologies is unclear. Here we show reduced, behaviourally driven gamma oscillations before the onset of plaque formation or cognitive decline in a mouse model of Alzheimer's disease. Optogenetically driving fast-spiking parvalbumin-positive (FS-PV)-interneurons at gamma (40&#x2009;Hz), but not other frequencies, reduces levels of amyloid-&#x3b2; (A&#x3b2;)<sub>1-40</sub> and A&#x3b2; <sub>1-42</sub> isoforms. Gene expression profiling revealed induction of genes associated with morphological transformation of microglia, and histological analysis confirmed increased microglia co-localization with A&#x3b2;. Subsequently, we designed a non-invasive 40&#x2009;Hz light-flickering regime that reduced A&#x3b2;<sub>1-40</sub> and A&#x3b2;<sub>1-42</sub> levels in the visual cortex of pre-depositing mice and mitigated plaque load in aged, depositing mice. Our findings uncover a previously unappreciated function of gamma rhythms in recruiting both neuronal and glial responses to attenuate Alzheimer's-disease-associated pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Hunter F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Annabelle C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martorell</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudenko</LastName><ForeName>Andrii</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillingham</LastName><ForeName>Tyler Z</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kritskiy</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdurrob</LastName><ForeName>Fatema</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adaikkan</LastName><ForeName>Chinnakkaruppan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canter</LastName><ForeName>Rebecca G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Emery N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Engineering and Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyden</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP1 NS087724</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY023173</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104948</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047661</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010320">Parvalbumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Dec 7;540(7632):207-208. doi: 10.1038/540207a.</RefSource><PMID Version="1">27929001</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2018 Oct;562(7725):E1. doi: 10.1038/s41586-018-0351-4.</RefSource><PMID Version="1">30046102</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2024 Dec;636(8042):E2. doi: 10.1038/s41586-024-08343-7.</RefSource><PMID Version="1">39592835</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048430" MajorTopicYN="N">Cell Shape</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065818" MajorTopicYN="Y">Gamma Rhythm</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062308" MajorTopicYN="N">Optogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010320" MajorTopicYN="N">Parvalbumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27929004</ArticleId><ArticleId IdType="mid">NIHMS886326</ArticleId><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="doi">10.1038/nature20587</ArticleId><ArticleId IdType="pii">nature20587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17180162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P, Nikoli&#x107; D, Singer W. The gamma cycle. Trends Neurosci. 2007;30:309&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17555828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin JA, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459:663&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655711</ArticleId><ArticleId IdType="pubmed">19396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model. Cell. 2012;149:708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci. 1996;777:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, et al. Generalized synchronization of MEG recordings in Alzheimer's disease: evidence for involvement of the gamma band. J Clin Neurophysiol. 2002;19:562&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">12488788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie AK, et al. Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples. Neuron. 2016;90:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097044</ArticleId><ArticleId IdType="pubmed">27161522</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgin LL, et al. Frequency of gamma oscillations routes flow of information in the hippocampus. Nature. 2009;462:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">19924214</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G. Rhythms of the brain. Oxford University Press; 2006.</Citation></Reference><Reference><Citation>Buzs&#xe1;ki G, et al. Hippocampal network patterns of activity in the mouse. Neuroscience. 2003;116:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535953</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MF, Karlsson MP, Frank LM. Transient slow gamma synchrony underlies hippocampal memory replay. Neuron. 2012;75:700&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428599</ArticleId><ArticleId IdType="pubmed">22920260</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster DJ, Wilson MA. Reverse replay of behavioural sequences in hippocampal place cells during the awake state. Nature. 2006;440:680&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474382</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MF, Jadhav SP, Frank LM. Hippocampal replay in the awake state: a potential substrate for memory consolidation and retrieval. Nat Neurosci. 2011;14:147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215304</ArticleId><ArticleId IdType="pubmed">21270783</ArticleId></ArticleIdList></Reference><Reference><Citation>Helwig M, et al. The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J Biol Chem. 2013;288:1114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542996</ArticleId><ArticleId IdType="pubmed">23172224</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, et al. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature. 2015;518:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CM, K&#xf6;nig P, Engel AK, Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature. 1989;338:334&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2922061</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckhorn R, et al. Coherent oscillations: a mechanism of feature linking in the visual cortex? Biol Cybern. 1988;60:121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">3228555</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericic D, Bujas M. Sex differences in the response to GABA antagonists depend on the route of drug administration. Exp Brain Res. 1997;25:187&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: Evidence for augmentation of a 42-specific &#x3b2;-amyloid secretase. Human Mol Genet. 2004;13:159&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, et al. Structural and molecular interrogation of intact biological systems. Nature. 2013;497:332&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092167</ArticleId><ArticleId IdType="pubmed">23575631</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron. 2007;53:337&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature. 2016 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Extended Data and Methods References</Title><Reference><Citation>Harvey CD, Collman F, Dombeck DA, Tank DW. Intracellular dynamics of hippocampal place cells during virtual navigation. Nature. 2009;461:941&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771429</ArticleId><ArticleId IdType="pubmed">19829374</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronov D, Tank DW. Engagement of Neural Circuits Underlying 2D Spatial Navigation in a Rodent Virtual Reality System. Neuron. 2014;84:442&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4454359</ArticleId><ArticleId IdType="pubmed">25374363</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G. Theta oscillations in the hippocampus. Neuron. 2002;33:325&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravassard P, et al. Multisensory control of hippocampal spatiotemporal selectivity. Science. 2013;340:1342&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049564</ArticleId><ArticleId IdType="pubmed">23641063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17:513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113004</ArticleId><ArticleId IdType="pubmed">24584051</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SCC, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014;15:846&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139419</ArticleId><ArticleId IdType="pubmed">25086775</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, et al. Tet3 regulates synaptic transmission and homeostatic plasticity via DNA oxidation and repair. Nat Neurosci. 2015;18:836&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4446239</ArticleId><ArticleId IdType="pubmed">25915473</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27942728</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>232</EndPage><MedlinePgn>225-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.3783</ELocationID><Abstract><AbstractText Label="IMPORTANCE">To our knowledge, no effective treatments exist for Alzheimer disease, and new molecules are years away. However, several drugs prescribed for other conditions have been associated with reducing its risk.</AbstractText><AbstractText Label="OBJECTIVE">To analyze the association between statin exposure and Alzheimer disease incidence among Medicare beneficiaries.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">We examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2006 to 2013 and compared rates of Alzheimer disease diagnosis for 399 979 statin users 65 years of age or older with high or low exposure to statins and with drug molecules for black, Hispanic, and non-Hispanic white people, and men and women of Asian, Native American, or unkown race/ethnicity who are referred to as "other."</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The main outcome was incident diagnosis of Alzheimer disease based on the International Classification of Diseases, Ninth Revision, Clinical Modification. We used Cox proportional hazard models to analyze the association between statin exposure and Alzheimer disease diagnosis for different sexes, races and ethnicities, and statin molecules.</AbstractText><AbstractText Label="RESULTS">The 399 979 study participants included 7794 (1.95%) black men, 24 484 (6.12%) black women, 11 200 (2.80%) Hispanic men, 21 458 (5.36%) Hispanic women, 115 059 (28.77%) white men, and 195 181 (48.80%) white women. High exposure to statins was associated with a lower risk of Alzheimer disease diagnosis for women (hazard ratio [HR], 0.85; 95% CI, 0.82-0.89; P&lt;.001) and men (HR, 0.88; 95% CI, 0.83-0.93; P&lt;.001). Simvastatin was associated with lower Alzheimer disease risk for white women (HR, 0.86; 95% CI, 0.81-0.92; P&lt;.001), white men (HR, 0.90; 95% CI, 0.82-0.99; P=.02), Hispanic women (HR, 0.82; 95% CI, 0.68-0.99; P=.04), Hispanic men (HR, 0.67; 95% CI, 0.50-0.91; P=.01), and black women (HR, 0.78; 95% CI, 0.66-0.93; P=.005). Atorvastatin was associated with a reduced risk of incident Alzheimer disease diagnosis for white women (HR, 0.84, 95% CI, 0.78-0.89), black women (HR, 0.81, 95% CI, 0.67-0.98), and Hispanic men (HR, 0.61, 95% CI, 0.42-0.89) and women (HR, 0.76, 95% CI, 0.60-0.97). Pravastatin and rosuvastatin were associated with reduced Alzheimer disease risk for white women only (HR, 0.82, 95% CI, 0.70-0.95 and HR, 0.81, 95% CI, 0.67-0.98, respectively). High statin exposure was not associated with a statistically significant lower Alzheimer disease risk among black men.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The reduction in Alzheimer disease risk varied across statin molecules, sex, and race/ethnicity. Clinical trials that include racial and ethnic groups need to confirm these findings. Because statins may affect Alzheimer disease risk, physicians should consider which statin is prescribed to each patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zissimopoulos</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthold</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Roberta Diaz</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles2Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG043073</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055401</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 AG049652</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 AG039036</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Jul 1;74(7):868. doi: 10.1001/jamaneurol.2017.0427.</RefSource><PMID Version="1">28459949</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001213" MajorTopicYN="N">Asian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27942728</ArticleId><ArticleId IdType="mid">NIHMS841673</ArticleId><ArticleId IdType="pmc">PMC5646357</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.3783</ArticleId><ArticleId IdType="pii">2591317</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003&#x2013;2012.  [Accessed March 30, 2016];  https://www.cdc.gov/nchs/data/databriefs/db177.pdf. Published December 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">25536410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111(5):390&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">11583643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer&#x2019;s disease. J Neurol Sci. 2009;283(1&#x2013;2):230&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">19321181</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Assocations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083819</ArticleId><ArticleId IdType="pubmed">24378418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesser GT, Beeri MS, Schmeidler J, Purohit DP, Haroutunian V. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Curr Alzheimer Res. 2011;8(3):303&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267087</ArticleId><ArticleId IdType="pubmed">21244352</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer&#x2019;s disease: will it work? J Mol Neurosci. 2002;19(1&#x2013;2):155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212773</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces &#x3b2;-amyloid pathology in a transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2001;8(5):890&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanceska SS, DeRosa S, Sharma A, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci. 2003;20(3):395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501024</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Passmore P. Can statins prevent or help treat Alzheimer&#x2019;s disease? J Alzheimers Dis. 2010;20(3):925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182019</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero J, Nahata M. Do statins slow down Alzheimer&#x2019;s disease? a review. J Clin Pharm Ther. 2004;29(3):209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">15153082</ArticleId></ArticleIdList></Reference><Reference><Citation>Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">22902202</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159(10):688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">24247674</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II, review of human trials and recommendations. Arch Neurol. 2011;68(11):1385&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248784</ArticleId><ArticleId IdType="pubmed">22084122</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia [published online January 4, 2016] Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003160.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003160.pub3</ArticleId><ArticleId IdType="pmc">PMC9346344</ArticleId><ArticleId IdType="pubmed">26727124</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Hake A, Lane K, et al. Statin use, incident dementia and Alzheimer disease in elderly African Americans. Ethn Dis. 2015;25(3):345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4671419</ArticleId><ArticleId IdType="pubmed">26673814</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2010;58(7):1311&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176730</ArticleId><ArticleId IdType="pubmed">20533968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F-C, Chuang Y-S, Hsieh H-M, et al. Early statin use and the progression of Alzheimer disease: a total population-based case-control study. Medicine (Baltimore) 2015;94(47):e2143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5059011</ArticleId><ArticleId IdType="pubmed">26632742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Wang SW, Li N-C, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson&#x2019;s disease. BMC Med. 2007;5(1):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955446</ArticleId><ArticleId IdType="pubmed">17640385</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell M, Iacus S, King G, Porro G. Cem: coarsened exact matching in Stata.  [Accessed April 25, 2016];Stata J. 2009 9(4):524&#x2013;546.  http://www.stata-journal.com/sjpdf.html?articlenum=st0176.</Citation></Reference><Reference><Citation>Li P, Kim MM, Doshi JA. Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality. BMC Health Serv Res. 2010;10(1):245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936901</ArticleId><ArticleId IdType="pubmed">20727154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonito A, Bann C, Eicheldinger C, Carpenter L. Creation of New Race-Ethnicity Codes and Socioeconomic Status (SES) Indicators for Medicare Beneficiaries. Rockville, MD: Agency for Healthcare Research and Quality, and Center for Medicare and Medicaid Services; 2008.</Citation></Reference><Reference><Citation>Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord. 2006;22(5&#x2013;6):392&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960448</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer&#x2019;s disease: is there a link? Neurology. 2001;57(6):1089&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149154</ArticleId><ArticleId IdType="pubmed">21795660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi PP, Sparks DL, Khachaturian AS, et al. Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? the Cache County Study. Arch Gen Psychiatry. 2005;62(2):217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699299</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I, review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):1239&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211071</ArticleId><ArticleId IdType="pubmed">21987540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006;6(6):360&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">16550210</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnich L, Dr&#xf6;gem&#xf6;ller BI, Pepper MS, Dandara C, Wright GE. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med. 2011;9(3):191&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228231</ArticleId><ArticleId IdType="pubmed">22563365</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KL, Pan J, Ohnuma S, et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res. 2014;74(2):598&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784985</ArticleId><ArticleId IdType="pubmed">24305879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ding K, Zhang Y, Jin L, Kullo IJ, He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics. 2007;17(8):667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622943</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zissimopoulos J, Crimmins E, St Clair P. The value of delaying Alzheimer&#x2019;s disease onset. Forum Health Econ Policy. 2014;18(1):25&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4851168</ArticleId><ArticleId IdType="pubmed">27134606</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health &amp; Human Services USA.  [Accessed April 21, 2016];A profile of older Americans: 2014.   http://www.aoa.acl.gov/aging_statistics/profile/2014/docs/2014-profile.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27974666</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>369</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.</ArticleTitle><Pagination><StartPage>369ra178</StartPage><MedlinePgn>369ra178</MedlinePgn></Pagination><Abstract><AbstractText>Emerging evidence supports a role for innate immunity and microglia in Alzheimer's disease (AD) pathophysiology. However, no marker related to microglia has been included in the temporal evolution models of AD. TREM2 is a transmembrane protein involved in innate immunity and is selectively expressed by microglia and genetically linked to AD and other neurodegenerative disorders. Its ectodomain is released by proteolysis as a soluble variant (sTREM2) and can be detected in the cerebrospinal fluid (CSF). In patients with autosomal dominant AD, we tested how many years before the expected symptom onset did CSF sTREM2 increase in mutation carriers (MCs) compared to noncarriers (NCs). We also determined the temporal sequence of changes in CSF sTREM2 and markers for amyloid deposition and neurodegeneration as well as cognitive performance. We included 218 participants consisting of 127 MC and 91 NC siblings from the Dominantly Inherited Alzheimer Network. We observed that CSF sTREM2 increased in MCs compared to NCs 5 years before the expected symptom onset and this difference remained significant until 5 years after the expected symptom onset. Changes in CSF sTREM2 occurred after alterations were observed in markers for brain amyloidosis and neuronal injury. We propose that microglial activation occurs several years before the expected symptom onset, but after amyloidosis and neuronal injury have already occurred.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araque Caballero</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Center, Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de michael.ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. christian.haass@mail03.med.uni-muenchen.de michael.ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Feb;13(2):65. doi: 10.1038/nrneurol.2016.203.</RefSource><PMID Version="1">28084325</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="N">Siblings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> C.H. is an advisor to F. Hoffmann&#x2013;La Roche. M.E. is senior editor of <i>Alzheimer&#x2019;s &amp; Dementia</i>. J.C.M. serves as a consultant and has received honoraria from Eli Lilly and Takeda Pharmaceuticals. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27974666</ArticleId><ArticleId IdType="mid">NIHMS854058</ArticleId><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aag1767</ArticleId><ArticleId IdType="pii">8/369/369ra178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: The amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: The role and consequences. Neurosci Res. 2014;79:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24144733</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. &#xdc;ber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschrift fur Psychiatr und Psych Medizin. 1907;64:146&#x2013;148.</Citation></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Sch&#xfc;rmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, H&#xfc;ll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O&#x2019;Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert J-C, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Boss&#xf9; P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanch&#xe9; H, Dartigues J-F, Tzourio C, Gut I, Van Broeckhoven C, Alp&#xe9;rovitch A, Lathrop M, Amouyel P European Alzheimer&#x2019;s Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EMC, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens ACJW, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM CHARGE Consortium; GERAD1 Consortium, EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP,CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ERLC, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, R&#xfc;ther E, Sch&#xfc;rmann B, Heun R, K&#xf6;lsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, Gallacher J, H&#xfc;ll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MMB, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues J-F, Tzourio C, Alp&#xe9;rovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Sn&#xe6;dal J, Bj&#xf6;rnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Boss&#xf9; P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O&#x2019;Donovan M, Amouyel P, Williams J EADI1 Consortium, CHARGE Consortium; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Common variants at ABCA7, MS4A6A/MS4A4E,EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert J-C, Gibbs JR, Bras J, Sassi C, Harari O, Bertelsen S, Lupton MK, Powell J, Bellenguez C, Brown K, Medway C, Haddick PCG, van der Brug MP, Bhangale T, Ortmann W, Behrens T, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Haines JL, Turton J, Braae A, Barber I, Fagan AM, Holtzman DM, Morris JC, Williams J, Kauwe JSK, Amouyel P, Morgan K, Singleton A, Hardy J, Goate AM, Cruchaga C EADI Consortium, 3C Study Group, Alzheimer&#x2019;s Disease Genetic Consortium (ADGC), Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI), GERAD Consortium. Missense variant in TREML2 protects against Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35:1510.e19&#x2013;1510.e26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961557</ArticleId><ArticleId IdType="pubmed">24439484</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, Corneveaux JJ, Hardy J, Vonsattel J-P, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Kamboh MI, Kofler JK, Mash DC, Duque L, Gilbert JR, Gwirtsman H, Buxbaum JD, Kramer P, Dickson DW, Farrer LA, Frosch MP, Ghetti B, Haines JL, Hyman BT, Kukull WA, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Reiman EM, Schellenberg GD, Montine TJ Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLOS Genet. 2014;10:e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y. TREM2 variants: New keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, III, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK, Dickson DW, Rademakers R, Ross OA. TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Mol Neurodegener. 2013;8:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C, Gennarelli M, Turla M, Scarpini E, Sorbi S, Padovani A. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35:934. e7&#x2013;934.e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, Maes G, Mattheijssens M, Peeters K, Cras P, Vandenberghe R, De Deyn PP, Van Broeckhoven C, Cruts M, Sleegers K BELNEU Consortium. Investigating the role of rare heterozygous TREM2 variants in Alzheimer&#x2019;s disease and frontotemporal dementia. Neurobiol Aging. 2014;35:726. e11&#x2013;726.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Br&#xe1;s JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bilgic B, Guven G, Br&#xe1;s J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M. A novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging. 2013;34:2890.e1&#x2013;2890.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898264</ArticleId><ArticleId IdType="pubmed">23870839</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebj&#xe6;rg L, Konttinen Y, Peltonen L. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, Levine AP, Hardy J, Pocock JM, Guerreiro R, Weale ME, Ryten M. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging. 2013;34:2699&#x2013;2714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988951</ArticleId><ArticleId IdType="pubmed">23855984</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber M, Kokiko-Cochran O, Puntambekar SS, Lathia JD, Lamb BT. Triggering receptor expressed on myeloid cells 2 deficiency alters acute macrophage distribution and improves recovery after traumatic brain injury. J Neurotrauma. 2016;2016 doi: 10.1089/neu.2016.4401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2016.4401</ArticleId><ArticleId IdType="pubmed">26976047</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest. 2015;125:2161&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hrfelt A, Axelsson M, Malmestr&#xf6;m C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016;22:1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">26754805</ArticleId></ArticleIdList></Reference><Reference><Citation>Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110943</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lle&#xf3; A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, S&#xe1;nchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J Biol Chem. 2013;288:33027&#x2013;33036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J, II, Naismith RT, Panina-Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131:3081&#x2013;3091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del-&#xc1;guila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, &#xd6;hrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol Neurodegener. 2016;11:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Kleinberger G, Araque Caballero M&#xc1;, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD, S&#xe1;nchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Trasch&#xfc;tz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellg&#xe5;rd B, Blennow K, Crispin A, Ewers M, Haass C. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Henjum K, Almdahl IS, &#xc5;rskog V, Minthon L, Hansson O, Fladby T, Nilsson LN. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res Ther. 2016;8:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848774</ArticleId><ArticleId IdType="pubmed">27121148</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Xue QS. Human CNS immune senescence and neurodegeneration. Curr Opin Immunol. 2014;29:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24908174</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer&#x2019;s disease: A review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res Ther. 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA, Trigg W, Di Carli MF, Lemere CA. In vivo detection of age- and disease-related increases in neuroinflammation by 18F-GE180 TSPO microPET imaging in wild-type and Alzheimer&#x2019;s transgenic mice. J Neurosci. 2015;35:15716&#x2013;15730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705465</ArticleId><ArticleId IdType="pubmed">26609163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O&#x2019;Shea D, Wynn D, Morisson-Iveson V, Ewan A, Thaning M, Mantzilas D, Gausemel I, Khan I, Black A, Avory M, Trigg W. [18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging translocator protein 18kDa (TSPO) Bioorg Med Chem Lett. 2012;22:1308&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">22244939</ArticleId></ArticleIdList></Reference><Reference><Citation>Phimister EG, Tanzi RE. TREM2 and risk of Alzheimer&#x2019;s disease&#x2014;Friend or foe? N Engl J Med. 2015;372:2564&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pubmed">26107057</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol. 2013;126:479&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">24052108</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Shen Y. A perspective on inflammation in Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2000;924:132&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193789</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain. 2013;136:2228&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefaniak J, O&#x2019;Brien J. Imaging of neuroinflammation in dementia: A review. J Neurol Neurosurg Psychiatry. 2016;87:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26384512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelin L, Lagarde J, Doroth&#xe9; G, Leroy C, Labit M, Comley RA, De Souza LC, Bottlaender M, Sarazin M. Early and protective microglial activation in Alzheimer&#x2019;s disease: A prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139:1252&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">26984188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Sch&#xf6;ll M, Chiotis K, Thordardottir S, Graff C, Wall A, L&#xe5;ngstr&#xf6;m B, Nordberg A. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer&#x2019;s disease. Brain. 2016;139:922&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766380</ArticleId><ArticleId IdType="pubmed">26813969</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, Wall A, Graff C, L&#xe5;ngstr&#xf6;m B, Nordberg A. Early astrocytosis in autosomal dominant Alzheimer&#x2019;s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep. 2015;5:16404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639762</ArticleId><ArticleId IdType="pubmed">26553227</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia. 2004;45:208&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">14730714</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta Neuropathol. 2009;118:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6:226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early A&#x3b2; accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Mielke ML, G&#xf3;mez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am J Pathol. 2011;179:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig. 2012;2:975&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN) Neuropsychology. 2014;28:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JSK, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Extreme cerebrospinal fluid amyloid &#x3b2; levels identify family with late-onset Alzheimer&#x2019;s disease presenilin 1 mutation. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Monserrate AE, Ryman DC, Ma S, Xiong C, Noble JM, Ringman JM, Morris JC, Danek A, M&#xfc;ller-Sarnowski F, Clifford DB, McDade EM, Brooks WS, Darby DG, Masters CL, Weston PSJ, Farlow MR, Graff-Radford NR, Salloway SP, Fagan AM, Oliver A, Bateman RJ Dominantly Inherited Alzheimer Network. Factors associated with the onset and persistence of post-lumbar puncture headache. JAMA Neurol. 2015;72:325&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364538</ArticleId><ArticleId IdType="pubmed">25622095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JBS, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27956742</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression.</ArticleTitle><Pagination><StartPage>1119</StartPage><EndPage>1125</EndPage><MedlinePgn>1119-1125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2016.226</ELocationID><Abstract><AbstractText>To assess the role of rare copy number variations in Alzheimer's disease (AD), we conducted a case-control study using whole-exome sequencing data from 522 early-onset cases and 584 controls. The most recurrent rearrangement was a 17q21.31 microduplication, overlapping the CRHR1, MAPT, STH and KANSL1 genes that was found in four cases, including one de novo rearrangement, and was absent in controls. The increased MAPT gene dosage led to a 1.6-1.9-fold expression of the MAPT messenger RNA. Clinical signs, neuroimaging and cerebrospinal fluid biomarker profiles were consistent with an AD diagnosis in MAPT duplication carriers. However, amyloid positon emission tomography (PET) imaging, performed in three patients, was negative. Analysis of an additional case with neuropathological examination confirmed that the MAPT duplication causes a complex tauopathy, including prominent neurofibrillary tangle pathology in the medial temporal lobe without amyloid-&#x3b2; deposits. 17q21.31 duplication is the genetic basis of a novel entity marked by prominent tauopathy, leading to early-onset dementia with an AD clinical phenotype. This entity could account for a proportion of probable AD cases with negative amyloid PET imaging recently identified in large clinical series.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Guennec</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenez</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>A-C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupoli, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paschou</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupoli, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonnier</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U1167, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Lille-Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm, U1167, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Lille-Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechner</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bihoreau</LastName><ForeName>M-T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olaso</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>J-F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Centre National de G&#xe9;notypage, Institut de G&#xe9;nomique, CEA, Evry, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondation Jean Dausset, Centre d'&#xe9;tudes du Polymorphisme Humain, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Lille-Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>McGill University and G&#xe9;nome Qu&#xe9;bec Innovation Centre, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourque</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>McGill University and G&#xe9;nome Qu&#xe9;bec Innovation Centre, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McGill University and G&#xe9;nome Qu&#xe9;bec Innovation Centre, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frebourg</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redon</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Inserm, UMR 1087, l'institut du thorax, CHU Nantes, Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, UMR 6291, Universit&#xe9; de Nantes, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letenneur</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3274-937X</Identifier><AffiliationInfo><Affiliation>INSERM, U1219, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>J-F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>INSERM, U1219, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinaud</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalev</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Pathology and Neuropathology, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehrabian</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alexandrovska University Hospital, Medical University-Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traykov</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alexandrovska University Hospital, Medical University-Sofia, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Str&#xf6;bel</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Medical University Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Inserm, CNRS, UPMC Univ Paris 06, UMR S 1127, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, IMMA, d&#xe9;partement des maladies du syst&#xe8;me nerveux, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroppo</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Inserm, CNRS, UPMC Univ Paris 06, UMR S 1127, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, IMMA, d&#xe9;partement des maladies du syst&#xe8;me nerveux, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Inserm, CNRS, UPMC Univ Paris 06, UMR S 1127, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, IMMA, d&#xe9;partement des maladies du syst&#xe8;me nerveux, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonveaux</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre M&#xe9;moire de Ressources et de Recherche de Lorraine, CHRU Nancy Service de G&#xe9;riatrie, H&#xf4;pital de Brabois, Vandoeuvre les Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire INTERPSY, EA 4432, Groupe de recherche sur les Communications (GRC), Universit&#xe9; de Lorraine, Psychologie, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CNR-MAJ Inserm U1171, Univ Lille, CHU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollin-Sillaire</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CNR-MAJ Inserm U1171, Univ Lille, CHU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xe9;nin</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Inserm, UMR1078, CHU Brest, Universit&#xe9; Bretagne Occidentale, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyant-Mar&#xe9;chal</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurophysiology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>G G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Medical University Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>J-C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Inserm, U1167, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Lille-Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Rouvray Psychiatric Hospital, Sotteville-l&#xe8;s-Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovelet-Lecrux</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm, U1079, facult&#xe9; de m&#xe9;decine, Rouen University, IRIB, Normandy University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic Medicine and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-MAJ, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="N">DNA Copy Number Variations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020440" MajorTopicYN="N">Gene Duplication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27956742</ArticleId><ArticleId IdType="doi">10.1038/mp.2016.226</ArticleId><ArticleId IdType="pii">mp2016226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Hum Genet. 2016 May;24(5):710-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26242991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2014 Oct;46(10):1063-71</Citation><ArticleIdList><ArticleId IdType="pubmed">25217958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1999 Oct;5(10):1090</Citation><ArticleIdList><ArticleId IdType="pubmed">10502791</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2010 Sep;5(9):1564-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21085122</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Genet. 2007 Jul-Aug;50(4):256-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17576104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;21(3):897-902</Citation><ArticleIdList><ArticleId IdType="pubmed">20634582</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jan 10;368(2):107-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jan 10;368(2):117-27</Citation><ArticleIdList><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2012 Nov 2;91(5):839-48</Citation><ArticleIdList><ArticleId IdType="pubmed">23103226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2012 Aug 1;21(15):3500-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2012 Jun;20(6):613-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22166940</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2000 Apr;8(4):259-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2016 Oct;48(10 ):1107-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27533299</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Feb;17(2):223-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21403675</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Res. 2010 Sep;20(9):1297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jun;19(6):676-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23752245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2014 Jul;42(12):e97</Citation><ArticleIdList><ArticleId IdType="pubmed">24771342</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2006 Jan;38(1):24-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2010 Mar 1;26(5):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20080505</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2015 May 19;313(19):1939-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Jul;21(7):861-71</Citation><ArticleIdList><ArticleId IdType="pubmed">27021818</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigascience. 2015 Feb 25;4:7</Citation><ArticleIdList><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2016 Jun;42:199-204</Citation><ArticleIdList><ArticleId IdType="pubmed">27143436</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2016 Jun 7;86(23 ):2134-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27037229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2015 Aug;14(8):814-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26141617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2012 Jun;71(6):765-75</Citation><ArticleIdList><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2009 Aug;46(8):524-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19502243</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(12):e50640</Citation><ArticleIdList><ArticleId IdType="pubmed">23227193</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2015 May;129(5):749-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 2012 Jan 15;492(1):319-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22037486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2015 May;47(5):445-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2014 Nov;10(6):713-723.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">24721526</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Dec 18;80(6):1347-58</Citation><ArticleIdList><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Paediatr Neurol. 2016 Jan;20(1):183-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26565673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2016 Feb;12(2):117-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2015 May;129(5):757-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25778618</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Jun;21(6):831-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2013 Jun;12(6):609-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Jan;21(1):108-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2012 Sep;9(7):801-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22486522</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2014 Jul 01;6(4):39</Citation><ArticleIdList><ArticleId IdType="pubmed">25324900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27992627</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations Between &#x3b2;-Amyloid Kinetics and the &#x3b2;-Amyloid Diurnal Pattern in the Central Nervous System.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>215</EndPage><MedlinePgn>207-215</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.4202</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Recent studies found that the concentration of amyloid-&#x3b2; (A&#x3b2;) fluctuates with the sleep-wake cycle. Although the amplitude of this day/night pattern attenuates with age and amyloid deposition, to our knowledge, the association of A&#x3b2; kinetics (ie, production, turnover, and clearance) with this oscillation has not been studied.</AbstractText><AbstractText Label="OBJECTIVE">To determine the association between A&#x3b2; kinetics, age, amyloid levels, and the A&#x3b2; day/night pattern in humans.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">We measured A&#x3b2; concentrations and kinetics in 77 adults aged 60 to 87 years with and without amyloid deposition by a novel precise mass spectrometry method at the Washington University School of Medicine in St Louis, Missouri. We compared findings of 2 orthogonal methods, enzyme-linked immunosorbent assay and mass spectrometry, to validate the day/night patterns and determine more precise estimates of the cosinor parameters. In vivo labeling of central nervous system proteins with stable isotopically labeled leucine was performed, and kinetics of A&#x3b2;40 and A&#x3b2;42 were measured.</AbstractText><AbstractText Label="INTERVENTIONS">Serial cerebrospinal fluid collection via indwelling lumbar catheter over 36 to 48 hours before, during, and after in vivo labeling, with a 9-hour primed constant infusion of 13C6-leucine.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The amplitude, linear increase, and other cosinor measures of each participant's serial cerebrospinal fluid A&#x3b2; concentrations and A&#x3b2; turnover rates.</AbstractText><AbstractText Label="RESULTS">Of the 77 participants studied, 46 (59.7%) were men, and the mean (range) age was 72.6 (60.4-87.7) years. Day/night patterns in A&#x3b2; concentrations were more sharply defined by the precise mass spectrometry method than by enzyme-linked immunosorbent assay (mean difference of SD of residuals: A&#x3b2;40, -7.42 pM; P&#x2009;&lt;&#x2009;.001; A&#x3b2;42, -3.72 pM; P&#x2009;&lt;&#x2009;.001). Amyloid deposition diminished day/night amplitude and linear increase of A&#x3b2;42 but not of A&#x3b2;40. Increased age diminished day/night amplitude of both A&#x3b2;40 and A&#x3b2;42. After controlling for amyloid deposition, amplitude of A&#x3b2;40 was positively associated with production rates (r&#x2009;=&#x2009;0.42; P&#x2009;&lt;&#x2009;.001), while the linear rise was associated with turnover rates (r&#x2009;=&#x2009;0.28; P&#x2009;&lt;&#x2009;.05). The amplitude and linear rise of A&#x3b2;42 were both associated with turnover (r&#x2009;=&#x2009;-0.38; P&#x2009;&lt;&#x2009;.001) and production (r&#x2009;=&#x2009;0.238; P&#x2009;&lt;&#x2009;.05) rates.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Amyloid deposition is associated with premature loss of normal A&#x3b2;42 day/night patterns in older adults, suggesting the previously reported effects of age and amyloid on A&#x3b2;42 amplitude at least partially affect each other. Production and turnover rates suggest that day/night A&#x3b2; patterns are modulated by both production and clearance mechanisms active in sleep-wake cycles and that amyloid deposition may impair normal circadian patterns. These findings may be important for the designs of future secondary prevention trials for Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lucey</LastName><ForeName>Brendan P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbert</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri5Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri5Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="Y">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Elbert reports no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27992627</ArticleId><ArticleId IdType="mid">NIHMS840238</ArticleId><ArticleId IdType="pmc">PMC5305432</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.4202</ArticleId><ArticleId IdType="pii">2593850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: 2015.</Citation></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human CNS amyloid-beta kinetics. Ann Neurol. 2015;78(3):439&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6(4):370&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-&#x3b2; dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, et al. Effects of age and amyloid deposition on A&#x3b2; dynamics in the human central nervous system. Arch Neurol. 2012;69(1):51&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid-&#x3b2; in mice with Alzheimer's disease pathology. Sci Transl Med. 2012;4(150):150ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, et al. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-&#x3b2; concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther. 2015;7:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518529</ArticleId><ArticleId IdType="pubmed">26225140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Bateman RJ. Amyloid-&#x3b2; diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. Neurobiol Aging. 2014;35:S29&#x2013;S34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24910393</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Storandt M, Duchek J, Morris JC, Rubin EH, et al. Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol. 1988;23:477&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">3389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, LaRossa GN, Sheline YI, Dence C, Lee S, Mach R, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Kasten T, Ovod V, Lucey B, Sigurdson W, Bateman RJ. Immuno-based-LC/SRM as a Diagnostic tool for Protein Dynamics of Amyloid &#x3b2; Isoforms Instead of ELISA in the Clinical Laboratory. 62nd Conference on Mass Spectrometry and Allied Topics; June 15-19, 2014; Baltimore, MD. 2014.</Citation></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-&#x3b2; synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Amyloid-beta-42 in humans. Ann Neurol. 2006;59(3):512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-&#x3b2; 42 production, exchange, and loss in presenilin mutation carriers Sci Transl Med. 2013;5(189):189ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbert DL, Patterson BW, Bateman RJ. Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans. Mathematical biosciences. 2015 Mar;261:48&#x2013;61. Epub 2014/12/17. eng.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323682</ArticleId><ArticleId IdType="pubmed">25497960</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016 Epub July 11, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-&#x3b2; levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-&#x3b2; levels. Alzheimer's &amp; Dementia. 2012;8:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22047633</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid A&#x3b2; and tau level fluctuation in an older clinical cohort. Arch Neurol. 2012;69(2):246&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310240</ArticleId><ArticleId IdType="pubmed">22332192</ArticleId></ArticleIdList></Reference><Reference><Citation>Slats D, Claassen JA, Spies PE, Borm G, Besse KT, Aalst Wv, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging. 2012;33(4):831.e1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21880396</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS ONE. 2014;9(3):e89998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960093</ArticleId><ArticleId IdType="pubmed">24646516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeck BV, Timmers M, Ramael S, Bogert J, Shaw LM, Mercken M, et al. Impact of frequent cerebrospinal fluid sampling on A&#x3b2; levels: systematic approach to elucidate influencing factors. Alzheimers Res Ther. 2016;8(1):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875639</ArticleId><ArticleId IdType="pubmed">27206648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27942718</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples.</ArticleTitle><Pagination><StartPage>155</StartPage><EndPage>162</EndPage><MedlinePgn>155-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.4614</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Early and accurate in vivo diagnosis of Creutzfeldt-Jakob disease (CJD) is necessary for quickly distinguishing treatable from untreatable rapidly progressive dementias and for future therapeutic trials. This early diagnosis is becoming possible using the real-time quaking-induced conversion (RT-QuIC) seeding assay, which detects minute amounts of the disease-specific pathologic prion protein in cerebrospinal fluid (CSF) or olfactory mucosa (OM) samples.</AbstractText><AbstractText Label="OBJECTIVE">To develop an algorithm for accurate and early diagnosis of CJD by using the RT-QuIC assay on CSF samples, OM samples, or both.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this case-control study, samples of CSF and OM were collected from 86 patients with a clinical diagnosis of probable (n&#x2009;=&#x2009;51), possible (n&#x2009;=&#x2009;24), or suspected (n&#x2009;=&#x2009;11) CJD and 104 negative control samples (54 CSF and 50 OM). The CSF and OM samples were analyzed using conventional RT-QuIC. The CSF samples underwent further testing using improved RT-QuIC conditions. In addition, the diagnostic performance of a novel, easy-to-use, gentle flocked swab for sampling of OM was evaluated. Data were collected from January 1 to June 30, 2015.</AbstractText><AbstractText Label="MAIN OUTCOME AND MEASURES">Correlations between RT-QuIC results and the final diagnosis of recruited patients.</AbstractText><AbstractText Label="RESULTS">Among the 86 patients (37 men [43%] and 49 women [57%]; mean [SD] age, 65.7 [11.5] years) included for analysis, all 61 patients with sporadic CJD had positive RT-QuIC findings using OM or CSF samples or both for an overall RT-QuIC diagnostic sensitivity of 100% (95% CI, 93%-100%). All patients with a final diagnosis of non-prion disease (71 CSF and 67 OM samples) had negative RT-QuIC findings for 100% specificity (95% CI, 94%-100%). Of 8 symptomatic patients with various mutations causing CJD or Gerstmann-Str&#xe4;ussler-Scheinker syndrome, 6 had positive and 2 had negative RT-QuIC findings for a sensitivity of 75% (95% CI, 36%-96%).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">A proposed diagnostic algorithm for sporadic CJD combines CSF and OM RT-QuIC testing to provide virtually 100% diagnostic sensitivity and specificity in the clinical phase of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bongianni</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orr&#xf9;</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groveman</LastName><ForeName>Bradley R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchetto</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, Dentistry, Gynecology, and Pediatrics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorini</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonoli</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Struttura Complessa di Otorinolaringoiatria, Ospedale Santa Maria della Misericordia, Rovigo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triva</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Copan Italia SpA, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capaldi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biocrystallography Laboratory, Department of Biotechnology, University of Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Testi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cagnin</LastName><ForeName>Annachiara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Padova, Padova, Italy8Istituto di Ricovero e Cura a Carattere Scientifico San Camillo Hospital, Venice, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladogana</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poleggi</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colaizzo</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiple</LastName><ForeName>Dorina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaianella</LastName><ForeName>Luana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castriciano</LastName><ForeName>Santina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Copan Italia SpA, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchioni</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, Dentistry, Gynecology, and Pediatrics, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughson</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imperiale</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Unit, Ospedale Maria Vittoria, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattaruzza</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurology Unit, Ospedale Cattinara, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabrizi</LastName><ForeName>Gian Maria</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pocchiari</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monaco</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caughey</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanusso</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Policlinico G. B. Rossi, Verona, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Feb 1;74(2):144-145. doi: 10.1001/jamaneurol.2016.4877.</RefSource><PMID Version="1">27942712</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="Y">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009831" MajorTopicYN="N">Olfactory Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27942718</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.4614</ArticleId><ArticleId IdType="pii">2591319</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28003548</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>370</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease.</ArticleTitle><Pagination><StartPage>370ra183</StartPage><MedlinePgn>370ra183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf6188</ELocationID><Abstract><AbstractText>Human prion diseases are infectious and invariably fatal neurodegenerative diseases. They include sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and variant CJD (vCJD), which is caused by interspecies transmission of prions from cattle infected by bovine spongiform encephalopathy. Development of a biochemical assay for the sensitive, specific, early, and noninvasive detection of prions (PrP<sup>Sc</sup>) in the blood of patients affected by prion disease is a top medical priority to increase the safety of the blood supply. vCJD has already been transmitted from human to human by blood transfusion, and the number of asymptomatic carriers of vCJD in the U.K. alone is estimated to be 1 in 2000 people. We used the protein misfolding cyclic amplification (PMCA) technique to analyze blood samples from 14 cases of vCJD and 153 controls, including patients affected by sCJD and other neurodegenerative or neurological disorders as well as healthy subjects. Our results showed that PrP<sup>Sc</sup> could be detected with 100% sensitivity and specificity in blood samples from vCJD patients. Detection was possible in any of the blood fractions analyzed and could be done with as little as a few microliters of sample volume. The PrP<sup>Sc</sup> concentration in blood was estimated to be ~0.5 pg/ml. Our findings suggest that PMCA may be useful for premortem noninvasive diagnosis of vCJD and to identify prion contamination of the blood supply. Further studies are needed to fully validate the technology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Concha-Marambio</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Houston Medical School, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de los Andes, Facultad de Medicina, Avenida San Carlos de Apoquindo 2200, Las Condes, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pritzkow</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Houston Medical School, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moda</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Houston Medical School, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ironside</LastName><ForeName>James W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Houston Medical School, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Houston Medical School, Houston, TX 77030, USA. claudio.soto@uth.tmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de los Andes, Facultad de Medicina, Avenida San Carlos de Apoquindo 2200, Las Condes, Santiago, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R42 NS079060</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900580</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS049173</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SB1 NS079060</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0600953</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AI106705</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000371</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006403" MajorTopicYN="N">Hematologic Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> C.S. is the inventor on several patents related to the PMCA technology: US7351526/WO02/04954, &#x201c;Early diagnosis of conformational disorders&#x201d;; US20110311997, &#x201c;Methods for estimating prion concentration in tissues and biological fluids by quantitative PMCA&#x201d;; and US7598046/WO2004/111652, &#x201c;Use of prion conversion modulating agents.&#x201d; C.S. is the founder, chief scientific officer, and vice-president of Amprion Inc., a biotech company focusing on the commercial utilization of PMCA for prion diagnosis. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28003548</ArticleId><ArticleId IdType="mid">NIHMS885921</ArticleId><ArticleId IdType="pmc">PMC5538786</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf6188</ArticleId><ArticleId IdType="pii">8/370/370ra183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Calella AM. Prions: Protein aggregation and infectious diseases. Physiol Rev. 2009;89:1105&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19789378</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci. 2001;24:519&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 2006;5:393&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632309</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A. Prion diseases, blood and the immune system: Concerns and reality. Haematologica. 2000;85:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10627667</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JDF, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet. 2001;358:171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476832</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P. Creutzfeldt-Jakob disease: Blood infectivity and screening tests. Semin Hematol. 2001;38(4 Suppl 9):2&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11685719</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. Eight prion strains have PrPSc molecules with different conformations. Nat Med. 1998;4:1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczius T, Groschup MH. Differences in proteinase K resistance and neuronal deposition of abnormal prion proteins characterize bovine spongiform encephalopathy (BSE) and scrapie strains. Mol Med. 1999;5:406&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230428</ArticleId><ArticleId IdType="pubmed">10415165</ArticleId></ArticleIdList></Reference><Reference><Citation>Thackray AM, Hopkins L, Bujdoso R. Proteinase K-sensitive disease-associated ovine prion protein revealed by conformation-dependent immunoassay. Biochem J. 2007;401:475&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820801</ArticleId><ArticleId IdType="pubmed">17018021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, Collinge J, Wadsworth JDF. Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J. 2008;416:297&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584334</ArticleId><ArticleId IdType="pubmed">18684106</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Serban A, Vey M, Baron H, Giles K, Miller BL, DeArmond SJ, Prusiner SB. Diagnosis of human prion disease. Proc Natl Acad Sci USA. 2005;102:3501&#x2013;3506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552933</ArticleId><ArticleId IdType="pubmed">15741275</ArticleId></ArticleIdList></Reference><Reference><Citation>Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411:810&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459061</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Saborio GP, Anderes L. Cyclic amplification of protein misfolding: Application to prion-related disorders and beyond. Trends Neurosci. 2002;25:390&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127750</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Anderes L, Suardi S, Cardone F, Castilla J, Frossard MJ, Peano S, Saa P, Limido L, Carbonatto M, Ironside J, Torres JM, Pocchiari M, Tagliavini F. Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. FEBS Lett. 2005;579:638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670821</ArticleId></ArticleIdList></Reference><Reference><Citation>Moda F, Gambetti P, Notari S, Concha-Marambio L, Catania M, Park KW, Maderna E, Suardi S, Ha&#xef;k S, Brandel JP, Ironside J, Knight R, Tagliavini F, Soto C. Prions in the urine of patients with variant Creutzfeldt&#x2013;Jakob disease. N Engl J Med. 2014;371:530&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162740</ArticleId><ArticleId IdType="pubmed">25099577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#xe1; P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem. 2006;281:35245&#x2013;35252.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982620</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Morales R, Barria MA, Soto C. Estimating prion concentration in fluids and tissues by quantitative PMCA. Nat Methods. 2010;7:519&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049222</ArticleId><ArticleId IdType="pubmed">20512142</ArticleId></ArticleIdList></Reference><Reference><Citation>Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. Nature. 2005;437:257&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513539</ArticleId><ArticleId IdType="pubmed">16148934</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla J, Sa&#xe1; P, Soto C. Detection of prions in blood. Nat Med. 2005;11:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#xe1; P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science. 2006;313:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16825570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, Litaise C, Simmons H, Jas-Duval C, Lantier I, B&#xe9;ringue V, Groschup M, Fichet G, Costes P, Streichenberger N, Lantier F, Deslys JP, Vilette D, Andr&#xe9;oletti O. Preclinical detection of variant CJD and BSE prions in blood. PLOS Pathog. 2014;10:e1004202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055790</ArticleId><ArticleId IdType="pubmed">24945656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med. 1999;5:240&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230327</ArticleId><ArticleId IdType="pubmed">10448646</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CJ, Phillips KE, Schramm PT, McKenzie D, Aiken JM, Pedersen JA. Prions adhere to soil minerals and remain infectious. PLOS Pathog. 2006;2:e32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435987</ArticleId><ArticleId IdType="pubmed">16617377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritzkow S, Morales R, Moda F, Khan U, Telling GC, Hoover E, Soto C. Grass plants bind, retain, uptake, and transport infectious prions. Cell Rep. 2015;11:1168&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449294</ArticleId><ArticleId IdType="pubmed">25981035</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari A, Fischer M, Gambetti P, Parker A, Ram A, Soto C, Concha-Marambio L, Cohen Y, Belay ED, Maddox RA, Mead S, Goodman C, Kass JS, Schonberger LB, Hussein HM. Recent US case of variant Creutzfeldt-Jakob Disease&#x2014;Global implications. Emerg Infect Dis. 2015;21:750&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412247</ArticleId><ArticleId IdType="pubmed">25897712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueston WD. BSE and variant CJD: Emerging science, public pressure and the vagaries of policy-making. Prev Vet Med. 2013;109:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">23287715</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D, Adkin A. Bovine spongiform encephalopathy: Is it time to relax BSE-related measures in the context of international trade? Rev Sci Tech. 2011;30:107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">21809757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrot C, Arnold M, de Koeijer A, Heim D, Calavas D. Review on the epidemiology and dynamics of BSE epidemics. Vet Res. 2008;39:15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson-Smith MA, Richt JA. Rare BSE mutation raises concerns over risks to public health. Nature. 2009;457:1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">19242452</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;ringue V, Herzog L, Reine F, Le Dur A, Casalone C, Vilotte JL, Laude H. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis. 2008;14:1898&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634647</ArticleId><ArticleId IdType="pubmed">19046515</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkema-Buschmann A, Fast C, Kaatz M, Eiden M, Ziegler U, McIntyre L, Keller M, Hills B, Groschup MH. Pathogenesis of classical and atypical BSE in cattle. Prev Vet Med. 2011;102:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">21592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Capobianco R, Casalone C, Suardi S, Mangieri M, Miccolo C, Limido L, Catania M, Rossi G, Di Fede G, Giaccone G, Bruzzone MG, Minati L, Corona C, Acutis P, Gelmetti D, Lombardi G, Groschup MH, Buschmann A, Zanusso G, Monaco S, Caramelli M, Tagliavini F. Conversion of the BASE prion strain into the BSE strain: The origin of BSE? PLOS Pathog. 2007;3:e31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1817656</ArticleId><ArticleId IdType="pubmed">17352534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AF, Collinge J. Subclinical prion infection in humans and animals. Br Med Bull. 2003;66:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14522857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasm&#xe9;zas CI, Fournier JG, Nouvel V, Boe H, Marc&#xe9; D, Lamoury F, Kopp N, Hauw JJ, Ironside J, Bruce M, Dormont D, Deslys JP. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt&#x2013;Jakob disease: Implications for human health. Proc Natl Acad Sci USA. 2001;98:4142&#x2013;4147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31193</ArticleId><ArticleId IdType="pubmed">11259641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M, Webb P, Bellerby P, Andrews N, Hilton DA, Ironside JW, Beck J, Poulter M, Mead S, Brandner S. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: Large scale survey. BMJ. 2013;347:f5675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805509</ArticleId><ArticleId IdType="pubmed">24129059</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, Preece MA, Brandel J-P, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, Huillard d&#x2019;Aignaux J, Cerven&#xe1;kov&#xe1; L, Fradkin J, Schonberger LB, Collins SJ. Iatrogenic Creutzfeldt-Jakob disease at the millenium. Neurology. 2000;55:1075&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071481</ArticleId></ArticleIdList></Reference><Reference><Citation>Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962520</ArticleId></ArticleIdList></Reference><Reference><Citation>Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302196</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JDF, Hewitt P, Collinge J. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet. 2006;368:2061&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161728</ArticleId></ArticleIdList></Reference><Reference><Citation>Orru CD, Wilham JM, Vascellari S, Hughson AG, Caughey B. New generation QuIC assays for prion seeding activity. Prion. 2012;6:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7082091</ArticleId><ArticleId IdType="pubmed">22421206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#xe1; P, Cervenakova L. Protein misfolding cyclic amplification (PMCA): Current status and future directions. Virus Res. 2015;207:47&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">25445341</ArticleId></ArticleIdList></Reference><Reference><Citation>Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, Nishida N. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17:175&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">21278748</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr&#xfa; CD, Groveman BR, Hughson AG, Zanusso G, Coulthart MB, Caughey B. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. MBio. 2015;6:e02451&#x2013;e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313917</ArticleId><ArticleId IdType="pubmed">25604790</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr&#xfa; CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman BR, Fiorini M, Pocchiari M, Monaco S, Caughey B, Zanusso G. A test for Creutzfeldt&#x2013;Jakob disease using nasal brushings. N Engl J Med. 2014;371:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4186748</ArticleId><ArticleId IdType="pubmed">25099576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bougard D, Brandel JP, B&#xe9;londrade M, B&#xe9;ringue V, Segarra C, Fleury H, Laplanche JL, Mayran C, Nicot S, Green A, Welaratne A, Narbey D, Fournier-Wirth C, Knight R, Will R, Tiberghien P, Ha&#xef;k S, Coste J. Detection of prions in the plasma of pre-symptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016;8:370ra182.</Citation><ArticleIdList><ArticleId IdType="pubmed">28003547</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV, Soto C. Protein misfolding cyclic amplification of infectious prions. Nat Protoc. 2012;7:1397&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049227</ArticleId><ArticleId IdType="pubmed">22743831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28052060</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>541</Volume><Issue>7636</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structural variation in amyloid-&#x3b2; fibrils from Alzheimer's disease clinical subtypes.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>221</EndPage><MedlinePgn>217-221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature20814</ELocationID><Abstract><AbstractText>Aggregation of amyloid-&#x3b2; peptides into fibrils or other self-assembled states is central to the pathogenesis of Alzheimer's disease. Fibrils formed in vitro by 40- and 42-residue amyloid-&#x3b2; peptides (A&#x3b2;40 and A&#x3b2;42) are polymorphic, with variations in molecular structure that depend on fibril growth conditions. Recent experiments suggest that variations in amyloid-&#x3b2; fibril structure in vivo may correlate with variations in Alzheimer's disease phenotype, in analogy to distinct prion strains that are associated with different clinical and pathological phenotypes. Here we investigate correlations between structural variation and Alzheimer's disease phenotype using solid-state nuclear magnetic resonance (ssNMR) measurements on A&#x3b2;40 and A&#x3b2;42 fibrils prepared by seeded growth from extracts of Alzheimer's disease brain cortex. We compared two atypical Alzheimer's disease clinical subtypes-the rapidly progressive form (r-AD) and the posterior cortical atrophy variant (PCA-AD)-with a typical prolonged-duration form (t-AD). On the basis of ssNMR data from 37 cortical tissue samples from 18 individuals, we find that a single A&#x3b2;40 fibril structure is most abundant in samples from patients with t-AD and PCA-AD, whereas A&#x3b2;40 fibrils from r-AD samples exhibit a significantly greater proportion of additional structures. Data for A&#x3b2;42 fibrils indicate structural heterogeneity in most samples from all patient categories, with at least two prevalent structures. These results demonstrate the existence of a specific predominant A&#x3b2;40 fibril structure in t-AD and PCA-AD, suggest that r-AD may relate to additional fibril structures and indicate that there is a qualitative difference between A&#x3b2;40 and A&#x3b2;42 aggregates in the brain tissue of patients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Wai-Ming</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jun-Xia</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA DK029061</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28052060</ArticleId><ArticleId IdType="mid">NIHMS832197</ArticleId><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="doi">10.1038/nature20814</ArticleId><ArticleId IdType="pii">nature20814</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc Natl Acad Sci U S A. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. Seeded growth of &#x3b2;-amyloid fibrils from Alzheimer&#x2019;s brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A. 2009;106:7443&#x2013;7448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="pubmed">19376973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini I, Gonnelli L, Luchinat C, Mao JF, Nesi A. A new structural model of A&#x3b2;(40) fibrils. J Am Chem Soc. 2011;133:16013&#x2013;16022.</Citation><ArticleIdList><ArticleId IdType="pubmed">21882806</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz AK, et al. Atomic-resolution three-dimensional structure of amyloid &#x3b2; fibrils bearing the Osaka mutation. Angew Chem-Int Edit. 2014;53:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502972</ArticleId><ArticleId IdType="pubmed">25395337</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao YL, et al. A&#x3b2;(1&#x2013;42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer&#x2019;s disease. Nat Struct Mol Biol. 2015;22:499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="pubmed">25938662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgourakis NG, Yau WM, Qiang W. Modeling an in-register, parallel &#x201c;Iowa&#x201d; A&#x3b2; fibril structure using solid state NMR data from labeled samples with Rosetta. Structure. 2015;23:216&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">25543257</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury C, Frey P, Olivieri V, Aebi U, Muller SA. Multiple assembly pathways underlie amyloid-&#x3b2; fibril polymorphisms. J Mol Biol. 2005;352:282&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095615</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Fandrich M. A&#x3b2;(1&#x2013;40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol. 2009;386:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760659</ArticleId><ArticleId IdType="pubmed">19038266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Interprotofilament interactions between Alzheimer&#x2019;s A&#x3b2;(1&#x2013;42) peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci U S A. 2009;106:4653&#x2013;4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660777</ArticleId><ArticleId IdType="pubmed">19264960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Williams AD, Chemuru S, Wetzel R. A&#x3b2;(1&#x2013;40) forms five distinct amyloid structures whose &#x3b2;-sheet contents and fibril stabilities are correlated. J Mol Biol. 2010;401:503&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919579</ArticleId><ArticleId IdType="pubmed">20600131</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F, et al. Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. J Neurosci. 2011;31:14488&#x2013;14495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohr J, et al. Distinct synthetic A&#x3b2; prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci U S A. 2014;111:10329&#x2013;10334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104853</ArticleId><ArticleId IdType="pubmed">24982137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ML, et al. Rapidly progressive Alzheimer&#x2019;s disease features distinct structures of amyloid-&#x3b2;. Brain. 2015;138:1009&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014074</ArticleId><ArticleId IdType="pubmed">25688081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol. 1994;68:7859&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237248</ArticleId><ArticleId IdType="pubmed">7966576</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of &#x2018;new variant&#x2019; CJD. Nature. 1996;383:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878476</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med. 1998;4:1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gath J, et al. Unlike twins: An NMR comparison of two &#x3b1;-synuclein polymorphs featuring different toxicity. PLoS One. 2014;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944079</ArticleId><ArticleId IdType="pubmed">24599158</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wel PCA, Lewandowski JR, Griffin RG. Solid state NMR study of amyloid nanocrystals and fibrils formed by the peptide GNNQQNY from yeast prion protein Sup35p. J Am Chem Soc. 2007;129:5117&#x2013;5130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17397156</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang-Wai DF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477533</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, et al. Rapidly progressive Alzheimer&#x2019;s disease: A multicenter update. J Alzheimers Dis. 2012;30:751&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">22460329</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry ER, Hofrichter J. Singular value decomposition: Application to analysis of experimental data. Method Enzymol. 1992;210:129&#x2013;192.</Citation></Reference><Reference><Citation>Qiang W, Yau WM, Luo YQ, Mattson MP, Tycko R. Antiparallel &#x3b2;-sheet architecture in Iowa-mutant &#x3b2;-amyloid fibrils. Proc Natl Acad Sci U S A. 2012;109:4443&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="pubmed">22403062</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, et al. Atomic resolution structure of monomorphic Ab42 amyloid fibrils. J Am Chem Soc. 2016;138:9663&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>Walti MA, et al. Atomic-resolution structure of a disease-relevant A&#x3b2;(1&#x2013;42) amyloid fibril. Proc Natl Acad Sci U S A. 2016 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, et al. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28049840</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.</ArticleTitle><Pagination><StartPage>574</StartPage><EndPage>579</EndPage><MedlinePgn>574-579</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1607215114</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) and other neurodegenerative disorders are associated with the cytoplasmic aggregation of microtubule-associated protein tau. Recent evidence supports transcellular transfer of tau misfolding (seeding) as the mechanism of spread within an affected brain, a process reminiscent of viral infection. However, whereas microbial pathogens can be recognized as nonself by immune receptors, misfolded protein assemblies evade detection, as they are host-derived. Here, we show that when misfolded tau assemblies enter the cell, they can be detected and neutralized via a danger response mediated by tau-associated antibodies and the cytosolic Fc receptor tripartite motif protein 21 (TRIM21). We developed fluorescent, morphology-based seeding assays that allow the formation of pathological tau aggregates to be measured in situ within 24 h in the presence of picomolar concentrations of tau seeds. We found that anti-tau antibodies accompany tau seeds into the cell, where they recruit TRIM21 shortly after entry. After binding, TRIM21 neutralizes tau seeds through the activity of the proteasome and the AAA ATPase p97/VCP in a similar manner to infectious viruses. These results establish that intracellular antiviral immunity can be redirected against host-origin endopathogens involved in neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-4408-0407</Identifier><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom; wmcewan@mrc-lmb.cam.ac.uk mg@mrc-lmb.cam.ac.uk lcj@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaysburd</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clift</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oblak</LastName><ForeName>Adrian L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom; wmcewan@mrc-lmb.cam.ac.uk mg@mrc-lmb.cam.ac.uk lcj@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Leo C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom; wmcewan@mrc-lmb.cam.ac.uk mg@mrc-lmb.cam.ac.uk lcj@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200594/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105181010</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U105181010</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C035401">SS-A antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2017 Jan 24;10(463):eaam8102. doi: 10.1126/scisignal.aam8102.</RefSource><PMID Version="1">28119462</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011961" MajorTopicYN="N">Receptors, Fc</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012261" MajorTopicYN="N">Ribonucleoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">immunoreceptors</Keyword><Keyword MajorTopicYN="N">intracellular immunity</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28049840</ArticleId><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="doi">10.1073/pnas.1607215114</ArticleId><ArticleId IdType="pii">1607215114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mallery DL, et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) Proc Natl Acad Sci USA. 2010;107(46):19985&#x2013;19990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993423</ArticleId><ArticleId IdType="pubmed">21045130</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, et al. Regulation of virus neutralization and the persistent fraction by TRIM21. J Virol. 2012;86(16):8482&#x2013;8491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421726</ArticleId><ArticleId IdType="pubmed">22647693</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14(4):327&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672961</ArticleId><ArticleId IdType="pubmed">23455675</ArticleId></ArticleIdList></Reference><Reference><Citation>James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA. 2007;104(15):6200&#x2013;6205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851072</ArticleId><ArticleId IdType="pubmed">17400754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC. AAA ATPase p97/VCP is essential for TRIM21-mediated virus neutralization. Proc Natl Acad Sci USA. 2012;109(48):19733&#x2013;19738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511720</ArticleId><ArticleId IdType="pubmed">23091005</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Neurodegeneration. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: The prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science. 2015;349(6248):1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM-Y. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286(17):15317&#x2013;15331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkinson RE, McEwan WA, Tam JCH, Vaysburd M, James LC. TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus. PLoS Pathog. 2015;11(10):e1005253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624778</ArticleId><ArticleId IdType="pubmed">26506431</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, et al. Swine TRIM21 restricts FMDV infection via an intracellular neutralization mechanism. Antiviral Res. 2016;127:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26777733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo A, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718588</ArticleId><ArticleId IdType="pubmed">26176913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996;384(1):25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797796</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J Neurochem. 2006;99(1):154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987243</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV, et al. The tau protein in human cerebrospinal fluid in Alzheimer&#x2019;s disease consists of proteolytically derived fragments. J Neurochem. 1997;68(1):430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978756</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3(4):519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray N. Neurodegenerative diseases: A tale of two taus in traumatic brain injury. Nat Rev Drug Discov. 2015;14(9):599.</Citation><ArticleIdList><ArticleId IdType="pubmed">26323539</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem. 2015;290(2):1049&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, James LC. TRIM21-dependent intracellular antibody neutralization of virus infection. Prog Mol Biol Transl Sci. 2015;129:167&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">25595804</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Gu J, Sait HBR, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fc&#x3b3; receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288(49):35452&#x2013;35465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853292</ArticleId><ArticleId IdType="pubmed">24163366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288(46):33081&#x2013;33095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829157</ArticleId><ArticleId IdType="pubmed">24089520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Reports. 2016;16(6):1690&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">27475227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou T-F, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci USA. 2011;108(12):4834&#x2013;4839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064330</ArticleId><ArticleId IdType="pubmed">21383145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou T-F, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013;8(2):297&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662613</ArticleId><ArticleId IdType="pubmed">23316025</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol. 2011;8(2):108&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">22187000</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. 2016;22(1):46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ, et al. Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human P301S tau. J Neurosci. 2016;36(3):762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelme D, Sauer RT. Origin and functional evolution of the Cdc48/p97/VCP AAA+ protein unfolding and remodeling machine. J Mol Biol. 2016;428(9 Pt B):1861&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860136</ArticleId><ArticleId IdType="pubmed">26608813</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, et al. Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457&#x2013;34467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One. 2015;10(5):e0125614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416899</ArticleId><ArticleId IdType="pubmed">25933020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer&#x2019;s disease. Trends Mol Med. 2015;21(6):394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">25846560</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of tau antibodies: Promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 2015;290(35):21652&#x2013;21662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571888</ArticleId><ArticleId IdType="pubmed">26126828</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9(13):4225&#x2013;4230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383(6600):550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8(1):159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimi R, Ishigatsubo Y, Ozato K. Autoantigen TRIM21/Ro52 as a possible target for treatment of systemic lupus erythematosus. Int J Rheumatol. 2012;2012:718237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373075</ArticleId><ArticleId IdType="pubmed">22701487</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin GMJ, 3rd, et al. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc. 2012;7(9):1741&#x2013;1754.</Citation><ArticleIdList><ArticleId IdType="pubmed">22936216</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol. 2004;78(22):12320&#x2013;12332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525062</ArticleId><ArticleId IdType="pubmed">15507619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84(3):265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28053038</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Large Soluble Oligomers of Amyloid &#x3b2;-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>163</EndPage><MedlinePgn>152-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1698-16.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Soluble oligomers of amyloid &#x3b2;-protein (oA&#x3b2;) isolated from the brains of Alzheimer's disease (AD) patients have been shown experimentally (in the absence of amyloid plaques) to impair hippocampal synaptic plasticity, decrease synapses, induce tau hyperphosphorylation and neuritic dystrophy, activate microglial inflammation, and impair memory in normal adult rodents. Nevertheless, there has been controversy about what types of oligomers actually confer these AD-like phenotypes. Here, we show that the vast majority of soluble A&#x3b2; species obtained from brains of humans who died with confirmed AD elute at high molecular weight (HMW) on nondenaturing size-exclusion chromatography. These species have little or no cytotoxic activity in several bioassays. However, incubation of HMW oA&#x3b2; in mildly alkaline buffer led to their quantitative dissociation into low molecular weight oligomers (&#x223c;8-70 kDa), and these were now far more bioactive: they impaired hippocampal LTP, decreased neuronal levels of &#x3b2;2-adrenergic receptors, and activated microglia in wt mice in vivo Thus, most soluble A&#x3b2; assemblies in AD cortex are large and inactive but under certain circumstances can dissociate into smaller, highly bioactive species. Insoluble amyloid plaques likely sequester soluble HMW oligomers, limiting their potential to dissociate. We conclude that conditions that destabilize HMW oligomers or retard the sequestration of their smaller, more bioactive components are important drivers of A&#x3b2; toxicity. Selectively targeting these small, cytotoxic forms should be therapeutically beneficial.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT">Oligomers of amyloid &#x3b2;-protein (oA&#x3b2;) are tought to play an important role in Alzheimer's disease (AD), but there is confusion and controversy about what types and sizes of oligomers have disease-relevant activity. Using size-exclusion chromatography and three distinct measures of bioactivity, we show that the predominant forms of A&#x3b2; in aqueous extracts of AD brain are high molecular weight (HMW) and relatively inactive. Importantly, under certain conditions, the abundant HMW oA&#x3b2; can dissociate into low molecular weight species, and these low molecular weight oligomers are significantly more bioactive on synapses and microglia than the HMW species from which they are derived. We conclude that conditions that destabilize HMW oA&#x3b2; or retard the sequestration of smaller, more bioactive components are important drivers of A&#x3b2; toxicity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the authors 0270-6474/17/370152-12$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huixin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4190-4244</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 dselkoe@partners.org dwalsh@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 dselkoe@partners.org dwalsh@partners.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018343">Receptors, Adrenergic, beta-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018343" MajorTopicYN="N">Receptors, Adrenergic, beta-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">A&#x3b2; aggregation</Keyword><Keyword MajorTopicYN="N">long-term potentiation</Keyword><Keyword MajorTopicYN="N">microglia activation</Keyword><Keyword MajorTopicYN="N">size-exclusion chromatography</Keyword><Keyword MajorTopicYN="N">&#x3b2;2-adrenergic receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28053038</ArticleId><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1698-16.2016</ArticleId><ArticleId IdType="pii">JNEUROSCI.1698-16.2016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barry AE, Klyubin I, McDonald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci. 2011;31:7259&#x2013;7263. doi: 10.1523/JNEUROSCI.6500-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6500-10.2011</ArticleId><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="pubmed">21593310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlikova GG, Trejo M, Mably AJ, McDonald JM, Sala Frigerio C, Regan CM, Murphy KJ, Masliah E, Walsh DM. Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging. 2013;34:1315&#x2013;1327. doi: 10.1016/j.neurobiolaging.2012.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.028</ArticleId><ArticleId IdType="pmc">PMC3570694</ArticleId><ArticleId IdType="pubmed">23182244</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill L, Pham CA, Setlow B. Impaired memory consolidation in rats produced with beta-adrenergic blockade. Neurobiol Learn Mem. 2000;74:259&#x2013;266. doi: 10.1006/nlme.1999.3950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nlme.1999.3950</ArticleId><ArticleId IdType="pubmed">11031131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain SR, M&#xfc;ller U, Blackwell AD, Robbins TW, Sahakian BJ. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology. 2006;188:397&#x2013;407. doi: 10.1007/s00213-006-0391-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-006-0391-6</ArticleId><ArticleId IdType="pubmed">16642355</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Nicoll AJ, Klyubin I, Panico S, McDonald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011;2:336. doi: 10.1038/ncomms1341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007;28:327&#x2013;335. doi: 10.1016/j.neurobiolaging.2006.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.02.007</ArticleId><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu NW, Nicoll AJ, Zhang D, Mably AJ, O'Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ. mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun. 2014;5:3374. doi: 10.1038/ncomms4374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4374</ArticleId><ArticleId IdType="pmc">PMC4354159</ArticleId><ArticleId IdType="pubmed">24594908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome) Proc Natl Acad Sci U S A. 1995;92:3586&#x2013;3590. doi: 10.1073/pnas.92.8.3586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3586</ArticleId><ArticleId IdType="pmc">PMC42212</ArticleId><ArticleId IdType="pubmed">7724603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80:1347&#x2013;1358. doi: 10.1016/j.neuron.2013.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108:5819&#x2013;5824. doi: 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561. doi: 10.1038/nm1234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1234</ArticleId><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Nicoll AJ, Khalili-Shirazi A, Farmer M, Canning S, Mably A, Linehan J, Brown A, Wakeling M, Brandner S, Walsh DM, Rowan MJ, Collinge J. Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Abeta synaptotoxicity. J Neurosci. 2014;34:6140&#x2013;6145. doi: 10.1523/JNEUROSCI.3526-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3526-13.2014</ArticleId><ArticleId IdType="pmc">PMC4004804</ArticleId><ArticleId IdType="pubmed">24790184</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017. doi: 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, M&#xf6;ller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils: a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 2014;6:16. doi: 10.1186/alzrt246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt246</ArticleId><ArticleId IdType="pmc">PMC4054967</ArticleId><ArticleId IdType="pubmed">25031633</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801. doi: 10.1016/j.neuron.2009.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.05.012</ArticleId><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638. doi: 10.1523/JNEUROSCI.0203-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron. 2013;77:929&#x2013;941. doi: 10.1016/j.neuron.2012.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.040</ArticleId><ArticleId IdType="pmc">PMC3596823</ArticleId><ArticleId IdType="pubmed">23473322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, S&#xf6;derberg L, Moller C, Gellerfors P, Lannfelt L, Pettersson FE, Nilsson LN. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009;36:425&#x2013;434. doi: 10.1016/j.nbd.2009.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.08.007</ArticleId><ArticleId IdType="pubmed">19703562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mably AJ, Liu W, McDonald JM, Dodart JC, Bard F, Lemere CA, O'Nuallain B, Walsh DM. Anti-Abeta antibodies incapable of reducing cerebral Abeta oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis. 2015;82:372&#x2013;384. doi: 10.1016/j.nbd.2015.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.07.008</ArticleId><ArticleId IdType="pmc">PMC4641028</ArticleId><ArticleId IdType="pubmed">26215784</ArticleId></ArticleIdList></Reference><Reference><Citation>Manaye KF, Mouton PR, Xu G, Drew A, Lei DL, Sharma Y, Rebeck GW, Turner S. Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age. 2013;35:139&#x2013;147. doi: 10.1007/s11357-011-9343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-011-9343-0</ArticleId><ArticleId IdType="pmc">PMC3543748</ArticleId><ArticleId IdType="pubmed">22127507</ArticleId></ArticleIdList></Reference><Reference><Citation>Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev. 2004;45:38&#x2013;78. doi: 10.1016/j.brainresrev.2004.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2004.02.002</ArticleId><ArticleId IdType="pubmed">15063099</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JM, O'Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, Wittbold WM, 3rd, Frosch MP, Walsh DM. The aqueous phase of Alzheimer's disease brain contains assemblies built from approximately 4 and approximately 7 kDa Abeta species. Alzheimers Dement. 2015;11:1286&#x2013;1305. doi: 10.1016/j.jalz.2015.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.01.005</ArticleId><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Malley TT, Oktaviani NA, Zhang D, Lomakin A, O'Nuallain B, Linse S, Benedek GB, Rowan MJ, Mulder FA, Walsh DM. Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem J. 2014;461:413&#x2013;426. doi: 10.1042/BJ20140219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20140219</ArticleId><ArticleId IdType="pubmed">24785004</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411&#x2013;14419. doi: 10.1523/JNEUROSCI.3537-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3537-10.2010</ArticleId><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM. Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol. 2011;670:33&#x2013;44. doi: 10.1007/978-1-60761-744-0_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-744-0_3</ArticleId><ArticleId IdType="pubmed">20967581</ArticleId></ArticleIdList></Reference><Reference><Citation>Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci. 2006;26:467&#x2013;478. doi: 10.1523/JNEUROSCI.4265-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4265-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674412</ArticleId><ArticleId IdType="pubmed">16407544</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya AR, Lungrin I, Yamaguchi H, F&#xe4;ndrich M, Thal DR. High-molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J Cell Mol Med. 2012;16:287&#x2013;295. doi: 10.1111/j.1582-4934.2011.01306.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01306.x</ArticleId><ArticleId IdType="pmc">PMC3823292</ArticleId><ArticleId IdType="pubmed">21418518</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Masters CL. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213&#x2013;228. doi: 10.2174/0929866043407174.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929866043407174</ArticleId><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Abeta oligomers: a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184. doi: 10.1111/j.1471-4159.2006.04426.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04426.x</ArticleId><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK. Amyloid beta peptide-(1&#x2013;42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J Biol Chem. 2011;286:31852&#x2013;31863. doi: 10.1074/jbc.M111.244335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.244335</ArticleId><ArticleId IdType="pmc">PMC3173113</ArticleId><ArticleId IdType="pubmed">21757762</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res. 2008;5:342&#x2013;345. doi: 10.2174/156720508784533286.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508784533286</ArticleId><ArticleId IdType="pubmed">18537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar G, Smith IM, She Y, Walsh DM, Dennis J, Selkoe M. A specific enzyme-linked immunosorbent assay for measuring &#x3b2;-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199. doi: 10.1001/archneurol.2008.565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.565</ArticleId><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gelyana E, Rajsombath M, Yang T, Li S, Selkoe D. Environmental enrichment potently prevents microglia-mediated neuroinflammation by human amyloid beta-protein oligomers. J Neurosci. 2016;36:9041&#x2013;9056. doi: 10.1523/JNEUROSCI.1023-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1023-16.2016</ArticleId><ArticleId IdType="pmc">PMC5005718</ArticleId><ArticleId IdType="pubmed">27581448</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement. 2013;9:99&#x2013;112. doi: 10.1016/j.jalz.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.005</ArticleId><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, O'Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, Selkoe DJ. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015;7:14. doi: 10.1186/s13195-015-0100-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0100-y</ArticleId><ArticleId IdType="pmc">PMC4369838</ArticleId><ArticleId IdType="pubmed">25802556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28063597</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>389</Volume><Issue>10070</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.</ArticleTitle><Pagination><StartPage>718</StartPage><EndPage>726</EndPage><MedlinePgn>718-726</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(16)32399-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(16)32399-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological diseases in Ontario, Canada.</AbstractText><AbstractText Label="METHODS">In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4&#xb7;4 million; multiple sclerosis cohort) and all adults aged 55-85 years (about 2&#xb7;2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity to major roadways based on their residential postal-code address in 1996, 5 years before cohort inception. Incident diagnoses of dementia, Parkinson's disease, and multiple sclerosis were ascertained from provincial health administrative databases with validated algorithms. We assessed the associations between traffic proximity and incident dementia, Parkinson's disease, and multiple sclerosis using Cox proportional hazards models, adjusting for individual and contextual factors such as diabetes, brain injury, and neighbourhood income. We did various sensitivity analyses, such as adjusting for access to neurologists and exposure to selected air pollutants, and restricting to never movers and urban dwellers.</AbstractText><AbstractText Label="FINDINGS">Between 2001, and 2012, we identified 243&#x2008;611 incident cases of dementia, 31&#x2008;577 cases of Parkinson's disease, and 9247 cases of multiple sclerosis. The adjusted hazard ratio (HR) of incident dementia was 1&#xb7;07 for people living less than 50 m from a major traffic road (95% CI 1&#xb7;06-1&#xb7;08), 1&#xb7;04 (1&#xb7;02-1&#xb7;05) for 50-100 m, 1&#xb7;02 (1&#xb7;01-1&#xb7;03) for 101-200 m, and 1&#xb7;00 (0&#xb7;99-1&#xb7;01) for 201-300 m versus further than 300 m (p for trend=0&#xb7;0349). The associations were robust to sensitivity analyses and seemed stronger among urban residents, especially those who lived in major cities (HR 1&#xb7;12, 95% CI 1&#xb7;10-1&#xb7;14 for people living &lt;50 m from a major traffic road), and who never moved (1&#xb7;12, 1&#xb7;10-1&#xb7;14 for people living &lt;50 m from a major traffic road). No association was found with Parkinson's disease or multiple sclerosis.</AbstractText><AbstractText Label="INTERPRETATION">In this large population-based cohort, living close to heavy traffic was associated with a higher incidence of dementia, but not with Parkinson's disease or multiple sclerosis.</AbstractText><AbstractText Label="FUNDING">Health Canada (MOA-4500314182).</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address: hong.chen@oahpp.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Copes</LastName><ForeName>Ray</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Public Health Ontario, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeneuve</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Health Sciences, Carleton University, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Donkelaar</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hystad</LastName><ForeName>Perry</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>College of Public Health and Human Sciences, Oregon State University, Corvallis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Randall V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada; Harvard-Smithsonian Centre for Astrophysics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessiman</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Population Studies Division, Health Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilton</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnett</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Population Studies Division, Health Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2017 Feb 18;389(10070):675-677. doi: 10.1016/S0140-6736(16)32596-X.</RefSource><PMID Version="1">28063596</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Mar;13(3):128-129. doi: 10.1038/nrneurol.2017.6.</RefSource><PMID Version="1">28106063</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2017 Jun 17;389(10087):2371-2372. doi: 10.1016/S0140-6736(17)31466-6.</RefSource><PMID Version="1">28635603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2017 Jun 17;389(10087):2371. doi: 10.1016/S0140-6736(17)31464-2.</RefSource><PMID Version="1">28635604</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Planet Health. 2017 Jun;1(3):e90-e91. doi: 10.1016/S2542-5196(17)30042-6.</RefSource><PMID Version="1">29851614</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018986" MajorTopicYN="Y">Motor Vehicles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="Y">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28063597</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)32399-6</ArticleId><ArticleId IdType="pii">S0140-6736(16)32399-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28073379</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Tau passive immunization inhibits not only tau but also A&#x3b2; pathology.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-016-0227-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer's disease (AD) and related tauopathies. Currently, there is no effective treatment available for these progressive neurodegenerative diseases. In recent years, tau immunotherapy has shown great potential in animal models. We report the effect of immunization with tau antibodies 43D against tau 6-18 and 77E9 against tau 184-195 on tau and amyloid-&#x3b2; (A&#x3b2;) pathologies and cognition in triple-transgenic (3&#xd7;Tg)-AD mice at mild to moderate stages of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We immunized 12-month-old female 3&#xd7;Tg-AD mice with two to six or seven intravenous weekly doses of 15&#xa0;&#x3bc;g of mouse monoclonal antibody 43D, 77E9, a combination of one-half dose each of 43D and 77E9, or as control of mouse immunoglobulin G (IgG). Age-matched wild-type mice treated with mouse IgG or a mixture of 43D and 77E9 were also used as controls. The effect of immunization with tau antibodies on tau and A&#x3b2; pathologies was assessed by Western blot and immunofluorescence analysis, and the effect on cognition was analyzed by using Morris water maze, one-trial novel object recognition, and novel object location tasks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that two doses of 43D and 77E9 reduced total tau but had no significant impact on hyperphosphorylation of tau. However, six doses of 43D reduced levels of both total tau and tau hyperphosphorylated at Ser262/356 and Ser396/404 sites in the hippocampus. Importantly, both 43D and 77E9 antibodies rescued spatial memory and short-term memory impairments in 3&#xd7;Tg-AD mice. The beneficial effect of 43D and 77E9 antibodies on cognitive performance was sustained up to 3&#xa0;months after the last dose. Six doses of immunization with 43D also decreased amyloid precursor protein (APP) level in CA1 and amyloid plaques in subiculum, and showed a trend toward reducing A&#x3b2;40 and A&#x3b2;42 in the forebrain. Immunization with 43D increased levels of complement components C1 and C9 and resulted in activation of microglia, especially surrounding A&#x3b2; plaques.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest the potential of passive immunization targeting proximal N-terminal domain tau 6-18 as a disease-modifying approach to AD and related tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Chun-Ling</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Inge Grundke-Iqbal Research Floor, 1050 Forest Hill Road, Staten Island, NY, 10314, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tung</LastName><ForeName>Yunn Chyn</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Inge Grundke-Iqbal Research Floor, 1050 Forest Hill Road, Staten Island, NY, 10314, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Inge Grundke-Iqbal Research Floor, 1050 Forest Hill Road, Staten Island, NY, 10314, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Cheng-Xin</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Inge Grundke-Iqbal Research Floor, 1050 Forest Hill Road, Staten Island, NY, 10314, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Inge Grundke-Iqbal Research Floor, 1050 Forest Hill Road, Staten Island, NY, 10314, USA. khalid.iqbal.ibr@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Tauopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28073379</ArticleId><ArticleId IdType="pmc">PMC5225540</ArticleId><ArticleId IdType="doi">10.1186/s13195-016-0227-5</ArticleId><ArticleId IdType="pii">10.1186/s13195-016-0227-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2015 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2015;11:332&#x2013;384. doi: 10.1016/j.jalz.2015.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.003</ArticleId><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890. doi: 10.1016/S0006-291X(84)80190-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(84)80190-4</ArticleId><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913&#x2013;4917. doi: 10.1073/pnas.83.13.4913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.13.4913</ArticleId><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E, Gold G. Alzheimer disease therapy&#x2014;moving from amyloid-&#x3b2; to tau. Nat Rev Neurol. 2013;9:677&#x2013;686. doi: 10.1038/nrneurol.2013.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.223</ArticleId><ArticleId IdType="pubmed">24217510</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C. Alzheimer&#x2019;s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313573</ArticleId><ArticleId IdType="pubmed">22506132</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370:311&#x2013;321. doi: 10.1056/NEJMoa1312889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer&#x2019;s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18. doi: 10.1186/s13195-016-0189-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0189-7</ArticleId><ArticleId IdType="pmc">PMC4866415</ArticleId><ArticleId IdType="pubmed">27176461</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer&#x2019;s disease. J Alzheimers Dis. 2016;51:1131&#x2013;1143. doi: 10.3233/JAD-150376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150376</ArticleId><ArticleId IdType="pubmed">26967206</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. 1987;74:209&#x2013;225. doi: 10.1007/BF00688184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00688184</ArticleId><ArticleId IdType="pubmed">3673513</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631&#x2013;639. doi: 10.1212/WNL.42.3.631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580. doi: 10.1002/ana.410300410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology. 2003;60:1495&#x2013;1500. doi: 10.1212/01.WNL.0000063311.58879.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000063311.58879.01</ArticleId><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau immunotherapy. Neurodegener Dis. 2016;16:34&#x2013;38. doi: 10.1159/000440842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000440842</ArticleId><ArticleId IdType="pmc">PMC4777344</ArticleId><ArticleId IdType="pubmed">26551002</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129. doi: 10.1523/JNEUROSCI.2361-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2361-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Ittner A, Ke YD, Gotz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860. doi: 10.1371/journal.pone.0026860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026860</ArticleId><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;485. doi: 10.1016/j.expneurol.2010.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.05.010</ArticleId><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118:658&#x2013;667. doi: 10.1111/j.1471-4159.2011.07337.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07337.x</ArticleId><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem. 2013;288:33081&#x2013;33095. doi: 10.1074/jbc.M113.494922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.494922</ArticleId><ArticleId IdType="pmc">PMC3829157</ArticleId><ArticleId IdType="pubmed">24089520</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397&#x2013;405. doi: 10.2174/156720512800492503.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512800492503</ArticleId><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, Lopez-Deber MP, Reis P, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747157</ArticleId><ArticleId IdType="pubmed">23977276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467. doi: 10.1074/jbc.M111.229633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.229633</ArticleId><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer&#x2019;s disease. Brain. 2014;137:2834&#x2013;2846. doi: 10.1093/brain/awu213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu213</ArticleId><ArticleId IdType="pubmed">25085375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One. 2015;10:e0125614. doi: 10.1371/journal.pone.0125614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125614</ArticleId><ArticleId IdType="pmc">PMC4416899</ArticleId><ArticleId IdType="pubmed">25933020</ArticleId></ArticleIdList></Reference><Reference><Citation>Umeda T, Eguchi H, Kunori Y, Matsumoto Y, Taniguchi T, Mori H, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol. 2015;2:241&#x2013;255. doi: 10.1002/acn3.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.171</ArticleId><ArticleId IdType="pmc">PMC4369274</ArticleId><ArticleId IdType="pubmed">25815351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai CL, Chen X, Kazim SF, Liu F, Gong CX, Iqbal K. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna) 2015;122:607&#x2013;617. doi: 10.1007/s00702-014-1315-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1315-y</ArticleId><ArticleId IdType="pubmed">25233799</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer&#x2019;s disease. Expert Opin Investig Drugs. 2015;24:1355&#x2013;1360. doi: 10.1517/13543784.2015.1075002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2015.1075002</ArticleId><ArticleId IdType="pmc">PMC5502785</ArticleId><ArticleId IdType="pubmed">26289787</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, et al. Defective brain microtubule assembly in Alzheimer&#x2019;s disease. Lancet. 1986;2:421&#x2013;426. doi: 10.1016/S0140-6736(86)92134-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(86)92134-3</ArticleId><ArticleId IdType="pubmed">2874414</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:5562&#x2013;5566. doi: 10.1073/pnas.91.12.5562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.12.5562</ArticleId><ArticleId IdType="pmc">PMC44036</ArticleId><ArticleId IdType="pubmed">8202528</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer&#x2019;s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2:783&#x2013;787. doi: 10.1038/nm0796-783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0796-783</ArticleId><ArticleId IdType="pubmed">8673924</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913. doi: 10.1038/ncb1901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110:9535&#x2013;9540. doi: 10.1073/pnas.1301175110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288. doi: 10.1016/j.neuron.2014.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Zhang X, Tung YC, Liu F, Iqbal K. Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement. 2016;12:1066&#x2013;1077. doi: 10.1016/j.jalz.2016.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.014</ArticleId><ArticleId IdType="pubmed">27133892</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed NV, Herrou T, Plouffe V, Piperno N, Leclerc N. Spreading of tau pathology in Alzheimer&#x2019;s disease by cell-to-cell transmission. Eur J Neurosci. 2013;37:1939&#x2013;1948. doi: 10.1111/ejn.12229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.12229</ArticleId><ArticleId IdType="pubmed">23773063</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Simon D, Diaz-Hernandez M, Pintor J, Hernandez F. Sources of extracellular tau and its signaling. J Alzheimers Dis. 2014;40(Suppl 1):S7&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">24531154</ArticleId></ArticleIdList></Reference><Reference><Citation>Flight MH. Neurodegenerative disease: tau immunotherapy targets transcellular propagation. Nat Rev Drug Discov. 2013;12:904. doi: 10.1038/nrd4179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4179</ArticleId><ArticleId IdType="pubmed">24232374</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852. doi: 10.1074/jbc.M808759200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis. 2008;15:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953106</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard J, Wanka L, Tung YC, Del Carmen C&#xe1;rdenas-Aguayo M, LaFerla FM, Iqbal K, et al. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting A&#x3b2; and tau pathologies in 3&#xd7;Tg-AD mice. Acta Neuropathol. 2010;120:605&#x2013;621. doi: 10.1007/s00401-010-0734-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0734-6</ArticleId><ArticleId IdType="pubmed">20697724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal K, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2014;71:110&#x2013;130. doi: 10.1016/j.nbd.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.07.001</ArticleId><ArticleId IdType="pubmed">25046994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987;61:3688&#x2013;3693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC255980</ArticleId><ArticleId IdType="pubmed">2446004</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O&#x2019;Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297:681&#x2013;683. doi: 10.1038/297681a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/297681a0</ArticleId><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev. 2001;36:60&#x2013;90. doi: 10.1016/S0165-0173(01)00067-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(01)00067-4</ArticleId><ArticleId IdType="pubmed">11516773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1:848&#x2013;858. doi: 10.1038/nprot.2006.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.116</ArticleId><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study &#x2018;recognition memory&#x2019;. Nat Protoc. 2006;1:1306&#x2013;1311. doi: 10.1038/nprot.2006.205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.205</ArticleId><ArticleId IdType="pubmed">17406415</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012;13:93&#x2013;110. doi: 10.1007/s10339-011-0430-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10339-011-0430-z</ArticleId><ArticleId IdType="pmc">PMC3332351</ArticleId><ArticleId IdType="pubmed">22160349</ArticleId></ArticleIdList></Reference><Reference><Citation>Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, Gasparini L. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest. 2013;123:348&#x2013;361. doi: 10.1172/JCI64650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI64650</ArticleId><ArticleId IdType="pmc">PMC3533293</ArticleId><ArticleId IdType="pubmed">23202733</ArticleId></ArticleIdList></Reference><Reference><Citation>Assini FL, Duzzioni M, Takahashi RN. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behav Brain Res. 2009;204:206&#x2013;211. doi: 10.1016/j.bbr.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2009.06.005</ArticleId><ArticleId IdType="pubmed">19523494</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai T, Okuda S, Tanaka T, Ohta H. Characteristics of object location memory in mice: behavioral and pharmacological studies. Physiol Behav. 2007;90:116&#x2013;124. doi: 10.1016/j.physbeh.2006.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2006.09.013</ArticleId><ArticleId IdType="pubmed">17049363</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Gu J, Sait HB, Sigurdsson EM. Antibody uptake into neurons occurs primarily via clathrin-dependent Fc&#x3b3; receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452&#x2013;35465. doi: 10.1074/jbc.M113.491001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.491001</ArticleId><ArticleId IdType="pmc">PMC3853292</ArticleId><ArticleId IdType="pubmed">24163366</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2011;2:59. doi: 10.3389/fpsyt.2011.00059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2011.00059</ArticleId><ArticleId IdType="pmc">PMC3198029</ArticleId><ArticleId IdType="pubmed">22025915</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkinson RE, McEwan WA, James LC. Intracellular antibody immunity. J Clin Immunol. 2014;34(Suppl 1):S30&#x2013;S34. doi: 10.1007/s10875-014-0017-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-014-0017-4</ArticleId><ArticleId IdType="pubmed">24722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamir DB, Rosenqvist N, Rasool S, Pedersen JT, Sigurdsson EM. Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. Alzheimers Dement. 2016;12:1098&#x2013;1107. doi: 10.1016/j.jalz.2016.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.013</ArticleId><ArticleId IdType="pmc">PMC5383206</ArticleId><ArticleId IdType="pubmed">27016263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer&#x2019;s disease. Trends Mol Med. 2015;21:394&#x2013;402. doi: 10.1016/j.molmed.2015.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2015.03.003</ArticleId><ArticleId IdType="pubmed">25846560</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis. 2012;48:356&#x2013;366. doi: 10.1016/j.nbd.2012.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.05.021</ArticleId><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah KH, Zhang B, Ramachandran V, Herman PK. Processing body and stress granule assembly occur by independent and differentially regulated pathways in Saccharomyces cerevisiae. Genetics. 2013;193:109&#x2013;123. doi: 10.1534/genetics.112.146993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.112.146993</ArticleId><ArticleId IdType="pmc">PMC3527240</ArticleId><ArticleId IdType="pubmed">23105015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-&#x3b2; and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re192.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, et al. Human secreted tau increases amyloid-&#x3b2; production. Neurobiol Aging. 2015;36:693&#x2013;709. doi: 10.1016/j.neurobiolaging.2014.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.007</ArticleId><ArticleId IdType="pubmed">25442111</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE, Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, et al. Characterization of novel CSF tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLoS One. 2013;8:e76523. doi: 10.1371/journal.pone.0076523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076523</ArticleId><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357. doi: 10.1016/S0197-4580(97)00056-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-&#x3b2; changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013;126:631&#x2013;641. doi: 10.1007/s00401-013-1139-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1139-0</ArticleId><ArticleId IdType="pubmed">23756600</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Yang L, Li R. What does complement do in Alzheimer&#x2019;s disease? Old molecules with new insights. Transl Neurodegener. 2013;2:21. doi: 10.1186/2047-9158-2-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-9158-2-21</ArticleId><ArticleId IdType="pmc">PMC3853043</ArticleId><ArticleId IdType="pubmed">24119446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer&#x2019;s disease brain. Am J Pathol. 1999;154:927&#x2013;936. doi: 10.1016/S0002-9440(10)65340-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65340-0</ArticleId><ArticleId IdType="pmc">PMC1866427</ArticleId><ArticleId IdType="pubmed">10079271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44:999&#x2013;1010. doi: 10.1016/j.molimm.2006.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2006.03.007</ArticleId><ArticleId IdType="pubmed">16698083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer&#x2019;s mice. Proc Natl Acad Sci U S A. 2002;99:10837&#x2013;10842. doi: 10.1073/pnas.162350199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162350199</ArticleId><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid &#x3b2; plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341. doi: 10.1523/JNEUROSCI.0829-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0829-08.2008</ArticleId><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, et al. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A&#x3b2; by microglia. Glia. 2012;60:993&#x2013;1003. doi: 10.1002/glia.22331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22331</ArticleId><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Choucair-Jaafar N, Laporte V, Levy R, Poindron P, Lombard Y, Gies JP. Complement receptor 3 (CD11b/CD18) is implicated in the elimination of &#x3b2;-amyloid peptides. Fundam Clin Pharmacol. 2011;25:115&#x2013;122. doi: 10.1111/j.1472-8206.2010.00811.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-8206.2010.00811.x</ArticleId><ArticleId IdType="pubmed">20199584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y, et al. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer&#x2019;s disease. J Neuroinflammation. 2011;8:4. doi: 10.1186/1742-2094-8-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-4</ArticleId><ArticleId IdType="pmc">PMC3033336</ArticleId><ArticleId IdType="pubmed">21235806</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: c.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639259</ArticleId><ArticleId IdType="pubmed">23638068</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y, Iqbal K, Grundke-Iqbal I. Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J Neurosci. 1999;19:5245&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782310</ArticleId><ArticleId IdType="pubmed">10377336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28099414</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>541</Volume><Issue>7638</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Neurotoxic reactive astrocytes are induced by activated microglia.</ArticleTitle><Pagination><StartPage>481</StartPage><EndPage>487</EndPage><MedlinePgn>481-487</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature21029</ELocationID><Abstract><AbstractText>Reactive astrocytes are strongly induced by central nervous system (CNS) injury and disease, but their role is poorly understood. Here we show that a subtype of reactive astrocytes, which we termed A1, is induced by classically activated neuroinflammatory microglia. We show that activated microglia induce A1 astrocytes by secreting Il-1&#x3b1;, TNF and C1q, and that these cytokines together are necessary and sufficient to induce A1 astrocytes. A1 astrocytes lose the ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and induce the death of neurons and oligodendrocytes. Death of axotomized CNS neurons in vivo is prevented when the formation of A1 astrocytes is blocked. Finally, we show that A1 astrocytes are abundant in various human neurodegenerative diseases including Alzheimer's, Huntington's and Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. Taken together these findings help to explain why CNS neurons die after axotomy, strongly suggest that A1 astrocytes contribute to the death of neurons and oligodendrocytes in neurodegenerative disorders, and provide opportunities for the development of new treatments for these diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guttenplan</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Frederick C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohlen</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schirmer</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich 81675, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Mariko L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Alexandra E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Won-Suk</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Todd C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurological Sciences, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilton</LastName><ForeName>Daniel K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Neurology, F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frouin</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napier</LastName><ForeName>Brooke A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panicker</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Manoj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckwalter</LastName><ForeName>Marion S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurological Sciences, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowitch</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics and Neurosurgery, University of California San Francisco, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Valina L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana 70130-2685, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana 70130-2685, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS084298</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA015043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS067525</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DA015043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090255</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048814</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053582">Interleukin-1alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014118">Toxins, Biological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Mar;18(3):130. doi: 10.1038/nrn.2017.13.</RefSource><PMID Version="1">28148955</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Mar;13(3):127. doi: 10.1038/nrneurol.2017.17.</RefSource><PMID Version="1">28155893</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019771" MajorTopicYN="N">Axotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="Y">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053582" MajorTopicYN="N">Interleukin-1alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014118" MajorTopicYN="N">Toxins, Biological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28099414</ArticleId><ArticleId IdType="mid">NIHMS854157</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pii">nature21029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Barres BA. Emerging roles of astrocytes in neural circuit development. Nat Rev Neurosci. 2013;14:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431630</ArticleId><ArticleId IdType="pubmed">23595014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WSS, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S, Barres B. SnapShot: Astrocytes in Health and Disease. Cell. 2015;162:1170&#x2013;1170 e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32:6391&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA, et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature. 2016;532:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Astrogliosis. Cold Spring Harb Perspect Biol. 2015;7:a020420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315924</ArticleId><ArticleId IdType="pubmed">25380660</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944738</ArticleId><ArticleId IdType="pubmed">24669294</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush TG, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron. 1999;23:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zador Z, Stiver S, Wang V, Manley GT. Role of aquaporin-4 in cerebral edema and stroke. Handb Exp Pharmacol. 2009:159&#x2013;70. doi: 10.1007/978-3-540-79885-9_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-79885-9_7</ArticleId><ArticleId IdType="pmc">PMC3516842</ArticleId><ArticleId IdType="pubmed">19096776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28:264&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron. 2016;89:37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA. 2016;113:E1738&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 330:841&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartmell T, Luheshi GN, Rothwell NJ. Brain sites of action of endogenous interleukin-1 in the febrile response to localized inflammation in the rat. J Physiol. 1999;518:585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269440</ArticleId><ArticleId IdType="pubmed">10381603</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo LC, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron. 2011;71:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172573</ArticleId><ArticleId IdType="pubmed">21903074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang W, et al. Astrocyte activation is suppressed in both normal and injured brain by FGF signaling. Proc Natl Acad Sci USA. 2014;111:E2987&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115557</ArticleId><ArticleId IdType="pubmed">25002516</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 2012;486:410&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383085</ArticleId><ArticleId IdType="pubmed">22722203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukdereli H, et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci USA. 2011;108:E440&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156217</ArticleId><ArticleId IdType="pubmed">21788491</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson KS, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker GA. Trophic interactions between astroglial cells and hippocampal neurons in culture. Science. 1980;209:809&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">7403847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigerl KA, et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29:13435&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788152</ArticleId><ArticleId IdType="pubmed">19864556</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrano A, Hererra AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction damage in nigrostriatal dopaminergic system. J Neurochem. 1998;70:1584&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580157</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. Dextromethorplan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 2003;305:212&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12649371</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner JR, et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24:2143&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730429</ArticleId><ArticleId IdType="pubmed">14999065</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada S, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med. 2006;12:829&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783372</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann JE, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28:7231&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583788</ArticleId><ArticleId IdType="pubmed">18614693</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33:13460&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber DJ, Harris BT. Purification and culture of spinal motor neurons from rat embryos. Cold Spring Harb Protoc. 2013;2013:319&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23547162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Sohet F, Daneman R. Purification of endothelial cells from rodent brain by immunopanning. Cold Spring Harb Protoc. 2014;2014:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">24371317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Sohet F, Daneman R. Purification of pericytes from rodent optic nerve by immunopanning. Cold Spring Harb Protoc. 2014;2014:608&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">24890207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustin SA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19246619</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle KP, Buckwalter MS. A mouse model of permanent focal ischemia: distal middle cerebral artery occlusion. Methods Mol Biol. 2014;1135:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">24510858</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg A, Rusnakova V, Forootan A, Anderova M, Kubista M. RT-qPCR work-flow for single-cell data analysis. Methods. 2013;59:80&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">23021995</ArticleId></ArticleIdList></Reference><Reference><Citation>Winzeler A, Wang JT. Purification and culture of retinal ganglion cells from rodents. Cold Spring Harb Protoc. 2013;2013:643&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23818667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XJJ, Liu M, Holden DW. SsaM and SpiC interact and regulate secretion of Salmonella pathogenicity island 2 type III secretion system effectors and translocators. Mol Microbiol. 2004;54:604&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriks S, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson&#x2019;s disease. Nature. 2011;480:547&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245796</ArticleId><ArticleId IdType="pubmed">22056989</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, Lee RJ, West BL, Green KN. Characterizing newly repopulated microglia in the adult mouse: impacts on animal behavior, cell morphology, and neuroinflammation. PLoS ONE. 2015;10:e0122912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388515</ArticleId><ArticleId IdType="pubmed">25849463</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkley PR, Jarvie PE, Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc. 2008;3:1718&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18927557</ArticleId></ArticleIdList></Reference><Reference><Citation>Larocca JN, Norton WT. Isolation of myelin. Curr Protoc Cell Biol. 2007;25 Chapter 3, Unit3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18228513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuchero JB, et al. CNS myelin wrapping is driven by actin disassembly. Dev Cell. 2015;34:152&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4519368</ArticleId><ArticleId IdType="pubmed">26166300</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AGG, Buchner AG. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28111074</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>26</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A&#x3b2; Secretion.</ArticleTitle><Pagination><StartPage>427</StartPage><EndPage>441.e21</EndPage><MedlinePgn>427-441.e21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.12.044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)31760-3</ELocationID><Abstract><AbstractText>Human apolipoprotein E (ApoE) apolipoprotein is primarily expressed in three isoforms (ApoE2, ApoE3, and ApoE4) that differ only by two residues. ApoE4 constitutes the most important genetic risk factor for Alzheimer's disease (AD), ApoE3 is neutral, and ApoE2 is protective. How ApoE isoforms influence AD pathogenesis, however, remains unclear. Using ES-cell-derived human neurons, we show that ApoE secreted by glia stimulates neuronal A&#x3b2; production with an ApoE4&#xa0;&gt; ApoE3&#xa0;&gt; ApoE2 potency rank order. We demonstrate that ApoE binding to ApoE receptors activates dual leucine-zipper kinase (DLK), a MAP-kinase kinase kinase that then activates MKK7 and ERK1/2 MAP kinases. Activated ERK1/2 induces cFos phosphorylation, stimulating the transcription factor AP-1, which in turn enhances transcription of amyloid-&#x3b2; precursor protein (APP) and thereby increases amyloid-&#x3b2; levels. This molecular mechanism also regulates APP transcription in mice in&#xa0;vivo. Our data describe a novel signal transduction pathway in neurons whereby ApoE activates a non-canonical MAP kinase cascade that enhances APP transcription and amyloid-&#x3b2; synthesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu-Wen Alvin</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University Medical School, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University Medical School, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University Medical School, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wernig</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University Medical School, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology and Howard Hughes Medical Institute, Stanford University Medical School, Stanford, CA 94305, USA. Electronic address: tcs1@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG048131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">CRISPRi</Keyword><Keyword MajorTopicYN="N">DLK</Keyword><Keyword MajorTopicYN="N">MAP kinase signaling</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">beta amyloid</Keyword><Keyword MajorTopicYN="N">cFos</Keyword><Keyword MajorTopicYN="N">dual leucine-zipper kinase</Keyword><Keyword MajorTopicYN="N">transcription</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28111074</ArticleId><ArticleId IdType="mid">NIHMS840280</ArticleId><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.12.044</ArticleId><ArticleId IdType="pii">S0092-8674(16)31760-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, Corsmit E, De Leenheir E, Martin JJ, De Deyn PP, et al. Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer&#x2019;s disease. Brain. 2006;129:2984&#x2013;2991.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931535</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci. Transl. Med. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Maloney JA, Kallop DY, Atwal JK, Tam SJ, Baer K, Kissel H, Kaminker JS, Lewcock JW, Weimer RM, et al. Spatially coordinated kinase signaling regulates local axon degeneration. J. Neurosci. 2012;32:13439&#x2013;13453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621382</ArticleId><ArticleId IdType="pubmed">23015435</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ A, Christa A, Kur E, Lioubinski O, Bachmann S, Willnow TE, Hammes A. LRP2 is an auxiliary SHH receptor required to condition the forebrain ventral midline for inductive signals. Dev. Cell. 2012;22:268&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">22340494</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 2014;12:1262&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262738</ArticleId><ArticleId IdType="pubmed">25184501</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouquet M, Besson FL, Gonneaud, La Joie JR, Ch&#xe9;telat G. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol. Rev. 24:290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">25146994</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama K, Yoshida M, Yamashita A, Deyama T, Baba M, Suzuki A, Mohri H, Ikezawa Z, Nakajima H, Hirai S, et al. MAPK upstream kinase (MUK)-binding inhibitory protein, a negative regulator of MUK/dual leucine zipper-bearing kinase/leucine zipper protein kinase. J. Biol. Chem. 2000;275:21247&#x2013;21254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801814</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: The prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science. 2015;349:1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525717</ArticleId><ArticleId IdType="pubmed">25815993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J. Biol. Chem. 2000;275:25616&#x2013;25624.</Citation><ArticleIdList><ArticleId IdType="pubmed">10827173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarlund M, Nix P, Hauth L, Jorgensen EM, Bastiani M. Axon regeneration requires a conserved MAP kinase pathway. Science. 2009;323:802&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729122</ArticleId><ArticleId IdType="pubmed">19164707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid &#x3b2; peptide. J. Neurosci. 2012;32:15181&#x2013;15192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem. 1991;266:21232&#x2013;21238.</Citation><ArticleIdList><ArticleId IdType="pubmed">1718973</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G. ApoE and A&#x3b2; in Alzheimer&#x2019;s disease: accidental encounters or partners? Neuron. 2014;81:740&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;14:16483&#x2013;16486.</Citation><ArticleIdList><ArticleId IdType="pubmed">7622446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Ge YW, Maloney B, Wavrant-De Vri&#xe8;ze F, Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer&#x2019;s disease. Neurobiol. Aging. 2005;26:1329&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">16243604</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat. Protoc. 2013;8:2180&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922765</ArticleId><ArticleId IdType="pubmed">24136345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Belin S, He Z. Signaling regulations of neuronal regenerative ability. Curr. Opin. Neurobiol. 2014;27:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546824</ArticleId><ArticleId IdType="pubmed">24727245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Merritt SE, Mata M, Nihalani D, Zhu C, Hu X, Holzman LB. The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate. J. Biol. Chem. 1999;274:10195&#x2013;10202.</Citation><ArticleIdList><ArticleId IdType="pubmed">10187804</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje P, Marinissen PM, Gutkind JS. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol. Cell. Biol. 2003;23:7030&#x2013;7043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193921</ArticleId><ArticleId IdType="pubmed">12972619</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison DK. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 2012;4:a011254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536342</ArticleId><ArticleId IdType="pubmed">23125017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkubo N, Mitsuda N, Tamatani M, Yamaguchi A, Lee YD, Ogihara T, Vitek MP, Tohyama M. Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J. Biol Chem. 2001;276:3046&#x2013;3053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11042199</ArticleId></ArticleIdList></Reference><Reference><Citation>Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem. 1997;272:18586&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, Yi F, Wernig M, S&#xfc;dhof TC. Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1. Cell Stem Cell. 2015;3:316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560990</ArticleId><ArticleId IdType="pubmed">26279266</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzke C, Acuna C, Giam LR, Wernig M, S&#xfc;dhof TC. Conditional deletion of L1CAM in human neurons impairs both axonal and dendritic arborization and action potential generation. J. Exp. Med. 2016;213:499&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821644</ArticleId><ArticleId IdType="pubmed">27001749</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer&#x2019;s disease pathogenesis. J. Neurosci. 2010;30:14946&#x2013;14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z, Hyman BT, Rebeck GW. Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J. Biol. Chem. 2004;279:34948&#x2013;34956.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169786</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerri&#xe8;re A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D&#x2019;Adamio L. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer&#x2019;s beta-amyloid precursor protein (APP) J. Biol. Chem. 2002;277:3767&#x2013;3775.</Citation><ArticleIdList><ArticleId IdType="pubmed">11724784</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V, DiAntonio A. Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron. 2012;74:1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383631</ArticleId><ArticleId IdType="pubmed">22726832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer&#x2019;s dementia with cerebral amyloid angiopathy. Brain. 129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X. LDL-receptor-related proteins in Wnt signal transduction. Nature. 2000;407:530&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11029007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi A, Bradke F. The DLK signalling pathway--a double-edged sword in neural development and regeneration. EMBO Rep. 2013;14:605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701236</ArticleId><ArticleId IdType="pubmed">23681442</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, De Pooter T, van Duijn CM, De Deyn PP, et al. Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease. Am. J. Hum. Genet. 2006;78:936&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474091</ArticleId><ArticleId IdType="pubmed">16685645</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97:689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Control of synapse number by glia. Science. 2001;291:657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">11158678</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc. Natl. Acad. Sci. U.S.A. 2015;110:E1807&#x2013;E1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade EJ, Klucher KM, Spector DH. An AP-1 binding site is the predominant cis-acting regulatory element in the 1.2-kilobase early RNA promoter of human cytomegalovirus. J. Virol. 1992;66:2407&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC289036</ArticleId><ArticleId IdType="pubmed">1312636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Eckel RH. What are lipoproteins doing in the brain? Trends Endocrinol. Metab. 2014;25:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062975</ArticleId><ArticleId IdType="pubmed">24189266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Wu Z, Chisholm AD, Jin Y. The DLK-1 kinase promotes mRNA stability and local translation in C. elegans synapses and axon regeneration. Cell. 2009;138:1005&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772821</ArticleId><ArticleId IdType="pubmed">19737525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28076797</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>570</EndPage><MedlinePgn>557-570</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.12.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)31684-9</ELocationID><Abstract><AbstractText>Gene expression studies suggest that aging of the human brain is determined by a complex interplay of molecular events, although both its region- and cell-type-specific consequences remain poorly understood. Here, we extensively characterized aging-altered gene expression changes across ten human brain regions from 480 individuals ranging in&#xa0;age from 16 to 106 years. We show that astrocyte-&#xa0;and oligodendrocyte-specific genes, but not neuron-specific genes, shift their regional expression patterns upon aging, particularly in the hippocampus and substantia nigra, while the expression of microglia- and endothelial-specific genes increase in all&#xa0;brain regions. In line with these&#xa0;changes, high-resolution immunohistochemistry demonstrated decreased numbers of oligodendrocytes and of neuronal subpopulations in the aging brain cortex. Finally, glial-specific genes predict age with greater precision than neuron-specific genes, thus highlighting the need for greater mechanistic understanding of neuron-glia interactions in aging and late-life diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soreq</LastName><ForeName>Lilach</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>UK Brain Expression Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>North American Brain Expression Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Edinburgh Brain Bank, Academic Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soreq</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The Computational, Cognitive and Clinical NeuroImaging Laboratory, Division of Brain Sciences, Imperial College, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; Reta Lila Weston Institute of Neurological Studies, UCL ION, 1 Wakefield Street, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; Departments of Genetics, King Faisal Specialist Hospital and Research Centre. Riyadh 12713, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MRC Edinburgh Brain Bank, Academic Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patani</LastName><ForeName>Rickie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Reta Lila Weston Institute of Neurological Studies, UCL ION, 1 Wakefield Street, London WC1N 1PJ, UK; Euan MacDonald Centre for MND, University of Edinburgh, Edinburgh EH8 9YL, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1TN, UK. Electronic address: rickie.patani@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ule</LastName><ForeName>Jernej</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London WC1N 3BG, UK; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: j.ule@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>617837</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>FC001002</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG000947</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>FC001002</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101149/Z/13/A</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0802462</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">brain</Keyword><Keyword MajorTopicYN="N">exon microarrays</Keyword><Keyword MajorTopicYN="N">gene expression</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurons</Keyword><Keyword MajorTopicYN="N">olgiodendrocytes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28076797</ArticleId><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.12.011</ArticleId><ArticleId IdType="pii">S2211-1247(16)31684-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baruch K., Deczkowska A., David E., Castellano J.M., Miller O., Kertser A., Berkutzki T., Barnett-Itzhaki Z., Bezalel D., Wyss-Coray T. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014;346:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornsson C.S., Lin G., Al-Kofahi Y., Narayanaswamy A., Smith K.L., Shain W., Roysam B. Associative image analysis: a method for automated quantification of 3D multi-parameter images of brain tissue. J.&#xa0;Neurosci. Methods. 2008;170:165&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700351</ArticleId><ArticleId IdType="pubmed">18294697</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy J.D., Emery B., Kaushal A., Foo L.C., Zamanian J.L., Christopherson K.S., Xing Y., Lubischer J.L., Krieg P.A., Krupenko S.A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a&#xa0;new resource for understanding brain development and function. J.&#xa0;Neurosci. 2008;28:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerbai F., Lana D., Nosi D., Petkova-Kirova P., Zecchi S., Brothers H.M., Wenk G.L., Giovannini M.G. The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS ONE. 2012;7:e45250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445467</ArticleId><ArticleId IdType="pubmed">23028880</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs D.H., Berchtold N.C., Perreau V., Coleman P.D., Rogers J., Tenner A.J., Cotman C.W. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J.&#xa0;Neuroinflammation. 2012;9:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419089</ArticleId><ArticleId IdType="pubmed">22824372</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R., Mazor Y., Rinon A., Blumenthal J., Golan Y., Buzhor E., Livnat I., Ben-Ari S., Lieder I., Shitrit A. LifeMap Discovery&#x2122;: the embryonic development, stem cells, and regenerative medicine research portal. PLoS ONE. 2013;8:e66629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714290</ArticleId><ArticleId IdType="pubmed">23874394</ArticleId></ArticleIdList></Reference><Reference><Citation>Erraji-Benchekroun L., Underwood M.D., Arango V., Galfalvy H., Pavlidis P., Smyrniotopoulos P., Mann J.J., Sibille E. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol. Psychiatry. 2005;57:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabricius K., Jacobsen J.S., Pakkenberg B. Effect of age on neocortical brain cells in 90+ year old human females&#x2014;a cell counting study. Neurobiol. Aging. 2013;34:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22878165</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S., Burbach G.J., Bonin M., Walter M., Streit W., Bechmann I., Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551625</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs J.R., van der Brug M.P., Hernandez D.G., Traynor B.J., Nalls M.A., Lai S.L., Arepalli S., Dillman A., Rafferty I.P., Troncoso J. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman J.P., Medalla M., Luebke J.I. Area-specific features of pyramidal neurons&#x2014;a comparative study in mouse and rhesus monkey. Cereb. Cortex. 2016:bhw062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6059164</ArticleId><ArticleId IdType="pubmed">26965903</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K., Michoel T., Karavolos M.H., Clohisey S., Baillie J.K., Stevens M.P., Freeman T.C., Summers K.M., McColl B.W. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 2016;19:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N.&#xa0;Engl. J. Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A., Inger A., Stelzer G., Strichman-Almashanu L., Dalah I., Safran M., Lancet D. GIFtS: annotation landscape analysis with GeneCards. BMC Bioinformatics. 2009;10:348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774327</ArticleId><ArticleId IdType="pubmed">19852797</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa N., Kato H., Araki T. Age-related changes of astorocytes, oligodendrocytes and microglia in the mouse hippocampal CA1 sector. Mech. Ageing Dev. 2007;128:311&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350671</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D., Buckner R.L., Shimony J.S., Williams L.E., Akbudak E., Conturo T.E., McAvoy M., Morris J.C., Snyder A.Z. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb. Cortex. 2004;14:410&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15028645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang I.K., Yoo K.Y., Kim D.S., Kang T.C., Lee B.H., Kim Y.S., Won M.H. Chronological distribution of Rip immunoreactivity in the gerbil hippocampus during normal aging. Neurochem. Res. 2006;31:1119&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">16927168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.K., Adelstein R.S., Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem. 2009;284:31052&#x2013;31061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781505</ArticleId><ArticleId IdType="pubmed">19713214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Gibbs J.R., Beilina A., Dillman A., Kumaran R., Trabzuni D., Ryten M., Walker R., Smith C., Traynor B.J. Age-associated changes in gene expression in human brain and isolated neurons. Neurobiol. Aging. 2013;34:1199&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545059</ArticleId><ArticleId IdType="pubmed">23177596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake B.B., Ai R., Kaeser G.E., Salathia N.S., Yung Y.C., Liu R., Wildberg A., Gao D., Fung H.L., Chen S. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352:1586&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T., Aron L., Zullo J., Pan Y., Kim H., Chen Y., Yang T.H., Kim H.M., Drake D., Liu X.S. REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature. 2014;507:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M., Salih D.A., Yasvoina M., Cummings D.M., Guelfi S., Liu W., Nahaboo Solim M.A., Moens T.G., Paublete R.M., Ali S.S. A&#xa0;genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10:633&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., Chang J., Thill G., Levesque M., Zhang M. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005;8:745&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895088</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky A.V., Kelley K.W., Tsai H.H., Redmond S.A., Chang S.M., Madireddy L., Chan J.R., Baranzini S.E., Ullian E.M., Rowitch D.H. Astrocyte-encoded positional cues maintain sensorimotor circuit integrity. Nature. 2014;509:189&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057936</ArticleId><ArticleId IdType="pubmed">24776795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher K.I., Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem. Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Norden D.M., Godbout J.P. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol. Appl. Neurobiol. 2013;39:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553257</ArticleId><ArticleId IdType="pubmed">23039106</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M., Kamphuis W., Dooves S., Kooijman L., Chan E.T., Kirk C.J., Dimayuga Smith V., Koot S., Mamber C., Jansen A.H. Reactive glia show increased immunoproteasome activity in Alzheimer&#x2019;s disease. Brain. 2013;136:1415&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">23604491</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelvig D.P., Pakkenberg H., Stark A.K., Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol. Aging. 2008;29:1754&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">17544173</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry V.H., Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin. Immunopathol. 2013;35:601&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742955</ArticleId><ArticleId IdType="pubmed">23732506</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Sethares C. Oligodendrocytes, their progenitors and other neuroglial cells in the aging primate cerebral cortex. Cereb. Cortex. 2004;14:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez J.J., Yeh C.Y., Terzieva S., Olabarria M., Kulijewicz-Nawrot M., Verkhratsky A. Complex and region-specific changes in astroglial markers in the aging brain. Neurobiol. Aging. 2014;35:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23969179</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimeda Y., Hirotani Y., Akimoto Y., Shindou K., Ijiri Y., Nishihori T., Tanaka K. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol. Pharm. Bull. 2005;28:1635&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibille E. Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders. Dialogues Clin. Neurosci. 2013;15:53&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622469</ArticleId><ArticleId IdType="pubmed">23576889</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan A.H., Madison D.V., Mateos J.M., Fraser D.A., Lovelett E.A., Coutellier L., Kim L., Tsai H.H., Huang E.J., Rowitch D.H. A dramatic increase of C1q protein in the CNS during normal aging. J.&#xa0;Neurosci. 2013;33:13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W.J., Xue Q.S. The brain&#x2019;s aging immune system. Aging Dis. 2010;1:254&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152305</ArticleId><ArticleId IdType="pubmed">21833348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Sun Y., Ling S.C., Ferraiuolo L., Mcalonis-Downes M., Zou Y., Drenner K., Want Y., Ditsworth D., Tokunaga S. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc. Natl. Acad. Sci. USA. 2015;112:E6993&#x2013;E7002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey J.R., Wang Z., Hortob&#xe1;gyi T., Witten J.T., Zarnack K., Kayikci M., Clark T.A., Schweitzer A.C., Rot G., Curk T. Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Res. 2011;21:1572&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202275</ArticleId><ArticleId IdType="pubmed">21846794</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D., Ryten M., Walker R., Smith C., Imran S., Ramasamy A., Weale M.E., Hardy J. Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J.&#xa0;Neurochem. 2011;119:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664422</ArticleId><ArticleId IdType="pubmed">21848658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M.E., Zettel M.L., Ison J.R., Allen P.D., Majewska A.K. Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia. 2012;60:541&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276747</ArticleId><ArticleId IdType="pubmed">22223464</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernooij M.W., de Groot M., van der Lugt A., Ikram M.A., Krestin G.P., Hofman A., Niessen W.J., Breteler M.M. White matter atrophy and lesion formation explain the loss of structural integrity of white matter in aging. Neuroimage. 2008;43:470&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeba M., Jovanov-Milosevi&#x107; N., Petanjek Z. Quantitative analysis of basal dendritic tree of layer III pyramidal neurons in different areas of adult human frontal cortex. Coll. Antropol. 2008;32(Suppl 1):161&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">18405077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O&#x2019;Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J.&#xa0;Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28076784</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>405</EndPage><MedlinePgn>391-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.12.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)31746-6</ELocationID><Abstract><AbstractText>Microglia play key roles in brain development, homeostasis, and function, and it is widely assumed that the adult population is long lived and maintained by self-renewal. However, the precise temporal and spatial dynamics of the microglial population are unknown. We show in mice and humans that the turnover of microglia is remarkably fast, allowing the whole population to be renewed several times during a lifetime. The number of microglial cells remains steady from late postnatal stages until aging and is maintained by the spatial and temporal coupling of proliferation and apoptosis, as shown by pulse-chase studies, chronic in&#xa0;vivo imaging of microglia, and the use of mouse models of dysregulated apoptosis. Our results reveal that the microglial population is constantly and rapidly remodeled, expanding our understanding of its role in the maintenance of brain homeostasis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Askew</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kaizhen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Physiology II, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olmos-Alonso</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Moreno</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yajie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Physiology II, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Philippa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tipton</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riecken</LastName><ForeName>Kristoffer</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beccari</LastName><ForeName>Sol</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Achucarro Basque Center for Neuroscience, Ikerbasque Foundation, University of the Basque Country (UPV/EHU), 48940 Leioa, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Achucarro Basque Center for Neuroscience, Ikerbasque Foundation, University of the Basque Country (UPV/EHU), 48940 Leioa, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moln&#xe1;r</LastName><ForeName>Zolt&#xe1;n</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cragg</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaschuk</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Physiology II, University of T&#xfc;bingen, 72074 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>V Hugh</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Nicola</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK. Electronic address: d.gomez-nicola@soton.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K022687/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026039/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BrdU</Keyword><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">CX3CR1</Keyword><Keyword MajorTopicYN="N">Macgreen</Keyword><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">Vav-Bcl2</Keyword><Keyword MajorTopicYN="N">self-renewal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28076784</ArticleId><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.12.041</ArticleId><ArticleId IdType="pii">S2211-1247(16)31746-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alliot F., Godin I., Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. 1999;117:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain&#xa0;and behavior: a critical role for the immune system. Front. Behav. Neurosci. 2009;3:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737431</ArticleId><ArticleId IdType="pubmed">19738918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J., Karram K., W&#xf6;rtge S., Regen T., Marini F., Hoppmann N., Klein M., Blank T., Yona S., Wolf Y. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43:92&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron I.L., Greulich R.C. Evidence for an essentially constant duration of DNA synthesis in renewing epithelia of the adult mouse. J.&#xa0;Cell Biol. 1963;18:31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2106275</ArticleId><ArticleId IdType="pubmed">14018040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C.L., Mart&#xed;nez-Cerde&#xf1;o V., Noctor S.C. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J.&#xa0;Neurosci. 2013;33:4216&#x2013;4233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711552</ArticleId><ArticleId IdType="pubmed">23467340</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., Gan W.B. ATP mediates rapid microglial response to local brain injury in&#xa0;vivo. Nat. Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lucia C., Rinchon A., Olmos-Alonso A., Riecken K., Fehse B., Boche D., Perry V.H., Gomez-Nicola D. Microglia regulate hippocampal neurogenesis during chronic neurodegeneration. Brain Behav. Immun. 2016;55:179&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907582</ArticleId><ArticleId IdType="pubmed">26541819</ArticleId></ArticleIdList></Reference><Reference><Citation>Egle A., Harris A.W., Bath M.L., O&#x2019;Reilly L., Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 2004;103:2276&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630790</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore M.R., Najafi A.R., Koike M.A., Dagher N.N., Spangenberg E.E., Rice R.A., Kitazawa M., Matusow B., Nguyen H., West B.L., Green K.N. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fendrick S.E., Xue Q.S., Streit W.J. Formation of multinucleated giant cells and microglial degeneration in rats expressing a mutant Cu/Zn superoxide dismutase gene. J.&#xa0;Neuroinflammation. 2007;4:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808448</ArticleId><ArticleId IdType="pubmed">17328801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Lim S., Hoeffel G., Low D., Huber T. Origin and differentiation of microglia. Front. Cell. Neurosci. 2013;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627983</ArticleId><ArticleId IdType="pubmed">23616747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D., Perry V.H. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist. 2015;21:169&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412879</ArticleId><ArticleId IdType="pubmed">24722525</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Nicola D., Fransen N.L., Suzzi S., Perry V.H. Regulation of microglial proliferation during chronic neurodegeneration. J.&#xa0;Neurosci. 2013;33:2481&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D., Riecken K., Fehse B., Perry V.H. In-vivo RGB marking and multicolour single-cell tracking in the adult brain. Sci. Rep. 2014;4:7520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273606</ArticleId><ArticleId IdType="pubmed">25531807</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K., Michoel T., Karavolos M.H., Clohisey S., Baillie J.K., Stevens M.P., Freeman T.C., Summers K.M., McColl B.W. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 2016;19:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto D., Chow A., Noizat C., Teo P., Beasley M.B., Leboeuf M., Becker C.D., See P., Price J., Lucas D. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38:792&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853406</ArticleId><ArticleId IdType="pubmed">23601688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayflick L. The limited in&#xa0;vitro lifetime of human diploid cell strains. Exp. Cell Res. 1965;37:614&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">14315085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., Beaudin A.E., Lum J., Low I., Forsberg E.C. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity. 2015;42:665&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545768</ArticleId><ArticleId IdType="pubmed">25902481</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson V.E., Stewart J.E., Begbie F.D., Trojanowski J.Q., Smith D.H., Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136:28&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3562078</ArticleId><ArticleId IdType="pubmed">23365092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee N., Sivalingam S., Boonstra R., Wojtowicz J.M. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J.&#xa0;Neurosci. Methods. 2002;115:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897369</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.M., Babcock A.A., Saeed H., Myhre C.L., Kassem M., Finsen B. Telomere dysfunction reduces microglial numbers without fully inducing an aging phenotype. Neurobiol. Aging. 2015;36:2164&#x2013;2175.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk Y., Homma R., Liang Y., Maslyukov A., Hermes M., Thestrup T., Griesbeck O., Ninkovic J., Cohen L.B., Garaschuk O. In&#xa0;vivo odourant response properties of migrating adult-born neurons in the mouse olfactory bulb. Nat. Commun. 2015;6:6349.</Citation><ArticleIdList><ArticleId IdType="pubmed">25695931</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D., Madhusudan A., Doehner J., Vogel P., Notter T., Imhof C., Manalastas A., Hilfiker M., Pfister S., Schwerdel C. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J.&#xa0;Neuroinflammation. 2012;9:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483167</ArticleId><ArticleId IdType="pubmed">22747753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueh H.Y., Champhekar A., Nutt S.L., Elowitz M.B., Rothenberg E.V. Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science. 2013;341:670&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913367</ArticleId><ArticleId IdType="pubmed">23868921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn H.G., Dickinson-Anson H., Gage F.H. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J.&#xa0;Neurosci. 1996;16:2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39:151&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">2089275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson L.J., Perry V.H., Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience. 1992;48:405&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignone J.L., Kukekov V., Chiang A.S., Steindler D., Enikolopov G. Neural stem and progenitor cells in nestin-GFP transgenic mice. J.&#xa0;Comp. Neurol. 2004;469:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14730584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelbronn M., Dietz K., Schluesener H.J., Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 2001;101:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307625</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikodemova M., Kimyon R.S., De I., Small A.L., Collier L.S., Watters J.J. Microglial numbers attain adult levels after undergoing a rapid decrease in cell number in the third postnatal week. J.&#xa0;Neuroimmunol. 2015;278:280&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297717</ArticleId><ArticleId IdType="pubmed">25468773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in&#xa0;vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A., Schetters S.T., Sri S., Askew K., Mancuso R., Vargas-Caballero M., Holscher C., Perry V.H., Gomez-Nicola D. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry V.H., Matyszak M.K., Fearn S. Altered antigen expression of microglia in the aged rodent CNS. Glia. 1993;7:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423063</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz J.M., Hutchinson M.R., Bilbo S.D. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression. J.&#xa0;Neurosci. 2011;31:17835&#x2013;17847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259856</ArticleId><ArticleId IdType="pubmed">22159099</ArticleId></ArticleIdList></Reference><Reference><Citation>Serbina N.V., Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 2006;7:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462739</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R., Miller O., Yovel G., Rosenzweig N., London A., Ruckh J., Kim K.W., Klein E., Kalchenko V., Bendel P. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity. 2013;38:555&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J., Ruedl C., Karjalainen K. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity. 2015;43:382&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">26287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A., Encinas J.M., Deudero J.J., Chancey J.H., Enikolopov G., Overstreet-Wadiche L.S., Tsirka S.E., Maletic-Savatic M. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7:483&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008496</ArticleId><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A., Abiega O., Shahraz A., Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front. Cell. Neurosci. 2013;7:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558702</ArticleId><ArticleId IdType="pubmed">23386811</ArticleId></ArticleIdList></Reference><Reference><Citation>Squarzoni P., Oller G., Hoeffel G., Pont-Lezica L., Rostaing P., Low D., Bessis A., Ginhoux F., Garel S. Microglia modulate wiring of the embryonic forebrain. Cell Rep. 2014;8:1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambuyzer B.R., Ponsaerts P., Nouwen E.J. Microglia: gatekeepers of central nervous system immunology. J.&#xa0;Leukoc. Biol. 2009;85:352&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M.E., Lowery R.L., Majewska A.K. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8:e1000527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970556</ArticleId><ArticleId IdType="pubmed">21072242</ArticleId></ArticleIdList></Reference><Reference><Citation>Uitdehaag J.C., S&#xfc;nnen C.M., van Doornmalen A.M., de Rouw N., Oubrie A., Azevedo R., Ziebell M., Nickbarg E., Karstens W.J., Ruygrok S. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way. J.&#xa0;Biomol. Screen. 2011;16:1007&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">21873591</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel N.H., Grathwohl S.A., Baumann F., Liebig C., Bosch A., Brawek B., Thal D.R., Charo I.F., Heppner F.L., Aguzzi A. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc. Natl. Acad. Sci. USA. 2012;109:18150&#x2013;18155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3497743</ArticleId><ArticleId IdType="pubmed">23071306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake H., Moorhouse A.J., Jinno S., Kohsaka S., Nabekura J. Resting microglia directly monitor the functional state of synapses in&#xa0;vivo and determine the fate of ischemic terminals. J.&#xa0;Neurosci. 2009;29:3974&#x2013;3980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665392</ArticleId><ArticleId IdType="pubmed">19339593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Li Y., Tang Z., Kumar A., Lee C., Zhang L., Zhu C., Klotzsche-von Ameln A., Wang B., Gao Z. Proliferative and survival effects of PUMA promote angiogenesis. Cell Rep. 2012;2:1272&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">23122957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28111080</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>533</StartPage><EndPage>541.e5</EndPage><MedlinePgn>533-541.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.12.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)30996-5</ELocationID><Abstract><AbstractText>The earliest stages of Alzheimer's disease (AD) are characterized by the formation of mature tangles in the entorhinal cortex and disorientation and confusion when navigating familiar places. The medial entorhinal cortex (MEC) contains specialized neurons called grid cells that form part of the spatial navigation system. Here we show in a transgenic mouse model expressing mutant human tau predominantly in the EC that the formation of mature tangles in old mice was associated with excitatory cell loss and deficits in grid cell function, including destabilized grid fields and reduced firing rates, as well as altered network activity. Overt tau pathology in the aged mice was accompanied by spatial memory deficits. Therefore, tau pathology initiated in the entorhinal cortex could lead to deficits in grid cell firing and underlie the deterioration of spatial cognition seen in human AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Gustavo A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emrani</LastName><ForeName>Sheina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahmani</LastName><ForeName>Eden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Helen Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussaini</LastName><ForeName>S Abid</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: sah2149@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Department of Integrative Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA. Electronic address: ked2115@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG050425</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074593</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081555</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071038" MajorTopicYN="N">Grid Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="Y">Spatial Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">cognitive deficits</Keyword><Keyword MajorTopicYN="N">electrophysiology</Keyword><Keyword MajorTopicYN="N">entorhinal cortex</Keyword><Keyword MajorTopicYN="N">grid cells</Keyword><Keyword MajorTopicYN="N">hypoactivity</Keyword><Keyword MajorTopicYN="N">neurofibrillary tangles</Keyword><Keyword MajorTopicYN="N">neuronal loss</Keyword><Keyword MajorTopicYN="N">spatial memory</Keyword><Keyword MajorTopicYN="N">tau pathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28111080</ArticleId><ArticleId IdType="mid">NIHMS843862</ArticleId><ArticleId IdType="pmc">PMC5363269</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.12.023</ArticleId><ArticleId IdType="pii">S0896-6273(16)30996-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allison SL, Fagan AM, Morris JC, Head D. Spatial Navigation in Preclinical Alzheimer's Disease. J Alzheimers Dis. 2016;52:77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091813</ArticleId><ArticleId IdType="pubmed">26967209</ArticleId></ArticleIdList></Reference><Reference><Citation>Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 2010;13:76&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797836</ArticleId><ArticleId IdType="pubmed">19915563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnevie T, Dunn B, Fyhn M, Hafting T, Derdikman D, Kubie JL, Roudi Y, Moser EI, Moser MB. Grid cells require excitatory drive from the hippocampus. Nat Neurosci. 2013;16:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334581</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth CA, Ridler T, Murray TK, Ward MA, de Groot E, Goodfellow M, Phillips KG, Randall AD, Brown JT. Electrical and Network Neuronal Properties Are Preferentially Disrupted in Dorsal, But Not Ventral, Medial Entorhinal Cortex in a Mouse Model of Tauopathy. J Neurosci. 2016;36:312&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710763</ArticleId><ArticleId IdType="pubmed">26758825</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandon MP, Bogaard AR, Libby CP, Connerney MA, Gupta K, Hasselmo ME. Reduction of theta rhythm dissociates grid cell spatial periodicity from directional tuning. Science. 2011;332:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252766</ArticleId><ArticleId IdType="pubmed">21527714</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Rawlins JN. T-maze alternation in the rodent. Nat Protoc. 2006;1:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406205</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods. 2004;134:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102499</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyhn M, Molden S, Witter MP, Moser EI, Moser MB. Spatial representation in the entorhinal cortex. Science. 2004;305:1258&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333832</ArticleId></ArticleIdList></Reference><Reference><Citation>Giocomo LM, Hussaini SA, Zheng F, Kandel ER, Moser MB, Moser EI. Grid cells use HCN1 channels for spatial scaling. Cell. 2011;147:1159&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">22100643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafting T, Fyhn M, Molden S, Moser MB, Moser EI. Microstructure of a spatial map in the entorhinal cortex. Nature. 2005;436:801&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965463</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7:e45881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Bussiere T, Gold G, Kovari E, Giannakopoulos P, Bouras C, Perl DP, Morrison JH. Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12528818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussaini SA, Kempadoo KA, Thuault SJ, Siegelbaum SA, Kandel ER. Increased size and stability of CA1 and CA3 place fields in HCN1 knockout mice. Neuron. 2011;72:643&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435580</ArticleId><ArticleId IdType="pubmed">22099465</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi KM. The entorhinal map of space. Brain Res. 2016;1637:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">26940561</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J, Kahana MJ, Ekstrom AD, Mollison MV, Fried I. A sense of direction in human entorhinal cortex. Proc Natl Acad Sci U S A. 2010;107:6487&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851993</ArticleId><ArticleId IdType="pubmed">20308554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol. 2004;115:1490&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">15203050</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, Small SA. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci. 2014;17:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kropff E, Carmichael JE, Moser MB, Moser EI. Speed cells in the medial entorhinal cortex. Nature. 2015;523:419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">26176924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz L, Schroder TN, Lee H, Montag C, Lachmann B, Sariyska R, Reuter M, Stirnberg R, Stocker T, Messing-Floeter PC, et al. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease. Science. 2015;350:430&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">26494756</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston RF, Ainge JA, Couey JJ, Canto CB, Bjerknes TL, Witter MP, Moser EI, Moser MB. Development of the spatial representation system in the rat. Science. 2010;328:1576&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lithfous S, Dufour A, Despres O. Spatial navigation in normal aging and the prodromal stage of Alzheimer's disease: insights from imaging and behavioral studies. Ageing Res Rev. 2013;12:201&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">22771718</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci. 2005;236:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961110</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, Lee VM. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>Montez T, Poil SS, Jones BF, Manshanden I, Verbunt JP, van Dijk BW, Brussaard AB, van Ooyen A, Stam CJ, Scheltens P, Linkenkaer-Hansen K. Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106:1614&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635782</ArticleId><ArticleId IdType="pubmed">19164579</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti DV, Fracassi C, Pievani M, Geroldi C, Binetti G, Zanetti O, Sosta K, Rossini PM, Frisoni GB. Increase of theta/gamma ratio is associated with memory impairment. Clin Neurophysiol. 2009;120:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">19121602</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser EI, Kropff E, Moser MB. Place cells, grid cells, and the brain's spatial representation system. Annu Rev Neurosci. 2008;31:69&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">18284371</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller R, Kubie J. The firing of hippocampal place cells predicts the future position of freely moving rats. J Neurosci. 1989;9:4101&#x2013;4110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569642</ArticleId><ArticleId IdType="pubmed">2592993</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol. 2014;127:257&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946978</ArticleId><ArticleId IdType="pubmed">24271788</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirk MC, Sosulski DL, Feierstein CE, Uchida N, Mainen ZF. A defined network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral contingencies and ketamine administration. Front Syst Neurosci. 2009;3:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802551</ArticleId><ArticleId IdType="pubmed">20057934</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitzer-Torbert N, Jackson J, Henze D, Harris K, Redish AD. Quantitative measures of cluster quality for use in extracellular recordings. Neuroscience. 2005;131:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz H, Sommer T, Peters J. The Role of the Human Entorhinal Cortex in a Representational Account of Memory. Front Hum Neurosci. 2015;9:628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653609</ArticleId><ArticleId IdType="pubmed">26635581</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwek ME, Muller R, Henseler C, Trog A, Lundt A, Wormuth C, Broich K, Ehninger D, Weiergraber M, Papazoglou A. Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease. Neural Plast. 2015;2015:781731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398951</ArticleId><ArticleId IdType="pubmed">25922768</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaggs WE, McNaughton BL, Gothard KM, Markus EJ. An information-theoretic approach to deciphering the hippocampal code. Advances in Neural Processing Systems. 1993;5:1030&#x2013;1037.</Citation></Reference><Reference><Citation>Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci. 2010;289:128&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19729174</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark E, Eichler R, Roux L, Fujisawa S, Rotstein HG, Buzsaki G. Inhibition-induced theta resonance in cortical circuits. Neuron. 2013;80:1263&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857586</ArticleId><ArticleId IdType="pubmed">24314731</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan AM, Mattson MP. Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer's disease. Neural Plast. 2010;2010:108190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039218</ArticleId><ArticleId IdType="pubmed">21331296</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M, Mayford MR. CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory. Neuron. 2006;50:309&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28114436</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of Delirium With Cognitive Decline in Late Life: A Neuropathologic Study of 3 Population-Based Cohort Studies.</ArticleTitle><Pagination><StartPage>244</StartPage><EndPage>251</EndPage><MedlinePgn>244-251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2016.3423</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Delirium is associated with accelerated cognitive decline. The pathologic substrates of this association are not yet known, that is, whether they are the same as those associated with dementia, are independent, or are interrelated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the accelerated cognitive decline observed after delirium is independent of the pathologic processes of classic dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Harmonized data from 987 individual brain donors from 3 observational cohort studies with population-based sampling (Vantaa 85+, Cambridge City Over-75s Cohort, Cognitive Function and Ageing Study) performed from January 1, 1985, through December 31, 2011, with a median follow-up of 5.2 years until death, were used in this study. Neuropathologic assessments were performed with investigators masked to clinical data. Data analysis was performed from January 1, 2012, through December 31, 2013. Clinical characteristics of brain donors were not different from the rest of the cohort. Outcome ascertainment was complete given that the participants were brain donors.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Delirium (never vs ever) and pathologic burden of neurofibrillary tangles, amyloid plaques, vascular lesions, and Lewy bodies. Effects modeled using random-effects linear regression and interactions between delirium and pathologic burden were assessed.</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Change in Mini-Mental State Examination (MMSE) scores during the 6 years before death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 987 participants (290 from Vantaa 85+, 241 from the Cambridge City Over-75s Cohort, and 456 from the Cognitive Function and Ageing Study) with neuropathologic data; mean (SD) age at death was 90 (6.4) years, including 682 women (69%). The mean MMSE score 6 years before death was 24.7 points. The 279 individuals with delirium (75% women) had worse initial scores (-2.8 points; 95% CI, -4.5 to -1.0; P&#x2009;&lt;&#x2009;.001). Cognitive decline attributable to delirium was -0.37 MMSE points per year (95% CI, -0.60 to -0.13; P&#x2009;&lt;&#x2009;.001). Decline attributable to the pathologic processes of dementia was -0.39 MMSE points per year (95% CI, -0.57 to -0.22; P&#x2009;&lt;&#x2009;.001). However, the combination of delirium and the pathologic processes of dementia resulted in the greatest decline, in which the interaction contributed an additional -0.16 MMSE points per year (95% CI, -0.29 to -0.03; P&#x2009;=&#x2009;.01). The multiplicative nature of these variables resulted in individuals with delirium and the pathologic processes of dementia declining 0.72 MMSE points per year faster than age-, sex-, and educational level-matched controls.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Delirium in the presence of the pathologic processes of dementia is associated with accelerated cognitive decline beyond that expected for delirium or the pathologic process itself. These findings suggest that additional unmeasured pathologic processes specifically relate to delirium. Age-related cognitive decline has many contributors, and these findings at the population level support a role for delirium acting independently and multiplicatively to the pathologic processes of classic dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Daniel H J</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, England2Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muniz-Terrera</LastName><ForeName>Graciela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Dementia Prevention, University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keage</LastName><ForeName>Hannah A D</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>School of Psychology, Social Work and Social Policy, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Blossom C M</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Institute of Health and Society, Newcastle University, Newcastle, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ince</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Fiona E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Institute of Health and Society, Newcastle University, Newcastle, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Biochemistry and Immunology, Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ely</LastName><ForeName>E Wesley</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee9Tennessee Valley Veterans Affairs Geriatric Research Education Clinical Center, Nashville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLullich</LastName><ForeName>Alasdair M J</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Edinburgh Delirium Research Group, University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Epidemiological Clinicopathological Studies in Europe (EClipSE) Collaborative Members</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107467/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00002/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K026992/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2017 Mar 1;74(3):212-213. doi: 10.1001/jamapsychiatry.2016.3812.</RefSource><PMID Version="1">28114516</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28114436</ArticleId><ArticleId IdType="mid">EMS78358</ArticleId><ArticleId IdType="pmc">PMC6037291</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2016.3423</ArticleId><ArticleId IdType="pii">2598162</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brayne C, Davis D. Making Alzheimer&#x2019;s and dementia research fit for populations. Lancet. 2012;380(9851):1441&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3974586</ArticleId><ArticleId IdType="pubmed">23084456</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Yu L, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013;74(3):478&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845973</ArticleId><ArticleId IdType="pubmed">23798485</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PloS Med. 2009;6(11):e1000180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765638</ArticleId><ArticleId IdType="pubmed">19901977</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">16648149</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong TG, Jones RN, Shi P, et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology. 2009;72(18):1570&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677515</ArticleId><ArticleId IdType="pubmed">19414723</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLullich AMJ, Beaglehole A, Hall RJ, Meagher DJ. Delirium and long-term cognitive impairment. Int Rev Psychiatry. 2009;21(1):30&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19219711</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DH, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain. 2012;135(pt 9):2809&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437024</ArticleId><ArticleId IdType="pubmed">22879644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med. 2014;370(2):185&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">24401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14(8):823&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4535349</ArticleId><ArticleId IdType="pubmed">26139023</ArticleId></ArticleIdList></Reference><Reference><Citation>Witlox J, Eurelings LSM, de Jonghe JFM, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA. 2010;304(4):443&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">20664045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Jones RN, Habtemariam DA, et al. Delirium and long-term cognitive trajectory among persons with dementia. Arch Intern Med. 2012;172(17):1324&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740440</ArticleId><ArticleId IdType="pubmed">23403619</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012;367(1):30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433229</ArticleId><ArticleId IdType="pubmed">22762316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25(40):9275&#x2013;9284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25(39):8843&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65(4):304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633437</ArticleId><ArticleId IdType="pubmed">18801476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119(6):737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">20309566</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK, Bogardus ST, Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10053175</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, McCracken C, Matthews FE, Medical Research Council Cognitive Function and Ageing Study (CFAS) Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS) Int J Epidemiol. 2006;35(5):1140&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980700</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming J, Zhao E, O'Connor DW, Pollitt PA, Brayne C. Cohort profile: the Cambridge City Over-75s Cohort (CC75C) Int J Epidemiol. 2007;36(1):40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510074</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, Sulkava R, Rastas S, et al. Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. Neuroepidemiology. 2006;26(2):76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16352910</ArticleId></ArticleIdList></Reference><Reference><Citation>EClipSE Collaborative Members. Cohort profile: Epidemiological Clinicopathological Studies in Europe (EClipSE) J Alzheimers Dis. 2009;18(3):659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661630</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Ince PG, Keage HA, et al. EClipSE Collaborative Members. Education, the brain and dementia: neuroprotection or compensation? Brain. 2010;133(pt 8):2210&#x2013;2216.</Citation><ArticleIdList><ArticleId IdType="pubmed">20826429</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DH, Barnes LE, Stephan BC, et al. MRC Cognitive Function and Ageing Study. The descriptive epidemiology of delirium symptoms in a large population-based cohort study: results from the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) BMC Geriatr. 2014;14:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126352</ArticleId><ArticleId IdType="pubmed">25066510</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahkonen T, Eloniemi-Sulkava U, Halonen P, et al. Delirium in the non-demented oldest old in the general population: risk factors and prognosis. Int J Geriatr Psychiatry. 2001;16(4):415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccinin AM, Muniz G, Matthews FE, Johansson B. Terminal decline from within- and between-person perspectives, accounting for incident dementia. J Gerontol B Psychol Sci Soc Sci. 2011;66(4):391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132263</ArticleId><ArticleId IdType="pubmed">21389088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beck TL, Bienias JL, Bennett DA. Terminal cognitive decline: accelerated loss of cognition in the last years of life. Psychosom Med. 2007;69(2):131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Segawa E, Hizel LP, Boyle PA, Bennett DA. Terminal dedifferentiation of cognitive abilities. Neurology. 2012;78(15):1116&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320052</ArticleId><ArticleId IdType="pubmed">22491858</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald SW, Hultsch DF, Dixon RA. Aging and the shape of cognitive change before death: terminal decline or terminal drop? J Gerontol B Psychol Sci Soc Sci. 2011;66(3):292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078759</ArticleId><ArticleId IdType="pubmed">21300703</ArticleId></ArticleIdList></Reference><Reference><Citation>Muniz-Terrera G, Matthews FE, Stephan B, Brayne C, CC75C Collaboration Group Are terminal decline and its potential indicators detectable in population studies of the oldest old? Int J Geriatr Psychiatry. 2011;26(6):584&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">21480375</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DH, Kreisel SH, Muniz Terrera G, et al. The epidemiology of delirium: challenges and opportunities for population studies. Am J Geriatr Psychiatry. 2013;21(12):1173&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837358</ArticleId><ArticleId IdType="pubmed">23907068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, MacLullich AM. At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun. 2013;28:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157329</ArticleId><ArticleId IdType="pubmed">22884900</ArticleId></ArticleIdList></Reference><Reference><Citation>Richwine AF, Parkin AO, Buchanan JB, et al. Architectural changes to CA1 pyramidal neurons in adult and aged mice after peripheral immune stimulation. Psychoneuroendocrinology. 2008;33(10):1369&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">18805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Field R, Campion S, Warren C, Murray C, Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFN&#x3b1;/&#x3b2; and IL-1&#x3b2; responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010;24(6):996&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334265</ArticleId><ArticleId IdType="pubmed">20399848</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DH, Skelly DT, Murray C, et al. Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium. Am J Geriatr Psychiatry. 2015;23(4):403&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4278840</ArticleId><ArticleId IdType="pubmed">25239680</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol. 2004;3(10):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380160</ArticleId></ArticleIdList></Reference><Reference><Citation>Treloar AJ, Macdonald AJ. Outcome of delirium, part 1: outcome of delirium diagnosed by DSM-III-R, ICD-10 and CAMDEX and derivation of the Reversible Cognitive Dysfunction Scale among acute geriatric inpatients. Int J Geriatr Psychiatry. 1997;12(6):609&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">9215940</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther ML, Morandi A, Krauskopf E, et al. VISIONS Investigation, VISualizing Icu SurvivOrs Neuroradiological Sequelae. The association between brain volumes, delirium duration, and cognitive outcomes in intensive care unit survivors: the VISIONS cohort magnetic resonance imaging study. Crit Care Med. 2012;40(7):2022&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3697780</ArticleId><ArticleId IdType="pubmed">22710202</ArticleId></ArticleIdList></Reference><Reference><Citation>Morandi A, Rogers BP, Gunther ML, et al. VISIONS Investigation, VISualizing Icu SurvivOrs Neuroradiological Sequelae. The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: the VISIONS prospective cohort magnetic resonance imaging study*. Crit Care Med. 2012;40(7):2182&#x2013;2189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378755</ArticleId><ArticleId IdType="pubmed">22584766</ArticleId></ArticleIdList></Reference><Reference><Citation>Janz DR, Abel TW, Jackson JC, Gunther ML, Heckers S, Ely EW. Brain autopsy findings in intensive care unit patients previously suffering from delirium: a pilot study. J Crit Care. 2010;25(3):538.e7&#x2013;538.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3755870</ArticleId><ArticleId IdType="pubmed">20580199</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006;354(11):1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16540616</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLullich AMJ, Hall RJ. Who understands delirium? Age Ageing. 2011;40(4):412&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">21636556</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Delirium: diagnosis, prevention and management.  [Accessed December 13, 2016];  https://www.nice.org.uk/guidance/cg103. Published July 2010.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28123067</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>374</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaag0481</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aag0481</ELocationID><Abstract><AbstractText>Accumulation of hyperphosphorylated tau directly correlates with cognitive decline in Alzheimer's disease and other primary tauopathies. One therapeutic strategy may be to reduce total tau expression. We identified antisense oligonucleotides (ASOs) that selectively decreased human tau mRNA and protein in mice expressing mutant P301S human tau. After reduction of human tau in this mouse model of tauopathy, fewer tau inclusions developed, and preexisting phosphorylated tau and Thioflavin S pathology were reversed. The resolution of tau pathology was accompanied by the prevention of hippocampal volume loss, neuronal death, and nesting deficits. In addition, mouse survival was extended, and pathological tau seeding was reversed. In nonhuman primates, tau ASOs distributed throughout the brain and spinal cord and reduced tau mRNA and protein in the brain, spinal cord, and cerebrospinal fluid. These data support investigation of a tau-lowering therapy in human patients who have tau-positive inclusions even after pathological tau deposition has begun.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoch</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Brandon B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kebodeaux</LastName><ForeName>Carey S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegener</LastName><ForeName>Amy J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Hien</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanardi</LastName><ForeName>Tom A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kordasiewicz</LastName><ForeName>Holly B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swayze</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 90201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA. miller.t@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG044719</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS074194</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> Both Ionis Pharmaceuticals and Washington University have filed for patents based on using Tau ASOs to treat CNS disorders (Patent#: PCT/US2013/031500; Date: 03/14/2013; Title: Methods for modulating Tau expression for reducing neurodegenerative syndromes; Co-inventors: S.L.D., C.F.B., T.M.M.; Patent#: 61/719,149; Date: 10/26/2012; Title: Methods for modulating Tau expression; Co-inventors: S.L.D., C.F.B, TMM). T.M.M. served on a medical advisory board for Ionis Pharmaceuticals and for Biogen Idec and is a consultant for Cytokinetics. The authors declare no other competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28123067</ArticleId><ArticleId IdType="mid">NIHMS935840</ArticleId><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aag0481</ArticleId><ArticleId IdType="pii">9/374/eaag0481</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer&#x2019;s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, K&#xf6;vari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, Hasegawa M. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One. 2012;7:e52389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527507</ArticleId><ArticleId IdType="pubmed">23285020</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21:1154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. 2016;22:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Sengupta U, Guerrero-Mu&#xf1;oz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett ADT, Dineley KT, Jackson GR, Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34:4260&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608097</ArticleId><ArticleId IdType="pubmed">24647946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Ittner A, Ke YD, G&#xf6;tz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A, Bertz J, Suh LS, Stevens CH, G&#xf6;tz J, Ittner LM. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem. 2015;132:135&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">25041093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BXW, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18:291&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging. 2013;34:1523&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596503</ArticleId><ArticleId IdType="pubmed">23332171</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hall AM, Kelinske M, Roberson ED. Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol Aging. 2014;35:2617&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171213</ArticleId><ArticleId IdType="pubmed">24908165</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33:12887&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VMY. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, Cleveland DW. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116:2290&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM, DeVos SL, Miller RL, Chun SJ, Norrbom M, Wozniak DF, Dawson HN, Bennett CF, Rigo F, Miller TM. Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron. 2016;90:941&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="pubmed">27210553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110:E4530&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Heusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, Maragakis N, Tienari PJ, Petrucelli L, Traynor BJ, Wang J, Rigo F, Bennett CF, Blackshaw S, Sattler R, Rothstein JD. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer&#x2019;s disease. Arch Pharm Res. 2010;33:1539&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052932</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. 2009;4:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784760</ArticleId><ArticleId IdType="pubmed">19917131</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul A, Sprenger F, Bayer TA, Wirths O. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34:2564&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23747045</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013;70:304&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014;111:E4376&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL, Holmes BB, Diamond MI. Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry. J Vis Exp. 2015:e53205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692784</ArticleId><ArticleId IdType="pubmed">26710240</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova NN, Yang L, Starkov AA, Beal F. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 2011;25:4063&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205832</ArticleId><ArticleId IdType="pubmed">21825035</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Iba M, Inoue H, Higuchi M, Takao K, Tsukita K, Karatsu Y, Iwamoto Y, Miyakawa T, Suhara T, Trojanowski JQ, Lee VMY, Takahashi R. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6:e21050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Lista V, Gim&#xe9;nez-Llort L. Impairment of nesting behaviour in 3xTg-AD mice. Behav Brain Res. 2013;247:153&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23523959</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgr&#xe4;fe K, Mandelkow EM, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2015;11:41&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25511894</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, de Calignon A, Su&#xe1;rez-Calvet M, Sanchez L, Kay KR, Nicholls SB, Roe AD, Pitstick R, Carlson GA, G&#xf3;mez-Isla T, Spires-Jones TL, Hyman BT. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer&#x2019;s disease. J Neurosci. 2013;33:13300&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742920</ArticleId><ArticleId IdType="pubmed">23946388</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, Brandner S, Jefferys JGR, Collinge J. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53:325&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270731</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang L-S, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu C-E, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, M&#xfc;ller U, Schellenberg DG PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, H&#xf6;glinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH. AL-108-231 Investigators, Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129545</ArticleId><ArticleId IdType="pubmed">24873720</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Boxer AL. Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. Nat Rev Neurol. 2016;12:74&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221610</ArticleId><ArticleId IdType="pubmed">26794651</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Ghetti B, Spillantini MG. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281593</ArticleId><ArticleId IdType="pubmed">22355793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 2012;124:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608475</ArticleId><ArticleId IdType="pubmed">22802095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JSK, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM-Y, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC, Goate AM GERAD Consortium, Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI), Alzheimer Disease Genetic Consortium (ADGC) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78:256&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK, Harold D, Williams J, Owen MJ, O&#x2019;Donovan MC, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Schellenberg GD, Heutink P, Singleton AB, Brice A, Wood NW, Hardy J, Martinez M, Choi SH, DeStefano A, Ikram MA, Bis JC, Smith A, Fitzpatrick AL, Launer L, van Duijn C, Seshadri S, Ulstein ID, Aarsland D, Fladby T, Djurovic S, Hyman BT, Snaedal J, Stefansson H, Stefansson K, Gasser T, Andreassen OA, Dale AM. ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators, Genetic overlap between Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease at the MAPT locus. Mol Psychiatry. 2015;20:1588&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="pubmed">25687773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang YW, St George-Hyslop P, Masliah E, Fraser P, Xu H. Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis. Neuron. 2015;87:963&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575284</ArticleId><ArticleId IdType="pubmed">26335643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, Yao Y, Lin YM, Driver JA, Sun Y, Wei S, Luo ML, Albayram O, Huang P, Rotenberg A, Ryo A, Goldstein LE, Pascual-Leone A, McKee AC, Meehan W, Zhou XZ, Lu KP. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523:431&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718588</ArticleId><ArticleId IdType="pubmed">26176913</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer&#x2019;s disease. J Neurosci. 2011;31:700&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K, Ando K, Laporte V, Dedecker R, Suain V, Authelet M, H&#xe9;raud C, Pierrot N, Yilmaz Z, Octave JN, Brion JP. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am J Pathol. 2012;181:1928&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-&#x3b2;. Nat Neurosci. 2013;16:613&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hummel A, Bi M, Ippati S, van der Hoven J, Volkerling A, Lee WS, Tan DCS, Bongers A, Ittner A, Ke YD, Ittner LM. No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PLoS One. 2016;11:e0163236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063411</ArticleId><ArticleId IdType="pubmed">27736877</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140425</ArticleId><ArticleId IdType="pubmed">21368223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013;10:486&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701770</ArticleId><ArticleId IdType="pubmed">23686823</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem. 1999;274:1715&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9880552</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller TM. Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp. 2013:e50326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Maury EA, Kirk MJ, Saqran L, Roe A, DeVos SL, Nicholls S, Fan Z, Takeda S, Cagsal-Getkin O, William CM, Spires-Jones TL, Pitstick R, Carlson GA, Pooler AM, Hyman BT. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 2015;34:3028&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, Costantino I, Frosch MP, M&#xfc;ller DJ, Irimia D, Hyman BT. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat Commun. 2015;6:8490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Commins C, DeVos SL, Nobuhara CK, Wegmann S, Roe AD, Costantino I, Fan Z, Nicholls SB, Sherman AE, Trisini Lipsanopoulos AT, Scherzer CR, Carlson GA, Pitstick R, Peskind ER, Raskind MA, Li G, Montine TJ, Frosch MP, Hyman BT. Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer&#x2019;s disease mouse model and human patients. Ann Neurol. 2016 doi: 10.1002/ana.24716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24716</ArticleId><ArticleId IdType="pmc">PMC5016222</ArticleId><ArticleId IdType="pubmed">27351289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon R. Assessing burrowing, nest construction, and hoarding in mice. J Vis Exp. 2012:e2607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369766</ArticleId><ArticleId IdType="pubmed">22258546</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28115709</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Gleevec shifts APP processing from a &#x3b2;-cleavage to a nonamyloidogenic cleavage.</ArticleTitle><Pagination><StartPage>1389</StartPage><EndPage>1394</EndPage><MedlinePgn>1389-1394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1620963114</ELocationID><Abstract><AbstractText>Neurotoxic amyloid-&#x3b2; peptides (A&#x3b2;) are major drivers of Alzheimer's disease (AD) and are formed by sequential cleavage of the amyloid precursor protein (APP) by &#x3b2;-secretase (BACE) and &#x3b3;-secretase. Our previous study showed that the anticancer drug Gleevec lowers A&#x3b2; levels through indirect inhibition of &#x3b3;-secretase activity. Here we report that Gleevec also achieves its A&#x3b2;-lowering effects through an additional cellular mechanism. It renders APP less susceptible to proteolysis by BACE without inhibiting BACE enzymatic activity or the processing of other BACE substrates. This effect closely mimics the phenotype of APP A673T, a recently discovered mutation that protects carriers against AD and age-related cognitive decline. In addition, Gleevec induces formation of a specific set of APP C-terminal fragments, also observed in cells expressing the APP protective mutation and in cells exposed to a conventional BACE inhibitor. These Gleevec phenotypes require an intracellular acidic pH and are independent of tyrosine kinase inhibition, given that a related compound lacking tyrosine kinase inhibitory activity, DV2-103, exerts similar effects on APP metabolism. In addition, DV2-103 accumulates at high concentrations in the rodent brain, where it rapidly lowers A&#x3b2; levels. This study suggests that long-term treatment with drugs that indirectly modulate BACE processing of APP but spare other BACE substrates and achieve therapeutic concentrations in the brain might be effective in preventing or delaying the onset of AD and could be safer than nonselective BACE inhibitor drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Netzer</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065 billnetzer@gmail.com greengard@rockefeller.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettayeb</LastName><ForeName>Karima</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Subhash C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flajolet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4437-0893</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065 billnetzer@gmail.com greengard@rockefeller.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Gleevec</Keyword><Keyword MajorTopicYN="N">nonamyloidogenic</Keyword><Keyword MajorTopicYN="N">&#x3b2;-cleavage</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28115709</ArticleId><ArticleId IdType="pmc">PMC5307477</ArticleId><ArticleId IdType="doi">10.1073/pnas.1620963114</ArticleId><ArticleId IdType="pii">1620963114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, Tanzi RE. Thirty years of Alzheimer&#x2019;s disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci. 2008;9(10):768&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Tanzi RE. Monogenic determinants of familial Alzheimer&#x2019;s disease: Presenilin-1 mutations. Cell Mol Life Sci. 1998;54(9):902&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11147232</ArticleId><ArticleId IdType="pubmed">9791532</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17(5):1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10(16):1665&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessel MM, Bernstein S, Kemper M, Teplow DB, Bowers MT. Familial Alzheimer&#x2019;s disease mutations differentially alter amyloid &#x3b2;-protein oligomerization. ACS Chem Neurosci. 2012;3(11):909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503339</ArticleId><ArticleId IdType="pubmed">23173071</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney JA, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014;289(45):30990&#x2013;31000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223305</ArticleId><ArticleId IdType="pubmed">25253696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One. 2009;4(12):e8477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Filser S, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry. 2015;77(8):729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer WJ, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA. 2003;100(21):12444&#x2013;12449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218777</ArticleId><ArticleId IdType="pubmed">14523244</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer&#x2019;s disease. Nature. 2010;467(7311):95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936959</ArticleId><ArticleId IdType="pubmed">20811458</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer&#x2019;s disease increases beta-protein production. Nature. 1992;360(6405):672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network. J Biol Chem. 2000;275(4):2568&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, et al. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature. 1993;361(6409):260&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">7678698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the &#x3b2; secretase BACE1 for Alzheimer&#x2019;s disease therapy. Lancet Neurol. 2014;13(3):319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeseth AS, et al. Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem. 2005;280(18):17792&#x2013;17797.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737955</ArticleId></ArticleIdList></Reference><Reference><Citation>Descamps O, et al. A&#x3b2;PP-selective BACE inhibitors (ASBI): Novel class of therapeutic agents for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;37(2):343&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971881</ArticleId><ArticleId IdType="pubmed">23948888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, et al. A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Anal Biochem. 2008;375(1):18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291073</ArticleId><ArticleId IdType="pubmed">18194660</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003;304(3):1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">12604685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff NC, Richardson JA, Egorin M, Ilaria RL., Jr The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood. 2003;101(12):5010&#x2013;5013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12595307</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama N, Sato N, O&#x2019;Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119(1):106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358909</ArticleId></ArticleIdList></Reference><Reference><Citation>Leis JF, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib (STI-571) Leuk Lymphoma. 2004;45(4):695&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">15160941</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger H, et al. Lysosomal sequestration determines intracellular imatinib levels. Mol Pharmacol. 2015;88(3):477&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">26108972</ArticleId></ArticleIdList></Reference><Reference><Citation>Puissant A, Dufies M, Raynaud S, Cassuto JP, Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia. 2010;24(5):1099&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">20376083</ArticleId></ArticleIdList></Reference><Reference><Citation>Marceau F, Bawolak MT, Bouthillier J, Morissette G. Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: A model for the distribution of lipophilic cationic drugs to autophagic vacuoles. Drug Metab Dispos. 2009;37(12):2271&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pubmed">19773536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazmi F, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells) Drug Metab Dispos. 2013;41(4):897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608459</ArticleId><ArticleId IdType="pubmed">23378628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D, et al. Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem. 2014;6(7):614&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205760</ArticleId><ArticleId IdType="pubmed">24950332</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Adhami BH, Thornhill J, Akhkha A, Doenhoff MJ, Kusel JR. The properties of acidic compartments in developing schistosomula of Schistosoma mansoni. Parasitology. 2003;127(Pt 3):253&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12964828</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707&#x2013;17712.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild-Bode C, et al. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem. 1997;272(26):16085&#x2013;16088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195901</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, et al. &#x3b7;-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526(7573):443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Welzel AT, et al. Secreted amyloid &#x3b2;-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry. 2014;53(24):3908&#x2013;3921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070750</ArticleId><ArticleId IdType="pubmed">24840308</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xed;nguez JL, et al. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. Biochemistry. 2010;49(34):7255&#x2013;7263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687525</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien J, et al. The metalloprotease meprin &#x3b2; generates amino terminal-truncated amyloid &#x3b2; peptide species. J Biol Chem. 2012;287(40):33304&#x2013;33313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460434</ArticleId><ArticleId IdType="pubmed">22879596</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, et al. Involvement of caspases in proteolytic cleavage of Alzheimer&#x2019;s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999;97(3):395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader-Fischer G, Paganetti PA. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 1996;716(1-2):91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738224</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins WK, et al. Parallel damage in mitochondrial and lysosomal compartments promotes efficient cell death with autophagy: The case of the pentacyclic triterpenoids. Sci Rep. 2015;5:12425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515638</ArticleId><ArticleId IdType="pubmed">26213355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 2011;25(6):1934&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101026</ArticleId><ArticleId IdType="pubmed">21368103</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem. 2005;280(37):32499&#x2013;32504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: Implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012;9(5):1384&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348458</ArticleId><ArticleId IdType="pubmed">22449202</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan R, Kong AC, Axcell E, Krise JP. Amine-containing molecules and the induction of an expanded lysosomal volume phenotype: A structure-activity relationship study. J Pharm Sci. 2014;103(5):1572&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647827</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan R, Kong A, Krise JP. Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distribution-based drug-drug interactions involving lysosomes. J Pharm Sci. 2013;102(11):4173&#x2013;4180.</Citation><ArticleIdList><ArticleId IdType="pubmed">23970383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28094793</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2017</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Caloric restriction improves health and survival of rhesus monkeys.</ArticleTitle><Pagination><StartPage>14063</StartPage><MedlinePgn>14063</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms14063</ELocationID><Abstract><AbstractText>Caloric restriction (CR) without malnutrition extends lifespan and delays the onset of age-related disorders in most species but its impact in nonhuman primates has been controversial. In the late 1980s two parallel studies were initiated to determine the effect of CR in rhesus monkeys. The University of Wisconsin study reported a significant positive impact of CR on survival, but the National Institute on Aging study detected no significant survival effect. Here we present a direct comparison of longitudinal data from both studies including survival, bodyweight, food intake, fasting glucose levels and age-related morbidity. We describe differences in study design that could contribute to differences in outcomes, and we report species specificity in the impact of CR in terms of optimal onset and diet. Taken together these data confirm that health benefits of CR are conserved in monkeys and suggest that CR mechanisms are likely translatable to human health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattison</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Translational Gerontology Branch, National Institute on Aging, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colman</LastName><ForeName>Ricki J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>T Mark</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Alabama, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Birmingham/Atlanta Veterans Administration Hospital, Birmingham, Alabama 35233, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Alabama, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemnitz</LastName><ForeName>Joseph W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>George S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>GeroScience, Pylesville, Maryland 21323, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingram</LastName><ForeName>Donald K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weindruch</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Cabo</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3354-2442</Identifier><AffiliationInfo><Affiliation>Translational Gerontology Branch, National Institute on Aging, Baltimore, Maryland 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Rozalyn M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P51 RR000167</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037000</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040178</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG047358</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG011915</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056336</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 OD011106</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031204" MajorTopicYN="Y">Caloric Restriction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002149" MajorTopicYN="N">Energy Intake</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>R.W. is a member of the board of LifeGen Technologies, a company focused on nutritional genomics. G.S.R. is Chief Executive Officer of GeroScience, Inc. and Vice President of Prolongevity Technologies. D.K.I. serves as Chief Scientific Officer for GeroScience, Inc., and Prolongevity Technologies, Inc. D.B.A. serves on the board of IKEA and has received consulting fees from multiple government, not for profit, and for profit organizations with interests in obesity and nutrition. None of these activities benefit directly from this research and no competing financial interests are declared. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28094793</ArticleId><ArticleId IdType="pmc">PMC5247583</ArticleId><ArticleId IdType="doi">10.1038/ncomms14063</ArticleId><ArticleId IdType="pii">ncomms14063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gibbs R. A. et al.. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222&#x2013;234 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17431167</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimin A. V. et al.. A new rhesus macaque assembly and annotation for next-generation sequencing analyses. Biol. Direct 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214606</ArticleId><ArticleId IdType="pubmed">25319552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden D. M. &amp; Williams D. D. Aging. Adv. Vet. Sci. Comp. Med. 28, 305&#x2013;341 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6395674</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno H. Age-related pathology and biosenescent markers in captive rhesus macaques. Age (Omaha) 20, 1&#x2013;13 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3456080</ArticleId><ArticleId IdType="pubmed">23604287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson J. C., Baum S. T., Frye D. M., Roecker E. B. &amp; Kemnitz J. W. Age and sex differences in body size and composition during rhesus monkey adulthood. Aging 8, 197&#x2013;204 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8862195</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya J. D. et al.. Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging. Neurobiol. Aging 36, 1903&#x2013;1913 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25726361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey J. J., Laatsch J. L. &amp; Kemnitz J. W. Age and gender differences in body composition, energy expenditure, and glucoregulation of adult rhesus monkeys. J. Med. Primatol. 29, 11&#x2013;19 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10870670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngwenya L. B., Heyworth N. C., Shwe Y., Moore T. L. &amp; Rosene D. L. Age-related changes in dentate gyrus cell numbers, neurogenesis, and associations with cognitive impairments in the rhesus monkey. Front. Syst. Neurosci. 9, 102 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500920</ArticleId><ArticleId IdType="pubmed">26236203</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoro E. J., Yu B. P. &amp; Bertrand H. A. Action of food restriction in delaying the aging process. Proc. Natl Acad. Sci. USA 79, 4239&#x2013;4241 (1982).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346614</ArticleId><ArticleId IdType="pubmed">6955798</ArticleId></ArticleIdList></Reference><Reference><Citation>Weindruch R., Walford R. L., Fligiel S. &amp; Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J. Nutr. 116, 641&#x2013;654 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3958810</ArticleId></ArticleIdList></Reference><Reference><Citation>Weindruch R. H. &amp; Walford R. L. The retardation of aging and disease by dietary restriction Charles C Thomas (1988).</Citation></Reference><Reference><Citation>Masoro E. J. Caloric restriction. Aging 10, 173&#x2013;174 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9666230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gems D. &amp; Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. Annu. rev. physiol. 75, 621&#x2013;644 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23190075</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarente L. Mitochondria&#x2014;a nexus for aging, calorie restriction, and sirtuins? Cell 132, 171&#x2013;176 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680180</ArticleId><ArticleId IdType="pubmed">18243090</ArticleId></ArticleIdList></Reference><Reference><Citation>Houthoofd K. &amp; Vanfleteren J. R. Public and private mechanisms of life extension in Caenorhabditis elegans. Mol. Genet. Genomics 277, 601&#x2013;617 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17364197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy B. K., Steffen K. K. &amp; Kaeberlein M. Ruminations on dietary restriction and aging. Cell. Mol. Life Sci. 64, 1323&#x2013;1328 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136230</ArticleId><ArticleId IdType="pubmed">17396225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair W. &amp; Dillin A. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 77, 727&#x2013;754 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18373439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodkin N. L., Alexander T. M., Ortmeyer H. K., Johnson E. &amp; Hansen B. C. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 58, 212&#x2013;219 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12634286</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman R. J. et al.. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325, 201&#x2013;204 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812811</ArticleId><ArticleId IdType="pubmed">19590001</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman R. J. et al.. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 5, 3557 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988801</ArticleId><ArticleId IdType="pubmed">24691430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattison J. A. et al.. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489, 318&#x2013;321 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832985</ArticleId><ArticleId IdType="pubmed">22932268</ArticleId></ArticleIdList></Reference><Reference><Citation>Weindruch R. &amp; Walford R. L. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science 215, 1415&#x2013;1418 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7063854</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council, Committee on Animal Nutrition, Agricultural Board. Nutrient requirements of nonhuman primates National Academy of Sciences (1978).</Citation></Reference><Reference><Citation>Lane M. A. et al.. Dietary restriction in nonhuman primates: progress report on the NIA study. Ann. NY Acad. Sci. 673, 36&#x2013;45 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1485732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemnitz J. W. et al.. Dietary restriction of adult male rhesus monkeys: design, methodology, and preliminary findings from the first year of study. J. Gerontol. 48, B17&#x2013;B26 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8418134</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke M. R. &amp; O'Neil J. A. Morphometric comparison of Chinese-origin and Indian-derived rhesus monkeys (Macaca mulatta). Am. J. Primatol. 47, 335&#x2013;346 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10206210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanthaswamy S. et al.. Development and validation of a SNP-based assay for inferring the genetic ancestry of rhesus macaques (Macaca mulatta). Am. J. Primatol. 76, 1105&#x2013;1113 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319213</ArticleId><ArticleId IdType="pubmed">24953496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhesus Macaque Genome S. et al.. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222&#x2013;234 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17431167</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman R. J. &amp; Anderson R. M. Nonhuman primate calorie restriction. Antioxid. Redox Signal. 14, 229&#x2013;239 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000242</ArticleId><ArticleId IdType="pubmed">20698791</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison P. D. Survival Analysis Using SAS: A Practical Guide 2nd edn SAS Institute (2010).</Citation></Reference><Reference><Citation>Hadfield R. M. et al.. Risk factors for endometriosis in the rhesus monkey (Macaca mulatta): a case-control study. Hum. Reprod. Update 3, 109&#x2013;115 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9286735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattison J. A., Ottinger M. A., Powell D., Longo D. L. &amp; Ingram D. K. Endometriosis: clinical monitoring and treatment procedures in Rhesus Monkeys. J. Med. Primatol. 36, 391&#x2013;398 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17976046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemnitz J. W. Calorie restriction and aging in nonhuman primates. ILAR j. 52, 66&#x2013;77 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278796</ArticleId><ArticleId IdType="pubmed">21411859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkland J. L. &amp; Peterson C. Healthspan, translation, and new outcomes for animal studies of aging. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 64, 209&#x2013;212 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655038</ArticleId><ArticleId IdType="pubmed">19196900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen B. C. &amp; Bodkin N. L. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 29, 713&#x2013;719 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3542671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez N. A. et al.. Clinical and histopathological evaluation of 13 cases of adenocarcinoma in aged rhesus macaques (Macaca mulatta). J. Med. Primatol. 31, 74&#x2013;83 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12110050</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno H. et al.. Colon cancer in aged captive rhesus monkeys (Macaca mulatta). Am. J. Primatol. 44, 19&#x2013;27 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9444320</ArticleId></ArticleIdList></Reference><Reference><Citation>Laakso M. &amp; Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10, 293&#x2013;302 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24663222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin. Therapeut. 26, 889&#x2013;901 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15262459</ArticleId></ArticleIdList></Reference><Reference><Citation>Polewski M. A. et al.. Plasma diacylglycerol composition is a biomarker of metabolic syndrome onset in rhesus monkeys. J. Lipid Res. 56, 1461&#x2013;1470 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513987</ArticleId><ArticleId IdType="pubmed">26063458</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove K. L., Fried S. K., Greenberg A. S., Xiao X. Q. &amp; Clegg D. J. A microarray analysis of sexual dimorphism of adipose tissues in high-fat-diet-induced obese mice. Int. J. Obes. (Lond) 34, 989&#x2013;1000 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667412</ArticleId><ArticleId IdType="pubmed">20157318</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana L. et al.. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab. 293, E197&#x2013;E202 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17389710</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilbronn L. K. et al.. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295, 1539&#x2013;1548 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692623</ArticleId><ArticleId IdType="pubmed">16595757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefevre M. et al.. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis 203, 206&#x2013;213 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692631</ArticleId><ArticleId IdType="pubmed">18602635</ArticleId></ArticleIdList></Reference><Reference><Citation>Racette S. B. et al.. One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 61, 943&#x2013;950 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376245</ArticleId><ArticleId IdType="pubmed">16960025</ArticleId></ArticleIdList></Reference><Reference><Citation>Redman L. M. et al.. Effect of calorie restriction with or without exercise on body composition and fat distribution. J. Clin. Endocrinol. Metab. 92, 865&#x2013;872 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692618</ArticleId><ArticleId IdType="pubmed">17200169</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss E. P. et al.. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am. J. Clin. Nutr. 84, 1033&#x2013;1042 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941677</ArticleId><ArticleId IdType="pubmed">17093155</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards I. J. et al.. Caloric restriction lowers plasma lipoprotein (a) in male but not female rhesus monkeys. Exp. Gerontol. 36, 1413&#x2013;1418 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11602214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gresl T. A. et al.. Dietary restriction and glucose regulation in aging rhesus monkeys: a follow-up report at 8.5 yr. Am. J. Physiol. Endocrinol. Metab. 281, E757&#x2013;E765 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11551852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezzi S. et al.. Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. Exp. Gerontol. 44, 356&#x2013;362 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822382</ArticleId><ArticleId IdType="pubmed">19264119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y. et al.. Long-term calorie restriction decreases metabolic cost of movement and prevents decrease of physical activity during aging in rhesus monkeys. Exp. Gerontol. 48, 1226&#x2013;1235 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882119</ArticleId><ArticleId IdType="pubmed">23954367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy B. K. et al.. Geroscience: linking aging to chronic disease. Cell 159, 709&#x2013;713 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852871</ArticleId><ArticleId IdType="pubmed">25417146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Otin C., Blasco M. A., Partridge L., Serrano M. &amp; Kroemer G. The hallmarks of aging. Cell 153, 1194&#x2013;1217 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville D. J. Multiple comparison procedures&#x2014;the practical solution. Am. Stat. 44, 174&#x2013;180 (1990).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28128235</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>541</Volume><Issue>7638</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 gene and processing of APP.</ArticleTitle><Pagination><StartPage>E1</StartPage><EndPage>E2</EndPage><MedlinePgn>E1-E2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature21030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fazzari</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KULeuven Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND), University Hospitals Leuven, and University of Leuven, O&amp;N4 Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horre</LastName><ForeName>Katrien</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KULeuven Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND), University Hospitals Leuven, and University of Leuven, O&amp;N4 Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arranz</LastName><ForeName>Amaia M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KULeuven Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND), University Hospitals Leuven, and University of Leuven, O&amp;N4 Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Carlo Sala</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KULeuven Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND), University Hospitals Leuven, and University of Leuven, O&amp;N4 Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Japan Science and Technology Agency, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KULeuven Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND), University Hospitals Leuven, and University of Leuven, O&amp;N4 Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17116</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28128235</ArticleId><ArticleId IdType="doi">10.1038/nature21030</ArticleId><ArticleId IdType="pii">nature21030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Neurosci. 2014 May;17(5):661-3</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33341</Citation><ArticleIdList><ArticleId IdType="pubmed">22428023</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 May 25;31(21):7817-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 Jan;16(1):186-99</Citation><ArticleIdList><ArticleId IdType="pubmed">8613784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Nov 26;285(48):37415-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Jun 15;474(7351):337-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21677750</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2013 Aug;19(8):983-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jan 23;505(7484):550-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28131823</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2405-4712</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell systems</Title><ISOAbbreviation>Cell Syst</ISOAbbreviation></Journal><ArticleTitle>In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons.</ArticleTitle><Pagination><StartPage>242</StartPage><EndPage>250.e4</EndPage><MedlinePgn>242-250.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cels.2017.01.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2405-4712(17)30002-9</ELocationID><Abstract><AbstractText>Synucleinopathies, including Parkinson's disease (PD), are associated with the misfolding and mistrafficking of alpha-synuclein (&#x3b1;-syn). Here, using an ascorbate peroxidase (APEX)-based labeling method combined with mass spectrometry, we defined a network of proteins in the immediate vicinity of &#x3b1;-syn in living neurons to shed light on &#x3b1;-syn function. This approach identified 225 proteins, including synaptic proteins, proteins involved in endocytic vesicle trafficking, the retromer complex, phosphatases and mRNA binding proteins. Many were in complexes with &#x3b1;-syn, and some were encoded by genes known to be risk factors for PD and other neurodegenerative diseases. Endocytic trafficking and mRNA translation proteins within this spatial &#x3b1;-syn map overlapped with genetic modifiers of &#x3b1;-syn toxicity, developed in an accompanying study (Khurana et&#xa0;al., this issue of Cell Systems). Our data suggest that perturbation of these particular pathways is directly related to the spatial localization of &#x3b1;-syn within the&#xa0;cell. These approaches provide new avenues to systematically examine protein function and pathology in living cells.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chee Yeun</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA. Electronic address: cychung@yumanity.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Ann Romney Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: vkhurana@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahni</LastName><ForeName>Nidhi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Ken H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auluck</LastName><ForeName>Pavan K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baru</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeshi</LastName><ForeName>Namrata D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freyzon</LastName><ForeName>Yelena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Alice Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM089903</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG001715</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG001715</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA184898</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG038546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM081871</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG001715</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Syst</MedlineTA><NlmUniqueID>101656080</NlmUniqueID><ISSNLinking>2405-4712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.11.1.11</RegistryNumber><NameOfSubstance UI="D060387">Ascorbate Peroxidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Jun;32(6):840. doi: 10.1002/mds.26985.</RefSource><PMID Version="1">28370358</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060387" MajorTopicYN="N">Ascorbate Peroxidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Potential Conflicts of Interest:</b> V.K., C.Y.C., and S.L. are scientific co-founders of Yumanity Therapeutics, a company focused on developing neurodegenerative disease therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28131823</ArticleId><ArticleId IdType="mid">NIHMS872631</ArticleId><ArticleId IdType="pmc">PMC5578869</ArticleId><ArticleId IdType="doi">10.1016/j.cels.2017.01.002</ArticleId><ArticleId IdType="pii">S2405-4712(17)30002-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Auluck PK, Caraveo G, Lindquist S. &#x3b1;-Synuclein: membrane interactions and toxicity in Parkinson&#x2019;s disease. Annual review of cell and developmental biology. 2010;26:211&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500090</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329(5999):1663&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, S&#xfc;dhof TC. &#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(40):E4274&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="pubmed">25246573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartier AE, et al. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy. P. J. Kahle, ed. PLoS ONE. 2012;7(4):e34713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326048</ArticleId><ArticleId IdType="pubmed">22514658</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123(3):383&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi P, et al. Co-association of parkin and alpha-synuclein. Neuroreport. 2001;12(13):2839&#x2013;2843.</Citation><ArticleIdList><ArticleId IdType="pubmed">11588587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, et al. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(52):22474&#x2013;22479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791667</ArticleId><ArticleId IdType="pubmed">20007772</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Edvardson S, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. C. Wider, ed. PLoS ONE. 2012;7(5):e36458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341348</ArticleId><ArticleId IdType="pubmed">22563501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm-Reed S, et al. Parkin-dependent degradation of the F-box protein Fbw7&#x3b2; promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol Cell Biol. 2013;33(18):3627&#x2013;3643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753862</ArticleId><ArticleId IdType="pubmed">23858059</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelender S, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nature genetics. 1999;22(1):110&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD, et al. The Parkinson&#x2019;s disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(1):145&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, et al. 100 years of Lewy pathology. Nature reviews. Neurology. 2013;9(1):13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten-Harrison B, et al. &#x3b1;&#x3b2;&#x3b3;-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(45):19573&#x2013;19578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984188</ArticleId><ArticleId IdType="pubmed">20974939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung V, et al. Proteomic mapping of the human mitochondrial intermembrane space in live cells via ratiometric APEX tagging. Molecular cell. 2014;55(2):332&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743503</ArticleId><ArticleId IdType="pubmed">25002142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunn BHM, et al. Impaired intracellular trafficking defines early Parkinson&#x2019;s disease. Trends in Neurosciences. 2015;38(3):178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740565</ArticleId><ArticleId IdType="pubmed">25639775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivatt RM, et al. Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus SREBF1 as a regulator of mitophagy. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(23):8494&#x2013;8499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060696</ArticleId><ArticleId IdType="pubmed">24912190</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PH, et al. alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274(36):25481&#x2013;25489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human molecular genetics. 2006;15(20):3012&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959795</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;ro&#x11f;lu &#xc7;, et al. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism &amp; related disorders. 2013;19(3):320&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">23211418</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs CE, et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Human mutation. 2013;34(9):1200&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790461</ArticleId><ArticleId IdType="pubmed">23804563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam SS, et al. Directed evolution of APEX2 for electron microscopy and proximity labeling. Nature methods. 2015;12(1):51&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296904</ArticleId><ArticleId IdType="pubmed">25419960</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, et al. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(12):4635&#x2013;4640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2651203</ArticleId><ArticleId IdType="pubmed">19261853</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1988;8(8):2804&#x2013;2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569395</ArticleId><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland MA, et al. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Molecular &amp; cellular proteomics: MCP. 2008;7(11):2123&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577212</ArticleId><ArticleId IdType="pubmed">18614564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno N, et al. Remodeling of lipid vesicles into cylindrical micelles by &#x3b1;-synuclein in an extended &#x3b1;-helical conformation. J Biol Chem. 2012;287(35):29301&#x2013;29311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436199</ArticleId><ArticleId IdType="pubmed">22767608</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-Kuller U, et al. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res. 2015;43(3):1577&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4330381</ArticleId><ArticleId IdType="pubmed">25605798</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakai M, et al. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson&#x2019;s disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007;358(1):104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17475220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nature genetics. 2014:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgiati S, et al. DNAJC6 mutations associated with early-onset Parkinson&#x2019;s disease. Annals of neurology 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26528954</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgiati S, et al. PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. Neurogenetics. 2014;15(3):183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">24816432</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri M, et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Human mutation. 2013;34(9):1208&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804577</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee HW, et al. Proteomic Mapping of Mitochondria in Living Cells via Spatially Restricted Enzymatic Tagging. Science 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916822</ArticleId><ArticleId IdType="pubmed">23371551</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30(24):8083&#x2013;8095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901533</ArticleId><ArticleId IdType="pubmed">20554859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, et al. CSP&#x3b1; knockout causes neurodegeneration by impairing SNAP-25 function. Embo J. 2012;31(4):829&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280561</ArticleId><ArticleId IdType="pubmed">22187053</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, De Jager PL, Feany MB. Parkinson&#x2019;s Disease: Genetics and Pathogenesis. Annual review of pathology 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">21034221</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagljar I, et al. A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proc Natl Acad Sci U S A. 1998;95(9):5187&#x2013;5192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20236</ArticleId><ArticleId IdType="pubmed">9560251</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP. Multisystem proteinopathy: Intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85(8):658&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">26208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Udeshi ND, et al. Large-scale identification of ubiquitination sites by mass spectrometry. Nature Protocols. 2013;8(10):1950&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725055</ArticleId><ArticleId IdType="pubmed">24051958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas KJ, et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014;34(28):9364&#x2013;9376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087213</ArticleId><ArticleId IdType="pubmed">25009269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda T, et al. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson&#x2019;s disease. J Neurochem. 2009;108(4):932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">19141079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. American journal of human genetics. 2011;89(1):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28131822</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2405-4712</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell systems</Title><ISOAbbreviation>Cell Syst</ISOAbbreviation></Journal><ArticleTitle>Genome-Scale Networks Link Neurodegenerative Disease Genes to &#x3b1;-Synuclein through Specific Molecular Pathways.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>170.e14</EndPage><MedlinePgn>157-170.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cels.2016.12.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2405-4712(16)30445-8</ELocationID><Abstract><AbstractText>Numerous genes and molecular pathways are implicated in neurodegenerative proteinopathies, but their inter-relationships are poorly understood. We systematically mapped molecular pathways underlying the toxicity of alpha-synuclein (&#x3b1;-syn), a protein central to Parkinson's disease. Genome-wide screens in yeast identified 332 genes that impact &#x3b1;-syn toxicity. To "humanize" this molecular network, we developed a computational method, TransposeNet. This integrates a Steiner prize-collecting approach with homology assignment through sequence, structure, and interaction topology. TransposeNet linked &#x3b1;-syn to multiple parkinsonism genes and druggable targets through perturbed protein trafficking and ER quality control as well as mRNA metabolism and translation. A calcium signaling hub linked these processes to perturbed mitochondrial quality control and function, metal ion transport, transcriptional regulation, and signal transduction. Parkinsonism gene interaction profiles spatially opposed in the network (ATP13A2/PARK9 and VPS35/PARK17) were highly distinct, and network relationships for specific genes (LRRK2/PARK8, ATXN2, and EIF4G1/PARK18) were confirmed in patient induced pluripotent stem cell (iPSC)-derived neurons. This cross-species platform connected diverse neurodegenerative genes to proteinopathy through specific mechanisms and may facilitate patient stratification for targeted therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Ann Romney Center for Neurologic Disease, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: vkhurana@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Computer Science and Artificial Intelligence Laboratory and Department of Mathematics, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chee Yeun</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auluck</LastName><ForeName>Pavan K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanning</LastName><ForeName>Saranna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tardiff</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeva</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichhorn</LastName><ForeName>Stephen W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benyamini</LastName><ForeName>Hadar</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Yali</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nutter-Upham</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baru</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freyzon</LastName><ForeName>Yelena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuncbag</LastName><ForeName>Nurcan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biological Engineering, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzo</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5G 1L6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Luis</LastName><ForeName>Bryan-Joseph</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5G 1L6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ndorf</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrasa</LastName><ForeName>M Inmaculada</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehsani</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanjana</LastName><ForeName>Neville</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; New York Genome Center and Department of Biology, New York University, New York, NY 10013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Wright State University, Dayton, OH 45435, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartel</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleidi</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boone</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5G 1L6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraenkel</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biological Engineering, MIT, Cambridge, MA 02139, USA. Electronic address: fraenkel-admin@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: bab@csail.mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; HHMI, Department of Biology, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM089903</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS091046</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG001715</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG004233</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA184898</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG038546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006061</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM081871</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM118135</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG001715</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089076</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Syst</MedlineTA><NlmUniqueID>101656080</NlmUniqueID><ISSNLinking>2405-4712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C113920">EIF4G1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039603">Eukaryotic Initiation Factor-4G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2017 Feb 8;9(376):eaam6058. doi: 10.1126/scitranslmed.aam6058.</RefSource><PMID Version="1">28179503</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Jun;32(6):840. doi: 10.1002/mds.26985.</RefSource><PMID Version="1">28370358</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039603" MajorTopicYN="N">Eukaryotic Initiation Factor-4G</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016681" MajorTopicYN="N">Genome, Fungal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LRRK2</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">RNA-binding protein</Keyword><Keyword MajorTopicYN="N">VPS35</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">iPS cell</Keyword><Keyword MajorTopicYN="N">mRNA translation</Keyword><Keyword MajorTopicYN="N">stem cell</Keyword><Keyword MajorTopicYN="N">vesicle trafficking</Keyword><Keyword MajorTopicYN="N">yeast</Keyword></KeywordList><CoiStatement><b>Potential Conflicts of Interest:</b> V.K., C.Y.C., D.F.T and S.L. are scientific co-founders of Yumanity Therapeutics, a company developing neurodegenerative disease therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28131822</ArticleId><ArticleId IdType="mid">NIHMS847778</ArticleId><ArticleId IdType="pmc">PMC5388136</ArticleId><ArticleId IdType="doi">10.1016/j.cels.2016.12.011</ArticleId><ArticleId IdType="pii">S2405-4712(16)30445-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403&#x2013;410. doi: 10.1016/S0022-2836(05)80360-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(05)80360-2</ArticleId><ArticleId IdType="pubmed">2231712</ArticleId></ArticleIdList></Reference><Reference><Citation>Altschul SF, Madden TL, Sch&#xe4;ffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389&#x2013;3402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC146917</ArticleId><ArticleId IdType="pubmed">9254694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25&#x2013;29. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly-Bechet M, Borgs C, Braunstein A, Chayes J, Dagkessamanskaia A, Fran&#xe7;ois JM, Zecchina R. Finding undetected protein associations in cell signaling by belief propagation. Proc Natl Acad Sci USA. 2011;108:882&#x2013;887. doi: 10.1073/pnas.1004751108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1004751108</ArticleId><ArticleId IdType="pmc">PMC3021011</ArticleId><ArticleId IdType="pubmed">21187432</ArticleId></ArticleIdList></Reference><Reference><Citation>Baryshnikova A, Costanzo M, Kim Y, Ding H, Koh J, Toufighi K, Youn JY, Ou J, San Luis BJ, Bandyopadhyay S, Hibbs M, Hess D, Gingras AC, Bader GD, Troyanskaya OG, Brown GW, Andrews B, Boone C, Myers CL. Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. Nat Methods. 2010;7:1017&#x2013;1024. doi: 10.1038/nmeth.1534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1534</ArticleId><ArticleId IdType="pmc">PMC3117325</ArticleId><ArticleId IdType="pubmed">21076421</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR International Parkinson&#x2019;s Disease Genomics Consortium, North American Brain Expression Consortium. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci USA. 2014;111:2626&#x2013;2631. doi: 10.1073/pnas.1318306111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318306111</ArticleId><ArticleId IdType="pmc">PMC3932908</ArticleId><ArticleId IdType="pubmed">24510904</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger B, Peng J, Singh M. Computational solutions for omics data. Nat Rev Genet. 2013;14:333&#x2013;346. doi: 10.1038/nrg3433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3433</ArticleId><ArticleId IdType="pmc">PMC3966295</ArticleId><ArticleId IdType="pubmed">23594911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bras J, Guerreiro R, Hardy J. SnapShot: Genetics of Parkinson&#x2019;s Disease. Cell. 2015;160:570&#x2013;570.e1. doi: 10.1016/j.cell.2015.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.019</ArticleId><ArticleId IdType="pubmed">25635463</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X, Ben-Johny M, Soste M, Picotti P, Kim H, Caldwell KA, Caldwell GA, Sulzer D, Yue DT, Lindquist S. Calcineurin determines toxic versus beneficial responses to -synuclein. Proc Natl Acad Sci USA. 2014 doi: 10.1073/pnas.1413201111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1413201111</ArticleId><ArticleId IdType="pmc">PMC4151770</ArticleId><ArticleId IdType="pubmed">25122673</ArticleId></ArticleIdList></Reference><Reference><Citation>Casals F, Bertranpetit J. Human Genetic Variation, Shared and Private. Science. 2012;337:39&#x2013;40. doi: 10.1126/science.1224528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1224528</ArticleId><ArticleId IdType="pubmed">22767915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27:275&#x2013;280. doi: 10.1038/nbt.1529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1529</ArticleId><ArticleId IdType="pmc">PMC2756723</ArticleId><ArticleId IdType="pubmed">19252484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Dachsel JC, Vilari&#xf1;o-G&#xfc;ell C, Lincoln SJ, Lepr&#xea;tre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Dest&#xe9;e A, Farrer MJ. Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. Am J Hum Genet. 2011;89:398&#x2013;406. doi: 10.1016/j.ajhg.2011.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.08.009</ArticleId><ArticleId IdType="pmc">PMC3169825</ArticleId><ArticleId IdType="pubmed">21907011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Peng J, Berger B. Diffusion Component Analysis: Unraveling Functional Topology in Biological Networks. RECOMB 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524124</ArticleId><ArticleId IdType="pubmed">28748230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Berger B, Peng J. Mashup: Compact Integration of Multi-Network Topology for Functional Analysis of Genes. Cell Systems. 2016 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225290</ArticleId><ArticleId IdType="pubmed">27889536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, Yu J, Xie C, Rudrabhatla P, Chen X, Wu J, Parisiadou L, Liu G, Sun L, Ma B, Ding J, Liu Z, Cai H. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. Embo J. 2014;33:2314&#x2013;2331. doi: 10.15252/embj.201487807.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201487807</ArticleId><ArticleId IdType="pmc">PMC4253522</ArticleId><ArticleId IdType="pubmed">25201882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Sch&#xfc;le B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S. Identification and rescue of &#x3b1;-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013;342:983&#x2013;987. doi: 10.1126/science.1245296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1245296</ArticleId><ArticleId IdType="pmc">PMC4022187</ArticleId><ArticleId IdType="pubmed">24158904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, LaBaer J, Rochet JC, Bonini NM, Lindquist S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x2019;s models. Science. 2006;313:324&#x2013;328. doi: 10.1126/science.1129462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1129462</ArticleId><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhungel N, Eleuteri S, Li L-B, Kramer NJ, Chartron JW, Spencer B, Kosberg K, Fields JA, Stafa K, Adame A, Lashuel H, Frydman J, Shen K, Masliah E, Gitler AD. Parkinson&#x2019;s Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on &#x3b1;-Synuclein. Neuron. 2014 doi: 10.1016/j.neuron.2014.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.11.027</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, R&#xfc;b U, Auburger G, Trojanowski JQ, Lee VMY, Van Deerlin VM, Bonini NM, Gitler AD. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. Faseb J. 2008;22:1327&#x2013;1334. doi: 10.1096/fj.07-9348com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-9348com</ArticleId><ArticleId IdType="pubmed">18162487</ArticleId></ArticleIdList></Reference><Reference><Citation>Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, Ohno K, Hattori N. CHCHD2 mutations in autosomal dominant late-onset Parkinson&#x2019;s disease: a genome-wide linkage and sequencing study. Lancet Neurol. 2015;14:274&#x2013;282. doi: 10.1016/S1474-4422(14)70266-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70266-2</ArticleId><ArticleId IdType="pubmed">25662902</ArticleId></ArticleIdList></Reference><Reference><Citation>Geetha V, Di Francesco V, Garnier J, Munson PJ. Comparing protein sequence-based and predicted secondary structure-based methods for identification of remote homologs. Protein Eng. 1999;12:527&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">10436078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrke S, Wu Z, Klinkenberg M, Sun Y, Auburger G, Guo S, Lu B. PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane. Cell Metab. 2015;21:95&#x2013;108. doi: 10.1016/j.cmet.2014.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.12.007</ArticleId><ArticleId IdType="pmc">PMC4455944</ArticleId><ArticleId IdType="pubmed">25565208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietz D, St Jean A, Woods RA, Schiestl RH. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 1992;20:1425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312198</ArticleId><ArticleId IdType="pubmed">1561104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietz RD, Schiestl RH, Willems AR, Woods RA. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast. 1995;11:355&#x2013;360. doi: 10.1002/yea.320110408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/yea.320110408</ArticleId><ArticleId IdType="pubmed">7785336</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580&#x2013;585. doi: 10.1038/ng.2653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2653</ArticleId><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bras J, Hardy J. SnapShot: Genetics of ALS and FTD. Cell. 2015;160:798&#x2013;798.e1. doi: 10.1016/j.cell.2015.01.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.052</ArticleId><ArticleId IdType="pubmed">25679767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasson SA, Kane LA, Yamano K, Huang CH, Sliter DA, Buehler E, Wang C, Heman-Ackah SM, Hessa T, Guha R, Martin SE, Youle RJ. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature. 2013;504:291&#x2013;295. doi: 10.1038/nature12748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12748</ArticleId><ArticleId IdType="pmc">PMC5841086</ArticleId><ArticleId IdType="pubmed">24270810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Flockhart I, Vinayagam A, Bergwitz C, Berger B, Perrimon N, Mohr SE. An integrative approach to ortholog prediction for disease-focused and other functional studies. BMC Bioinformatics. 2011;12:357. doi: 10.1186/1471-2105-12-357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-357</ArticleId><ArticleId IdType="pmc">PMC3179972</ArticleId><ArticleId IdType="pubmed">21880147</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Rolfs A, Bhullar B, Murthy TVS, Zhu C, Berger MF, Camargo AA, Kelley F, McCarron S, Jepson D, Richardson A, Raphael J, Moreira D, Taycher E, Zuo D, Mohr S, Kane MF, Williamson J, Simpson A, Bulyk ML, Harlow E, Marsischky G, Kolodner RD, LaBaer J. Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae. Genome Res. 2007;17:536&#x2013;543. doi: 10.1101/gr.6037607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.6037607</ArticleId><ArticleId IdType="pmc">PMC1832101</ArticleId><ArticleId IdType="pubmed">17322287</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-SC, Fraenkel E. Integrating proteomic, transcriptional, and interactome data reveals hidden components of signaling and regulatory networks. Science signaling. 2009;2:ra40. doi: 10.1126/scisignal.2000350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2000350</ArticleId><ArticleId IdType="pmc">PMC2889494</ArticleId><ArticleId IdType="pubmed">19638617</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Chen K, Zhang J, Li Y, Wang H, Cui D, Tang J, Liu Y, Shi X, Li W, Liu D, Chen R, Sucgang RS, Pan X. A functional variomics tool for discovering drug-resistance genes and drug targets. CellReports. 2013;3:577&#x2013;585. doi: 10.1016/j.celrep.2013.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.01.019</ArticleId><ArticleId IdType="pmc">PMC3594652</ArticleId><ArticleId IdType="pubmed">23416056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachroo AH, Laurent JM, Yellman CM, Meyer AG, Wilke CO, Marcotte EM. Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. Science. 2015;348:921&#x2013;925. doi: 10.1126/science.aaa0769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa0769</ArticleId><ArticleId IdType="pmc">PMC4718922</ArticleId><ArticleId IdType="pubmed">25999509</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Lindquist S. Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker&#x2019;s yeast? Nat Rev Neurosci. 2010;11:436&#x2013;449. doi: 10.1038/nrn2809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2809</ArticleId><ArticleId IdType="pubmed">20424620</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Tardiff DF, Chung CY, Lindquist S. Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat Rev Neurol. 2015;11:339&#x2013;350. doi: 10.1038/nrneurol.2015.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.79</ArticleId><ArticleId IdType="pubmed">25986505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VMY, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2. Nat Genet. 2013;46:152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, O&#x2019;Sullivan ML, Sanchez CA, Hwang M, Israel MA, Brennand K, Deerinck TJ, Goldstein LSB, Gage FH, Ellisman MH, Ghosh A. Investigating synapse formation and function using human pluripotent stem cell-derived neurons. Proc Natl Acad Sci USA. 2011;108:3005&#x2013;3010. doi: 10.1073/pnas.1007753108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1007753108</ArticleId><ArticleId IdType="pmc">PMC3041068</ArticleId><ArticleId IdType="pubmed">21278334</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014 doi: 10.1038/nature14136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14136</ArticleId><ArticleId IdType="pmc">PMC4420636</ArticleId><ArticleId IdType="pubmed">25494202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong SMY, Chan BKK, Park JS, Hill KJ, Aitken JB, Cottle L, Farghaian H, Cole AR, Lay PA, Sue CM, Cooper AA. Parkinson&#x2019;s disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes &#x3b1;-Synuclein externalization via exosomes. Hum Mol Genet. 2014;23:2816&#x2013;2833. doi: 10.1093/hmg/ddu099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu099</ArticleId><ArticleId IdType="pubmed">24603074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson&#x2019;s disease. Nature. 2011;480:547&#x2013;551. doi: 10.1038/nature10648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10648</ArticleId><ArticleId IdType="pmc">PMC3245796</ArticleId><ArticleId IdType="pubmed">22056989</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25. doi: 10.1186/gb-2009-10-3-r25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2009-10-3-r25</ArticleId><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Aliaga L, Cai H. &#x3b1;-synuclein, LRRK2 and their interplay in Parkinson&#x2019;s disease. Future Neurol. 2012;7:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343692</ArticleId><ArticleId IdType="pubmed">22563296</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Guo J, Li K, Qin L, Kang J, Shu L, Zhang Y, Wei Y, Yang N, Luo Y, Sun Q, Xu Q, Yan X, Tang B. Mutation analysis of CHCHD2 gene in Chinese familial Parkinson&#x2019;s disease. Neurobiol Aging. 2015;36:3117.e7&#x2013;8. doi: 10.1016/j.neurobiolaging.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.010</ArticleId><ArticleId IdType="pubmed">26343503</ArticleId></ArticleIdList></Reference><Reference><Citation>Macleod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, Maccabe BD, Marder KS, Honig LS, Clark LN, Small SA, Abeliovich A. RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson&#x2019;s Disease Risk. Neuron. 2013;77:425&#x2013;439. doi: 10.1016/j.neuron.2012.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.11.033</ArticleId><ArticleId IdType="pmc">PMC3646583</ArticleId><ArticleId IdType="pubmed">23395371</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin I, Dawson VL, Dawson TM. Recent Advances in the Genetics of Parkinson&#x2019;s Disease. Annual review of genomics and human genetics. 2011;12:301&#x2013;325. doi: 10.1146/annurev-genom-082410-101440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genom-082410-101440</ArticleId><ArticleId IdType="pmc">PMC4120236</ArticleId><ArticleId IdType="pubmed">21639795</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, Stankowski J, Kim MS, Zhong J, Kumar M, Andrabi SA, Xiong Y, Dickson DW, Wszolek ZK, Pandey A, Dawson TM, Dawson VL. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson&#x2019;s disease. Cell. 2014;157:472&#x2013;485. doi: 10.1016/j.cell.2014.01.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.01.064</ArticleId><ArticleId IdType="pmc">PMC4040530</ArticleId><ArticleId IdType="pubmed">24725412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stef&#xe1;nsson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JPA, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale metaanalysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet. 2014:1&#x2013;7. doi: 10.1038/ng.3043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3043</ArticleId><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu SA, Fraser D, Warren L, Aponte J, Zawistowski M, Liu X, Zhang H, Zhang Y, Li J, Li Y, Li L, Woollard P, Topp S, Hall MD, Nangle K, Wang J, Abecasis G, Cardon LR, Z&#xf6;llner S, Whittaker JC, Chissoe SL, Novembre J, Mooser V. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337:100&#x2013;104. doi: 10.1126/science.1217876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217876</ArticleId><ArticleId IdType="pmc">PMC4319976</ArticleId><ArticleId IdType="pubmed">22604722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Bademci G, Inchausti V, Dressen A, Kinnamon DD, Mehta A, Wang L, Z&#xfc;chner S, Beecham GW, Martin ER, Scott WK, Vance JM. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology. 2013;80:982&#x2013;989. doi: 10.1212/WNL.0b013e31828727d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828727d4</ArticleId><ArticleId IdType="pmc">PMC3653206</ArticleId><ArticleId IdType="pubmed">23408866</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykjaer A, Willnow TE. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012;35:261&#x2013;270. doi: 10.1016/j.tins.2012.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2012.01.003</ArticleId><ArticleId IdType="pubmed">22341525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogaki K, Koga S, Heckman MG, Fiesel FC, Ando M, Labb&#xe9; C, Lorenzo-Betancor O, Moussaud-Lamodi&#xe8;re EL, Soto-Ortolaza AI, Walton RL, Strongosky AJ, Uitti RJ, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Puschmann A, Nishioka K, Funayama M, Hattori N, Parisi JE, Petersen RC, Graff-Radford NR, Boeve BF, Springer W, Wszolek ZK, Dickson DW, Ross OA. Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology. 2015 doi: 10.1212/WNL.0000000000002170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002170</ArticleId><ArticleId IdType="pmc">PMC4676755</ArticleId><ArticleId IdType="pubmed">26561290</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappat&#xe0; S, Quarantelli M, Barone P, De Michele G, Bonifati V. PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family. Neurogenetics. 2014;15:183&#x2013;188. doi: 10.1007/s10048-014-0406-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0406-0</ArticleId><ArticleId IdType="pubmed">24816432</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn MJ, Miller JR. Rescuing yeast mutants with human genes. Brief Funct Genomic Proteomic. 2007;6:104&#x2013;111. doi: 10.1093/bfgp/elm017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bfgp/elm017</ArticleId><ArticleId IdType="pubmed">17698857</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science. 2003;302:1772&#x2013;1775. doi: 10.1126/science.1090439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090439</ArticleId><ArticleId IdType="pmc">PMC1780172</ArticleId><ArticleId IdType="pubmed">14657500</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM. Parkinson&#x2019;s disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum Mol Genet. 2014;23:2802&#x2013;2815. doi: 10.1093/hmg/ddt623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt623</ArticleId><ArticleId IdType="pmc">PMC4014187</ArticleId><ArticleId IdType="pubmed">24399444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajput A, Dickson DW, Robinson CA, Ross OA, D&#xe4;chsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology. 2006;67:1506&#x2013;1508. doi: 10.1212/01.wnl.0000240220.33950.0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000240220.33950.0c</ArticleId><ArticleId IdType="pubmed">17060589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramonet D, Podhajska A, Stafa K, Sonnay S, Trancikova A, Tsika E, Pletnikova O, Troncoso JC, Glauser L, Moore DJ. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet. 2012;21:1725&#x2013;1743. doi: 10.1093/hmg/ddr606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr606</ArticleId><ArticleId IdType="pmc">PMC3465694</ArticleId><ArticleId IdType="pubmed">22186024</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P, Schmid B, Burbulla LF, Sch&#xf6;ndorf DC, Wagner L, Glatza M, H&#xf6;ing S, Hargus G, Heck SA, Dhingra A, Wu G, M&#xfc;ller S, Brockmann K, Kluba T, Maisel M, Kr&#xfc;ger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, M&#xfc;ller H, Gasser T, Sch&#xf6;ler HR, Sterneckert J. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem cell. 2013;12:354&#x2013;367. doi: 10.1016/j.stem.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.01.008</ArticleId><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNAseq data. Genome Biol. 2010;11:R25. doi: 10.1186/gb-2010-11-3-r25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2010-11-3-r25</ArticleId><ArticleId IdType="pmc">PMC2864565</ArticleId><ArticleId IdType="pubmed">20196867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177. doi: 10.1038/ng1943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1943</ArticleId><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland T, Ta&#x15f;an M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, Yi S, Lemmens I, Fontanillo C, Mosca R, Kamburov A, Ghiassian SD, Yang X, Ghamsari L, Balcha D, Begg BE, Braun P, Brehme M, Broly MP, Carvunis AR, Convery-Zupan D, Corominas R, Coulombe-Huntington J, Dann E, Dreze M, Dricot A, Fan C, Franzosa E, Gebreab F, Gutierrez BJ, Hardy MF, Jin M, Kang S, Kiros R, Lin GN, Luck K, MacWilliams A, Menche J, Murray RR, Palagi A, Poulin MM, Rambout X, Rasla J, Reichert P, Romero V, Ruyssinck E, Sahalie JM, Scholz A, Shah AA, Sharma A, Shen Y, Spirohn K, Tam S, Tejeda AO, Trigg SA, Twizere JC, Vega K, Walsh J, Cusick ME, Xia Y, Barab&#xe1;si AL, Iakoucheva LM, Aloy P, De Las Rivas J, Tavernier J, Calderwood MA, Hill DE, Hao T, Roth FP, Vidal M. A proteome-scale map of the human interactome network. Cell. 2014;159:1212&#x2013;1226. doi: 10.1016/j.cell.2014.10.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.10.050</ArticleId><ArticleId IdType="pmc">PMC4266588</ArticleId><ArticleId IdType="pubmed">25416956</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, Cotsapas C, Daly MJ International Inflammatory Bowel Disease Genetics Constortium. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011;7:e1001273. doi: 10.1371/journal.pgen.1001273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001273</ArticleId><ArticleId IdType="pmc">PMC3020935</ArticleId><ArticleId IdType="pubmed">21249183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat Protoc. 2012;7:171&#x2013;192. doi: 10.1038/nprot.2011.431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2011.431</ArticleId><ArticleId IdType="pmc">PMC3684555</ArticleId><ArticleId IdType="pubmed">22222791</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider SA, Paisan-Ruiz C, Quinn NP, Lees AJ, Houlden H, Hardy J, Bhatia KP. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord. 2010;25:979&#x2013;984. doi: 10.1002/mds.22947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22947</ArticleId><ArticleId IdType="pubmed">20310007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK, Hedrich U, Berg D, Shihabuddin LS, Hu J, Pruszak J, Gygi SP, Sonnino S, Gasser T, Deleidi M. iPSC-derived neurons from GBA1-associated Parkinson&#x2019;s disease patients show autophagic defects and impaired calcium homeostasis. Nature Communications. 2014;5:1&#x2013;17. doi: 10.1038/ncomms5028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5028</ArticleId><ArticleId IdType="pubmed">24905578</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, Marcusson EG, Cereghino JL, Emr SD. Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products. J Cell Biol. 1997;137:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139870</ArticleId><ArticleId IdType="pubmed">9105038</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84&#x2013;87. doi: 10.1126/science.1247005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1247005</ArticleId><ArticleId IdType="pmc">PMC4089965</ArticleId><ArticleId IdType="pubmed">24336571</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, De Jager PL, Feany MB. Parkinson&#x2019;s Disease: Genetics and Pathogenesis. Annual review of pathology. 2010 doi: 10.1146/annurev-pathol-011110-130242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-011110-130242</ArticleId><ArticleId IdType="pubmed">21034221</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Xu J, Berger B. Global alignment of multiple protein interactionnetworks with application to functionalorthology detection. Proc Natl Acad Sci U S A. 2008;105:12763&#x2013;12768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2522262</ArticleId><ArticleId IdType="pubmed">18725631</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann Neurol. 2005;58:909&#x2013;919. doi: 10.1002/ana.20667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20667</ArticleId><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F, Lagani&#xe8;re J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318&#x2013;331. doi: 10.1016/j.cell.2011.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.06.019</ArticleId><ArticleId IdType="pmc">PMC3155290</ArticleId><ArticleId IdType="pubmed">21757228</ArticleId></ArticleIdList></Reference><Reference><Citation>Soper JH, Kehm V, Burd CG, Bankaitis VA, Lee VMY. Aggregation of &#x3b1;-Synuclein in S. cerevisiae is Associated with Defects in Endosomal Trafficking and Phospholipid Biosynthesis. J Mol Neurosci. 2011;43:391&#x2013;405. doi: 10.1007/s12031-010-9455-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9455-5</ArticleId><ArticleId IdType="pmc">PMC3147281</ArticleId><ArticleId IdType="pubmed">20890676</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;ding J, Biegert A, Lupas AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 2005;33:W244&#x2013;8. doi: 10.1093/nar/gki408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki408</ArticleId><ArticleId IdType="pmc">PMC1160169</ArticleId><ArticleId IdType="pubmed">15980461</ArticleId></ArticleIdList></Reference><Reference><Citation>Subtelny AO, Eichhorn SW, Chen GR, Sive H, Bartel DP. Poly(A)-tail profiling reveals an embryonic switch in translational control. Nature. 2014;508:66&#x2013;71. doi: 10.1038/nature13007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13007</ArticleId><ArticleId IdType="pmc">PMC4086860</ArticleId><ArticleId IdType="pubmed">24476825</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. STRING v10: proteinprotein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014 doi: 10.1093/nar/gku1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1003</ArticleId><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarazona S, Garc&#xed;a-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. Genome Res. 2011;21:2213&#x2013;2223. doi: 10.1101/gr.124321.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.124321.111</ArticleId><ArticleId IdType="pmc">PMC3227109</ArticleId><ArticleId IdType="pubmed">21903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiff DF, Jui NT, Khurana V, Tambe MA, Thompson ML, Chung CY, Kamadurai HB, Kim HT, Lancaster AK, Caldwell KA, Caldwell GA, Rochet JC, Buchwald SL, Lindquist S. Yeast reveal a &#x201c;druggable&#x201d; Rsp5/Nedd4 network that ameliorates &#x3b1;-synuclein toxicity in neurons. Science. 2013;342:979&#x2013;983. doi: 10.1126/science.1245321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1245321</ArticleId><ArticleId IdType="pmc">PMC3993916</ArticleId><ArticleId IdType="pubmed">24158909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiff DF, Khurana V, Chung CY, Lindquist S. From yeast to patient neurons and back again: A powerful new discovery platform. Mov Disord. 2014;10:1231&#x2013;1240. doi: 10.1002/mds.25989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25989</ArticleId><ArticleId IdType="pubmed">25131316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennessen JA, Bigham AW, O&#x2019;Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM, Broad GO, Seattle GO NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64&#x2013;69. doi: 10.1126/science.1219240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1219240</ArticleId><ArticleId IdType="pmc">PMC3708544</ArticleId><ArticleId IdType="pubmed">22604720</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong AHY. Global Mapping of the Yeast Genetic Interaction Network. Science. 2004;303:808&#x2013;813. doi: 10.1126/science.1091317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1091317</ArticleId><ArticleId IdType="pubmed">14764870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong AHY, Boone C. Synthetic genetic array analysis in Saccharomyces cerevisiae. Methods Mol Biol. 2006;313:171&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16118434</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S. Functional links between A&#x3b2; toxicity, endocytic trafficking, and Alzheimer&#x2019;s disease risk factors in yeast. Science. 2011;334:1241&#x2013;1245. doi: 10.1126/science.1213210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1213210</ArticleId><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T, Krainc D. Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet. 2014;23:2791&#x2013;2801. doi: 10.1093/hmg/ddt572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt572</ArticleId><ArticleId IdType="pmc">PMC4014186</ArticleId><ArticleId IdType="pubmed">24334770</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Z, Argmann C, Wong KK, Mitnaul LJ, Edwards S, Sach IC, Zhu J, Schadt EE. Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. Genome Res. 2009;19:1057&#x2013;1067. doi: 10.1101/gr.087890.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.087890.108</ArticleId><ArticleId IdType="pmc">PMC2694478</ArticleId><ArticleId IdType="pubmed">19261841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuncbag N, Braunstein A, Pagnani A, Huang S-SC, Chayes J, Borgs C, Zecchina R, Fraenkel E. Simultaneous reconstruction of multiple signaling pathways via the prize-collecting steiner forest problem. J Comput Biol. 2013;20:124&#x2013;136. doi: 10.1089/cmb.2012.0092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cmb.2012.0092</ArticleId><ArticleId IdType="pmc">PMC3576906</ArticleId><ArticleId IdType="pubmed">23383998</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuncbag N, Gosline SJC, Kedaigle A, Soltis AR, Gitter A, Fraenkel E. Network-Based Interpretation of Diverse High-Throughput Datasets through the Omics Integrator Software Package. PLoS Comput Biol. 2016;12:e1004879. doi: 10.1371/journal.pcbi.1004879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004879</ArticleId><ArticleId IdType="pmc">PMC4838263</ArticleId><ArticleId IdType="pubmed">27096930</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140&#x2013;149. doi: 10.1016/j.tig.2015.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2015.01.004</ArticleId><ArticleId IdType="pubmed">25703649</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilella AJ, Severin J, Ureta-Vidal A, Heng L, Durbin R, Birney E. EnsemblCompara GeneTrees: Complete, duplication-aware phylogenetic trees in vertebrates. Genome Res. 2009;19:327&#x2013;335. doi: 10.1101/gr.073585.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.073585.107</ArticleId><ArticleId IdType="pmc">PMC2652215</ArticleId><ArticleId IdType="pubmed">19029536</ArticleId></ArticleIdList></Reference><Reference><Citation>Voevodski K, Teng SH, Xia Y. Finding local communities in protein networks. BMC Bioinformatics. 2009;10:297. doi: 10.1186/1471-2105-10-297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-10-297</ArticleId><ArticleId IdType="pmc">PMC2755114</ArticleId><ArticleId IdType="pubmed">19765306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPRCas9 system. Science. 2014;343:80&#x2013;84. doi: 10.1126/science.1246981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1246981</ArticleId><ArticleId IdType="pmc">PMC3972032</ArticleId><ArticleId IdType="pubmed">24336569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson GR, Sim JCH, McLean C, Giannandrea M, Galea CA, Riseley JR, Stephenson SEM, Fitzpatrick E, Haas SA, Pope K, Hogan KJ, Gregg RG, Bromhead CJ, Wargowski DS, Lawrence CH, James PA, Churchyard A, Gao Y, Phelan DG, Gillies G, Salce N, Stanford L, Marsh APL, Mignogna ML, Hayflick SJ, Leventer RJ, Delatycki MB, Mellick GD, Kalscheuer VM, D&#x2019;Adamo P, Bahlo M, Amor DJ, Lockhart PJ. Mutations in RAB39B Cause X-Linked Intellectual Disability and Early-Onset Parkinson Disease with &#x3b1;-Synuclein Pathology. Am J Hum Genet. 2014;95:729&#x2013;735. doi: 10.1016/j.ajhg.2014.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2014.10.015</ArticleId><ArticleId IdType="pmc">PMC4259921</ArticleId><ArticleId IdType="pubmed">25434005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, Lindquist S, Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet. 2009;41:316&#x2013;323. doi: 10.1038/ng.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.337</ArticleId><ArticleId IdType="pmc">PMC2733244</ArticleId><ArticleId IdType="pubmed">19234470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Benet-Pag&#xe8;s A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Br&#xfc;cke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. Am J Hum Genet. 2011;89:168&#x2013;175. doi: 10.1016/j.ajhg.2011.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.06.008</ArticleId><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28137833</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>1690</StartPage><EndPage>1695</EndPage><MedlinePgn>1690-1695</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1610909114</ELocationID><Abstract><AbstractText>Cognitive reserve (CR) prevents cognitive decline and delays neurodegeneration. Recent epidemiological evidence suggests that lifelong bilingualism may act as CR delaying the onset of dementia by &#x223c;4.5 y. Much controversy surrounds the issue of bilingualism and its putative neuroprotective effects. We studied brain metabolism, a direct index of synaptic function and density, and neural connectivity to shed light on the effects of bilingualism in vivo in Alzheimer's dementia (AD). Eighty-five patients with probable AD and matched for disease duration (45 German-Italian bilingual speakers and 40 monolingual speakers) were included. Notably, bilingual individuals were on average 5 y older than their monolingual peers. In agreement with our predictions and with models of CR, cerebral hypometabolism was more severe in the group of bilingual individuals with AD. The metabolic connectivity analyses crucially supported the neuroprotective effect of bilingualism by showing an increased connectivity in the executive control and the default mode networks in the bilingual, compared with the monolingual, AD patients. Furthermore, the degree of lifelong bilingualism (i.e., high, moderate, or low use) was significantly correlated to functional modulations in crucial neural networks, suggesting both neural reserve and compensatory mechanisms. These findings indicate that lifelong bilingualism acts as a powerful CR proxy in dementia and exerts neuroprotective effects against neurodegeneration. Delaying the onset of dementia is a top priority of modern societies, and the present in vivo neurobiological evidence should stimulate social programs and interventions to support bilingual or multilingual education and the maintenance of the second language among senior citizens.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perani</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Psychology, Vita-Salute San Raffaele University, 20132 Milan, Italy; perani.daniela@hsr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuclear Medicine Unit, San Raffaele Hospital, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farsad</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballarini</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubian</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Memory Clinic, Geriatric Department, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malpetti</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Psychology, Vita-Salute San Raffaele University, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fracchetti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physics, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, San Raffaele Hospital, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>March</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic, Geriatric Department, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abutalebi</LastName><ForeName>Jubin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Psychology, Vita-Salute San Raffaele University, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058245" MajorTopicYN="N">Cognitive Reserve</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019303" MajorTopicYN="Y">Multilingualism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s dementia</Keyword><Keyword MajorTopicYN="N">bilingualism</Keyword><Keyword MajorTopicYN="N">brain metabolic connectivity</Keyword><Keyword MajorTopicYN="N">brain reserve</Keyword><Keyword MajorTopicYN="N">fluorine-18-fluorodeoxyglucose PET</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28137833</ArticleId><ArticleId IdType="pmc">PMC5320960</ArticleId><ArticleId IdType="doi">10.1073/pnas.1610909114</ArticleId><ArticleId IdType="pii">1610909114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11(11):1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. Trends Cogn Sci. 2013;17(10):502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840716</ArticleId><ArticleId IdType="pubmed">24018144</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, et al. Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Neuroimage. 2013;83:450&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">23796547</ArticleId></ArticleIdList></Reference><Reference><Citation>Piras F, Cherubini A, Caltagirone C, Spalletta G. Education mediates microstructural changes in bilateral hippocampus. Hum Brain Mapp. 2011;32(2):282&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870355</ArticleId><ArticleId IdType="pubmed">20336658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem. 1977;29(1):13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">407330</ArticleId></ArticleIdList></Reference><Reference><Citation>Perani D. FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol. 2014;27(4):405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">24927239</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science. 1999;283(5401):496&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988650</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002;25(12):621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446129</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, et al. Schooling mediates brain reserve in Alzheimer&#x2019;s disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry. 2006;77(9):1060&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077756</ArticleId><ArticleId IdType="pubmed">16709580</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibotto V, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology. 2008;71(17):1342&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18936426</ArticleId></ArticleIdList></Reference><Reference><Citation>Morbelli S, et al. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med. 2013;54(6):894&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">23591639</ArticleId></ArticleIdList></Reference><Reference><Citation>Perani D, Abutalebi J. Bilingualism, dementia, cognitive and neural reserve. Curr Opin Neurol. 2015;28(6):618&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">26544028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialystok E, Craik FIM, Freedman M. Bilingualism as a protection against the onset of symptoms of dementia. Neuropsychologia. 2007;45(2):459&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17125807</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, et al. Bilingualism delays age at onset of dementia, independent of education and immigration status. Neurology. 2013;81(22):1938&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">24198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Woumans E, et al. Bilingualism delays clinical manifestation of Alzheimer&#x2019;s disease. Biling Lang Cogn. 2015;18(3):568&#x2013;574.</Citation></Reference><Reference><Citation>Alladi S, et al. Impact of bilingualism on cognitive outcome after stroke. Stroke. 2016;47(1):258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">26585392</ArticleId></ArticleIdList></Reference><Reference><Citation>Green DW, Abutalebi J. Language control in bilinguals: the adaptive control hypothesis. J Cogn Psychol (Hove) 2013;25(5):515&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095950</ArticleId><ArticleId IdType="pubmed">25077013</ArticleId></ArticleIdList></Reference><Reference><Citation>Abutalebi J, Green DW. Neuroimaging of language control in bilinguals: Neural adaptation and reserve. Biling Lang Cogn. 2016;19(4):689&#x2013;698.</Citation></Reference><Reference><Citation>Abutalebi J, Green D. Bilingual language production: the neurocognition of language representation and control. J Neurolinguist. 2007;20(3):242&#x2013;275.</Citation></Reference><Reference><Citation>Abutalebi J, Weekes BS. The cognitive neurology of bilingualism in the age of globalization. Behav Neurol. 2014;2014:536727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034485</ArticleId><ArticleId IdType="pubmed">24895486</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk G, Bialystok E, Craik FIM, Grady CL. Lifelong bilingualism maintains white matter integrity in older adults. J Neurosci. 2011;31(46):16808&#x2013;16813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259110</ArticleId><ArticleId IdType="pubmed">22090506</ArticleId></ArticleIdList></Reference><Reference><Citation>Abutalebi J, et al. Bilingualism protects anterior temporal lobe integrity in aging. Neurobiol Aging. 2014;35(9):2126&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pubmed">24721820</ArticleId></ArticleIdList></Reference><Reference><Citation>Abutalebi J, Canini M, Della Rosa PA, Green DW, Weekes BS. The neuroprotective effects of bilingualism upon the inferior parietal lobule&#x202f;: a structural neuroimaging study in aging Chinese bilinguals. J Neurolinguist. 2015;33:3&#x2013;13.</Citation></Reference><Reference><Citation>Bialystok E, Abutalebi J, Bak TH, Burke DM, Kroll JF. Aging in two languages: implications for public health. Ageing Res Rev. 2016;27:56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837064</ArticleId><ArticleId IdType="pubmed">26993154</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Luk G, Craik FIM, Bialystok E. Brain network activity in monolingual and bilingual older adults. Neuropsychologia. 2015;66:170&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898959</ArticleId><ArticleId IdType="pubmed">25445783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold BT. Lifelong bilingualism and neural reserve against Alzheimer&#x2019;s disease: a review of findings and potential mechanisms. Behav Brain Res. 2015;281:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305453</ArticleId><ArticleId IdType="pubmed">25496781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton DM, Gasquoine PG, Weimer AA. Age of dementia diagnosis in community dwelling bilingual and monolingual Hispanic Americans. Cortex. 2015;66:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426973</ArticleId><ArticleId IdType="pubmed">25598395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak TH, Alladi S. Bilingualism, dementia and the tale of many variables: why we need to move beyond the Western World. Commentary on Lawton et al. (2015) and Fuller-Thomson (2015) Cortex. 2016;74:315&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">26537794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DS, et al. Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging. 2008;35(9):1681&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">18491089</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo N, Ib&#xe1;&#xf1;ez A, Garc&#xed;a AM. The impact of bilingualism on working memory: a null effect on the whole may not be so on the parts. Front Psychol. 2016;7:265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766303</ArticleId><ArticleId IdType="pubmed">26941704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerrigan L, Thomas MSC, Bright P, Filippi R. Evidence of an advantage in visuo-spatial memory for bilingual compared to monolingual speakers. Biling Lang Cogn. February 1, 2016 doi: 10.1017/S1366728915000917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1366728915000917</ArticleId></ArticleIdList></Reference><Reference><Citation>Linck JA, Osthus P, Koeth JT, Bunting MF. Working memory and second language comprehension and production: a meta-analysis. Psychon Bull Rev. 2014;21(4):861&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">24366687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialystok E, Craik FIM, Green DW, Gollan TH. Bilingual minds. Psychol Sci Public Interest. 2009;10(3):89&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">26168404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialystok E, Craik F, Luk G. Cognitive control and lexical access in younger and older bilinguals. J Exp Psychol Learn Mem Cogn. 2008;34(4):859&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">18605874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gollan TH, Montoya RI, Fennema-Notestine C, Morris SK. Bilingualism affects picture naming but not picture classification. Mem Cognit. 2005;33(7):1220&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532855</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Legault J, Litcofsky KA. Neuroplasticity as a function of second language learning: anatomical changes in the human brain. Cortex. 2014;58:301&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">24996640</ArticleId></ArticleIdList></Reference><Reference><Citation>Abutalebi J, et al. Bilingualism provides a neural reserve for aging populations. Neuropsychologia. 2015;69:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">25637228</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RK, et al. The effect of lifelong bilingualism on regional grey and white matter volume. Brain Res. 2015;1612:128&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">25725380</ArticleId></ArticleIdList></Reference><Reference><Citation>Abutalebi J, et al. Bilingualism tunes the anterior cingulate cortex for conflict monitoring. Cereb Cortex. 2012;22(9):2076&#x2013;2086.</Citation><ArticleIdList><ArticleId IdType="pubmed">22038906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O. Network attributes for segregation and integration in the human brain. Curr Opin Neurobiol. 2013;23(2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23294553</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SW, Dennis NA, Daselaar SM, Fleck MS, Cabeza R. Que PASA? The posterior-anterior shift in aging. Cereb Cortex. 2008;18(5):1201&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760260</ArticleId><ArticleId IdType="pubmed">17925295</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer&#x2019;s disease. Brain. 2010;133(Pt 5):1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, et al. Altered functional connectivity in early Alzheimer&#x2019;s disease: a resting-state fMRI study. Hum Brain Mapp. 2007;28(10):967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871392</ArticleId><ArticleId IdType="pubmed">17133390</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer&#x2019;s disease. J Neurosci. 2003;23(3):986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741917</ArticleId><ArticleId IdType="pubmed">12574428</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosjean F. Bilingual: Life and Reality. Harvard University Press; Cambridge, MA: 2010.</Citation></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradis M, Libben G. The Assessment of Bilingual Aphasia. Lawrence Erlbaum Associates; Mahwah, NJ: 1987.</Citation></Reference><Reference><Citation>Capitani E, Laiacona M. The Italian Group for the Neuropsychological Study of Ageing Composite neuropsychological batteries and demographic correction: Standardization based on equivalent scores, with a review of published data. J Clin Exp Neuropsychol. 1997;19(6):795&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">9524875</ArticleId></ArticleIdList></Reference><Reference><Citation>Perani D, et al. EADC-PET Consortium Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4225527</ArticleId><ArticleId IdType="pubmed">25389519</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Rosa PA, et al. EADC-PET Consortium A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12(4):575&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">24952892</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, et al. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp. 1995;2(4):189&#x2013;210.</Citation></Reference><Reference><Citation>Horwitz B, Duara R, Rapoport SI. Intercorrelations of glucose metabolic rates between brain regions: Application to healthy males in a state of reduced sensory input. J Cereb Blood Flow Metab. 1984;4(4):484&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">6501442</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cereb Cortex. 2012;22(1):158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236795</ArticleId><ArticleId IdType="pubmed">21616982</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner S, Tucha O, Lange KW. 2000. Regensburg Word Fluency Test [Regensburger Wortfl&#xfc;ssigkeits-Test (RWT)]. (Hogrefe, Goettingen, Germany). German.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860564</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli P, Capitani L, Vallar C, Cappa S. Test di fluenza verbale. Archivio di Psicologia, Neurologia e Psichiatria. 1986;47:278&#x2013;296.</Citation></Reference><Reference><Citation>Spinnler H, Tognoni G. Taratura e standardizzazione italiana di test neuropsicologici. Italian J Neurol Sci. 1987;8(Suppl 6):8&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">3330072</ArticleId></ArticleIdList></Reference><Reference><Citation>Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. Rey-Osterrieth complex figure: Normative values in an Italian population sample. Neurol Sci. 2002;22(6):443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">11976975</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmst&#xe4;dter C, Lendt M, Lux S. 2001 Verbaler Lern- und Merkf&#xe4;higkeitstest: VLMT (Beltz Test GmbH, Goettingen). Available at  https://www.psychologie.uni-freiburg.de/studium.lehre/klin-master/skripte/Vergangene_Semester/psychologische-diagnostik-m2-baumeister-SS2012/Test/VLMT. Accessed January 15, 2016.</Citation></Reference><Reference><Citation>Carlesimo GA, et al. The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment. Eur Neurol. 1996;36(6):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8954307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri M, et al. Standardizzazione di due nuovi test di memoria: Apprendimento di liste di parole correlate e non correlate semanticamente. Archivio di Psicologia Neurologia e Psichiatria. 1997;58:621&#x2013;645.</Citation></Reference><Reference><Citation>Della Sala S, Laiacona M, Spinnler H, Ubezio C. A cancellation test: Its reliability in assessing attentional deficits in Alzheimer's disease. Psychol Med. 1992;22(4):885&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1488486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28159908</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Regulation of Synaptic Amyloid-&#x3b2; Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>2639</StartPage><EndPage>2655</EndPage><MedlinePgn>2639-2655</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2851-16.2017</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) peptides play a key role in synaptic damage and memory deficits in the early pathogenesis of Alzheimer's disease (AD). Abnormal accumulation of A&#x3b2; at nerve terminals leads to synaptic pathology and ultimately to neurodegeneration. &#x3b2;-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is the major neuronal &#x3b2;-secretase for A&#x3b2; generation. However, the mechanisms regulating BACE1 distribution in axons and &#x3b2; cleavage of APP at synapses remain largely unknown. Here, we reveal that dynein-Snapin-mediated retrograde transport regulates BACE1 trafficking in axons and APP processing at presynaptic terminals. BACE1 is predominantly accumulated within late endosomes at the synapses of AD-related mutant human APP (hAPP) transgenic (Tg) mice and patient brains. Defective retrograde transport by genetic ablation of <i>snapin</i> in mice recapitulates late endocytic retention of BACE1 and increased APP processing at presynaptic sites. Conversely, overexpressing Snapin facilitates BACE1 trafficking and reduces synaptic BACE1 accumulation by enhancing the removal of BACE1 from distal AD axons and presynaptic terminals. Moreover, elevated Snapin expression via stereotactic hippocampal injections of adeno-associated virus particles in mutant hAPP Tg mouse brains decreases synaptic A&#x3b2; levels and ameliorates synapse loss, thus rescuing cognitive impairments associated with hAPP mice. Altogether, our study provides new mechanistic insights into the complex regulation of BACE1 trafficking and presynaptic localization through Snapin-mediated dynein-driven retrograde axonal transport, thereby suggesting a potential approach of modulating A&#x3b2; levels and attenuating synaptic deficits in AD.<b>SIGNIFICANCE STATEMENT</b> &#x3b2;-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) trafficking and synaptic localization significantly influence its &#x3b2; secretase activity and amyloid-&#x3b2; (A&#x3b2;) production. In AD brains, BACE1 is accumulated within dystrophic neurites, which is thought to augment A&#x3b2;-induced synaptotoxicity by A&#x3b2; overproduction. However, it remains largely unknown whether axonal transport regulates synaptic APP processing. Here, we demonstrate that Snapin-mediated retrograde transport plays a critical role in removing BACE1 from presynaptic terminals toward the soma, thus reducing synaptic A&#x3b2; production. Adeno-associated virus-mediated Snapin overexpression in the hippocampus of mutant hAPP mice significantly decreases synaptic A&#x3b2; levels, attenuates synapse loss, and thus rescues cognitive deficits. Our study uncovers a new pathway that controls synaptic APP processing by enhancing axonal BACE1 trafficking, thereby advancing our fundamental knowledge critical for ameliorating A&#x3b2;-linked synaptic pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the authors 0270-6474/17/372640-17$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Tuancheng</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4833-2659</Identifier><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tammineni</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2963-7473</Identifier><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Psychology, Rutgers University, Piscataway, New Jersey 08854 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Yu Young</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolis</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-2678-4216</Identifier><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Huaibin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusnecov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Psychology, Rutgers University, Piscataway, New Jersey 08854 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8525-2749</Identifier><AffiliationInfo><Affiliation>Departments of Cell Biology and Neuroscience and cai@biology.rutgers.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 AG033658</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094450</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089737</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH104800</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH108994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2017 Aug 2;37(31):7291-7293. doi: 10.1523/JNEUROSCI.1260-17.2017.</RefSource><PMID Version="1">28768792</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP processing</Keyword><Keyword MajorTopicYN="N">BACE1 trafficking</Keyword><Keyword MajorTopicYN="N">Snapin</Keyword><Keyword MajorTopicYN="N">axonal transport</Keyword><Keyword MajorTopicYN="N">late endosome</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28159908</ArticleId><ArticleId IdType="pmc">PMC5354320</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2851-16.2017</ArticleId><ArticleId IdType="pii">JNEUROSCI.2851-16.2017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banker GA, Cowan WM (1979) Further observations on hippocampal neurons in dispersed cell culture. J Comp Neurol 187:469&#x2013;493. 10.1002/cne.901870302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.901870302</ArticleId><ArticleId IdType="pubmed">385643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, Vetanovetz CP, Morel E, Chamoun Z, Di Paolo G, Small SA (2012) The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol Dis 47:126&#x2013;134. 10.1016/j.nbd.2012.03.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.030</ArticleId><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239&#x2013;259. 10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggia-Pr&#xe9;vot V, Thinakaran G (2015) Significance of transcytosis in Alzheimer's disease: BACE1 takes the scenic route to axons. Bioessays 37:888&#x2013;898. 10.1002/bies.201500019</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201500019</ArticleId><ArticleId IdType="pmc">PMC4512854</ArticleId><ArticleId IdType="pubmed">26126792</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggia-Pr&#xe9;vot V, Fernandez CG, Riordan S, Vetrivel KS, Roseman J, Waters J, Bindokas VP, Vassar R, Thinakaran G (2014) Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. Mol Neurodegener 9:1. 10.1186/1750-1326-9-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-1</ArticleId><ArticleId IdType="pmc">PMC4031619</ArticleId><ArticleId IdType="pubmed">24386896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4:233&#x2013;234. 10.1038/85064</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Lu L, Tian JH, Zhu YB, Qiao H, Sheng ZH (2010) Snapin-regulated late endosomal transport is critical for efficient autophagy-lysosomal function in neurons. Neuron 68:73&#x2013;86. 10.1016/j.neuron.2010.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.022</ArticleId><ArticleId IdType="pmc">PMC2953270</ArticleId><ArticleId IdType="pubmed">20920792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Zakaria HM, Simone A, Sheng ZH (2012) Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr Biol 22:545&#x2013;552. 10.1016/j.cub.2012.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2012.02.005</ArticleId><ArticleId IdType="pmc">PMC3313683</ArticleId><ArticleId IdType="pubmed">22342752</ArticleId></ArticleIdList></Reference><Reference><Citation>Campsall KD, Mazerolle CJ, De Repentingy Y, Kothary R, Wallace VA (2002) Characterization of transgene expression and Cre recombinase activity in a panel of Thy-1 promoter-Cre transgenic mice. Dev Dynam 224:135&#x2013;143. 10.1002/dvdy.10092</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.10092</ArticleId><ArticleId IdType="pubmed">12112467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818&#x2013;23828. 10.1074/jbc.M701078200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701078200</ArticleId><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng XT, Zhou B, Lin MY, Cai Q, Sheng ZH (2015) Axonal autophagosomes recruit dynein for retrograde transport through fusion with late endosomes. J Cell Biol 209:377&#x2013;386. 10.1083/jcb.201412046</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201412046</ArticleId><ArticleId IdType="pmc">PMC4427784</ArticleId><ArticleId IdType="pubmed">25940348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25:9694&#x2013;9703. 10.1523/JNEUROSCI.2980-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2980-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciss&#xe9; M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 31:10427&#x2013;10431. 10.1523/JNEUROSCI.1459-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1459-11.2011</ArticleId><ArticleId IdType="pmc">PMC3314063</ArticleId><ArticleId IdType="pubmed">21775587</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24:1023&#x2013;1027. 10.1016/j.neurobiolaging.2003.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2003.09.001</ArticleId><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumming JN, Iserloh U, Kennedy ME (2004) Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Devel 7:536&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338962</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S (2013) Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 79:447&#x2013;460. 10.1016/j.neuron.2013.05.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.035</ArticleId><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Wang L, Ganguly A, Saikia JM, Wagner SL, Koo EH, Roy S (2016) Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat Neurosci 19:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782935</ArticleId><ArticleId IdType="pubmed">26642089</ArticleId></ArticleIdList></Reference><Reference><Citation>DiGiovanni J, Sun T, Sheng ZH (2012) Characterizing synaptic vesicle proteins using synaptosomal fractions and cultured hippocampal neurons. Curr Protoc Neurosci 2:2.7.1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532315</ArticleId><ArticleId IdType="pubmed">22470148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B, Lichtenthaler SF (2012) The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol 3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281277</ArticleId><ArticleId IdType="pubmed">22363289</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KB, Paxinos G (2001) The mouse brain in stereotaxic coordinates, Ed 2 San Diego: Academic.</Citation></Reference><Reference><Citation>Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC (2004) Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164:719&#x2013;725. 10.1016/S0002-9440(10)63159-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63159-8</ArticleId><ArticleId IdType="pmc">PMC1602259</ArticleId><ArticleId IdType="pubmed">14742275</ArticleId></ArticleIdList></Reference><Reference><Citation>Goslin K, Asmussen H, Banker G (1998) Rat hippocampal neurons in low density. In: Culturing nerve cells, Ed 2 (Banker G, Goslin K, eds), pp 339&#x2013;370. Cambridge, MA: MIT.</Citation></Reference><Reference><Citation>Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S (1988) The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52:329&#x2013;341. 10.1016/S0092-8674(88)80026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(88)80026-6</ArticleId><ArticleId IdType="pubmed">2964276</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ (1992) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357:500&#x2013;503. 10.1038/357500a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/357500a0</ArticleId><ArticleId IdType="pubmed">1608449</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L (2010) Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci 30:372&#x2013;381. 10.1523/JNEUROSCI.5341-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5341-09.2010</ArticleId><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Li F, Chang WP, Tang J (2005) GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem 280:11696&#x2013;11703. 10.1074/jbc.M411296200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M411296200</ArticleId><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96:3228&#x2013;3233. 10.1073/pnas.96.6.3228</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.6.3228</ArticleId><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW (2000) Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem 275:33729&#x2013;33737. 10.1074/jbc.M004175200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M004175200</ArticleId><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2:e355. 10.1371/journal.pmed.0020355</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020355</ArticleId><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28:11650&#x2013;11661. 10.1523/JNEUROSCI.3024-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3024-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671312</ArticleId><ArticleId IdType="pubmed">18987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, Carmona-Cuenca I, Caballero C, Ruano D, Gutierrez A, Vitorica J (2011) Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 286:18414&#x2013;18425. 10.1074/jbc.M110.209718</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.209718</ArticleId><ArticleId IdType="pmc">PMC3099658</ArticleId><ArticleId IdType="pubmed">21460223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R (2013) The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 126:329&#x2013;352. 10.1007/s00401-013-1152-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1152-3</ArticleId><ArticleId IdType="pmc">PMC3753469</ArticleId><ArticleId IdType="pubmed">23820808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang EL, Biscaro B, Piazza F, Tesco G (2012) BACE1 protein endocytosis and trafficking are differentially regulated by ubiquitination at lysine 501 and the Di-leucine motif in the carboxyl terminus. J Biol Chem 287:42867&#x2013;42880. 10.1074/jbc.M112.407072</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.407072</ArticleId><ArticleId IdType="pmc">PMC3522283</ArticleId><ArticleId IdType="pubmed">23109336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JS, Tian JH, Pan PY, Zald P, Li C, Deng C, Sheng ZH (2008) Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 132:137&#x2013;148. 10.1016/j.cell.2007.11.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.024</ArticleId><ArticleId IdType="pmc">PMC2259239</ArticleId><ArticleId IdType="pubmed">18191227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486&#x2013;489. 10.1126/science.1079469</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G (2005) BACE is degraded via the lysosomal pathway. J Biol Chem 280:32499&#x2013;32504. 10.1074/jbc.M506199200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M506199200</ArticleId><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Leenders M, Gerwin C, Sheng ZH (2004) Multidisciplinary approaches for characterizing synaptic vesicle proteins. Curr Protoc Neurosci 2:2.7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefort R, Pozueta J, Shelanski M (2012) Cross-linking of cell surface amyloid precursor protein leads to increased beta-amyloid peptide production in hippocampal neurons: implications for Alzheimer's disease. J Neurosci 32:10674&#x2013;10685. 10.1523/JNEUROSCI.6473-11.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6473-11.2012</ArticleId><ArticleId IdType="pmc">PMC3539764</ArticleId><ArticleId IdType="pubmed">22855816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853&#x2013;862. 10.1016/S0002-9440(10)65184-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65184-X</ArticleId><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Yan R (2010) Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int J Clin Exp Pathol 3:618&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907124</ArticleId><ArticleId IdType="pubmed">20661410</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S, Wallace KE, Holzbaur EL (2012) Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J Cell Biol 196:407&#x2013;417. 10.1083/jcb.201106120</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201106120</ArticleId><ArticleId IdType="pmc">PMC3283992</ArticleId><ArticleId IdType="pubmed">22331844</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A&#x3b2; oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29:1977&#x2013;1986. 10.1523/JNEUROSCI.2984-08.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2984-08.2009</ArticleId><ArticleId IdType="pmc">PMC2768427</ArticleId><ArticleId IdType="pubmed">19228952</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KE, Sheetz MP (2004) Axonal mitochondrial transport and potential are correlated. J Cell Sci 117:2791&#x2013;2804. 10.1242/jcs.01130</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.01130</ArticleId><ArticleId IdType="pubmed">15150321</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV Jr, Gan L (2014) Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nature medicine 20:1157&#x2013;1164. 10.1038/nm.3672</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3672</ArticleId><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15:331&#x2013;337. 10.1038/nm.1912</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1912</ArticleId><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, Koo EH, Masliah E, Tuszynski MH (2013) Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 33:15596&#x2013;15602. 10.1523/JNEUROSCI.5195-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5195-12.2013</ArticleId><ArticleId IdType="pmc">PMC3782628</ArticleId><ArticleId IdType="pubmed">24068826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. (2013) The role of autophagy in neurodegenerative disease. Nat Med 19:983&#x2013;997. 10.1038/nm.3232</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3232</ArticleId><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips RG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274&#x2013;285. 10.1037/0735-7044.106.2.274</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.106.2.274</ArticleId><ArticleId IdType="pubmed">1590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750&#x2013;754. 10.1126/science.1141736</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, Kandalepas PC, Buggia-Pr&#xe9;vot V, Nicholson DA, Thinakaran G, Vassar R (2016) Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A&#x3b2; generation in Alzheimer's disease. Acta Neuropathol 132:235&#x2013;256. 10.1007/s00401-016-1558-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1558-9</ArticleId><ArticleId IdType="pmc">PMC4947125</ArticleId><ArticleId IdType="pubmed">26993139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, Declerck I, Peric A, Raemaekers T, Menendez G, Zhou L, Veerle B, Coen K, Munck S, De Strooper B, Schiavo G, Annaert W (2011) ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. Proc Natl Acad Sci U S A 108:E559&#x2013;E568. 10.1073/pnas.1100745108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100745108</ArticleId><ArticleId IdType="pmc">PMC3161548</ArticleId><ArticleId IdType="pubmed">21825135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Walsh DM (2009) Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 4:48. 10.1186/1750-1326-4-48</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-4-48</ArticleId><ArticleId IdType="pmc">PMC2788538</ArticleId><ArticleId IdType="pubmed">19930651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci 22:9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537&#x2013;540. 10.1038/990114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990114</ArticleId><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933&#x2013;944. 10.1097/00005072-199708000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199708000-00011</ArticleId><ArticleId IdType="pubmed">9258263</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869&#x2013;1879. 10.1016/S0002-9440(10)64463-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64463-X</ArticleId><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24:3592&#x2013;3599. 10.1523/JNEUROSCI.5167-03.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5167-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK (2013) Accumulation of intraneuronal beta-amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses. PLoS one 8:e51965. 10.1371/journal.pone.0051965</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051965</ArticleId><ArticleId IdType="pmc">PMC3553177</ArticleId><ArticleId IdType="pubmed">23372648</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK (2010) Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci 30:14299&#x2013;14304. 10.1523/JNEUROSCI.3383-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3383-10.2010</ArticleId><ArticleId IdType="pmc">PMC2972675</ArticleId><ArticleId IdType="pubmed">20980585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Rahman N, Lin MT, Capetillo-Zarate E, Gouras GK (2011) Impaired beta-amyloid secretion in Alzheimer's disease pathogenesis. J Neurosci 31:15384&#x2013;15390. 10.1523/JNEUROSCI.2986-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2986-11.2011</ArticleId><ArticleId IdType="pmc">PMC3225957</ArticleId><ArticleId IdType="pubmed">22031884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW, Tanzi RE (2007) Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54:721&#x2013;737. 10.1016/j.neuron.2007.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.05.012</ArticleId><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian JH, Wu ZX, Unzicker M, Lu L, Cai Q, Li C, Schirra C, Matti U, Stevens D, Deng C, Rettig J, Sheng ZH (2005) The role of Snapin in neurosecretion: snapin knock-out mice exhibit impaired calcium-dependent exocytosis of large dense-core vesicles in chromaffin cells. J Neurosci 25:10546&#x2013;10555. 10.1523/JNEUROSCI.3275-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3275-05.2005</ArticleId><ArticleId IdType="pmc">PMC1803083</ArticleId><ArticleId IdType="pubmed">16280592</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735&#x2013;741. 10.1126/science.286.5440.735</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787&#x2013;12794. 10.1523/JNEUROSCI.3657-09.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3657-09.2009</ArticleId><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, Chowdhury S, Shepherd JD, Dehoff M, Li Y, Kuhl D, Huganir RL, Price DL, Scannevin R, Troncoso JC, Wong PC, Worley PF (2011) Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent beta-amyloid generation. Cell 147:615&#x2013;628. 10.1016/j.cell.2011.09.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.09.036</ArticleId><ArticleId IdType="pmc">PMC3207263</ArticleId><ArticleId IdType="pubmed">22036569</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Tripoli DL, Czerniewski L, Ballabio A, Cirrito JR, Diwan A, Lee JM (2015) Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing A&#x3b2; generation and amyloid plaque pathogenesis. J Neurosci 35:12137&#x2013;12151. 10.1523/JNEUROSCI.0705-15.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0705-15.2015</ArticleId><ArticleId IdType="pmc">PMC4556784</ArticleId><ArticleId IdType="pubmed">26338325</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH (2015) Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS mice. Neuron 87:355&#x2013;370. 10.1016/j.neuron.2015.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.06.026</ArticleId><ArticleId IdType="pmc">PMC4511489</ArticleId><ArticleId IdType="pubmed">26182418</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402:533&#x2013;537. 10.1038/990107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/990107</ArticleId><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P, Westaway D, Mathews PM, Levy E, Cuervo AM, Nixon RA (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 134:258&#x2013;277. 10.1093/brain/awq341</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq341</ArticleId><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9:3&#x2013;4. 10.1038/nm0103-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0103-3</ArticleId><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Cai Q (2014) Snapin-mediated BACE1 retrograde transport is essential for its degradation in lysosomes and regulation of APP processing in neurons. Cell Rep 6:24&#x2013;31. 10.1016/j.celrep.2013.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.12.008</ArticleId><ArticleId IdType="pmc">PMC3905048</ArticleId><ArticleId IdType="pubmed">24373968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Sun X, Starovoytov V, Cai Q (2015) Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet 24:2938&#x2013;2951. 10.1093/hmg/ddv056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv056</ArticleId><ArticleId IdType="pmc">PMC4406302</ArticleId><ArticleId IdType="pubmed">25678552</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, N&#xe4;slund J, Mathews PM, Cataldo AM, Nixon RA (2005) Macroautophagy&#x2013;a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171:87&#x2013;98. 10.1083/jcb.200505082</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200505082</ArticleId><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30:11938&#x2013;11950. 10.1523/JNEUROSCI.2357-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2357-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Yan XX (2009) Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30:2271&#x2013;2283. 10.1111/j.1460-9568.2009.07017.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2009.07017.x</ArticleId><ArticleId IdType="pmc">PMC2869535</ArticleId><ArticleId IdType="pubmed">20092570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Cai Q, Xie Y, Sheng ZH (2012) Snapin recruits dynein to BDNF-TrkB signaling endosomes for retrograde axonal transport and is essential for dendrite growth of cortical neurons. Cell Rep 2:42&#x2013;51. 10.1016/j.celrep.2012.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.06.010</ArticleId><ArticleId IdType="pmc">PMC3408618</ArticleId><ArticleId IdType="pubmed">22840395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28135241</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>[<sup>18</sup>F]FDG PET signal is driven by astroglial glutamate transport.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>395</EndPage><MedlinePgn>393-395</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4492</ELocationID><Abstract><AbstractText>Contributions of glial cells to neuroenergetics have been the focus of extensive debate. Here we provide positron emission tomography evidence that activation of astrocytic glutamate transport via the excitatory amino acid transporter GLT-1 triggers widespread but graded glucose uptake in the rodent brain. Our results highlight the need for a reevaluation of the interpretation of [<sup>18</sup>F]FDG positron emission tomography data, whereby astrocytes would be recognized as contributing to the [<sup>18</sup>F]FDG signal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Eduardo R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health University Institute, Departments of Neurology and Neurosurgery, Psychiatry, and Pharmacology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parent</LastName><ForeName>Maxime J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health University Institute, Departments of Neurology and Neurosurgery, Psychiatry, and Pharmacology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>D&#xe9;bora G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health University Institute, Departments of Neurology and Neurosurgery, Psychiatry, and Pharmacology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecrux</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyoung-Ihl</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Medical System Engineering &amp;School of Mechatronics, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Presbyterian Medical Center, Jeonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health University Institute, Departments of Neurology and Neurosurgery, Psychiatry, and Pharmacology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellerin</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamel</LastName><ForeName>Edith</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5223-7315</Identifier><AffiliationInfo><Affiliation>Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9116-1376</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging (MCSA), Douglas Mental Health University Institute, Departments of Neurology and Neurosurgery, Psychiatry, and Pharmacology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>115131-1</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027341">Excitatory Amino Acid Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>75J73V1629</RegistryNumber><NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2017 Feb 23;20(3):382-384. doi: 10.1038/nn.4513.</RefSource><PMID Version="1">28230843</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002443" MajorTopicYN="N">Ceftriaxone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027341" MajorTopicYN="N">Excitatory Amino Acid Transporter 1</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014738" MajorTopicYN="N">Vibrissae</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest</b>. The authors declare no conflict of interest. <b>Competing Financial Interests</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28135241</ArticleId><ArticleId IdType="mid">CAMS6451</ArticleId><ArticleId IdType="pmc">PMC5378483</ArticleId><ArticleId IdType="doi">10.1038/nn.4492</ArticleId><ArticleId IdType="pii">nn.4492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sokoloff L. Developmental neuroscience. 1993;15:194&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">7805571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzilotta JC, Phelps ME, Miller J, Kuhl DE. Neurology. 1981;31:503&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">6972012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008;49:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703818</ArticleId><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehlig A, Coles JA. Glia. 2007;55:1238&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17659529</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley CR, Stroman PW. The European journal of neuroscience. 2011;33:577&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">21314846</ArticleId></ArticleIdList></Reference><Reference><Citation>Volterra A, Meldolesi J. Nature reviews. Neuroscience. 2005;6:626&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2003;23:1282&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">14600434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32:1152&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390819</ArticleId><ArticleId IdType="pubmed">22027938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellerin L, Magistretti PJ. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:10625&#x2013;10629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45074</ArticleId><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutsinos-Porche B, et al. Cerebral cortex. 2003;13:1110&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">12967927</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutsinos-Porche B, et al. Neuron. 2003;37:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">12546822</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Pellerin L. Molecular psychiatry. 1996;1:445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154245</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, et al. Nature. 2005;433:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, et al. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2015</Citation></Reference><Reference><Citation>Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1995;15:1835&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578153</ArticleId><ArticleId IdType="pubmed">7891138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chugani HT, Phelps ME, Mazziotta JC. Annals of neurology. 1987;22:487&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">3501693</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps ME, Mazziotta JC. Science. 1985;228:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">2860723</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H, et al. NeuroImage. 2014;99:226&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen M. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2001;21:1367&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740198</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. The Lancet. Neurology. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends Neurosci. 2014 Nov;37(11):629&#x2013;41. doi: 10.1016/j.tins.2014.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.07.002</ArticleId><ArticleId IdType="pubmed">25151336</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta A, Rothstein JD, Martin LJ. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1997;17:8363&#x2013;8375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573756</ArticleId><ArticleId IdType="pubmed">9334410</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza DG, Bellaver B, Souza DO, Quincozes-Santos A. PloS one. 2013;8:e60282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610681</ArticleId><ArticleId IdType="pubmed">23555943</ArticleId></ArticleIdList></Reference><Reference><Citation>Debernardi R, Magistretti PJ, Pellerin L. Brain research. 1999;850:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10629746</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza DG, et al. Neurochemical research. 2016;41:1578&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">26915106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, et al. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2015;35:1169&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4640271</ArticleId><ArticleId IdType="pubmed">25806702</ArticleId></ArticleIdList></Reference><Reference><Citation>Worsley KJ, et al. Human brain mapping. 1996;4:58&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20408186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28178240</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>542</Volume><Issue>7641</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>C. elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress.</ArticleTitle><Pagination><StartPage>367</StartPage><EndPage>371</EndPage><MedlinePgn>367-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature21362</ELocationID><Abstract><AbstractText>The toxicity of misfolded proteins and mitochondrial dysfunction are pivotal factors that promote age-associated functional neuronal decline and neurodegenerative disease. Accordingly, neurons invest considerable cellular resources in chaperones, protein degradation, autophagy and mitophagy to maintain proteostasis and mitochondrial quality. Complicating the challenges of neuroprotection, misfolded human disease proteins and mitochondria can move into neighbouring cells via unknown mechanisms, which may promote pathological spread. Here we show that adult neurons from Caenorhabditis elegans extrude large (approximately 4&#x2009;&#x3bc;m) membrane-surrounded vesicles called exophers that can contain protein aggregates and organelles. Inhibition of chaperone expression, autophagy or the proteasome, in addition to compromising mitochondrial quality, enhances the production of exophers. Proteotoxically stressed neurons that generate exophers subsequently function better than similarly stressed neurons that did not produce exophers. The extruded exopher transits through surrounding tissue in which some contents appear degraded, but some non-degradable materials can subsequently be found in more remote cells, suggesting secondary release. Our observations suggest that exopher-genesis is a potential response to rid cells of neurotoxic components when proteostasis and organelle function are challenged. We propose that exophers are components of a conserved mechanism that constitutes a fundamental, but formerly unrecognized, branch of neuronal proteostasis and mitochondrial quality control, which, when dysfunctional or diminished with age, might actively contribute to pathogenesis in human neurodegenerative disease and brain ageing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Melentijevic</LastName><ForeName>Ilija</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Marton L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Meghan L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guasp</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harinath</LastName><ForeName>Girish</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Ken C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Photonics Center, Boston, Massachusetts 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurosciences, Universit&#xe9; de Montr&#xe9;al CRCHUM, Montr&#xe9;al H2X 0A9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neri</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CNRS, UMR 8256, Brain-C team, Paris, France, and Sorbonnes Universit&#xe9;s, University Pierre and Marie Curie (UPMC) Univ Paris 06, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabel</LastName><ForeName>Christopher V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Photonics Center, Boston, Massachusetts 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driscoll</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Nelson Biological Laboratories, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R24 OD010943</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD010440</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077929</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD071593</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008339</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046358</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2017 Feb 21;10(467):eaam9984. doi: 10.1126/scisignal.aam9984.</RefSource><PMID Version="1">28223419</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Apr;18(4):195. doi: 10.1038/nrn.2017.27.</RefSource><PMID Version="1">28228637</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Jun;32(6):841. doi: 10.1002/mds.27007.</RefSource><PMID Version="1">28394086</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055252" MajorTopicYN="N">Cell-Derived Microparticles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests statement</b> The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28178240</ArticleId><ArticleId IdType="mid">NIHMS840667</ArticleId><ArticleId IdType="pmc">PMC5336134</ArticleId><ArticleId IdType="doi">10.1038/nature21362</ArticleId><ArticleId IdType="pii">nature21362</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41&#x2013;66. doi: 10.1146/annurev.pathmechdis.2.010506.092044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathmechdis.2.010506.092044</ArticleId><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference><Reference><Citation>Federico A, et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322:254&#x2013;262. doi: 10.1016/j.jns.2012.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2012.05.030</ArticleId><ArticleId IdType="pubmed">22669122</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 2008;22:1427&#x2013;1438. doi: 10.1101/gad.1657108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1657108</ArticleId><ArticleId IdType="pmc">PMC2732416</ArticleId><ArticleId IdType="pubmed">18519635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Gedalya T, Cohen E. Quality control compartments coming of age. Traffic. 2012;13:635&#x2013;642. doi: 10.1111/j.1600-0854.2012.01330.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2012.01330.x</ArticleId><ArticleId IdType="pubmed">22280095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol. 2010;6:702&#x2013;706. doi: 10.1038/nrneurol.2010.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.145</ArticleId><ArticleId IdType="pmc">PMC4996353</ArticleId><ArticleId IdType="pubmed">21045796</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CH, et al. Transcellular degradation of axonal mitochondria. Proc Natl Acad Sci U S A. 2014;111:9633&#x2013;9638. doi: 10.1073/pnas.1404651111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1404651111</ArticleId><ArticleId IdType="pmc">PMC4084443</ArticleId><ArticleId IdType="pubmed">24979790</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth ML, et al. Neurite sprouting and synapse deterioration in the aging Caenorhabditis elegans nervous system. J Neurosci. 2012;32:8778&#x2013;8790. doi: 10.1523/JNEUROSCI.1494-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1494-11.2012</ArticleId><ArticleId IdType="pmc">PMC3427745</ArticleId><ArticleId IdType="pubmed">22745480</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig AL, Moser SC, Bailly AP, Gartner A. Methods for studying the DNA damage response in the Caenorhabdatis elegans germ line. Methods in cell biology. 2012;107:321&#x2013;352. doi: 10.1016/b978-0-12-394620-1.00011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-394620-1.00011-4</ArticleId><ArticleId IdType="pubmed">22226529</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins LA, Hedgecock EM, Thomson JN, Culotti JG. Mutant sensory cilia in the nematode Caenorhabditis elegans. Dev Biol. 1986;117:456&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">2428682</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker JA, et al. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci U S A. 2001;98:13318&#x2013;13323. doi: 10.1073/pnas.231476398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.231476398</ArticleId><ArticleId IdType="pmc">PMC60868</ArticleId><ArticleId IdType="pubmed">11687635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vayndorf EM, et al. Morphological remodeling of C. elegans neurons during aging is modified by compromised protein homeostasis. NPJ Aging Mech Dis. 2016;2 doi: 10.1038/npjamd.2016.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npjamd.2016.1</ArticleId><ArticleId IdType="pmc">PMC4920063</ArticleId><ArticleId IdType="pubmed">27347427</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbadia J, Morimoto RI. Proteostasis and longevity: when does aging really begin? F1000Prime Rep. 2014;6:7. doi: 10.12703/p6-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.12703/p6-7</ArticleId><ArticleId IdType="pmc">PMC3914504</ArticleId><ArticleId IdType="pubmed">24592319</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbadia J, Morimoto RI. Repression of the Heat Shock Response Is a Programmed Event at the Onset of Reproduction. Mol Cell. 2015;59:639&#x2013;650. doi: 10.1016/j.molcel.2015.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.06.027</ArticleId><ArticleId IdType="pmc">PMC4546525</ArticleId><ArticleId IdType="pubmed">26212459</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Rogers J, Murphy CT, Rongo C. EGF signalling activates the ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J. 2011;30:2990&#x2013;3003. doi: 10.1038/emboj.2011.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.195</ArticleId><ArticleId IdType="pmc">PMC3160178</ArticleId><ArticleId IdType="pubmed">21673654</ArticleId></ArticleIdList></Reference><Reference><Citation>Samann J, et al. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. The Journal of biological chemistry. 2009;284:16482&#x2013;16491. doi: 10.1074/jbc.M808255200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808255200</ArticleId><ArticleId IdType="pmc">PMC2713553</ArticleId><ArticleId IdType="pubmed">19251702</ArticleId></ArticleIdList></Reference><Reference><Citation>Springer W, Hoppe T, Schmidt E, Baumeister R. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet. 2005;14:3407&#x2013;3423. doi: 10.1093/hmg/ddi371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi371</ArticleId><ArticleId IdType="pubmed">16204351</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti C, Haynes CM, Yang Y, Harding HP, Ron D. Ubiquitin-like protein 5 positively regulates chaperone gene expression in the mitochondrial unfolded protein response. Genetics. 2006;174:229&#x2013;239. doi: 10.1534/genetics.106.061580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.106.061580</ArticleId><ArticleId IdType="pmc">PMC1569816</ArticleId><ArticleId IdType="pubmed">16816413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon MB, Remington SJ. Redox-sensitive green fluorescent protein: probes for dynamic intracellular redox responses. A review. Methods Mol Biol. 2008;476:51&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">19157008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghose P, Park EC, Tabakin A, Salazar-Vasquez N, Rongo C. Anoxia-reoxygenation regulates mitochondrial dynamics through the hypoxia response pathway, SKN-1/Nrf, and stomatin-like protein STL-1/SLP-2. PLoS Genet. 2013;9:e1004063. doi: 10.1371/journal.pgen.1004063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004063</ArticleId><ArticleId IdType="pmc">PMC3873275</ArticleId><ArticleId IdType="pubmed">24385935</ArticleId></ArticleIdList></Reference><Reference><Citation>Laker RC, et al. A novel MitoTimer reporter gene for mitochondrial content, structure, stress, and damage in vivo. The Journal of biological chemistry. 2014;289:12005&#x2013;12015. doi: 10.1074/jbc.M113.530527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.530527</ArticleId><ArticleId IdType="pmc">PMC4002107</ArticleId><ArticleId IdType="pubmed">24644293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji YB, Qu ZY, Zou X. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 2011;63:69&#x2013;78. doi: 10.1016/j.etp.2009.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etp.2009.09.010</ArticleId><ArticleId IdType="pubmed">19815401</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton A, et al. Endocytosis function of a ligand-gated ion channel homolog in Caenorhabditis elegans. Current biology : CB. 2005;15:1045&#x2013;1050. doi: 10.1016/j.cub.2005.04.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2005.04.057</ArticleId><ArticleId IdType="pubmed">15936276</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath S, et al. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. J Neurosci. 2012;32:8767&#x2013;8777. doi: 10.1523/JNEUROSCI.0615-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0615-12.2012</ArticleId><ArticleId IdType="pmc">PMC6622335</ArticleId><ArticleId IdType="pubmed">22745479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum-Krammer CI, Park KW, Li L, Melki R, Morimoto RI. Spreading of a prion domain from cell-to-cell by vesicular transport in Caenorhabditis elegans. PLoS Genet. 2013;9:e1003351. doi: 10.1371/journal.pgen.1003351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003351</ArticleId><ArticleId IdType="pmc">PMC3610634</ArticleId><ArticleId IdType="pubmed">23555277</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo M, et al. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J Cell Sci. 2013;126:3678&#x2013;3685. doi: 10.1242/jcs.126086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.126086</ArticleId><ArticleId IdType="pubmed">23781027</ArticleId></ArticleIdList></Reference><Reference><Citation>Abounit S, Zurzolo C. Wiring through tunneling nanotubes--from electrical signals to organelle transfer. J Cell Sci. 2012;125:1089&#x2013;1098. doi: 10.1242/jcs.083279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.083279</ArticleId><ArticleId IdType="pubmed">22399801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousset K, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol. 2009;11:328&#x2013;336. doi: 10.1038/ncb1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1841</ArticleId><ArticleId IdType="pubmed">19198598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce MM, Spartz EJ, Hong W, Luo L, Kopito RR. Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat Commun. 2015;6:6768. doi: 10.1038/ncomms7768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7768</ArticleId><ArticleId IdType="pmc">PMC4515032</ArticleId><ArticleId IdType="pubmed">25866135</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier J, et al. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med. 2013;11:94. doi: 10.1186/1479-5876-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-11-94</ArticleId><ArticleId IdType="pmc">PMC3668949</ArticleId><ArticleId IdType="pubmed">23574623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551&#x2013;555. doi: 10.1038/nature18928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18928</ArticleId><ArticleId IdType="pmc">PMC4968589</ArticleId><ArticleId IdType="pubmed">27466127</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Z, Sesti F. A Caenorhabditis elegans model system for amylopathy study. Journal of visualized experiments : JoVE. 2013:e50435. doi: 10.3791/50435.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50435</ArticleId><ArticleId IdType="pmc">PMC3698905</ArticleId><ArticleId IdType="pubmed">23711592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapes J, et al. CED-1, CED-7, and TTR-52 regulate surface phosphatidylserine expression on apoptotic and phagocytic cells. Curr Biol. 2012;22:1267&#x2013;1275. doi: 10.1016/j.cub.2012.05.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2012.05.052</ArticleId><ArticleId IdType="pmc">PMC3816170</ArticleId><ArticleId IdType="pubmed">22727702</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann B, et al. EFF-1-mediated regenerative axonal fusion requires components of the apoptotic pathway. Nature. 2015;517:219&#x2013;222. doi: 10.1038/nature14102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14102</ArticleId><ArticleId IdType="pubmed">25567286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachur TM, Audhya A, Pilgrim DB. UNC-45 is required for NMY-2 contractile function in early embryonic polarity establishment and germline cellularization in C. elegans. Developmental biology. 2008;314:287&#x2013;299. doi: 10.1016/j.ydbio.2007.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2007.11.028</ArticleId><ArticleId IdType="pubmed">18190904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 2003;30:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">12828945</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto A, Chelur D, Topalidou I, Chen X, Chalfie M. Enhanced neuronal RNAi in C. elegans using SID-1. Nat Methods. 2010;7:554&#x2013;559. doi: 10.1038/nmeth.1463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1463</ArticleId><ArticleId IdType="pmc">PMC2894993</ArticleId><ArticleId IdType="pubmed">20512143</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223&#x2013;234. doi: 10.1016/j.cell.2011.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.08.037</ArticleId><ArticleId IdType="pmc">PMC3441147</ArticleId><ArticleId IdType="pubmed">21962518</ArticleId></ArticleIdList></Reference><Reference><Citation>Scerbak C, et al. Insulin signaling in the aging of healthy and proteotoxically stressed mechanosensory neurons. Front Genet. 2014;5:212. doi: 10.3389/fgene.2014.00212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2014.00212</ArticleId><ArticleId IdType="pmc">PMC4107846</ArticleId><ArticleId IdType="pubmed">25101108</ArticleId></ArticleIdList></Reference><Reference><Citation>Topalidou I, et al. Genetically separable functions of the MEC-17 tubulin acetyltransferase affect microtubule organization. Curr Biol. 2012;22:1057&#x2013;1065. doi: 10.1016/j.cub.2012.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2012.03.066</ArticleId><ArticleId IdType="pmc">PMC3382010</ArticleId><ArticleId IdType="pubmed">22658602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabel CV, Antoine F, Chuang CF, Samuel AD, Chang C. Distinct cellular and molecular mechanisms mediate initial axon development and adult-stage axon regeneration in C. elegans. Development. 2008;135:1129&#x2013;1136. doi: 10.1242/dev.013995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.013995</ArticleId><ArticleId IdType="pubmed">18296652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends in cell biology. 2000;10:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann GJ, et al. Genetic analysis of lysosomal trafficking in Caenorhabditis elegans. Mol Biol Cell. 2005;16:3273&#x2013;3288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1165410</ArticleId><ArticleId IdType="pubmed">15843430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Hartwieg E, Horvitz HR. CED-1 is a transmembrane receptor that mediates cell corpse engulfment in C. elegans. Cell. 2001;104:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y, Roy R, Ambros V. Developmental regulation of a cyclin-dependent kinase inhibitor controls postembryonic cell cycle progression in Caenorhabditis elegans. Development. 1998;125:3585&#x2013;3597.</Citation><ArticleIdList><ArticleId IdType="pubmed">9716524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastelowitz N, Yin H. Exosomes and microvesicles: identification and targeting by particle size and lipid chemical probes. Chem Bio Chem. 2014;15:923&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098878</ArticleId><ArticleId IdType="pubmed">24740901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015;25:364&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">25683921</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015;25:24&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4650581</ArticleId><ArticleId IdType="pubmed">25342562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28176819</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota.</ArticleTitle><Pagination><StartPage>41802</StartPage><MedlinePgn>41802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">41802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep41802</ELocationID><Abstract><AbstractText>Alzheimer's disease is the most common form of dementia in the western world, however there is no cure available for this devastating neurodegenerative disorder. Despite clinical and experimental evidence implicating the intestinal microbiota in a number of brain disorders, its impact on Alzheimer's disease is not known. To this end we sequenced bacterial 16S rRNA from fecal samples of A&#x3b2; precursor protein (APP) transgenic mouse model and found a remarkable shift in the gut microbiota as compared to non-transgenic wild-type mice. Subsequently we generated germ-free APP transgenic mice and found a drastic reduction of cerebral A&#x3b2; amyloid pathology when compared to control mice with intestinal microbiota. Importantly, colonization of germ-free APP transgenic mice with microbiota from conventionally-raised APP transgenic mice increased cerebral A&#x3b2; pathology, while colonization with microbiota from wild-type mice was less effective in increasing cerebral A&#x3b2; levels. Our results indicate a microbial involvement in the development of Abeta amyloid pathology, and suggest that microbiota may contribute to the development of neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harach</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratoire d'Optique biom&#xe9;dicale, Institute of Microengineering, School of Engineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne, CH1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marungruang</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Food for Health Science Centre, Lund University, Medicon Village, 22381 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duthilleul</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratoire d'Optique biom&#xe9;dicale, Institute of Microengineering, School of Engineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne, CH1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheatham</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratoire d'Optique biom&#xe9;dicale, Institute of Microengineering, School of Engineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne, CH1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mc Coy</LastName><ForeName>K D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Mucosal Immunology Lab, Department of Clinical Research, University of Bern, Murtenstrasse, 35 CH - 3010 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neher</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe5;k</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Food for Health Science Centre, Lund University, Medicon Village, 22381 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Centre for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasser</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratoire d'Optique biom&#xe9;dicale, Institute of Microengineering, School of Engineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne, CH1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratoire d'Optique biom&#xe9;dicale, Institute of Microengineering, School of Engineering, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne, CH1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stemedica International, Avenue de S&#xe9;velin 20, CH1004 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Rep. 2017 Jul 10;7:46856. doi: 10.1038/srep46856.</RefSource><PMID Version="1">28691712</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28176819</ArticleId><ArticleId IdType="pmc">PMC5297247</ArticleId><ArticleId IdType="doi">10.1038/srep41802</ArticleId><ArticleId IdType="pii">srep41802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J. &amp; Selkoe D. J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356, doi: 10.1126/science.1072994 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y. &amp; Hand T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121&#x2013;141, doi: 10.1016/j.cell.2014.03.011 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId><ArticleId IdType="pmc">PMC4056765</ArticleId><ArticleId IdType="pubmed">24679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper L. V., Littman D. R. &amp; Macpherson A. J. Interactions between the microbiota and the immune system. Science 336, 1268&#x2013;1273, doi: 10.1126/science.1223490 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223490</ArticleId><ArticleId IdType="pmc">PMC4420145</ArticleId><ArticleId IdType="pubmed">22674334</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole P. W. &amp; Jeffery I. B. Gut microbiota and aging. Science 350, 1214&#x2013;1215, doi: 10.1126/science.aac8469 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac8469</ArticleId><ArticleId IdType="pubmed">26785481</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F. et al.. Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov Disord, doi: 10.1002/mds.26069 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26069</ArticleId><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins S. M. &amp; Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003&#x2013;2014, doi: 10.1053/j.gastro.2009.01.075 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.01.075</ArticleId><ArticleId IdType="pubmed">19457424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan J. F. &amp; O&#x2019;Mahony S. M. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 23, 187&#x2013;192, doi: 10.1111/j.1365-2982.2010.01664.x (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2010.01664.x</ArticleId><ArticleId IdType="pubmed">21303428</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan T. G. &amp; Cryan J. F. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 37, 1369&#x2013;1378, doi: 10.1016/j.psyneuen.2012.03.007 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2012.03.007</ArticleId><ArticleId IdType="pubmed">22483040</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsythe P., Sudo N., Dinan T., Taylor V. H. &amp; Bienenstock J. Mood and gut feelings. Brain, behavior, and immunity 24, 9&#x2013;16, doi: 10.1016/j.bbi.2009.05.058 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2009.05.058</ArticleId><ArticleId IdType="pubmed">19481599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao E. Y. et al.. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451&#x2013;1463, doi: 10.1016/j.cell.2013.11.024 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.11.024</ArticleId><ArticleId IdType="pmc">PMC3897394</ArticleId><ArticleId IdType="pubmed">24315484</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer K. et al.. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538&#x2013;541, doi: 10.1038/nature10554 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10554</ArticleId><ArticleId IdType="pubmed">22031325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A. et al.. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiology of aging 49, 60&#x2013;68, doi: 10.1016/j.neurobiolaging.2016.08.019 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.08.019</ArticleId><ArticleId IdType="pubmed">27776263</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter M. R. et al.. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer&#x2019;s disease. Scientific reports 6, 30028, doi: 10.1038/srep30028 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep30028</ArticleId><ArticleId IdType="pmc">PMC4956742</ArticleId><ArticleId IdType="pubmed">27443609</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R. et al.. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940&#x2013;946, doi: 10.1038/sj.embor.7400784 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabot S. et al.. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 4948&#x2013;4959, doi: 10.1096/fj.10-164921 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-164921</ArticleId><ArticleId IdType="pubmed">20724524</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Gamba A., Leal M. C., Morelli L. &amp; Castano E. M. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Current pharmaceutical design 15, 3644&#x2013;3655 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19925417</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners J. S., Barua N., Kehoe P. G., Gill S. &amp; Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. Journal of neuropathology and experimental neurology 70, 944&#x2013;959, doi: 10.1097/NEN.0b013e3182345e46 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182345e46</ArticleId><ArticleId IdType="pubmed">22002425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S. &amp; Lukiw W. J. Alzheimer&#x2019;s disease and the microbiome. Front Cell Neurosci 7, 153, doi: 10.3389/fncel.2013.00153 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00153</ArticleId><ArticleId IdType="pmc">PMC3775450</ArticleId><ArticleId IdType="pubmed">24062644</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins S. M., Surette M. &amp; Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10, 735&#x2013;742, doi: 10.1038/nrmicro2876 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2876</ArticleId><ArticleId IdType="pubmed">23000955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson J. K. et al.. Host-gut microbiota metabolic interactions. Science 336, 1262&#x2013;1267, doi: 10.1126/science.1223813 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223813</ArticleId><ArticleId IdType="pubmed">22674330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ericsson A. C. et al.. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PloS one 10, e0116704, doi: 10.1371/journal.pone.0116704 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116704</ArticleId><ArticleId IdType="pmc">PMC4326421</ArticleId><ArticleId IdType="pubmed">25675094</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon S. A mouse&#x2019;s house may ruin experiments. Nature 530, 264, doi: 10.1038/nature.2016.19335 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature.2016.19335</ArticleId><ArticleId IdType="pubmed">26887470</ArticleId></ArticleIdList></Reference><Reference><Citation>Couturier-Maillard A. et al.. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. The Journal of clinical investigation 123, 700&#x2013;711, doi: 10.1172/JCI62236 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62236</ArticleId><ArticleId IdType="pmc">PMC3561825</ArticleId><ArticleId IdType="pubmed">23281400</ArticleId></ArticleIdList></Reference><Reference><Citation>Everard A. et al.. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110, 9066&#x2013;9071, doi: 10.1073/pnas.1219451110 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1219451110</ArticleId><ArticleId IdType="pmc">PMC3670398</ArticleId><ArticleId IdType="pubmed">23671105</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan M. N. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer&#x2019;s disease. Nature clinical practice. Neurology 2, 159&#x2013;166, doi: 10.1038/ncpneuro0124 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneuro0124</ArticleId><ArticleId IdType="pubmed">16932542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi K., Onishi A., Fujiwara Y., Ishiwata K. &amp; Ishii K. Plasma Glucose Levels Affect Cerebral 18F-FDG Distribution in Cognitively Normal Subjects With Diabetes. Clinical nuclear medicine, doi: 10.1097/RLU.0000000000001147 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000001147</ArticleId><ArticleId IdType="pubmed">26859211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar S. W. Neuroinflammation in Alzheimer&#x2019;s disease: from pathogenesis to a therapeutic target. Journal of clinical immunology 34 Suppl 1, S64&#x2013;69, doi: 10.1007/s10875-014-0032-5 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-014-0032-5</ArticleId><ArticleId IdType="pubmed">24711006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y. et al.. Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APP/PSEN1dE9 mouse model of Alzheimer&#x2019;s disease. Journal of neurochemistry, doi: 10.1111/jnc.13437 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13437</ArticleId><ArticleId IdType="pubmed">26578392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D. K. et al.. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Science translational medicine 8, 340ra372, doi: 10.1126/scitranslmed.aaf1059 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf1059</ArticleId><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolpady J. et al.. Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment. Journal of diabetes research 2016, 7569431, doi: 10.1155/2016/7569431 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/7569431</ArticleId><ArticleId IdType="pmc">PMC4686713</ArticleId><ArticleId IdType="pubmed">26779542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavasani S. et al.. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PloS one 5, e9009, doi: 10.1371/journal.pone.0009009 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009009</ArticleId><ArticleId IdType="pmc">PMC2814855</ArticleId><ArticleId IdType="pubmed">20126401</ArticleId></ArticleIdList></Reference><Reference><Citation>Schippa S. et al.. A distinctive &#x2018;microbial signature&#x2019; in celiac pediatric patients. BMC microbiology 10, 175, doi: 10.1186/1471-2180-10-175 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-10-175</ArticleId><ArticleId IdType="pmc">PMC2906462</ArticleId><ArticleId IdType="pubmed">20565734</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X. J. et al.. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut microbes 1, 138&#x2013;147, doi: 10.4161/gmic.1.3.12360 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.1.3.12360</ArticleId><ArticleId IdType="pmc">PMC2927011</ArticleId><ArticleId IdType="pubmed">20740058</ArticleId></ArticleIdList></Reference><Reference><Citation>Matziouridou C., Marungruang N., Nguyen T. D., Nyman M. &amp; Fak F. Lingonberries reduce atherosclerosis in Apoe-/- mice in association with altered gut microbiota composition and improved lipid profile. Molecular nutrition &amp; food research, doi: 10.1002/mnfr.201500738 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201500738</ArticleId><ArticleId IdType="pubmed">26890232</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand R., Gill K. D. &amp; Mahdi A. A. Therapeutics of Alzheimer&#x2019;s disease: Past, present and future. Neuropharmacology 76 Pt A, 27&#x2013;50, doi: 10.1016/j.neuropharm.2013.07.004 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.07.004</ArticleId><ArticleId IdType="pubmed">23891641</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D. et al.. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18, 965&#x2013;977, doi: 10.1038/nn.4030 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4030</ArticleId><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M. T. et al.. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678, doi: 10.1038/nature11729 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay-Kumar M. et al.. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228&#x2013;231, doi: 10.1126/science.1179721 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1179721</ArticleId><ArticleId IdType="pmc">PMC4714868</ArticleId><ArticleId IdType="pubmed">20203013</ArticleId></ArticleIdList></Reference><Reference><Citation>Klindworth A. et al.. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 41, e1, doi: 10.1093/nar/gks808 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks808</ArticleId><ArticleId IdType="pmc">PMC3592464</ArticleId><ArticleId IdType="pubmed">22933715</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso J. G. et al.. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, 335&#x2013;336, doi: 10.1038/nmeth.f.303 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.f.303</ArticleId><ArticleId IdType="pmc">PMC3156573</ArticleId><ArticleId IdType="pubmed">20383131</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460&#x2013;2461, doi: 10.1093/bioinformatics/btq461 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq461</ArticleId><ArticleId IdType="pubmed">20709691</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSantis T. Z. et al.. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 72, 5069&#x2013;5072, doi: 10.1128/AEM.03006-05 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.03006-05</ArticleId><ArticleId IdType="pmc">PMC1489311</ArticleId><ArticleId IdType="pubmed">16820507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Garrity G. M., Tiedje J. M. &amp; Cole J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73, 5261&#x2013;5267, doi: 10.1128/AEM.00062-07 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00062-07</ArticleId><ArticleId IdType="pmc">PMC1950982</ArticleId><ArticleId IdType="pubmed">17586664</ArticleId></ArticleIdList></Reference><Reference><Citation>Klipper-Aurbach Y. et al.. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Medical hypotheses 45, 486&#x2013;490 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8748093</ArticleId></ArticleIdList></Reference><Reference><Citation>Segata N. et al.. Metagenomic biomarker discovery and explanation. Genome Biol 12, R60, doi: 10.1186/gb-2011-12-6-r60 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-6-r60</ArticleId><ArticleId IdType="pmc">PMC3218848</ArticleId><ArticleId IdType="pubmed">21702898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28179466</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.</ArticleTitle><Pagination><StartPage>930</StartPage><EndPage>937</EndPage><MedlinePgn>930-937</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000003680</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study included 3 independent prospective cohorts: the Lund (n = 278) and London (n = 117) cohorts, comprising healthy controls and patients with PD, progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), as well as an early disease cohort (n = 109) of patients with PD, PSP, MSA, or CBS with disease duration &#x2264;3 years. Blood NfL concentration was measured using an ultrasensitive single molecule array (Simoa) method, and the diagnostic accuracy to distinguish PD from APD was investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found strong correlations between blood and CSF concentrations of NfL (&#x3c1; &#x2265; 0.73-0.84, <i>p</i> &#x2264; 0.001). Blood NfL was increased in patients with MSA, PSP, and CBS (i.e., all APD groups) when compared to patients with PD as well as healthy controls in all cohorts (<i>p</i> &lt; 0.001). Furthermore, in the Lund cohort, blood NfL could accurately distinguish PD from APD (area under the curve [AUC] 0.91) with similar results in both the London cohort (AUC 0.85) and the early disease cohort (AUC 0.81).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Quantification of blood NfL concentration can be used to distinguish PD from APD. Blood-based NfL might consequently be included in the diagnostic workup of patients with parkinsonian symptoms in both primary care and specialized clinics.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class III evidence that blood NfL levels discriminate between PD and APD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden. Oskar.Hansson@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magdalinou</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsgren</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Radu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Clinical Memory Research Unit (O.H., S.J., S.H.), Department of Clinical Sciences, Lund University; Memory Clinic (O.H., S.J., S.H.), Sk&#xe5;ne University Hospital, Sweden; UCL Institute of Neurology (N.M., A.J.L., H.Z.), Queen Square, London, UK; Clinical Neurochemistry Laboratory (R.C., H.Z., K.B.), Institute of Neuroscience and Physiology (U.A.), The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal; UmanDiagnostics (N.N.), Ume&#xe5;; and Department of Pharmacology and Clinical Neuroscience (J.L., L.F.), Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Swedish BioFINDER study</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 88(10):922.</RefSource><PMID Version="1">28179467</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="Y">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28179466</ArticleId><ArticleId IdType="pmc">PMC5333515</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003680</ArticleId><ArticleId IdType="pii">WNL.0000000000003680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361025</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 2010;16:142&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19647470</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert MK, Aerts MB, Beenes M, et al. . CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 2015;6:91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419719</ArticleId><ArticleId IdType="pubmed">25999911</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007;28:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, Ohrfelt A, Constantinescu R, et al. . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">22925882</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdalinou NK, Paterson RW, Schott JM, et al. . A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015;86:1240&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4564944</ArticleId><ArticleId IdType="pubmed">25589779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, et al. . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016;54:1655&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015;84:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336091</ArticleId><ArticleId IdType="pubmed">25411441</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Lindqvist D, Francardo V, et al. . Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 2015;85:1834&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662706</ArticleId><ArticleId IdType="pubmed">26511451</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen Krut J, Mellberg T, Price RW, et al. . Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One 2014;9:e88591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921217</ArticleId><ArticleId IdType="pubmed">24523921</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Richard WP, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV Infection: a cross-sectional study. EBioMedicine 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. . Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Karydas A, Bang J, et al. . Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016;3:216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, et al. . Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 2016;91:56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjalmarsson C, Bjerke M, Andersson B, et al. . Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis 2014;6:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039292</ArticleId><ArticleId IdType="pubmed">24932109</ArticleId></ArticleIdList></Reference><Reference><Citation>Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 2012;7:e33606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319096</ArticleId><ArticleId IdType="pubmed">22496755</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2015;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS, Hall T, Berisha F, et al. . Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, Farahmand B, Bartlett JW, et al. . CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014;83:1945&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">25339208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajjadi SA, Acosta-Cabronero J, Patterson K, Diaz-de-Grenu LZ, Williams GB, Nestor PJ. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. Brain 2013;136:2253&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pubmed">23729473</ArticleId></ArticleIdList></Reference><Reference><Citation>Surova Y, Szczepankiewicz F, Latt J, et al. . Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. PLoS One 2013;8:e66022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681971</ArticleId><ArticleId IdType="pubmed">23785466</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto K, Matsusue E, Kanasaki Y, et al. . Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology 2012;54:947&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">22274571</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtbernd F, Eidelberg D. The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin Neurol 2014;34:202&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556352</ArticleId><ArticleId IdType="pubmed">24963679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012;7:e29868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261152</ArticleId><ArticleId IdType="pubmed">22279551</ArticleId></ArticleIdList></Reference><Reference><Citation>Silajdzic E, Minthon L, Bjorkqvist M, Hansson O. No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS One 2012;7(11):e50237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509147</ArticleId><ArticleId IdType="pubmed">23209684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28188218</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Focal Solute Trapping and Global Glymphatic Pathway Impairment in a Murine Model of Multiple Microinfarcts.</ArticleTitle><Pagination><StartPage>2870</StartPage><EndPage>2877</EndPage><MedlinePgn>2870-2877</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2112-16.2017</ELocationID><Abstract><AbstractText>Microinfarcts occur commonly in the aging brain as a consequence of diffuse embolic events and are associated with the development of vascular dementia and Alzheimer's disease. However, the manner in which disperse microscopic lesions reduce global cognitive function and increase the risk for Alzheimer's disease is unclear. The glymphatic system, which is a brain-wide perivascular network that supports the recirculation of CSF through the brain parenchyma, facilitates the clearance of interstitial solutes including amyloid &#x3b2; and tau. We investigated whether glymphatic pathway function is impaired in a murine model of multiple microinfarcts induced by intraarterial injection of cholesterol crystals. The analysis showed that multiple microinfarcts markedly impaired global influx of CSF along the glymphatic pathway. Although suppression of global glymphatic function was transient, resolving within 2 weeks of injury, CSF tracers also accumulated within tissue associated with microinfarcts. The effect of diffuse microinfarcts on global glymphatic pathway function was exacerbated in the mice aged 12 months compared with the 2- to 3-month-old mice. These findings indicate that glymphatic function is focally disrupted around microinfarcts and that the aging brain is more vulnerable to this disruption than the young brain. These observations suggest that microlesions may trap proteins and other interstitial solutes within the brain parenchyma, increasing the risk of amyloid plaque formation.<b>SIGNIFICANCE STATEMENT</b> Microinfarcts, small (&lt;1 mm) ischemic lesions, are strongly associated with age-related dementia. However, how these microscopic lesions affect global cognitive function and predispose to Alzheimer's disease is unclear. The glymphatic system is a brain-wide network of channels surrounding brain blood vessels that allows CSF to exchange with interstitial fluid, clearing away cellular wastes such as amyloid &#x3b2;. We observed that, in mice, microinfarcts impaired global glymphatic function and solutes from the CSF became trapped in tissue associated with microinfarcts. These data suggest that small, disperse ischemic lesions can impair glymphatic function across the brain and trapping of solutes in these lesions may promote protein aggregation and neuroinflammation and eventually lead to neurodegeneration, especially in the aging brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the authors 0270-6474/17/372870-08$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tongii Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan, China 430030.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Fengfei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tongii Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan, China 430030.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>SaiYue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tongii Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan, China 430030.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xuequn</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tongii Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan, China 430030.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tongii Hospital, Tongii Medical College, Huazhong University of Science and Technology, Wuhan, China 430030.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iliff</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642, iliffj@ohsu.edu Nedergaard@URMC.Rochester.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon 97239, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedergaard</LastName><ForeName>Maiken</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6502-6031</Identifier><AffiliationInfo><Affiliation>Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642, iliffj@ohsu.edu Nedergaard@URMC.Rochester.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Basic and Translational Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048769</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075177</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100366</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2024 May 1;44(18):e0636242024. doi: 10.1523/JNEUROSCI.0636-24.2024.</RefSource><PMID Version="1">38631916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">glymphatic</Keyword><Keyword MajorTopicYN="N">microinfarct</Keyword><Keyword MajorTopicYN="N">vascular dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28188218</ArticleId><ArticleId IdType="pmc">PMC5354332</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2112-16.2017</ArticleId><ArticleId IdType="pii">JNEUROSCI.2112-16.2017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212:991&#x2013;999. 10.1084/jem.20142290</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM (2001) Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study: the Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 70:9&#x2013;14. 10.1136/jnnp.70.1.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.70.1.9</ArticleId><ArticleId IdType="pmc">PMC1763449</ArticleId><ArticleId IdType="pubmed">11118240</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Haltia M, Palo J, Sulkava R, Paetau A (1988) Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatry 51:1037&#x2013;1044. 10.1136/jnnp.51.8.1037</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.51.8.1037</ArticleId><ArticleId IdType="pmc">PMC1033111</ArticleId><ArticleId IdType="pubmed">3216206</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri MM, Wilcock GK, Morris JH (1997) Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 63:749&#x2013;753. 10.1136/jnnp.63.6.749</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.63.6.749</ArticleId><ArticleId IdType="pmc">PMC2169843</ArticleId><ArticleId IdType="pubmed">9416809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaberel T, Gakuba C, Goulay R, Martinez De Lizarrondo S, Hanouz JL, Emery E, Touze E, Vivien D, Gauberti M (2014) Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis? Stroke 45:3092&#x2013;3096. 10.1161/STROKEAHA.114.006617</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.006617</ArticleId><ArticleId IdType="pubmed">25190438</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund M, Passant U, Sj&#xf6;beck M, Ghebremedhin E, Englund E (2006) Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry 21:681&#x2013;687. 10.1002/gps.1550</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1550</ArticleId><ArticleId IdType="pubmed">16802283</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4:147ra111. 10.1126/scitranslmed.3003748</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003748</ArticleId><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H (2013a) Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 123:1299&#x2013;1309. 10.1172/JCI67677</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI67677</ArticleId><ArticleId IdType="pmc">PMC3582150</ArticleId><ArticleId IdType="pubmed">23434588</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, Deane R, Nedergaard M (2013b) Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 33:18190&#x2013;18199. 10.1523/JNEUROSCI.1592-13.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1592-13.2013</ArticleId><ArticleId IdType="pmc">PMC3866416</ArticleId><ArticleId IdType="pubmed">24227727</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, Singh I, Deane R, Nedergaard M (2014) Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci 34:16180&#x2013;16193. 10.1523/JNEUROSCI.3020-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3020-14.2014</ArticleId><ArticleId IdType="pmc">PMC4252540</ArticleId><ArticleId IdType="pubmed">25471560</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x308;ovari E, Herrmann FR, Hof PR, Bouras C (2013) The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 39:498&#x2013;509. 10.1111/nan.12003</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12003</ArticleId><ArticleId IdType="pmc">PMC3637988</ArticleId><ArticleId IdType="pubmed">23163235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, Liew JA, Plog BA, Ding F, Deane R, Nedergaard M (2014) Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76:845&#x2013;861. 10.1002/ana.24271</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24271</ArticleId><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337&#x2013;341. 10.1038/nature14432</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Iliff JJ, Yang L, Yang J, Chen X, Chen MJ, Giese RN, Wang B, Shi X, Nedergaard M (2013) &#x2018;Hit and Run&#x2019; model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. J Cereb Blood Flow Metab 33:834&#x2013;845. 10.1038/jcbfm.2013.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2013.30</ArticleId><ArticleId IdType="pmc">PMC3677112</ArticleId><ArticleId IdType="pubmed">23443171</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MJ, Iliff JJ (2016) Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochim Biophys Acta 1862:442&#x2013;451. 10.1016/j.bbadis.2015.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.10.014</ArticleId><ArticleId IdType="pmc">PMC4755861</ArticleId><ArticleId IdType="pubmed">26499397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62:406&#x2013;413. 10.1002/ana.21208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21208</ArticleId><ArticleId IdType="pubmed">17879383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, Jack CR, Kaye J, Lim K, Larson EB, White L, Montine TJ (2011) Ecology of the aging human brain. Arch Neurol 68:1049&#x2013;1056. 10.1001/archneurol.2011.157</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.157</ArticleId><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC (2000) Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 59:931&#x2013;945. 10.1093/jnen/59.11.931</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.11.931</ArticleId><ArticleId IdType="pubmed">11089571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Iliff JJ, Liao Y, Chen MJ, Shinseki MS, Venkataraman A, Cheung J, Wang W, Nedergaard M (2012) Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts. J Neurosci 32:17948&#x2013;17960. 10.1523/JNEUROSCI.1860-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-12.2012</ArticleId><ArticleId IdType="pmc">PMC3541041</ArticleId><ArticleId IdType="pubmed">23238711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M (2013) Sleep drives metabolite clearance from the adult brain. Science 342:373&#x2013;377. 10.1126/science.1241224</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28199828</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>248</EndPage><MedlinePgn>235-248</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2016.12.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(16)30309-5</ELocationID><Abstract><AbstractText>Transplantation of neural stem cells (NSCs) can improve cognition in animal models of Alzheimer's disease (AD). However, AD is a protracted disorder, and prior studies have examined only short-term effects. We therefore used an immune-deficient model of AD (Rag-5xfAD mice) to examine long-term transplantation of human NSCs (StemCells Inc.; HuCNS-SCs). Five months after transplantation, HuCNS-SCs had engrafted and migrated throughout the hippocampus and exhibited no differences in survival or migration in response to &#x3b2;-amyloid pathology. Despite robust engraftment, HuCNS-SCs failed to terminally differentiate and over a quarter of the animals exhibited ectopic human cell clusters within the lateral ventricle. Unlike prior short-term experiments with research-grade HuCNS-SCs, we also found no evidence of improved cognition, no changes in brain-derived neurotrophic factor, and no increase in synaptic density. These data, while disappointing, reinforce the notion that individual human NSC lines need to be carefully assessed for efficacy and safety in appropriate long-term models.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Samuel E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Sue &amp; Bill Gross Stem Cell Research Center, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Stephen T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monuki</LastName><ForeName>Edwin S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Sue &amp; Bill Gross Stem Cell Research Center, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Department of Pathology &amp; Laboratory Medicine, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology &amp; Behavior, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Sue &amp; Bill Gross Stem Cell Research Center, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA; Institute for Memory Impairments &amp; Neurological Disorders, University of California Irvine, 845 Health Sciences Road, 3200 Gross Hall, Irvine, CA 92697, USA. Electronic address: mblurton@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD010420</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS082174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Stem Cell Reports. 2017 Feb 14;8(2):191-193. doi: 10.1016/j.stemcr.2017.01.024.</RefSource><PMID Version="1">28199825</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stem Cell Reports. 2017 Feb 14;8(2):195-197. doi: 10.1016/j.stemcr.2017.02.002.</RefSource><PMID Version="1">28199827</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002449" MajorTopicYN="N">Cell Aggregation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">HuCNS-SC</Keyword><Keyword MajorTopicYN="N">NSC</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword><Keyword MajorTopicYN="N">translation</Keyword><Keyword MajorTopicYN="N">transplantation</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28199828</ArticleId><ArticleId IdType="pmc">PMC5312253</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2016.12.019</ArticleId><ArticleId IdType="pii">S2213-6711(16)30309-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ager R.R., Davis J.L., Agazaryan A., Benavente F., Poon W.W., LaFerla F.M., Blurton-Jones M. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer&#x2019;s disease and neuronal loss. Hippocampus. 2015;25:813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722865</ArticleId><ArticleId IdType="pubmed">25530343</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12:459&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A.J., Haus D.L., Hooshmand M.J., Perez H., Sontag C.J., Cummings B.J. Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient. Regen. Med. 2011;6:367&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403688</ArticleId><ArticleId IdType="pubmed">21548741</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A.J., Piltti P.M., Hooshmand M.J., Nishi R.A., Cummings B.J. Preclinical Efficacy Failure of Human CNS-Derived Stem Cells for Use in the Pathway Study of Cervical Spinal Cord Injury. Stem Cell Rep. 2017;8 in this issue.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5312249</ArticleId><ArticleId IdType="pubmed">28199829</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkowitz A.L., Miller M.B., Mir S.A., Cagney D., Chavakula V., Guleria I., Aizer A., Ligon K.L., Chi J.H. Glioproliferative lesion of the spinal cord as a complication of &#x201c;Stem-Cell Tourism&#x201d;. N.&#xa0;Engl. J. Med. 2016;375:196&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">27331440</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 2009;106:13594&#x2013;13599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M., Spencer B., Michel S., Castello N.A., Agazaryan A.A., Davis J.L., M&#xfc;ller F.-J., Loring J.F., Masliah E., LaFerla F.M. Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cells Res. Ther. 2014;5:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055090</ArticleId><ArticleId IdType="pubmed">25022790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimadamore F., Amador-Arjona A., Chen C., Huang C.T., Terskikh A.V. SOX2-LIN28/let-7 pathway regulates proliferation and neurogenesis in neural precursors. Proc. Natl. Acad. Sci. USA. 2013;110:E3017&#x2013;E3026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740872</ArticleId><ArticleId IdType="pubmed">23884650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings B.J., Uchida N., Tamaki S.J., Salazar D.L., Hooshmand M., Summers R., Gage F.H., Anderson A.J. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc. Natl. Acad. Sci. USA. 2005;102:14069&#x2013;14074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1216836</ArticleId><ArticleId IdType="pubmed">16172374</ArticleId></ArticleIdList></Reference><Reference><Citation>Darr H., Benvenisty N. Genetic analysis of the role of the reprogramming gene LIN-28 in human embryonic stem cells. Stem Cells. 2009;27:352&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19038789</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L., Ohno M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer&#x2019;s disease. Neuropsychopharmacology. 2012;37:434&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242305</ArticleId><ArticleId IdType="pubmed">21900882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert A.D., Beres A.J., Barber A.E., Svendsen C.N. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson&#x2019;s disease. Exp. Neurol. 2008;209:213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18061591</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg N.R., Caesar J., Park A., Sedgh S., Finogenov G., Masliah E., Davis J., Blurton-Jones M. Neural stem cells rescue cognitive and motor dysfunction in a transgenic model of dementia with Lewy bodies through a BDNF-dependent mechanism. Stem Cell Reports. 2015;5:791&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649255</ArticleId><ArticleId IdType="pubmed">26489892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta N., Henry R.G., Strober J., Kang S.M., Lim D.A., Bucci M., Caverzasi E., Gaetano L., Mandelli M.L., Ryan T. Neural stem cell engraftment and myelination in the human brain. Sci. Transl. Med. 2012;4:155ra137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893824</ArticleId><ArticleId IdType="pubmed">23052294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton D.W., Webber D.J., Bilican B., Goedert M., Spillantini M.G., Chandran S. Cell-mediated neuroprotection in&#xa0;a mouse model of human tauopathy. J.&#xa0;Neurosci. 2010;30:9973&#x2013;9983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633376</ArticleId><ArticleId IdType="pubmed">20668182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassoun J., S&#xf6;ylemezoglu F., Gambarelli D., Figarella-Branger D., von Ammon K., Kleihues P. Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol. 1993;3:297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">8293189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA. 2003;100:15178&#x2013;15183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299944</ArticleId><ArticleId IdType="pubmed">14645703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hongpaisan J., Sun M.K., Alkon D.L. PKC &#x3b5; activation prevents synaptic loss, A&#x3b2; elevation, and cognitive deficits in Alzheimer&#x2019;s disease transgenic mice. J.&#xa0;Neurosci. 2011;31:630&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623433</ArticleId><ArticleId IdType="pubmed">21228172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P., Chen C., Wang R., Chechneva O.V., Chung S.H., Rao M.S., Pleasure D.E., Liu Y., Zhang Q., Deng W. hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury. Nat. Commun. 2013;4:2196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903179</ArticleId><ArticleId IdType="pubmed">23880652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara H., Okada Y., Imai T., Iwanami A., Mischel P.S., Okano H. Musashi1 cooperates in abnormal cell lineage protein 28 (Lin28)-mediated let-7 family microRNA biogenesis in early neural differentiation. J.&#xa0;Biol. Chem. 2011;286:16121&#x2013;16130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091221</ArticleId><ArticleId IdType="pubmed">21378162</ArticleId></ArticleIdList></Reference><Reference><Citation>Laywell E.D., Rakic P., Kukekov V.G., Holland E.C., Steindler D.A. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc. Natl. Acad. Sci. USA. 2000;97:13883&#x2013;13888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17670</ArticleId><ArticleId IdType="pubmed">11095732</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh S.E., Abud E.M., Lakatos A., Karimzadeh A., Yeung S.T., Davtyan H., Fote G.M., Lau L., Weinger J.G., Lane T.E. The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. USA. 2016;113:E1316&#x2013;E1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollison K.W., Fey T.A., Krause R.A., Andrews J.M., Bretheim P.T., Cusick P.K., Hsieh G.C., Luly J.R. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology. 1998;125:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">9570331</ArticleId></ArticleIdList></Reference><Reference><Citation>Njie E.G., Kantorovich S., Astary G.W., Green C., Zheng T., Semple-Rowland S.L., Steindler D.A., Sarntinoranont M., Streit W.J., Borchelt D.R. A preclinical assessment of neural stem cells as delivery vehicles for anti-amyloid therapeutics. PLoS One. 2012;7:e34097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319561</ArticleId><ArticleId IdType="pubmed">22496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J.&#xa0;Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard D., Miller S., Hawkins C.E., Bouffet E., Rogers H.A., Chan T.S.Y., Kim S.-K., Ra Y.-S., Fangusaro J., Korshunov A. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012;13:838&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615440</ArticleId><ArticleId IdType="pubmed">22691720</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodini C.O., Suzuki D.E., Saba-Silva N., Cappellano A., de Souza J.E., Cavalheiro S., Toledo S.R., Okamoto O.K. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J.&#xa0;Neurooncol. 2012;106:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">21725800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozkalne A., Hyman B.T., Spires-Jones T.L. Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiol. Dis. 2011;41:650&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031746</ArticleId><ArticleId IdType="pubmed">21134458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu J.K., Cho T., Wang Y.T., McLarnon J.G. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in&#xa0;an animal model of inflamed AD brain. J.&#xa0;Neuroinflammation. 2009;6:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804572</ArticleId><ArticleId IdType="pubmed">20030829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D., Basi G.S., Pangalos M.N. Treatment strategies targeting amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2012;2:a006387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426815</ArticleId><ArticleId IdType="pubmed">22951439</ArticleId></ArticleIdList></Reference><Reference><Citation>Selden N.R., Al-Uzri A., Huhn S.L., Koch T.K., Sikora D.M., Nguyen-Driver M.D., Guillaume D.J., Koh J.L., Gultekin S.H., Anderson J.C. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J.&#xa0;Neurosurg. Pediatr. 2013;11:643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">23581634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J., Chiao P., Bussi&#xe8;re T., Weinreb P.H., Williams L., Maier M., Dunstan R., Salloway S., Chen T., Ling Y. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim F.J., Keyoung H.M., Goldman J.E., Kim D.K., Jung H.W., Roy N.S., Goldman S.A. Neurocytoma is a tumor of adult neuronal progenitor cells. J.&#xa0;Neurosci. 2006;26:12544&#x2013;12555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674894</ArticleId><ArticleId IdType="pubmed">17135416</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821&#x2013;5828.</Citation><ArticleIdList><ArticleId IdType="pubmed">14522905</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag C.J., Uchida N., Cummings B.J., Anderson A.J. Injury to the spinal cord niche alters the engraftment dynamics of human neural stem cells. Stem Cell Reports. 2014;2:620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050489</ArticleId><ArticleId IdType="pubmed">24936450</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;ylemezoglu F., Scheithauer B.W., Esteve J., Kleihues P. Atypical central neurocytoma. J.&#xa0;Neuropathol. Exp. Neurol. 1997;56:551&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E.E., Lee R.J., Najafi A.R., Rice R.A., Elmore M.R., Blurton-Jones M., West B.L., Green K.N. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain. 2016;139:1265&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., McHugh J., Tork C., Shelley B., Klein S.M., Aebischer P., Svendsen C.N. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007;2:e689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglialatela G., Hogan D., Zhang W.R., Dineley K.T. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav. Brain Res. 2009;200:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663011</ArticleId><ArticleId IdType="pubmed">19162087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki S.J., Jacobs Y., Dohse M., Capela A., Cooper J.D., Reitsma M., He D., Tushinski R., Belichenko P.V., Salehi A. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell. 2009;5:310&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733542</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida N., Buck D.W., He D., Reitsma M.J., Masek M., Phan T.V., Tsukamoto A.S., Gage F.H., Weissman I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA. 2000;97:14720&#x2013;14725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18985</ArticleId><ArticleId IdType="pubmed">11121071</ArticleId></ArticleIdList></Reference><Reference><Citation>von Deimling A., Janzer R., Kleihues P., Wiestler O.D. Patterns of differentiation in central neurocytoma. An immunohistochemical study of eleven biopsies. Acta Neuropathol. 1990;79:473&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">2109481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., O&#x2019;Bara M.A., Pol S.U., Sim F.J. CD133/CD140a-based isolation of distinct human multipotent neural progenitor cells and oligodendrocyte progenitor cells. Stem Cells Dev. 2013;22:2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715795</ArticleId><ArticleId IdType="pubmed">23488628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki T.R., Blurton-Jones M., Morrissette D.A., Kitazawa M., Oddo S., LaFerla F.M. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J.&#xa0;Neurosci. 2007;27:11925&#x2013;11933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673368</ArticleId><ArticleId IdType="pubmed">17978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Deng W., Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28192553</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>452</EndPage><MedlinePgn>445-452</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.4847</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Patients carrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of disease, suggesting the presence of modifying factors.</AbstractText><AbstractText Label="OBJECTIVE">To provide clinical-based evidence for disease anticipation in families carrying a C9orf72 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generations.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study was performed from June 16, 2000, to June 1, 2016, in 36 extended Belgian families in which a C9orf72 repeat expansion was segregating. The generational effect on age at onset, disease duration, and age at death was estimated using a mixed effects Cox proportional hazards regression model, including random-effects terms for within-family correlation and kinship. Time until disease onset or last examination, time from disease onset until death or last examination, or age at death was collected for for 244 individuals (132 proven or obligate C9orf72 carriers), of whom 147 were clinically affected (89 proven or obligate C9orf72 carriers).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Generational effect on age at onset, disease duration, and age at death.</AbstractText><AbstractText Label="RESULTS">Among the 111 individuals with age at onset available (66 men and 45 women; mean [SD] age, 57.2 [9.1] years), the mean (SD) age at onset per generation (from earliest-born to latest-born generation) was 62.5 (8.3), 57.1 (8.2), 54.6 (10.2), and 49.3 (7.5) years. Censored regression analysis on all affected and unaffected at-risk relatives confirmed a decrease in age at onset in successive generations (P&#x2009;&lt;&#x2009;.001). No generational effect was observed for disease duration or age at death.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The clinical data provide supportive evidence for the occurrence of disease anticipation in families carrying a C9orf72 repeat expansion by means of a decrease in age at onset across successive generations. This finding may help clinicians decide from which age onward it may be relevant to clinically follow presymptomatic individuals who carry a C9orf72 repeat expansion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Mossevelde</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium3Department of Neurology and Memory Clinic, Hospital Network Antwerp Middelheim and Hoge Beuken, Antwerp, Belgium4Department of Neurology, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Zee</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijselinck</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bleecker</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieben</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium5Department of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Faculty of Medicine, KU Leuven, Leuven, Belgium7Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Langenhove</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium4Department of Neurology, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baets</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium4Department of Neurology, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deryck</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, General Hospital Sint-Jan Brugge-Oostende, Brugge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santens</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanoiu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Saint-Luc University Hospital and Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Christiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jessa Hospital, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe4;umer</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Broeck</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattheijssens</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jonghe</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium4Department of Neurology, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cras</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute Born-Bunge, University of Antwerp, Antwerp, Belgium4Department of Neurology, Antwerp University Hospital, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruts</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Institute Born-Bunge, University of Antwerp, Antwerp, Belgium3Department of Neurology and Memory Clinic, Hospital Network Antwerp Middelheim and Hoge Beuken, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute Born-Bunge, University of Antwerp, Antwerp, Belgium3Department of Neurology and Memory Clinic, Hospital Network Antwerp Middelheim and Hoge Beuken, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurology, VIB, Antwerp, Belgium2Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Belgian Neurology (BELNEU) Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="Y">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28192553</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.4847</ArticleId><ArticleId IdType="pii">2601228</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28209725</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>214</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Soluble TREM2 induces inflammatory responses and enhances microglial survival.</ArticleTitle><Pagination><StartPage>597</StartPage><EndPage>607</EndPage><MedlinePgn>597-607</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20160844</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor expressed in microglia in the brain. A soluble form of TREM2 (sTREM2) derived from proteolytic cleavage of the cell surface receptor is increased in the preclinical stages of AD and positively correlates with the amounts of total and phosphorylated tau in the cerebrospinal fluid. However, the physiological and pathological functions of sTREM2 remain unknown. Here, we show that sTREM2 promotes microglial survival in a PI3K/Akt-dependent manner and stimulates the production of inflammatory cytokines depending on NF-&#x3ba;B. Variants of sTREM2 carrying AD risk-associated mutations were less potent in both suppressing apoptosis and triggering inflammatory responses. Importantly, sTREM2 delivered to the hippocampi of both wild-type and <i>Trem2</i>-knockout mice elevated the expression of inflammatory cytokines and induced morphological changes of microglia. Collectively, these data indicate that sTREM2 triggers microglial activation inducing inflammatory responses and promoting survival. This study has implications for the pathogenesis of AD and provides insights into targeting sTREM2 pathway for AD therapy.</AbstractText><CopyrightInformation>&#xa9; 2017 Zhong et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Fen</ForeName><Initials>XF</Initials><Identifier Source="ORCID">0000-0002-2435-7982</Identifier><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China bu.guojun@mayo.edu chenxf@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen Research Institute of Xiamen University, Shenzhen 518063, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zongqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ruizhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Daxin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinxiu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Linbei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Honghua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Painter</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5950-2449</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atagi</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5194-4269</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-7203-3926</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Wu</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Aging Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, Medical College, Xiamen University, Xiamen 361102, China bu.guojun@mayo.edu chenxf@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2017 Mar 14;10(470):eaan1468. doi: 10.1126/scisignal.aan1468.</RefSource><PMID Version="1">28292955</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28209725</ArticleId><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="doi">10.1084/jem.20160844</ArticleId><ArticleId IdType="pii">jem.20160844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y., Liu C.C., Painter M.M., Chen X.F., Verbeeck C., Zheng H., Li X., Rademakers R., Kang S.S., Xu H., et al. . 2015. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J. Biol. Chem. 290:26043&#x2013;26050. 10.1074/jbc.M115.679043</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.C., DeVaux L.B., and Farzan M.. 2015. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J. Biol. Chem. 290:26033&#x2013;26042. 10.1074/jbc.M115.677286</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.677286</ArticleId><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B., Ferrari F., Galimberti D., Nacmias B., Barone C., Bagnoli S., Fenoglio C., Piaceri I., Archetti S., Bonvicini C., et al. . 2014. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging. 35:934.e7&#x2013;934.e10. 10.1016/j.neurobiolaging.2013.09.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.017</ArticleId><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A., Dietrich J., and Colonna M.. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164:4991&#x2013;4995. 10.4049/jimmunol.164.10.4991</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.10.4991</ArticleId><ArticleId IdType="pubmed">10799849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispert J.D., Su&#xe1;rez-Calvet M., Mont&#xe9; G.C., Tucholka A., Falcon C., Rojas S., Rami L., S&#xe1;nchez-Valle R., Llad&#xf3; A., Kleinberger G., et al. . 2016. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer&#x2019;s disease. Alzheimers Dement. 12:1259&#x2013;1272. 10.1016/j.jalz.2016.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.005</ArticleId><ArticleId IdType="pubmed">27423963</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., and Hardy J.. 2013. TREM2 and neurodegenerative disease. N. Engl. J. Med. 369:1569&#x2013;1570. 10.1056/NEJMc1306509</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1306509</ArticleId><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R.J., Lohmann E., Br&#xe1;s J.M., Gibbs J.R., Rohrer J.D., Gurunlian N., Dursun B., Bilgic B., Hanagasi H., Gurvit H., et al. . 2013b Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70:78&#x2013;84. 10.1001/jamaneurol.2013.579</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.579</ArticleId><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. Alzheimer Genetic Analysis Group . 2013a TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A., Heywood W., Paterson R., Magdalinou N., Svensson J., Johansson P., &#xd6;hrfelt A., Blennow K., Hardy J., Schott J., et al. . 2016. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol. Neurodegener. 11:3 10.1186/s13024-016-0071-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0071-x</ArticleId><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.C., Benitez B.A., Karch C.M., Cooper B., Skorupa T., Carrell D., Norton J.B., Hsu S., Harari O., Cai Y., et al. . 2014. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum. Mol. Genet. 23:5838&#x2013;5846. 10.1093/hmg/ddu277</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.C., Carrasquillo M.M., Benitez B.A., Skorupa T., Carrell D., Patel D., Lincoln S., Krishnan S., Kachadoorian M., Reitz C., et al. . 2015. TREM2 is associated with increased risk for Alzheimer&#x2019;s disease in African Americans. Mol. Neurodegener. 10:19 10.1186/s13024-015-0016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0016-9</ArticleId><ArticleId IdType="pmc">PMC4426167</ArticleId><ArticleId IdType="pubmed">25886450</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. . 2013. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:107&#x2013;116. 10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G., Yamanishi Y., Su&#xe1;rez-Calvet M., Czirr E., Lohmann E., Cuyvers E., Struyfs H., Pettkus N., Wenninger-Weinzierl A., Mazaheri F., et al. . 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6:243ra86 10.1126/scitranslmed.3009093</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009093</ArticleId><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xfc;nemann H.H., Ridha B.H., Magy L., Wherrett J.R., Hemelsoet D.M., Keen R.W., De Bleecker J.L., Rossor M.N., Marienhagen J., Klein H.E., et al. . 2005. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 64:1502&#x2013;1507. 10.1212/01.WNL.0000160304.00003.CA</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000160304.00003.CA</ArticleId><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Korvatska O., Leverenz J.B., Jayadev S., McMillan P., Kurtz I., Guo X., Rumbaugh M., Matsushita M., Girirajan S., Dorschner M.O., et al. . 2015. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: Clinical, genetic, and neuropathological study. JAMA Neurol. 72:920&#x2013;927. 10.1001/jamaneurol.2015.0979</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0979</ArticleId><ArticleId IdType="pmc">PMC4825672</ArticleId><ArticleId IdType="pubmed">26076170</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I., De Septenville A., Guerreiro R., Bras J., Camuzat A., Caroppo P., Lattante S., Couarch P., Kabashi E., Bouya-Ahmed K., et al. . 2014. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol. Aging. 35:2419.e23&#x2013;2419.e25. 10.1016/j.neurobiolaging.2014.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.04.010</ArticleId><ArticleId IdType="pmc">PMC4208293</ArticleId><ArticleId IdType="pubmed">24910390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.C., Liu W., Brosnan C.F., and Dickson D.W.. 1994. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia. 12:309&#x2013;318. 10.1002/glia.440120407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.440120407</ArticleId><ArticleId IdType="pubmed">7890333</ArticleId></ArticleIdList></Reference><Reference><Citation>Numasawa Y., Yamaura C., Ishihara S., Shintani S., Yamazaki M., Tabunoki H., and Satoh J.I.. 2011. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur. J. Neurol. 18:1179&#x2013;1183. 10.1111/j.1468-1331.2010.03311.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03311.x</ArticleId><ArticleId IdType="pubmed">21834902</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M.M., Atagi Y., Liu C.C., Rademakers R., Xu H., Fryer J.D., and Bu G.. 2015. TREM2 in CNS homeostasis and neurodegenerative disease. Mol. Neurodegener. 10:43 10.1186/s13024-015-0040-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0040-9</ArticleId><ArticleId IdType="pmc">PMC4560063</ArticleId><ArticleId IdType="pubmed">26337043</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., et al. . 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71:656&#x2013;662. 10.1086/342259</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L., Buonsanti C., Cella M., Tassi I., Schmidt R.E., Fenoglio C., Rinker J. II, Naismith R.T., Panina-Bordignon P., Passini N., et al. . 2008. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 131:3081&#x2013;3091. 10.1093/brain/awn217</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn217</ArticleId><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L., Deming Y., Del-&#xc1;guila J.L., Ghezzi L., Holtzman D.M., Fagan A.M., Fenoglio C., Galimberti D., Borroni B., and Cruchaga C.. 2016. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 131:925&#x2013;933. 10.1007/s00401-016-1533-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G., Ouyang G., and Bao S.. 2005. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9:59&#x2013;71. 10.1111/j.1582-4934.2005.tb00337.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2005.tb00337.x</ArticleId><ArticleId IdType="pmc">PMC6741304</ArticleId><ArticleId IdType="pubmed">15784165</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M., Kleinberger G., Araque Caballero M.A., Brendel M., Rominger A., Alcolea D., Fortea J., Lle&#xf3; A., Blesa R., Gispert J.D., et al. . 2016. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol. Med. 8:466&#x2013;476. 10.15252/emmm.201506123</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomozawa Y., Inoue T., Takahashi M., Adachi M., and Satoh M.. 1996. Apoptosis of cultured microglia by the deprivation of macrophage colony-stimulating factor. Neurosci. Res. 25:7&#x2013;15. 10.1016/0168-0102(96)01021-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-0102(96)01021-8</ArticleId><ArticleId IdType="pubmed">8808795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. . 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 160:1061&#x2013;1071. 10.1016/j.cell.2015.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Byers D.E., Jin X., Agapov E., Alexander-Brett J., Patel A.C., Cella M., Gilfilan S., Colonna M., Kober D.L., et al. . 2015. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J. Exp. Med. 212:681&#x2013;697. 10.1084/jem.20141732</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20141732</ArticleId><ArticleId IdType="pmc">PMC4419356</ArticleId><ArticleId IdType="pubmed">25897174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., and Walter J.. 2013. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J. Biol. Chem. 288:33027&#x2013;33036. 10.1074/jbc.M113.517540</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.517540</ArticleId><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L., Chen X.F., Zhang Z.L., Wang Z., Shi X.Z., Xu K., Zhang Y.W., Xu H., and Bu G.. 2015. DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response. J. Biol. Chem. 290:15866&#x2013;15877. 10.1074/jbc.M115.645986</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.645986</ArticleId><ArticleId IdType="pmc">PMC4505493</ArticleId><ArticleId IdType="pubmed">25957402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W., Zheng H., Shao X., Wang W., Yao Q., and Li Z.. 2010. Excitotoxicity of TNFalpha derived from KA activated microglia on hippocampal neurons in vitro and in vivo. J. Neurochem. 114:386&#x2013;396. 10.1111/j.1471-4159.2010.06763.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06763.x</ArticleId><ArticleId IdType="pubmed">20438614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Wang S., Yu L., Yang H., Tan R., Yin K., Jin J., Zhao H., Guan D., and Xu Y.. 2014. TL-2 attenuates &#x3b2;-amyloid induced neuronal apoptosis through the AKT/GSK-3&#x3b2;/&#x3b2;-catenin pathway. Int. J. Neuropsychopharmacol. 17:1511&#x2013;1519. 10.1017/S1461145714000315</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145714000315</ArticleId><ArticleId IdType="pubmed">24641999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28241356</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>317</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>727</EndPage><MedlinePgn>717-727</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2016.21044</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions.</AbstractText><AbstractText Label="OBJECTIVE">To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Testosterone Trials (TTrials) were 7 trials to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n&#x2009;=&#x2009;394) or placebo (n&#x2009;=&#x2009;394). A subgroup of 493 men met criteria for AAMI based on baseline subjective memory complaints and objective memory performance. Enrollment in the TTrials began June 24, 2010; the final participant completed treatment and assessment in June 2014.</AbstractText><AbstractText Label="INTERVENTIONS">Testosterone gel (adjusted to maintain the testosterone level within the normal range for young men) or placebo gel for 1 year.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was the mean change from baseline to 6 months and 12 months for delayed paragraph recall (score range, 0 to 50) among men with AAMI. Secondary outcomes were mean changes in visual memory (Benton Visual Retention Test; score range, 0 to -26), executive function (Trail-Making Test B minus A; range, -290 to 290), and spatial ability (Card Rotation Test; score range, -80 to 80) among men with AAMI. Tests were administered at baseline, 6 months, and 12 months.</AbstractText><AbstractText Label="RESULTS">Among the 493 men with AAMI (mean age, 72.3 years [SD, 5.8]; mean baseline testosterone, 234 ng/dL [SD, 65.1]), 247 were assigned to receive testosterone and 246 to receive placebo. Of these groups, 247 men in the testosterone group and 245 men in the placebo completed the memory study. There was no significant mean change from baseline to 6 and 12 months in delayed paragraph recall score among men with AAMI in the testosterone and placebo groups (adjusted estimated difference, -0.07 [95% CI, -0.92 to 0.79]; P&#x2009;=&#x2009;.88). Mean scores for delayed paragraph recall were 14.0 at baseline, 16.0 at 6 months, and 16.2 at 12 months in the testosterone group and 14.4 at baseline, 16.0 at 6 months, and 16.5 at 12 months in the placebo group. Testosterone was also not associated with significant differences in visual memory (-0.28 [95% CI, -0.76 to 0.19]; P&#x2009;=&#x2009;.24), executive function (-5.51 [95% CI, -12.91 to 1.88]; P&#x2009;=&#x2009;.14), or spatial ability (-0.12 [95% CI, -1.89 to 1.65]; P&#x2009;=&#x2009;.89).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among older men with low testosterone and age-associated memory impairment, treatment with testosterone for 1 year compared with placebo was not associated with improved memory or other cognitive functions.</AbstractText><AbstractText Label="TRIAL REGISTRATION">clinicaltrials.gov Identifier: NCT00799617.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Alvin M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington3Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington School of Medicine, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens-Shields</LastName><ForeName>Alisa J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellenberg</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Geriatric Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumaker</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pleasants</LastName><ForeName>Debbie D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett-Connor</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Division of Epidemiology, Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhasin</LastName><ForeName>Shalender</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health, Aging, and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauley</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crandall</LastName><ForeName>Jill P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Divisions of Endocrinology and Geriatrics, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Glenn R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Molecular and Cellular Biology, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas13Baylor St Luke's Medical Center, Houston, Texas14Department of Medicine, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ensrud</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis15Minneapolis Veterans Affairs Health Care System. Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrar</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Cora E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Preventive Medicine, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molitch</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahor</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Aging and Geriatric Research, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdloff</LastName><ForeName>Ronald S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Harbor-University of California at Los Angeles Medical Center, Torrance21Los Angeles Biomedical Research Institute, Torrance, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cifelli</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anton</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Aging and Geriatric Research, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basaria</LastName><ForeName>Shehzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diem</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Harbor-University of California at Los Angeles Medical Center, Torrance21Los Angeles Biomedical Research Institute, Torrance, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00799617</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K07 AG043587</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG031679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG030644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK079626</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG021342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK079626</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020541</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005782">Gels</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Feb 21;317(7):699-701. doi: 10.1001/jama.2017.0129.</RefSource><PMID Version="1">28241336</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2017 May;159(8):42. doi: 10.1007/s15006-017-9573-x.</RefSource><PMID Version="1">28466321</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2017 May 16;166(10):JC56. doi: 10.7326/ACPJC-2017-166-10-056.</RefSource><PMID Version="1">28505640</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Asian J Androl. 2017 Sep-Oct;19(5):512-514. doi: 10.4103/aja.aja_14_17.</RefSource><PMID Version="1">28566558</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Jun 13;317(22):2335. doi: 10.1001/jama.2017.5241.</RefSource><PMID Version="1">28609527</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Resnick reports receiving grants from the National Institute on Aging (NIA), National Institutes of Health (NIH), and AbbVie (formerly Solvay &amp; Abbott Lab) and being an intramural employee of NIA/NIH. Dr Matsumoto reports receiving personal fees from AbbVie, Endo, Lilly, Lipocine, and Clarus Therapeutics. Dr Stephens-Shields reports receiving grants from NIA, NIH, and AbbVie. Dr Ellenberg reports receiving grants from NIH and AbbVie. Dr Gill reports receiving grants from NIH. Dr Bhasin reports receiving grants from NIA, AbbVie, Lilly, and Transition Therapeutics; personal fees from AbbVie, Lilly, and Regeneron; a patent pending for a free testosterone calculator; and holding equity interest in FPC, LLC. Dr Cunningham reports receiving personal fees from AbbVie, Apricus Biosciences, Besins Healthcare, Clarus Therapeutics, Endo, Ferring Pharmaceuticals, Lilly, Pfizer, Repros Therapeutics. Dr Ensrud reports receiving grants from NIA. Dr Farrar reports receiving grants from NIA, NIH, and AbbVie. Dr Lewis reports receiving grants from NIH and AbbVie. Dr Molitch reports receiving grants from NIH and Abbott Laboratories and personal fees from AbbVie, Lilly, and Pfizer. Dr Swerdloff reports receiving grant funding from the Bone Trial of the Testosterone Trial, Clarus Therapeutics, Lipocine, and Antares Pharma and personal fees from Clarus Therapeutics and Antares Pharma. Dr Basaria reports receiving personal fees from Lilly and Takeda. Dr Diem reports receiving grants from NIA. Dr Wang reports receiving grants from Besins Health International, Clarus Therapeutics, and Lipocine and personal fees from Antares, TesoRx, and Besins Health International. Dr Snyder reports receiving grants from NIA, NIH, and AbbVie and personal fees from Watson Laboratories. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28241356</ArticleId><ArticleId IdType="mid">NIHMS857019</ArticleId><ArticleId IdType="pmc">PMC5433758</ArticleId><ArticleId IdType="doi">10.1001/jama.2016.21044</ArticleId><ArticleId IdType="pii">2603930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schaie KW, Willis SL. Age difference patterns of psychometric intelligence in adulthood: generalizability within and across ability domains. Psychol Aging. 1993;8(1):44&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">8461114</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK. Models of visuospatial and verbal memory across the adult life span. Psychol Aging. 2002;17(2):299&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061414</ArticleId></ArticleIdList></Reference><Reference><Citation>Price L, Said K, Haaland KY. Age-associated memory impairment of logical memory and visual reproduction. J Clin Exp Neuropsychol. 2004;26(4):531&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15512940</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">11158037</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, &#x3b2;-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussiere JR, Beer TM, Neiss MB, Janowsky JS. Androgen deprivation impairs memory in older men. Behav Neurosci. 2005;119(6):1429&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420147</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001&#x2013;5007.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50(4):707&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">11982672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445632</ArticleId></ArticleIdList></Reference><Reference><Citation>Liverman CT, Blazer DG, editors. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">25009850</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Morris JC. Evidence that age-associated memory impairment is not a normal variant of aging. Alzheimer Dis Assoc Disord. 2001;15(2):72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403335</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change&#x2014;report of a National Institute of Mental Health Work Group. Dev Neuropsychol. 1986;2(4):261&#x2013;276.</Citation></Reference><Reference><Citation>Smith G, Ivnik RJ, Petersen RC, Malec JF, Kokmen E, Tangalos E. Age-associated memory impairment diagnoses: problems of reliability and concerns for terminology. Psychol Aging. 1991;6(4):551&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">1777143</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4182174</ArticleId><ArticleId IdType="pubmed">24686158</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PJ, Bhasin S, Cunningham GR, et al. Testosterone Trials Investigators Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209754</ArticleId><ArticleId IdType="pubmed">26886521</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B, Un&#xfc;tzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004;42(12):1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550799</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook TH, III, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr. 1992;4(2):165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">1477304</ArticleId></ArticleIdList></Reference><Reference><Citation>Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974;15(5):443&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">4597226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">1100130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228) 228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A. Revised Visual Retention Test. New York, NY: Psychological Corporation; 1974.</Citation></Reference><Reference><Citation>Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19(6):604&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875839</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004;1(5):440&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279282</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl. 2003;24(4):568&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale&#x2014;Revised. New York, NY: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64(11):1853&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, An Y, Lang A, et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement. 2014;10(6):735&#x2013;742.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253313</ArticleId><ArticleId IdType="pubmed">25035155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H, Utsugisawa K, Yamagata M, Yoshimura M. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res. 1995;700(1-2):245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005;64(2):290&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668427</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138(3):1015&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310318</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999;84(10):3681&#x2013;3685.</Citation><ArticleIdList><ArticleId IdType="pubmed">10523014</ArticleId></ArticleIdList></Reference><Reference><Citation>Thilers PP, Macdonald SW, Herlitz A. The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology. 2006;31(5):565&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">16487665</ArticleId></ArticleIdList></Reference><Reference><Citation>Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90(4):427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12175403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Matsumoto AM, Amory JK, et al. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007;32(1):72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864939</ArticleId><ArticleId IdType="pubmed">17145137</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl. 2007;28(6):875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">17609296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MM, Anawalt BD, Herbst KL, et al. Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab. 2002;87(7):3090&#x2013;3096.</Citation><ArticleIdList><ArticleId IdType="pubmed">12107206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28238547</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Hallmarks of Alzheimer's Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain.</ArticleTitle><Pagination><StartPage>1066</StartPage><EndPage>1081.e8</EndPage><MedlinePgn>1066-1081.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30058-2</ELocationID><Abstract><AbstractText>Human pluripotent stem cells (PSCs) provide a unique entry to study species-specific aspects of human disorders such as Alzheimer's disease (AD). However, in&#xa0;vitro culture of neurons deprives them of their natural environment. Here we transplanted human PSC-derived cortical neuronal precursors into the brain of a murine AD model. Human neurons differentiate and integrate into the brain, express 3R/4R Tau splice forms, show abnormal phosphorylation and conformational Tau changes, and undergo neurodegeneration. Remarkably, cell death was dissociated from tangle formation in this natural 3D model of AD. Using genome-wide expression analysis, we observed upregulation of genes involved in myelination and downregulation of genes related to memory and cognition, synaptic transmission, and neuron projection. This novel chimeric model for AD displays human-specific pathological features and allows the analysis of different genetic backgrounds and mutations during the course of the disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Espuny-Camacho</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arranz</LastName><ForeName>Amaia M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium. Electronic address: amaia.arranz@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiers</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellinx</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Kunie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Histology, Neuroanatomy and Neuropathology and ULB Neuroscience Institute (UNI), Universit&#xe9; Libre de Bruxelles, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium; VIB Bio Imaging Core, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnefont</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Libre de Bruxelles (ULB), Institute for Interdisciplinary Research (IRIBHM), and ULB Institute of Neuroscience (UNI), 1070 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambot</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and ULB Neuroscience Institute (UNI), 808 Route de Lennik, 1070 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corthout</LastName><ForeName>Nikky</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium; VIB Bio Imaging Core, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omodho</LastName><ForeName>Lorna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanden Eynden</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radaelli</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesseur</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neurology and Dementia Research Institute, University College London, Queen Square, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebneth</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Johnson &amp; Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neurology and Dementia Research Institute, University College London, Queen Square, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroy</LastName><ForeName>Karelle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Histology, Neuroanatomy and Neuropathology and ULB Neuroscience Institute (UNI), Universit&#xe9; Libre de Bruxelles, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brion</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Laboratory of Histology, Neuroanatomy and Neuropathology and ULB Neuroscience Institute (UNI), Universit&#xe9; Libre de Bruxelles, 1070, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderhaeghen</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Universit&#xe9; Libre de Bruxelles (ULB), Institute for Interdisciplinary Research (IRIBHM), and ULB Institute of Neuroscience (UNI), 1070 Brussels, Belgium; WELBIO, Universit&#xe9; Libre de Bruxelles, 1070 Brussels, Belgium. Electronic address: pvdhaegh@ulb.ac.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, VIB-Leuven, 3000 Leuven, Belgium; Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, 3000 Leuven, Belgium; Institute of Neurology and Dementia Research Institute, University College London, Queen Square, WC1N 3BG London, UK. Electronic address: bart.destrooper@vib.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17116</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Apr;13(4):193. doi: 10.1038/nrneurol.2017.37.</RefSource><PMID Version="1">28281533</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2017 Mar 15;9(381):eaam9867. doi: 10.1126/scitranslmed.aam9867.</RefSource><PMID Version="1">28298426</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Mar 17;18(4):193. doi: 10.1038/nrn.2017.38.</RefSource><PMID Version="1">28303018</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">cell death</Keyword><Keyword MajorTopicYN="N">chimeric mouse</Keyword><Keyword MajorTopicYN="N">dystrophic neurites</Keyword><Keyword MajorTopicYN="N">expression analysis</Keyword><Keyword MajorTopicYN="N">human neurons</Keyword><Keyword MajorTopicYN="N">modeling</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">pluripotent stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28238547</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.02.001</ArticleId><ArticleId IdType="pii">S0896-6273(17)30058-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28228567</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia.</ArticleTitle><Pagination><StartPage>1172</StartPage><EndPage>1179</EndPage><MedlinePgn>1172-1179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000003732</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association between sleep duration and the risk of incident dementia and brain aging.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Self-reported total hours of sleep were examined in the Framingham Heart Study (n = 2,457, mean age 72 &#xb1; 6 years, 57% women) as a 3-level variable: &lt;6 hours (short), 6-9 hours (reference), and &gt;9 hours (long), and was related to the risk of incident dementia over 10 years, and cross-sectionally to total cerebral brain volume (TCBV) and cognitive performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed 234 cases of all-cause dementia over 10 years of follow-up. In multivariable analyses, prolonged sleep duration was associated with an increased risk of incident dementia (hazard ratio [HR] 2.01; 95% confidence interval [CI] 1.24-3.26). These findings were driven by persons with baseline mild cognitive impairment (HR 2.83; 95% CI 1.06-7.55) and persons without a high school degree (HR 6.05; 95% CI 3.00-12.18). Transitioning to sleeping &gt;9 hours over a mean period of 13 years before baseline was associated with an increased risk of all-cause dementia (HR 2.43; 95% CI 1.44-4.11) and clinical Alzheimer disease (HR 2.20; 95% CI 1.17-4.13). Relative to sleeping 6-9 hours, long sleep duration was also associated cross-sectionally with smaller TCBV (&#x3b2; &#xb1; SE, -1.08 &#xb1; 0.41 mean units of TCBV difference) and poorer executive function (&#x3b2; &#xb1; SE, -0.41 &#xb1; 0.13 SD units of Trail Making Test B minus A score difference).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prolonged sleep duration may be a marker of early neurodegeneration and hence a useful clinical tool to identify those at a higher risk of progressing to clinical dementia within 10 years.</AbstractText><CopyrightInformation>&#xa9; 2017 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Westwood</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himali</LastName><ForeName>Jayandra J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auerbach</LastName><ForeName>Sanford H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pase</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia. matthewpase@gmail.com suseshad@bu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.J.W., A.B., J.J.H., S.H.A., M.P.P., S.S.), Boston University School of Medicine; Department of Biostatistics (A.B., J.J.H.), Boston University School of Public Health; Framingham Heart Study (A.B., J.J.H., S.H.A., M.P.P., S.S.); Department of Neuroscience (N.J.), Boston University, MA; University of California at Davis (C.D.), Sacramento; and Center for Human Psychopharmacology (M.P.P.), Swinburne University of Technology, Australia. matthewpase@gmail.com suseshad@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Oct 3;89(14):1532. doi: 10.1212/WNL.0000000000004551.</RefSource><PMID Version="1">28972108</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Oct 3;89(14):1532-1533. doi: 10.1212/WNL.0000000000004550.</RefSource><PMID Version="1">28972109</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Oct 3;89(14):1533. doi: 10.1212/WNL.0000000000004554.</RefSource><PMID Version="1">28972110</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Oct 3;89(14):1533. doi: 10.1212/WNL.0000000000004555.</RefSource><PMID Version="1">28972111</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28228567</ArticleId><ArticleId IdType="pmc">PMC5373785</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003732</ArticleId><ArticleId IdType="pii">WNL.0000000000003732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benito-Le&#xf3;n J, Bermejo-Pareja F, Vega S, Louis ED. Total daily sleep duration and the risk of dementia: a prospective population-based study. Eur J Neurol 2009;16:990&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">19473367</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JC, Espeland MA, Brunner RL, et al. . Sleep duration, cognitive decline, and dementia risk in older women. Alzheimers Dement 2016;12:21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4679723</ArticleId><ArticleId IdType="pubmed">26086180</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. . Sleep drives metabolite clearance from the adult brain. Science 2013;342:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007;8:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">17383938</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal AD. Psychiatric disorders and sleep. Neurol Clin 2012;30:1389&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493205</ArticleId><ArticleId IdType="pubmed">23099143</ArticleId></ArticleIdList></Reference><Reference><Citation>Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry 2005;17:237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">16194795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951;41:279&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525365</ArticleId><ArticleId IdType="pubmed">14819398</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Massaro J, Harvey D, et al. . Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 2005;26:491&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Himali JJ, Mitchell GF, et al. . Association of aortic stiffness with cognition and brain aging in young and middle-aged adults: the Framingham Third Generation Cohort Study. Hypertension 2016;67:513&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752398</ArticleId><ArticleId IdType="pubmed">26754644</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Beiser AS, Lee A, et al. . Development and validation of a brief dementia screening indicator for primary care. Alzheimers Dement 2014;10:656&#x2013;665. e651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119094</ArticleId><ArticleId IdType="pubmed">24491321</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Beiser A, Selhub J, et al. . Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl J Med 2002;346:476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844848</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Laffan AM, Harrison S, et al. . Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011;306:613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Potvin O, Lorrain D, Forget H, et al. . Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. Sleep 2012;35:491&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296791</ArticleId><ArticleId IdType="pubmed">22467987</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhola P, Polo-Kantola P. Sleep deprivation: impact on cognitive performance. Neuropsychiatr Dis Treat 2007;3:553&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656292</ArticleId><ArticleId IdType="pubmed">19300585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Dinges DF. A meta-analysis of the impact of short-term sleep deprivation on cognitive variables. Psychol Bull 2010;136:375&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290659</ArticleId><ArticleId IdType="pubmed">20438143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrie JE, Shipley MJ, Akbaraly TN, Marmot MG, Kivim&#xe4;ki M, Singh-Manoux A. Change in sleep duration and cognitive function: findings from the Whitehall II Study. Sleep 2011;34:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079935</ArticleId><ArticleId IdType="pubmed">21532949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmutte T, Harris S, Levin R, Zweig R, Katz M, Lipton R. The relation between cognitive functioning and self-reported sleep complaints in nondemented older adults: results from the Bronx Aging Study. Behav Sleep Med 2007;5:39&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17313323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo JC, Loh KK, Zheng H, Sim SKY, Chee MWL. Sleep duration and age-related changes in brain structure and cognitive performance. Sleep 2014;37:1171&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098802</ArticleId><ArticleId IdType="pubmed">25061245</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 2003;38:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543278</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease. Exp Mol Med 2015;47:e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351409</ArticleId><ArticleId IdType="pubmed">25766617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fronczek R, van Geest S, Frolich M, et al. . Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 2012;33:1642&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pubmed">21546124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. . Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Abeta and pTau in a mouse model of Alzheimer's disease. Brain Res 2013;1529:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779872</ArticleId><ArticleId IdType="pubmed">23856323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol 2014;71:971&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Biddle DJ, Robillard R, Hermens DF, Hickie IB, Glozier N. Accuracy of self-reported sleep parameters compared with actigraphy in young people with mental ill-health. Sleep Health 2015;1:214&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">29073443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28241163</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.</ArticleTitle><Pagination><StartPage>427</StartPage><EndPage>436</EndPage><MedlinePgn>427-436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.5755</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegeneration pattern. Validating these associations in vivo will lead to new diagnostic tools for Alzheimer disease and better understanding of its neurobiology.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether topographical distribution and severity of hyperphosphorylated tau pathologic findings measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging are linked with clinical phenotype and cortical atrophy in patients with Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This observational case series, conducted from July 1, 2012, to July 30, 2015, in an outpatient referral center for patients with neurodegenerative diseases, included 6 patients: 3 with typical amnesic Alzheimer disease and 3 with atypical variants (posterior cortical atrophy, logopenic variant primary progressive aphasia, and corticobasal syndrome). Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and structural magnetic resonance imaging to measure cortical thickness. Seventy-seven age-matched controls with normal cognitive function also underwent structural magnetic resonance imaging but not tau or amyloid PET imaging.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Tau burden, amyloid burden, and cortical thickness.</AbstractText><AbstractText Label="RESULTS">In all 6 patients (3 women and 3 men; mean age 61.8 years), the underlying clinical phenotype was associated with the regional distribution of the [18F]AV-1451 signal. Furthermore, within 68 cortical regions of interest measured from each patient, the magnitude of cortical atrophy was strongly correlated with the magnitude of [18F]AV-1451 binding (3 patients with amnesic Alzheimer disease, r&#x2009;=&#x2009;-0.82; P&#x2009;&lt;&#x2009;.001; r&#x2009;=&#x2009;-0.70; P&#x2009;&lt;&#x2009;.001; r&#x2009;=&#x2009;-0.58; P&#x2009;&lt;&#x2009;.001; and 3 patients with nonamnesic Alzheimer disease, r&#x2009;=&#x2009;-0.51; P&#x2009;&lt;&#x2009;.001; r&#x2009;=&#x2009;-0.63; P&#x2009;&lt;&#x2009;.001; r&#x2009;=&#x2009;-0.70; P&#x2009;&lt;&#x2009;.001), but not of [11C]PiB binding.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These findings provide further in vivo evidence that distribution of the [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and neurodegeneration. By localizing and quantifying hyperphosphorylated tau in vivo, results of tau PET imaging will likely serve as a key biomarker that links a specific type of molecular Alzheimer disease neuropathologic condition with clinically significant neurodegeneration, which will likely catalyze additional efforts to develop disease-modifying therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Chenjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makaretz</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caso</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGinnis</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasdev</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown3Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston5Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown2Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DC014296</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS077059</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG051987</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS079905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Apr 1;74(4):390-392. doi: 10.1001/jamaneurol.2016.5701.</RefSource><PMID Version="1">28241165</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hyman reported receiving personal fees from Siemens, Calico, ISIS Pharma, Eli Lilly, Neurophage Pharmaceuticals, Pfizer, Biogen, Genentech, Sanofi, AbbVie, and Novartis; receving grants from Siemens, Biogen Idec, BMS, AZTherapies, Acumen, Prothena, Fidelity Biosciences, Spark, and Intellect; and having a family member employed by Novartis. Dr Vasdev reported holding patent number WO 2014194169 A1 20141204, &#x201c;Radiosynthesis of Tau Radio-Pharmaceuticals&#x201d; (2014). Dr Johnson reported receiving personal fees from Piramal, Novartis, Siemens, Lilly/Avid, Janssen, AZTherapies, Roche, Genentech, GE Healthcare, Biogen Idec, and ISIS Pharma; receiving grants from Lilly/Avid, Merck, Janssen, Eisai, Biogen Idec, the National Institutes of Health, and the Michael J. Fox Foundation. Dr Dickerson reported receiving personal fees from Merck, Forum, and Ionis Pharma. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28241163</ArticleId><ArticleId IdType="mid">NIHMS869766</ArticleId><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.5755</ArticleId><ArticleId IdType="pii">2604134</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer&#x2019;s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123(pt 3):484-498.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686172</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. ; National Institute on Aging; Alzheimer&#x2019;s Association . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42(3, pt 1):631-639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA. Amyloid imaging in atypical presentations of Alzheimer&#x2019;s disease. Curr Neurol Neurosci Rep. 2013;13(12):412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863595</ArticleId><ArticleId IdType="pubmed">24136459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Bouras C, Constantinidis J, Morrison JH. Balint&#x2019;s syndrome in Alzheimer&#x2019;s disease: specific disruption of the occipito-parietal visual pathway. Brain Res. 1989;493(2):368-375.</Citation><ArticleIdList><ArticleId IdType="pubmed">2765903</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56(10):1233-1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520939</ArticleId></ArticleIdList></Reference><Reference><Citation>Gefen T, Gasho K, Rademaker A, et al. . Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain. 2012;135(pt 5):1554-1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338929</ArticleId><ArticleId IdType="pubmed">22522938</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky D, Bakkour A, Negreira A, et al. . Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia. Neurology. 2010;75(4):358-366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918888</ArticleId><ArticleId IdType="pubmed">20660866</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2002;14(1):33-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053130</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ, Schott JM, Rabinovici GD, et al. . Shining a light on posterior cortical atrophy. Alzheimers Dement. 2013;9(4):463-465.</Citation><ArticleIdList><ArticleId IdType="pubmed">23274153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, Yokell DL, Rice PA, et al. . A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807. J Labelled Comp Radiopharm. 2013;56(14):736-740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AA, Garcia A, Chestakova A, et al. . A rapid one-step radiosynthesis of the &#x3b2;-amyloid imaging radiotracer N-methyl-[11C]2-(4&#x2032;-methylaminophenyl)-6-hydroxybenzothiazole([11C]-6-OH-BTA-1). J Labelled Comp Radiopharm. 2004;47:679-682. doi:10.1002/jlcr.854</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlcr.854</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. . Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, et al. . Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2013;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740-747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Fenstermacher E, Salat DH, et al. . Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. Neuroimage. 2008;39(1):10-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141650</ArticleId><ArticleId IdType="pubmed">17942325</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787-800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Wibom M, Olsson T, et al. . Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer&#x2019;s disease patient with presenilin-1 mutation. J Alzheimers Dis. 2016;51(2):339-343.</Citation><ArticleIdList><ArticleId IdType="pubmed">26836192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual B, Masdeu JC. Tau, amyloid, and hypometabolism in the logopenic variant of primary progressive aphasia. Neurology. 2016;86(5):487-488.</Citation><ArticleIdList><ArticleId IdType="pubmed">26833938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Baker SL, et al. . Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338-342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DHS, Small GW, Chang CY, et al. . Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120-2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, et al. . Changes in premorbid brain volume predict Alzheimer&#x2019;s disease pathology. Neurology. 2003;61(4):487-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, et al. . Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41(1):17-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. . MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743-749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid-&#x3b2; associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011;70(4):657-661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368003</ArticleId><ArticleId IdType="pubmed">22002658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-&#x3b2; and tau. Front Aging Neurosci. 2013;5:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795312</ArticleId><ArticleId IdType="pubmed">24130528</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11(3):205-242.</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. . Guidelines for brain amyloid imaging published. J Nucl Med. 2013;54:476-490.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Madeira C, et al. . Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8(5):389-398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517915</ArticleId><ArticleId IdType="pubmed">22285638</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28241148</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>543</Volume><Issue>7645</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Cytosolic proteostasis through importing of misfolded proteins into mitochondria.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>446</EndPage><MedlinePgn>443-446</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature21695</ELocationID><Abstract><AbstractText>Loss of proteostasis underlies ageing and neurodegeneration characterized by the accumulation of protein aggregates and mitochondrial dysfunction. Although many neurodegenerative-disease-associated proteins can be found in mitochondria, it remains unclear how mitochondrial dysfunction and protein aggregation could be related. In dividing yeast cells, protein aggregates that form under stress or during ageing are preferentially retained by the mother cell, in part through tethering to mitochondria, while the disaggregase Hsp104 helps to dissociate aggregates and thereby enables refolding or degradation of misfolded proteins. Here we show that, in yeast, cytosolic proteins prone to aggregation are imported into mitochondria for degradation. Protein aggregates that form under heat shock contain both cytosolic and mitochondrial proteins and interact with the mitochondrial import complex. Many aggregation-prone proteins enter the mitochondrial intermembrane space and matrix after heat shock, and some do so even without stress. Timely dissolution of cytosolic aggregates requires the mitochondrial import machinery and proteases. Blocking mitochondrial import but not proteasome activity causes a marked delay in the degradation of aggregated proteins. Defects in cytosolic Hsp70s leads to enhanced entry of misfolded proteins into mitochondria and elevated mitochondrial stress. We term this mitochondria-mediated proteostasis mechanism MAGIC (mitochondria as guardian in cytosol) and provide evidence that it may exist in human cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Linhao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Cell Dynamics, Department of Cell Biology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chuankai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Erli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kucharavy</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Cell Dynamics, Department of Cell Biology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florens</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Cell Dynamics, Department of Cell Biology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland 21218, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM118172</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Mar 16;543(7645):324-325. doi: 10.1038/nature21892.</RefSource><PMID Version="1">28241137</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Biochem Sci. 2018 Jul;43(7):485-487. doi: 10.1016/j.tibs.2018.04.008.</RefSource><PMID Version="1">29789218</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cardiovasc Res. 2018 Aug 1;114(10):e68-e69. doi: 10.1093/cvr/cvy159.</RefSource><PMID Version="1">30052919</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018869" MajorTopicYN="N">Heat-Shock Response</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="Y">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058849" MajorTopicYN="N">Protein Refolding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="Y">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28241148</ArticleId><ArticleId IdType="mid">NIHMS851430</ArticleId><ArticleId IdType="pmc">PMC5793917</ArticleId><ArticleId IdType="doi">10.1038/nature21695</ArticleId><ArticleId IdType="pii">nature21695</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">21776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Mitochondrial diseases. Lancet (London, England) 2012;379:1825&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsell DA, Kowal AS, Singer MA, Lindquist S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature. 1994;372:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">7984243</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle SM, Genest O, Wickner S. Protein rescue from aggregates by powerful molecular chaperone machines. Nature reviews. Molecular cell biology. 2013;14:617&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24061228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, et al. Organelle-based aggregation and retention of damaged proteins in asymmetrically dividing cells. Cell. 2014;159:530&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726438</ArticleId><ArticleId IdType="pubmed">25417105</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SB, Mogk A, Bukau B. Spatially organized aggregation of misfolded proteins as cellular stress defense strategy. Journal of molecular biology. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25681695</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, et al. Firefly luciferase mutants as sensors of proteome stress. Nature methods. 2011;8:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">21892152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace EW, et al. Reversible, Specific, Active Aggregates of Endogenous Proteins Assemble upon Heat Stress. Cell. 2015;162:1286&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567705</ArticleId><ArticleId IdType="pubmed">26359986</ArticleId></ArticleIdList></Reference><Reference><Citation>Neupert W, Herrmann JM. Translocation of proteins into mitochondria. Annual review of biochemistry. 2007;76:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">17263664</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J, Mahlke K, Pfanner N. Role of an energized inner membrane in mitochondrial protein import. Delta psi drives the movement of presequences. The Journal of biological chemistry. 1991;266:18051&#x2013;18057.</Citation><ArticleIdList><ArticleId IdType="pubmed">1833391</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano R. Energy requirements for maltose transport in yeast. European journal of biochemistry / FEBS. 1977;80:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">21792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens HC, Nichols JW. The proton electrochemical gradient across the plasma membrane of yeast is necessary for phospholipid flip. The Journal of biological chemistry. 2007;282:17563&#x2013;17567.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pareek G, Krishnamoorthy V, D&#x2019;Silva P. Molecular insights revealing interaction of Tim23 and channel subunits of presequence translocase. Molecular and cellular biology. 2013;33:4641&#x2013;4659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838011</ArticleId><ArticleId IdType="pubmed">24061477</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabantous S, Terwilliger TC, Waldo GS. Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. Nature biotechnology. 2005;23:102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehrenbacher KL, Yang HC, Gay AC, Huckaba TM, Pon LA. Live cell imaging of mitochondrial movement along actin cables in budding yeast. Curr Biol. 2004;14:1996&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15556861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Human molecular genetics. 2010;19:R46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker J, Walter W, Yan W, Craig EA. Functional interaction of cytosolic hsp70 and a DnaJ-related protein, Ydj1p, in protein translocation in vivo. Molecular and cellular biology. 1996;16:4378&#x2013;4386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231436</ArticleId><ArticleId IdType="pubmed">8754838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer E, Oguchi Y, Seyffer F, Bukau B, Mogk A. Mechanism of Hsp104/ClpB inhibition by prion curing Guanidinium hydrochloride. FEBS letters. 2013;587:810&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">23416293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan MT, Voos W, Pfanner N. Assaying protein import into mitochondria. Methods in cell biology. 2001;65:189&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381594</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. The Journal of biological chemistry. 2008;283:9089&#x2013;9100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2431021</ArticleId><ArticleId IdType="pubmed">18245082</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker MJ, Tatsuta T, Langer T. Quality control of mitochondrial proteostasis. Cold Spring Harbor perspectives in biology. 2011;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119916</ArticleId><ArticleId IdType="pubmed">21628427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rep M, et al. Promotion of mitochondrial membrane complex assembly by a proteolytically inactive yeast Lon. Science. 1996;274:103&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DH, Goldberg AL. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. The Journal of biological chemistry. 1996;271:27280&#x2013;27284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910302</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GA, Gomez TA, Deshaies RJ, Tansey WP. Combined chemical and genetic approach to inhibit proteolysis by the proteasome. Yeast (Chichester, England) 2010;27:965&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566228</ArticleId><ArticleId IdType="pubmed">20625982</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nature reviews. Neuroscience. 2008;9:505&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711514</ArticleId><ArticleId IdType="pubmed">18568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyedmers J, Mogk A, Bukau B. Cellular strategies for controlling protein aggregation. Nature reviews. Molecular cell biology. 2010;11:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944667</ArticleId></ArticleIdList></Reference><Reference><Citation>Longtine MS, et al. Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast. 1998;14:953&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">9717241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, et al. Firefly luciferase mutants as sensors of proteome stress. Nat Methods. 2011;8:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">21892152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumberg D, Muller R, Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene. 1995;156:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7737504</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh WK, et al. Global analysis of protein localization in budding yeast. Nature. 2003;425:686&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">14562095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, et al. Organelle-based aggregation and retention of damaged proteins in asymmetrically dividing cells. Cell. 2014;159:530&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726438</ArticleId><ArticleId IdType="pubmed">25417105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran PT, Paoletti A, Chang F. Imaging green fluorescent protein fusions in living fission yeast cells. Methods. 2004;33:220&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">15157889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, et al. Motility and segregation of Hsp104-associated protein aggregates in budding yeast. Cell. 2011;147:1186&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237388</ArticleId><ArticleId IdType="pubmed">22118470</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura H, et al. Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:15651&#x2013;15656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735558</ArticleId><ArticleId IdType="pubmed">19720993</ArticleId></ArticleIdList></Reference><Reference><Citation>Florens L, Washburn MP. Proteomic analysis by multidimensional protein identification technology. Methods Mol Biol. 2006;328:159&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785648</ArticleId></ArticleIdList></Reference><Reference><Citation>Washburn MP, Wolters D, Yates JR., 3rd Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001;19:242&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231557</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng JK, McCormack AL, Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Journal of the American Society for Mass Spectrometry. 1994;5:976&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">24226387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabb DL, McDonald WH, Yates JR., 3rd DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J Proteome Res. 2002;1:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811961</ArticleId><ArticleId IdType="pubmed">12643522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wen Z, Washburn MP, Florens L. Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. Analytical chemistry. 2010;82:2272&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20166708</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinders J, Zahedi RP, Pfanner N, Meisinger C, Sickmann A. Toward the complete yeast mitochondrial proteome: multidimensional separation techniques for mitochondrial proteomics. J Proteome Res. 2006;5:1543&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">16823961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam SS, et al. Directed evolution of APEX2 for electron microscopy and proximity labeling. Nat Methods. 2015;12:51&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296904</ArticleId><ArticleId IdType="pubmed">25419960</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldogh IR, Pon LA. Purification and subfractionation of mitochondria from the yeast Saccharomyces cerevisiae. Methods in cell biology. 2007;80:45&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17445688</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovski D, Pfanner N, Wiedemann N. Import of proteins into mitochondria. Methods in cell biology. 2007;80:783&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">17445722</ArticleId></ArticleIdList></Reference><Reference><Citation>Desantis ME, et al. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell. 2012;151:778&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496281</ArticleId><ArticleId IdType="pubmed">23141537</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Higuero JA, et al. Allosteric communication between the nucleotide binding domains of caseinolytic peptidase B. J Biol Chem. 2011;286:25547&#x2013;25555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138311</ArticleId><ArticleId IdType="pubmed">21642426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28272510</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome.</ArticleTitle><Pagination><StartPage>43701</StartPage><MedlinePgn>43701</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">43701</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep43701</ELocationID><Abstract><AbstractText>Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive decline and late onset Alzheimer's disease (AD). E4-associated phenotypes and insulin resistance (IR) share several features and appear to interact in driving cognitive dysfunction. However, shared mechanisms that could explain their overlapping pathophysiology have yet to be found. We hypothesized that, compared to E3 mice, E4 mice would be more susceptible to the harmful cognitive effects of high fat diet (HFD)-induced IR due to apoE isoform-specific differences in brain metabolism. While both E3 and E4 mice fed HFD displayed impairments in peripheral metabolism and cognition, deficits in hippocampal-dependent spatial learning and memory were exaggerated in E4 mice. Combining genome-wide measures of DNA hydroxymethylation with comprehensive untargeted metabolomics, we identified novel alterations in purine metabolism, glutamate metabolism, and the pentose phosphate pathway. Finally, in E4 mice, the metabolic and cognitive deficiencies caused by HFD were rescued by switching to a low fat diet for one month, suggesting a functional role was associated with reversal of the same metabolic pathways described above. These results suggest a susceptibility of E4&#x2009;carriers to metabolic impairments brought on by IR, and may guide development of novel therapies for cognitive decline and dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Lance A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Behavioral Neuroscience, Oregon Health &amp;Science University, Portland, OR 97239, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Eileen Ruth S</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Behavioral Neuroscience, Oregon Health &amp;Science University, Portland, OR 97239, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Impey</LastName><ForeName>Soren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oregon Stem Cell Center and Department of Pediatrics, Oregon Health &amp;Science University, Portland, OR 97239, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell, Developmental and Cancer Biology, Oregon Health &amp;Science University, Portland, OR 97239 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Jan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Oregon State University, Corvallis, OR 97331 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Linus Pauling Institute, Oregon State University, Corvallis, OR 97331 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raber</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Behavioral Neuroscience, Oregon Health &amp;Science University, Portland, OR 97239, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology and Radiation Medicine, Division of Neuroscience, ONPRC, Oregon Health &amp;Science University, Portland, OR 97239 USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 DA007262</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007060</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL094294</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG043857</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR027878</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES000210</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018149" MajorTopicYN="N">Glucose Intolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28272510</ArticleId><ArticleId IdType="pmc">PMC5341123</ArticleId><ArticleId IdType="doi">10.1038/srep43701</ArticleId><ArticleId IdType="pii">srep43701</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raber J., Huang Y. &amp; Ashford J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 25, 641&#x2013;50 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15172743</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D. T., Kuzawa C. W. &amp; Hayes M. G. Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys. Anthropol. 143, 100&#x2013;11 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20734437</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley R. W., Huang Y. &amp; Weisgraber K. H. Detrimental effects of apolipoprotein E4: potential therapeutic targets in AD. Curr Alzheimer Res. 4, 537&#x2013;540 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18220516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendse A. A., Arbones-Mainar J. M., Johnson L. A., Altenburg M. K. &amp; Maeda N. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 50, S178&#x2013;S182 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674752</ArticleId><ArticleId IdType="pubmed">19060252</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan K. M., Boyle J. P., Geiss L. S., Saaddine J. B. &amp; Thompson T. J. Impact of recent increase in incidence on future diabetes burden: U.S., 2005&#x2013;2050. Diabetes Care. 29, 2114&#x2013;2116 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16936162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudala K., Bansal D., Schifano F. &amp; Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 4, 640&#x2013;50 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020261</ArticleId><ArticleId IdType="pubmed">24843720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellbom K. S. &amp; Gunstad J. Cognitive function and decline in obesity. J. Alzheimers Dis. 30, S89&#x2013;S95 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22258511</ArticleId></ArticleIdList></Reference><Reference><Citation>Janson J., Laedtke T., Parisi J. E., O&#x2019;Brien P., Petersen R. C. &amp; Butler P. C. Increased risk of T2D in Alzheimer disease. Diabetes. 53, 474&#x2013;81 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14747300</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. et al.. Demonstrated brain insulin resistance in AD patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 122, 1316&#x2013;38 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314463</ArticleId><ArticleId IdType="pubmed">22476197</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore G. A., Elias M. F., Robbins M. A., Elias P. K. &amp; Nagy Z. Presence of the APOE epsilon4 allele modifies the relationship between T2D and cognitive performance: the Maine-Syracuse Study. Diabetologia. 52, 2551&#x2013;60 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19693485</ArticleId></ArticleIdList></Reference><Reference><Citation>Peila R., Rodriguez B. L. &amp; Launer L. J. Honolulu-Asia Aging Study. T2D, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 51, 1256&#x2013;62 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11916953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M. et al.. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci USA 101, 284&#x2013;9 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte S. M. Therapeutic targets of brain insulin resistance in sporadic AD. Front Biosci (Elite Ed) 4, 1582&#x2013;1605 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550311</ArticleId><ArticleId IdType="pubmed">22201977</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson A. J. et al.. Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E &#x25b;4 Carriers and Adults with Mild Cognitive Impairment. J Alzheimers Dis. 48, 205&#x2013;18 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26401941</ArticleId></ArticleIdList></Reference><Reference><Citation>Convit A., Wolf O. T., Tarshish C. &amp; de Leon M. J. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100, 2019&#x2013;22 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149951</ArticleId><ArticleId IdType="pubmed">12571363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson A. J., Banks W. A., Hernandez Saucedo H. &amp; Craft S. Apolipoprotein E Genotype and Sex Influence Glucose Tolerance in Older Adults: A Cross-Sectional Study. Dement Geriatr Cogn Dis Extra. 6, 78&#x2013;89 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821139</ArticleId><ArticleId IdType="pubmed">27065114</ArticleId></ArticleIdList></Reference><Reference><Citation>Helkala E. L. et al.. Associations between apolipoprotein E phenotype, glucose metabolism and cognitive function in men. An explorative study in a population sample. Diabet Med. 18, 991&#x2013;7 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11903399</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nn T. &amp; Ling C. DNA methylation as a diagnostic and therapeutic target in the battle against T2D. Epigenomics. 7, 451&#x2013;60 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26077431</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J. et al.. Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. Nat Neurosci. 18, 536&#x2013;44 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617315</ArticleId><ArticleId IdType="pubmed">25774451</ArticleId></ArticleIdList></Reference><Reference><Citation>Impey S., Pelz C., Tafessu A., Marzulla T., Turker M. &amp; Raber J. Proton irradiation Induces Persistent and Tissue-Specific DNA Methylation Changes in the Left Ventricle and Hippocampus. BMC Genomics. 17, 273 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815246</ArticleId><ArticleId IdType="pubmed">27036964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiacchiera F., Piunti A. &amp; Pasini D. Epigenetic methylations and their connections with metabolism. Cell Mol Life Sci. 70, 1495&#x2013;508 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11113834</ArticleId><ArticleId IdType="pubmed">23456257</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson L. A. et al.. Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. EBioMedicine. 26, 42 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739422</ArticleId><ArticleId IdType="pubmed">26870815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamat P. K. Streptozotocin induced Alzheimer&#x2019;s disease like changes and the underlying neural degeneration and regeneration mechanism. Neural Regen Res. 10, 1050&#x2013;1052 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541228</ArticleId><ArticleId IdType="pubmed">26330820</ArticleId></ArticleIdList></Reference><Reference><Citation>Brands A. M., Biessels G. J., de Haan E. H., Kappelle L. J. &amp; Kessels R. P. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care. 3, 726&#x2013;735 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15735218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruis C., Biessels G. J., Gorter K. J., van den Donk M., Kappelle L. J. &amp; Rutten G. E. Cognition in the early stage of type 2 diabetes. Diabetes Care. 7, 1261&#x2013;1265 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699741</ArticleId><ArticleId IdType="pubmed">19366968</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A., Ng B., Landau S. M., Jagust W. J., Greicius M. D. &amp; Neuroimaging A. D. Initiative. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain. 138, 3734&#x2013;46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806718</ArticleId><ArticleId IdType="pubmed">26419799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong Q. R., Chan E. S., Lim M. L., Cole G. M. &amp; Wong B. S. Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci Rep. 4, 3754 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894554</ArticleId><ArticleId IdType="pubmed">24435134</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins M. et al.. Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E &#x25b;4 Carriers. J. Alzheimers Dis. 53, 95&#x2013;106 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942726</ArticleId><ArticleId IdType="pubmed">27128370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson A. J., Craft S. &amp; Banks W. A. The APOE genotype: modification of therapeutic responses in AD. Curr Pharm Des. 21, 114&#x2013;20 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25330331</ArticleId></ArticleIdList></Reference><Reference><Citation>Maioli S. et al.. Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. J Alzheimers Dis. 32, 341&#x2013;55 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22836186</ArticleId></ArticleIdList></Reference><Reference><Citation>To A. W., Ribe E. M., Chuang T. T., Schroeder J. E. &amp; Lovestone S. The &#x3b5;3 and &#x3b5;4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One. 6, e16991 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037394</ArticleId><ArticleId IdType="pubmed">21347323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mut J. V. &amp; Gr&#xe4;ff J. Epigenetic Alterations in AD. Front Behav Neurosci. 9, 347 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681781</ArticleId><ArticleId IdType="pubmed">26734709</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nzel M. et al.. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl. 49, 5375&#x2013;7 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20583021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanoski S. E. &amp; Davidson T. L. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol. Behav. 103, 59&#x2013;68 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056912</ArticleId><ArticleId IdType="pubmed">21167850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansoleaga B. et al.. Deregulation of purine metabolism in AD. Neurobiol Aging. 36, 68&#x2013;80 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25311278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaddurah-Daouk R. et al.. Pharmacometabolomics Research Network. Alterations in metabolic pathways and networks in AD. Transl. Psychiatr. 3, e244 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641405</ArticleId><ArticleId IdType="pubmed">23571809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims B., Powers R. E., Sabina R. L. &amp; Theibert A. B. Elevated adenosine monophosphate deaminase activity in AD brain. Neurobiol Aging. 19, 385&#x2013;91 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9880040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim A. M., Moss G. &amp; Gollomp S. M. The effect of hypoxia on the pentose phosphate pathway in brain. J Neurochem. 26, 683&#x2013;688 (1976).</Citation><ArticleIdList><ArticleId IdType="pubmed">965959</ArticleId></ArticleIdList></Reference><Reference><Citation>del Castillo Velasco-Mart&#xed;nez I, Hern&#xe1;ndez-Camacho C. J., M&#xe9;ndez-Rodr&#xed;guez L. C. &amp; Zenteno-Sav&#xed;n T. Purine metabolism in response to hypoxic conditions associated with breath-hold diving and exercise in erythrocytes and plasma from bottlenose dolphins (Tursiops truncatus). Comp. Biochem. Physiol. A Mol. Integr. Physiol. 191, 196&#x2013;201 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B. V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 70, 440&#x2013;4 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanis S. B., DiBattista A. M., Miessau M., Moussa C. E. &amp; Rebeck G. W. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem. 124, 4&#x2013;14 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509249</ArticleId><ArticleId IdType="pubmed">22862561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Durakoglugil M. S., Xian X. &amp; Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA 107, 12011&#x2013;6 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins R. N., Harper C. G., Stokes G. B. &amp; Masters C. L. Increased cerebral glucose-6-phosphate dehydrogenase activity in AD may reflect oxidative stress. J. Neurochem. 46, 1042&#x2013;1045 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3950618</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer A. M. The activity of the pentose phosphate pathway is increased in response to oxidative stress in AD. J. Neural Transm. 106, 317&#x2013;28 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10392540</ArticleId></ArticleIdList></Reference><Reference><Citation>Warburg O. On the origin of cancer cells. Science 123, 309&#x2013;314 (1956).</Citation><ArticleIdList><ArticleId IdType="pubmed">13298683</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi S. N., Vlassenko A. G., Rundle M. M., Snyder A. Z., Mintun M. A. &amp; Raichle M. E. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA 107, 17757&#x2013;62 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955101</ArticleId><ArticleId IdType="pubmed">20837536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko A. G. et al.. Spatial correlation between brain aerobic glycolysis and A-beta deposition. Proc Natl Acad Sci USA 41, 17763&#x2013;17767 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ore&#x161;i&#x10d; M. et al.. Metabolome in progression to AD. Transl. Psychiatry. 1, e57 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309497</ArticleId><ArticleId IdType="pubmed">22832349</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbones-Mainar J. M. et al.. Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4. Int. J. Obes. 40, 1574&#x2013;1581 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063049</ArticleId><ArticleId IdType="pubmed">27163745</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouff C., Hinsdale M. E., Mezdour H., Altenburg M. K., Watanabe M., Quarfordt S. H., Sullivan P. M. &amp; Maeda N. ApoE structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579&#x2013;86 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408371</ArticleId><ArticleId IdType="pubmed">10359567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkwood J. S., Maier C. &amp; Stevens J. F. Simultaneous, untargeted metabolic profiling of polar and nonpolar metabolites by LC-Q-TOF mass spectrometry. Curr. Protoc. Toxicol. 4, 39 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707319</ArticleId><ArticleId IdType="pubmed">23670865</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J. &amp; Wishart D. S. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 26, 2342&#x2013;2344 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20628077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28279356</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Mnemonic Training Reshapes Brain Networks to Support Superior Memory.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1235.e6</EndPage><MedlinePgn>1227-1235.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.02.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30087-9</ELocationID><Abstract><AbstractText>Memory skills strongly differ across the general population; however, little is known about the brain characteristics supporting superior memory performance. Here we assess functional brain network organization of 23 of the world's most successful memory athletes and matched controls with fMRI during both task-free resting state baseline and active memory encoding. We demonstrate that, in a group of naive controls, functional connectivity changes induced by 6&#xa0;weeks of mnemonic training were correlated with the network organization that distinguishes athletes from controls. During rest, this effect was mainly driven by connections between rather than within the visual, medial temporal lobe and default mode networks, whereas during task it was driven by connectivity within these networks. Similarity with memory athlete connectivity patterns predicted memory improvements up to 4&#xa0;months after training. In conclusion, mnemonic training drives distributed rather than regional changes, reorganizing the brain's functional network organization to enable superior memory performance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dresler</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, 80804 Munich, Germany; Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, the Netherlands. Electronic address: martin.dresler@donders.ru.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirer</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Boris N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, 80804 Munich, Germany; Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Nils C J</ForeName><Initials>NCJ</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Isabella C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Guill&#xe9;n</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czisch</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, 80804 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS073498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2017 Mar 29;9(383):eaan0770. doi: 10.1126/scitranslmed.aan0770.</RefSource><PMID Version="1">28356506</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">brain networks</Keyword><Keyword MajorTopicYN="N">cognitive training</Keyword><Keyword MajorTopicYN="N">dynamics</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">memory championships</Keyword><Keyword MajorTopicYN="N">memory sports</Keyword><Keyword MajorTopicYN="N">method of loci</Keyword><Keyword MajorTopicYN="N">mnemonic</Keyword><Keyword MajorTopicYN="N">resting state</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28279356</ArticleId><ArticleId IdType="mid">NIHMS851183</ArticleId><ArticleId IdType="pmc">PMC5439266</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.02.003</ArticleId><ArticleId IdType="pii">S0896-6273(17)30087-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aidroos N, Said CP, Turk-Browne NB. Top-down attention switches coupling between low-level and high-level areas of human visual cortex. Proc Natl Acad Sci U S A. 2012;109:14675&#x2013;14680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437858</ArticleId><ArticleId IdType="pubmed">22908274</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Ng B, Landau SM, Jagust WJ, Greicius MD. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain. 2015;138:3734&#x2013;3746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806718</ArticleId><ArticleId IdType="pubmed">26419799</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JLR, Jenkinson M, Smith S. FMRIB technical reports TR07JA1 and TR07JA2. 2007 available at  www.fmrib.ox.ac.uk/analysis/techrep.</Citation></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2013;the methods. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;umler G. Lern- und Ged&#xe4;chtnistest LGT-3. G&#xf6;ttingen: Hogrefe; 1974.</Citation></Reference><Reference><Citation>Becchetti A. Hippocampal formation and the classical art of memory. Proc Natl Acad Sci USA. 2010;107:E104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895100</ArticleId><ArticleId IdType="pubmed">20534505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmund JL, Deuker L, Navarro Schr&#xf6;der T, Doeller CF. Grid-cell representations in mental simulation. Elife. 2016;30:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5005038</ArticleId><ArticleId IdType="pubmed">27572056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bor D, Duncan J, Wiseman RJ, Owen AM. Encoding strategies dissociate prefrontal activity from working memory demand. Neuron. 2003;37:361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">12546829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chase HW, Clark L, Sahakian BJ, Bullmore ET, Robbins TW. Dissociable roles of prefrontal subregions in self-ordered working memory performance. Neuropsychologia. 2008;46:2650&#x2013;2661.</Citation><ArticleIdList><ArticleId IdType="pubmed">18556028</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresler M, Konrad BN. Mnemonic expertise during wakefulness and sleep. Behav Brain Sci. 2013;36:616&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">24304757</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan K, Tompary A, Davachi L. Associative encoding and retrieval are predicted by functional connectivity in distinct hippocampal area CA1 pathways. J Neurosci. 2014;34:11188&#x2013;11198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138331</ArticleId><ArticleId IdType="pubmed">25143600</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein CM, Sekino M, Yamaguchi K, Kamiya S, Ueno S. Asymmetries of prefrontal cortex in human episodic memory: effects of transcranial magnetic stimulation on learning abstract patterns. Neurosci Lett. 2002;320:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11849750</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, Yang Z, Chu C, Xie S, Laird AR, et al. The Human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26:3508&#x2013;3526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961028</ArticleId><ArticleId IdType="pubmed">27230218</ArticleId></ArticleIdList></Reference><Reference><Citation>Foer J. Moonwalking with Einstein. London: Penguin Books; 2011.</Citation></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson M, Driesen NR, Skudlarski P, Gore JC, Constable RT. Brain connectivity related to working memory performance. J Neurosci. 2006;26:13338&#x2013;13343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677699</ArticleId><ArticleId IdType="pubmed">17182784</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeggi SM, Buschkuehl M, Jonides J, Perrig WJ. Improving fluid intelligence with training on working memory. Proc Natl Acad Sci USA. 2008;105:6829&#x2013;6833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2383929</ArticleId><ArticleId IdType="pubmed">18443283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley WM, Miezin FM, McDermott KB, Buckner RL, Raichle ME, Cohen NJ, Ollinger JM, Akbudak E, Conturo TE, Snyder AZ, et al. Hemispheric specialization in human dorsal frontal cortex and medial temporal lobe for verbal and nonverbal memory encoding. Neuron. 1998;20:927&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo Y, Suzuki M, Mugikura S, Abe N, Takahashi S, Iijima T, Fujii T. Changes in brain activation associated with use of a memory strategy: a functional MRI study. Neuroimage. 2005;24:1154&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670693</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Valentine ER, Wilding JM, Kapur N. Routes to remembering: the brains behind superior memory. Nat Neurosci. 2003;6:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483214</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenti R, Cotelli M, Calabria M, Maioli C, Miniussi C. The role of the dorsolateral prefrontal cortex in retrieval from long-term memory depends on strategies: a repetitive transcranial magnetic stimulation study. Neuroscience. 2010;166:501&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">20034547</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel V, Gramfort A, Varoquaux G, Eger E, Keribin C, Thirion B. A supervised clustering approach for fMRI-based inference of brain states. Patt Recog. 2012;45:2041&#x2013;731.</Citation></Reference><Reference><Citation>Miller JF, Neufang M, Solway A, Brandt A, Trippel M, Mader I, Hefft S, Merkow M, Polyn SM, Jacobs J, et al. Neural activity in human hippocampal formation reveals the spatial context of retrieved memories. Science. 2013;342:1111&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669102</ArticleId><ArticleId IdType="pubmed">24288336</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco JD, Rao G, Roth ED, Knierim JJ. Attentive scanning behavior drives one-trial potentiation of hippocampal place fields. Nat Neurosci. 2014;17:725&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036486</ArticleId><ArticleId IdType="pubmed">24686786</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg L, Sandblom J, Jones S, Neely AS, Petersson KM, Ingvar M, B&#xe4;ckman L. Neural correlates of training-related memory improvement in adulthood and aging. Proc Natl Acad Sci USA. 2003;100:13728&#x2013;13733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263881</ArticleId><ArticleId IdType="pubmed">14597711</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Richiardi J, Gschwind M, Simioni S, Annoni JM, Greco B, Hagmann P, Schluep M, Vuilleumier P, Van De Ville D. Classifying minimally disabled multiple sclerosis patients from resting state functional connectivity. Neuroimage. 2012;62:2021&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pubmed">22677149</ArticleId></ArticleIdList></Reference><Reference><Citation>Richiardi J, Altmann A, Milazzo AC, Chang C, Chakravarty MM, Banaschewski T, Barker GJ, Bokde AL, Bromberg U, B&#xfc;chel C, et al. Correlated gene expression supports synchronous activity in brain networks. Science. 2015;348:1241&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829082</ArticleId><ArticleId IdType="pubmed">26068849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18:712&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10534053</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter DL, Addis DR, Buckner RL. Remembering the past to imagine the future: the prospective brain. Nat Rev Neurosci. 2007;8:657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17700624</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville WB, Milner BJ. Loss of recent memory after bilateral hippocampal lesions. Neurol Neurosurg Psychiatry. 1957;20:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497229</ArticleId><ArticleId IdType="pubmed">13406589</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shine JM, Bissett PG, Bell PT, Koyejo O, Balsters JH, Gorgolewski KJ, Moodie CA, Poldrack RA. The Dynamics of Functional Brain Networks: Integrated Network States during Cognitive Task Performance. Neuron. 2016;92:544&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073034</ArticleId><ArticleId IdType="pubmed">27693256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cereb Cortex. 2012;22:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236795</ArticleId><ArticleId IdType="pubmed">21616982</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23:S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">18501637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavor I, Parker Jones O, Mars RB, Smith SM, Behrens TE, Jbabdi S. Task-free MRI predicts individual differences in brain activity during task performance. Science. 2016;352:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309730</ArticleId><ArticleId IdType="pubmed">27124457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tognoli E, Kelso JA. The metastable brain. Neuron. 2014;81:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997258</ArticleId><ArticleId IdType="pubmed">24411730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompary A, Duncan K, Davachi L. Consolidation of Associative and Item Memory Is Related to Post-Encoding Functional Connectivity between the Ventral Tegmental Area and Different Medial Temporal Lobe Subregions during an Unrelated Task. J Neurosci. 2015;35:7326&#x2013;7331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429149</ArticleId><ArticleId IdType="pubmed">25972163</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse D, Langston RF, Kakeyama M, Bethus I, Spooner PA, Wood ER, Witter MP, Morris RG. Schemas and memory consolidation. Science. 2007;316:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412951</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, Ugurbil K. The future of the human connectome. Neuroimage. 2012;62:1299&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350760</ArticleId><ArticleId IdType="pubmed">22245355</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kesteren MT, Rijpkema M, Ruiter DJ, Fern&#xe1;ndez G. Retrieval of associative information congruent with prior knowledge is related to increased medial prefrontal activity and connectivity. J Neurosci. 2010a;30:15888&#x2013;15894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633736</ArticleId><ArticleId IdType="pubmed">21106827</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kesteren MT, Fern&#xe1;ndez G, Norris DG, Hermans EJ. Persistent schema-dependent hippocampal-neocortical connectivity during memory encoding and postencoding rest in humans. Proc Natl Acad Sci USA. 2010b;107:7550&#x2013;7555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867741</ArticleId><ArticleId IdType="pubmed">20363957</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei&#xdf; HR, Wei&#xdf; B. Grundintelligenztest Skala 2 &#x2013; Revision. G&#xf6;ttingen: Hogrefe; 2006. CFT 20-R.</Citation></Reference><Reference><Citation>Worthen JB, Hunt RR. Mnemonology. New York: Psychology Press; 2011.</Citation></Reference><Reference><Citation>Yates FA. The Art of Memory. London: Routledge &amp; Kegan Paul; 1966.</Citation></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28267788</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data.</ArticleTitle><Pagination><StartPage>e1002235</StartPage><MedlinePgn>e1002235</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002235</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002235</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent reports have suggested declining age-specific incidence rates of dementia in high-income countries over time. Improved education and cardiovascular health in early age have been suggested to be bringing about this effect. The aim of this study was to estimate the age-specific dementia incidence trend in primary care records from a large population in the Netherlands.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">A dynamic cohort representative of the Dutch population was composed using primary care records from general practice registration networks (GPRNs) across the country. Data regarding dementia incidence were obtained using general-practitioner-recorded diagnosis of dementia within the electronic health records. Age-specific dementia incidence rates were calculated for all persons aged 60 y and over; negative binomial regression analysis was used to estimate the time trend. Nine out of eleven GPRNs provided data on more than 800,000 older people for the years 1992 to 2014, corresponding to over 4 million person-years and 23,186 incident dementia cases. The annual growth in dementia incidence rate was estimated to be 2.1% (95% CI 0.5% to 3.8%), and incidence rates were 1.08 (95% CI 1.04 to 1.13) times higher for women compared to men. Despite their relatively low numbers of person-years, the highest age groups contributed most to the increasing trend. There was no significant overall change in incidence rates since the start of a national dementia program in 2003 (-0.025; 95% CI -0.062 to 0.011). Increased awareness of dementia by patients and doctors in more recent years may have influenced dementia diagnosis by general practitioners in electronic health records, and needs to be taken into account when interpreting the data.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within the clinical records of a large, representative sample of the Dutch population, we found no evidence for a declining incidence trend of dementia in the Netherlands. This could indicate true stability in incidence rates, or a balance between increased detection and a true reduction. Irrespective of the exact rates and mechanisms underlying these findings, they illustrate that the burden of work for physicians and nurses in general practice associated with newly diagnosed dementia has not been subject to substantial change in the past two decades. Hence, with the ageing of Western societies, we still need to anticipate a dramatic absolute increase in dementia occurrence over the years to come.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Bussel</LastName><ForeName>Emma F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Edo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arts</LastName><ForeName>Derk L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0001-5702-5856</Identifier><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nooyens</LastName><ForeName>Astrid C J</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-1412-3338</Identifier><AffiliationInfo><Affiliation>Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Preciosa M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Waal</LastName><ForeName>Margot W M</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Akker</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CAPHRI School for Public Health and Primary Care, Department of Family Medicine, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Center for General Practice, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biermans</LastName><ForeName>Marion C J</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-5401-3817</Identifier><AffiliationInfo><Affiliation>Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielen</LastName><ForeName>Markus M J</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of General Practice, Netherlands Institute for Health Services Research, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Boven</LastName><ForeName>Kees</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeets</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9718-1180</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Fiona E</ForeName><Initials>FE</Initials><Identifier Source="ORCID">0000-0002-1728-2388</Identifier><AffiliationInfo><Affiliation>Institute for Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5307-663X</Identifier><AffiliationInfo><Affiliation>Institute of Public Health, Cambridge University, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busschers</LastName><ForeName>Wim B</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gool</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll van Charante</LastName><ForeName>Eric P</ForeName><Initials>EP</Initials><Identifier Source="ORCID">0000-0002-1489-5218</Identifier><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>PLoS Med. 2017 Mar 7;14(3):e1002236. doi: 10.1371/journal.pmed.1002236.</RefSource><PMID Version="1">28267775</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057187" MajorTopicYN="Y">Independent Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and the authors of this manuscript have the following competing interests: CB is a member of the Editorial Board of PLOS Medicine and a Guest Editor for the Dementia Special Issue. FEM has received research grants from the UK Medical Research Council, Alzheimers Society UK, and received travel grants from the National Institutes of Health. PMC joined F. Hoffmann La Roche Ltd., a global health care company, after the study was completed but before publication. PMC is currently a full-time employee of, and own shares at, Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28267788</ArticleId><ArticleId IdType="pmc">PMC5340347</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002235</ArticleId><ArticleId IdType="pii">PMEDICINE-D-16-01995</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Guerchet M, Prina M. Policy brief for heads of government: the global impact of dementia 2013&#x2013;2050. London: Alzheimer&#x2019;s Disease International; 2013.</Citation></Reference><Reference><Citation>Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer report 2015: the global impact of dementia, an analysis of prevalence, incidence, costs and trends. London: Alzheimer&#x2019;s Disease International; 2015.</Citation></Reference><Reference><Citation>Christensen K, Thinggaard M, Oksuzyan A, Steenstrup T, Andersen-Ranberg K, Jeune B, et al. Physical and cognitive functioning of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. Lancet. 2013;382(9903):1507&#x2013;13. 10.1016/S0140-6736(13)60777-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60777-1</ArticleId><ArticleId IdType="pmc">PMC3818336</ArticleId><ArticleId IdType="pubmed">23849796</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013;369(24):2275&#x2013;7. 10.1056/NEJMp1311405</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1311405</ArticleId><ArticleId IdType="pmc">PMC4130738</ArticleId><ArticleId IdType="pubmed">24283198</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382(9902):1405&#x2013;12. 10.1016/S0140-6736(13)61570-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61570-6</ArticleId><ArticleId IdType="pmc">PMC3906607</ArticleId><ArticleId IdType="pubmed">23871492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogren M, Mattisson C, Horstmann V, Bhugra D, Munk-Jorgensen P, Nettelbladt P. Lundby revisited: first incidence of mental disorders 1947&#x2013;1997. Aust N Z J Psychiatry. 2007;41(2):178&#x2013;86. 10.1080/00048670601109964</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00048670601109964</ArticleId><ArticleId IdType="pubmed">17464697</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of Alzheimer&#x2019;s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7(1):80&#x2013;93. 10.1016/j.jalz.2010.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.11.002</ArticleId><ArticleId IdType="pmc">PMC3026476</ArticleId><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacuiu S, Gustafson D, Sjogren M, Guo X, Ostling S, Johansson B, et al. Secular changes in cognitive predictors of dementia and mortality in 70-year-olds. Neurology. 2010;75(9):779&#x2013;85. 10.1212/WNL.0b013e3181f0737c</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f0737c</ArticleId><ArticleId IdType="pmc">PMC2938967</ArticleId><ArticleId IdType="pubmed">20805523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456&#x2013;63. 10.1212/WNL.0b013e3182553be6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553be6</ArticleId><ArticleId IdType="pubmed">22551732</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523&#x2013;32. 10.1056/NEJMoa1504327</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504327</ArticleId><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasset L, Brayne C, Joly P, Jacqmin-Gadda H, Peres K, Foubert-Samier A, et al. Trends in dementia incidence: evolution over a 10-year period in France. Alzheimers Dement. 2016;12(3):272&#x2013;80. 10.1016/j.jalz.2015.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.11.001</ArticleId><ArticleId IdType="pubmed">26693893</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23 10.1186/s13195-016-0188-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0188-8</ArticleId><ArticleId IdType="pmc">PMC4967299</ArticleId><ArticleId IdType="pubmed">27473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116&#x2013;24. 10.1016/S1474-4422(15)00092-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00092-7</ArticleId><ArticleId IdType="pubmed">26300044</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Dungen C, Hoeymans N, van den Akker M, Biermans MC, van BK, Joosten JH, et al. Do practice characteristics explain differences in morbidity estimates between electronic health record based general practice registration networks? BMC Fam Pract. 2014;15:176 10.1186/s12875-014-0176-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-014-0176-7</ArticleId><ArticleId IdType="pmc">PMC4231185</ArticleId><ArticleId IdType="pubmed">25358247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberts H, Wood M. The birth of the International Classification of Primary Care (ICPC). Serendipity at the border of Lac Leman. Fam Pract. 2002;19(5):433&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12356688</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Dungen C, Hoeymans N, Gijsen R, van den Akker M, Boesten J, Brouwer H, et al. What factors explain the differences in morbidity estimations among general practice registration networks in the Netherlands? A first analysis. Eur J Gen Pract. 2008;14(Suppl 1):53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18949646</ArticleId></ArticleIdList></Reference><Reference><Citation>Meerveld J, Schumacher J, Krijger E, Bal R, Nies H. Landelijk Dementieprogramma: werkboek. Utrecht: Nederlands Instituut voor Zorg en Welzijn; 2004.</Citation></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing. Version 3.1.2. Vienna: R Foundation for Statistical Computing; 
https://www.r-project.org/.</Citation></Reference><Reference><Citation>Wickham H. The split-apply-combine strategy for data analysis. J Stat Softw. 2011;40(1):1&#x2013;29.</Citation></Reference><Reference><Citation>Bolker B, Skaug H, Laake J. R2admb: &#x2018;ADMB&#x2019; to R interface functions. Version 0.7.13. https://cran.r-project.org/web/packages/R2admb/index.html.</Citation></Reference><Reference><Citation>Fournier DA, Skaug HJ, Ancheta J, Ianelli J, Magnusson A, Maunder M, et al. AD Model Builder: using automatic differentiation for statistical inference of highly parameterized complex nonlinear models. Optim Methods Softw. 2012;27(2):233&#x2013;49.</Citation></Reference><Reference><Citation>Iliffe S, Robinson L, Brayne C, Goodman C, Rait G, Manthorpe J, et al. Primary care and dementia: 1. diagnosis, screening and disclosure. Int J Geriatr Psychiatry. 2009;24(9):895&#x2013;901. 10.1002/gps.2204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2204</ArticleId><ArticleId IdType="pubmed">19226529</ArticleId></ArticleIdList></Reference><Reference><Citation>van Baal PH, Engelfriet PM, Hoogenveen RT, Poos MJ, van den Dungen C, Boshuizen HC. Estimating and comparing incidence and prevalence of chronic diseases by combining GP registry data: the role of uncertainty. BMC Public Health. 2011;11:163 10.1186/1471-2458-11-163</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-163</ArticleId><ArticleId IdType="pmc">PMC3064641</ArticleId><ArticleId IdType="pubmed">21406092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamford C, Eccles M, Steen N, Robinson L. Can primary care record review facilitate earlier diagnosis of dementia? Fam Pract. 2007;24(2):108&#x2013;16. 10.1093/fampra/cml068</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cml068</ArticleId><ArticleId IdType="pubmed">17237496</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Dungen P, van Marwijk HW, van der Horst HE, Moll van Charante EP, MacNeil VJ, van de Ven PM, et al. The accuracy of family physicians&#x2019; dementia diagnoses at different stages of dementia: a systematic review. Int J Geriatr Psychiatry. 2012;27(4):342&#x2013;54. 10.1002/gps.2726</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2726</ArticleId><ArticleId IdType="pubmed">21626568</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Europe. Dutch dementia care plan. Luxembourg: Alzheimer Europe; 2014 [cited 2016 May 1]. http://www.alzheimer-europe.org/Policy-in-Practice2/National-Dementia-Strategies/Netherlands#fragment2.</Citation></Reference><Reference><Citation>BeterOud. The national care for the elderly programme. Utrecht: BeterOud; 2016 [cited 2016 May 1]. http://www.beteroud.nl/ouderen/dutch-national-care-programme-for-the-elderly.html.</Citation></Reference><Reference><Citation>Grimmer T, Beringer S, Kehl V, Alexopoulos P, Busche A, Forstl H, et al. Trends of patient referral to a memory clinic and towards earlier diagnosis from 1985&#x2013;2009. Int Psychogeriatr. 2015;27(12):1939&#x2013;44. 10.1017/S104161021500157X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S104161021500157X</ArticleId><ArticleId IdType="pubmed">26424328</ArticleId></ArticleIdList></Reference><Reference><Citation>Garssen J, Harmsen C. Elderly people live independently to increasingly older ages. The Hague: Statistics Netherlands; 2011. 
July
12 [cited 2016 May 1]. https://www.cbs.nl/en-gb/news/2011/28/elderly-people-live-independently-to-increasingly-older-ages.</Citation></Reference><Reference><Citation>van den Dungen C, Hoeymans N, Boshuizen HC, van den Akker M, Biermans MC, van Boven K, et al. The influence of population characteristics on variation in general practice based morbidity estimations. BMC Public Health. 2011;11:887 10.1186/1471-2458-11-887</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-887</ArticleId><ArticleId IdType="pmc">PMC3280203</ArticleId><ArticleId IdType="pubmed">22111707</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51(3):728&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A, Saz P, Marcos G, Dia JL, De la Camara C, Ventura T, et al. Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project. Acta Psychiatr Scand. 2007;116(4):299&#x2013;307. 10.1111/j.1600-0447.2007.01006.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2007.01006.x</ArticleId><ArticleId IdType="pubmed">17803760</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Stephan BC, Robinson L, Jagger C, Barnes LE, Arthur A, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun. 2016;7:11398 10.1038/ncomms11398</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11398</ArticleId><ArticleId IdType="pmc">PMC4838896</ArticleId><ArticleId IdType="pubmed">27092707</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauvaget C, Tsuji I, Haan MN, Hisamichi S. Trends in dementia-free life expectancy among elderly members of a large health maintenance organization. Int J Epidemiol. 1999;28(6):1110&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10661655</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80(20):1888&#x2013;94. 10.1212/WNL.0b013e318292a2f9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318292a2f9</ArticleId><ArticleId IdType="pubmed">23596063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28274718</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Sugary beverage intake and preclinical Alzheimer's disease in the community.</ArticleTitle><Pagination><StartPage>955</StartPage><EndPage>964</EndPage><MedlinePgn>955-964</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2017.01.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(17)30050-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Excess sugar consumption has been linked with Alzheimer's disease (AD) pathology in animal models.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the cross-sectional association of sugary beverage consumption with neuropsychological (N&#xa0;=&#xa0;4276) and magnetic resonance imaging (N&#xa0;=&#xa0;3846) markers of preclinical Alzheimer's disease and vascular brain injury (VBI) in the community-based Framingham Heart Study. Intake of sugary beverages was estimated using a food frequency questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative to consuming less than one sugary beverage per day, higher intake of sugary beverages was associated with lower total brain volume (1-2/day, &#x3b2; &#xb1; standard error [SE]&#xa0;=&#xa0;-0.55&#xa0;&#xb1;&#xa0;0.14 mean percent difference, P&#xa0;=&#xa0;.0002; &gt;2/day, &#x3b2; &#xb1; SE&#xa0;=&#xa0;-0.68&#xa0;&#xb1;&#xa0;0.18, P&#xa0;&lt;&#xa0;.0001), and poorer performance on tests of episodic memory (all P&#xa0;&lt;&#xa0;.01). Daily fruit juice intake was associated with lower total brain volume, hippocampal volume, and poorer episodic memory (all P&#xa0;&lt;&#xa0;.05). Sugary beverage intake was not associated with VBI in a consistent manner across outcomes.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Higher intake of sugary beverages was associated cross-sectionally with markers of preclinical AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pase</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA; Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Australia. Electronic address: matthewpase@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himali</LastName><ForeName>Jayandra J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacques</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA; Jean Mayer-U.S. Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA; Department of Neurology, School of Medicine &amp; Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA; Sections of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG036697</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073893">Sugars</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001628" MajorTopicYN="N">Beverages</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004327" MajorTopicYN="N">Drinking Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002149" MajorTopicYN="N">Energy Intake</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073893" MajorTopicYN="N">Sugars</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Diet</Keyword><Keyword MajorTopicYN="N">Framingham Heart Study</Keyword><Keyword MajorTopicYN="N">Sugar</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28274718</ArticleId><ArticleId IdType="mid">NIHMS1028109</ArticleId><ArticleId IdType="pmc">PMC6820519</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2017.01.024</ArticleId><ArticleId IdType="pii">S1552-5260(17)30050-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Welsh JA, Sharma AJ, Grellinger L, Vos MB. Consumption of added sugars is decreasing in the United States. Am J Clin Nutr 2011; 94:726&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155936</ArticleId><ArticleId IdType="pubmed">21753067</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007;116:480&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646581</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr 2009;89:1037&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667454</ArticleId><ArticleId IdType="pubmed">19211821</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr ME, Salinas A, Buffenstein R, Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer&#x2019;s disease pathology. Neurobiol Aging 2014; 35:1233&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973159</ArticleId><ArticleId IdType="pubmed">24411482</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu L, Han D, Xu RL, Han B, Zhou X, Wu HW, et al. A high-sugar high-fat diet induced metabolic syndrome shows some symptoms of Alzheimer&#x2019;s disease in rats. J Nutr Health Aging 2016;20:509&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27102788</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan AM, Norman ED, Lee K, Cutler RG, Telljohann RS, Egan JM, et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008;18:1085&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694409</ArticleId><ArticleId IdType="pubmed">18651634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007;282:36275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Meadors GF, Moore FE. Epidemiological Approaches to Heart Disease: The Framingham Study. Am J Public Health Nations Health 1951;41:279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525365</ArticleId><ArticleId IdType="pubmed">14819398</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP The framingham offspring study. Design and preliminary data. Prev Med 1975;4:518&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA. Benjamin EJ, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute&#x2019;s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol 2007;165:1328&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and Validity of an Expanded Self-Administered Semiquantitative Food Frequency Questionnaire among Male Health Professionals. Am J Epidemiol 1992;135:1114&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">1632423</ArticleId></ArticleIdList></Reference><Reference><Citation>Feskanich D, Rimm EB, Giovannucci EL, Colditz GA, Stampfer MJ, Litin LB, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc 1993;93:790&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8320406</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett WC, Sampson L, Browne ML, Stampfer MJ, Rosner B, Hennekens CH, et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol 1988;127:188&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB, Rimm E, Smith-Warner SA, Feskanich D, Stampfer MJ, Ascherio A, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr 1999; 69:243&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989687</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989; 18:858&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">2621022</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljabar P, Heckemann RA, Hammers A, Hajnal JV, Rueckert D. Multiatlas based segmentation of brain images: Atlas selection and its effect on accuracy. Neuroimage 2009;46:726&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245840</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging 2005; 26:491&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816357</ArticleId><ArticleId IdType="pubmed">15576652</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher E, Carmichael O, Decarli C. MRI non-uniformity correction through interleaved bias estimation and B-spline deformation with a template. Conf Proc IEEE Eng Med Biol Soc 2012;2012:106&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775836</ArticleId><ArticleId IdType="pubmed">23365843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher E, Singh B, Harvey D, Carmichael O, Decarli C. Adaptive image segmentation for robust measurement of longitudinal brain tissue change. Conf Proc IEEE Eng Med Biol Soc 2012;2012:5319&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776590</ArticleId><ArticleId IdType="pubmed">23367130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alz-heimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Beiser A, Enserro D, Xanthakis V, Aparicio H, Satizabal C, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke 2016;47:1201&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006676</ArticleId><ArticleId IdType="pubmed">27073239</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Himali JJ, Mitchell GF, Beiser A, Maillard P, Tsao C, et al. Association of Aortic Stiffness With Cognition and Brain Aging in Young and Middle-Aged Adults: The Framingham Third Generation Cohort Study. Hypertension 2016;67:513&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752398</ArticleId><ArticleId IdType="pubmed">26754644</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsycho-logicalTests: Administration, Norms, and Commentary. USA: Oxford Press; 2006.</Citation></Reference><Reference><Citation>Au R, Seshadri S, Wolf PA, Elias M, Elias P, Sullivan L, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res 2004;30:333&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Dietz WH. Trends in energy intake among adults in the United States: findings from NHANES. Am J Clin Nutr 2013;97:848&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598942</ArticleId><ArticleId IdType="pubmed">23426032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002; 112:803&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12088740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 2013;14:401&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">23674053</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D, et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol 2014;71:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056186</ArticleId><ArticleId IdType="pubmed">24276217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Gao X, Scott T, Tucker KL. Habitual sugar intake and cognitive function among middle-aged and older Puerto Ricans without diabetes. Br J Nutr 2011;106:1423&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876724</ArticleId><ArticleId IdType="pubmed">21736803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Floel A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 2013;81:1746&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24153444</ArticleId></ArticleIdList></Reference><Reference><Citation>2015 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement 2015; 11:332&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015&#x2013;2020 Dietary Guidelines for Americans. 8th ed.; 2015.</Citation></Reference><Reference><Citation>United States Department of Agriculture. National Nutrient Database for Standard Reference. Available at: https://ndb.nal.usda.gov/2015. Accessed October 1, 2016.</Citation></Reference><Reference><Citation>Boulton J, Hashem KM, Jenner KH, Lloyd-Williams F, Bromley H, Capewell S. How much sugar is hidden in drinks marketed to children? A survey of fruit juices, juice drinks and smoothies. BMJ Open 2016; 6:e010330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809069</ArticleId><ArticleId IdType="pubmed">27009146</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill JM, Sattar N. Fruit juice: just another sugary drink? Lancet Diabetes Endocrinol 2014;2:444&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24731678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28288263</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design.</ArticleTitle><Pagination><StartPage>540</StartPage><EndPage>548</EndPage><MedlinePgn>540-548</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.5953</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The heterogeneity of rate of clinical progression among patients with Alzheimer disease leads to difficulty in providing clinical counseling and diminishes the power of clinical trials using disease-modifying agents.</AbstractText><AbstractText Label="OBJECTIVE">To gain a better understanding of the factors that affect the natural history of progression in Alzheimer disease for the purpose of improving both clinical care and clinical trial design.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A longitudinal cohort study of aging from 2005 to 2014 in the National Alzheimer Coordinating Center. Clinical evaluation of the participants was conducted in 31 National Institute on Aging's Alzheimer Disease Centers. Nine hundred eighty-four participants in the National Alzheimer Coordinating Center cohort study who died and underwent autopsy and met inclusion and exclusion criteria.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">We sought to model the possibility that knowledge of neurofibrillary tangle burden in the presence of moderate or frequent plaques would add to the ability to predict clinical rate of progression during the ensuing 2 to 3 years. We examined the National Alzheimer Coordinating Center autopsy data to evaluate the effect of different neurofibrillary tangle stages on the rates of progression on several standard clinical instruments: the Clinical Dementia Rating Scale sum of boxes, a verbal memory test (logical memory), and a controlled oral word association task (vegetable naming), implementing a reverse-time longitudinal modeling approach in conjunction with latent class estimation to adjust for unmeasured sources of heterogeneity.</AbstractText><AbstractText Label="RESULTS">Several correlations between clinical variables and neurocognitive performance suggest a basis for heterogeneity: Higher education level was associated with lower Clinical Dementia Rating Scale sum of boxes (&#x3b2;&#x2009;=&#x2009;-0.19; P&#x2009;&lt;&#x2009;.001), and frequent vs moderate neuritic plaques were associated with higher Clinical Dementia Rating Scale sum of boxes (&#x3b2; = 1.64; P &lt; .001) and lower logical memory score (&#x3b2;&#x2009;=&#x2009;-1.07; P&#x2009;=&#x2009;.005). The rate of change of the clinical and cognitive scores varied depending on Braak stage, when adjusting for plaques, age of death, sex, education, and APOE genotype. For example, comparing high vs low Braak stage with other variables fixed, the logical memory score decreased a substantial 0.38 additional units per year (95% CI, -0.70 to -0.06; P&#x2009;=&#x2009;.02). Using these data, we estimate that a 300-participant clinical trial with end point of a 20% improvement in slope in rate of change of Clinical Dementia Rating Scale sum of boxes has 89% power when all participants in the trial are from the high Braak stage, compared with 29% power if Braak stage had not used for eligibility.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">We found that knowledge of neurofibrillary tangle stage, modeled as the sort of information that could be available from tau positron-emission tomography scans and its use to determine eligibility to a trial, could dramatically improve the power of clinical trials and equivalently reduce the required sample sizes of clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Neurology Service, Massachusetts General Hospital, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betensky</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094610</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG053695</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28288263</ArticleId><ArticleId IdType="mid">NIHMS875641</ArticleId><ArticleId IdType="pmc">PMC5547572</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.5953</ArticleId><ArticleId IdType="pii">2610472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer&#x2019;s disease: an appraisal from 1984 to 2014. J Intern Med. 2014 Mar;275(3):251&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956752</ArticleId><ArticleId IdType="pubmed">24605808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle P, Wilson RS, et al. A random change point model for cognitive decline in Alzheimer&#x2019;s disease and mild cognitive impairment. Neuroepidemiology. 2012;39(2):73&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484884</ArticleId><ArticleId IdType="pubmed">22814083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle PA, Leurgans S, et al. Effect of common neuropathologies on progression of late life cognitive impairment. Neurobiol Aging. 2015 Jul;36(7):2225&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457559</ArticleId><ArticleId IdType="pubmed">25976345</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain : a journal of neurology. 2016 May;139(Pt 5):1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of neurology. 2016 Jan;79(1):110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of neurology. 2015 Nov;78(5):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 2002 May 15;20(10):2495&#x2013;2499.</Citation><ArticleIdList><ArticleId IdType="pubmed">12011127</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013 Dec;72(12):1182&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Sene M, Taylor JM, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res. 2014 Feb;23(1):74&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863083</ArticleId><ArticleId IdType="pubmed">22517270</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle P, Schneider JA, et al. APOE epsilon4, Alzheimer&#x2019;s disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol Aging. 2013 Dec;28(4):1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766432</ArticleId><ArticleId IdType="pubmed">23647000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DL, Alzheimer&#x2019;s Disease Neuroimaging I Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology. 2016 Sep 20;87(12):1235&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035986</ArticleId><ArticleId IdType="pubmed">27558378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Suhy J, Chiao P, et al. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial. Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26885819</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of neurology. 2014 Apr;75(4):597&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016558</ArticleId><ArticleId IdType="pubmed">24585367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Ching CR, Mezher A, et al. MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiol Aging. 2016 Jan;37:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4827255</ArticleId><ArticleId IdType="pubmed">26545631</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin E, Blacker D, Hyman B, Betensky R. Improved design of prodromal Alzheimer&#x2019;s disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis. 2013;36(3):475&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779898</ArticleId><ArticleId IdType="pubmed">23629586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer&#x2019;s disease. Alzheimers Dement. 2014 May;10(3):349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900604</ArticleId><ArticleId IdType="pubmed">23712001</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28287086</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2017</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Pre-plaque conformational changes in Alzheimer's disease-linked A&#x3b2; and APP.</ArticleTitle><Pagination><StartPage>14726</StartPage><MedlinePgn>14726</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14726</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms14726</ELocationID><Abstract><AbstractText>Reducing levels of the aggregation-prone A&#x3b2; peptide that accumulates in the brain with Alzheimer's disease (AD) has been a major target of experimental therapies. An alternative approach may be to stabilize the physiological conformation of A&#x3b2;. To date, the physiological state of A&#x3b2; in brain remains unclear, since the available methods used to process brain tissue for determination of A&#x3b2; aggregate conformation can in themselves alter the structure and/or composition of the aggregates. Here, using synchrotron-based Fourier transform infrared micro-spectroscopy, non-denaturing gel electrophoresis and conformational specific antibodies we show that the physiological conformations of A&#x3b2; and amyloid precursor protein (APP) in brain of transgenic mouse models of AD are altered before formation of amyloid plaques. Furthermore, focal A&#x3b2; aggregates in brain that precede amyloid plaque formation localize to synaptic terminals. These changes in the states of A&#x3b2; and APP that occur prior to plaque formation may provide novel targets for AD therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klementieva</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Will&#xe9;n</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinsson</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelsson</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engdahl</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MAX IV Laboratory, Lund University, 22100 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cladera</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Universitat Aut&#xf2;noma de Barcelona, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uvdal</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>MAX IV Laboratory, Lund University, 22100 Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemical Physics, Department of Chemistry, Lund University, 22100 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>G K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569015">Syp protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C053386">drebrins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063347" MajorTopicYN="N">Native Polyacrylamide Gel Electrophoresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017356" MajorTopicYN="N">Synchrotrons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28287086</ArticleId><ArticleId IdType="pmc">PMC5355803</ArticleId><ArticleId IdType="doi">10.1038/ncomms14726</ArticleId><ArticleId IdType="pii">ncomms14726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marshall K. E., Marchante R., Xue W.-F. &amp; Serpell L. C. The relationship between amyloid structure and cytotoxicity. Prion 8, 192&#x2013;196 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189889</ArticleId><ArticleId IdType="pubmed">24819071</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M. J. et al.. Using Fourier transform IR spectroscopy to analyze biological materials. Nat. Protoc. 9, 1771&#x2013;1791 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4480339</ArticleId><ArticleId IdType="pubmed">24992094</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L. M. &amp; Dumas P. From structure to cellular mechanism with infrared microspectroscopy. Curr. Opin. Struct. Biol. 20, 649&#x2013;656 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140183</ArticleId><ArticleId IdType="pubmed">20739176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretlow A. et al.. FTIR-microspectroscopy of prion-infected nervous tissue. Biochim. Biophys. Acta 1758, 948&#x2013;959 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16887095</ArticleId></ArticleIdList></Reference><Reference><Citation>Diem M., Romeo M., Boydston-White S., Miljkovi&#x107; M. &amp; Matth&#xe4;us C. A decade of vibrational micro-spectroscopy of human cells and tissue (1994&#x2013;2004). Analyst 129, 880&#x2013;885 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713762</ArticleId><ArticleId IdType="pubmed">15457314</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman H.-Y. N., Martin M. C. &amp; McKinney W. R. Synchrotron-based FTIR spectromicroscopy: cytotoxicity and heating considerations. J. Biol. Phys. 29, 275&#x2013;286 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3456410</ArticleId><ArticleId IdType="pubmed">23345845</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew Chan K. L. &amp; Kazarian S. G. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) imaging of tissues and live cells. Chem. Soc. Rev. 45, 1850&#x2013;1864 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26488803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandomeneghi G., Krebs M. R. H., McCammon M. G. &amp; F&#xe4;ndrich M. FTIR reveals structural differences between native &#x3b2;-sheet proteins and amyloid fibrils. Protein Sci. 13, 3314&#x2013;3321 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287307</ArticleId><ArticleId IdType="pubmed">15537750</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez J. L. et al.. The protofilament structure of insulin amyloid fibrils. Proc. Natl Acad. Sci. 99, 9196&#x2013;9201 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123117</ArticleId><ArticleId IdType="pubmed">12093917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ami D. et al.. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Sci. Rep. 6, 29096 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931462</ArticleId><ArticleId IdType="pubmed">27373200</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L. M., Bourassa M. W. &amp; Smith R. J. FTIR spectroscopic imaging of protein aggregation in living cells. Biochim. Biophys. Acta BBA&#x2013;Biomembr. 1828, 2339&#x2013;2346 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722250</ArticleId><ArticleId IdType="pubmed">23357359</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F. et al.. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89, 1308&#x2013;1312 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15147524</ArticleId></ArticleIdList></Reference><Reference><Citation>de Arag&#xe3;o B. J. G. &amp; Messaddeq Y. Peak separation by derivative spectroscopy applied to ftir analysis of hydrolized silica. J. Braz. Chem. Soc 19, 1582&#x2013;1594 (2008).</Citation></Reference><Reference><Citation>Benseny-Cases N., Klementieva O., Cotte M., Ferrer I. &amp; Cladera J. Microspectroscopy (&#x3bc;FTIR) reveals co-localization of lipid oxidation and amyloid plaques in human Alzheimer disease brains. Anal. Chem. 86, 12047&#x2013;12054 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R. et al.. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkins M. R. et al.. Structural polymorphism of Alzheimer's &#x3b2;-amyloid fibrils as controlled by an E22 Switch: a solid-state NMR study. J. Am. Chem. Soc. 138, 9840&#x2013;9852 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149419</ArticleId><ArticleId IdType="pubmed">27414264</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenning M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils&#x2014;current status. J. Chem. Biol. 3, 1&#x2013;18 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2816742</ArticleId><ArticleId IdType="pubmed">19693614</ArticleId></ArticleIdList></Reference><Reference><Citation>Benseny-Cases N., C&#xf3;cera M. &amp; Cladera J. Conversion of non-fibrillar &#x3b2;-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation. Biochem. Biophys. Res. Commun. 361, 916&#x2013;921 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17679138</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama B. H. &amp; Weissman J. S. Amyloid structure: conformational diversity and consequences. Annu. Rev. Biochem. 80, 557&#x2013;585 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817101</ArticleId><ArticleId IdType="pubmed">21456964</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R. H. et al.. Oligomerization of Alzheimer's &#x3b2;-Amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592&#x2013;3599 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. G. et al.. Cholesterol loss enhances TrkB signalling in hippocampal neurons aging in vitro. Mol. Biol. Cell 19, 2101&#x2013;2112 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366859</ArticleId><ArticleId IdType="pubmed">18287532</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S., Midthune B., Cottrell B. &amp; Koo E. H. Induced dimerization of the amyloid precursor protein leads to decreased amyloid- protein production. J. Biol. Chem. 284, 28943&#x2013;28952 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781440</ArticleId><ArticleId IdType="pubmed">19596858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedikian G. et al.. Secreted amyloid precursor protein and holo-APP bind amyloid &#x3b2; through distinct domains eliciting different toxic responses on hippocampal neurons. J. Neurosci. Res. 88, 1795&#x2013;1803 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20155808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A. et al.. Dispersible amyloid &#x3b2;-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol. Aging 33, 2641&#x2013;2660 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22305478</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R. H. et al.. Intraneuronal Alzheimer A&#x3b2;42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869&#x2013;1879 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J. N. &amp; Reixach N. Transthyretin: the servant of many masters. Cell Mol. Life Sci. 66, 3095&#x2013;3101 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820353</ArticleId><ArticleId IdType="pubmed">19644733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J. W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11&#x2013;17 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8696966</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson S. A. et al.. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl Acad. Sci. USA 95, 12956&#x2013;12960 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23669</ArticleId><ArticleId IdType="pubmed">9789022</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. et al.. Defining the Native State of &#x3b1;-Synuclein. Neurodegener. Dis. 13, 114&#x2013;117 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24192542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D. et al.. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J. Neurosci. 29, 9704&#x2013;9713 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763626</ArticleId><ArticleId IdType="pubmed">19657023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha C., Ryu J. &amp; Park C. B. Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry 46, 6118&#x2013;6125 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17455909</ArticleId></ArticleIdList></Reference><Reference><Citation>Petoukhov M. V. et al.. New developments in the ATSAS program package for small-angle scattering data analysis. J. Appl. Crystallogr. 45, 342&#x2013;350 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4233345</ArticleId><ArticleId IdType="pubmed">25484842</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P., Cukalevski R., Frohm B., Knowles T. P. J. &amp; Linse S. Quantification of the concentration of A&#x3b2;42 propagons during the lag phase by an amyloid chain reaction assay. J. Am. Chem. Soc. 136, 219&#x2013;225 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24313551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindgren J. et al.. Microspectroscopic evidence of cretaceous bone proteins. PLoS ONE 6, e19445 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084868</ArticleId><ArticleId IdType="pubmed">21559386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindgren J. et al.. Molecular preservation of the pigment melanin in fossil melanosomes. Nat. Commun. 3, 824 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22569368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J. &amp; Yu S. Fourier Transform Infrared Spectroscopic Analysis of Protein Secondary Structures. Acta Biochim. Biophys. Sin. 39, 549&#x2013;559 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17687489</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerf E. et al.. Antiparallel &#x3b2;-sheet: a signature structure of the oligomeric amyloid &#x3b2;-peptide. Biochem. J. 421, 415&#x2013;423 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19435461</ArticleId></ArticleIdList></Reference><Reference><Citation>Capetillo-Zarate E. et al.. High-resolution 3D reconstruction reveals intra-synaptic amyloid fibrils. Am. J. Pathol. 179, 2551&#x2013;2558 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204026</ArticleId><ArticleId IdType="pubmed">21925470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28287632</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function.</ArticleTitle><Pagination><StartPage>419</StartPage><EndPage>430</EndPage><MedlinePgn>419-430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.3389</ELocationID><Abstract><AbstractText>In the nervous system, rapidly occurring processes such as neuronal transmission and calcium signaling are affected by short-term inhibition of proteasome function. It is unclear how proteasomes are able to acutely regulate such processes, as this action is inconsistent with their canonical role in proteostasis. Here we describe a mammalian nervous-system-specific membrane proteasome complex that directly and rapidly modulates neuronal function by degrading intracellular proteins into extracellular peptides that can stimulate neuronal signaling. This proteasome complex is closely associated with neuronal plasma membranes, exposed to the extracellular space, and catalytically active. Selective inhibition of the membrane proteasome complex by a cell-impermeable proteasome inhibitor blocked the production of extracellular peptides and attenuated neuronal-activity-induced calcium signaling. Moreover, we observed that membrane-proteasome-derived peptides were sufficient to induce neuronal calcium signaling. Our discoveries challenge the prevailing notion that proteasomes function primarily to maintain proteostasis, and highlight a form of neuronal communication that takes place through a membrane proteasome complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramachandran</LastName><ForeName>Kapil V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolis</LastName><ForeName>Seth S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH102364</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007445</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C083480">Gpm6a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y0900I3U8U</RegistryNumber><NameOfSubstance UI="C078846">epoxomicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009420" MajorTopicYN="N">Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28287632</ArticleId><ArticleId IdType="mid">NIHMS853129</ArticleId><ArticleId IdType="pmc">PMC5383508</ArticleId><ArticleId IdType="doi">10.1038/nsmb.3389</ArticleId><ArticleId IdType="pii">nsmb.3389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801&#x2013;847. doi: 10.1146/annurev.bi.65.070196.004101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.65.070196.004101</ArticleId><ArticleId IdType="pubmed">8811196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. Embo J. 1998;17:7151&#x2013;7160. doi: 10.1093/emboj/17.24.7151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/17.24.7151</ArticleId><ArticleId IdType="pmc">PMC1171061</ArticleId><ArticleId IdType="pubmed">9857172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A. 1998;95:2727&#x2013;2730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34259</ArticleId><ArticleId IdType="pubmed">9501156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Nissan G, Sharon M. Regulating the 20S proteasome ubiquitin-independent degradation pathway. Biomolecules. 2014;4:862&#x2013;884. doi: 10.3390/biom4030862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom4030862</ArticleId><ArticleId IdType="pmc">PMC4192676</ArticleId><ArticleId IdType="pubmed">25250704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol. 2012;19:99&#x2013;115. doi: 10.1016/j.chembiol.2012.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2012.01.003</ArticleId><ArticleId IdType="pmc">PMC3503453</ArticleId><ArticleId IdType="pubmed">22284358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003;6:231&#x2013;242. doi: 10.1038/nn1013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1013</ArticleId><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HR et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science. 2003;302:1775&#x2013;1779. doi: 10.1126/science.1090772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090772</ArticleId><ArticleId IdType="pubmed">14657501</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpova A, Mikhaylova M, Thomas U, Knopfel T, Behnisch T. Involvement of protein synthesis and degradation in long-term potentiation of Schaffer collateral CA1 synapses. J Neurosci. 2006;26:4949&#x2013;4955. doi: 10.1523/JNEUROSCI.4573-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4573-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674165</ArticleId><ArticleId IdType="pubmed">16672670</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Upadhya SC, Ding L, Smith TK, Hegde AN. Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Learn Mem. 2008;15:335&#x2013;347. doi: 10.1101/lm.984508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.984508</ArticleId><ArticleId IdType="pmc">PMC2364605</ArticleId><ArticleId IdType="pubmed">18441292</ArticleId></ArticleIdList></Reference><Reference><Citation>Djakovic SN, Schwarz LA, Barylko B, DeMartino GN, Patrick GN. Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II. J Biol Chem. 2009;284:26655&#x2013;26665. doi: 10.1074/jbc.M109.021956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.021956</ArticleId><ArticleId IdType="pmc">PMC2785353</ArticleId><ArticleId IdType="pubmed">19638347</ArticleId></ArticleIdList></Reference><Reference><Citation>Bingol B, Schuman EM. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature. 2006;441:1144&#x2013;1148. doi: 10.1038/nature04769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04769</ArticleId><ArticleId IdType="pubmed">16810255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai F, Frey JU, Sanna PP, Behnisch T. Protein degradation by the proteasome is required for synaptic tagging and the heterosynaptic stabilization of hippocampal late-phase long-term potentiation. Neuroscience. 2010;169:1520&#x2013;1526. doi: 10.1016/j.neuroscience.2010.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.06.032</ArticleId><ArticleId IdType="pubmed">20600658</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinetti GV, Schweizer FE. Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons. J Neurosci. 2010;30:3157&#x2013;3166. doi: 10.1523/JNEUROSCI.3712-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3712-09.2010</ArticleId><ArticleId IdType="pmc">PMC2905680</ArticleId><ArticleId IdType="pubmed">20203175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, et al. Cellular calcium deficiency plays a role in neuronal death caused by proteasome inhibitors. J Neurochem. 2009;109:1225&#x2013;1236. doi: 10.1111/j.1471-4159.2009.06037.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06037.x</ArticleId><ArticleId IdType="pmc">PMC2690718</ArticleId><ArticleId IdType="pubmed">19476541</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca R, Vabulas RM, Hartl FU, Bonhoeffer T, Nagerl UV. A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron. 2006;52:239&#x2013;245. doi: 10.1016/j.neuron.2006.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.08.015</ArticleId><ArticleId IdType="pubmed">17046687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pines J, Lindon C. Proteolysis: anytime, any place, anywhere? Nat Cell Biol. 2005;7:731&#x2013;735. doi: 10.1038/ncb0805-731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb0805-731</ArticleId><ArticleId IdType="pubmed">16056263</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano S, et al. Proteasomes. A molecular census of 26S proteasomes in intact neurons. Science. 2015;347:439&#x2013;442. doi: 10.1126/science.1261197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261197</ArticleId><ArticleId IdType="pubmed">25613890</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Bingol B, Weld HA, Schuman EM. Ubiquitin-mediated proteasome activity is required for agonist-induced endocytosis of GluRs. Curr Biol. 2003;13:2073&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">14653997</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomen VA, et al. Gene essentiality and synthetic lethality in haploid human cells. Science. 2015;350:1092&#x2013;1096. doi: 10.1126/science.aac7557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac7557</ArticleId><ArticleId IdType="pubmed">26472760</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weering JR, et al. Intracellular membrane traffic at high resolution. Methods Cell Biol. 2010;96:619&#x2013;648. doi: 10.1016/S0091-679X(10)96026-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-679X(10)96026-3</ArticleId><ArticleId IdType="pmc">PMC4067575</ArticleId><ArticleId IdType="pubmed">20869541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. PSD-95 family MAGUKs are essential for anchoring AMPA and NMDA receptor complexes at the postsynaptic density. Proc Natl Acad Sci U S A. 2015;112:E6983&#x2013;6992. doi: 10.1073/pnas.1517045112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1517045112</ArticleId><ArticleId IdType="pmc">PMC4687590</ArticleId><ArticleId IdType="pubmed">26604311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazula VR, et al. Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons. J Comp Neurol. 2010;518:3205&#x2013;3220. doi: 10.1002/cne.22393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.22393</ArticleId><ArticleId IdType="pmc">PMC2894291</ArticleId><ArticleId IdType="pubmed">20575068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46:745&#x2013;760. doi: 10.1016/j.neuron.2005.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.04.031</ArticleId><ArticleId IdType="pubmed">15924861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JG, Khatri L, Hanson PI, Ziff EB. NSF ATPase and alpha-/beta-SNAPs disassemble the AMPA receptor-PICK1 complex. Neuron. 2002;34:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931741</ArticleId></ArticleIdList></Reference><Reference><Citation>Peebles CL, et al. Arc regulates spine morphology and maintains network stability in vivo. Proc Natl Acad Sci U S A. 2010;107:18173&#x2013;18178. doi: 10.1073/pnas.1006546107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006546107</ArticleId><ArticleId IdType="pmc">PMC2964216</ArticleId><ArticleId IdType="pubmed">20921410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DT, et al. Regulation of AMPA receptor extrasynaptic insertion by 4.1N, phosphorylation and palmitoylation. Nat Neurosci. 2009;12:879&#x2013;887. doi: 10.1038/nn.2351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2351</ArticleId><ArticleId IdType="pmc">PMC2712131</ArticleId><ArticleId IdType="pubmed">19503082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting. Neuron. 2000;28:511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144360</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterina MJ, Hereld D, Devreotes PN. Occupancy of the Dictyostelium cAMP receptor, cAR1, induces a reduction in affinity which depends upon COOH-terminal serine residues. J Biol Chem. 1995;270:4418&#x2013;4423.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu PP, et al. Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin. J Biol Chem. 2003;278:49063&#x2013;49071. doi: 10.1074/jbc.M306702200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M306702200</ArticleId><ArticleId IdType="pubmed">14506257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunder C, Lippincott-Schwartz J, Lorenz H. Determining membrane protein topologies in single cells and high-throughput screening applications. Curr Protoc Cell Biol. 2010 doi: 10.1002/0471143030.cb0507s49. Chapter 5, Unit 57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471143030.cb0507s49</ArticleId><ArticleId IdType="pmc">PMC3018527</ArticleId><ArticleId IdType="pubmed">21154552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YC, Srajer Gajdosik M, Josic D, Lin SH. Plasma membrane isolation using immobilized concanavalin A magnetic beads. Methods Mol Biol. 2012;909:29&#x2013;41. doi: 10.1007/978-1-61779-959-4_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-959-4_3</ArticleId><ArticleId IdType="pubmed">22903707</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MJ, Koch GL. Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major calcium binding ER/SR protein. Embo J. 1989;8:3581&#x2013;3586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC402037</ArticleId><ArticleId IdType="pubmed">2583110</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, et al. GDE2 promotes neurogenesis by glycosylphosphatidylinositol-anchor cleavage of RECK. Science. 2013;339:324&#x2013;328. doi: 10.1126/science.1231921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231921</ArticleId><ArticleId IdType="pmc">PMC3644959</ArticleId><ArticleId IdType="pubmed">23329048</ArticleId></ArticleIdList></Reference><Reference><Citation>Besche HC, Haas W, Gygi SP, Goldberg AL. Isolation of mammalian 26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins. Biochemistry. 2009;48:2538&#x2013;2549. doi: 10.1021/bi802198q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi802198q</ArticleId><ArticleId IdType="pmc">PMC3811022</ArticleId><ArticleId IdType="pubmed">19182904</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner H, Dimou L, Klugmann M, Pfeiffer S, Nave KA. Multiple splice isoforms of proteolipid M6B in neurons and oligodendrocytes. Mol Cell Neurosci. 2001;18:593&#x2013;605. doi: 10.1006/mcne.2001.1044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2001.1044</ArticleId><ArticleId IdType="pubmed">11749036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchsova B, Fernandez ME, Alfonso J, Frasch AC. Cysteine residues in the large extracellular loop (EC2) are essential for the function of the stress-regulated glycoprotein M6a. J Biol Chem. 2009;284:32075&#x2013;32088. doi: 10.1074/jbc.M109.012377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.012377</ArticleId><ArticleId IdType="pmc">PMC2797278</ArticleId><ArticleId IdType="pubmed">19737934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947. doi: 10.1523/JNEUROSCI.1860-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilchez D, et al. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature. 2012;489:304&#x2013;308. doi: 10.1038/nature11468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11468</ArticleId><ArticleId IdType="pmc">PMC5215918</ArticleId><ArticleId IdType="pubmed">22972301</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert U, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404:770&#x2013;774. doi: 10.1038/35008096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35008096</ArticleId><ArticleId IdType="pubmed">10783891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisselev AF, Akopian TN, Goldberg AL. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J Biol Chem. 1998;273:1982&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pubmed">9442034</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, et al. Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nat Protoc. 2013;8:1155&#x2013;1168. doi: 10.1038/nprot.2013.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.065</ArticleId><ArticleId IdType="pubmed">23702832</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999;96:10403&#x2013;10408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17900</ArticleId><ArticleId IdType="pubmed">10468620</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel TP, Man K, Firestein BL, Meaney DF. Automated quantification of neuronal networks and single-cell calcium dynamics using calcium imaging. J Neurosci Methods. 2015;243:26&#x2013;38. doi: 10.1016/j.jneumeth.2015.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2015.01.020</ArticleId><ArticleId IdType="pmc">PMC5553047</ArticleId><ArticleId IdType="pubmed">25629800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Watanabe N, Fukushima N, Mita S, Hirata T. Actin-independent behavior and membrane deformation exhibited by the four-transmembrane protein M6a. PLoS One. 2011;6:e26702. doi: 10.1371/journal.pone.0026702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026702</ArticleId><ArticleId IdType="pmc">PMC3230579</ArticleId><ArticleId IdType="pubmed">22162747</ArticleId></ArticleIdList></Reference><Reference><Citation>Besche HC, Goldberg AL. Affinity purification of mammalian 26S proteasomes using an ubiquitin-like domain. Methods in molecular biology. 2012;832:423&#x2013;432. doi: 10.1007/978-1-61779-474-2_29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-474-2_29</ArticleId><ArticleId IdType="pubmed">22350902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci. 2008;9:826&#x2013;838. doi: 10.1038/nrn2499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2499</ArticleId><ArticleId IdType="pubmed">18931696</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov P, et al. Operational definition of intrinsically unstructured protein sequences based on susceptibility to the 20S proteasome. Proteins. 2008;70:1357&#x2013;1366. doi: 10.1002/prot.21614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.21614</ArticleId><ArticleId IdType="pubmed">17879262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov P, Reuven N, Prives C, Shaul Y. Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response. J Biol Chem. 2009;284:26234&#x2013;26242. doi: 10.1074/jbc.M109.040493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.040493</ArticleId><ArticleId IdType="pmc">PMC2785311</ArticleId><ArticleId IdType="pubmed">19617345</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843:13&#x2013;25. doi: 10.1016/j.bbamcr.2013.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.08.012</ArticleId><ArticleId IdType="pmc">PMC3858528</ArticleId><ArticleId IdType="pubmed">23994620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nature reviews Neuroscience. 2008;9:826&#x2013;838. doi: 10.1038/nrn2499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2499</ArticleId><ArticleId IdType="pubmed">18931696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Dupont N, Castillo EF, Deretic V. Secretory versus degradative autophagy: unconventional secretion of inflammatory mediators. J Innate Immun. 2013;5:471&#x2013;479. doi: 10.1159/000346707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000346707</ArticleId><ArticleId IdType="pmc">PMC3723810</ArticleId><ArticleId IdType="pubmed">23445716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG, Takahama S, Zhang G, Tomarev SI, Ye Y. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat Cell Biol. 2016;18:765&#x2013;776. doi: 10.1038/ncb3372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3372</ArticleId><ArticleId IdType="pmc">PMC10701763</ArticleId><ArticleId IdType="pubmed">27295555</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS, et al. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290:2155&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron. 2009;64:40&#x2013;45. doi: 10.1016/j.neuron.2009.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.09.044</ArticleId><ArticleId IdType="pmc">PMC2773547</ArticleId><ArticleId IdType="pubmed">19840547</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z, Dudek H, Miranti CK, Greenberg ME. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci. 1996;16:5425&#x2013;5436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578897</ArticleId><ArticleId IdType="pubmed">8757255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA, Roche KW. Long-term potentiation: peeling the onion. Neuropharmacology. 2013;74:18&#x2013;22. doi: 10.1016/j.neuropharm.2013.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.02.010</ArticleId><ArticleId IdType="pmc">PMC3718856</ArticleId><ArticleId IdType="pubmed">23439383</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Nicoll RA. Long-term potentiation&#x2013;a decade of progress? Science. 1999;285:1870&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489359</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis SS, et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell. 2010;143:442&#x2013;455. doi: 10.1016/j.cell.2010.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.09.038</ArticleId><ArticleId IdType="pmc">PMC2967209</ArticleId><ArticleId IdType="pubmed">21029865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, et al. Central terminal sensitization of TRPV1 by descending serotonergic facilitation modulates chronic pain. Neuron. 2014;81:873&#x2013;887. doi: 10.1016/j.neuron.2013.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.011</ArticleId><ArticleId IdType="pmc">PMC3943838</ArticleId><ArticleId IdType="pubmed">24462040</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28306503</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4164</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Molecular cell</Title><ISOAbbreviation>Mol Cell</ISOAbbreviation></Journal><ArticleTitle>Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics.</ArticleTitle><Pagination><StartPage>1044</StartPage><EndPage>1055.e5</EndPage><MedlinePgn>1044-1055.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2017.02.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1097-2765(17)30128-4</ELocationID><Abstract><AbstractText>Liquid-liquid phase separation (LLPS) of RNA-binding proteins plays an important role in the formation of multiple membrane-less organelles involved in RNA metabolism, including stress granules. Defects in stress granule homeostasis constitute a cornerstone of ALS/FTLD pathogenesis. Polar residues (tyrosine and glutamine) have been previously demonstrated to be critical for phase separation of ALS-linked stress granule proteins. We now identify an active role for arginine-rich domains in these phase separations. Moreover, arginine-rich dipeptide repeats (DPRs) derived from C9orf72 hexanucleotide repeat expansions similarly undergo LLPS and induce phase separation of a large set of proteins involved in RNA and stress granule metabolism. Expression of arginine-rich DPRs in cells induced spontaneous stress granule assembly that required both eIF2&#x3b1; phosphorylation and G3BP. Together with recent reports showing that DPRs affect nucleocytoplasmic transport, our results point to an important role for arginine-rich DPRs in the pathogenesis of C9orf72 ALS/FTLD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boeynaems</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogaert</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Denes</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Structural Biology (CSB), VIB, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konijnenberg</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomolecular and Analytical Mass Spectrometry Group, Department of Chemistry, University of Antwerp, 2020 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmerman</LastName><ForeName>Evy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB-UGent Center for Medical Biotechnology, 9000 Gent, Belgium; VIB Proteomics Core, 9000 Gent, Belgium; Department of Biochemistry, Ghent University, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volkov</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Structural Biology (CSB), VIB, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guharoy</LastName><ForeName>Mainak</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Structural Biology (CSB), VIB, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Decker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaspers</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Veronica H</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janke</LastName><ForeName>Abigail M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baatsen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB, Bioimaging Core Facility, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vercruysse</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolaitis</LastName><ForeName>Regina-Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daelemans</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kedersha</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology, and Allergy, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology, and Allergy, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Impens</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>VIB-UGent Center for Medical Biotechnology, 9000 Gent, Belgium; VIB Proteomics Core, 9000 Gent, Belgium; Department of Biochemistry, Ghent University, 9000 Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobott</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biomolecular and Analytical Mass Spectrometry Group, Department of Chemistry, University of Antwerp, 2020 Antwerp, Belgium; Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK; School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Switch Laboratory, Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium; Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Switch Laboratory, Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium; Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fawzi</LastName><ForeName>Nicolas L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium; Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tompa</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Structural Biology (CSB), VIB, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium; Institute of Enzymology, Research Centre for Natural Sciences of the Hungarian Academy of Sciences, 1117 Budapest, Hungary. Electronic address: ptompa@vub.ac.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Department of Neurosciences, KU Leuven - University of Leuven, 3000 Leuven, Belgium; Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, 3000 Leuven, Belgium. Electronic address: ludo.vandenbosch@vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH020068</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM111700</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM104937</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM118530</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>647458</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell</MedlineTA><NlmUniqueID>9802571</NlmUniqueID><ISSNLinking>1097-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015852">Eukaryotic Initiation Factor-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064267">Intrinsically Disordered Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067776">RNA Recognition Motif Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="C116070">G3BP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015852" MajorTopicYN="N">Eukaryotic Initiation Factor-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064267" MajorTopicYN="N">Intrinsically Disordered Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066292" MajorTopicYN="N">Lipid Droplets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067776" MajorTopicYN="N">RNA Recognition Motif Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">LLPS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">hnRNP</Keyword><Keyword MajorTopicYN="N">intrinsically disordered protein</Keyword><Keyword MajorTopicYN="N">low complexity domain</Keyword><Keyword MajorTopicYN="N">phase transition</Keyword><Keyword MajorTopicYN="N">prion-like domain</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28306503</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pii">S1097-2765(17)30128-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A., Altmeyer M. Phase separation: linking cellular compartmentalization to disease. Trends Cell Biol. 2016;26:547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">27051975</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmeyer M., Neelsen K.J., Teloni F., Pozdnyakova I., Pellegrino S., Gr&#xf8;fte M., Rask M.B.D., Streicher W., Jungmichel S., Nielsen M.L., Lukas J. Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose) Nat. Commun. 2015;6:8088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560800</ArticleId><ArticleId IdType="pubmed">26286827</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen J.S., Lam Y.W., Leung A.K., Ong S.E., Lyon C.E., Lamond A.I., Mann M. Nucleolar proteome dynamics. Nature. 2005;433:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., 3rd, Rademakers R. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Aumiller W.M., Jr., Keating C.D. Phosphorylation-mediated RNA/peptide complex coacervation as a model for intracellular liquid organelles. Nat. Chem. 2016;8:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">26791895</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Michiels E., Gijselinck I., Sieben A., Jovi&#x10d;i&#x107; A., De Baets G., Scheveneels W., Steyaert J., Cuijt I. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 2016;6:20877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S., Bogaert E., Van Damme P., Van Den Bosch L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 2016;132:159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne C.P., Eckmann C.R., Courson D.S., Rybarska A., Hoege C., Gharakhani J., J&#xfc;licher F., Hyman A.A. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science. 2009;324:1729&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">19460965</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne C.P., Mitchison T.J., Hyman A.A. Active liquid-like behavior of nucleoli determines their size and shape in Xenopus laevis oocytes. Proc. Natl. Acad. Sci. USA. 2011;108:4334&#x2013;4339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060270</ArticleId><ArticleId IdType="pubmed">21368180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne C.P., Tompa P., Pappu R.V. Polymer physics of intracellular phase transitions. Nat. Phys. 2015;11:899&#x2013;904.</Citation></Reference><Reference><Citation>Burke K.A., Janke A.M., Rhine C.L., Fawzi N.L. Residue-by-residue view of in&#xa0;vitro FUS granules that bind the C-terminal domain of RNA polymerase II. Mol. Cell. 2015;60:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609301</ArticleId><ArticleId IdType="pubmed">26455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A., Fischer B., Eichelbaum K., Horos R., Beckmann B.M., Strein C., Davey N.E., Humphreys D.T., Preiss T., Steinmetz L.M. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149:1393&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P., Tartaglia G.G., Morimoto R.I., Dobson C.M., Vendruscolo M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 2013;5:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883113</ArticleId><ArticleId IdType="pubmed">24183671</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella A.E., Zerze G.H., Mittal J., Fawzi N.L. ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24:1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J., Hein M.Y., Luber C.A., Paron I., Nagaraj N., Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics. 2014;13:2513&#x2013;2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>David A., Netzer N., Strader M.B., Das S.R., Chen C.Y., Gibbs J., Pierre P., Bennink J.R., Yewdell J.W. RNA binding targets aminoacyl-tRNA synthetases to translating ribosomes. J.&#xa0;Biol. Chem. 2011;286:20688&#x2013;20700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121505</ArticleId><ArticleId IdType="pubmed">21460219</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Madl T., Valori C.F., Bentmann E., Tahirovic S., Abou-Ajram C., Kremmer E., Ansorge O., Mackenzie I.R.A., Neumann M., Haass C. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31:4258&#x2013;4275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D., Haass C. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr. Opin. Neurobiol. 2016;36:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26555807</ArticleId></ArticleIdList></Reference><Reference><Citation>Emara M.M., Fujimura K., Sciaranghella D., Ivanova V., Ivanov P., Anderson P. Hydrogen peroxide induces stress granule formation independent of eIF2&#x3b1; phosphorylation. Biochem. Biophys. Res. Commun. 2012;423:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3399031</ArticleId><ArticleId IdType="pubmed">22705549</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley M.D., Bieri G., Kolaitis R.M., Taylor J.P., Gitler A.D. Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J.&#xa0;Neurosci. 2014;34:8083&#x2013;8097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051967</ArticleId><ArticleId IdType="pubmed">24920614</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.H., Badders N., Valentine M., Miller B.L., Wong P.C. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S., Richter R.P., G&#xf6;rlich D. FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science. 2006;314:815&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawe A., Sutter M., Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 2008;25:1487&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440933</ArticleId><ArticleId IdType="pubmed">18172579</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig S., Kong G., Mannen T., Sadowska A., Kobelke S., Blythe A., Knott G.J., Iyer K.S., Ho D., Newcombe E.A. Prion-like domains in RNA binding proteins are essential for building subnuclear paraspeckles. J.&#xa0;Cell Biol. 2015;210:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539981</ArticleId><ArticleId IdType="pubmed">26283796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Wheeler J.R., Walters R.W., Agrawal A., Barsic A., Parker R. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell. 2016;164:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., 3rd, Sun S., Herdy J.R., Bieri G. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Han T.W., Xie S., Shi K., Du X., Wu L.C., Mirzaei H., Goldsmith E.J., Longgood J., Pei J. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N., Chen S., Gilks N., Li W., Miller I.J., Stahl J., Anderson P. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol. Biol. Cell. 2002;13:195&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65082</ArticleId><ArticleId IdType="pubmed">11809833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N., Ivanov P., Anderson P. Stress granules and cell signaling: more than just a passing phase? Trends Biochem. Sci. 2013;38:494&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832949</ArticleId><ArticleId IdType="pubmed">24029419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N., Panas M.D., Achorn C.A., Lyons S., Tisdale S., Hickman T., Thomas M., Lieberman J., McInerney G.M., Ivanov P., Anderson P. G3BP-Caprin1-USP10 complexes mediate stress granule condensation and associate with 40S subunits. J.&#xa0;Cell Biol. 2016;212:845&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810302</ArticleId><ArticleId IdType="pubmed">27022092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Raphael A.R., LaDow E.S., McGurk L., Weber R.A., Trojanowski J.Q., Lee V.M., Finkbeiner S., Gitler A.D., Bonini N.M. Therapeutic modulation of eIF2&#x3b1; phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 2014;46:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>King O.D., Gitler A.D., Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., McKnight S.L. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.H., Zhang P., Kim H.J., Mitrea D.M., Sarkar M., Freibaum B.D., Cika J., Coughlin M., Messing J., Molliex A. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167:774&#x2013;788.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Protter D.S., Rosen M.K., Parker R. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol. Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Mori E., Kato M., Xiang S., Wu L., Kwon I., McKnight S.L. Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell. 2016;167:789&#x2013;802.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Song Y., Tian B., Qian J., Dong Y., Liu J., Liu B., Sun Z. Functional proteomic analysis of promyelocytic leukaemia nuclear bodies in irradiation-induced MCF-7 cells. J.&#xa0;Biochem. 2010;148:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">20823370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92:383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>March Z.M., King O.D., Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res. 2016;1647:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003744</ArticleId><ArticleId IdType="pubmed">26996412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrea D.M., Cika J.A., Guy C.S., Ban D., Banerjee P.R., Stanley C.B., Nourse A., Deniz A.A., Kriwacki R.W. Nucleophosmin integrates within the nucleolus via multi-modal interactions with proteins displaying R-rich linear motifs and rRNA. eLife. 2016;5:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786410</ArticleId><ArticleId IdType="pubmed">26836305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gr&#xf6;nke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O.C., Pietrzyk J. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A., Temirov J., Lee J., Coughlin M., Kanagaraj A.P., Kim H.J., Mittag T., Taylor J.P. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T., Qamar S., Lin J.Q., Schierle G.S., Rees E., Miyashita A., Costa A.R., Dodd R.B., Chan F.T., Michel C.H. ALS/FTD mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott T.J., Petsalaki E., Farber P., Jervis D., Fussner E., Plochowietz A., Craggs T.D., Bazett-Jones D.P., Pawson T., Forman-Kay J.D., Baldwin A.J. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol. Cell. 2015;57:936&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H., Schermann S.M., Woerner A.C., Pinkert S., Hecht M.H., Tartaglia G.G., Vendruscolo M., Hayer-Hartl M., Hartl F.U., Vabulas R.M. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell. 2011;144:67&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A., Lee H.O., Jawerth L., Maharana S., Jahnel M., Hein M.Y., Stoynov S., Mahamid J., Saha S., Franzmann T.M. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M., Taylor J.P., Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013;154:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., ITALSGEN Consortium A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J.C., Wang X., Podell E.R., Cech T.R. RNA seeds higher-order assembly of FUS protein. Cell Rep. 2013;5:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925748</ArticleId><ArticleId IdType="pubmed">24268778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z., Wang H., Xia Q., Li K., Li K., Jiang X., Xu G., Wang G., Ying Z. Nucleolar stress and impaired stress granule formation contribute to&#xa0;C9orf72 RAN translation-induced cytotoxicity. Hum. Mol. Genet. 2015;24:2426&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Thandapani P., O&#x2019;Connor T.R., Bailey T.L., Richard S. Defining the RGG/RG motif. Mol. Cell. 2013;50:613&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraferri A., Maroni P., Borkovec M. Adsorption of polyelectrolytes to like-charged substrates induced by multivalent counterions as exemplified by poly(styrene sulfonate) and silica. Phys. Chem. Chem. Phys. 2015;17:10348&#x2013;10352.</Citation><ArticleIdList><ArticleId IdType="pubmed">25820795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompa P. The principle of conformational signaling. Chem. Soc. Rev. 2016;45:4252&#x2013;4284.</Citation><ArticleIdList><ArticleId IdType="pubmed">27242242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompa P., Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem. Sci. 2008;33:2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18054235</ArticleId></ArticleIdList></Reference><Reference><Citation>Topisirovic I., Siddiqui N., Lapointe V.L., Trost M., Thibault P., Bangeranye C., Pi&#xf1;ol-Roma S., Borden K.L.B. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP. EMBO J. 2009;28:1087&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683702</ArticleId><ArticleId IdType="pubmed">19262567</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadi M., Zsolyomi F., Guharoy M., Tompa P. Functional advantages of conserved intrinsic disorder in RNA-binding proteins. PLoS ONE. 2015;10:e0139731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595337</ArticleId><ArticleId IdType="pubmed">26439842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S.S., Shi Y., Lin S., Shneider N.A., Monaghan J., Pandey U.B. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in&#xa0;vitro and in&#xa0;vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler J.R., Matheny T., Jain S., Abrisch R., Parker R. Distinct stages in stress granule assembly and disassembly. eLife. 2016;5:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014549</ArticleId><ArticleId IdType="pubmed">27602576</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa M., Ito D., Honda T., Kubo K., Noda M., Nakajima K., Suzuki N. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Hum. Mol. Genet. 2015;24:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">25398948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Elbaum-Garfinkle S., Langdon E.M., Taylor N., Occhipinti P., Bridges A.A., Brangwynne C.P., Gladfelter A.S. RNA controls PolyQ protein phase transitions. Mol. Cell. 2015;60:220&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221516</ArticleId><ArticleId IdType="pubmed">26474065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28319243</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).</ArticleTitle><Pagination><StartPage>567</StartPage><EndPage>573</EndPage><MedlinePgn>567-573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.5778</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia.</AbstractText><AbstractText Label="OBJECTIVE">To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen.</AbstractText><AbstractText Label="RESULTS">The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kryscio</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington4Department of Statistics, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington3Department of Biostatistics, University of Kentucky, Lexington5Department of Epidemiology, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caban-Holt</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovell</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington6Department of Chemistry, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Phyllis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darke</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SWOG Statistical Center, Cancer Research and Biostatistics, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>SWOG Statistical Center, Cancer Research and Biostatistics, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington2Alzheimer's Disease Center, University of Kentucky, Lexington9Department of Neurology, College of Medicine, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U10 CA037429</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA189974</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA182883</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>H6241UJ22B</RegistryNumber><NameOfSubstance UI="D012643">Selenium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 May 1;74(5):508-510. doi: 10.1001/jamaneurol.2017.0045.</RefSource><PMID Version="1">28319236</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012643" MajorTopicYN="N">Selenium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b><i>Conflict of interest:</i></b> All authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28319243</ArticleId><ArticleId IdType="mid">NIHMS870934</ArticleId><ArticleId IdType="pmc">PMC5506489</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.5778</ArticleId><ArticleId IdType="pii">2612477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3:186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer&#x2019;s disease: an appraisal from 1984 to 2014. J Int Med. 2014;275(3):251&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956752</ArticleId><ArticleId IdType="pubmed">24605808</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer&#x2019; disease and dementia. J Intern Med. 2014;275:229&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390027</ArticleId><ArticleId IdType="pubmed">24605807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9(6):657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">23332672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet. 2015;385(9984):2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ. Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. JAMA Neurol. 2014;71(8):847&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375727</ArticleId><ArticleId IdType="pubmed">24886838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogen-Shtern N, Ben David T, Lederkremer GZ. Protein aggregation and ER stress. Brain Res. doi: 10.1016/jbrainres2016.03.044. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/jbrainres2016.03.044</ArticleId><ArticleId IdType="pubmed">27037184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24(7):915&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928050</ArticleId></ArticleIdList></Reference><Reference><Citation>Vina J, Lloret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer&#x2019;s disease with antioxidants; prevention of oxidative stress. Molecular Aspects of Medicine. 2004;25(10):117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer&#x2019;s disease. The Alzheimer&#x2019;s Disease Cooperative Study. N Engl J Med. 1997;336:1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69(7):836&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661272</ArticleId><ArticleId IdType="pubmed">22431837</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RT, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. NEJM. 2005;353(24):2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Loef M, Schrauzer GN, Walach H. Selenium and Alzheimer&#x2019;s disease: a systematic review. J Alzheimers Dis. 2011;26(1):81&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593562</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud J, Akbaraly NT, Hininger I, Roussel AM, Berr C. Factors associated with longitudinal plasma selenium decline in the elderly: The EVA Study. J Nutr Biochem. 2007;18(7):482&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913201</ArticleId><ArticleId IdType="pubmed">17142028</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Yinlong J, Hall KS, Liang C, Unverzagt FW, Ji R, Murrell JR, Cao J, Shen J, Ma F, Matesan J, Ying B, Cheng Y, Bian J, Li P, Hendrie HC. Selenium level and cognitive function in rural elderly. Chinese Am J Epidemiol. 2007;165:955&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760949</ArticleId><ArticleId IdType="pubmed">17272290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA: the journal of the American Medical Association. 2009;301(1):39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682779</ArticleId><ArticleId IdType="pubmed">19066370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ, Abner EL, Schmitt FA, et al. A randomized controlled Alzheimer&#x2019;s disease prevention trial&#x2019;s evolution into an exposure study: the PREADViSE trial. J Nutrition: Health and Aging. 2013;17(1):72&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636980</ArticleId><ArticleId IdType="pubmed">23299383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR. Designing a large prevention trial: statistical issues. Stat Med. 2004;23:285&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716729</ArticleId></ArticleIdList></Reference><Reference><Citation>Caban-Holt A, Schmitt FA, Runyons CR, et al. Studying the effects of vitamin E and selenium for Alzheimer&#x2019;s disease prevention: the PREADViSE model. Research and Practice in Alzheimer&#x2019;s Disease. 2006;11:124&#x2013;130.</Citation></Reference><Reference><Citation>Goodman PJ, Hartline JA, Tangen CM, et al. Moving a randomized clinical trial into an observational cohort. Clin Trials. 2013;10:131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636982</ArticleId><ArticleId IdType="pubmed">23064404</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. Neurology. 1999;52:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932936</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psych. 2003;18:318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673608</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer&#x2019;s disease. Neurology. 1989;39(9):1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews M, Abner E, Caban-Holt A, Kryscio R, Schmitt F. CERAD practice effects and attrition bias in a dementia prevention trial. Int Psychogeriatr. 2013;25:1115&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012228</ArticleId><ArticleId IdType="pubmed">23570673</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Roe CM, Powlishta KK, et al. A brief informant interview to detect dementia. Neurology. 2005;65:559&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psych Neur. 1999 Winter;12(4):168&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616864</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Gingko biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253&#x2013;2262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823569</ArticleId><ArticleId IdType="pubmed">19017911</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker LH, Espeland MA, Rapp SR, et al. Postmenopausal Hormone Therapy and Cognitive Outcomes: the Women&#x2019;s Health Initiative Memory Study (WHIMS) The Journal of steroid biochemistry and molecular biology. 2010;118(0):304&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547365</ArticleId><ArticleId IdType="pubmed">19932751</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella B, Coley N, Ousset PJ, et al. Long term use of standardized Ginkgo biloba extract for the prevention of Alzheimer&#x2019;s disease (GuidAge): a randomized placebo-controlled trial. Lancet Neurol. 2012;11(10):851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">22959217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Xiong S, Lyubartseva G, Markesbery WR. Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radic Biol Med. 2009;46(11):1527&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683469</ArticleId><ArticleId IdType="pubmed">19303433</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincenti M, Mandrioli J, Borella P, Michalke B, Tsatsakis A, Finkelstein Y. Selenium neurotoxicity in humans: bridging laboratory and epidemiologic studies. Toxicology Letters. 2014;230:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">24269718</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am Jin Nutr. 1983;37(5):872&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">6846228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301(1):39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682779</ArticleId><ArticleId IdType="pubmed">19066370</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005 Jan 4;142(1):37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537682</ArticleId></ArticleIdList></Reference><Reference><Citation>Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4(2):158&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030744</ArticleId><ArticleId IdType="pubmed">21235492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler NR, Frame A, Perkins AJ, et al. Traits of patients who screen positive for dementia and refuse diagnostic assessment. Alzheimers Dement. 2015;1(2):236&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527161</ArticleId><ArticleId IdType="pubmed">26258162</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Morris JC. Ascertainment bias in the clinical diagnosis of Alzheimer&#x2019;s disease. Arch Neurol. 2010;67(11):1364&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999470</ArticleId><ArticleId IdType="pubmed">21060013</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Roe CM, Coats MA, Morris JC. Patient&#x2019;s rating of cognitive ability using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol. 2007;64(5):725&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502472</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro IM, Boksay I, Auer SR, Torossian C, Sinaiko E, Reisberg B. Reliability of routine clinical instruments for the assessment of Alzheimer&#x2019;s disease administered by telephone. J Geriatr Psychiatry Neurol. 1998;11:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9686748</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Beglinger LJ, Adams WH. Validation of the modified Telephone Interview for cognitive status in amnestic mild cognitive impairment and intact elders. Alzheimer Dis Assoc Disord. 2009;23(1):38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649962</ArticleId><ArticleId IdType="pubmed">18695589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28323831</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score.</ArticleTitle><Pagination><StartPage>e1002258</StartPage><MedlinePgn>e1002258</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002258</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002258</ELocationID><Abstract><AbstractText Label="BACKGROUND">Identifying individuals at risk for developing Alzheimer disease (AD) is of utmost importance. Although genetic studies have identified AD-associated SNPs in APOE and other genes, genetic information has not been integrated into an epidemiological framework for risk prediction.</AbstractText><AbstractText Label="METHODS AND FINDINGS">Using genotype data from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer's Project (IGAP Stage 1), we identified AD-associated SNPs (at p &lt; 10-5). We then integrated these AD-associated SNPs into a Cox proportional hazard model using genotype data from a subset of 6,409 AD patients and 9,386 older controls from Phase 1 of the Alzheimer's Disease Genetics Consortium (ADGC), providing a polygenic hazard score (PHS) for each participant. By combining population-based incidence rates and the genotype-derived PHS for each individual, we derived estimates of instantaneous risk for developing AD, based on genotype and age, and tested replication in multiple independent cohorts (ADGC Phase 2, National Institute on Aging Alzheimer's Disease Center [NIA ADC], and Alzheimer's Disease Neuroimaging Initiative [ADNI], total n = 20,680). Within the ADGC Phase 1 cohort, individuals in the highest PHS quartile developed AD at a considerably lower age and had the highest yearly AD incidence rate. Among APOE &#x3b5;3/3 individuals, the PHS modified expected age of AD onset by more than 10 y between the lowest and highest deciles (hazard ratio 3.34, 95% CI 2.62-4.24, p = 1.0 &#xd7; 10-22). In independent cohorts, the PHS strongly predicted empirical age of AD onset (ADGC Phase 2, r = 0.90, p = 1.1 &#xd7; 10-26) and longitudinal progression from normal aging to AD (NIA ADC, Cochran-Armitage trend test, p = 1.5 &#xd7; 10-10), and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 &#xd7; 10-6, and Consortium to Establish a Registry for Alzheimer's Disease score for neuritic plaques, p = 6.8 &#xd7; 10-6) and in vivo markers of AD neurodegeneration (ADNI, volume loss within the entorhinal cortex, p = 6.3 &#xd7; 10-6, and hippocampus, p = 7.9 &#xd7; 10-5). Additional prospective validation of these results in non-US, non-white, and prospective community-based cohorts is necessary before clinical use.</AbstractText><AbstractText Label="CONCLUSIONS">We have developed a PHS for quantifying individual differences in age-specific genetic risk for AD. Within the cohorts studied here, polygenic architecture plays an important role in modifying AD risk beyond APOE. With thorough validation, quantification of inherited genetic variation may prove useful for stratifying AD risk and as an enrichment strategy in therapeutic trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0002-4151-6017</Identifier><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Chun Chieh</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-9437-2128</Identifier><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9831-1090</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schork</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-4164-9335</Identifier><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1185-8331</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Institute for Biological Psychiatry, Sankt Hans Psychiatric Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besser</LastName><ForeName>Lilah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chi-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karow</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauppi</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witoelar</LastName><ForeName>Aree</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0971-6868</Identifier><AffiliationInfo><Affiliation>Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-7274-2634</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillon</LastName><ForeName>William P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0002-5132-5302</Identifier><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Case Western University, Cleveland, Ohio, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Computational Biology, Case Western University, Cleveland, Ohio, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0003-4583-7798</Identifier><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6126-2966</Identifier><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH100351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG049152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104400</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS Med. 2017 Mar 28;14(3):e1002289. doi: 10.1371/journal.pmed.1002289.</RefSource><PMID Version="1">28350793</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J R Coll Physicians Edinb. 2017 Jun;47(2):151-152. doi: 10.4997/JRCPE.2017.211.</RefSource><PMID Version="1">28675188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="Y">Multifactorial Inheritance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and the authors of this manuscript have the following competing interests: JBB served on advisory boards for Elan, Bristol-Myers Squibb, Avanir, Novartis, Genentech, and Eli Lilly and holds stock options in CorTechs Labs, Inc. and Human Longevity, Inc. AMD is a founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and receives research funding from General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. AG served on or have served on in the last 3 years the scientific advisory boards of the following companies: Denali Therapeutics, Cognition Therapeutics and AbbVie. BM served as guest editor on PLOS Medicine&#x2019;s Special Issue on Dementia.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28323831</ArticleId><ArticleId IdType="pmc">PMC5360219</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002258</ArticleId><ArticleId IdType="pii">PMEDICINE-D-16-02950</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kelley AS, McGarry K, Gorges R, Skinner JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163:729&#x2013;736. 10.7326/M15-0381</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-0381</ArticleId><ArticleId IdType="pmc">PMC4809412</ArticleId><ArticleId IdType="pubmed">26502320</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Cruchaga C, Goate AM. Alzheimer&#x2019;s disease genetics: from the bench to the clinic. Neuron. 2014;83:11&#x2013;26. 10.1016/j.neuron.2014.05.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.041</ArticleId><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;8. 10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, et al. Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation. 2015;131:2061&#x2013;9. 10.1161/CIRCULATIONAHA.115.015489</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.015489</ArticleId><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007;17:1520&#x2013;8. 10.1101/gr.6665407</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.6665407</ArticleId><ArticleId IdType="pmc">PMC1987352</ArticleId><ArticleId IdType="pubmed">17785532</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;41. 10.1038/ng.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21:108&#x2013;17. 10.1038/mp.2015.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Hyman BT, Jack CR Jr, Kawas CH, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, et al. The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007;21:249&#x2013;58. 10.1097/WAD.0b013e318142774e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318142774e</ArticleId><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1&#x2013;13. 10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44:369&#x2013;75. 10.1038/ng.2213</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2213</ArticleId><ArticleId IdType="pmc">PMC3593158</ArticleId><ArticleId IdType="pubmed">22426310</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9(3):e1003348 10.1371/journal.pgen.1003348</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003348</ArticleId><ArticleId IdType="pmc">PMC3605113</ArticleId><ArticleId IdType="pubmed">23555274</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein JP, Houwelingen HC, Ibrahim JG, Scheike TH, editors. Handbook of survival analysis. London: Chapman and Hall/CRC; 2013.</Citation></Reference><Reference><Citation>Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed Philadelphia: Lippincott Williams &amp; Wilkins; 2008.</Citation></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer&#x2019;s disease. Brain. 2015;138(Pt 12):3673&#x2013;84. 10.1093/brain/awv268</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv268</ArticleId><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Bonham LW, Sears RL, Klein E, Karydas A, Kramer JH, et al. Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer&#x2019;s disease. BMC Neurol. 2015;15:47 10.1186/s12883-015-0304-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-015-0304-6</ArticleId><ArticleId IdType="pmc">PMC4459447</ArticleId><ArticleId IdType="pubmed">25880661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, et al. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology. 2016;87(5):481&#x2013;8. 10.1212/WNL.0000000000002922</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002922</ArticleId><ArticleId IdType="pmc">PMC4970660</ArticleId><ArticleId IdType="pubmed">27385740</ArticleId></ArticleIdList></Reference><Reference><Citation>Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, et al. Effects of Alzheimer&#x2019;s disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. J Alzheimers Dis. 2015;43(2):565&#x2013;73. 10.3233/JAD-140777</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140777</ArticleId><ArticleId IdType="pubmed">25096612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hern&#xe1;ndez I, Wolfsgruber S, et al. Genome-wide significant risk factors for Alzheimer&#x2019;s disease: role in progression to dementia due to Alzheimer&#x2019;s disease among subjects with mild cognitive impairment. Mol Psychiatry. 2017;22(1):153&#x2013;160. 10.1038/mp.2016.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.18</ArticleId><ArticleId IdType="pmc">PMC5414086</ArticleId><ArticleId IdType="pubmed">26976043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki V, Reitz C, Maury F, Bis JC, Bellenguez C, Yu L, et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2016;53(3):921&#x2013;32. 10.3233/JAD-150749</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150749</ArticleId><ArticleId IdType="pmc">PMC5036102</ArticleId><ArticleId IdType="pubmed">27340842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, Williams J. Defining the genetic architecture of Alzheimer&#x2019;s disease: where next. Neurodegener Dis. 2016;16(1&#x2013;2):6&#x2013;11. 10.1159/000440841</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000440841</ArticleId><ArticleId IdType="pubmed">26550988</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee N, Shi J, Garc&#xed;a-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392&#x2013;406. 10.1038/nrg.2016.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2016.27</ArticleId><ArticleId IdType="pmc">PMC6021129</ArticleId><ArticleId IdType="pubmed">27140283</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349&#x2013;58. 10.1056/NEJMoa1605086</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1605086</ArticleId><ArticleId IdType="pmc">PMC5338864</ArticleId><ArticleId IdType="pubmed">27959714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5):djv036 10.1093/jnci/djv036</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djv036</ArticleId><ArticleId IdType="pmc">PMC4754625</ArticleId><ArticleId IdType="pubmed">25855707</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, Jacobs DM, Jacobs DM, Small S, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E &#x3f5;4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309:1483&#x2013;92. 10.1001/jama.2013.2973</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.2973</ArticleId><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28345579</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2017</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>14740</StartPage><MedlinePgn>14740</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14740</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms14740</ELocationID><Abstract><AbstractText>&#x3b4;-secretase, also known as asparagine endopeptidase (AEP) or legumain, is a lysosomal cysteine protease that cleaves both amyloid precursor protein (APP) and tau, mediating the amyloid-&#x3b2; and tau pathology in Alzheimer's disease (AD). Here we report the therapeutic effect of an orally bioactive and brain permeable &#x3b4;-secretase inhibitor in mouse models of AD. We performed a high-throughput screen and identified a non-toxic and selective &#x3b4;-secretase inhibitor, termed compound 11, that specifically blocks &#x3b4;-secretase but not other related cysteine proteases. Co-crystal structure analysis revealed a dual active site-directed and allosteric inhibition mode of this compound class. Chronic treatment of tau P301S and 5XFAD transgenic mice with this inhibitor reduces tau and APP cleavage, ameliorates synapse loss and augments long-term potentiation, resulting in protection of memory. Therefore, these findings demonstrate that this &#x3b4;-secretase inhibitor may be an effective clinical therapeutic agent towards AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhentao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obianyo</LastName><ForeName>Obiamaka</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall</LastName><ForeName>Elfriede</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University of Salzburg, Salzburg A-5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Haian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Seong Su</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Mingke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shan-Ping</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrele</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University of Salzburg, Salzburg A-5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0278-4091</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology, University of Salzburg, Salzburg A-5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pathophysiology Department, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian-Zhi</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Pathophysiology Department, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Co-innovation Center of Neuroregeneration, Nantong 226001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandstetter</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University of Salzburg, Salzburg A-5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Keqiang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS060680</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.34</RegistryNumber><NameOfSubstance UI="C069586">asparaginylendopeptidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28345579</ArticleId><ArticleId IdType="pmc">PMC5378956</ArticleId><ArticleId IdType="doi">10.1038/ncomms14740</ArticleId><ArticleId IdType="pii">ncomms14740</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watts C., Matthews S. P., Mazzeo D., Manoury B. &amp; Moss C. X. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol. Rev. 207, 218&#x2013;228 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16181339</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller G., Matthews S. P., Reinheckel T., Fleming S. &amp; Watts C. Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25, 1606&#x2013;1617 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21292981</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J. M. et al.. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J. Biol. Chem. 272, 8090&#x2013;8098 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9065484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chwieralski C. E., Welte T. &amp; Buhling F. Cathepsin-regulated apoptosis. Apoptosis 11, 143&#x2013;149 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16502253</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehr R. et al.. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. J. Immunol. 174, 7066&#x2013;7074 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15905550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajjuri K. M., Liu Y., Liu C. &amp; Sinha S. C. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem 6, 54&#x2013;59 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549592</ArticleId><ArticleId IdType="pubmed">21154805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C. B. et al.. Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc. Natl Acad. Sci. USA 106, 468&#x2013;473 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626726</ArticleId><ArticleId IdType="pubmed">19106291</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Sun C., Huang H., Janda K. &amp; Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63, 2957&#x2013;2964 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12782603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawenda J., Traub F., Luck H. J., Kreipe H. &amp; von Wasielewski R. Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res. Treat. 102, 1&#x2013;6 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17028987</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs J. J. et al.. Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer 10, 17 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822816</ArticleId><ArticleId IdType="pubmed">20074384</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz J. H. et al.. Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics 12, 2455&#x2013;2463 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787696</ArticleId><ArticleId IdType="pubmed">22718532</ArticleId></ArticleIdList></Reference><Reference><Citation>Basurto-Islas G., Grundke-Iqbal I., Tung Y. C., Liu F. &amp; Iqbal K. Activation of asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer disease. J. Biol. Chem. 288, 17495&#x2013;17507 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682549</ArticleId><ArticleId IdType="pubmed">23640887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. et al.. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. Nat. Commun. 6, 8762 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659940</ArticleId><ArticleId IdType="pubmed">26549211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. et al.. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20, 1254.-&#x2013;1262 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224595</ArticleId><ArticleId IdType="pubmed">25326800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovat A. et al.. Aza-peptidyl Michael acceptor and epoxide inhibitors&#x2013;potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases). J. Med. Chem. 52, 7192&#x2013;7210 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19848405</ArticleId></ArticleIdList></Reference><Reference><Citation>Loak K. et al.. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol. Chem. 384, 1239&#x2013;1246 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12974392</ArticleId></ArticleIdList></Reference><Reference><Citation>Niestroj A. J. et al.. Inhibition of mammalian legumain by Michael acceptors and AzaAsn-halomethylketones. Biol. Chem. 383, 1205&#x2013;1214 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12437107</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang R., Luo Y., Niethammer A. G. &amp; Reisfeld R. A. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol. Rev. 222, 117&#x2013;128 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18363997</ArticleId></ArticleIdList></Reference><Reference><Citation>Shultz M. D. Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters. Bioorg. Med. Chem. Lett. 23, 5980&#x2013;5991 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24018190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonassi S. et al.. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28, 625&#x2013;631 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16973674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobel C. S., Kimland M., Nicholson D. W., Orrenius S. &amp; Slater A. F. Disulfiram is a potent inhibitor of proteases of the caspase family. Chem. Res. Toxicol. 10, 1319&#x2013;1324 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9437520</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph B., Moon R. S. C. &amp; Robert P. Reversible covalent inhibition of Papain by a peptide nitrile. 13C-NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc. 108, 1350&#x2013;1352 (1985).</Citation></Reference><Reference><Citation>Baell J. B. Screening-based translation of public research encounters painful problems. ACS Med. Chem. Lett. 6, 229&#x2013;234 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416424</ArticleId><ArticleId IdType="pubmed">25941544</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth J. R. et al.. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc. 127, 217&#x2013;224 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15631471</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlin J. L. et al.. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J. Med. Chem. 58, 2091&#x2013;2113 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4360378</ArticleId><ArticleId IdType="pubmed">25634295</ArticleId></ArticleIdList></Reference><Reference><Citation>Baell J. B. &amp; Holloway G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719&#x2013;2740 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20131845</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino M. A graphical method for determining inhibition parameters for partial and complete inhibitors. Biochem. J. 248, 815&#x2013;820 (1987).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1148622</ArticleId><ArticleId IdType="pubmed">3435487</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland R. A. Enzymes: A Practical Introduction to Structure, Mechanism and Data Analysis Second edn Wiley and Sons (2002).</Citation></Reference><Reference><Citation>Obianyo O. et al.. A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem 11, 1219&#x2013;1223 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060404</ArticleId><ArticleId IdType="pubmed">20480486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dockal M. et al.. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J. Biol. Chem. 289, 1732&#x2013;1741 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894350</ArticleId><ArticleId IdType="pubmed">24275667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall E. &amp; Brandstetter H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Natl Acad. Sci. USA 110, 10940&#x2013;10945 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703970</ArticleId><ArticleId IdType="pubmed">23776206</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B. H. et al.. Clusterin contributes to caspase-3&#x2013;independent brain injury following neonatal hypoxia-ischemia. Nat. Med. 7, 338&#x2013;343 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11231633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton J. Z. et al.. Development and implementation of a high throughput screen for the human sperm-specific isoform of glyceraldehyde 3-phosphate dehydrogenase (GAPDHS). Curr. Chem. Genomics 5, 30 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134944</ArticleId><ArticleId IdType="pubmed">21760877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y. et al.. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S. W., Price D. A., Schmitt F. A., Scheff M. A. &amp; Mufson E. J. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 24, 547&#x2013;557 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098316</ArticleId><ArticleId IdType="pubmed">21297265</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H. et al.. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z. et al.. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol. Cell 29, 665&#x2013;678 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819101</ArticleId><ArticleId IdType="pubmed">18374643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R. &amp; Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33, 229&#x2013;235 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741400</ArticleId><ArticleId IdType="pubmed">19026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozics K., Valovicova Z. &amp; Slamenova D. Structure of flavonoids influences the degree inhibition of Benzo(a)pyrene - induced DNA damage and micronuclei in HepG2 cells. Neoplasma 58, 516&#x2013;524 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21895405</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall E. &amp; Brandstetter H. Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68, 24&#x2013;31 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253828</ArticleId><ArticleId IdType="pubmed">22232165</ArticleId></ArticleIdList></Reference><Reference><Citation>Battye T. G., Kontogiannis L., Johnson O., Powell H. R. &amp; Leslie A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271&#x2013;281 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069742</ArticleId><ArticleId IdType="pubmed">21460445</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn M. D. et al.. Overview of the CCP4 suite and current developments. Acta. Crystallogr. D Biol. Crystallogr. 67, 235&#x2013;242 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069738</ArticleId><ArticleId IdType="pubmed">21460441</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy A. J. et al.. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658&#x2013;674 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P. &amp; Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126&#x2013;2132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine P. V. et al.. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352&#x2013;367 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322595</ArticleId><ArticleId IdType="pubmed">22505256</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov G. N., Vagin A. A. &amp; Dodson E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240&#x2013;255 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedev A. A. et al.. JLigand: a graphical tool for the CCP4 template-restraint library. Acta Crystallogr. Sect. D 68, 431&#x2013;440 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322602</ArticleId><ArticleId IdType="pubmed">22505263</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowski R. A., Moss D. S. &amp; Thornton J. M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231, 1049&#x2013;1067 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8515464</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis I. W. et al.. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375&#x2013;W383 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933162</ArticleId><ArticleId IdType="pubmed">17452350</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano W. L. PyMol DeLano Scientific (2002).</Citation></Reference><Reference><Citation>Laskowski R. A. &amp; Swindells M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778&#x2013;2786 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21919503</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker N. A., Sept D., Joseph S., Holst M. J. &amp; McCammon J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl Acad. Sci. USA 98, 10037&#x2013;10041 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC56910</ArticleId><ArticleId IdType="pubmed">11517324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinsky T. J., Nielsen J. E., McCammon J. A. &amp; Baker N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665&#x2013;W667 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441519</ArticleId><ArticleId IdType="pubmed">15215472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. et al.. 7, 8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 39, 638&#x2013;650 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895241</ArticleId><ArticleId IdType="pubmed">24022672</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28346578</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>566</EndPage><MedlinePgn>557-566</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.6117</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias.</AbstractText><AbstractText Label="OBJECTIVE">To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. The study dates were September 7, 2005, to February 13, 2012. The plasma NFL analysis was performed in September 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Associations were tested between plasma NFL and diagnosis, A&#x3b2; pathologic features, CSF biomarkers of neuronal injury, cognition, brain structure, and metabolism.</AbstractText><AbstractText Label="RESULTS">Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman &#x3c1;&#x2009;=&#x2009;0.59, P&#x2009;&lt;&#x2009;.001). Plasma NFL was increased in patients with MCI (mean, 42.8 ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean, 34.7 ng/L) (P&#x2009;&lt;&#x2009;.001) and had high diagnostic accuracy for patients with AD with dementia vs controls (area under the receiver operating characteristic curve, 0.87, which is comparable to established CSF biomarkers). Plasma NFL was particularly high in patients with MCI and patients with AD dementia with A&#x3b2; pathologic features. High plasma NFL correlated with poor cognition and AD-related atrophy (at baseline and longitudinally) and with brain hypometabolism (longitudinally).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. This finding implies a potential usefulness for plasma NFL as a noninvasive biomarker in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden2Memory Clinic, Sk&#xe5;ne University Hospital, Scania, Sweden3Department of Neurology, Sk&#xe5;ne University Hospital, Scania, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden6Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 May 1;74(5):510-511. doi: 10.1001/jamaneurol.2017.0010.</RefSource><PMID Version="1">28346580</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 May;13(5):257. doi: 10.1038/nrneurol.2017.57.</RefSource><PMID Version="1">28418024</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Zetterberg reported serving on advisory boards for Roche Diagnostics, Pharmasum, and Eli Lilly and Company and reported being a Wallenberg Academy Fellow. Dr Blennow reported serving as a consultant to or on advisory boards for Alzheon, Eli Lilly and Company, Fujirebio Europe, IBL International, Novartis Pharmaceuticals Corporation, and Roche Diagnostics and reported holding a Torsten S&#xf6;derberg Professorship in Medicine. Drs Zetterberg and Blennow reported being cofounders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures&#x2013;based platform company at the University of Gothenburg. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28346578</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pii">2611175</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattsson N, Carrillo MC, Dean RA, et al. . Revolutionizing Alzheimer&#x2019;s disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015;1(4):412-419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879481</ArticleId><ArticleId IdType="pubmed">27239522</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Rinne JO, Kadir A, L&#xe5;ngstr&#xf6;m B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6(2):78-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">20139997</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 2015;36(5):297-309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016;91(1):1-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27387643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillb&#xe4;ck T, Mattsson N, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60-67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. . Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, et al. . Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(1):56-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, et al. . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655-1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Karydas A, Bang J, et al. . Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IOC, Dick KM, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bernstein MA, Fox NC, et al. . The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685-691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(pt 12):3747-3759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655341</ArticleId><ArticleId IdType="pubmed">26428666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009;21:239-251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864489</ArticleId><ArticleId IdType="pubmed">19694267</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman J, Dring A, Zetterberg H, et al. . Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972001</ArticleId><ArticleId IdType="pubmed">27536708</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Janelidze S, et al. ; ADNI Investigators . Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827-1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of &#x3b2;-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98-106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119-128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med. 2011;49(3):345-352.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer&#x2019;s disease. EMBO Mol Med. 2016;8(10):1184-1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048367</ArticleId><ArticleId IdType="pubmed">27534871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28350801</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.</ArticleTitle><Pagination><StartPage>e1002270</StartPage><MedlinePgn>e1002270</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002270</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002270</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) &#x2264;65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 &#xb1; 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid &#x3b2; (A&#x3b2;)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanoisel&#xe9;e</LastName><ForeName>H&#xe9;l&#xe8;ne-Marie</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Orleans Regional Hospital, Orleans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovelet-Lecrux</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacour</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Anne-Claire</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and CNR-MAJ, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1171, Universit&#xe9; Lille Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollin-Sillaire</LastName><ForeName>Adeline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and CNR-MAJ, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR-S 1171, Universit&#xe9; Lille Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quillard-Muraine</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biochemistry Laboratory, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Sayette</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Caen University Hospital, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutoleau-Bretonniere</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nantes University Hospital, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etcharry-Bouyx</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Angers University Hospital, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauvir&#xe9;</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Angers University Hospital, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Saint Anne University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CNR-MAJ, AP-HP, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; and ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Universit&#xe9;s, UPMC-P6 UMR S 1127 - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CNR-MAJ, AP-HP, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France; and ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Universit&#xe9;s, UPMC-P6 UMR S 1127 - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonveaux</LastName><ForeName>Th&#xe9;r&#xe8;se</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nancy University Hospital, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dijon University Hospital, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccaldi</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aix Marseille University, Inserm, INS, Institut de Neurosciences des Syst&#xe8;mes, Marseille, France; AP-HM, Service de Neurologie et Neuropsychologie, CHU Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe9;lician</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Aix Marseille University, Inserm, INS, Institut de Neurosciences des Syst&#xe8;mes, Marseille, France; AP-HM, Service de Neurologie et Neuropsychologie, CHU Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godefroy</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amiens University Hospital Center, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formaglio</LastName><ForeName>Maite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and CMRR Lyon University Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croisile</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and CMRR Lyon University Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auriacombe</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamard</LastName><ForeName>Ludivine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Besan&#xe7;on University Hospital, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Biochemistry Laboratory, Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauv&#xe9;e</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Grenoble University Hospital, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marelli-Tosi</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabelle</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozsancak</LastName><ForeName>Canan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Orleans Regional Hospital, Orleans, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Toulouse University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CMRR Paris Nord AP-HP, H&#xf4;pital Lariboisi&#xe8;re, INSERM, U942, Universit&#xe9; Paris Diderot, Sorbonne Paris Cit&#xe9;, UMRS 942, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Centre Hospitalier du Rouvray, Sotteville-l&#xe8;s-Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>collaborators of the CNR-MAJ project</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28350801</ArticleId><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002270</ArticleId><ArticleId IdType="pii">PMEDICINE-D-16-02900</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. American journal of human genetics. 1999;65(3):664&#x2013;70. 10.1086/302553</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302553</ArticleId><ArticleId IdType="pmc">PMC1377972</ArticleId><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375(6534):754&#x2013;60. 10.1038/375754a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375754a0</ArticleId><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995;269(5226):970&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376(6543):775&#x2013;8. 10.1038/376775a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/376775a0</ArticleId><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Human molecular genetics. 1996;5(7):985&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353(6347):844&#x2013;6. 10.1038/353844a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/353844a0</ArticleId><ArticleId IdType="pubmed">1944558</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704&#x2013;6. 10.1038/349704a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/349704a0</ArticleId><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, et al. More missense in amyloid gene. Nature genetics. 1992;2(4):255&#x2013;6. 10.1038/ng1292-255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1292-255</ArticleId><ArticleId IdType="pubmed">1303275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature genetics. 2006;38(1):24&#x2013;6. 10.1038/ng1718</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1718</ArticleId><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012;2(5):a006270 10.1101/cshperspect.a006270</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006270</ArticleId><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A. Alzheimer disease: modeling an Abeta-centered biological network. Molecular psychiatry. 2016;21(7):861&#x2013;71. 10.1038/mp.2016.38</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.38</ArticleId><ArticleId IdType="pubmed">27021818</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Baquero M, Blesa R, Boada M, Bras JM, Bullido MJ, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of aging. 2010;31(5):725&#x2013;31. 10.1016/j.neurobiolaging.2008.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.06.012</ArticleId><ArticleId IdType="pmc">PMC2850052</ArticleId><ArticleId IdType="pubmed">18667258</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer's research &amp; therapy. 2013;5(5):48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Marechal L, Martinaud O, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. Journal of Alzheimer's disease: JAD. 2012;30(4):847&#x2013;56. 10.3233/JAD-2012-120172</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120172</ArticleId><ArticleId IdType="pubmed">22475797</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard AC, et al. Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European journal of human genetics: EJHG. 2016;24(5):710&#x2013;6. 10.1038/ejhg.2015.173</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2015.173</ArticleId><ArticleId IdType="pmc">PMC4930083</ArticleId><ArticleId IdType="pubmed">26242991</ArticleId></ArticleIdList></Reference><Reference><Citation>Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome biology. 2016;17(1):241 10.1186/s13059-016-1110-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1110-1</ArticleId><ArticleId IdType="pmc">PMC5125044</ArticleId><ArticleId IdType="pubmed">27894357</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; dementia: the journal of the Alzheimer's Association. 2011;7(3):263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's research &amp; therapy. 2014;6(3):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255520</ArticleId><ArticleId IdType="pubmed">25478015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellal F, Wallon D, Martinez-Almoyna L, Marelli C, Dhar A, Oesterle H, et al. APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review. Journal of Alzheimer's disease: JAD. 2017;56(1):37&#x2013;46. 10.3233/JAD-160709</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160709</ArticleId><ArticleId IdType="pubmed">27858710</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MN, Pottier C, et al. De novo deleterious genetic variations target a biological network centered on Abeta peptide in early-onset Alzheimer disease. Molecular psychiatry. 2015;20(9):1046&#x2013;56. 10.1038/mp.2015.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.100</ArticleId><ArticleId IdType="pubmed">26194182</ArticleId></ArticleIdList></Reference><Reference><Citation>Raux G, Guyant-Marechal L, Martin C, Bou J, Penet C, Brice A, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. Journal of medical genetics. 2005;42(10):793&#x2013;5. 10.1136/jmg.2005.033456</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2005.033456</ArticleId><ArticleId IdType="pmc">PMC1735922</ArticleId><ArticleId IdType="pubmed">16033913</ArticleId></ArticleIdList></Reference><Reference><Citation>Portet F, Dauvilliers Y, Campion D, Raux G, Hauw JJ, Lyon-Caen O, et al. Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu). Neurology. 2003;61(8):1136&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14581682</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin C, Brice A, Campion D, Hannequin D, Martin C, Moreau V, et al. De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. Journal of medical genetics. 1998;35(8):672&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1051395</ArticleId><ArticleId IdType="pubmed">9719376</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin C, Tournier I, Martin C, Didic M, Belliard S, Carlander B, et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Human mutation. 2006;27(10):1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">16941492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285&#x2013;91. 10.1038/nature19057</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253&#x2013;60. 10.1212/WNL.0000000000000596</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000596</ArticleId><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Human mutation. 2006;27(7):686&#x2013;95. 10.1002/humu.20336</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20336</ArticleId><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of neurology. 2007;61(5):446&#x2013;53. 10.1002/ana.21099</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21099</ArticleId><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS ONE. 2012;7(2):e31039 10.1371/journal.pone.0031039</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031039</ArticleId><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Human molecular genetics. 1998;7(1):43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384602</ArticleId></ArticleIdList></Reference><Reference><Citation>Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. American journal of human genetics. 2000;66(1):110&#x2013;7. 10.1086/302702</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302702</ArticleId><ArticleId IdType="pmc">PMC1288316</ArticleId><ArticleId IdType="pubmed">10631141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Roks G, Theuns J, Aulchenko YS, Rademakers R, Cruts M, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain: a journal of neurology. 2004;127(Pt 7):1641&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130954</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Annals of medicine. 2008;40(8):562&#x2013;83. 10.1080/07853890802186905</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890802186905</ArticleId><ArticleId IdType="pubmed">18608129</ArticleId></ArticleIdList></Reference><Reference><Citation>To MD, Gokgoz N, Doyle TG, Donoviel DB, Knight JA, Hyslop PS, et al. Functional characterization of novel presenilin-2 variants identified in human breast cancers. Oncogene. 2006;25(25):3557&#x2013;64. 10.1038/sj.onc.1209397</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209397</ArticleId><ArticleId IdType="pubmed">16474849</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. Familial Alzheimer disease associated with A713T mutation in APP. Neuroscience letters. 2004;370(2&#x2013;3):241&#x2013;3. 10.1016/j.neulet.2004.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.08.026</ArticleId><ArticleId IdType="pubmed">15488330</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology. 2004;63(5):910&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">15365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Geracitano S, Colao R, Puccio G, Gallo M, Anfossi M, et al. AbetaPP A713T mutation in late onset Alzheimer's disease with cerebrovascular lesions. Journal of Alzheimer's disease: JAD. 2009;17(2):383&#x2013;9. 10.3233/JAD-2009-1061</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1061</ArticleId><ArticleId IdType="pubmed">19363265</ArticleId></ArticleIdList></Reference><Reference><Citation>Conidi ME, Bernardi L, Puccio G, Smirne N, Muraca MG, Curcio SA, et al. Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. Neurology. 2015;84(22):2266&#x2013;73. 10.1212/WNL.0000000000001648</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001648</ArticleId><ArticleId IdType="pmc">PMC4456653</ArticleId><ArticleId IdType="pubmed">25948718</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber IS, Garcia-Cardenas JM, Sakdapanichkul C, Deacon C, Zapata Erazo G, Guerreiro R, et al. Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. Neurobiology of aging. 2016;39:220 e1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5155438</ArticleId><ArticleId IdType="pubmed">26803359</ArticleId></ArticleIdList></Reference><Reference><Citation>Golan MP, Styczynska M, Jozwiak K, Walecki J, Maruszak A, Pniewski J, et al. Early-onset Alzheimer's disease with a de novo mutation in the presenilin 1 gene. Experimental neurology. 2007;208(2):264&#x2013;8. 10.1016/j.expneurol.2007.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.08.016</ArticleId><ArticleId IdType="pubmed">17931627</ArticleId></ArticleIdList></Reference><Reference><Citation>Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al. A framework for the interpretation of de novo mutation in human disease. Nature genetics. 2014;46(9):944&#x2013;50. 10.1038/ng.3050</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3050</ArticleId><ArticleId IdType="pmc">PMC4222185</ArticleId><ArticleId IdType="pubmed">25086666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008&#x2013;2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Journal of Alzheimer's disease: JAD. 2013;34(1):297&#x2013;305. 10.3233/JAD-121549</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-121549</ArticleId><ArticleId IdType="pubmed">23186986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Molecular psychiatry. 2012;17(9):875&#x2013;9. 10.1038/mp.2012.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.15</ArticleId><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, Charbonnier C, Wallon D, Quenez O, Bellenguez C, Grenier-Boley B, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular psychiatry. 2016;21(6):831&#x2013;6. 10.1038/mp.2015.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.121</ArticleId><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28346588</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later.</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>590</EndPage><MedlinePgn>583-590</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.6091</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The effect of childhood epilepsy on later-life cognitive and brain health is an unclear and little-explored issue.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether adults with a history of childhood-onset epilepsy exhibit increased brain amyloid accumulation, possibly predisposing to accelerated cognitive impairment or even frank cognitive disorders in later life.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Forty-one adults from a population-based cohort of individuals with childhood-onset epilepsy in southwestern Finland, together with 46 matched population-based controls, underwent amyloid ligand carbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective follow-up. The PiB uptake was quantified as a region to cerebellar cortex ratio. Tracer uptake was evaluated visually and analyzed voxel by voxel over the entire brain to investigate the spatial distribution of amyloid deposition. The study was conducted from May 2011 to October 2013; data analysis was performed from January 2014 to October 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Brain amyloid accumulation.</AbstractText><AbstractText Label="RESULTS">The 41 individuals with epilepsy were originally enrolled in the Turku Adult Childhood Onset Epilepsy study at the mean (SD) age of 5.1 (4.5) years (range, 0-14 years). After a mean 52.5 (4.0) years of follow-up, the participants were evaluated (26 [63%] were women; the mean [SD] age was 56.0 [4.3] years). Nine individuals with childhood-onset epilepsy (22%) and 3 control participants (7%) had a visually abnormal PiB scan showing high cortical uptake in at least 1 of the evaluated brain regions (P&#x2009;=&#x2009;.04). In semiquantitative analyses, there was a significant interaction effect indicating higher prefrontal cortex uptake in apolipoprotein E (APOE) &#x3b5;4 allele carriers than in noncarriers in participants (mean [SD], 1.66 [0.41] vs 1.43 [0.15]) compared with controls (1.40 [0.26) vs 1.41 [0.12]) (group&#x2009;&#xd7;&#x2009;APOE interaction, F&#x2009;=&#x2009;6.8; P&#x2009;=&#x2009;.01). In addition, there was a significant group effect showing higher tracer uptake in participants compared with controls (group effect, F&#x2009;=&#x2009;8.0; P&#x2009;=&#x2009;.006).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Adults with childhood-onset epilepsy, particularly APOE &#x3b5;4 carriers, have an increased brain amyloid load at late middle age. Thus, epilepsy is linked with a biomarker that might be related to accelerated brain aging and can be considered a neurobiological predisposition to later-life cognitive disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joutsa</LastName><ForeName>Juho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Turku PET Centre, Turku University Hospital, Turku, Finland 2Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland3Department of Clinical Neurophysiology, Turku University Hospital, Turku, Finland4now with the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre, Turku University Hospital, Turku, Finland 2Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karrasch</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, &#xc5;bo Akademi University, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anttinen</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinnar</LastName><ForeName>Shlomo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York8Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York9Department of Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sillanp&#xe4;&#xe4;</LastName><ForeName>Matti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health, University of Turku, Turku, Finland11Department of Child Neurology, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Joutsa has received research grants from the Orion Research Foundation and Lunbeck, lecturer honoraria from Boehringer-Ingelheim, and travel grants from Abbvie and Orion. Dr Rinne has received grants from the Sigrid Juselius Foundation and Turku University Hospital during the conduct of the study and serves as a consultant for Clinical Research Services Turku. Dr Hermann has received grants from Citizens United for Epilepsy Research during the conduct of the study. Dr Shinnar has received personal fees from Accorda, AstraZeneca, Questcor, Upsher-Smith, and UCB Pharma; has provided consulting services for Neurelis and Xeris outside the submitted work; and has received royalties as coeditor of <i>Febrile Seizures</i>. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28346588</ArticleId><ArticleId IdType="pmc">PMC5822199</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.6091</ArticleId><ArticleId IdType="pii">2611174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silverberg JI, Joks R, Durkin HG. Allergic disease is associated with epilepsy in childhood: a US population-based study. Allergy. 2014;69(1):95-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380(9848):1180-1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838617</ArticleId><ArticleId IdType="pubmed">23021287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann BP, Seidenberg M, Dow C, et al. . Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006;60(1):80-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann B, Seidenberg M, Sager M, et al. . Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy. Epilepsia. 2008;49(5):731-740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742493</ArticleId><ArticleId IdType="pubmed">18031544</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. Epileptic seizures in AD patients. Neuromolecular Med. 2010;12(1):71-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">19557550</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Scharfman HE. Shared cognitive and behavioral impairments in epilepsy and Alzheimer&#x2019;s disease and potential underlying mechanisms. Epilepsy Behav. 2013;26(3):343-351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924321</ArticleId><ArticleId IdType="pubmed">23321057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. . Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48(6):913-922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal &#x3b2;-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1&#x3b1; immunoreactivity. J Neurochem. 1994;63(5):1872-1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833617</ArticleId><ArticleId IdType="pubmed">7931344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994;87(5):504-510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch LJ. ApoE, MemorE, and EpilepsE. Epilepsy Curr. 2007;7(6):149-150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2096726</ArticleId><ArticleId IdType="pubmed">18049720</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch RM, Lineweaver TT, Naugle RI, et al. . ApoE-&#x3b5;4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology. 2007;68(6):409-414.</Citation><ArticleIdList><ArticleId IdType="pubmed">17283313</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboud O, Mrak RE, Boop FA, Griffin WS. Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. Acta Neuropathol Commun. 2013;1:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893449</ArticleId><ArticleId IdType="pubmed">24252240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M. Medico-social prognosis of children with epilepsy: epidemiological study and analysis of 245 patients. Acta Paediatr Scand Suppl. 1973;237:3-104.</Citation><ArticleIdList><ArticleId IdType="pubmed">4520970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med. 1998;338(24):1715-1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624191</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M, Jalava M, Shinnar S. Epilepsy syndromes in patients with childhood-onset seizures in Finland. Pediatr Neurol. 1999;21(2):533-537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10465138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M, Anttinen A, Rinne JO, et al. . Childhood-onset epilepsy five decades later: a prospective population-based cohort study. Epilepsia. 2015;56(11):1774-1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">26434398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med. 2010;363(26):2522-2529.</Citation><ArticleIdList><ArticleId IdType="pubmed">21175314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Manual of the Finnish Version of WAIS-R. Helsinki, Finland: Psykologien Kustannus; 1992.</Citation></Reference><Reference><Citation>Poutiainen E, Kalska H, Laasonen M. Finnish Manual for the Trail Making Test. Helsinki, Finland: Hogrefe Psykologien Kustannus; 2010.</Citation></Reference><Reference><Citation>Wechsler D. Manual of the Finnish Version of WMS-R. Helsinki, Finland: Psykologien Kustannus; 1996.</Citation></Reference><Reference><Citation>Benton AL, Hamsher K. Controlled Word Association Test. Iowa City, IA: University of Iowa; 1976.</Citation></Reference><Reference><Citation>Laine M, Koivuselk&#xe4;-Sallinen P, H&#xe4;nninen R, Niemi J. Finnish Version of the Boston Naming Test. Helsinki, Finland: Psykologien Kustannus; 1997.</Citation></Reference><Reference><Citation>Pulliainen V, Hokkanen L, Salo J, H&#xe4;nninen T. Manual of the Finnish CERAD Cognitive Test Battery. Kuopio, Finland: Suomen Alzheimer-tutkimusseura; 1999.</Citation></Reference><Reference><Citation>Karrasch M, Tiitta P, Hermann B, et al. . Cognitive outcome in childhood-onset epilepsy: a five-decade prospective cohort study. J Int Neuropsychol Soc. 2017;1-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893911</ArticleId><ArticleId IdType="pubmed">28069097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10(1):120-124. doi:10.1037/0894-4105.10.1.120</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0894-4105.10.1.120</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;nis MT, Siggins S, Tahvanainen E, et al. . Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res. 2004;45(12):2303-2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Wilson IA, et al. . Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67(9):1575-1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95-113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, et al. . Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, et al. . Assessment of &#x3b2;-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11&#x2013;labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304-1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. . Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469-1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Johnson K, et al. ; AV45-A11 Study Group . Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="pubmed">24614494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M, Liu JY, Thompson P, et al. . Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. Brain. 2011;134(pt 10):2969-2981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187539</ArticleId><ArticleId IdType="pubmed">21903728</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, A&#x3b2;-amyloid and the onset of Alzheimer&#x2019;s disease. Neurosci Lett. 1996;210(2):87-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8783279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54(11):2072-2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28837163</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-4349</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature chemistry</Title><ISOAbbreviation>Nat Chem</ISOAbbreviation></Journal><ArticleTitle>A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells.</ArticleTitle><Pagination><StartPage>874</StartPage><EndPage>881</EndPage><MedlinePgn>874-881</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchem.2754</ELocationID><Abstract><AbstractText>The self-propagation of misfolded conformations of tau underlies neurodegenerative diseases, including Alzheimer's. There is considerable interest in discovering the minimal sequence and active conformational nucleus that defines this self-propagating event. The microtubule-binding region, spanning residues 244-372, reproduces much of the aggregation behaviour of tau in cells and animal models. Further dissection of the amyloid-forming region to a hexapeptide from the third microtubule-binding repeat resulted in a peptide that rapidly forms fibrils in vitro. We show that this peptide lacks the ability to seed aggregation of tau<sub>244-372</sub> in cells. However, as the hexapeptide is gradually extended to 31 residues, the peptides aggregate more slowly and gain potent activity to induce aggregation of tau<sub>244-372</sub> in cells. X-ray fibre diffraction, hydrogen-deuterium exchange and solid-state NMR studies map the beta-forming region to a 25-residue sequence. Thus, the nucleus for self-propagating aggregation of tau<sub>244-372</sub> in cells is packaged in a remarkably small peptide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>St&#xf6;hr</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Haifan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nick</LastName><ForeName>Mimi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yibing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhate</LastName><ForeName>Manasi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemmin</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acharya</LastName><ForeName>Srabasti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Mark J S</ForeName><Initials>MJS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee 37235, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeGrado</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM104605</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM054616</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007731</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM054616</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Chem</MedlineTA><NlmUniqueID>101499734</NlmUniqueID><ISSNLinking>1755-4330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002477" MajorTopicYN="N">Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING INTERESTS</b>. UCSF is conducting research sponsored by Daiichi Sankyo (Tokyo, Japan) to develop diagnostics and therapeutics for tau. Currently, there is no direct relationship between these agreements and the present manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28837163</ArticleId><ArticleId IdType="mid">NIHMS931592</ArticleId><ArticleId IdType="pmc">PMC5759337</ArticleId><ArticleId IdType="doi">10.1038/nchem.2754</ArticleId><ArticleId IdType="pii">nchem.2754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prusiner SB. A unifying role for prions in neurodegenerative diseases. Science. 2012;336:1511&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110:9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S, et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer&#x2019;s disease or corticobasal degeneration brains. Acta Neuropathol. 2015;129:221&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci. 2015;18:1183&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Falcon B, Clavaguera F, Tolnay M. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep. 2014;14:495-491&#x2013;495-411.</Citation><ArticleIdList><ArticleId IdType="pubmed">25218483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA. 1988;85:4884&#x2013;4888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol. 1992;118:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of &#x3c4; protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK)311)) forming &#x3b2; structure. Proc Natl Acad Sci USA. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers SA, et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature. 2011;475:96&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073670</ArticleId><ArticleId IdType="pubmed">21677644</ArticleId></ArticleIdList></Reference><Reference><Citation>Daebel V, et al. &#x3b2;-sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc. 2012;134:13982&#x2013;13989.</Citation><ArticleIdList><ArticleId IdType="pubmed">22862303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoo K, et al. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation. J Biochem. 2005;138:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">16272135</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamcik J, et al. Microtubule-binding R3 fragment from tau self-assembles into giant multistranded amyloid ribbons. Angew Chem Int Ed Engl. 2016;55:618&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">26636567</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H. Thioflavine T interaction with synthetic Alzheimer&#x2019;s disease b-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383:550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer&#x2019;s disease. Am J Pathol. 1997;150:2181&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858305</ArticleId><ArticleId IdType="pubmed">9176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, et al. Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci USA. 2015;112:E4949&#x2013;E4958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568231</ArticleId><ArticleId IdType="pubmed">26286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Nukina N. Tau protein assembles into isoform- and disulfide-dependent polymorphic fibrils with distinct structural properties. J Biol Chem. 2011;286:27236&#x2013;27246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149317</ArticleId><ArticleId IdType="pubmed">21659525</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeda Y, et al. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat Commun. 2015;6:10216-10211&#x2013;10216-10212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703892</ArticleId><ArticleId IdType="pubmed">26671725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya K, Rank KB, Evans DB, Sharma SK. Role of cysteine-291 and cysteine-322 in the polymerization of human tau into Alzheimer-like filaments. Biochem Biophys Res Commun. 2001;285:20&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11437366</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry. 2002;41:14885&#x2013;14896.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475237</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco A, et al. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene] FEBS Lett. 2008;582:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726283</ArticleId><ArticleId IdType="pubmed">18291106</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, et al. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer&#x2019;s disease brain. Mol Imaging Biol. 2014;16:19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23868612</ArticleId></ArticleIdList></Reference><Reference><Citation>Astbury WT, Dickinson S, Bailey K. CCLXXIX. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J. 1935;29:2351&#x2013;2361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266766</ArticleId><ArticleId IdType="pubmed">16745914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, et al. Natural and synthetic prion structure from X-ray fiber diffraction. Proc Natl Acad Sci USA. 2009;106:16990&#x2013;16995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761340</ArticleId><ArticleId IdType="pubmed">19805070</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn TR, et al. The common architecture of cross-beta amyloid. J Mol Biol. 2010;395:717&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">19781557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan W, et al. Degradation of fungal prion HET-s(218-289) induces formation of a generic amyloid fold. Biophys J. 2012;102:2339&#x2013;2344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353098</ArticleId><ArticleId IdType="pubmed">22677387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan W, et al. Heterogeneous seeding of a prion structure by a generic amyloid form of the fungal prion-forming domain HET-s(218&#x2013;289) J Biol Chem. 2013;288:29604&#x2013;29612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795258</ArticleId><ArticleId IdType="pubmed">23986444</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci USA. 2006;103:19105&#x2013;19110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748184</ArticleId><ArticleId IdType="pubmed">17142317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YZ, Paterson Y, Roder H. Rapid amide proton exchange rates in peptides and proteins measured by solvent quenching and two-dimensional NMR. Protein Sci. 1995;4:804&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2143101</ArticleId><ArticleId IdType="pubmed">7613478</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C&#x2013;1H dipolar-driven 13C&#x2013;13C recoupling without 13C rf irradiation in nuclear magnetic resonance of rotating solids. J Chem Phys. 2003;118:2325&#x2013;2341.</Citation></Reference><Reference><Citation>Wang Y, Jardetzky O. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 2002;11:852&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373532</ArticleId><ArticleId IdType="pubmed">11910028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter C, et al. Correlation of structural elements and infectivity of the HET-s prion. Nature. 2005;435:844&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567094</ArticleId><ArticleId IdType="pubmed">15944710</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada LT, Geschwind MD. Prion diseases. Semin Neurol. 2013;33:348&#x2013;356. doi: 10.1055/s-0033-1359314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0033-1359314</ArticleId><ArticleId IdType="pubmed">24234356</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmer C, et al. Amyloid fibrils of the HET-s(218&#x2013;289) prion form a beta solenoid with a triangular hydrophobic core. Science. 2008;319:1523&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">18339938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan W, Stubbs G. Fungal prion HET-s as a model for structural complexity and self-propagation in prions. Proc Natl Acad Sci USA. 2014;111:5201&#x2013;5206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986130</ArticleId><ArticleId IdType="pubmed">24706820</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler-Abramovich L, et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol. 2012;8:701&#x2013;706. doi: 10.1038/nchembio.1002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1002</ArticleId><ArticleId IdType="pubmed">22706200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan W, St&#xf6;hr J, Kendall A, Stubbs G. Truncated forms of the prion protein PrP demonstrate the need for complexity in prion structure. Prion. 2015;9:333&#x2013;338. doi: 10.1080/19336896.2015.1084464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336896.2015.1084464</ArticleId><ArticleId IdType="pmc">PMC4964866</ArticleId><ArticleId IdType="pubmed">26325658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28399252</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>317</Volume><Issue>14</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.</ArticleTitle><Pagination><StartPage>1443</StartPage><EndPage>1450</EndPage><MedlinePgn>1443-1450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2017.3090</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Midlife vascular risk factors have been associated with late-life dementia. Whether these risk factors directly contribute to brain amyloid deposition is less well understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if midlife vascular risk factors are associated with late-life brain amyloid deposition, measured using florbetapir positron emission tomography (PET).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study, a prospective cohort study among 346 participants without dementia in 3 US communities (Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi) who have been evaluated for vascular risk factors and markers since 1987-1989 with florbetapir PET scans in 2011-2013. Positron emission tomography image analysis was completed in 2015.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Vascular risk factors at ARIC baseline (age 45-64 years; risk factors included body mass index &#x2265;30, current smoking, hypertension, diabetes, and total cholesterol &#x2265;200 mg/dL) were evaluated in multivariable models including age, sex, race, APOE genotype, and educational level.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Standardized uptake value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated. Elevated florbetapir (defined as a SUVR &gt;1.2) was the dependent variable.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 322 participants without dementia and with nonmissing midlife vascular risk factors at baseline (mean age, 52 years; 58% female; 43% black), the SUVR (elevated in 164 [50.9%] participants) was measured more than 20 years later (median follow-up, 23.5 years; interquartile range, 23.0-24.3 years) when participants were between 67 and 88 (mean, 76) years old. Elevated body mass index in midlife was associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65). At baseline, 65 participants had no vascular risk factors, 123 had 1, and 134 had 2 or more; a higher number of midlife risk factors was associated with elevated amyloid SUVR at follow-up (30.8% [n&#x2009;=&#x2009;20], 50.4% [n&#x2009;=&#x2009;62], and 61.2% [n&#x2009;=&#x2009;82], respectively). In adjusted models, compared with 0 midlife vascular risk factors, the OR for elevated SUVR associated with 1 vascular risk factor was 1.88 (95% CI, 0.95-3.72) and for 2 or more vascular risk factors was 2.88 (95% CI, 1.46-5.69). No significant race &#xd7; risk factor interactions were found. Late-life vascular risk factors were not associated with late-life brain amyloid deposition (for &#x2265;2 late-life vascular risk factors vs 0: OR, 1.66; 95% CI, 0.75-3.69).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">An increasing number of midlife vascular risk factors was significantly associated with elevated amyloid SUVR; this association was not significant for late-life risk factors. These findings are consistent with a role of vascular disease in the development of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea L C</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Section of High Resolution Brain PET Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coresh</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hagerstown Imaging, Hagerstown, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>Akiva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmim</LastName><ForeName>Arman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Section of High Resolution Brain PET Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharrett</LastName><ForeName>A Richey</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagenknecht</LastName><ForeName>Lynne E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Dean F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Radiology, Section of High Resolution Brain PET Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland9Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland10Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland11Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="Y">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="N">Diabetes Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28399252</ArticleId><ArticleId IdType="mid">NIHMS951989</ArticleId><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="doi">10.1001/jama.2017.3090</ArticleId><ArticleId IdType="pii">2616396</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke. 2006;37(1):33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339468</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Mosley TH, Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009;80(11):1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783764</ArticleId><ArticleId IdType="pubmed">19692426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. British Medical Journal. 2001;322(7300):1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology. 2008;19(3):448&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414087</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer&#x2019;s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28(1):75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814023</ArticleId><ArticleId IdType="pubmed">19648749</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nature Reviews Neuroscience. 2011;12(12):723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262670</ArticleId></ArticleIdList></Reference><Reference><Citation>The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke. 2015;46(2):433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308430</ArticleId><ArticleId IdType="pubmed">25563642</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) Alzheimer&#x2019;s and Dementia: Diagnosis, Assessment, and Disease Monitoring. 2016;2:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772876</ArticleId><ArticleId IdType="pubmed">26949733</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. The ARIC-PET Amyloid Imaging Study: Brain Amyloid Differences by Age, Race, Sex, and APOE. Neurology. 2016;87(5):473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Perrotin A, Barre L, et al. Region-specific hierarchy between atrophy, hypometabolism, and Beta-amyloid (AB) load in Alzheimer&#x2019;s disease dementia. Journal of Neuroscience. 2012;32(46):16265&#x2013;16273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L, Nemmi F, Peran P, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imag. 2014;41(5):836&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978219</ArticleId><ArticleId IdType="pubmed">24435769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45. J Nucl Med. 2010;51(6):913&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer&#x2019;s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambless LE, Heiss G, Shahar E, Earp MJ, Toole J. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2004;160(3):259&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">15257999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1994;14(7):1098&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018665</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29(6):1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1&#x2013;2):125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med. 2014;55(5):759&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011952</ArticleId><ArticleId IdType="pubmed">24652830</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85(13):1123&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573049</ArticleId><ArticleId IdType="pubmed">26333802</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed BR, Marchant NL, Jagust WJ, DeCarli CC, Mack W, Chui HC. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979&#x2013;1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371309</ArticleId><ArticleId IdType="pubmed">22078485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuentes D, Poittevin M, Dere E, et al. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension. 2015;65(1):218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">25331846</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, Park L, Zhou P, et al. Hypertension enhances AB-induced neurovascular dysfunction, promotes B-secretase activity, and leads to amyloidogenic processing of APP. Journal of Cerebral Blood Flow and Metabolism. 2016;36(1):241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758560</ArticleId><ArticleId IdType="pubmed">25920959</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurology. 2013;70(5):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968915</ArticleId><ArticleId IdType="pubmed">23553344</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek-Ahmadi M, Beach T, Obradov A, et al. Increased Alzheimer&#x2019;s Disease Neuropathology is Associated with Type 2 Diabetes and APOE e4 Carrier Status. Current Alzheimer Research. 2013;10(6):654&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105218</ArticleId><ArticleId IdType="pubmed">23627755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Samuels LR, Liu D, et al. Stroke risk interacts with Alzheimer&#x2019;s disease biomarkers no brain aging outcomes. Neurobiol Aging. 2015;36(9):2501&#x2013;2508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523400</ArticleId><ArticleId IdType="pubmed">26119224</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(Pt 3):761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, Reed BR, Sanossian N, et al. The Aging Brain and Cognition. JAMA Neurology. 2013;70(4):488&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771392</ArticleId><ArticleId IdType="pubmed">23400560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez J, Honig L, Elkind MSV, et al. Brain arterial aging and its relationship to Alzheimer dementia. Neurology. 2016;86(16):1507&#x2013;1515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836884</ArticleId><ArticleId IdType="pubmed">26984942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Iadecola C. Impaired A-beta clearance: a potential link between atherosclerosis and Alzheimer&#x2019;s Disease. Frontiers in Aging Neuroscience. 2015;7(115) eCollection.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468824</ArticleId><ArticleId IdType="pubmed">26136682</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin-Padilla M, Knopman DS. Developmental aspects of the intracerebral microvasculature and perivascular spaces: Insights into brain response to late-life diseases. J Neuropathol Exp Neurol. 2011;70(12):1060&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227674</ArticleId><ArticleId IdType="pubmed">22082663</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the U.S., 1988-1994 and 1999-2010. Ann Intern Med. 2014;160(8):517&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442608</ArticleId><ArticleId IdType="pubmed">24733192</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28405022</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>544</Volume><Issue>7650</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.</ArticleTitle><Pagination><StartPage>367</StartPage><EndPage>371</EndPage><MedlinePgn>367-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature22038</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and that leads to paralysis and death 2-5 years after disease onset. Nearly all patients with ALS have aggregates of the RNA-binding protein TDP-43 in their brains and spinal cords, and rare mutations in the gene encoding TDP-43 can cause ALS. There are no effective TDP-43-directed therapies for ALS or related TDP-43 proteinopathies, such as frontotemporal dementia. Antisense oligonucleotides (ASOs) and RNA-interference approaches are emerging as attractive therapeutic strategies in neurological diseases. Indeed, treatment of a rat model of inherited ALS (caused by a mutation in Sod1) with ASOs against Sod1 has been shown to substantially slow disease progression. However, as SOD1 mutations account for only around 2-5% of ALS cases, additional therapeutic strategies are needed. Silencing TDP-43 itself is probably not appropriate, given its critical cellular functions. Here we present a promising alternative therapeutic strategy for ALS that involves targeting ataxin-2. A decrease in ataxin-2 suppresses TDP-43 toxicity in yeast and flies, and intermediate-length polyglutamine expansions in the ataxin-2 gene increase risk of ALS. We used two independent approaches to test whether decreasing ataxin-2 levels could mitigate disease in a mouse model of TDP-43 proteinopathy. First, we crossed ataxin-2 knockout mice with TDP-43 (also known as TARDBP) transgenic mice. The decrease in ataxin-2 reduced aggregation of TDP-43, markedly increased survival and improved motor function. Second, in a more therapeutically applicable approach, we administered ASOs targeting ataxin-2 to the central nervous system of TDP-43 transgenic mice. This single treatment markedly extended survival. Because TDP-43 aggregation is a component of nearly all cases of ALS, targeting ataxin-2 could represent a broadly effective therapeutic strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Neurosciences Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paymaan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messing</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong Joo</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Armand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auburger</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurology, Goethe University, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulst</LastName><ForeName>Stefan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurology, Goethe University, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS081182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065317</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073660</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097903</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Apr 20;544(7650):302-303. doi: 10.1038/nature21911.</RefSource><PMID Version="1">28405020</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2017 Jun;16(6):384-385. doi: 10.1038/nrd.2017.104.</RefSource><PMID Version="1">28529318</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2019 Feb;20(2):67. doi: 10.1038/s41580-018-0062-6.</RefSource><PMID Version="1">30279566</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="Y">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>P.J.-N., A.S. and F.R. are employed by Ionis Pharmaceuticals, a for-profit company that develops ASO therapies. The other authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28405022</ArticleId><ArticleId IdType="mid">NIHMS857154</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pii">nature22038</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med. 2012;18:634&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026741</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116:2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W, et al. ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging. 2017;51:178e171&#x2013;178e179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107:3858&#x2013;3863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Joyce PI, Fisher EM, Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013;1832:1421&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol. 2013;48:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiehl TR, et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun. 2006;339:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I, et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet. 2008;17:1465&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell. 2007;18:1385&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaehler C, et al. Ataxin-2-like is a regulator of stress granules and processing bodies. PLoS One. 2012;7:e50134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507954</ArticleId><ArticleId IdType="pubmed">23209657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013;154:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int. 2012;60:415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306778</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of Cultured Cells and Pathological Brain Tissue. PLoS One. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65:636&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem. 2009;284:8516&#x2013;8524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111:E1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci. 2012;32:9133&#x2013;9142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418890</ArticleId><ArticleId IdType="pubmed">22764223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017&#x2013;3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyenet SJ, et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121238</ArticleId><ArticleId IdType="pubmed">20495529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S. Asymptotic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J Mach Learn Res. 2010;11:3571&#x2013;3594.</Citation></Reference><Reference><Citation>Carpenter B, et al. Stan: A probabilistic programming language. J Stat Softw. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788645</ArticleId><ArticleId IdType="pubmed">36568334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28424326</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>386</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaal2029</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aal2029</ELocationID><Abstract><AbstractText>Tauopathies are a group of disorders in which the cytosolic protein tau aggregates and accumulates in cells within the brain, resulting in neurodegeneration. A promising treatment being explored for tauopathies is passive immunization with anti-tau antibodies. We previously found that administration of an anti-tau antibody to human tau transgenic mice increased the concentration of plasma tau. We further explored the effects of administering an anti-tau antibody on plasma tau. After peripheral administration of an anti-tau antibody to human patients with tauopathy and to mice expressing human tau in the central nervous system, there was a dose-dependent increase in plasma tau. In mouse plasma, we found that tau had a short half-life of 8 min that increased to more than 3 hours after administration of anti-tau antibody. As tau transgenic mice accumulated insoluble tau in the brain, brain soluble and interstitial fluid tau decreased. Administration of anti-tau antibody to tau transgenic mice that had decreased brain soluble tau and interstitial fluid tau resulted in an increase in plasma tau, but this increase was less than that observed in tau transgenic mice without these brain changes. Tau transgenic mice subjected to acute neuronal injury using 3-nitropropionic acid showed increased interstitial fluid tau and plasma tau. These data suggest that peripheral administration of an anti-tau antibody results in increased plasma tau, which correlates with the concentration of extracellular and soluble tau in the brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yanamandra</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AbbVie Inc. Foundational Neuroscience Center, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Tirth K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Clinical Trials Program, Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Clinical Trials Program, Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Texas Alzheimer's and Memory Disorders, Texas Health Presbyterian Hospital Dallas, Dallas, TX 75231, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogelman</LastName><ForeName>Ilana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyser</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knapik</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders and Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University, St. Louis, MO 63110,USA. holtzman@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 NS096719</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048678</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009574">Nitro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011422">Propionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>QY4L0FOX0D</RegistryNumber><NameOfSubstance UI="C015392">3-nitropropionic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009574" MajorTopicYN="N">Nitro Compounds</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28424326</ArticleId><ArticleId IdType="mid">NIHMS924558</ArticleId><ArticleId IdType="pmc">PMC5727571</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aal2029</ArticleId><ArticleId IdType="pii">9/386/eaal2029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275678</ArticleId><ArticleId IdType="pubmed">1421571</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell. 1995;6:1887&#x2013;1902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC366657</ArticleId><ArticleId IdType="pubmed">8590813</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Langui D, Lautenschlager C, Ulrich J, Brion JP, Anderton BH. Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol. 1988;77:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">3149122</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Tolnay M, Langui D, Goedert M, Spillantini MG. Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol. 1996;92:588&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">8960316</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Falcon B, Clavaguera F, Tolnay M. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep. 2014;14:495.</Citation><ArticleIdList><ArticleId IdType="pubmed">25218483</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgrafe K, Mandelkow EM, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118:658&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30:16559&#x2013;16566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34:4260&#x2013;4272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608097</ArticleId><ArticleId IdType="pubmed">24647946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder SK, Joly-Amado A, Gordon MN, Morgan D. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol. 2016;11:9&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746105</ArticleId><ArticleId IdType="pubmed">26538351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369277</ArticleId><ArticleId IdType="pubmed">25815354</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Fournier DR, Piech T, Kan CW, Campbell TG, Song L, Chang L, Rivnak AJ, Patel PP, Provuncher GK, Ferrell EP, Howes SC, Pink BA, Minnehan KA, Wilson DH, Duffy DC. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal Chem. 2011;83:2279&#x2013;2285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056883</ArticleId><ArticleId IdType="pubmed">21344864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther. 2013;5:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110&#x2013;13117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, Singh R, Finn SL, Culver JP, Milbrandt J, Holtzman DM. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Ann Clin Transl Neurol. 2016;3:434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891997</ArticleId><ArticleId IdType="pubmed">27547771</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B, Masliah E. Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci. 2014;6:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051211</ArticleId><ArticleId IdType="pubmed">24959143</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-beta, alpha-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics. 2016;13:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720672</ArticleId><ArticleId IdType="pubmed">26494242</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends Mol Med. 2015;21:394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">25846560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Patel TK, Hochgrafe K, Mahan TE, Jiang H, Stewart FR, Mandelkow EM, Holtzman DM. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol Neurodegener. 2015;10:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med. 2012;4:150ra122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910111</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672770</ArticleId></ArticleIdList></Reference><Reference><Citation>Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, Takahashi H, Fukumoto H, Horiguchi T, Suzuki N, Shoji M. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis. 2005;2:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909001</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT, Abramowski D, Danner S, Zurini M, Paganetti P, Tolnay M, Staufenbiel M. Rapid cerebral amyloid binding by Abeta antibodies infused into beta-amyloid precursor protein transgenic mice. Biol Psychiatry. 2010;68:971&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">20359696</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci U S A. 2012;109:15502&#x2013;15507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458349</ArticleId><ArticleId IdType="pubmed">22927427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>d'Abramo C, Acker CM, Schachter JB, Terracina G, Wang X, Forest SK, Davies P. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment. Neurobiol Aging. 2016;37:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4688074</ArticleId><ArticleId IdType="pubmed">26508157</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, Machida N, Lee VM, Trojanowski JQ, Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997;236:262&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9240421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, Kramer JH, Rabinovici GD, Rosen HJ, Miller BL, Meredith J, Boxer AL. Divergent CSF tau alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86:244&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256124</ArticleId><ArticleId IdType="pubmed">24899730</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re192.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. Academic Press; San Diego: 1997.</Citation></Reference><Reference><Citation>Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, Meyer RE, Fishburn MW, Cabrera C, Patel PP, Frew E, Chen Y, Chang L, Ferrell EP, von Einem V, McGuigan W, Reinhardt M, Sayer H, Vielsack C, Duffy DC. The Simoa HD-1 Analyzer: A Novel Fully Automated Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. J Lab Autom. 2016;21:533&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">26077162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28428346</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1524-4628</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month></PubDate></JournalIssue><Title>Stroke</Title><ISOAbbreviation>Stroke</ISOAbbreviation></Journal><ArticleTitle>Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study.</ArticleTitle><Pagination><StartPage>1139</StartPage><EndPage>1146</EndPage><MedlinePgn>1139-1146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/STROKEAHA.116.016027</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Sugar- and artificially-sweetened beverage intake have been linked to cardiometabolic risk factors, which increase the risk of cerebrovascular disease and dementia. We examined whether sugar- or artificially sweetened beverage consumption was associated with the prospective risks of incident stroke or dementia in the community-based Framingham Heart Study Offspring cohort.</AbstractText><AbstractText Label="METHODS">We studied 2888 participants aged &gt;45 years for incident stroke (mean age 62 [SD, 9] years; 45% men) and 1484 participants aged &gt;60 years for incident dementia (mean age 69 [SD, 6] years; 46% men). Beverage intake was quantified using a food-frequency questionnaire at cohort examinations 5 (1991-1995), 6 (1995-1998), and 7 (1998-2001). We quantified recent consumption at examination 7 and cumulative consumption by averaging across examinations. Surveillance for incident events commenced at examination 7 and continued for 10 years. We observed 97 cases of incident stroke (82 ischemic) and 81 cases of incident dementia (63 consistent with Alzheimer's disease).</AbstractText><AbstractText Label="RESULTS">After adjustments for age, sex, education (for analysis of dementia), caloric intake, diet quality, physical activity, and smoking, higher recent and higher cumulative intake of artificially sweetened soft drinks were associated with an increased risk of ischemic stroke, all-cause dementia, and Alzheimer's disease dementia. When comparing daily cumulative intake to 0 per week (reference), the hazard ratios were 2.96 (95% confidence interval, 1.26-6.97) for ischemic stroke and 2.89 (95% confidence interval, 1.18-7.07) for Alzheimer's disease. Sugar-sweetened beverages were not associated with stroke or dementia.</AbstractText><AbstractText Label="CONCLUSIONS">Artificially sweetened soft drink consumption was associated with a higher risk of stroke and dementia.</AbstractText><CopyrightInformation>&#xa9; 2017 American Heart Association, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pase</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.). matthewpase@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himali</LastName><ForeName>Jayandra J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Hugo J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacques</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., S.S.) and Sections of Preventive Medicine and Epidemiology, Department of Medicine (R.S.V), Boston University School of Medicine, MA; Framingham Heart Study, MA (M.P.P., J.J.H., A.S.B., H.J.A., C.L.S., R.S.V., S.S., P.F.J.); Centre for Human Psychopharmacology, Swinburne University of Technology, Australia (M.P.P.); Department of Biostatistics (J.J.H., A.S.B.) and Department of Epidemiology (R.S.V.), Boston University School of Public Health, MA; and Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (P.F.J.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 NS093634</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stroke</MedlineTA><NlmUniqueID>0235266</NlmUniqueID><ISSNLinking>0039-2499</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064306">Non-Nutritive Sweeteners</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064427">Nutritive Sweeteners</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 May;48(5):1129-1131. doi: 10.1161/STROKEAHA.117.017198.</RefSource><PMID Version="1">28428347</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 Jul;48(7):e181. doi: 10.1161/STROKEAHA.117.017863.</RefSource><PMID Version="1">28583997</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 Jul;48(7):e180. doi: 10.1161/STROKEAHA.117.017812.</RefSource><PMID Version="1">28583998</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 Aug;48(8):e236. doi: 10.1161/STROKEAHA.117.018032.</RefSource><PMID Version="1">28720656</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 Sep;48(9):e269. doi: 10.1161/STROKEAHA.117.018603.</RefSource><PMID Version="1">28784919</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Stroke. 2017 Sep;48(9):e268. doi: 10.1161/STROKEAHA.117.018261.</RefSource><PMID Version="1">28784923</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001628" MajorTopicYN="N">Beverages</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002149" MajorTopicYN="N">Energy Intake</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008404" MajorTopicYN="N">Massachusetts</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064306" MajorTopicYN="N">Non-Nutritive Sweeteners</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064427" MajorTopicYN="N">Nutritive Sweeteners</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Framingham Heart Study</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">soft drinks</Keyword><Keyword MajorTopicYN="N">stroke</Keyword><Keyword MajorTopicYN="N">sugar</Keyword></KeywordList><CoiStatement><b>Disclosures -</b> All other authors report no disclosures or potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28428346</ArticleId><ArticleId IdType="mid">NIHMS860316</ArticleId><ArticleId IdType="pmc">PMC5405737</ArticleId><ArticleId IdType="doi">10.1161/STROKEAHA.116.016027</ArticleId><ArticleId IdType="pii">STROKEAHA.116.016027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116:480&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646581</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. American Journal of Clinical Nutrition. 2009;89:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667454</ArticleId><ArticleId IdType="pubmed">19211821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Beiser A, Enserro D, Xanthakis V, Aparicio H, Satizabal CL, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke. 2016;47:1201&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006676</ArticleId><ArticleId IdType="pubmed">27073239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein AM, de Koning L, Flint AJ, Rexrode KM, Willett WC. Soda consumption and the risk of stroke in men and women. American Journal of Clinical Nutrition. 2012;95:1190&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325840</ArticleId><ArticleId IdType="pubmed">22492378</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardener H, Rundek T, Markert M, Wright CB, Elkind MSV, Sacco RL. Diet soft drink consumption is associated with an increased risk of vascular events in the northern manhattan study. Journal of General Internal Medicine. 2012;27:1120&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514985</ArticleId><ArticleId IdType="pubmed">22282311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. American Journal of Epidemiology. 1992;135:1114&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">1632423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB, Rimm E, Smith-Warner SA, Feskanich D, Stampfer MJ, Ascherio A, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. American Journal of Clininical Nutrition. 1999;69:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989687</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: The effects of week-to-week variation in food consumption. International Journal of Epidemiology. 1989;18:858&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">2621022</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychatric Association. Diagnostic and statistical manual of mental disorders. 4. American Psychatric Association; Arlington, VA: 2000. Text revision.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M. Clinical diagnosis of alzheimer&#x2019;s disease: Report of the nincds-adrda work group under the auspices of department of health and human services task force on alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogli-Cawley JJ, Dwyer JT, Saltzman E, McCullough ML, Troy LM, Jacques PF. The 2005 dietary guidelines for americans adherence index: Development and application. Journal of Nutrition. 2006;136:2908&#x2013;2915.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannel WB, Sorlie P. Some health benefits of physical activity: The framingham study. Archives of Internal Medicine. 1979;139:857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">464698</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura F, O&#x2019;Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: Systematic review, meta-analysis, and estimation of population attributable fraction. British Medical Journal. 2015;351:h3576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510779</ArticleId><ArticleId IdType="pubmed">26199070</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SPG, Williams K, Hazuda HP. Diet soda intake is associated with long-term increases in waist circumference in a biethnic cohort of older adults: The san antonio longitudinal study of aging. Journal of the American Geriatrics Society. 2015;63:708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498394</ArticleId><ArticleId IdType="pubmed">25780952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf PA, D&#x2019;Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the framingham study. Stroke. 1991;22:312&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">2003301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig DS. Artificially sweetened beverages: Cause for concern. JAMA. 2009;302:2477&#x2013;2478.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996404</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, et al. Nonnutritive sweeteners: Current use and health perspectives. A scientific statement from the american heart association and the american diabetes association. Circulation. 2012;126:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">22777177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattes RD, Popkin BM. Nonnutritive sweetener consumption in humans: Effects on appetite and food intake and their putative mechanisms. American Journal of Clinical Nutrition. 2009;89:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650084</ArticleId><ArticleId IdType="pubmed">19056571</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Peters SAE, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722942</ArticleId><ArticleId IdType="pubmed">26681727</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">25231862</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA. 2005;294:2330&#x2013;2335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16278361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvetsky AC, Welsh JA, Brown RJ, Vos MB. Low-calorie sweetener consumption is increasing in the united states. American Journal of Clinical Nutrition. 2012;96:640&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417218</ArticleId><ArticleId IdType="pubmed">22854409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Shafe ACE, Cowie MR. Uk stroke incidence, mortality and cardiovascular risk management 1999&#x2013;2008: Time-trend analysis from the general practice research database. BMJ Open. 2011;1:e000269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211058</ArticleId><ArticleId IdType="pubmed">22021893</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and meta analysis. Alzheimer&#x2019;s &amp; Dementia. 2013;9:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28405024</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>544</Volume><Issue>7650</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.</ArticleTitle><Pagination><StartPage>362</StartPage><EndPage>366</EndPage><MedlinePgn>362-366</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature22044</ELocationID><Abstract><AbstractText>There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease. Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function. We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scoles</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meera</LastName><ForeName>Pratap</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of California Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Sharan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dansithong</LastName><ForeName>Warunee</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Karla P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Gene</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otis</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of California Los Angeles, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulst</LastName><ForeName>Stefan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, Utah 84132, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090930</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56NS33123</GrantID><Agency>National Institutes of Neurological Disorders and Stroke</Agency><Country>International</Country></Grant><Grant><GrantID>R01 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 NS073009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097903</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS103009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS103883</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS081182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593754">Atxn2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Apr 20;544(7650):302-303. doi: 10.1038/nature21911.</RefSource><PMID Version="1">28405020</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2017 Jun;16(6):384-385. doi: 10.1038/nrd.2017.104.</RefSource><PMID Version="1">28529318</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cardiovasc Res. 2017 Oct 1;113(12):e43-e44. doi: 10.1093/cvr/cvx170.</RefSource><PMID Version="1">28957542</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="N">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests. S.M.P. is a consultant for Progenitor Life Sciences and Ataxion Pharmaceuticals. T.S.O. is an employee of F. Hoffmann-La Roche, Ltd. G.H., F.R., and C.F.B are employed by Ionis Pharmaceuticals, which supplied the ASOs used in the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28405024</ArticleId><ArticleId IdType="mid">NIHMS857881</ArticleId><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="doi">10.1038/nature22044</ArticleId><ArticleId IdType="pii">nature22044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulst SM, Nechiporuk A &amp; Starkman S Anticipation in spinocerebellar ataxia type 2. Nat Genet 5, 8&#x2013;10, doi:10.1038/ng0993-8c (1993).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0993-8c</ArticleId><ArticleId IdType="pubmed">8220431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigo F, Seth PP &amp; Bennett CF Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv. Exp. Med. Biol 825, 303&#x2013;352, doi:10.1007/978-1-4939-1221-6_9 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-1221-6_9</ArticleId><ArticleId IdType="pubmed">25201110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong W et al. Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet 11, e1005182, doi:10.1371/journal.pgen.1005182 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005182</ArticleId><ArticleId IdType="pmc">PMC4406435</ArticleId><ArticleId IdType="pubmed">25902068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen ST, Meera P, Otis TS &amp; Pulst SM Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum Mol Genet 22, 271&#x2013;283, doi:10.1093/hmg/dds427 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds427</ArticleId><ArticleId IdType="pmc">PMC3526159</ArticleId><ArticleId IdType="pubmed">23087021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst SM Degenerative ataxias, from genes to therapies: The 2015 Cotzias Lecture. Neurology 86, 2284&#x2013;2290, doi:10.1212/WNL.0000000000002777 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002777</ArticleId><ArticleId IdType="pmc">PMC4909556</ArticleId><ArticleId IdType="pubmed">27298447</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H &amp; Singleton AB The genetics and neuropathology of Parkinson&#x2019;s disease. Acta Neuropathol 124, 325&#x2013;338, doi:10.1007/s00401-012-1013-5 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1013-5</ArticleId><ArticleId IdType="pmc">PMC3589971</ArticleId><ArticleId IdType="pubmed">22806825</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR et al. Repeat Associated Non-AUG Translation (RAN Translation) Dependent on Sequence Downstream of the ATXN2 CAG Repeat. PLoS One 10, e0128769, doi:10.1371/journal.pone.0128769 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128769</ArticleId><ArticleId IdType="pmc">PMC4472729</ArticleId><ArticleId IdType="pubmed">26086378</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Figueroa K, Hoang N &amp; Pulst SM Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 26, 44&#x2013;50, doi:10.1038/79162 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/79162</ArticleId><ArticleId IdType="pubmed">10973246</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Maalouf M, Silva AJ, Schweizer FE &amp; Pulst SM Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PLoS One 4, e6235, doi:10.1371/journal.pone.0006235 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006235</ArticleId><ArticleId IdType="pmc">PMC2707006</ArticleId><ArticleId IdType="pubmed">19617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Saugstad JA, Marino MJ, Folk JA, Hepler JR &amp; Conn PJ RGS4 inhibits signaling by group I metabotropic glutamate receptors. J Neurosci 18, 905&#x2013;913 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792754</ArticleId><ArticleId IdType="pubmed">9437012</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Ghani MA, Valiante TA, Carlen PL &amp; Pennefather PS Metabotropic glutamate receptors coupled to IP3 production mediate inhibition of IAHP in rat dentate granule neurons. J Neurophysiol 76, 2691&#x2013;2700 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8899638</ArticleId></ArticleIdList></Reference><Reference><Citation>Meera P, Pulst SM &amp; Otis TS Cellular and circuit mechanisms underlying spinocerebellar ataxias. The Journal of physiology, doi:10.1113/JP271897 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP271897</ArticleId><ArticleId IdType="pmc">PMC4983629</ArticleId><ArticleId IdType="pubmed">27198167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani A, Kuroda Y, Futatsugi A, Furuichi T &amp; Mikoshiba K Phosphorylation of Homer3 by calcium/calmodulin-dependent kinase II regulates a coupling state of its target molecules in Purkinje cells. J Neurosci 28, 5369&#x2013;5382, doi:10.1523/JNEUROSCI.4738-07.2008 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4738-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670636</ArticleId><ArticleId IdType="pubmed">18480293</ArticleId></ArticleIdList></Reference><Reference><Citation>Iscru E et al. Sensorimotor enhancement in mouse mutants lacking the Purkinje cell-specific Gi/o modulator, Pcp2(L7). Mol. Cell. Neurosci 40, 62&#x2013;75, doi:10.1016/j.mcn.2008.09.002 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2008.09.002</ArticleId><ArticleId IdType="pmc">PMC2637474</ArticleId><ArticleId IdType="pubmed">18930827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei P, Blundon JA, Rong Y, Zakharenko SS &amp; Morgan JI Impaired locomotor learning and altered cerebellar synaptic plasticity in pep-19/PCP4-null mice. Mol Cell Biol 31, 2838&#x2013;2844, doi:10.1128/MCB.05208-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.05208-11</ArticleId><ArticleId IdType="pmc">PMC3133400</ArticleId><ArticleId IdType="pubmed">21576365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang WY et al. Cep76, a centrosomal protein that specifically restrains centriole reduplication. Dev Cell 16, 649&#x2013;660, doi:10.1016/j.devcel.2009.03.004 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2009.03.004</ArticleId><ArticleId IdType="pmc">PMC4062978</ArticleId><ArticleId IdType="pubmed">19460342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram M et al. Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways. Neuron 89, 1194&#x2013;1207, doi:10.1016/j.neuron.2016.02.011 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4795980</ArticleId><ArticleId IdType="pubmed">26948890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fittschen M et al. Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics 16, 181&#x2013;192, doi:10.1007/s10048-015-0441-5 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0441-5</ArticleId><ArticleId IdType="pmc">PMC4475250</ArticleId><ArticleId IdType="pubmed">25721894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH et al. Circuit mechanisms underlying motor memory formation in the cerebellum. Neuron 86, 529&#x2013;540, doi:10.1016/j.neuron.2015.03.010 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.03.010</ArticleId><ArticleId IdType="pmc">PMC4417109</ArticleId><ArticleId IdType="pubmed">25843404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang EJ et al. The Roles of the Olivocerebellar Pathway in Motor Learning and Motor Control. A Consensus Paper. Cerebellum, doi:10.1007/s12311-016-0787-8 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12311-016-0787-8</ArticleId><ArticleId IdType="pmc">PMC5116294</ArticleId><ArticleId IdType="pubmed">27193702</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 29, 9148&#x2013;9162, doi:29/29/9148 [pii] 10.1523/JNEUROSCI.0660-09.2009 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0660-09.2009</ArticleId><ArticleId IdType="pmc">PMC2749883</ArticleId><ArticleId IdType="pubmed">19625506</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12, 435&#x2013;442, doi:10.1016/S1474-4422(13)70061-9 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Skotte NH et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9, e107434, doi:10.1371/journal.pone.0107434 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107434</ArticleId><ArticleId IdType="pmc">PMC4160241</ArticleId><ArticleId IdType="pubmed">25207939</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JB et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular therapy : the journal of the American Society of Gene Therapy 19, 2178&#x2013;2185, doi:10.1038/mt.2011.201 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.201</ArticleId><ArticleId IdType="pmc">PMC3242664</ArticleId><ArticleId IdType="pubmed">21971427</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10, 816&#x2013;820, doi:10.1038/nm1076nm1076 [pii] (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1076nm1076</ArticleId><ArticleId IdType="pubmed">15235598</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser MS, Boudreau RL &amp; Davidson BL Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy. Mol Ther, doi:10.1038/mt.2013.279 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.279</ArticleId><ArticleId IdType="pmc">PMC3944323</ArticleId><ArticleId IdType="pubmed">24419082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Lebron E, Liu G, Keiser M, Behlke MA &amp; Davidson BL Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis 54, 456&#x2013;463, doi:10.1016/j.nbd.2013.01.019 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.01.019</ArticleId><ArticleId IdType="pmc">PMC3629010</ArticleId><ArticleId IdType="pubmed">23376683</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA et al. Therapeutic reduction of ataxin 2 extends lifespan and rescues pathological features of ALS in TDP-43 transgenic mice. Nature XXXXX (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong W et al. Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet 11, e1005182, doi:10.1371/journal.pgen.1005182 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005182</ArticleId><ArticleId IdType="pmc">PMC4406435</ArticleId><ArticleId IdType="pubmed">25902068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen ST, Meera P, Otis TS &amp; Pulst SM Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum Mol Genet 22, 271&#x2013;283, doi:10.1093/hmg/dds427 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds427</ArticleId><ArticleId IdType="pmc">PMC3526159</ArticleId><ArticleId IdType="pubmed">23087021</ArticleId></ArticleIdList></Reference><Reference><Citation>Swayze EE et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687&#x2013;700, doi:10.1093/nar/gkl1071 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl1071</ArticleId><ArticleId IdType="pmc">PMC1802611</ArticleId><ArticleId IdType="pubmed">17182632</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M &amp; Salzberg SL Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10, R25, doi:10.1186/gb-2009-10-3-r25 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2009-10-3-r25</ArticleId><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Meera P, Wallner M &amp; Otis TS Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors. J Neurophysiol 106, 2057&#x2013;2064, doi:10.1152/jn.00450.2011 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00450.2011</ArticleId><ArticleId IdType="pmc">PMC3191842</ArticleId><ArticleId IdType="pubmed">21795619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28450713</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1225</StartPage><MedlinePgn>1225</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1225</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-017-01327-w</ELocationID><Abstract><AbstractText>The relationship between body-mass index (BMI) and Alzheimer&#xb4;s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD) have not yet been investigated. We analyzed cross-sectional data from 230 asymptomatic members of families with ADAD participating in the Dominantly Inherited Alzheimer Network (DIAN) study including 120 preclinical mutation carriers (MCs) and 110 asymptomatic non-carriers (NCs). Differences in BMI and their relation with cerebral amyloid load and episodic memory as a function of estimated years to symptom onset (EYO) were analyzed. Preclinical MCs showed significantly lower BMIs compared to NCs, starting 11.2 years before expected symptom onset. However, the BMI curves begun to diverge already at 17.8 years before expected symptom onset. Lower BMI in preclinical MCs was significantly associated with less years before estimated symptom onset, higher global A&#x3b2; brain burden, and with lower delayed total recall scores in the logical memory test. The study provides cross-sectional evidence that weight loss starts one to two decades before expected symptom onset of ADAD. Our findings point toward a link between the pathophysiology of ADAD and disturbance of weight control mechanisms. Longitudinal follow-up studies are warranted to investigate BMI changes over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid R</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0001-8017-8682</Identifier><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Perth, WA, 6027, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xe4;ber</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Dementia Research, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dietzsch</LastName><ForeName>Janko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section for Dementia Research, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Keck School of Medicine of USC, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Perth, WA, 6027, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, WA, 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Department of Neurology, 3471 5th Ave, Suite 811, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-2967-9662</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, Sydney, NSW, 2031, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, Queen Square, London, WC1 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida and Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), M&#xfc;nchen, Germany and Department of Neurology, Ludwig-Maximilians Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shiley-Marcos Alzheimer's Disease Research Center, Department of Neurosciences, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaid</LastName><ForeName>Kimberly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Indiana University Center for Bioethics, 410 West 10th Street, Indianapolis, IN, 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, The Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute, University of Melbourne, Level 5, Kenneth Myer Building, 30 Royal Parade, Parkville, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076, T&#xfc;bingen, Germany. christoph.laske@med.uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Dementia Research, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, 72076, T&#xfc;bingen, Germany. christoph.laske@med.uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002353" MajorTopicYN="Y">Carrier State</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="Y">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>S.M., O.P., H.S., S.G., M.J., B.G., E.D., M.R., N.G., J.D., J.L., V.B., K.Q., C.X., T.B., C.M., R.S., and C.L. report no disclosures or potential conflicts of interest. RB has received personal compensation for activities with Link Medicine, J.A.I., Bristol-Myers Squibb Company, Pfizer Inc., Merck, SPRI, Elan Corporation, Eisai Inc., and Medtronic, Inc., received royalty payments from Washington University, and received research support from Astra Zeneca Pharmaceuticals and Merck &amp; Co., Inc. R.N.M. is the founder and owns stock in Alzhyme. HRS has received personal compensation for activities with Pfizer and Wyeth and is the Western Australian Site Neuropsych Lead for TOMMORROW Study by the Takeda Pharmaceuticals. J.M. reports disclosures: Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Morris has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Janssen Immunotherapy, and Pfizer. Dr. Morris has served as a consultant for Lilly USA. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and U19AG032438&#x201d;. JMR reports research support from NIH, Biogen Idec, and Eli-Lilly during the conduct of this study which is outside of the submitted work. PRS has received speaking fees from Janssen Pharmaceuticals and philanthropic support for the DIAN study from the Wicking and Mason Trusts. D.G. has served as a consultant for Prothena Pharmaceuticals, Astra-Zeneca, Balance Pharmaceuticals and Stemedica, Inc., and participates in clinical trials sponsored by Eli Lilly, Inc, Toyama and Merck Pharmaceuticals. He is funded by NIH grant AGO5131. S.S. received research support from Functional Neuromodulation, Biogen, Merck, Genentech, Roche, Lilly, and Avid Radiopharmaceuticals. He received consultation fees from Biogen, Merck, Piramal, Lilly, Genentech, and Roche. He owns no stock options or royalties and he reports no conflict of interest with this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28450713</ArticleId><ArticleId IdType="pmc">PMC5430642</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-01327-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-017-01327-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garcia-Ptacek S, Faxen-Irving G, Cermakova P, Eriksdotter M, Religa D. Body mass index in dementia. European journal of clinical nutrition. 2014;68:1204&#x2013;1209. doi: 10.1038/ejcn.2014.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2014.199</ArticleId><ArticleId IdType="pubmed">25271014</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003&#x2013;2013: a decade of body mass index, Alzheimer&#x2019;s disease, and dementia. Journal of Alzheimer&#x2019;s disease: JAD. 2015;43:739&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">25147111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang, Y. F. et al. Midlife adiposity predicts earlier onset of Alzheimer&#x2019;s dementia, neuropathology and presymptomatic cerebral amyloid accumulation. Molecular psychiatry, 10.1038/mp.2015.129 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811225</ArticleId><ArticleId IdType="pubmed">26324099</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, et al. Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005;65:892&#x2013;897. doi: 10.1212/01.wnl.0000176061.33817.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000176061.33817.90</ArticleId><ArticleId IdType="pubmed">16186530</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Archives of neurology. 2005;62:55&#x2013;60. doi: 10.1001/archneur.62.1.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.1.55</ArticleId><ArticleId IdType="pubmed">15642850</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Archives of neurology. 2006;63:1312&#x2013;1317. doi: 10.1001/archneur.63.9.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.9.1312</ArticleId><ArticleId IdType="pubmed">16966511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Archives of neurology. 2009;66:336&#x2013;342. doi: 10.1001/archneurol.2008.582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.582</ArticleId><ArticleId IdType="pmc">PMC3513375</ArticleId><ArticleId IdType="pubmed">19273752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB. Association between late-life body mass index and dementia: The Kame Project. Neurology. 2009;72:1741&#x2013;1746. doi: 10.1212/WNL.0b013e3181a60a58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a60a58</ArticleId><ArticleId IdType="pmc">PMC2683740</ArticleId><ArticleId IdType="pubmed">19451529</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clinical investigation. 2012;2:975&#x2013;984. doi: 10.4155/cli.12.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/cli.12.93</ArticleId><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer&#x2019;s research &amp; therapy. 2013;5:48. doi: 10.1186/alzrt213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt213</ArticleId><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. The New England journal of medicine. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414. doi: 10.1212/WNL.43.11.2412-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.11.2412-a</ArticleId><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series894, i&#x2013;xii, 1&#x2013;253 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11234459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;260. doi: 10.1212/WNL.0000000000000596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000596</ArticleId><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>R: A Language and Environment for Statistical Computing (The R Foundation for Statistical Computing, Vienna, Austria, 2011).</Citation></Reference><Reference><Citation>Wickham, W. ggplot2: elegant graphics for data analysis. (Springer, 2009).</Citation></Reference><Reference><Citation>Soto ME, et al. Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer&#x2019;s disease. Journal of Alzheimer&#x2019;s disease: JAD. 2012;28:647&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">22045479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, et al. 37 years of body mass index and dementia: observations from the prospective population study of women in Gothenburg, Sweden. Journal of Alzheimer&#x2019;s disease: JAD. 2012;28:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965312</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE. Anorexia and weight loss in older persons. The journals of gerontology. Series A, Biological sciences and medical sciences. 2003;58:131&#x2013;137. doi: 10.1093/gerona/58.2.M131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/58.2.M131</ArticleId><ArticleId IdType="pubmed">12586850</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer disease biomarkers are associated with body mass index. Neurology. 2011;77:1913&#x2013;1920. doi: 10.1212/WNL.0b013e318238eec1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318238eec1</ArticleId><ArticleId IdType="pmc">PMC3233188</ArticleId><ArticleId IdType="pubmed">22105948</ArticleId></ArticleIdList></Reference><Reference><Citation>Donini LM, Savina C, Cannella C. Eating habits and appetite control in the elderly: the anorexia of aging. International psychogeriatrics/IPA. 2003;15:73&#x2013;87. doi: 10.1017/S1041610203008779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610203008779</ArticleId><ArticleId IdType="pubmed">12834202</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Schneider JA, Wilson RS, Bienias JL, Bennett DA. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology. 2006;67:1949&#x2013;1954. doi: 10.1212/01.wnl.0000247046.90574.0f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000247046.90574.0f</ArticleId><ArticleId IdType="pubmed">17159099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, et al. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer&#x2019;s disease. Neurobiology of aging. 2012;33:1599&#x2013;1608. doi: 10.1016/j.neurobiolaging.2011.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.05.005</ArticleId><ArticleId IdType="pmc">PMC3208117</ArticleId><ArticleId IdType="pubmed">21684041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Progress in cardiovascular diseases. 2014;56:369&#x2013;381. doi: 10.1016/j.pcad.2013.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2013.10.016</ArticleId><ArticleId IdType="pubmed">24438728</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer&#x2019;s disease. Journal of the American Geriatrics Society. 1993;41:710&#x2013;714. doi: 10.1111/j.1532-5415.1993.tb07458.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1993.tb07458.x</ArticleId><ArticleId IdType="pubmed">8315179</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Archives of neurology. 2003;60:729&#x2013;736. doi: 10.1001/archneur.60.5.729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.60.5.729</ArticleId><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">10766253</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008) Behavioral neuroscience. 2008;122:730&#x2013;732. doi: 10.1037/0735-7044.122.3.730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.122.3.730</ArticleId><ArticleId IdType="pmc">PMC2706527</ArticleId><ArticleId IdType="pubmed">18513144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vloeberghs E, et al. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behavioral neuroscience. 2008;122:491&#x2013;497. doi: 10.1037/0735-7044.122.3.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.122.3.491</ArticleId><ArticleId IdType="pubmed">18513119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014;34:9096&#x2013;9106. doi: 10.1523/JNEUROSCI.0872-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0872-14.2014</ArticleId><ArticleId IdType="pmc">PMC4078086</ArticleId><ArticleId IdType="pubmed">24990930</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, et al. Cardiovascular risk factors, cortisol, and amyloid-beta deposition in Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s &amp; dementia: the journal of the Alzheimer&#x2019;s Association. 2012;8:483&#x2013;489. doi: 10.1016/j.jalz.2011.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.08.008</ArticleId><ArticleId IdType="pmc">PMC3668456</ArticleId><ArticleId IdType="pubmed">23102118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan RJ, Greenwood CE, Winocur G, Wolever TM. Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. The American journal of clinical nutrition. 2000;72:825&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study. The American journal of clinical nutrition. 2009;89:601&#x2013;607. doi: 10.3945/ajcn.2008.26482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2008.26482</ArticleId><ArticleId IdType="pmc">PMC2714395</ArticleId><ArticleId IdType="pubmed">19073790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. Jama. 2004;292:2237&#x2013;2242. doi: 10.1001/jama.292.18.2237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.18.2237</ArticleId><ArticleId IdType="pubmed">15536110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettcher BM, et al. Body mass and white matter integrity: the influence of vascular and inflammatory markers. PloS one. 2013;8:e77741. doi: 10.1371/journal.pone.0077741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077741</ArticleId><ArticleId IdType="pmc">PMC3797689</ArticleId><ArticleId IdType="pubmed">24147070</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28438992</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>19</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Microglial NF&#x3ba;B-TNF&#x3b1; hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia.</ArticleTitle><Pagination><StartPage>5029</StartPage><EndPage>5034</EndPage><MedlinePgn>5029-5034</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1700477114</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is the second most common dementia before 65 years of age. Haploinsufficiency in the progranulin (<i>GRN</i>) gene accounts for 10% of all cases of familial FTD. <i>GRN</i> mutation carriers have an increased risk of autoimmune disorders, accompanied by elevated levels of tissue necrosis factor (TNF) &#x3b1;. We examined behavioral alterations related to obsessive-compulsive disorder (OCD) and the role of TNF&#x3b1; and related signaling pathways in FTD patients with <i>GRN</i> mutations and in mice lacking progranulin (PGRN). We found that patients and mice with <i>GRN</i> mutations displayed OCD and self-grooming (an OCD-like behavior in mice), respectively. Furthermore, medium spiny neurons in the nucleus accumbens, an area implicated in development of OCD, display hyperexcitability in PGRN knockout mice. Reducing levels of TNF&#x3b1; in PGRN knockout mice abolished excessive self-grooming and the associated hyperexcitability of medium spiny neurons of the nucleus accumbens. In the brain, PGRN is highly expressed in microglia, which are a major source of TNF&#x3b1;. We therefore deleted PGRN specifically in microglia and found that it was sufficient to induce excessive grooming. Importantly, excessive grooming in these mice was prevented by inactivating nuclear factor &#x3ba;B (NF-&#x3ba;B) in microglia/myeloid cells. Our findings suggest that PGRN deficiency leads to excessive NF-&#x3ba;B activation in microglia and elevated TNF&#x3b1; signaling, which in turn lead to hyperexcitability of medium spiny neurons and OCD-like behavior.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krabbe</LastName><ForeName>Grietje</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>S Sakura</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etchegaray</LastName><ForeName>Jon I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taneja</LastName><ForeName>Praveen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djukic</LastName><ForeName>Biljana</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davalos</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichert</LastName><ForeName>Meredith C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayed</LastName><ForeName>Faten</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlini</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sias</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkhurst</LastName><ForeName>Christopher N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Wen-Biao</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Skirball Institute of Biomolecular Medicine, New York University Medical Center, New York, NY 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akassoglou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farese</LastName><ForeName>Robert V</ForeName><Initials>RV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Diseases, University of California, San Francisco, CA 94158; lgan@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG036884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097976</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS076239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG039414</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030207</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS087198</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">OCD</Keyword><Keyword MajorTopicYN="N">TNF</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28438992</ArticleId><ArticleId IdType="pmc">PMC5441749</ArticleId><ArticleId IdType="doi">10.1073/pnas.1700477114</ArticleId><ArticleId IdType="pii">1700477114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol. 2008;21:708&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744321</ArticleId><ArticleId IdType="pubmed">18989117</ArticleId></ArticleIdList></Reference><Reference><Citation>Viskontas IV, Possin KL, Miller BL. Symptoms of frontotemporal dementia provide insights into orbitofrontal cortex function and social behavior. Ann N Y Acad Sci. 2007;1121:528&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846163</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: A mouse model of frontotemporal dementia. FASEB J. 2010;24:4639&#x2013;4647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis. 2012;45:395&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225509</ArticleId><ArticleId IdType="pubmed">21933710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122:3955&#x2013;3959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352&#x2013;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel R, Daniels E, He Z, Bateman A. Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn. 2003;227:593&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8:e1000527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970556</ArticleId><ArticleId IdType="pubmed">21072242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013;84:956&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840954</ArticleId><ArticleId IdType="pubmed">23543794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104397</ArticleId><ArticleId IdType="pubmed">21393509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. J Neurosci. 2013;33:9202&#x2013;9213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707136</ArticleId><ArticleId IdType="pubmed">23699531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809675</ArticleId><ArticleId IdType="pubmed">26656660</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135:794&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage. 2010;53:1070-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941039</ArticleId><ArticleId IdType="pubmed">20045477</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci. 2012;32:6525&#x2013;6541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3362928</ArticleId><ArticleId IdType="pubmed">22573675</ArticleId></ArticleIdList></Reference><Reference><Citation>Konuk N, et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediators Inflamm. 2007;2007:65704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847475</ArticleId><ArticleId IdType="pubmed">17497035</ArticleId></ArticleIdList></Reference><Reference><Citation>Figee M, et al. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nat Neurosci. 2013;16:386&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmari SE, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340:1234&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3954809</ArticleId><ArticleId IdType="pubmed">23744948</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgui&#xe8;re E, Monteiro P, Feng G, Graybiel AM. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science. 2013;340:1243&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3876800</ArticleId><ArticleId IdType="pubmed">23744950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17:400&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">24487234</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in mice. Neuron. 2002;33:23&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11779477</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yona S, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908543</ArticleId><ArticleId IdType="pubmed">23273845</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen BE, Burkhardt C, Reith W, Renkawitz R, F&#xf6;rster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">10621974</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294155</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, et al. Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia. Eur J Neurol. 2012;19:911&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351534</ArticleId><ArticleId IdType="pubmed">22284815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165:921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SK, et al. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell. 2010;141:775&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894573</ArticleId><ArticleId IdType="pubmed">20510925</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho IH, et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008;131:3019&#x2013;3033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577806</ArticleId><ArticleId IdType="pubmed">18819987</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM. Assessing nest building in mice. Nat Protoc. 2006;1:1117&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JT, Daigle TL, Chen Q, Feng G. Acute brain slice methods for adult and aging animals: Application of targeted patch clamp analysis and optogenetics. Methods Mol Biol. 2014;1183:221&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4219416</ArticleId><ArticleId IdType="pubmed">25023312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami SS, et al. Progranulin protects against amyloid &#x3b2; deposition and toxicity in Alzheimer&#x2019;s disease mouse models. Nat Med. 2014;20:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28414331</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A new fate mapping system reveals context-dependent random or clonal expansion of microglia.</ArticleTitle><Pagination><StartPage>793</StartPage><EndPage>803</EndPage><MedlinePgn>793-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4547</ELocationID><Abstract><AbstractText>Microglia constitute a highly specialized network of tissue-resident immune cells that is important for the control of tissue homeostasis and the resolution of diseases of the CNS. Little is known about how their spatial distribution is established and maintained in vivo. Here we establish a new multicolor fluorescence fate mapping system to monitor microglial dynamics during steady state and disease. Our findings suggest that microglia establish a dense network with regional differences, and the high regional turnover rates found challenge the universal concept of microglial longevity. Microglial self-renewal under steady state conditions constitutes a stochastic process. During pathology this randomness shifts to selected clonal microglial expansion. In the resolution phase, excess disease-associated microglia are removed by a dual mechanism of cell egress and apoptosis to re-establish the stable microglial network. This study unravels the dynamic yet discrete self-organization of mature microglia in the healthy and diseased CNS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tay</LastName><ForeName>Tuan Leng</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Computer Science, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dautzenberg</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Klett</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry &amp;Laboratory of Molecular Psychiatry, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagar</LastName><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datta</LastName><ForeName>Moumita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drougard</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stempfl</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Excellence for Fluorescent Bioanalytics, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardura-Fabregat</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszewski</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margineanu</LastName><ForeName>Anca</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Advanced Light Microscopy Technology Platform, Max Delbr&#xfc;ck Center for Molecular Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sporbert</LastName><ForeName>Anje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Advanced Light Microscopy Technology Platform, Max Delbr&#xfc;ck Center for Molecular Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinmetz</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Genome Technology Center, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pospisilik</LastName><ForeName>J Andrew</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4290-5716</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry &amp;Laboratory of Molecular Psychiatry, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence 'NeuroCure', German Center for Neurodegenerative Diseases (DZNE) and Berlin Institute of Health (BIH), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;n</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronneberger</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute for Computer Science, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_16031</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2017 May 25;20(6):762-763. doi: 10.1038/nn.4570.</RefSource><PMID Version="1">28542157</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006652" MajorTopicYN="N">Histological Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28414331</ArticleId><ArticleId IdType="doi">10.1038/nn.4547</ArticleId><ArticleId IdType="pii">nn.4547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain. 2016 Mar;139(Pt 3):891-907</Citation><ArticleIdList><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 1999 Nov 18;117(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10567732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2013 May 1;41(10):e108</Citation><ArticleIdList><ArticleId IdType="pubmed">23558742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Dec 19;155(7):1596-609</Citation><ArticleIdList><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2013 Jan 24;38(1):79-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23273845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2014 May;15(5):300-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1992;48(2):405-15</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2012 May 14;9:92</Citation><ArticleIdList><ArticleId IdType="pubmed">22583833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jun 14;447(7146):869-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17568749</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microsc. 2009 Jan;233(1):42-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19196411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2005 Jun;8(6):752-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2009 Jun 1;25(11):1463-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19346324</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Apr 16;82(2):380-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2013 Nov 22;342(6161):1242974</Citation><ArticleIdList><ArticleId IdType="pubmed">24264994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2000 Jun;20(11):4106-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2013 Oct 10;122(15):2714-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23974197</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2013 Apr 18;38(4):792-804</Citation><ArticleIdList><ArticleId IdType="pubmed">23601688</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2016 Aug 15;35(16):1730-44</Citation><ArticleIdList><ArticleId IdType="pubmed">27412700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1996 Sep 15;157(6):2577-85</Citation><ArticleIdList><ArticleId IdType="pubmed">8805660</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2009;27:119-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Jul 31;14(9):1142-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21804537</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Mar;16(3):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Dec 4;159(6):1312-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 May 27;308(5726):1314-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Dec;10 (12 ):1538-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Apr 6;336(6077):86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Cell. 2015 Sep 28;34(6):632-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26418294</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 2016 Jun 1;30(11):1261-77</Citation><ArticleIdList><ArticleId IdType="pubmed">27284162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Dec;10(12):1544-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Nov 5;330(6005):841-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Oct 1;143(1):134-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20887898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2015 Apr;12(4):357-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25751142</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2015 Jan;63(1):1-22</Citation><ArticleIdList><ArticleId IdType="pubmed">25132502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2013 Aug 26;210(9):1657-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23940255</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2015 Aug 18;43(2):382-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2010 Dec;7(12):981-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20966916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2016 Jul;17(7):797-805</Citation><ArticleIdList><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Dec 17;311:56-66</Citation><ArticleIdList><ArticleId IdType="pubmed">26432953</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2415-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18272492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2007 Aug 15;85(11):2374-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17551981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2016 Mar;19(3):504-16</Citation><ArticleIdList><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2015 Oct;36(10):614-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26431939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Feb 26;518(7540):547-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25470051</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Dec 4;159(6):1327-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Nov;10(11):1387-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Aug 3;31(31):11159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2015 Jul 21;43(1):92-106</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1990;39(1):151-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2089275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Feb 6;33(6):2481-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2014;15(12):550</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Nov;16(11):1618-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24077561</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28459436</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>678</StartPage><EndPage>680</EndPage><MedlinePgn>678-680</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.4330</ELocationID><Abstract><AbstractText>We directly assessed mesial temporal activity using intracranial foramen ovale electrodes in two patients with Alzheimer's disease (AD) without a history or EEG evidence of seizures. We detected clinically silent hippocampal seizures and epileptiform spikes during sleep, a period when these abnormalities were most likely to interfere with memory consolidation. The findings in these index cases support a model in which early development of occult hippocampal hyperexcitability may contribute to the pathogenesis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>MGH Epilepsy Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deck</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MGH Epilepsy Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Alica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskandar</LastName><ForeName>Emad N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noebels</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>MGH Epilepsy Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 NS088568</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS029709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 NS065743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS090362</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2018 Sep-Oct;18(5):292-294. doi: 10.5698/1535-7597.18.5.292.</RefSource><PMID Version="1">30464725</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Epilepsy Curr. 2018 Sep-Oct;18(5):295-297. doi: 10.5698/1535-7597.18.5.295.</RefSource><PMID Version="1">30464726</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004566" MajorTopicYN="N">Electrodes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054085" MajorTopicYN="N">Foramen Ovale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069077" MajorTopicYN="N">Memory Consolidation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Financial Interests:</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28459436</ArticleId><ArticleId IdType="mid">NIHMS861286</ArticleId><ArticleId IdType="pmc">PMC5461182</ArticleId><ArticleId IdType="doi">10.1038/nm.4330</ArticleId><ArticleId IdType="pii">nm.4330</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A. &#xdc;ber einen eigenartigen schweren Erkrankungsproze&#x3b2; der Hirnrinde. Neurol Cent. 1906;23:1129&#x2013;36.</Citation></Reference><Reference><Citation>Blocq P, Marinesco G. Sur les lesions et la pathogenie de l&#x2019;epilepsie dite essentielle. La Sem Medicale. 1892;12:445&#x2013;446.</Citation></Reference><Reference><Citation>Noebels J. A perfect storm: Converging paths of epilepsy and Alzheimer&#x2019;s dementia intersect in the hippocampal formation. Epilepsia. 2011;52:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058398</ArticleId><ArticleId IdType="pubmed">21214538</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, et al. Brain Changes in Older Adults at Very Low Risk for Alzheimer&#x2019;s Disease. J Neurosci. 2013;33:8237&#x2013;8242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050197</ArticleId><ArticleId IdType="pubmed">23658162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt BC, et al. Mapping limbic network organization in temporal lobe epilepsy using morphometric correlations: insights on the relation between mesiotemporal connectivity and cortical atrophy. Neuroimage. 2008;42:515&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18554926</ArticleId></ArticleIdList></Reference><Reference><Citation>Koliatsos VE, et al. Early involvement of small inhibitory cortical interneurons in Alzheimer&#x2019;s disease. Acta Neuropathol. 2006;112:147&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieser HG, Elger CE, Stodieck SR. The &#x2018;foramen ovale electrode&#x2019;: a new recording method for the preoperative evaluation of patients suffering from mesio-basal temporal lobe epilepsy. Electroencephalogr Clin Neurophysiol. 1985;61:314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">2411510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer&#x2019;s disease model. Proc Natl Acad Sci. 2012;109:E2895&#x2013;E2903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch BA, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci. 2004;101:9861&#x2013;9866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470764</ArticleId><ArticleId IdType="pubmed">15210974</ArticleId></ArticleIdList></Reference><Reference><Citation>White JC, Langston JW, Pedley TA. Benign epileptiform transients of sleep. Clarification of the small sharp spike controversy. Neurology. 1977;27:1061&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">563001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth SA, et al. Utility of foramen ovale electrodes in mesial temporal lobe epilepsy. Epilepsia. 2014;55:713&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">24605889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor J, Sola RG, Hernando-Requejo V, Navarrete EG, Pulido P. Morbidity associated with the use of foramen ovale electrodes. Epilepsia. 2008;49:464&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18494094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleen JK, et al. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. 2013;81:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770206</ArticleId><ArticleId IdType="pubmed">23685931</ArticleId></ArticleIdList></Reference><Reference><Citation>Binnie CD. Cognitive impairment during epileptiform discharges: Is it ever justifiable to treat the EEG? Lancet Neurol. 2003;2:725&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">14636777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatum WO, Ross J, Cole AJ. Epileptic pseudodementia. Neurology. 1998;50:1472&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596011</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer&#x2019;s disease. Ann Neurol. 2016:1&#x2013;13. doi: 10.1002/ana.24794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24794</ArticleId><ArticleId IdType="pmc">PMC5177487</ArticleId><ArticleId IdType="pubmed">27696483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer&#x2019;s Disease? Trends Neurosci. 2016;39:552&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Born HA, et al. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer&#x2019;s disease. J Neurosci. 2014;34:3826&#x2013;3840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam K, Duffy &#xc1;M, Moretto J, LaFrancois JJ, Scharfman HE. Interictal spikes during sleep are an early defect in the Tg2576 mouse model of &#x3b2;-amyloid neuropathology. Sci Rep. 2016;6:20119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730189</ArticleId><ArticleId IdType="pubmed">26818394</ArticleId></ArticleIdList></Reference><Reference><Citation>Malow BA, Lin X, Kushwaha R, Aldrich MS. Interictal spiking increases with sleep depth in temporal lobe epilepsy. Epilepsia. 1998;39:1309&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9860066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SC, Dove G, Cascino GD, Petersen RC. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14:118&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875670</ArticleId><ArticleId IdType="pubmed">18782632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkis RA, Dickerson BC, Cole AJ, Chemali ZN. Clinical and Neurophysiologic Characteristics of Unprovoked Seizures in Patients Diagnosed With Dementia. J Neuropsychiatry Clin Neurosci. 2016;28:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26404175</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Klassen T, et al. Exome sequencing of ion channel genes reveals complex profiles confounding personal risk assessment in epilepsy. Cell. 2011;145:1036&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131217</ArticleId><ArticleId IdType="pubmed">21703448</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid JG, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics. 2014;15:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922167</ArticleId><ArticleId IdType="pubmed">24475911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28483841</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury.</ArticleTitle><Pagination><StartPage>1186</StartPage><EndPage>1198</EndPage><MedlinePgn>1186-1198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.201743922</ELocationID><Abstract><AbstractText>Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration. In the brain, TREM2 is predominantly expressed in microglia. Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques. We here investigate the consequences of TREM2 loss of function on the microglia transcriptome. Among the differentially expressed messenger RNAs in wild-type and Trem2<sup>-/-</sup> microglia, gene clusters are identified which represent gene functions in chemotaxis, migration and mobility. Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels. In an <i>ex vivo</i> organotypic brain slice assay, absence of TREM2 reduces the distance migrated by microglia. Moreover, migration towards defined chemo-attractants is reduced upon ablation of TREM2 and can be rescued by TREM2 re-expression. <i>In vivo</i>, microglia lacking TREM2 migrate less towards injected apoptotic neurons, and outgrowth of microglial processes towards sites of laser-induced focal CNS damage in the somatosensory cortex is slowed. The apparent lack of chemotactic stimulation upon depletion of TREM2 is consistent with a stable expression profile of genes characterizing the homoeostatic signature of microglia.</AbstractText><CopyrightInformation>&#xa9; 2017 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazaheri</LastName><ForeName>Fargol</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6896-651X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaidero</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5811-8226</Identifier><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madore</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daria</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasemann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tr&#xfc;mbach</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Genetics, Technical University Munich-Weihenstephan, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bultmann</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biology and Center for Integrated Protein Science Munich (CIPSM), Ludwig Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4403-9559</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerschensteiner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misgeld</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9875-6794</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butovsky</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>R01 AG051812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002633" MajorTopicYN="Y">Chemotaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073658" MajorTopicYN="N">Loss of Function Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">chemotaxis</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28483841</ArticleId><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="doi">10.15252/embr.201743922</ArticleId><ArticleId IdType="pii">embr.201743922</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302: 814&#x2013;818</Citation><ArticleIdList><ArticleId IdType="pubmed">14593165</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta&#x2010;peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC (2013) Self&#x2010;propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501: 45&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss&#x2010;Coray T, Vitorica J, Ransohoff RM et al (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14: 388&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C et al (2014) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934.e7&#x2013;934.e10</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel&#x2010;Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH et al (2014) TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71: 449&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M (2013) Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia&#x2010;like family. Neurobiol Aging 34: 2890.e1&#x2013;2890.e5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898264</ArticleId><ArticleId IdType="pubmed">23870839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J Med 369: 1569&#x2013;1570</Citation><ArticleIdList><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S et al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H et al (2013) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia&#x2010;like syndrome without bone involvement. JAMA Neurol 70: 78&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH et al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE et al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502&#x2013;1507</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17: 201&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE et al (2014) Identification of a unique TGF&#x2010;beta&#x2010;dependent molecular and functional signature in microglia. Nat Neurosci 17: 131&#x2013;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016) A polarizing question: do M1 and M2 microglia exist? Nat Neurosci 19: 987&#x2013;991</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and gamma&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3: 445&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz&#x2010;Gerlach B, Neumann H, Witte OW, Frahm C (2013) Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock&#x2010;out mice following stroke. PLoS ONE 8: e52982</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H et al (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290: 26043&#x2013;26050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh Felix L, Wang Y, Tom I, Gonzalez Lino C, Sheng M (2016) TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid&#x2010;beta by microglia. Neuron 91: 328&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M (2015) The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290: 26033&#x2013;26042</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del&#x2010;Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925&#x2013;933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J et al (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C et al (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM (2014) Altered microglial response to Abeta plaques in APPPS1&#x2010;21 mice heterozygous for TREM2. Mol Neurodegener 9: 20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S et al (2016) TREM2&#x2010;mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213: 667&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90: 724&#x2013;739</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL et al (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Zhou Y, Xu J, Liu X, Wang Y, Deng Y, Wang G, Xu W, Ren R, Liu X et al (2014) Association study of TREM2 polymorphism rs75932628 with late&#x2010;onset Alzheimer's disease in Chinese Han population. Neurol Res 36: 894&#x2013;896</Citation><ArticleIdList><ArticleId IdType="pubmed">24725293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WQ, Huang SH, Huang X, Li JH, Ye P, Xu J, Zheng PZ, Shen HY, Huang JR (2016) Regulation of human mesenchymal stem cell differentiation by TREM&#x2010;2. Hum Immunol 77: 476&#x2013;482</Citation><ArticleIdList><ArticleId IdType="pubmed">26079507</ArticleId></ArticleIdList></Reference><Reference><Citation>Daria A, Colombo A, Llovera G, Hampel H, Willem M, Liesz A, Haass C, Tahirovic S (2016) Young microglia restore amyloid plaque clearance of aged microglia. EMBO J 36: 583&#x2013;603</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331757</ArticleId><ArticleId IdType="pubmed">28007893</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S et al (2006) Abeta42&#x2010;driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940&#x2013;946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20: 4106&#x2013;4114</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Badie B, Schartner J, Klaver J, Vorpahl J (1999) In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery 44: 1077&#x2013;1082; discussion 1082&#x2010;3</Citation><ArticleIdList><ArticleId IdType="pubmed">10232541</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradowska&#x2010;Gorycka A, Jurkowska M (2013) Structure, expression pattern and biological activity of molecular complex TREM&#x2010;2/DAP12. Hum Immunol 74: 730&#x2013;737</Citation><ArticleIdList><ArticleId IdType="pubmed">23459077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi&#x2010;Castagnoli P, Di Virgilio F (1996) Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 156: 1531&#x2013;1539</Citation><ArticleIdList><ArticleId IdType="pubmed">8568257</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91: 461&#x2013;553</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina CB, Ravichandran KS (2016) Do not let death do us part: &#x201c;find&#x2010;me&#x201d; signals in communication between dying cells and the phagocytes. Cell Death Differ 23: 979&#x2013;989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987731</ArticleId><ArticleId IdType="pubmed">26891690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran KS, Lorenz U (2007) Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 7: 964&#x2013;974</Citation><ArticleIdList><ArticleId IdType="pubmed">18037898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirasawa T, Ohsawa K, Imai Y, Ondo Y, Akazawa C, Uchino S, Kohsaka S (2005) Visualization of microglia in living tissues using Iba1&#x2010;EGFP transgenic mice. J Neurosci Res 81: 357&#x2013;362</Citation><ArticleIdList><ArticleId IdType="pubmed">15948177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo . Science 308: 1314&#x2013;1318</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo . Nat Neurosci 8: 752&#x2013;758</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, Traves PG, Tufail Y, Leal&#x2010;Bailey H, Lew ED, Burrola PG, Callaway P, Zagorska A, Rothlin CV, Nimmerjahn A et al (2016) TAM receptors regulate multiple features of microglial physiology. Nature 532: 240&#x2013;244</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O et al (2015) Targeting miR&#x2010;155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol 77: 75&#x2013;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, Wes PD, Moller T, Orre M, Kamphuis W et al (2015) Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co&#x2010;expression meta&#x2010;analysis. Acta Neuropathol Commun 3: 31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O'Keeffe S, Phatnani HP, Muratet M, Carroll MC, Levy S, Tavazoie S et al (2013) A neurodegeneration&#x2010;specific gene&#x2010;expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 4: 385&#x2013;401</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet&#x2010;Wadiche LS, Tsirka SE, Maletic&#x2010;Savatic M (2010) Microglia shape adult hippocampal neurogenesis through apoptosis&#x2010;coupled phagocytosis. Cell Stem Cell 7: 483&#x2013;495</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008496</ArticleId><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer Dorothy P, Lehrman Emily K, Kautzman Amanda G, Koyama R, Mardinly Alan R, Yamasaki R, Ransohoff Richard M, Greenberg Michael E, Barres Ben A, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement&#x2010;dependent manner. Neuron 74: 691&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Stevens B (2013) The &#x201c;quad&#x2010;partite&#x201d; synapse: microglia&#x2010;synapse interactions in the developing and mature CNS. Glia 61: 24&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082974</ArticleId><ArticleId IdType="pubmed">22829357</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B et al (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164&#x2013;1178</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Breus O, Durdu S, Haas P, Wittbrodt J, Gilmour D, Peri F (2014) Distinct roles for BAI1 and TIM&#x2010;4 in the engulfment of dying neurons by microglia. Nat Commun 5: 4046</Citation><ArticleIdList><ArticleId IdType="pubmed">24898390</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L et al (2011) Synaptic pruning by microglia is necessary for normal brain development. Science 333: 1456&#x2013;1458</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P et al (2000) Loss&#x2010;of&#x2010;function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 25: 357&#x2013;361</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, Nishinakamura R, Becher B, Greter M (2016) Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol 17: 1397&#x2013;1406</Citation><ArticleIdList><ArticleId IdType="pubmed">27776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016) Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther 8: 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848774</ArticleId><ArticleId IdType="pubmed">27121148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM (2016) TREM2 function in Alzheimer's Disease and neurodegeneration. ACS Chem Neurosci 7: 420&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WC, Yen FC, Shie F&#x2010;S, Pan C&#x2010;M, Shiao Y&#x2010;J, Yang C&#x2010;N, Huang F&#x2010;L, Sung Y&#x2010;J, Tsay H&#x2010;J (2010) TGF&#x2010;&#x3b2;1 blockade of microglial chemotaxis toward A&#x3b2; aggregates involves SMAD signaling and down&#x2010;regulation of CCL5. J Neuroinflammation 7: 11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878297</ArticleId><ArticleId IdType="pubmed">20429874</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM&#x2010;2 attenuates macrophage activation. J Immunol 177: 3520&#x2013;3524</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini YHY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 57: 289&#x2013;300</Citation></Reference><Reference><Citation>Schindelin J, Arganda&#x2010;Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open&#x2010;source platform for biological&#x2010;image analysis. Nat Methods 9: 676&#x2013;682</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Bonhoeffer T, Chow DK, Chuckowree J, De Paola V, Hofer SB, Hubener M, Keck T, Knott G, Lee WC et al (2009) Long&#x2010;term, high&#x2010;resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc 4: 1128&#x2013;1144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Berriz GF, King OD, Bryant B, Sander C, Roth FP (2003) Characterizing gene sets with FuncAssociate. Bioinformatics 19: 2502&#x2013;2504</Citation><ArticleIdList><ArticleId IdType="pubmed">14668247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28481360</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>A chronic low dose of &#x394;<sup>9</sup>-tetrahydrocannabinol (THC) restores cognitive function in old mice.</ArticleTitle><Pagination><StartPage>782</StartPage><EndPage>787</EndPage><MedlinePgn>782-787</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.4311</ELocationID><Abstract><AbstractText>The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it modulates the physiological processes underlying aging. The activity of the ECS declines during aging, as CB1 receptor expression and coupling to G proteins are reduced in the brain tissues of older animals and the levels of the major endocannabinoid 2-arachidonoylglycerol (2-AG) are lower. However, a direct link between endocannabinoid tone and aging symptoms has not been demonstrated. Here we show that a low dose of &#x394;<sup>9</sup>-tetrahydrocannabinol (THC) reversed the age-related decline in cognitive performance of mice aged 12 and 18 months. This behavioral effect was accompanied by enhanced expression of synaptic marker proteins and increased hippocampal spine density. THC treatment restored hippocampal gene transcription patterns such that the expression profiles of THC-treated mice aged 12 months closely resembled those of THC-free animals aged 2 months. The transcriptional effects of THC were critically dependent on glutamatergic CB1 receptors and histone acetylation, as their inhibition blocked the beneficial effects of THC. Thus, restoration of CB1 signaling in old individuals could be an effective strategy to treat age-related cognitive impairments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilkei-Gorzo</LastName><ForeName>Andras</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albayram</LastName><ForeName>Onder</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draffehn</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genomics and Immunoregulation, LIMES Institute, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piyanova</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oppenheimer</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Dental Sciences, Hebrew University, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvir-Ginzberg</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Dental Sciences, Hebrew University, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;cz</LastName><ForeName>Ildiko</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulas</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9785-4197</Identifier><AffiliationInfo><Affiliation>Genomics and Immunoregulation, LIMES Institute, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imbeault</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bab</LastName><ForeName>Itai</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Dental Sciences, Hebrew University, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultze</LastName><ForeName>Joachim L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Genomics and Immunoregulation, LIMES Institute, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063388">Endocannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2017 Jun 6;23(6):661-662. doi: 10.1038/nm.4348.</RefSource><PMID Version="1">28586333</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066492" MajorTopicYN="N">Cognitive Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063388" MajorTopicYN="N">Endocannabinoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042421" MajorTopicYN="N">Histone Code</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="N">Memory, Long-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043884" MajorTopicYN="N">Receptor, Cannabinoid, CB1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28481360</ArticleId><ArticleId IdType="doi">10.1038/nm.4311</ArticleId><ArticleId IdType="pii">nm.4311</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Learn Mem. 2004 Sep-Oct;11(5):625-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15466318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2011 Nov 23;6:79</Citation><ArticleIdList><ArticleId IdType="pubmed">22112803</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Model Mech. 2009 Jul-Aug;2(7-8):412-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19535498</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Mar 21;319(5870):1683-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18309046</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2006 Jun;186(2):226-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16572263</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Mar 2;148(5):1039-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22385967</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Jan 23;421(6921):373-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2009 Jul;30(7):1125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18006193</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2012 Jan;37(1):247-60</Citation><ArticleIdList><ArticleId IdType="pubmed">21593731</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):621-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22190495</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2001 Dec;25(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107</Citation><ArticleIdList><ArticleId IdType="pubmed">15837565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2015 Sep;150:55-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26278494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2012 May 14;5:14</Citation><ArticleIdList><ArticleId IdType="pubmed">22583753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Mar;6(3):313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10700234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Jul 17;388(6639):272-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9230435</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Nov 24;10(11):e0143623</Citation><ArticleIdList><ArticleId IdType="pubmed">26599613</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Mar;178(2-3):317-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15322725</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3326-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23108550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2012 Mar 07;13(4):240-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2011 Feb;32(2):249-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19328595</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol A Biol Sci Med Sci. 2011 Jul;66(7):794-800</Citation><ArticleIdList><ArticleId IdType="pubmed">21474560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2015 Jan;16(1):30-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25524120</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):E1072-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24616510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2014 Jun;20(6):659-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367 (1607):3254-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23108544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2013 Sep;134(9):391-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23954857</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1999 May;23(1):11-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10402188</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11256-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21690345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Jun 6;27(23):6128-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17553985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2016 Apr 13;36(15):4351-61</Citation><ArticleIdList><ArticleId IdType="pubmed">27076430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 May 10;447(7141):178-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17468743</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2008 Dec 29;9:559</Citation><ArticleIdList><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 1998 Sep 30;1407(3):205-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9748581</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15670-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16221768</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2001 Jul;14(2):342-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11553284</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Mar 15;23 (6):2371-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12657697</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 May 7;328(5979):753-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20448184</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Aug 17;51(4):455-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16908411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1998 Apr;20(4):727-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9581764</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2008 Jan 1;56(1):106-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17963266</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11024-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11572963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2014 May 22;7(4):1065-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2007;18(2):137-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17593876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Dec;14 (12 ):1068-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19920834</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2008 Nov;11(11):1311-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 May 11;96(10 ):5780-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10318961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2016 Sep;53(7):4772-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26328539</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Sep 18;79(6):1136-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23993699</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1829-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurosci. 2011;22(2):153-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21476939</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12538878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2013 Feb;14(2):97-111</Citation><ArticleIdList><ArticleId IdType="pubmed">23324667</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2011 Oct 12;12(11):623-37</Citation><ArticleIdList><ArticleId IdType="pubmed">21989194</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3017-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1998 Jun;84(4):1075-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9578396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28609829</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-7197</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Body Mass Index and Risk of Alzheimer's Disease: A Mendelian Randomization Study of 399,536 Individuals.</ArticleTitle><Pagination><StartPage>2310</StartPage><EndPage>2320</EndPage><MedlinePgn>2310-2320</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/jc.2017-00195</ELocationID><Abstract><AbstractText Label="CONTEXT">Recently, data on 2,000,000 people established that low body mass index (BMI) is associated with increased risk of dementia. Whether this observational association reflects a causal effect remains to be clarified.</AbstractText><AbstractText Label="OBJECTIVE">We tested the hypothesis that there is a causal association between low BMI and high risk of Alzheimer's disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Using a Mendelian randomization approach, we studied 95,578 individuals from the Copenhagen General Population Study (CGPS) with up to 36 years of follow-up and consortia data on 303,958 individuals from the Genetic Investigation of Anthropometric Traits (GIANT) and the International Genomics of Alzheimer's Project (IGAP).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE">Risk of Alzheimer's disease.</AbstractText><AbstractText Label="RESULTS">The causal odds ratio for a 1-kg/m2 genetically determined lower BMI was 0.98 [95% confidence interval (CI), 0.77 to 1.23] for a weighted allele score in the CGPS. Using 32 BMI-decreasing variants from GIANT and IGAP the causal odds ratio for Alzheimer's disease for a 1-standard deviation (SD) lower genetically determined BMI was 1.02 (95% CI, 0.86 to 1.22). Corresponding observational hazard ratios from the CGPS were 1.07 (95% CI, 1.05 to 1.09) and 1.32 (95% CI, 1.20 to 1.46) for a 1-kg/m2 and a 1-SD lower BMI, respectively.</AbstractText><AbstractText Label="CONCLUSIONS">Genetic and hence lifelong low BMI is not associated with increased risk of Alzheimer's disease in the general population. These data suggest that low BMI is not a causal risk factor for Alzheimer's disease and that the corresponding observational association likely is explained by reverse causation or confounding.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Endocrine Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nordestgaard</LastName><ForeName>Liv Tybj&#xe6;rg</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tybj&#xe6;rg-Hansen</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordestgaard</LastName><ForeName>B&#xf8;rge G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frikke-Schmidt</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>082604/2/07/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>503480</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>N01 AG012100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000886" MajorTopicYN="N">Anthropometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013851" MajorTopicYN="N">Thinness</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28609829</ArticleId><ArticleId IdType="pmc">PMC5505195</ArticleId><ArticleId IdType="doi">10.1210/jc.2017-00195</ArticleId><ArticleId IdType="pii">3805501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) . National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9&#xb7;1 million participants. Lancet. 2011;377(9765):557&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4472365</ArticleId><ArticleId IdType="pubmed">21295846</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Guerchet M, Prina M. The epidemiology and impact of dementia: current state and future trends. Geneva: World Health Organization; 2015.</Citation></Reference><Reference><Citation>Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pubmed">18607383</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O&#x2019;Meara ES, Longstreth WT Jr, Luchsinger JA. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009;66(3):336&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513375</ArticleId><ArticleId IdType="pubmed">19273752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, K&#xe5;reholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62(10):1556&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71(14):1057&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367704</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504):1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC558283</ArticleId><ArticleId IdType="pubmed">15863436</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: a decade of body mass index, Alzheimer&#x2019;s disease, and dementia. J Alzheimers Dis. 2015;43(3):739&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">25147111</ArticleId></ArticleIdList></Reference><Reference><Citation>Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, Evans SJ, Pocock SJ. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol. 2015;3(6):431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">25866264</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89&#x2013;R98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170722</ArticleId><ArticleId IdType="pubmed">25064373</ArticleId></ArticleIdList></Reference><Reference><Citation>Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, M&#xe4;gi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segr&#xe8; AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpel&#xe4;inen TO, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ, Johansson A, Johnson T, Ketkar S, Lamina C, Li S, Moffatt MF, Myers RH, Narisu N, Perry JR, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi J, Thiering E, Alavere H, Alibrandi MT, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, Busonero F, Campbell H, Cappuccio FP, Cavalcanti-Proen&#xe7;a C, Chen YD, Chen CM, Chines PS, Clarke R, Coin L, Connell J, Day IN, den Heijer M, Duan J, Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, Erdos MR, Eriksson JG, Facheris MF, Felix SB, Fischer-Posovszky P, Folsom AR, Friedrich N, Freimer NB, Fu M, Gaget S, Gejman PV, Geus EJ, Gieger C, Gjesing AP, Goel A, Goyette P, Grallert H, Gr&#xe4;ssler J, Greenawalt DM, Groves CJ, Gudnason V, Guiducci C, Hartikainen AL, Hassanali N, Hall AS, Havulinna AS, Hayward C, Heath AC, Hengstenberg C, Hicks AA, Hinney A, Hofman A, Homuth G, Hui J, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, John U, J&#xf8;rgensen T, Jousilahti P, Jula A, Kaakinen M, Kajantie E, Kaplan LM, Kathiresan S, Kettunen J, Kinnunen L, Knowles JW, Kolcic I, K&#xf6;nig IR, Koskinen S, Kovacs P, Kuusisto J, Kraft P, Kval&#xf8;y K, Laitinen J, Lantieri O, Lanzani C, Launer LJ, Lecoeur C, Lehtim&#xe4;ki T, Lettre G, Liu J, Lokki ML, Lorentzon M, Luben RN, Ludwig B, Manunta P, Marek D, Marre M, Martin NG, McArdle WL, McCarthy A, McKnight B, Meitinger T, Melander O, Meyre D, Midthjell K, Montgomery GW, Morken MA, Morris AP, Mulic R, Ngwa JS, Nelis M, Neville MJ, Nyholt DR, O&#x2019;Donnell CJ, O&#x2019;Rahilly S, Ong KK, Oostra B, Par&#xe9; G, Parker AN, Perola M, Pichler I, Pietil&#xe4;inen KH, Platou CG, Polasek O, Pouta A, Rafelt S, Raitakari O, Rayner NW, Ridderstr&#xe5;le M, Rief W, Ruokonen A, Robertson NR, Rzehak P, Salomaa V, Sanders AR, Sandhu MS, Sanna S, Saramies J, Savolainen MJ, Scherag S, Schipf S, Schreiber S, Schunkert H, Silander K, Sinisalo J, Siscovick DS, Smit JH, Soranzo N, Sovio U, Stephens J, Surakka I, Swift AJ, Tammesoo ML, Tardif JC, Teder-Laving M, Teslovich TM, Thompson JR, Thomson B, T&#xf6;njes A, Tuomi T, van Meurs JB, van Ommen GJ, Vatin V, Viikari J, Visvikis-Siest S, Vitart V, Vogel CI, Voight BF, Waite LL, Wallaschofski H, Walters GB, Widen E, Wiegand S, Wild SH, Willemsen G, Witte DR, Witteman JC, Xu J, Zhang Q, Zgaga L, Ziegler A, Zitting P, Beilby JP, Farooqi IS, Hebebrand J, Huikuri HV, James AL, K&#xe4;h&#xf6;nen M, Levinson DF, Macciardi F, Nieminen MS, Ohlsson C, Palmer LJ, Ridker PM, Stumvoll M, Beckmann JS, Boeing H, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Gr&#xf6;nberg H, Gyllensten U, Hall P, Hansen T, Harris TB, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe F, Khaw KT, Kiemeney LA, Krude H, Laakso M, Lawlor DA, Metspalu A, Munroe PB, Ouwehand WH, Pedersen O, Penninx BW, Peters A, Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PE, Shuldiner AR, Spector TD, Tuomilehto J, Uda M, Uitterlinden A, Valle TT, Wabitsch M, Waeber G, Wareham NJ, Watkins H, Wilson JF, Wright AF, Zillikens MC, Chatterjee N, McCarroll SA, Purcell S, Schadt EE, Visscher PM, Assimes TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, Mohlke KL, O&#x2019;Connell JR, Peltonen L, Schlessinger D, Strachan DP, van Duijn CM, Wichmann HE, Frayling TM, Thorsteinsdottir U, Abecasis GR, Barroso I, Boehnke M, Stefansson K, North KE, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos RJ; MAGIC; Procardis Consortium . Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014648</ArticleId><ArticleId IdType="pubmed">20935630</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj&#xe6;rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24941082</ArticleId></ArticleIdList></Reference><Reference><Citation>Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524&#x2013;2532.</Citation><ArticleIdList><ArticleId IdType="pubmed">18523221</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol. 2015;77(2):301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">25469919</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard LT, Tybj&#xe6;rg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer&#x2019;s disease and cerebrovascular disease. Alzheimers Dement. 2015;11(12):1430&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">26079414</ArticleId></ArticleIdList></Reference><Reference><Citation>Phung TK, Andersen BB, H&#xf8;gh P, Kessing LV, Mortensen PB, Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord. 2007;24(3):220&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690555</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Dementia Research Center. Forekomst af Alzheimers sygdom og risikofaktorer. Available at: http://www.videnscenterfordemens.dk/viden-om-demens/demenssygdomme/neurodegenerative-demenssygdomme/alzheimers-sygdom/forekomst-af-alzheimers-sygdom-og-risikofaktorer/. Accessed 1 May 2016.</Citation></Reference><Reference><Citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">4337382</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase CL, Tybj&#xe6;rg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes. 2015;64(9):3328&#x2013;3333.</Citation><ArticleIdList><ArticleId IdType="pubmed">25972569</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381(9874):1293&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">23433573</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">2657958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">17886233</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-InterAct Consortium . Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516908</ArticleId><ArticleId IdType="pubmed">25773750</ArticleId></ArticleIdList></Reference><Reference><Citation>Loef M, Walach H. Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity (Silver Spring). 2013;21(1):E51&#x2013;E55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23401370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl AK, L&#xf6;pp&#xf6;nen M, Isoaho R, Berg S, Kivel&#xe4; SL. Overweight and obesity in old age are not associated with greater dementia risk. J Am Geriatr Soc. 2008;56(12):2261&#x2013;2266.</Citation><ArticleIdList><ArticleId IdType="pubmed">19093925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2002;73(4):371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738075</ArticleId><ArticleId IdType="pubmed">12235302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Mor&#xf3;n FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fi&#xe9;vet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Boss&#xf9; P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O&#x2019;Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, N&#xf6;then MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium . Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Boss&#xf9; P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanch&#xe9; H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alp&#xe9;rovitch A, Lathrop M, Amouyel P; European Alzheimer&#x2019;s Disease Initiative Investigators . Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Walter S, Kauwe JS, Saykin AJ, Bennett DA, Larson EB, Crane PK, Glymour MM; Adult Changes in Thought Study Investigators; Religious Orders Study/Memory and Aging Project Investigators; Alzheimer&#x2019;s Disease Genetics Consortium . Genetically predicted body mass index and Alzheimer&#x2019;s disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement. 2015;11(12):1439&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676945</ArticleId><ArticleId IdType="pubmed">26079416</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JRB, Boehme KL, Walter S, Kauwe JS, Gibbons LE, Larson EB, Powell JF, Langenberg C, Crane PK, Wareham NJ, Scott RA; Alzheimer&#x2019;s Disease Genetics Consortium; GERAD1 Consortium; EPIC-InterAct Consortium . Associations between potentially modifiable risk factors and alzheimer disease: a Mendelian randomization study. PLoS Med. 2015;12(6):e1001841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469461</ArticleId><ArticleId IdType="pubmed">26079503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Karlsson C, Skoog I, Rosengren L, Lissner L, Blennow K. Mid-life adiposity factors relate to blood-brain barrier integrity in late life. J Intern Med. 2007;262(6):643&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986201</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage. 2006;31(4):1419&#x2013;1425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545583</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson D, Lissner L, Bengtsson C, Bj&#xf6;rkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2004;63(10):1876&#x2013;1881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557505</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnoldussen IA, Kiliaan AJ, Gustafson DR. Obesity and dementia: adipokines interact with the brain. Eur Neuropsychopharmacol. 2014;24(12):1982&#x2013;1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169761</ArticleId><ArticleId IdType="pubmed">24704273</ArticleId></ArticleIdList></Reference><Reference><Citation>Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension. 2009;54(1):84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28504673</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A fluoro-Nissl dye identifies pericytes as distinct vascular mural cells during in vivo brain imaging.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1032</EndPage><MedlinePgn>1023-1032</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4564</ELocationID><Abstract><AbstractText>Pericytes and smooth muscle cells are integral components of the brain microvasculature. However, no techniques exist to unambiguously identify these cell types, greatly limiting their investigation in vivo. Here we show that the fluorescent Nissl dye NeuroTrace 500/525 labels brain pericytes with specificity, allowing high-resolution optical imaging in the live mouse. We demonstrate that capillary pericytes are a population of mural cells with distinct morphological, molecular and functional features that do not overlap with precapillary or arteriolar smooth muscle actin-expressing cells. The remarkable specificity for dye uptake suggests that pericytes have molecular transport mechanisms not present in other brain cells. We demonstrate feasibility of longitudinal pericyte imaging during microvascular development and aging and in models of brain ischemia and Alzheimer's disease. The ability to easily label pericytes in any mouse model opens the possibility of a broad range of investigations of mural cells in vascular development, neurovascular coupling and neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damisah</LastName><ForeName>Eyiyemisi C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-6080-8712</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Katie N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5000-243X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS090820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG048181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS088411</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027855</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS087511</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006652" MajorTopicYN="N">Histological Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061848" MajorTopicYN="N">Optical Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28504673</ArticleId><ArticleId IdType="mid">NIHMS869896</ArticleId><ArticleId IdType="pmc">PMC5550770</ArticleId><ArticleId IdType="doi">10.1038/nn.4564</ArticleId><ArticleId IdType="pii">nn.4564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rouget C. Note on the development of the contractile walls of blood vessels. C R Acad Sci. 1874</Citation></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21:193&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10:1369&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965657</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih AY, et al. Robust and fragile aspects of cortical blood flow in relation to the underlying angioarchitecture. Microcirculation. 2015;22:204&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393797</ArticleId><ArticleId IdType="pubmed">25705966</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, et al. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron. 2015;87:95&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487786</ArticleId><ArticleId IdType="pubmed">26119027</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14:1398&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020628</ArticleId><ArticleId IdType="pubmed">22030551</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CN, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976267</ArticleId><ArticleId IdType="pubmed">24670647</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Klett F, Offenhauser N, Dirnagl U, Priller J, Lindauer U. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci U S A. 2010;107:22290&#x2013;22295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009761</ArticleId><ArticleId IdType="pubmed">21135230</ArticleId></ArticleIdList></Reference><Reference><Citation>Yemisci M, et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009;15:1031&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">19718040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann DA, et al. Pericyte structure and distribution in the cerebral cortex revealed by high-resolution imaging of transgenic mice. Neurophotonics. 2015;2:041402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4478963</ArticleId><ArticleId IdType="pubmed">26158016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei HS, et al. Erythrocytes Are Oxygen-Sensing Regulators of the Cerebral Microcirculation. Neuron. 2016;91:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405863</ArticleId><ArticleId IdType="pubmed">27499087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vates GE, Takano T, Zlokovic B, Nedergaard M. Pericyte constriction after stroke: the jury is still out. Nat Med. 2010;16:959. author reply 960.</Citation><ArticleIdList><ArticleId IdType="pubmed">20823870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19:771&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745011</ArticleId><ArticleId IdType="pubmed">27227366</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Mishra A, Hall CN, O&#x2019;Farrell FM, Dalkara T. What is a pericyte? J Cereb Blood Flow Metab. 2016;36:451&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759679</ArticleId><ArticleId IdType="pubmed">26661200</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn B, Toga AW, Motamed S, Merlic CA. Fluoro nissl green: a novel fluorescent counterstain for neuroanatomy. Neurosci Lett. 1995;184:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Kerr JND, Helmchen F. Sulforhodamine 101 as a specific marker of astroglia in the neocortex in vivo. Nat Methods. 2004;1:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15782150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, Grutzendler J. In vivo imaging of oligodendrocytes with sulforhodamine 101. Nat Methods. 2014;11:1081&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539948</ArticleId><ArticleId IdType="pubmed">25357236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuttler AS, et al. Characterization of Pdgfrb-Cre transgenic mice reveals reduction of ROSA26 reporter activity in remodeling arteries. Genesis. 2011;49:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244048</ArticleId><ArticleId IdType="pubmed">21557454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development. 2008;135:145&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">18045844</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, et al. Age-dependent fate and lineage restriction of single NG2 cells. Development. 2011;138:745&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026417</ArticleId><ArticleId IdType="pubmed">21266410</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisslitzer-Ruppitsch C, R&#xf6;hrl C, Neum&#xfc;ller J, Pavelka M, Ellinger A. Photooxidation technology for correlated light and electron microscopy. J Microsc. 2009;235:322&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">19754726</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiblitzer-Ruppitsch C, et al. Electron microscopic visualization of fluorescent signals in cellular compartments and organelles by means of DAB-photoconversion. Histochem Cell Biol. 2008;130:407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182540</ArticleId><ArticleId IdType="pubmed">18463889</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AWJ, et al. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 2016;131:725&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835509</ArticleId><ArticleId IdType="pubmed">26975356</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong JJ, Larina IV, Dickinson ME, Zimmer WE, Hirschi KK. Characterization of bacterial artificial chromosome transgenic mice expressing mCherry fluorescent protein substituted for the murine smooth muscle alpha-actin gene. Genesis. 2010;48:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906650</ArticleId><ArticleId IdType="pubmed">20506352</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, Lu Z, Chhatbar PY, O&#x2019;Herron P, Kara P. An artery-specific fluorescent dye for studying neurovascular coupling. Nat Methods. 2012;9:273&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392962</ArticleId><ArticleId IdType="pubmed">22266543</ArticleId></ArticleIdList></Reference><Reference><Citation>Harb R, Whiteus C, Freitas C, Grutzendler J. In vivo imaging of cerebral microvascular plasticity from birth to death. J Cereb Blood Flow Metab. 2013;33:146&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597363</ArticleId><ArticleId IdType="pubmed">23093067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S, Chan-Ling T. Characterization of smooth muscle cell and pericyte differentiation in the rat retina in vivo. Invest Ophthalmol Vis Sci. 2004;45:2795&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277506</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy TH, Li P, Betts K, Liu R. Two-photon imaging of stroke onset in vivo reveals that NMDA-receptor independent ischemic depolarization is the major cause of rapid reversible damage to dendrites and spines. J Neurosci. 2008;28:1756&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671530</ArticleId><ArticleId IdType="pubmed">18272696</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew PJ, Shih AY, Kleinfeld D. Fluctuating and sensory-induced vasodynamics in rodent cortex extend arteriole capacity. Proc Natl Acad Sci U S A. 2011;108:8473&#x2013;8478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100929</ArticleId><ArticleId IdType="pubmed">21536897</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M. Signaling at the gliovascular interface. J Neurosci. 2003;23:9254&#x2013;9262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740832</ArticleId><ArticleId IdType="pubmed">14534260</ArticleId></ArticleIdList></Reference><Reference><Citation>Borysova L, Wray S, Eisner DA, Burdyga T. How calcium signals in myocytes and pericytes are integrated across in situ microvascular networks and control microvascular tone. Cell Calcium. 2013;54:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775125</ArticleId><ArticleId IdType="pubmed">23867002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas P, et al. Pericyte endothelial gap junctions in human cerebral capillaries. Anat Embryol. 1984;170:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">6517350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2010;13:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840225</ArticleId><ArticleId IdType="pubmed">20023653</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4:1128&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteus C, Freitas C, Grutzendler J. Perturbed neural activity disrupts cerebral angiogenesis during a postnatal critical period. Nature. 2014;505:407&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947100</ArticleId><ArticleId IdType="pubmed">24305053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano H, et al. Study on PDGF receptor beta pathway in glomerular formation in neonate mice. Ann N Y Acad Sci. 2001;947:303&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11795278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill RA, Natsume R, Sakimura K, Nishiyama A. NG2 cells are uniformly distributed and NG2 is not required for barrel formation in the somatosensory cortex. Mol Cell Neurosci. 2011;46:689&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068479</ArticleId><ArticleId IdType="pubmed">21292011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28515043</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4571</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Circulation research</Title><ISOAbbreviation>Circ Res</ISOAbbreviation></Journal><ArticleTitle>Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer A&#x3b2; Peptides.</ArticleTitle><Pagination><StartPage>258</StartPage><EndPage>269</EndPage><MedlinePgn>258-269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.117.311054</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Increasing evidence indicates that alterations of the cerebral microcirculation may play a role in Alzheimer disease, the leading cause of late-life dementia. The amyloid-&#x3b2; peptide (A&#x3b2;), a key pathogenic factor in Alzheimer disease, induces profound alterations in neurovascular regulation through the innate immunity receptor CD36 (cluster of differentiation 36), which, in turn, activates a Nox2-containing NADPH oxidase, leading to cerebrovascular oxidative stress. Brain perivascular macrophages (PVM) located in the perivascular space, a major site of brain A&#x3b2; collection and clearance, are juxtaposed to the wall of intracerebral resistance vessels and are a powerful source of reactive oxygen species.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We tested the hypothesis that PVM are the main source of reactive oxygen species responsible for the cerebrovascular actions of A&#x3b2; and that CD36 and Nox2 in PVM are the molecular substrates of the effect.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Selective depletion of PVM using intracerebroventricular injection of clodronate abrogates the reactive oxygen species production and cerebrovascular dysfunction induced by A&#x3b2; applied directly to the cerebral cortex, administered intravascularly, or overproduced in the brain of transgenic mice expressing mutated forms of the amyloid precursor protein (Tg2576 mice). In addition, using bone marrow chimeras, we demonstrate that PVM are the cells expressing CD36 and Nox2 responsible for the dysfunction. Thus, deletion of CD36 or Nox2 from PVM abrogates the deleterious vascular effects of A&#x3b2;, whereas wild-type PVM reconstitute the vascular dysfunction in CD36-null mice.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data identify PVM as a previously unrecognized effector of the damaging neurovascular actions of A&#x3b2; and unveil a new mechanism by which brain-resident innate immune cells and their receptors may contribute to the pathobiology of Alzheimer disease.</AbstractText><CopyrightInformation>&#xa9; 2017 American Heart Association, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Laibaik</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.). lap2003@med.cornell.edu coi2001@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uekawa</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Bonilla</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Kenzo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistik</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anrather</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iadecola</LastName><ForeName>Costantino</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.). lap2003@med.cornell.edu coi2001@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS037853</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095441</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS100447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS089323</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Res</MedlineTA><NlmUniqueID>0047103</NlmUniqueID><ISSNLinking>0009-7330</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circ Res. 2017 Jul 21;121(3):203-205. doi: 10.1161/CIRCRESAHA.117.311386.</RefSource><PMID Version="1">28729449</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013003" MajorTopicYN="N">Somatosensory Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">brain</Keyword><Keyword MajorTopicYN="N">cerebrovascular disease</Keyword><Keyword MajorTopicYN="N">endothelium</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28515043</ArticleId><ArticleId IdType="mid">NIHMS877716</ArticleId><ArticleId IdType="pmc">PMC5522360</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311054</ArticleId><ArticleId IdType="pii">CIRCRESAHA.117.311054</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B, Karran E. The Cellular Phase of Alzheimer&#x2019;s Disease. Cell. 2016;164:603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association. 2013;9:63&#x2013;75. e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2004;5:347&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer&#x2019;s disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064035</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12574528</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Bird TD, Bennett DA, Boeve BF, Brickman AM, Cruchaga C, Faber K, Foroud TM, Farlow M, Goate AM, Graff-Radford NR, Lantigua R, Manly J, Ottman R, Rosenberg R, Schaid DJ, Schupf N, Stern Y, Sweet RA, Mayeux R National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease Family Study G. The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA neurology. 2016;73:1231&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5155512</ArticleId><ArticleId IdType="pubmed">27533593</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC Alzheimer&#x2019;s Disease Neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer&#x2019;s disease based on multifactorial data-driven analysis. Nature communications. 2016;7:11934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005;57:789&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2014;42:S411&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5279221</ArticleId><ArticleId IdType="pubmed">25159672</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva TM, Faraci FM. Microvascular Dysfunction and Cognitive Impairment. Cell Mol Neurobiol. 2016;36:241&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846472</ArticleId><ArticleId IdType="pubmed">26988697</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat Rev Neurosci. 2011;12:723&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J. 2014;35:888&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977136</ArticleId><ArticleId IdType="pubmed">24357508</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi K, Wang G, Park L. Endothelial Dysfunction and Amyloid-beta-Induced Neurovascular Alterations. Cell Mol Neurobiol. 2016;36:155&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4775455</ArticleId><ArticleId IdType="pubmed">26328781</ArticleId></ArticleIdList></Reference><Reference><Citation>Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci. 2008;28:13542&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626633</ArticleId><ArticleId IdType="pubmed">19074028</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2:157&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C. Abeta 1&#x2013;40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A. 2000;97:9735&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16934</ArticleId><ArticleId IdType="pubmed">10944232</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol. 2002;283:H315&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12063304</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer&#x2019;s disease cerebrovascular and memory deficits. J Neurosci. 2012;32:4705&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6620905</ArticleId><ArticleId IdType="pubmed">22492027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997;17:7655&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793926</ArticleId><ArticleId IdType="pubmed">9315887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sery O, Janoutova J, Ewerlingova L, Halova A, Lochman J, Janout V, Khan NA, Balcar VJ. CD36 gene polymorphism is associated with Alzheimer&#x2019;s disease. Biochimie. 2017;135:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">28111291</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci. 2005;25:1769&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725936</ArticleId><ArticleId IdType="pubmed">15716413</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A. 2008;105:1347&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234141</ArticleId><ArticleId IdType="pubmed">18202172</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Wang G, Zhou P, Zhou J, Pitstick R, Previti ML, Younkin L, Younkin SG, Van Nostrand WE, Cho S, Anrather J, Carlson GA, Iadecola C. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A. 2011;108:5063&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064396</ArticleId><ArticleId IdType="pubmed">21383152</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Zhou J, Zhou P, Pistick R, El Jamal S, Younkin L, Pierce J, Arreguin A, Anrather J, Younkin SG, Carlson GA, McEwen BS, Iadecola C. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2013;110:3089&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581946</ArticleId><ArticleId IdType="pubmed">23382216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem. 2006;281:20842&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16728400</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Science signaling. 2009;2:re3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811062</ArticleId><ArticleId IdType="pubmed">19471024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, Berezuk C, McNeely AA, Gao F, McLaurin J, Black SE. Imaging the Perivascular Space as a Potential Biomarker of Neurovascular and Neurodegenerative Diseases. Cell Mol Neurobiol. 2016;36:289&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11482437</ArticleId><ArticleId IdType="pubmed">26993511</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Brain Pathol. 2008;18:253&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg H, Wisniewski T, de Leon MJ. Clearance systems in the brain--implications for Alzheimer diseaser. Nat Rev Neurol. 2016;12:248.</Citation><ArticleIdList><ArticleId IdType="pubmed">27020556</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraco G, Sugiyama Y, Lane D, Garcia-Bonilla L, Chang H, Santisteban MM, Racchumi G, Murphy M, Van Rooijen N, Anrather J, Iadecola C. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest. 2016;126:4674&#x2013;4689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127678</ArticleId><ArticleId IdType="pubmed">27841763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Prinz M, Geissmann F, Gomez Perdiguero E. Development and function of tissue resident macrophages in mice. Semin Immunol. 2015;27:369&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948121</ArticleId><ArticleId IdType="pubmed">27036090</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Polfliet MM, Goede PH, van Kesteren-Hendrikx EM, van Rooijen N, Dijkstra CD, van den Berg TK. A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. J Neuroimmunol. 2001;116:188&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438173</ArticleId></ArticleIdList></Reference><Reference><Citation>Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208483</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Song Y, Zhao L, Gaidosh G, Laties AM, Wen R. Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc. 2008;3:1703&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811090</ArticleId><ArticleId IdType="pubmed">18846097</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Jordao MJ, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, Locatelli G, Hochgerner H, Zeiser R, Epelman S, Geissmann F, Priller J, Rossi FM, Bechmann I, Kerschensteiner M, Linnarsson S, Jung S, Prinz M. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Wang G, Moore J, Girouard H, Zhou P, Anrather J, Iadecola C. The key role of transient receptor potential melastatin-2 channels in amyloid-beta-induced neurovascular dysfunction. Nature communications. 2014;5:5318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283829</ArticleId><ArticleId IdType="pubmed">25351853</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Bonilla L, Racchumi G, Murphy M, Anrather J, Iadecola C. Endothelial CD36 Contributes to Postischemic Brain Injury by Promoting Neutrophil Activation via CSF3. J Neurosci. 2015;35:14783&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635129</ArticleId><ArticleId IdType="pubmed">26538649</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Nitric oxide participates in the cerebrovasodilation elicited from cerebellar fastigial nucleus. Am J Physiol. 1992;263:R1156&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">1443234</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia? Proc Natl Acad Sci U S A. 1992;89:3913&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525601</ArticleId><ArticleId IdType="pubmed">1570313</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev. 1998;78:53&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9457169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schlevogt B, Kierdorf K, Bottcher C, Erny D, Kummer MP, Quinn M, Bruck W, Bechmann I, Heneka MT, Priller J, Prinz M. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer&#x2019;s disease. J Neurosci. 2011;31:11159&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, Arendash GW. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer&#x2019;s mice. Neuroscience. 2009;163:55&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5966834</ArticleId><ArticleId IdType="pubmed">19500657</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Zhou P, Koizumi K, El Jamal S, Previti ML, Van Nostrand WE, Carlson G, Iadecola C. Brain and circulating levels of Abeta1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke. 2013;44:198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530010</ArticleId><ArticleId IdType="pubmed">23204056</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomis M, Sobrino T, Ois A, Millan M, Rodriguez-Campello A, Perez de la Ossa N, Rodriguez-Gonzalez R, Jimenez-Conde J, Cuadrado-Godia E, Roquer J, Davalos A. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke. 2009;40:3197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19696416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401840</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis. 2011;23:399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219221</ArticleId><ArticleId IdType="pubmed">21116050</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti-Fabregas J, Delgado-Mederos R, Marin R, de la Ossa NP, Alonso de Lecinana M, Rodriguez-Yanez M, Sanahuja J, Purroy F, De Arce AM, Carrera D, Dinia L, Guardia-Laguarta C, Lleo A. Prognostic value of plasma beta-amyloid levels in patients with acute intracerebral hemorrhage. Stroke. 2014;45:413&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24385273</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab. 2004;24:334&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15091114</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrats J, Grigoleit JS, Alvarez-Salas E, Sawchenko PE. Pro-inflammatory immune-to-brain signaling is involved in neuroendocrine responses to acute emotional stress. Brain Behav Immun. 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28179107</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrats J, Schiltz JC, Garcia-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron. 2010;65:94&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873837</ArticleId><ArticleId IdType="pubmed">20152116</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med. 2001;193:905&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193403</ArticleId><ArticleId IdType="pubmed">11304551</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires PW, Girgla SS, McClain JL, Kaminski NE, van Rooijen N, Dorrance AM. Improvement in middle cerebral artery structure and endothelial function in stroke-prone spontaneously hypertensive rats after macrophage depletion. Microcirculation. 2013;20:650&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603760</ArticleId><ArticleId IdType="pubmed">23647512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CE, Harney AS, Pollard JW. The Multifaceted Role of Perivascular Macrophages in Tumors. Cancer Cell. 2016;30:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024543</ArticleId><ArticleId IdType="pubmed">27411586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2009;106:1261&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer&#x2019;s disease. Nat Immunol. 2015;16:229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer&#x2019;s disease: the role, regulation and restoration of LRP1. Front Aging Neurosci. 2015;7:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502358</ArticleId><ArticleId IdType="pubmed">26236233</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011;37:56&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020267</ArticleId><ArticleId IdType="pubmed">20946471</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin SA, Katusic ZS. Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer&#x2019;s Disease. Circ Res. 2016;119:1128&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5085902</ArticleId><ArticleId IdType="pubmed">27601478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28542120</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>20</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Deaths from Alzheimer's Disease - United States, 1999-2014.</ArticleTitle><Pagination><StartPage>521</StartPage><EndPage>526</EndPage><MedlinePgn>521-526</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm6620a1</ELocationID><Abstract><AbstractText>Alzheimer's disease (Alzheimer's), an ultimately fatal form of dementia, is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths in 2014 (1,2). Alzheimer's deaths can be an indicator of paid and unpaid caregiver burden because nearly everyone in the final stages of Alzheimer's needs constant care, regardless of the setting, as the result of functional and cognitive declines (2). To examine deaths with Alzheimer's as the underlying cause, state-level and county-level death certificate data from the National Vital Statistics System for the period 1999-2014 were analyzed. A total of 93,541 Alzheimer's deaths occurred in the United States in 2014 at an age-adjusted (to the 2000 standard population) rate of 25.4 deaths per 100,000 population, a 54.5% increase compared with the 1999 rate of 16.5 deaths per 100,000. Most deaths occurred in a nursing home or long-term care facility. The percentage of Alzheimer's decedents who died in a medical facility (e.g., hospital) declined from 14.7% in 1999 to 6.6% in 2014, whereas the percentage who died at home increased from 13.9% in 1999 to 24.9% in 2014. Significant increases in Alzheimer's deaths coupled with an increase in the number of persons with Alzheimer's dying at home have likely added to the burden on family members or other unpaid caregivers. Caregivers might benefit from interventions such as education, respite care, and case management that can lessen the potential burden of caregiving and can improve the care received by persons with Alzheimer's.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Greenlund</LastName><ForeName>Sujay F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Lisa C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Janet B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003644" MajorTopicYN="N">Death Certificates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28542120</ArticleId><ArticleId IdType="pmc">PMC5657871</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm6620a1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heron M. Deaths: leading causes for 2014. Natl Vital Stat Rep 2016;65:1&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">27376998</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. 2017 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement 2017;13:325&#x2013;73. 10.1016/j.jalz.2017.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement 2007;3:186&#x2013;91. 10.1016/j.jalz.2007.04.381</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.04.381</ArticleId><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Mortality from Alzheimer disease&#x2014;United States, 1979&#x2013;1987. MMWR Morb Mortal Wkly Rep 1990;39:785&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122209</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council; Division of Behavioral and Social Sciences and Education; Committee on Population; Panel on Race, Ethnicity, and Health in Later Life. Critical perspectives on racial and ethnic differences in health in late life. Anderson NB, Bulatao RA, Cohen B, eds. Washington, DC: The National Academies Press; 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669464</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Health Statistics. Health, United States, 2014: with special feature on adults aged 55&#x2013;64. Hyattsville, MD: CDC, National Center for Health Statistics; 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26086064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper JD, Freedman VA, Spillman BC, Wolff JL. The disproportionate impact of dementia on family and unpaid caregiving to older adults. Health Aff (Millwood) 2015;34:1642&#x2013;9. 10.1377/hlthaff.2015.0536</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2015.0536</ArticleId><ArticleId IdType="pmc">PMC4635557</ArticleId><ArticleId IdType="pubmed">26438739</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology 2014;82:1045&#x2013;50. 10.1212/WNL.0000000000000240</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000240</ArticleId><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="pubmed">24598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011;12:e426&#x2013;37. 10.1111/j.1467-789X.2010.00825.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2010.00825.x</ArticleId><ArticleId IdType="pubmed">21348917</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004;52:195&#x2013;204. 10.1111/j.1532-5415.2004.52058.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52058.x</ArticleId><ArticleId IdType="pubmed">14728627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28537274</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5438</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of human genetics : EJHG</Title><ISOAbbreviation>Eur J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy.</ArticleTitle><Pagination><StartPage>973</StartPage><EndPage>981</EndPage><MedlinePgn>973-981</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ejhg.2017.87</ELocationID><Abstract><AbstractText>Accumulating evidence suggests that genetic variants in the SORL1 gene are associated with Alzheimer disease (AD), but a strategy to identify which variants are pathogenic is lacking. In a discovery sample of 115 SORL1 variants detected in 1908 Dutch AD cases and controls, we identified the variant characteristics associated with SORL1 variant pathogenicity. Findings were replicated in an independent sample of 103 SORL1 variants detected in 3193 AD cases and controls. In a combined sample of the discovery and replication samples, comprising 181 unique SORL1 variants, we developed a strategy to classify SORL1 variants into five subtypes ranging from pathogenic to benign. We tested this pathogenicity screen in SORL1 variants reported in two independent published studies. SORL1 variant pathogenicity is defined by the Combined Annotation Dependent Depletion (CADD) score and the minor allele frequency (MAF) reported by the Exome Aggregation Consortium (ExAC) database. Variants predicted strongly damaging (CADD score &gt;30), which are extremely rare (ExAC-MAF &lt;1 &#xd7; 10<sup>-5</sup>) increased AD risk by 12-fold (95% CI 4.2-34.3; P=5 &#xd7; 10<sup>-9</sup>). Protein-truncating SORL1 mutations were all unknown to ExAC and occurred exclusively in AD cases. More common SORL1 variants (ExAC-MAF&#x2265;1 &#xd7; 10<sup>-5</sup>) were not associated with increased AD risk, even when predicted strongly damaging. Findings were independent of gender and the APOE-&#x25b;4 allele. High-risk SORL1 variants were observed in a substantial proportion of the AD cases analyzed (2%). Based on their effect size, we propose to consider high-risk SORL1 variants next to variants in APOE, PSEN1, PSEN2 and APP for personalized risk assessments in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tsz Hang</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rooij</LastName><ForeName>Jeroen Gj</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louwersheimer</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Consortium on Health Aging and National Genomics Initiative, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijers-Heijboer</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology &amp;Biostatistics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinders</LastName><ForeName>Marcel Jt</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Metabolomics Centre, Leiden University, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Hum Genet</MedlineTA><NlmUniqueID>9302235</NlmUniqueID><ISSNLinking>1018-4813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28537274</ArticleId><ArticleId IdType="pmc">PMC5567154</ArticleId><ArticleId IdType="doi">10.1038/ejhg.2017.87</ArticleId><ArticleId IdType="pii">ejhg201787</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association: 2016 Alzheimer's disease facts and figures. Alzheimers Dement 2016; 12: 459&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L et al: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63: 168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S et al: High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012; 17: 875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Zhang Y, Lee JH et al: Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 2015; 77: 215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, Charbonnier C, Wallon D et al: SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry 2015; 21: 831&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303663</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J, Van den Bossche T, van der Zee J et al: A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathol 2016; 132: 213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Rudolph IM, Willnow TE: Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease. Acta Neuropathol 2016; 132: 653&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073117</ArticleId><ArticleId IdType="pubmed">27638701</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Andersen OM: Sorting receptor SORLA&#x2014;a trafficking path to avoid Alzheimer disease. J Cell Sci 2013; 126: 2751&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">23813966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehmedbasic A, Christensen SK, Nilsson J et al: SorLA complement-type repeat domains protect the amyloid precursor protein against processing. J Biol Chem 2015; 290: 3359&#x2013;3376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319007</ArticleId><ArticleId IdType="pubmed">25525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Schmidt V, Spoelgen R et al: Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 2006; 45: 2618&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G: The Vps10p-domain receptor family. Cell Mol Life Sci 2009; 66: 2677&#x2013;2689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115710</ArticleId><ArticleId IdType="pubmed">19434368</ArticleId></ArticleIdList></Reference><Reference><Citation>Caglayan S, Takagi-Niidome S, Liao F et al: Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med 2014; 6: 223ra220.</Citation><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M et al: Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004; 61: 1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V et al: Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2005; 102: 13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT et al: The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 2006; 26: 1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen R, von Arnim CA, Thomas AV et al: Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci 2006; 26: 418&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH et al: The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39: 168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K: SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat 2008; 29: 769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Caglayan S, Bauerfeind A, Schmidt V et al: Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. Arch Neurol 2012; 69: 373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">22410445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL: SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging 2009; 30: 1048&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Yamamoto M, Morihara T et al: SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett 2009; 461: 177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539718</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Ikram MA, Janssens AC et al: A study of the SORL1 gene in Alzheimer's disease and cognitive function. J Alzheimer's Dis 2009; 18: 51&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584446</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E et al: Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol 2011; 68: 99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J, Ibrahim-Verbaas C, Harold D et al: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K: The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016; 18: 421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberg GD, Bird TD, Wijsman EM et al: Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">1411576</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P et al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J: A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014; 46: 310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski K, Minikel E et al: Analysis of protein-coding genetic variation in 60,706 humans. bioRxiv 2015; 536: 285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis Y, Payne S, McAnulty C et al Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics: Association for Clinical Genetic Science, 2013.</Citation></Reference><Reference><Citation>Hofman A, Brusselle GG, Darwish Murad S et al: The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 2015; 30: 661&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4579264</ArticleId><ArticleId IdType="pubmed">26386597</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Pijnenburg YA, Prins N et al: Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 2014; 41: 313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, Gil L, Hunt SE et al: The Ensembl variant effect predictor. Genome Biol 2016; 17: 122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Abecasis GR, Boehnke M, Lin X: Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet 2014; 95: 5&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085641</ArticleId><ArticleId IdType="pubmed">24995866</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core TeamR: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.</Citation></Reference><Reference><Citation>Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA et al: Rare genetic variant in SORL1 may increase penetrance of Alzheimer's disease in a family with several generations of APOE-varepsilon4 homozygosity. J Alzheimer's Dis 2017; 56: 63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240543</ArticleId><ArticleId IdType="pubmed">27911290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR, Wegmann D, Ehm MG et al: An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 2012; 337: 100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319976</ArticleId><ArticleId IdType="pubmed">22604722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W, O'Connor TD, Jun G et al: Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013; 493: 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676746</ArticleId><ArticleId IdType="pubmed">23201682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28552073</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Intrastriatal injection of &#x3b1;-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.</ArticleTitle><Pagination><StartPage>40</StartPage><MedlinePgn>40</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">40</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-017-0182-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prionoid transmission of &#x3b1;-synuclein (&#x3b1;Syn) aggregates along neuroanatomically connected projections is posited to underlie disease progression in &#x3b1;-synucleinopathies. Here, we specifically wanted to study whether this prionoid progression occurs via direct inter-neuronal transfer and, if so, would intrastriatal injection of &#x3b1;Syn aggregates lead to nigral degeneration.</AbstractText><AbstractText Label="METHODS">To test prionoid transmission of &#x3b1;Syn aggregates along the nigro-striatal pathway, we injected amyloidogenic &#x3b1;Syn aggregates into two different regions of the striatum of adult human wild type &#x3b1;Syn transgenic mice (Line M20) or non-transgenic (NTG) mice and aged for 4&#xa0;months.</AbstractText><AbstractText Label="RESULTS">M20 mice injected in internal capsule (IC) or caudate putamen (CPu) regions of the striatum showed florid &#x3b1;Syn inclusion pathology distributed throughout the neuraxis, irrespective of anatomic connectivity. These &#x3b1;Syn inclusions were found in different cell types including neurons, astrocytes and even ependymal cells. On the other hand, intra-striatal injection of &#x3b1;Syn fibrils into NTG mice resulted in sparse &#x3b1;Syn pathology, mostly localized in the striatum and entorhinal cortex. Interestingly, NTG mice injected with preformed human &#x3b1;Syn fibrils showed no induction of &#x3b1;Syn inclusion pathology, suggesting the presence of a species barrier for &#x3b1;Syn fibrillar seeds. Modest levels of nigral dopaminergic (DA) neuronal loss was observed exclusively in substantia nigra (SN) of M20 cohorts injected in the IC, even in the absence of frank &#x3b1;Syn inclusions in DA neurons. None of the NTG mice or CPu-injected M20 mice showed DA neurodegeneration. Interestingly, the pattern and distribution of induced &#x3b1;Syn pathology corresponded with neuroinflammation especially in the SN of M20 cohorts. Hypermorphic reactive astrocytes laden with &#x3b1;Syn inclusions were abundantly present in the brains of M20 mice.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, our findings show that the pattern and extent of dissemination of &#x3b1;Syn pathology does not necessarily follow expected neuroanatomic connectivity. Further, the presence of intra-astrocytic &#x3b1;Syn pathology implies that glial cells participate in &#x3b1;Syn transmission and possibly have a role in non-cell autonomous disease modification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Mieu M T</ForeName><Initials>MMT</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Current address: Department of Neuroscience, Mayo Clinic, Jacksonville, FL, -32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutherford</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA. bgiasson@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA. bgiasson@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA. bgiasson@ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, 1275 Center Drive, PO Box 100159, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA. pchakrabarty@ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089622</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">Astrocyte</Keyword><Keyword MajorTopicYN="N">Dopaminergic Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Prion</Keyword><Keyword MajorTopicYN="N">Striatum</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28552073</ArticleId><ArticleId IdType="pmc">PMC5447308</ArticleId><ArticleId IdType="doi">10.1186/s13024-017-0182-z</ArticleId><ArticleId IdType="pii">10.1186/s13024-017-0182-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Waxman EA, Giasson BI. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta. 2009;1792(7):616&#x2013;624. doi: 10.1016/j.bbadis.2008.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.09.013</ArticleId><ArticleId IdType="pmc">PMC2756732</ArticleId><ArticleId IdType="pubmed">18955133</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13&#x2013;24. doi: 10.1038/nrneurol.2012.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.242</ArticleId><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem. 2005;74:29&#x2013;52. doi: 10.1146/annurev.biochem.74.082803.133400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.74.082803.133400</ArticleId><ArticleId IdType="pubmed">15952880</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al. Phosphorylation of ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739&#x2013;29752. doi: 10.1074/jbc.M600933200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 2008;67(5):402&#x2013;416. doi: 10.1097/NEN.0b013e3186fc995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3186fc995</ArticleId><ArticleId IdType="pmc">PMC2930078</ArticleId><ArticleId IdType="pubmed">18451726</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131(1):49&#x2013;73. doi: 10.1007/s00401-015-1485-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1485-1</ArticleId><ArticleId IdType="pmc">PMC4698305</ArticleId><ArticleId IdType="pubmed">26446103</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014;20(2):130&#x2013;138. doi: 10.1038/nm.3457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3457</ArticleId><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010;33(7):317&#x2013;325. doi: 10.1016/j.tins.2010.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2010.04.003</ArticleId><ArticleId IdType="pubmed">20493564</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain. 2016;140(Pt 2):266&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J, Giasson BI, Golde TE. Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener. 2013;8:17. doi: 10.1186/1750-1326-8-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-17</ArticleId><ArticleId IdType="pmc">PMC3671973</ArticleId><ArticleId IdType="pubmed">23714769</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem. 2010;113(2):374&#x2013;388. doi: 10.1111/j.1471-4159.2010.06592.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06592.x</ArticleId><ArticleId IdType="pmc">PMC2907888</ArticleId><ArticleId IdType="pubmed">20132485</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106(47):20051&#x2013;20056. doi: 10.1073/pnas.0908005106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908005106</ArticleId><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Covell DJ, Kehm VM, Zhang B, Song IY, Byrne MD, Pitkin RM, Decker SC, Trojanowski JQ, Lee VM. Molecular and biological compatibility with host alpha-Synuclein influences fibril Pathogenicity. Cell Rep. 2016;16(12):3373&#x2013;3387. doi: 10.1016/j.celrep.2016.08.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.053</ArticleId><ArticleId IdType="pmc">PMC5087609</ArticleId><ArticleId IdType="pubmed">27653697</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148(6):1188&#x2013;1203. doi: 10.1016/j.cell.2012.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.022</ArticleId><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol. 2007;8(7):552&#x2013;561. doi: 10.1038/nrm2204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2204</ArticleId><ArticleId IdType="pubmed">17585315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, Giasson BI. Brain injection of alpha-Synuclein induces multiple Proteinopathies, Gliosis, and a neuronal injury marker. J Neurosci. 2014;34(37):12368&#x2013;12378. doi: 10.1523/JNEUROSCI.2102-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2102-14.2014</ArticleId><ArticleId IdType="pmc">PMC6615494</ArticleId><ArticleId IdType="pubmed">25209277</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209(5):975&#x2013;986. doi: 10.1084/jem.20112457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112457</ArticleId><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Breid S, Bernis ME, Babila JT, Garza MC, Wille H, Tamguney G. Neuroinvasion of alpha-Synuclein Prionoids after Intraperitoneal and Intraglossal inoculation. J Virol. 2016;90(20):9182&#x2013;9193. doi: 10.1128/JVI.01399-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01399-16</ArticleId><ArticleId IdType="pmc">PMC5044858</ArticleId><ArticleId IdType="pubmed">27489279</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340&#x2013;344. doi: 10.1038/nature14547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14547</ArticleId><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A. 2014;111(29):10732&#x2013;10737. doi: 10.1073/pnas.1321785111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1321785111</ArticleId><ArticleId IdType="pmc">PMC4115570</ArticleId><ArticleId IdType="pubmed">25002524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ, Giasson BI. Robust central nervous system pathology in transgenic mice following peripheral injection of alpha-Synuclein fibrils. J Virol. 2017;91(2):pii: e02095-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215322</ArticleId><ArticleId IdType="pubmed">27852849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ, Ceballos-Diaz C, Robertson J, Golde TE, Giasson BI. Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 2014;127(5):645&#x2013;665. doi: 10.1007/s00401-014-1268-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1268-0</ArticleId><ArticleId IdType="pmc">PMC4869357</ArticleId><ArticleId IdType="pubmed">24659240</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949&#x2013;953. doi: 10.1126/science.1227157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013;136(Pt 4):1128&#x2013;1138. doi: 10.1093/brain/awt037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt037</ArticleId><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P. Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med. 2016;213(9):1759&#x2013;1778. doi: 10.1084/jem.20160368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160368</ArticleId><ArticleId IdType="pmc">PMC4995088</ArticleId><ArticleId IdType="pubmed">27503075</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308&#x2013;E5317. doi: 10.1073/pnas.1514475112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1514475112</ArticleId><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103&#x2013;117. doi: 10.1016/j.cell.2013.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.057</ArticleId><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrianni JA. The genetics of prion diseases. Genet Med. 2010;12(4):187&#x2013;195. doi: 10.1097/GIM.0b013e3181cd7374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e3181cd7374</ArticleId><ArticleId IdType="pubmed">20216075</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, Unni VK. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10(8):1252&#x2013;1260. doi: 10.1016/j.celrep.2015.01.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.01.060</ArticleId><ArticleId IdType="pmc">PMC4351119</ArticleId><ArticleId IdType="pubmed">25732816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302(5646):819&#x2013;822. doi: 10.1126/science.1087753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1087753</ArticleId><ArticleId IdType="pubmed">14593166</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34(4):521&#x2013;533. doi: 10.1016/S0896-6273(02)00682-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00682-7</ArticleId><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. The J Biol Chem. 2001;276(4):2380&#x2013;2386. doi: 10.1074/jbc.M008919200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M008919200</ArticleId><ArticleId IdType="pubmed">11060312</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008;116(1):37&#x2013;46. doi: 10.1007/s00401-008-0375-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0375-1</ArticleId><ArticleId IdType="pmc">PMC2664556</ArticleId><ArticleId IdType="pubmed">18414880</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Tong Y, Gautier CA, Shen J. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem. 2009;111(3):696&#x2013;702. doi: 10.1111/j.1471-4159.2009.06350.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06350.x</ArticleId><ArticleId IdType="pmc">PMC2952933</ArticleId><ArticleId IdType="pubmed">19694908</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron. 2012;74(5):858&#x2013;873. doi: 10.1016/j.neuron.2012.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.017</ArticleId><ArticleId IdType="pubmed">22681690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan WX, Mao T, Dudman JT. Inputs to the dorsal striatum of the mouse reflect the parallel circuit architecture of the forebrain. Front Neuroanat. 2010;4:147. doi: 10.3389/fnana.2010.00147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2010.00147</ArticleId><ArticleId IdType="pmc">PMC3014656</ArticleId><ArticleId IdType="pubmed">21212837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruck D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurodegeneration: a complex interaction. Neurobiol Dis. 2016;85:262&#x2013;274. doi: 10.1016/j.nbd.2015.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.03.003</ArticleId><ArticleId IdType="pmc">PMC4730552</ArticleId><ArticleId IdType="pubmed">25766679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009;452:181&#x2013;197. doi: 10.1016/S0076-6879(08)03612-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(08)03612-4</ArticleId><ArticleId IdType="pubmed">19200883</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, Hasegawa M. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun. 2014;2:88. doi: 10.1186/s40478-014-0088-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0088-8</ArticleId><ArticleId IdType="pmc">PMC4147188</ArticleId><ArticleId IdType="pubmed">25095794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Ayers JI, Brooks MM, Chakrabarty P, Hudson VJ, 3rd, Howard JK, Golde TE, Giasson BI, Borchelt DR. Non-prion-type transmission in A53T alpha-synuclein transgenic mice: a normal component of spinal homogenates from naive non-transgenic mice induces robust alpha-synuclein pathology. Acta Neuropathol. 2016;131(1):151&#x2013;154. doi: 10.1007/s00401-015-1505-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1505-1</ArticleId><ArticleId IdType="pmc">PMC4852859</ArticleId><ArticleId IdType="pubmed">26541429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason DM, Nouraei N, Pant DB, Miner KM, Hutchison DF, Luk KC, Stolz JF, Leak RK. Transmission of alpha-synucleinopathy from olfactory structures deep into the temporal lobe. Mol Neurodegener. 2016;11(1):49. doi: 10.1186/s13024-016-0113-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0113-4</ArticleId><ArticleId IdType="pmc">PMC4929736</ArticleId><ArticleId IdType="pubmed">27363576</ArticleId></ArticleIdList></Reference><Reference><Citation>Croisier E, Graeber MB. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol. 2006;112(5):517&#x2013;530. doi: 10.1007/s00401-006-0119-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0119-z</ArticleId><ArticleId IdType="pubmed">16896905</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol. 2011;121(6):675&#x2013;693. doi: 10.1007/s00401-011-0833-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0833-z</ArticleId><ArticleId IdType="pmc">PMC4730553</ArticleId><ArticleId IdType="pubmed">21562886</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930&#x2013;936. doi: 10.1126/science.1138718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1138718</ArticleId><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushnirov VV, Kryndushkin DS, Boguta M, Smirnov VN, Ter-Avanesyan MD. Chaperones that cure yeast artificial [PSI+] and their prion-specific effects. Curr Biol. 2000;10(22):1443&#x2013;1446. doi: 10.1016/S0960-9822(00)00802-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(00)00802-2</ArticleId><ArticleId IdType="pubmed">11102806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien P, Weissman JS, DePace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem. 2004;73:617&#x2013;656. doi: 10.1146/annurev.biochem.72.121801.161837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.72.121801.161837</ArticleId><ArticleId IdType="pubmed">15189155</ArticleId></ArticleIdList></Reference><Reference><Citation>George JM. The synucleins. Genome Biol. 2002;3(1):REVIEWS3002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150459</ArticleId><ArticleId IdType="pubmed">11806835</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochet JC, Conway KA, Lansbury PT., Jr Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 2000;39(35):10619&#x2013;10626. doi: 10.1021/bi001315u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi001315u</ArticleId><ArticleId IdType="pubmed">10978144</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkatch IL, Chernoff YO, Kushnirov VV, Inge-Vechtomov SG, Liebman SW. Genesis and variability of [PSI] prion factors in Saccharomyces cerevisiae. Genetics. 1996;144(4):1375&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1207691</ArticleId><ArticleId IdType="pubmed">8978027</ArticleId></ArticleIdList></Reference><Reference><Citation>Masison DC, Maddelein ML, Wickner RB. The prion model for [URE3] of yeast: spontaneous generation and requirements for propagation. Proc Natl Acad Sci U S A. 1997;94(23):12503&#x2013;12508. doi: 10.1073/pnas.94.23.12503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.23.12503</ArticleId><ArticleId IdType="pmc">PMC25018</ArticleId><ArticleId IdType="pubmed">9356479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Bae EJ, Lee SJ. Extracellular alpha--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10(2):92&#x2013;98. doi: 10.1038/nrneurol.2013.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.275</ArticleId><ArticleId IdType="pubmed">24468877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562. doi: 10.1038/ncomms2534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2534</ArticleId><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008;40(9):1835&#x2013;1849. doi: 10.1016/j.biocel.2008.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2008.01.017</ArticleId><ArticleId IdType="pubmed">18291704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285(12):9262&#x2013;9272. doi: 10.1074/jbc.M109.081125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.081125</ArticleId><ArticleId IdType="pmc">PMC2838344</ArticleId><ArticleId IdType="pubmed">20071342</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179(2):954&#x2013;963. doi: 10.1016/j.ajpath.2011.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.04.013</ArticleId><ArticleId IdType="pmc">PMC3157205</ArticleId><ArticleId IdType="pubmed">21801874</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. Paxinos and Franklin's the mouse brain in stereotaxic coordinates. fourth. Amsterdam: Academic Press, an imprint of Elsevier; 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28559417</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>13</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.</ArticleTitle><Pagination><StartPage>1837</StartPage><EndPage>1853</EndPage><MedlinePgn>1837-1853</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.201796516</ELocationID><Abstract><AbstractText>Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk for several neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia (FTD). Homozygous TREM2 missense mutations, such as p.T66M, lead to the FTD-like syndrome, but how they cause pathology is unknown. Using CRISPR/Cas9 genome editing, we generated a knock-in mouse model for the disease-associated Trem2 p.T66M mutation. Consistent with a loss-of-function mutation, we observe an intracellular accumulation of immature mutant Trem2 and reduced generation of soluble Trem2 similar to patients with the homozygous p.T66M mutation. Trem2 p.T66M knock-in mice show delayed resolution of inflammation upon <i>in&#xa0;vivo</i> lipopolysaccharide stimulation and cultured macrophages display significantly reduced phagocytic activity. Immunohistochemistry together with <i>in&#xa0;vivo</i> TSPO small animal positron emission tomography (&#x3bc;PET) demonstrates an age-dependent reduction in microglial activity. Surprisingly, perfusion magnetic resonance imaging and FDG-&#x3bc;PET imaging reveal a significant reduction in cerebral blood flow and brain glucose metabolism. Thus, we demonstrate that a TREM2 loss-of-function mutation causes brain-wide metabolic alterations pointing toward a possible function of microglia in regulating brain glucose metabolism.</AbstractText><CopyrightInformation>&#xa9; 2017 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5811-8226</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mracsko</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NORD Discovery &amp; Translational Area, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wefers</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groeneweg</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NORD Discovery &amp; Translational Area, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Focke</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deu&#xdf;ing</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazaheri</LastName><ForeName>Fargol</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6896-651X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Samira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettkus</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technische Universit&#xe4;t M&#xfc;nchen, Freising-Weihenstephan, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz Center Munich, German Research Center for Environmental Health, Institute for Diabetes and Obesity, Core Facility Monoclonal Antibody Development, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartenstein</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueggler</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NORD Discovery &amp; Translational Area, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knuesel</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NORD Discovery &amp; Translational Area, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rominger</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2017 Jun 14;9(394):eaan5227. doi: 10.1126/scitranslmed.aan5227.</RefSource><PMID Version="1">28615359</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>EMBO J. 2017 Jul 3;36(13):1803-1805. doi: 10.15252/embj.201797465.</RefSource><PMID Version="1">28623242</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="Y">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">regulated intramembrane proteolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28559417</ArticleId><ArticleId IdType="pmc">PMC5494459</ArticleId><ArticleId IdType="doi">10.15252/embj.201796516</ArticleId><ArticleId IdType="pii">embj.201796516</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, Younkin S, Das P, Fryer JD, Bu G (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290: 26043&#x2013;26050</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M (2015) The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290: 26033&#x2013;26042</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C, Gennarelli M, Turla M, Scarpini E, Sorbi S, Padovani A (2014) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934 e937&#x2013;910</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl C, Ortiz O, Rottig B, Wefers B, Wurst W, Kuhn R (2015) Creation of targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one&#x2010;cell mouse embryos. FEBS Open Bio 5: 26&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309836</ArticleId><ArticleId IdType="pubmed">25685662</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A (2015) Amyloid&#x2010;PET predicts inhibition of de novo plaque formation upon chronic gamma&#x2010;secretase modulator treatment. Mol Psychiatry 20: 1179&#x2013;1187</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759098</ArticleId><ArticleId IdType="pubmed">26055427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R, Lindner S, Gildehaus FJ, Baumann K, Bartenstein P, Kleinberger G, Haass C, Herms J, Rominger A (2016) Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple&#x2010;tracer PET study. J Nucl Med 57: 954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pubmed">26912428</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ, Ozmen L, Suarez&#x2010;Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C, Rominger A (2017) Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. Front Aging Neurosci 9: 8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282474</ArticleId><ArticleId IdType="pubmed">28197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruns A, Kunnecke B, Risterucci C, Moreau JL, von Kienlin M (2009) Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med 61: 1451&#x2013;1458</Citation><ArticleIdList><ArticleId IdType="pubmed">19358231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L (2015) TREM2 regulates microglial cell activation in response to demyelination in&#xa0;vivo . Acta Neuropathol 129: 429&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kuhn R (2015) Increasing the efficiency of homology&#x2010;directed repair for CRISPR&#x2010;Cas9&#x2010;induced precise gene editing in mammalian cells. Nat Biotechnol 33: 543&#x2013;548</Citation><ArticleIdList><ArticleId IdType="pubmed">25803306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, Maes G, Mattheijssens M, Peeters K, Cras P, Vandenberghe R, De Deyn PP, Van Broeckhoven C, Cruts M, Sleegers K, Consortium B (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35: 726.e11&#x2013;726.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Sleegers K (2016) Genetic variations underlying Alzheimer's disease: evidence from genome&#x2010;wide association studies and beyond. Lancet Neurol 15: 857&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">27302364</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE (2003) Pattern recognition by TREM&#x2010;2: binding of anionic ligands. J Immunol 171: 594&#x2013;599</Citation><ArticleIdList><ArticleId IdType="pubmed">12847223</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickens AM, Vainio S, Marjamaki P, Johansson J, Lehtiniemi P, Rokka J, Rinne J, Solin O, Haaparanta&#x2010;Solin M, Jones PA, Trigg W, Anthony DC, Airas L (2014) Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C&#x2010;(R)&#x2010;PK11195 and 18F&#x2010;GE&#x2010;180. J Nucl Med 55: 466&#x2013;472</Citation><ArticleIdList><ArticleId IdType="pubmed">24516258</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr A, Sled JG, Kabani N (2007) Three&#x2010;dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. NeuroImage 35: 1409&#x2013;1423</Citation><ArticleIdList><ArticleId IdType="pubmed">17369055</ArticleId></ArticleIdList></Reference><Reference><Citation>Glebov K, Wunderlich P, Karaca I, Walter J (2016) Functional involvement of gamma&#x2010;secretase in signaling of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2). J Neuroinflammation 13: 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721188</ArticleId><ArticleId IdType="pubmed">26792193</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K et&#xa0;al (2013a) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, Emre M, Singleton A, Hardy J (2013b) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia&#x2010;like syndrome without bone involvement. JAMA Neurol 70: 78&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase A, Frahm J, Matthaei D, Hanicke W, Bomsdorf H, Kunz D, Tischler R (1986) MR imaging using stimulated echoes (STEAM). Radiology 160: 787&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">3737918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)&#x2010;2 and DAP12. J Immunol 177: 2051&#x2013;2055</Citation><ArticleIdList><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016) Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimer's Res Ther 8: 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848774</ArticleId><ArticleId IdType="pubmed">27121148</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K (2011) Perfusion SPECT and FDG&#x2010;PET. Int Psychogeriatr 23(Suppl. 2): S25&#x2013;S31</Citation><ArticleIdList><ArticleId IdType="pubmed">21729421</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener 11: 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J (2013) The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 16: 1896&#x2013;1905</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109: 1144&#x2013;1156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Hamerman JA (2012) TREM&#x2010;2, triggering receptor expressed on myeloid cell&#x2010;2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 42: 176&#x2013;185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3444819</ArticleId><ArticleId IdType="pubmed">21956652</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim&#x2010;Verbaas C, Hofman A, Ikram MA et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez&#x2010;Valle R, Antonell A, Ramirez A et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra286</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, Peltonen L, Paloneva J (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502&#x2013;1507</Citation><ArticleIdList><ArticleId IdType="pubmed">15883308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, Alexander&#x2010;Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ (2016) Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss&#x2010;of&#x2010;function mechanisms. eLife 5: e20391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LJ, Perry VH, Gordon S (1992) Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48: 405&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, Harrison&#x2010;Brown M, Dodson E, Veale K, Banati RB (2014) The 18&#xa0;kDa translocator protein, microglia and neuroinflammation. Brain Pathol 24: 631&#x2013;653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029074</ArticleId><ArticleId IdType="pubmed">25345894</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA, Trigg W, Di Carli MF, Lemere CA (2015) In vivo detection of age&#x2010; and disease&#x2010;related increases in neuroinflammation by 18F&#x2010;GE180 TSPO microPET imaging in wild&#x2010;type and Alzheimer's transgenic mice. J Neurosci 35: 15716&#x2013;15730</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705465</ArticleId><ArticleId IdType="pubmed">26609163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourbopoulos A, Erturk A, Hellal F (2015) Microglia in action: how aging and injury can change the brain's guardians. Front Cell Neurosci 9: 54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4337366</ArticleId><ArticleId IdType="pubmed">25755635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Tr&#xfc;mbach D, Wurst W, Brunner B, Bultmann S, Tahirovic S, Kerschensteiner M, Misgeld T, Butovsky O, Haass C (2017) TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18: 1186&#x2013;1198</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36: 587&#x2013;597</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900881</ArticleId><ArticleId IdType="pubmed">23968694</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbetti L, Ratti MT, Greco B, Aprile C, Moglia A, Soragna D (2005) Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu&#x2010;Hakola disease heterozygotes. Funct Neurol 20: 71&#x2013;75</Citation><ArticleIdList><ArticleId IdType="pubmed">15966270</ArticleId></ArticleIdList></Reference><Reference><Citation>N'Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, Hamerman JA, Seaman WE (2009) TREM&#x2010;2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 184: 215&#x2013;223</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654305</ArticleId><ArticleId IdType="pubmed">19171755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in&#xa0;vivo . Science 308: 1314&#x2013;1318</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M (2012) TREM2 and beta&#x2010;catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 188: 2612&#x2013;2621</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732181</ArticleId><ArticleId IdType="pubmed">22312126</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, Focke C, Gildehaus FJ, Carlsen J, Baumann K, Haass C, Bartenstein P, Herms J, Rominger A (2016) Automated spatial brain normalization and hindbrain white matter reference tissue give improved [(18)F]&#x2010;Florbetaben PET quantitation in Alzheimer's model mice. Front Neurosci 10: 45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770021</ArticleId><ArticleId IdType="pubmed">26973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M (2001) CNS manifestations of Nasu&#x2010;Hakola disease: a frontal dementia with bone cysts. Neurology 56: 1552&#x2013;1558</Citation><ArticleIdList><ArticleId IdType="pubmed">11402114</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, Yoon SY (2015) Disease&#x2010;associated mutations of TREM2 alter the processing of N&#x2010;linked oligosaccharides in the golgi apparatus. Traffic 16: 510&#x2013;518</Citation><ArticleIdList><ArticleId IdType="pubmed">25615530</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn San Diego, CA: Academic Press;</Citation></Reference><Reference><Citation>Paxinos G, Franklin K (2001) The mouse brain in stereotaxic coordinates. New York: Academic Press;</Citation></Reference><Reference><Citation>Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J II, Naismith RT, Panina&#x2010;Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH (2008) Identification of soluble TREM&#x2010;2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131: 3081&#x2013;3091</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del&#x2010;Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131: 925&#x2013;933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M (2015) TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125: 2161&#x2013;2170</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463196</ArticleId><ArticleId IdType="pubmed">25893602</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME (1998) Behind the scenes of functional brain imaging: a historical and physiological perspective. Proc Natl Acad Sci USA 95: 765&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33796</ArticleId><ArticleId IdType="pubmed">9448239</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL III, Caselli R, Mackenzie IR, Miller BL, Boczarska&#x2010;Jedynak M, Opala G, Krygowska&#x2010;Wajs A et&#xa0;al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Beggs S (2014) Sublime microglia: expanding roles for the guardians of the CNS. Cell 158: 15&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">24995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J, Hasler L, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA (2016) Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimer's Dement 13: 701&#x2013;709</Citation><ArticleIdList><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Bruck W (2013) Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol 125: 595&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3611040</ArticleId><ArticleId IdType="pubmed">23354834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L (1977) Relation between physiological function and energy metabolism in the central nervous system. J Neurochem 29: 13&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pubmed">407330</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897&#x2013;916</Citation><ArticleIdList><ArticleId IdType="pubmed">864466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L (1999) Energetics of functional activation in neural tissues. Neurochem Res 24: 321&#x2013;329</Citation><ArticleIdList><ArticleId IdType="pubmed">9972882</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Caballero M, Kleinberger G, Bateman R, Fagan AM, Morris J, Levin J, Danek A, Ewers M, Haass C, Network ftDIA (2016a) Early changes of CSF sTREM2 in dominantly inherited Alzheimer's disease follow markers of amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, Sanchez&#x2010;Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschutz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K et&#xa0;al (2016b) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells&#x2010;2. J Exp Med 201: 647&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshita T, Kaminaga T, Tatsumi T, Hatanaka Y, Furui S (2005) Regional cerebral blood flow in a patient with Nasu&#x2010;Hakola disease. Ann Nucl Med 19: 309&#x2013;312</Citation><ArticleIdList><ArticleId IdType="pubmed">16097640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Rabinovici GD, Ayakta N, Miller BL, Jagust W, Kramer J, Weiner MM, Rosen HJ (2016) Diagnostic utility of ASL&#x2010;MRI and FDG&#x2010;PET in the behavioral variant of FTD and AD. Ann Clin Transl Neurol 3: 740&#x2013;751</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048385</ArticleId><ArticleId IdType="pubmed">27752510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Majewska AK (2011) A role for microglia in synaptic plasticity? Commun Integr Biol 4: 220&#x2013;222</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104585</ArticleId><ArticleId IdType="pubmed">21655446</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM&#x2010;2 attenuates macrophage activation. J Immunol 177: 3520&#x2013;3524</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki Y, Kohara N, Oga T, Fukuyama H, Akiguchi I, Kimura J, Shibasaki H (2000) Membranous lipodystrophy presenting with palilalia: a PET study of cerebral glucose metabolism. Acta Neurol Scand 102: 60&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">10893065</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Nagren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K, European Association of Nuclear Medicine Neuroimaging C (2009) EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 36: 2103&#x2013;2110</Citation><ArticleIdList><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Verfaillie SC, Adriaanse SM, Binnewijzend MA, Benedictus MR, Ossenkoppele R, Wattjes MP, Pijnenburg YA, van der Flier WM, Lammertsma AA, Kuijer JP, Boellaard R, Scheltens P, van Berckel BN, Barkhof F (2015) Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin? Eur Radiol 25: 3050&#x2013;3059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562004</ArticleId><ArticleId IdType="pubmed">25899416</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas&#x2010;Llerena C, Phillips A, Garcia&#x2010;Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol 36: 74&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">26517285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wefers B, Panda SK, Ortiz O, Brandl C, Hensler S, Hansen J, Wurst W, Kuhn R (2013) Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA. Nat Protoc 8: 2355&#x2013;2379</Citation><ArticleIdList><ArticleId IdType="pubmed">24177293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickstrom T, Clarke A, Gausemel I, Horn E, Jorgensen K, Khan I, Mantzilas D, Rajanayagam T, in&#x2018;t Veld DJ, Trigg W (2014) The development of an automated and GMP compliant FASTlab Synthesis of [(18) F]GE&#x2010;180; a radiotracer for imaging translocator protein (TSPO). J Labelled Compd Radiopharm 57: 42&#x2013;48</Citation><ArticleIdList><ArticleId IdType="pubmed">24448744</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DS, Detre JA, Leigh JS, Koretsky AP (1992) Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA 89: 212&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48206</ArticleId><ArticleId IdType="pubmed">1729691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Byers DE, Jin X, Agapov E, Alexander&#x2010;Brett J, Patel AC, Cella M, Gilfilan S, Colonna M, Kober DL, Brett TJ, Holtzman MJ (2015) TREM&#x2010;2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med 212: 681&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419356</ArticleId><ArticleId IdType="pubmed">25897174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) protein by ectodomain shedding and gamma&#x2010;secretase&#x2010;dependent intramembranous cleavage. J Biol Chem 288: 33027&#x2013;33036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Tu Z, Sun Q, Li XJ (2016) CRISPR/Cas9: implications for modeling and therapy of neurodegenerative diseases. Front Mol Neurosci 9: 30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848312</ArticleId><ArticleId IdType="pubmed">27199655</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M (2016) TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid&#x2010;beta by microglia. Neuron 91: 328&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen XF, Zhang ZL, Wang Z, Shi XZ, Xu K, Zhang YW, Xu H, Bu G (2015) DAP12 stabilizes the C&#x2010;terminal fragment of the triggering receptor expressed on myeloid cells&#x2010;2 (TREM2) and protects against LPS&#x2010;induced pro&#x2010;inflammatory response. J Biol Chem 290: 15866&#x2013;15877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505493</ArticleId><ArticleId IdType="pubmed">25957402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X, Wu L, Jia L, Zheng H, Painter M, Atagi Y, Liu CC, Zhang YW, Fryer JD, Xu H, Bu G (2017) Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med 214: 597&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28558094</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.</ArticleTitle><Pagination><StartPage>813</StartPage><EndPage>820</EndPage><MedlinePgn>813-820</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.0263</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Abnormal accumulation of tau and amyloid-&#x3b2; (A&#x3b2;) proteins in the human brain are 2 pathologic hallmarks of Alzheimer disease (AD). Because pathologic processes begin decades before the onset of the clinical manifestations, the study of the cortical distribution of early-stage pathologic alterations is critical in understanding the underpinnings of the disease.</AbstractText><AbstractText Label="OBJECTIVES">To identify the in vivo brain spatial distributions of tau and A&#x3b2; deposits in a sample of cognitively normal participants in the Harvard Aging Brain Study, determine spatial patterns of pathologic alterations, and provide means for improved individual in vivo staging.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Eighty-eight individuals from the general community underwent flortaucipir 18 T807 (18F-T807) and carbon 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging. A voxel-level hierarchical clustering approach was used to obtain the main clustering partitions corresponding to the cortical distribution maps of 18F-T807 and 11C-PiB. Hierarchical relationships between areas of distinctive pathologic deposits were then studied. Using cerebellar gray reference, 18F-T807 data were expressed as standardized uptake value ratio, and 11C-PiB were given as distribution volume ratio.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Main in vivo and hierarchically organized tau and A&#x3b2; deposits in the elderly brain.</AbstractText><AbstractText Label="RESULTS">Of the 88 study participants, 39 (44%) were men, with a mean (SD) age of 76.2 (6.2) years. The tau and A&#x3b2; maps both displayed optimal cortical partitions at 4 clusters. The tau deposits were grouped in the temporal lobe, distributed in heteromodal areas, medial and visual regions, and primary somatomotor cortex; the A&#x3b2; deposits were clustered in the heteromodal areas and rather patchy in distributed regions involving the primary cortices, medial structures, and temporal areas. Moreover, tau deposits in the temporal lobe and distributed heteromodal areas were tightly nested.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Tau and A&#x3b2; deposits in the elderly brain generally display well-defined hierarchical cortical relationships as well as overlaps between the principal clusters of both pathologic alterations in the heteromodal association regions. These findings represent systematic, large-scale mechanisms of early AD pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts2Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabuncu</LastName><ForeName>Mert</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Fakhri</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts4Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts4Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Jul 1;74(7):766-768. doi: 10.1001/jamaneurol.2017.0323.</RefSource><PMID Version="1">28558092</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28558094</ArticleId><ArticleId IdType="pmc">PMC5710537</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.0263</ArticleId><ArticleId IdType="pii">2628758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Cereb Cortex. 1991;1(1):103-116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1(3):213-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(pt 6):1630-1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430(7000):631-639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M. &#x3b2;-Protein amyloid is widely distributed in the central nervous system of patients with Alzheimer&#x2019;s disease. Am J Pathol. 1989;134(2):243-251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879581</ArticleId><ArticleId IdType="pubmed">2464938</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11(3):213-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457-468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, et al. . Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Harada R, et al. . Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54(8):1420-1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">23857514</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. . In vivo evaluation of a novel tau imaging tracer for Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2014;41(5):816-826.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514874</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K, Becker AJ, Sepulcre J, et al. . Tau PET imaging in aging and early Alzheimer&#x2019;s disease. Ann Neurol. 2016;79(1):110-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2000;924:53-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193802</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73(6):1204-1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Fouquet M, Baron JC, et al. . Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer&#x2019;s disease. Brain. 2010;133(11):3301-3314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291528</ArticleId><ArticleId IdType="pubmed">20688814</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund E, Brun A, Alling C. White matter changes in dementia of Alzheimer&#x2019;s type: biochemical and neuropathological correlates. Brain. 1988;111(pt 6):1425-1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">3208064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczynski B, Targan E, Madison C, et al. . White matter integrity and cortical metabolic associations in aging and dementia. Alzheimers Dement. 2010;6(1):54-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817977</ArticleId><ArticleId IdType="pubmed">20129319</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, et al. . Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55(5):697-711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;&#x2013;induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812-818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42-52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain. 2013;136(pt 7):2239-2252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692037</ArticleId><ArticleId IdType="pubmed">23801740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216-1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW; Alzheimer&#x2019;s Disease NeuroImaging Initiative . Spatial patterns of brain amyloid-&#x3b2; burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134(pt 4):1077-1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069703</ArticleId><ArticleId IdType="pubmed">21429865</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel S, Grothe MJ, Zhou J, et al. . Measuring cortical connectivity in Alzheimer&#x2019;s disease as a brain neural network pathology: toward clinical applications. J Int Neuropsychol Soc. 2016;22(2):138-163.</Citation><ArticleIdList><ArticleId IdType="pubmed">26888613</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Edland S, Clark C, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD)&#x2014;part IV: rates of cognitive change in the longitudinal assessment of probable Alzheimer&#x2019;s disease. Neurology. 1993;43(12):2457-2465.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255439</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. . Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Haworth Press, Inc; 1986:165-173.</Citation></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740-2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, et al. . Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIBin a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Schultz AP, Sabuncu M, et al. . In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci. 2016;36(28):7364-7374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="pubmed">27413148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987;20:53-65.</Citation></Reference><Reference><Citation>Yeo BT, Krienen FM, Sepulcre J, et al. . The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106(3):1125-1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DCA. A population-average, landmark- and surface-based (PALS) atlas of human cerebral cortex. Neuroimage. 2005;28(3):635-662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119-128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(4):a006213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Driscoll I, Iacono D, et al. . In vivo fibrillar &#x3b2;-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68(2):232-240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082956</ArticleId><ArticleId IdType="pubmed">21320990</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, et al. . Amyloid-Beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70(5):857-861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl. 1996;165:3-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Avila J. The role of extracellular tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005959</ArticleId><ArticleId IdType="pubmed">24795568</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501(7465):45-51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11(3):155-159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100(1):253-258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME. The brain&#x2019;s default mode network. Annu Rev Neurosci. 2015;38:433-447.</Citation><ArticleIdList><ArticleId IdType="pubmed">25938726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME. Resting state functional connectivity in preclinical Alzheimer&#x2019;s disease. Biol Psychiatry. 2013;74(5):340-347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537262</ArticleId><ArticleId IdType="pubmed">23290495</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28556232</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Decreased plasma &#x3b2;-amyloid in the Alzheimer's disease APP A673T variant carriers.</ArticleTitle><Pagination><StartPage>128</StartPage><EndPage>132</EndPage><MedlinePgn>128-132</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24969</ELocationID><Abstract><AbstractText>We investigated the association of Alzheimer's disease (AD)-related rare variants APP A673T and ABCA7 rs200538373-C with the levels of &#x3b2;-amyloid (A&#x3b2;) and parameters of metabolic and cardiovascular health in a population-based cohort of healthy middle-aged and elderly men. Carriers of protective APP A673T variant had, on average, 28% lower levels of A&#x3b2;40 and A&#x3b2;42 in plasma as compared to the controls and the carriers of ABCA7 rs200538373-C. This is the first report to show decreased A&#x3b2; levels in plasma in APP A673T carriers and thus provides evidence that lower A&#x3b2; levels throughout life may be protective against AD. Ann Neurol 2017;82:128-132.</AbstractText><CopyrightInformation>&#xa9; 2017 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martiskainen</LastName><ForeName>Henna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine-Neurology, University of Eastern Finland, and Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stan&#x10d;&#xe1;kov&#xe1;</LastName><ForeName>Alena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paananen</LastName><ForeName>Jussi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine and Bioinformatics Center, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine-Neurology, University of Eastern Finland, and Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuusisto</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laakso</LastName><ForeName>Markku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine University of Eastern Finland and Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411895">ABCA7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28556232</ArticleId><ArticleId IdType="doi">10.1002/ana.24969</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28566429</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>392</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaf6295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf6295</ELocationID><Abstract><AbstractText>The complement cascade not only is an innate immune response that enables removal of pathogens but also plays an important role in microglia-mediated synaptic refinement during brain development. Complement C3 is elevated in Alzheimer's disease (AD), colocalizing with neuritic plaques, and appears to contribute to clearance of A&#x3b2; by microglia in the brain. Previously, we reported that C3-deficient C57BL/6 mice were protected against age-related and region-specific loss of hippocampal synapses and cognitive decline during normal aging. Furthermore, blocking complement and downstream iC3b/CR3 signaling rescued synapses from A&#x3b2;-induced loss in young AD mice before amyloid plaques had accumulated. We assessed the effects of C3 deficiency in aged, plaque-rich APPswe/PS1dE9 transgenic mice (APP/PS1;<i>C3</i> KO). We examined the effects of C3 deficiency on cognition, A&#x3b2; plaque deposition, and plaque-related neuropathology at later AD stages in these mice. We found that 16-month-old APP/PS1;<i>C3</i> KO mice performed better on a learning and memory task than did APP/PS1 mice, despite having more cerebral A&#x3b2; plaques. Aged APP/PS1;<i>C3</i> KO mice also had fewer microglia and astrocytes localized within the center of hippocampal A&#x3b2; plaques compared to APP/PS1 mice. Several proinflammatory cytokines in the brain were reduced in APP/PS1;<i>C3</i> KO mice, consistent with an altered microglial phenotype. C3 deficiency also protected APP/PS1 mice against age-dependent loss of synapses and neurons. Our study suggests that complement C3 or downstream complement activation fragments may play an important role in A&#x3b2; plaque pathology, glial responses to plaques, and neuronal dysfunction in the brains of APP/PS1 mice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Qiaoqiao</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-4035-9272</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Building for Transformative Medicine, 9th Floor, 60 Fenwood Road, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Saba</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2945-7007</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Building for Transformative Medicine, 9th Floor, 60 Fenwood Road, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4644-805X</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Building for Transformative Medicine, 9th Floor, 60 Fenwood Road, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Kevin X</ForeName><Initials>KX</Initials><Identifier Source="ORCID">0000-0002-6879-8595</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Building for Transformative Medicine, 9th Floor, 60 Fenwood Road, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5744-4871</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Center for Life Sciences, 12th Floor, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldarone</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard NeuroDiscovery Center NeuroBehavior Laboratory, Department of Neurology, Brigham and Women's Hospital, Harvard Institute of Medicine, Room 945, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4226-1201</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Center for Life Sciences, 12th Floor, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-2983-7870</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Building for Transformative Medicine, 9th Floor, 60 Fenwood Road, Boston, MA 02115, USA. clemere@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG044713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28566429</ArticleId><ArticleId IdType="mid">NIHMS1043931</ArticleId><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf6295</ArticleId><ArticleId IdType="pii">9/392/eaaf6295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Veerhuis R, Nielsen HM, Tenner AJ, Complement in the brain. Mol Immunol 48, 1592&#x2013;1603 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142281</ArticleId><ArticleId IdType="pubmed">21546088</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA, The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Stevens B, TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci 16, 1773&#x2013;1782 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973738</ArticleId><ArticleId IdType="pubmed">24162655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029&#x2013;13042 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605437</ArticleId><ArticleId IdType="pubmed">26400934</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW, Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol 27, 457&#x2013;464 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA, Temporal accrual of complement proteins in amyloid plaques in Down&#x2019;s syndrome with Alzheimer&#x2019;s disease. Am J Pathol 156, 489&#x2013;499 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850044</ArticleId><ArticleId IdType="pubmed">10666378</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM, Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer&#x2019;s disease. Res Immunol 143, 617&#x2013;620 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1455052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerhuis R, Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8, 34&#x2013;58 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21143154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner AJ, Complement in Alzheimer&#x2019;s disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22, 849&#x2013;861 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11754992</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga S, Ikeda K, Sato M, Ishii T, Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 601, 88&#x2013;94 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8431789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, Shim DJ, Rodriguez-Rivera J, Taglialatela G, Jankowsky JL, Lu HC, Zheng H, NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer&#x2019;s disease. Neuron 85, 101&#x2013;115 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289109</ArticleId><ArticleId IdType="pubmed">25533482</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O&#x2019;Banion MK, Tenner AJ, Lemere CA, Duff K, Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer&#x2019;s disease. Am J Pathol 158, 1345&#x2013;1354 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan R, DeFilippis K, Van Nostrand WE, Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J Neuroinflammation 4, 22 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099424</ArticleId><ArticleId IdType="pubmed">17877807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ, Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer&#x2019;s disease. J Neurochem 106, 2080&#x2013;2092 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574638</ArticleId><ArticleId IdType="pubmed">18624920</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichwald J, Danner S, Wiederhold KH, Staufenbiel M, Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation 6, 35 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784442</ArticleId><ArticleId IdType="pubmed">19917141</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Veerhuis R, The role of complement and activated microglia in the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol Aging 17, 673&#x2013;680 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8892339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA, Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Abeta by microglia. Glia 60, 993&#x2013;1003 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA, Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28, 6333&#x2013;6341 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E, Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer&#x2019;s mice. Proc Natl Acad Sci U S A 99, 10837&#x2013;10842 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ, Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer&#x2019;s disease. J Neurosci 24, 6457&#x2013;6465 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ, Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer&#x2019;s disease. J Immunol 183, 1375&#x2013;1383 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067320</ArticleId><ArticleId IdType="pubmed">19561098</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM, Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891, 42&#x2013;53 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11164808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinknecht KR, Bedenk BT, Kaltwasser SF, Grunecker B, Yen YC, Czisch M, Wotjak CT, Hippocampus-dependent place learning enables spatial flexibility in C57BL6/N mice. Front Behav Neurosci 6, 87 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530747</ArticleId><ArticleId IdType="pubmed">23293591</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O&#x2019;Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T, Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging 21, 383&#x2013;421 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D, Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23, 5219&#x2013;5226 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741153</ArticleId><ArticleId IdType="pubmed">12832546</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Nanclares L, Merino-Serrais P, Gonzalez S, DeFelipe J, Synaptic changes in the dentate gyrus of APP/PS1 transgenic mice revealed by electron microscopy. J Neuropathol Exp Neurol 72, 386&#x2013;395 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678882</ArticleId><ArticleId IdType="pubmed">23584198</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Bach G, Soderman A, Jensen JL, Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice. Neurobiol Aging 30, 1756&#x2013;1776 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18336954</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai HH, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA, A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 33, 13460&#x2013;13474 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Filali M, Lalonde R, Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer&#x2019;s disease. Brain Res 1292, 93&#x2013;99 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19643098</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Alcazar M, Daborg J, Stokowska A, Wasling P, Bjorefeldt A, Kalm M, Zetterberg H, Carlstrom KE, Blomgren K, Ekdahl CT, Hanse E, Pekna M, Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3. Exp Neurol 253, 154&#x2013;164 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24378428</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Green KN, Inflammation in Alzheimer&#x2019;s disease: Lessons learned from microglia-depletion models. Brain Behav Immun, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218993</ArticleId><ArticleId IdType="pubmed">27395435</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, West BL, Green KN, Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain 139, 1265&#x2013;1281 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, Schetters ST, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holscher C, Perry VH, Gomez-Nicola D, Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain 139, 891&#x2013;907 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman SM, Kim BJ, Howell GR, Miller J, John SW, Wordinger RJ, Clark AF, C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. Mol Neurodegener 11, 24 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806521</ArticleId><ArticleId IdType="pubmed">27008854</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams PA, Tribble JR, Pepper KW, Cross SD, Morgan BP, Morgan JE, John SW, Howell GR, Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Mol Neurodegener 11, 26 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822272</ArticleId><ArticleId IdType="pubmed">27048300</ArticleId></ArticleIdList></Reference><Reference><Citation>Choucair-Jaafar N, Laporte V, Levy R, Poindron P, Lombard Y, Gies JP, Complement receptor 3 (CD11b/CD18) is implicated in the elimination of beta-amyloid peptides. Fundam Clin Pharmacol 25, 115&#x2013;122 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20199584</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL, Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, Ferrer I, DeFelipe J, Widespread changes in dendritic spines in a model of Alzheimer&#x2019;s disease. Cereb Cortex 19, 586&#x2013;592 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18632740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Verghese PB, Chakraborty C, Joung J, Hyman BT, Ulrich JD, Holtzman DM, Barres BA, Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A 113, 10186&#x2013;10191 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018780</ArticleId><ArticleId IdType="pubmed">27559087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H, Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer&#x2019;s Disease. J Neurosci 36, 577&#x2013;589 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710776</ArticleId><ArticleId IdType="pubmed">26758846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducruet AF, Zacharia BE, Sosunov SA, Gigante PR, Yeh ML, Gorski JW, Otten ML, Hwang RY, DeRosa PA, Hickman ZL, Sergot P, Connolly ES Jr., Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. PLoS One 7, e38664 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383680</ArticleId><ArticleId IdType="pubmed">22761695</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, Tenner AJ, A Commentary On: &#x201c;NFkappaB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer&#x2019;s Disease&#x201d;. A cautionary note regarding C3aR. Front Immunol 6, 220 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423305</ArticleId><ArticleId IdType="pubmed">25999955</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner M, Bach G, West MJ, Over expression of amyloid beta-protein reduces the number of neurons in the striatum of APPswe/PS1DeltaE9. Brain Res 1266, 87&#x2013;92 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19245800</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh ES, Savonenko AV, King JF, Fangmark Tucker SM, Rudow GL, Xu G, Borchelt DR, Troncoso JC, Amyloid precursor protein increases cortical neuron size in transgenic mice. Neurobiol Aging 30, 1238&#x2013;1244 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796369</ArticleId><ArticleId IdType="pubmed">18304698</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskerville KA, Kent C, Nicolle MM, Gallagher M, McKinney M, Aging causes partial loss of basal forebrain but no loss of pontine reticular cholinergic neurons. Neuroreport 17, 1819&#x2013;1823 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17164671</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Wang J, Yew DT, Lucy Forster E, Yao Z, Age-related alterations of Nestin-immunoreactive neurons in rat basal forebrain with aged memory deficit. Neurochem Int 53, 270&#x2013;277 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18805450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al., Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89, 10016&#x2013;10020 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Krafft GA, Holzman RB, Holzman TF, Complement C1q does not bind monomeric beta-amyloid. Exp Neurol 128, 136&#x2013;142 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8070518</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y, Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol 94, 316&#x2013;322 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9341931</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Glabe C, Rogers J, Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun 217, 869&#x2013;875 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8554610</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Holmes C, Microglial priming in neurodegenerative disease. Nat Rev Neurol 10, 217&#x2013;224 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodea LG, Wang Y, Linnartz-Gerlach B, Kopatz J, Sinkkonen L, Musgrove R, Kaoma T, Muller A, Vallar L, Di Monte DA, Balling R, Neumann H, Neurodegeneration by activation of the microglial complement-phagosome pathway. J Neurosci 34, 8546&#x2013;8556 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608212</ArticleId><ArticleId IdType="pubmed">24948809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, Huitinga I, Baas F, Neal JW, Morgan BP, C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A 109, 965&#x2013;970 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3271873</ArticleId><ArticleId IdType="pubmed">22219359</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF, Deficiency of complement receptors CR2/CR1 in Cr2(&#x2212;)/(&#x2212;) mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation 11, 95 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050415</ArticleId><ArticleId IdType="pubmed">24885042</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg A, Zelano J, Stephan A, Thams S, Barres BA, Pekny M, Pekna M, Cullheim S, Reduced removal of synaptic terminals from axotomized spinal motoneurons in the absence of complement C3. Exp Neurol 237, 8&#x2013;17 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22721768</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB, Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596&#x2013;1609 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD, Shen J, Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 279, 46907&#x2013;46914 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15345711</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Norstrom EM, Garbett K, Choi SH, Zhang X, Ebert P, Sisodia SS, Molecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice. Mol Neurodegener 3, 14 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569036</ArticleId><ArticleId IdType="pubmed">18834536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC, Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A 92, 11490&#x2013;11494 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40427</ArticleId><ArticleId IdType="pubmed">8524789</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordao JF, Thevenot E, Markham-Coultes K, Scarcelli T, Weng YQ, Xhima K, O&#x2019;Reilly M, Huang Y, McLaurin J, Hynynen K, Aubert I, Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol 248, 16&#x2013;29 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000699</ArticleId><ArticleId IdType="pubmed">23707300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ippolito DM, Eroglu C, Quantifying synapses: an immunocytochemistry-based assay to quantify synapse number. J Vis Exp, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159596</ArticleId><ArticleId IdType="pubmed">21113117</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819&#x2013;5824 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Gundersen HJ, Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296, 1&#x2013;22 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison HW, Filosa JA, A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J Neuroinflammation 10, 4 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570327</ArticleId><ArticleId IdType="pubmed">23311642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L, High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28562589</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>546</Volume><Issue>7657</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>RNA phase transitions in repeat expansion disorders.</ArticleTitle><Pagination><StartPage>243</StartPage><EndPage>247</EndPage><MedlinePgn>243-247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature22386</ELocationID><Abstract><AbstractText>Expansions of short nucleotide repeats produce several neurological and neuromuscular disorders including Huntington disease, muscular dystrophy, and amyotrophic lateral sclerosis. A common pathological feature of these diseases is the accumulation of the repeat-containing transcripts into aberrant foci in the nucleus. RNA foci, as well as the disease symptoms, only manifest above a critical number of nucleotide repeats, but the molecular mechanism governing foci formation above this characteristic threshold remains unresolved. Here we show that repeat expansions create templates for multivalent base-pairing, which causes purified RNA to undergo a sol-gel transition in vitro at a similar critical repeat number as observed in the diseases. In human cells, RNA foci form by phase separation of the repeat-containing RNA and can be dissolved by agents that disrupt RNA gelation in vitro. Analogous to protein aggregation disorders, our results suggest that the sequence-specific gelation of RNAs could be a contributing factor to neurological disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Ankur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute Summer Institute, Marine Biological Laboratory, Woods Hole, Massachusetts 02543, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vale</LastName><ForeName>Ronald D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute Summer Institute, Marine Biological Laboratory, Woods Hole, Massachusetts 02543, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM038499</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Jun 8;546(7657):215-216. doi: 10.1038/nature22503.</RefSource><PMID Version="1">28562583</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2017 Aug;18(8):454-455. doi: 10.1038/nrg.2017.54.</RefSource><PMID Version="1">28649133</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Cell Biol. 2017 Aug 7;216(8):2235-2237. doi: 10.1083/jcb.201706034.</RefSource><PMID Version="1">28667121</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Chem Biol. 2017 Jul 18;13(8):817. doi: 10.1038/nchembio.2444.</RefSource><PMID Version="1">28853737</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020029" MajorTopicYN="Y">Base Pairing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044367" MajorTopicYN="Y">Phase Transition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013698" MajorTopicYN="N">Templates, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="Y">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28562589</ArticleId><ArticleId IdType="mid">NIHMS871040</ArticleId><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="doi">10.1038/nature22386</ArticleId><ArticleId IdType="pii">nature22386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005;6:743&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">16205714</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet. 2010;11:247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4704680</ArticleId><ArticleId IdType="pubmed">20177426</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzyzosiak WJ, et al. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res. 2012;40:11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245940</ArticleId><ArticleId IdType="pubmed">21908410</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, McMurray CT. Trinucleotide expansion in disease: why is there a length threshold? Curr Opin Genet Dev. 2014;26:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252851</ArticleId><ArticleId IdType="pubmed">25282113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, et al. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankodi A, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000;289:1769&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">10976074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron. 2003;39:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948442</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA. 2011;108:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JD, Ranum LPW. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet. 2013;22:R45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782068</ArticleId><ArticleId IdType="pubmed">23918658</ArticleId></ArticleIdList></Reference><Reference><Citation>Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128:995&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120416</ArticleId><ArticleId IdType="pubmed">7896884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojciechowska M, Krzyzosiak WJ. Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet. 2011;20:3811&#x2013;3821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168290</ArticleId><ArticleId IdType="pubmed">21729883</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC302046</ArticleId><ArticleId IdType="pubmed">10970838</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5:345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Timchenko NA, et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001;276:7820&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124939</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 2010;67:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852186</ArticleId><ArticleId IdType="pubmed">20373340</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Gendron TF, Petrucelli L. RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci. 2013;56:406&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791208</ArticleId><ArticleId IdType="pubmed">23280309</ArticleId></ArticleIdList></Reference><Reference><Citation>Flory PJ. Principles of Polymer Chemistry. Cornell University Press; 1953.</Citation></Reference><Reference><Citation>Li P, et al. Phase transitions in the assembly of multivalent signalling proteins. Nature. 2012;483:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343696</ArticleId><ArticleId IdType="pubmed">22398450</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockmayer WH. Theory of Molecular Size Distribution and Gel Formation in Branched Polymers II. General Cross Linking. The Journal of Chemical Physics. 1944;12:125&#x2013;131.</Citation></Reference><Reference><Citation>Semenov AN, Rubinstein M. Thermoreversible gelation in solutions of associative polymers. 1. Statics. Macromolecules. 1998;31:1373&#x2013;1385.</Citation></Reference><Reference><Citation>Falkenberg CV, Blinov ML, Loew LM. Pleomorphic ensembles: formation of large clusters composed of weakly interacting multivalent molecules. Biophys J. 2013;105:2451&#x2013;2460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853317</ArticleId><ArticleId IdType="pubmed">24314076</ArticleId></ArticleIdList></Reference><Reference><Citation>Aumiller WM, Keating CD. Phosphorylation-mediated RNA/peptide complex coacervation as a model for intracellular liquid organelles. Nat Chem. 2016;8:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">26791895</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RG. The Structure and Rheology of Complex Fluids. Oxford University Press; 1999.</Citation></Reference><Reference><Citation>Bertrand E, et al. Localization of ASH1 mRNA particles in living yeast. Molecular Cell. 1998;2:437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearse MG, et al. CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins. Molecular Cell. 2016;62:314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854189</ArticleId><ArticleId IdType="pubmed">27041225</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne CP, et al. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science. 2009;324:1729&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">19460965</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanek MO, Jazurek M, Switonski PM, Figura G, Krzyzosiak WJ. Nuclear speckles are detention centers for transcripts containing expanded CAG repeats. Biochim Biophys Acta. 2016;1862:1513&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">27239700</ArticleId></ArticleIdList></Reference><Reference><Citation>Spector DL, Lamond AI. Nuclear speckles. Cold Spring Harb Perspect Biol. 2011;3:a000646&#x2013;a000646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039535</ArticleId><ArticleId IdType="pubmed">20926517</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LB, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature. 2008;453:1107&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574630</ArticleId><ArticleId IdType="pubmed">18449188</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods. 2008;5:877&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126653</ArticleId><ArticleId IdType="pubmed">18806792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi MS, Watanabe K, Hamaguchi Y. Regulation of intracellular pH in sea urchin eggs by medium containing both weak acid and base. Cell Struct Funct. 1997;22:387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9368712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick CA, et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990;29:2538&#x2013;2549.</Citation><ArticleIdList><ArticleId IdType="pubmed">2334681</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SYR, Macgregor RB, Pearson CE. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem. 2013;288:9860&#x2013;9866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JU, Bartel DP. RNA G-quadruplexes are globally unfolded in eukaryotic cells and depleted in bacteria. Science. 2016;353:aaf5371&#x2013;aaf5371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5367264</ArticleId><ArticleId IdType="pubmed">27708011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman AA, Weber CA, J&#xfc;licher F. Liquid-liquid phase separation in biology. Annu Rev Cell Dev Biol. 2014;30:39&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25288112</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes SE, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet. 2001;29:377&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694876</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoi H, Lau TCK, Tsang SY, Lau KF, Chan HYE. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc Natl Acad Sci USA. 2012;109:13428&#x2013;13433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421186</ArticleId><ArticleId IdType="pubmed">22847428</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Scior A, Preissler S, Koch M, Deuerling E. Directed PCR-free engineering of highly repetitive DNA sequences. BMC Biotechnol. 2011;11:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187725</ArticleId><ArticleId IdType="pubmed">21943395</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, et al. Probing cellular protein complexes using single-molecule pull-down. Nature. 2011;473:484&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103084</ArticleId><ArticleId IdType="pubmed">21614075</ArticleId></ArticleIdList></Reference><Reference><Citation>Shav-Tal Y, et al. Dynamics of single mRNPs in nuclei of living cells. Science. 2004;304:1797&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765737</ArticleId><ArticleId IdType="pubmed">15205532</ArticleId></ArticleIdList></Reference><Reference><Citation>Phair RD, Gorski SA, Misteli T. Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. Meth Enzymol. 2004;375:393&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">14870680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28521131</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures.</ArticleTitle><Pagination><StartPage>759</StartPage><EndPage>773.e8</EndPage><MedlinePgn>759-773.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.04.043</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30400-2</ELocationID><Abstract><AbstractText>Microglia, the resident macrophages of the CNS, engage in various CNS-specific functions that are critical for development and health. To better study microglia and the properties that distinguish them from other tissue macrophage populations, we have optimized serum-free culture conditions to permit robust survival of highly ramified adult microglia under defined-medium conditions. We find that&#xa0;astrocyte-derived factors prevent microglial death ex&#xa0;vivo and that this activity results from three primary components, CSF-1/IL-34, TGF-&#x3b2;2, and cholesterol. Using microglial cultures that have never been exposed to serum, we demonstrate a dramatic and lasting change in phagocytic capacity after serum exposure. Finally, we find that mature microglia rapidly lose signature gene expression after isolation, and that this loss can be reversed by engrafting cells back into an intact CNS environment.&#xa0;These data indicate that the specialized gene expression profile of mature microglia requires continuous instructive signaling from the intact CNS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bohlen</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: cjbohlen@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>F Chris</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Hannah Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulinyawe</LastName><ForeName>Sara B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 MH112120</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA015043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DA015043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019938</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509041">TGFB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053781">Transforming Growth Factor beta2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552364">interleukin-34, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053781" MajorTopicYN="N">Transforming Growth Factor beta2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">TGF-&#x3b2;</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">maturation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">transplant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28521131</ArticleId><ArticleId IdType="mid">NIHMS873935</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pii">S0896-6273(17)30400-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Eberhard C, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 2016;44:W3&#x2013;W10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987906</ArticleId><ArticleId IdType="pubmed">27137889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA, Schmid R, Sendnter M, Raff MC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development. 1993;118:283&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">8375338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A. 2016;113:E1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci. 2014;15:209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N, Klein M, Blank T, Yona S, Wolf Y, et al. Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System. Immunity. 2015;43:92&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, Nishinakamura R, Becher B, Greter M. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Jalabi W, Shpargel KB, Farabaugh KT, Dutta R, Yin X, Kidd GJ, Bergmann CC, Stohlman SA, Trapp BD. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci. 2012;32:11706&#x2013;11715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461442</ArticleId><ArticleId IdType="pubmed">22915113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O&#x2019;Keeffe S, Phatnani HP, Muratet M, Carroll MC, Levy S, Tavazoie S, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756160</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (&#x2212;/&#x2212;), and human apoE transgenic mice. J Biol Chem. 1999;274:30001&#x2013;30007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo LC, Allen NJ, Bushong EA, Ventura PB, Chung WS, Zhou L, Cahoy JD, Daneman R, Zong H, Ellisman MH, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron. 2011;71:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172573</ArticleId><ArticleId IdType="pubmed">21903074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, Traves PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zagorska A, Rothlin CV, Nimmerjahn A, et al. TAM receptors regulate multiple features of microglial physiology. Nature. 2016;532:240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SA, Grinstein S. Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunol Rev. 2014;262:193&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">25319336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13:1118&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558276</ArticleId><ArticleId IdType="pubmed">23023392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentek R, Molawi K, Sieweke MH. Tissue macrophage identity and self-renewal. Immunol Rev. 2014;262:56&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25319327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Guilliams M. Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016;44:439&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">26982352</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S, Pluddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev. 2014;262:36&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4231239</ArticleId><ArticleId IdType="pubmed">25319326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh AD, David S. Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci. 2014;34:6316&#x2013;6322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608120</ArticleId><ArticleId IdType="pubmed">24790202</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, Kundig TM, Frei K, Ginhoux F, Merad M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity. 2012;37:1050&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291117</ArticleId><ArticleId IdType="pubmed">23177320</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9:1512&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoosein NM, Brattain DE, McKnight MK, Brattain MG. Comparison of the effects of transforming growth factor beta, N,N-dimethylformamide, and retinoic acid on transformed and nontransformed fibroblasts. Exp Cell Res. 1988;175:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">3162213</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, Riemke P, Holscher C, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655817</ArticleId><ArticleId IdType="pubmed">25751142</ArticleId></ArticleIdList></Reference><Reference><Citation>Koso H, Tsuhako A, Lai CY, Baba Y, Otsu M, Ueno K, Nagasaki M, Suzuki Y, Watanabe S. Conditional rod photoreceptor ablation reveals Sall1 as a microglial marker and regulator of microglial morphology in the retina. Glia 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27459098</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>Larocca JN, Norton WT. Isolation of myelin. Curr Protoc Cell Biol. 2007;Chapter 3(Unit 3&#x2013;25)</Citation><ArticleIdList><ArticleId IdType="pubmed">18228513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol. 2015;15:731&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706379</ArticleId><ArticleId IdType="pubmed">26603899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Tse W, Smith JD, Landreth GE. Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem. 2012;287:2032&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265883</ArticleId><ArticleId IdType="pubmed">22130662</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551245</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Brosnan CF, Dickson DW, Lee SC. Macrophage colony-stimulating factor mediates astrocyte-induced microglial ramification in human fetal central nervous system culture. Am J Pathol. 1994;145:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887299</ArticleId><ArticleId IdType="pubmed">8030755</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F, et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell. 2016;165:921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuch A, van der Pijl R, Funer L, Wolf Y, Eggen B, Boddeke E, Biber K. Microglia replenished OHSC: A culture system to study in vivo like adult microglia. Glia. 2016;64:1285&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">27145902</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353:aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser DM, Zhang X. Measuring opsonic phagocytosis via Fcgamma receptors and complement receptors on macrophages. Curr Protoc Immunol. 2011;Chapter 14(Unit 14&#x2013;27)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465686</ArticleId><ArticleId IdType="pubmed">22048802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller TD, Nickel J. Promiscuity and specificity in BMP receptor activation. FEBS Lett. 2012;586:1846&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell. 2014;157:832&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137874</ArticleId><ArticleId IdType="pubmed">24792964</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res. 2011;50:357&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741992</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">24385147</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabani M, Raychowdhury R, Jovanovic M, Rooney M, Stumpo DJ, Pauli A, Hacohen N, Schier AF, Blackshear PJ, Friedman N, et al. High-resolution sequencing and modeling identifies distinct dynamic RNA regulatory strategies. Cell. 2014;159:1698&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272607</ArticleId><ArticleId IdType="pubmed">25497548</ArticleId></ArticleIdList></Reference><Reference><Citation>Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983;303:390&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">6304520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, Kannaiyan N, Snaidero N, Brioschi S, Biber K, Yona S, Edinger AL, Jung S, Rossner MJ, Simons M. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat Neurosci. 2016;19:995&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Salimi K, Moser KV, Marksteiner J, Reindl M, Humpel C. GDNF and TGF-beta1 promote cell survival in serum-free cultures of primary rat microglia. Cell Tissue Res. 2003;312:135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12712323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato JD, Kan M. Media for culture of mammalian cells. Curr Protoc Cell Biol. 2001;Chapter 1(Unit 1&#x2013;2)</Citation><ArticleIdList><ArticleId IdType="pubmed">18228290</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling M, Besselmann M, Muller M, Strecker JK, Ringelstein EB, Kiefer R. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol. 2005;196:290&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153641</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling T, Nitsch R, Heinemann U, Haas D, Eder C. Astrocyte-released cytokines induce ramification and outward K+ channel expression in microglia via distinct signalling pathways. Eur J Neurosci. 2001;14:463&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers J, Parwaresch R, Wottge HU. Blood monocytes and spleen macrophages differentiate into microglia-like cells on monolayers of astrocytes: morphology. Glia. 1994;12:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890329</ArticleId></ArticleIdList></Reference><Reference><Citation>Stansley B, Post J, Hensley K. A comparative review of cell culture systems for the study of microglial biology in Alzheimer&#x2019;s disease. J Neuroinflammation. 2012;9:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407712</ArticleId><ArticleId IdType="pubmed">22651808</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: aknowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka J, Maeda N. Microglial ramification requires nondiffusible factors derived from astrocytes. Exp Neurol. 1996;137:367&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635553</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146043</ArticleId><ArticleId IdType="pubmed">20436464</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinder PK, Faust D, Petry F, Loos M. Modulation of mRNA expression and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: evidence for the partial involvement of a pathway that includes cyclooxygenase, prostaglandin E2 and adenylate cyclase. Immunology. 1995;84:638&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415162</ArticleId><ArticleId IdType="pubmed">7790039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng Q, Duchemin-Pelletier E, Deshiere A, Balland M, Guillou H, Filhol O, Thery M. Spatial organization of the extracellular matrix regulates cell-cell junction positioning. Proc Natl Acad Sci U S A. 2012;109:1506&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277177</ArticleId><ArticleId IdType="pubmed">22307605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu Rev Neurosci. 2007;30:153&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">17506644</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A, Yu J, Perez-Torres C, Frouin A, Wilton DK, et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016;534:538&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452615</ArticleId><ArticleId IdType="pubmed">27337340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, Williams LT, Lin H, Stanley ER. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010;88:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924605</ArticleId><ArticleId IdType="pubmed">20504948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes PD, Sayed FA, Bard F, Gan L. Targeting microglia for the treatment of Alzheimer&#x2019;s Disease. Glia. 2016;64:1710&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">27100611</ArticleId></ArticleIdList></Reference><Reference><Citation>Witmer-Pack MD, Hughes DA, Schuler G, Lawson L, McWilliam A, Inaba K, Steinman RM, Gordon S. Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse. J Cell Sci. 1993;104(Pt 4):1021&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314887</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting A, Moller T. Microglia cell culture: a primer for the novice. Methods Mol Biol. 2011;758:49&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">21815058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28546318</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>356</Volume><Issue>6344</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>An environment-dependent transcriptional network specifies human microglia identity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaal3222</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aal3222</ELocationID><Abstract><AbstractText>Microglia play essential roles in central nervous system (CNS) homeostasis and influence diverse aspects of neuronal function. However, the transcriptional mechanisms that specify human microglia phenotypes are largely unknown. We examined the transcriptomes and epigenetic landscapes of human microglia isolated from surgically resected brain tissue ex vivo and after transition to an in vitro environment. Transfer to a tissue culture environment resulted in rapid and extensive down-regulation of microglia-specific genes that were induced in primitive mouse macrophages after migration into the fetal brain. Substantial subsets of these genes exhibited altered expression in neurodegenerative and behavioral diseases and were associated with noncoding risk variants. These findings reveal an environment-dependent transcriptional network specifying microglia-specific programs of gene expression and facilitate efforts to understand the roles of microglia in human brain diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gosselin</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5327-2868</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skola</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3655-1643</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coufal</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0001-6547-1733</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtman</LastName><ForeName>Inge R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials><Identifier Source="ORCID">0000-0002-7801-9743</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajti</LastName><ForeName>Eniko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaeger</LastName><ForeName>Baptiste N</ForeName><Initials>BN</Initials><Identifier Source="ORCID">0000-0001-8728-797X</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3301-7912</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Conor</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasillas</LastName><ForeName>Martina P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-9337-0136</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pena</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adair</LastName><ForeName>Amy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2952-7987</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonda</LastName><ForeName>David D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0002-4681-7337</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California, San Diego-Rady Children's Hospital, San Diego, CA 92123, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0001-7545-8620</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California, San Diego-Rady Children's Hospital, San Diego, CA 92123, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-0175-6910</Identifier><AffiliationInfo><Affiliation>Neuroimmunology, Biogen, 225 Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><Identifier Source="ORCID">0000-0002-0938-4106</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037-1002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0003-4344-3592</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA. ckg@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK063491</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>T32 DK007541</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 GM085764</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA014195</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2017 Aug;18(8):454-455. doi: 10.1038/nrg.2017.55.</RefSource><PMID Version="1">28669982</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="Y">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28546318</ArticleId><ArticleId IdType="mid">NIHMS948147</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pii">science.aal3222</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009;9:429&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">19461673</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumoto A, Lu H, Miranda AS, Ransohoff RM. Ontogeny and functions of central nervous system macrophages. J Immunol. 2014;193:2615&#x2013;2621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157312</ArticleId><ArticleId IdType="pubmed">25193935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemer A, Erny D, Jung S, Prinz M. Microglia Plasticity During Health and Disease: An Immunological Perspective. Trends Immunol. 2015;36:614&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">26431939</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Stevens B. Microglia Function in Central Nervous System Development and Plasticity. Cold Spring Harb Perspect Biol. 2015;7:a020545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588063</ArticleId><ArticleId IdType="pubmed">26187728</ArticleId></ArticleIdList></Reference><Reference><Citation>Casano AM, Peri F. Microglia: multitasking specialists of the brain. Dev Cell. 2015;32:469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">25710533</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Jay TR, Landreth GE. The evolving biology of microglia in Alzheimer's disease. Neurotherapeutics. 2015;12:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322081</ArticleId><ArticleId IdType="pubmed">25404051</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki NC, Katzmarski N, Kipnis J, Meyer-Luehmann M. Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathol. 2014;128:333&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131160</ArticleId><ArticleId IdType="pubmed">25056803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">22166438</ArticleId></ArticleIdList></Reference><Reference><Citation>Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177985</ArticleId><ArticleId IdType="pubmed">15935098</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology. 2012;62:2154&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pubmed">22361232</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754279</ArticleId><ArticleId IdType="pubmed">19345186</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113004</ArticleId><ArticleId IdType="pubmed">24584051</ArticleId></ArticleIdList></Reference><Reference><Citation>Politis M, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 2011;32:258&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870088</ArticleId><ArticleId IdType="pubmed">21229614</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai YF, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007;130:1759&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilimoria PM, Stevens B. Microglia function during brain development: New insights from animal models. Brain Res. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">25463024</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol. 2013;2013:608654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652125</ArticleId><ArticleId IdType="pubmed">23690824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM, et al. The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia. 2013;61:929&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">23483680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier EL, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13:1118&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558276</ArticleId><ArticleId IdType="pubmed">23023392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol. 2015;16:144&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517609</ArticleId><ArticleId IdType="pubmed">25650801</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular cell. 2010;38:576&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, et al. Effect of natural genetic variation on enhancer selection and function. Nature. 2013;503:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994126</ArticleId><ArticleId IdType="pubmed">24121437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaikkonen MU, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Molecular cell. 2013;51:310&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779836</ArticleId><ArticleId IdType="pubmed">23932714</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Roadmap Epigenomics et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanoski CE, Glass CK, Stunnenberg HG, Wilson L, Almouzni G. Epigenomics: Roadmap for regulation. Nature. 2015;518:314&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">25693562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasowski M, et al. Extensive variation in chromatin states across humans. Science. 2013;342:750&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075767</ArticleId><ArticleId IdType="pubmed">24136358</ArticleId></ArticleIdList></Reference><Reference><Citation>McVicker G, et al. Identification of genetic variants that affect histone modifications in human cells. Science. 2013;342:747&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947669</ArticleId><ArticleId IdType="pubmed">24136359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpinen H, et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science. 2013;342:744&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502466</ArticleId><ArticleId IdType="pubmed">24136355</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramopoulos D, Szymanski M, Wang R, Bassett S. Gene expression reveals overlap between normal aging and Alzheimer's disease genes. Neurobiol Aging. 2011;32:2319, e2327&#x2013;2334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945399</ArticleId><ArticleId IdType="pubmed">20570407</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Capurro A, Bodea LG, Schaefer P, Luthi-Carter R, Perreau VM. Computational deconvolution of genome wide expression data from Parkinson's and Huntington's disease brain tissues using population-specific expression analysis. Front Neurosci. 2014;8:441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288238</ArticleId><ArticleId IdType="pubmed">25620908</ArticleId></ArticleIdList></Reference><Reference><Citation>Colangelo V, et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 2002;70:462&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391607</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics. 2008;33:240&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826117</ArticleId><ArticleId IdType="pubmed">18270320</ArticleId></ArticleIdList></Reference><Reference><Citation>McClintick JN, et al. Ethanol treatment of lymphoblastoid cell lines from alcoholics and non-alcoholics causes many subtle changes in gene expression. Alcohol. 2014;48:603&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730944</ArticleId><ArticleId IdType="pubmed">25129674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, et al. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007;114:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569064</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, Yamamoto Y, Asahina N, Kitano S, Kino Y. RNA-Seq data mining: downregulation of NeuroD6 serves as a possible biomarker for alzheimer's disease brains. Dis Markers. 2014;2014:123165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4274867</ArticleId><ArticleId IdType="pubmed">25548427</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Borjabad A, et al. Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog. 2011;7:e1002213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164642</ArticleId><ArticleId IdType="pubmed">21909266</ArticleId></ArticleIdList></Reference><Reference><Citation>Maycox PR, et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry. 2009;14:1083&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">19255580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley BE, et al. Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PLoS One. 2014;9:e102909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149353</ArticleId><ArticleId IdType="pubmed">25170892</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, et al. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet. 2008;17:1349&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900863</ArticleId><ArticleId IdType="pubmed">18223198</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S, Geschwind DH. Genes and pathways underlying regional and cell type changes in Alzheimer's disease. Genome Med. 2013;5:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic acids research. 2014;42:D1001&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns TC, Li MD, Mehta S, Awad AJ, Morgan AA. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models. Eur J Pharmacol. 2015;759:101&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">25814260</ArticleId></ArticleIdList></Reference><Reference><Citation>Mass E, et al. Specification of tissue-resident macrophages during organogenesis. Science. 2016;353</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5066309</ArticleId><ArticleId IdType="pubmed">27492475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature genetics. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte WA, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653129</ArticleId><ArticleId IdType="pubmed">23582322</ArticleId></ArticleIdList></Reference><Reference><Citation>Loven J, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760967</ArticleId><ArticleId IdType="pubmed">23582323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hnisz D, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3841062</ArticleId><ArticleId IdType="pubmed">24119843</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353:aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit A, et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22:1358&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. An optimized protocol for the acute isolation of human microglia from autopsy brain samples. Glia. 2012;60:96&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 2012;9:357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J, Passos A, Cournapeau D, Brucher M, Perrot M, Duchesnay E. Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research. 2011;12:2825&#x2013;2830.</Citation></Reference><Reference><Citation>Tripathi S, et al. Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. Cell Host Microbe. 2015;18:723&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829074</ArticleId><ArticleId IdType="pubmed">26651948</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen R, Sugawara H, Shumway M. C. International Nucleotide Sequence Database, The sequence read archive. Nucleic acids research. 2011;39:D19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013647</ArticleId><ArticleId IdType="pubmed">21062823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Guo Y, Sheng Q, Shyr Y. Advanced heat map and clustering analysis using heatmap3. Biomed Res Int. 2014;2014:986048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124803</ArticleId><ArticleId IdType="pubmed">25143956</ArticleId></ArticleIdList></Reference><Reference><Citation>Whickam H. Ggplot2 : elegant graphics for data analysis. Springer. 2009</Citation></Reference><Reference><Citation>M. Developers, matplotlib: v1.5.3 [Data set] Zenodo; 2016.</Citation></Reference><Reference><Citation>Kent WJ, et al. The human genome browser at UCSC. Genome Res. 2002;12:996&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186604</ArticleId><ArticleId IdType="pubmed">12045153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28591569</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's Disease &#x3b3;-Secretase Generates Higher 42:40 Ratios for &#x3b2;-Amyloid Than for p3 Peptides.</ArticleTitle><Pagination><StartPage>1967</StartPage><EndPage>1976</EndPage><MedlinePgn>1967-1976</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.05.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)30676-9</ELocationID><Abstract><AbstractText>Alzheimer's disease is characterized by intracerebral deposition of &#x3b2;-amyloid (A&#x3b2;). While A&#x3b2;<sub>40</sub> is the most abundant form, neurotoxicity is mainly mediated by&#xa0;A&#x3b2;<sub>42</sub>. Sequential cleavage of amyloid precursor protein (APP) by &#x3b2;- and &#x3b3;-secretases gives rise to full-length A&#x3b2; (A&#x3b2;<sub>1-x</sub>) and N-terminally truncated A&#x3b2;' (A&#x3b2;<sub>11-x</sub>) whereas cleavage by &#x3b1;- and &#x3b3;-secretases leads to the shorter p3 peptides (A&#x3b2;<sub>17-x</sub>). We uncovered significantly higher ratios of 42- versus 40-ending variants for A&#x3b2; and A&#x3b2;' than for p3 secreted by mouse neurons and human induced pluripotent stem cell (iPSC)-derived neurons or produced in a cell-free &#x3b3;-secretase assay with recombinant APP-CTFs. The 42:40 ratio was highest for A&#x3b2;', followed by A&#x3b2; and then p3. Mass spectrometry analysis of&#xa0;APP intracellular domains revealed differential processing of APP-C83, APP-C89, and APP-C99 by &#x3b3;-secretase already at the &#x3b5;-cleavage stage. This mechanistic insight could aid in developing substrate-targeted modulators of APP-C99 processing to specifically lower the A&#x3b2;<sub>42</sub>:A&#x3b2;<sub>40</sub> ratio without compromising &#x3b3;-secretase function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren Campus, 8952 Schlieren, Switzerland. Electronic address: gabriele.siegel@irem.uzh.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Hermeto</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Foundation Eclosion, 1228 Plan-les-Ouates &amp; Campus Biotech Innovation Park, 1202 Geneva, Switzerland; Brain Mind Institute and School of Life Sciences, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland; Department of Biology, University of Fribourg, 1700 Fribourg, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Reconstructive Neurobiology, University of Bonn Medical Faculty, 53127 Bonn, Germany; LIFE &amp; BRAIN GmbH, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruestle</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Reconstructive Neurobiology, University of Bonn Medical Faculty, 53127 Bonn, Germany; LIFE &amp; BRAIN GmbH, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraering</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Foundation Eclosion, 1228 Plan-les-Ouates &amp; Campus Biotech Innovation Park, 1202 Geneva, Switzerland; Brain Mind Institute and School of Life Sciences, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren Campus, 8952 Schlieren, Switzerland. Electronic address: rajendran@bli.uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100690">amyloid beta-protein p3, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AICD</Keyword><Keyword MajorTopicYN="N">APP CTF</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">amyloidogenic pathway</Keyword><Keyword MajorTopicYN="N">beta-Amyloid</Keyword><Keyword MajorTopicYN="N">gamma-secretase</Keyword><Keyword MajorTopicYN="N">iPS cells</Keyword><Keyword MajorTopicYN="N">p3 peptide</Keyword><Keyword MajorTopicYN="N">primary neurons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28591569</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.05.034</ArticleId><ArticleId IdType="pii">S2211-1247(17)30676-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28587718</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Amyloid Precursor Protein Intracellular Domain Controls Mitochondrial Function by Modulating Phosphatase and Tensin Homolog-Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models.</ArticleTitle><Pagination><StartPage>416</StartPage><EndPage>427</EndPage><MedlinePgn>416-427</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2017.04.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(17)31515-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mitophagy and mitochondrial dynamics alterations are two major hallmarks of neurodegenerative diseases. Dysfunctional mitochondria accumulate in Alzheimer's disease-affected brains by yet unexplained mechanisms.</AbstractText><AbstractText Label="METHODS">We combined cell biology, molecular biology, and pharmacological approaches to unravel a novel molecular pathway by which presenilins control phosphatase and tensin homolog-induced kinase 1 (Pink-1) expression and transcription. In&#xa0;vivo approaches were carried out on various transgenic and knockout animals as well as in adeno-associated virus-infected mice. Functional readout and mitochondrial physiology (mitochondrial potential) were assessed by combined procedures including flow cytometry, live imaging analysis, and immunohistochemistry.</AbstractText><AbstractText Label="RESULTS">We show that presenilins 1 and 2 trigger opposite effects on promoter transactivation, messenger RNA, and protein expression of Pink-1. This control is linked to &#x3b3;-secretase activity and &#x3b2;-amyloid precursor protein but is independent of phosphatase and tensin homolog. We show that amyloid precursor protein intracellular domain (AICD) accounts for presenilin-dependent phenotype and upregulates Pink-1 transactivation in cells as well as in&#xa0;vivo in a Forkhead box O3a-dependent manner. Interestingly, the modulation of &#x3b3;-secretase activity or AICD expression affects Pink-1-related control of mitophagy and mitochondrial dynamics. Finally, we show that parkin acts upstream of presenilins to control Pink-1 promoter transactivation and protein expression.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, we delineate a molecular cascade presenilins-AICD-Forkhead box O3a linking parkin to Pink-1. Our study demonstrates AICD-mediated Pink-1-dependent control of mitochondrial physiology by presenilins. Furthermore, it unravels a parkin-Pink-1 feedback loop controlling mitochondrial physiology that could be disrupted in neurodegenerative conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goiran</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duplan</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chami</LastName><ForeName>Mounia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Manaa</LastName><ForeName>Wejdane</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouland</LastName><ForeName>Lila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunys</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauritzen</LastName><ForeName>Inger</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stambolic</LastName><ForeName>Vuk</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Princess Margaret Center, University Health Network and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bif&#xe9;ri</LastName><ForeName>Maria-Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Center of Research on Myology, Pierre and Marie Curie University, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkats</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Research on Myology, Pierre and Marie Curie University, CNRS, INSERM, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pimplikar</LastName><ForeName>Sanjay W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sergeant</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer &amp; Taopathies, Jean-Pierre Aubert Research Centre, Facult&#xe9; de M&#xe9;decine, L'Institut de M&#xe9;decine Pr&#xe9;dictive et de Recherche Th&#xe9;rapeutique, INSERM, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colin</LastName><ForeName>Morvane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer &amp; Taopathies, Jean-Pierre Aubert Research Centre, Facult&#xe9; de M&#xe9;decine, L'Institut de M&#xe9;decine Pr&#xe9;dictive et de Recherche Th&#xe9;rapeutique, INSERM, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morais</LastName><ForeName>Vanessa A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardossi-Piquard</LastName><ForeName>Raphaelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Checler</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves da Costa</LastName><ForeName>Cristine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut de Pharmacologie Mol&#xe9;culaire et Cellulaire, Universit&#xe9; C&#xf4;te d'Azur, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Valbonne, France. Electronic address: acosta@ipmc.cnrs.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071316">Forkhead Box Protein O3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474033">FoxO3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Biol Psychiatry. 2023 Feb 1;93(3):291-292. doi: 10.1016/j.biopsych.2022.11.015.</RefSource><PMID Version="1">36567088</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071316" MajorTopicYN="N">Forkhead Box Protein O3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042541" MajorTopicYN="N">Intracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3xTgAD Mice</Keyword><Keyword MajorTopicYN="N">AICD</Keyword><Keyword MajorTopicYN="N">FOXO3a</Keyword><Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">Mitophagy</Keyword><Keyword MajorTopicYN="N">Parkin</Keyword><Keyword MajorTopicYN="N">Pink-1</Keyword><Keyword MajorTopicYN="N">Presenilins</Keyword><Keyword MajorTopicYN="N">&#x3b3;-Secretase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28587718</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2017.04.011</ArticleId><ArticleId IdType="pii">S0006-3223(17)31515-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28590010</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.</ArticleTitle><Pagination><StartPage>1969</StartPage><EndPage>1974</EndPage><MedlinePgn>1969-1974</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.14956</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the risk associated with the use of proton pump inhibitors (PPIs) of conversion to mild cognitive impairment (MCI), dementia, and specifically Alzheimer's disease (AD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Observational, longitudinal study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary academic Alzheimer's Disease Centers funded by the National Institute on Aging.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Research volunteers aged 50 and older with two to six annual visits; 884 were taking PPIs at every visit, 1,925 took PPIs intermittently, and 7,677 never reported taking PPIs. All had baseline normal cognition or MCI.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Multivariable Cox regression analyses evaluated the association between PPI use and annual conversion of baseline normal cognition to MCI or dementia or annual conversion of baseline MCI to dementia, controlling for demographic characteristics, vascular comorbidities, mood, and use of anticholinergics and histamine-2 receptor antagonists.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Continuous (always vs never) PPI use was associated with lower risk of decline in cognitive function (hazard ratio (HR) = 0.78, 95% confidence interval (CI) =0.66-0.93, P = .005) and lower risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.69-0.98, P = .03). Intermittent use was also associated with lower risk of decline in cognitive function (HR = 0.84, 95% CI = 0.76-0.93, P = .001) and risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.74-0.91, P = .001). This lower risk was found for persons with normal cognition or MCI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Proton pump inhibitors were not associated with greater risk of dementia or of AD, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data. Prospective studies are needed to confirm these results to guide empirically based clinical treatment recommendations.</AbstractText><CopyrightInformation>&#xa9; 2017, Copyright the Authors Journal compilation &#xa9; 2017, The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Felicia C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenland</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, School of Public Health, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Whitney</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Ihab</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Geriatr Soc. 2018 Sep;66(9):1850. doi: 10.1111/jgs.15498.</RefSource><PMID Version="1">30094827</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Am Geriatr Soc. 2018 Sep;66(9):1848-1850. doi: 10.1111/jgs.15474.</RefSource><PMID Version="1">30094831</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">cognitive functioning</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">proton pump inhibitors</Keyword></KeywordList><CoiStatement>Conflict of Interest Disclosures: The authors have no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28590010</ArticleId><ArticleId IdType="mid">NIHMS937501</ArticleId><ArticleId IdType="pmc">PMC5797939</ArticleId><ArticleId IdType="doi">10.1111/jgs.14956</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomm W, Von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurology. 2016;73(4):410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">26882076</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience. 2015;265:419&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">25341874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaudig M, Hiller W. SIDAM &#x2013; Strukturiertes Interview f&#xfc;r die Diagnose einer Demenz vom Alzheimer Typ, der Multi-Infarkt-(oder vaskul&#xe4;ren) Demenz und Demenzen anderer &#xc4;tiologie nach DSM-III-R, DSM-IV und ICD-10 (SIDAM-Handbuch) Huber, Bern. 1996</Citation></Reference><Reference><Citation>Kuller LH. Do proton pump inhibitors increase the risk of dementia? JAMA Neurology. 2016;73(4):379&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">26882528</ArticleId></ArticleIdList></Reference><Reference><Citation>Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. International Psychogeriatrics. 2016;28(7):1059&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">26744954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999&#x2013;2012. The Journal of the American Medical Association. 2015;314(17):1818&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752169</ArticleId><ArticleId IdType="pubmed">26529160</ArticleId></ArticleIdList></Reference><Reference><Citation>Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. Journal of the American Geriatrics Society. 2007;55:1248&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860609</ArticleId><ArticleId IdType="pubmed">17661965</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, van Belle G, et al. The National Alzheimer&#x2019;s Coordinating Center (NACC) Database. Alzheimer Disease and Associated Disorders. 2004;18:270&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592144</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Disease and Associated Disorders. 2009;23:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004;256(3):240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Campbell N, Kahn B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimer&#x2019;s &amp; Dementia. 2013;9:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674201</ArticleId><ArticleId IdType="pubmed">23183138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: Prevalence and contributing factors. Alzheimer Disease and Associated Disorders. 2009;23:306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787842</ArticleId><ArticleId IdType="pubmed">19568149</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarten JR, Anderson P, Kuskowski MA, McPherson SE, Borson S, Dysken MW. Finding dementia in primary care: The results of a clinical demonstration project. Journal of the American Geriatrics Society. 2012;60:210&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">22332672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray SL, Walker R, Dublin S, et al. Histamine-2 receptor antagonist use and incident dementia in an older cohort. Journal of the American Geriatrics Society. 2011;59(2):251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115775</ArticleId><ArticleId IdType="pubmed">21314645</ArticleId></ArticleIdList></Reference><Reference><Citation>Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8:e58837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592824</ArticleId><ArticleId IdType="pubmed">23520537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Journal of the American Medical Association. 2013;310(22):2435&#x2013;2442.</Citation><ArticleIdList><ArticleId IdType="pubmed">24327038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng FO, Ho YF, Hung LC, Chen CF, Tsai TH. Determination and pharmacokinetic profile of omeprazole in rat blood, brain, and bile by microdialysis and high-performance liquid chromatography. Journal of Chromatography. 2002;949(1&#x2013;2):35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11999751</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer&#x2019;s disease. Journal of Alzheimer&#x2019;s Disease. 2010;19(2):573&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951486</ArticleId><ArticleId IdType="pubmed">20110603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28602351</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1276</StartPage><EndPage>1290.e17</EndPage><MedlinePgn>1276-1290.e17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2017.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(17)30578-0</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathways associated with these cells. Immunohistochemical staining of mice and human brain slices shows DAM with intracellular/phagocytic A&#x3b2; particles. Single-cell analysis of DAM in Tg-AD and triggering receptor expressed on myeloid cells 2 (Trem2)<sup>-/-</sup> Tg-AD reveals that the DAM program is activated in a two-step process. Activation is initiated in a Trem2-independent manner that involves downregulation of microglia checkpoints, followed by activation of a Trem2-dependent program. This unique microglia-type has the potential to restrict neurodegeneration, which may have important implications for future treatment of AD and other neurodegenerative diseases. VIDEO ABSTRACT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keren-Shaul</LastName><ForeName>Hadas</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinrad</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Assaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences), and University Medical Center, Cancer Genomics Netherlands, 3584 CG Utrecht, the Netherlands. Electronic address: assaf.weiner@weizmann.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matcovitch-Natan</LastName><ForeName>Orit</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvir-Szternfeld</LastName><ForeName>Raz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baruch</LastName><ForeName>Kuti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara-Astaiso</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itzkovitz</LastName><ForeName>Shalev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: michal.schwartz@weizmann.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amit</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: ido.amit@weizmann.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2017 Jun 16;356(6343):1123-1124. doi: 10.1126/science.aan7893.</RefSource><PMID Version="1">28619900</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2017 Jun 15;169(7):1172-1174. doi: 10.1016/j.cell.2017.05.039.</RefSource><PMID Version="1">28622503</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2017 Aug;18(8):454. doi: 10.1038/nrn.2017.83.</RefSource><PMID Version="1">28655881</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">single cell RNA-seq</Keyword><Keyword MajorTopicYN="N">systems biology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pii">S0092-8674(17)30578-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28592453</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.</ArticleTitle><Pagination><StartPage>88</StartPage><EndPage>100</EndPage><MedlinePgn>88-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000004058</ELocationID><Abstract><AbstractText>The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and <sup>123</sup>iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article. ian.mckeith@newcastle.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>John-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galvin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayston</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanc</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohnen</LastName><ForeName>Nicolaas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Agnaf</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferman</LastName><ForeName>Tanis J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ffytche</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujishiro</LastName><ForeName>Hiroshige</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jennifer G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iranzo</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunde</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Etsuro</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orimo</LastName><ForeName>Sotoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramaswamy</LastName><ForeName>Shankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jon B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Masahito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosaka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Author affiliations are provided at the end of the article.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078086</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13 NS095618</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS091856</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS082134</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS097056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082265</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Feb 6;90(6):298-299. doi: 10.1212/WNL.0000000000004920.</RefSource><PMID Version="1">29438025</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Feb 6;90(6):299. doi: 10.1212/WNL.0000000000004915.</RefSource><PMID Version="1">29438026</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Feb 6;90(6):299-300. doi: 10.1212/WNL.0000000000004917.</RefSource><PMID Version="1">29438027</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Feb 6;90(6):300. doi: 10.1212/WNL.0000000000004918.</RefSource><PMID Version="1">29438028</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2018 Feb 6;90(6):300-301. doi: 10.1212/WNL.0000000000004919.</RefSource><PMID Version="1">29438029</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J R Coll Physicians Edinb. 2018 Mar;48(1):44-45. doi: 10.4997/JRCPE.2018.110.</RefSource><PMID Version="1">29741526</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28592453</ArticleId><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004058</ArticleId><ArticleId IdType="pii">WNL.0000000000004058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. . Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014;44:673&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Attems J, Thomas A, et al. . Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load. Neurology 2015;84:496&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336072</ArticleId><ArticleId IdType="pubmed">25552579</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007;69:356&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646627</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Cairns NJ, Da X, et al. . Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013;1:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893373</ArticleId><ArticleId IdType="pubmed">24252435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L, Salmon D, Galasko D, et al. . The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. Am J Geriatr Psychiatry 2012;20:773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260388</ArticleId><ArticleId IdType="pubmed">21997600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, Smith GE, Boeve BF, et al. . Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006;20:623&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi K, Nishio Y, Uchiyama M, Shimomura T, Iizuka O, Mori E. Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 2014;56:245&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">24491313</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792067</ArticleId><ArticleId IdType="pubmed">26595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimers Dement 2015;1:316&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576496</ArticleId><ArticleId IdType="pubmed">26405688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw JSM, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75:382&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738966</ArticleId><ArticleId IdType="pubmed">14966152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, Smith GE, Boeve BF, et al. . DLB fluctuations: specific features that reliably differentiate from AD and normal aging. Neurology 2004;62:181&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745051</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker MP, Ayre GA, Cummings JL, et al. . The clinician assessment of fluctuation and the one day fluctuation assessment scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">11040887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DR, McKeith I, Mosimann U, et al. . The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 2014;22:926&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">24332982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosimann UP, Collerton D, Dudley R, et al. . A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry 2008;23:712&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">18181237</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Berg D, Stern M, et al. . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, Boeve BF, Smith GE, et al. . Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011;77:875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162640</ArticleId><ArticleId IdType="pubmed">21849645</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828948</ArticleId><ArticleId IdType="pubmed">19109537</ArticleId></ArticleIdList></Reference><Reference><Citation>Iranzo A, Fernandez-Arcos A, Tolosa E, et al. . Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014;9:e89741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935943</ArticleId><ArticleId IdType="pubmed">24587002</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Silber MH, Ferman TJ, et al. . Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013;14:754&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3745815</ArticleId><ArticleId IdType="pubmed">23474058</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Molano JR, Ferman TJ, et al. . Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083495</ArticleId><ArticleId IdType="pubmed">21349763</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Arnulf I, Hogl B, et al. . A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012;27:913&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4043389</ArticleId><ArticleId IdType="pubmed">22729987</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:667&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">19448090</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, O'Brien J, Walker Z, et al. . Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362834</ArticleId></ArticleIdList></Reference><Reference><Citation>Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012;135:2798&#x2013;2808.</Citation><ArticleIdList><ArticleId IdType="pubmed">22961551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshita M, Arai H, Arai H, et al. . Diagnostic accuracy of I-123-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One 2015;10:e0120540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4368705</ArticleId><ArticleId IdType="pubmed">25793585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Corso A, Guerra UP, et al. . (123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: a comparative study. Ann Neurol 2016;80:368&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">27398636</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. . Medial temporal lobe atrophy on MRI differentiates Alzheimers disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">19022858</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper L, Fumagalli GG, Barkhof F, et al. . MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain 2016;139:1211&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806219</ArticleId><ArticleId IdType="pubmed">26936938</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelska Z, Ferman TJ, Boeve BF, et al. . Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015;36:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4268128</ArticleId><ArticleId IdType="pubmed">25128280</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Tashiro M, Arai H, et al. . Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739631</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11558792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobotesis K, Fenwick JD, Phipps A, et al. . Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245717</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JT, Firbank MJ, Davison C, et al. . F-18-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med 2014;55:1959&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">25453043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SM, Katsifis A, Villemagne VL, et al. . The F-18-FDG PET cingulate island sign and comparison to I-123-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009;50:1638&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19759102</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Murray ME, Lowe VJ, et al. . Dementia with Lewy bodies basis of cingulate island sign. Neurology 2014;83:801&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155048</ArticleId><ArticleId IdType="pubmed">25056580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimers disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008;131:690&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202105</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou M, Dwamena BA, Foerster BR, et al. . Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015;30:928&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4478091</ArticleId><ArticleId IdType="pubmed">25879534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe VJ, Boeve BF, et al. . Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33:2091&#x2013;2105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288845</ArticleId><ArticleId IdType="pubmed">22018896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Escott-Price V, Darwent L, et al. . Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging 2016:38;214.e7&#x2013;214.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759606</ArticleId><ArticleId IdType="pubmed">26643944</ArticleId></ArticleIdList></Reference><Reference><Citation>Peuralinna T, Myllykangas L, Oinas M, et al. . Genome-wide association study of neocortical Lewy-related pathology. Ann Clin Transl Neurol 2015;2:920&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574809</ArticleId><ArticleId IdType="pubmed">26401513</ArticleId></ArticleIdList></Reference><Reference><Citation>Guella I, Evans DM, Szu-Tu C, et al. . Alpha-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016;79:991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">27091628</ArticleId></ArticleIdList></Reference><Reference><Citation>Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther 2015;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448151</ArticleId><ArticleId IdType="pubmed">26029267</ArticleId></ArticleIdList></Reference><Reference><Citation>Uc EY, Doerschug KC, Magnotta V, et al. . Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 2014;83:413&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132568</ArticleId><ArticleId IdType="pubmed">24991037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HF, Yu JT, Tang SW, et al. . Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86:135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">24828899</ArticleId></ArticleIdList></Reference><Reference><Citation>Stinton C, McKeith I, Taylor JP, et al. . Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 2015;172:731&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">26085043</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Del Ser T, Spano P, et al. . Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145488</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1882909</ArticleId><ArticleId IdType="pubmed">1356550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Isaacson S, Mills R, et al. . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183563</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23:2248&#x2013;2250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18823039</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurora RN, Zak RS, Maganti RK, et al. . Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823283</ArticleId><ArticleId IdType="pubmed">20191945</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Lue L, et al. . Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757320</ArticleId><ArticleId IdType="pubmed">19399512</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishiro H, Tsuboi Y, Lin W-L, Uchikado H, Dickson DW. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 2008;116:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719249</ArticleId><ArticleId IdType="pubmed">18446351</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchikado H, Lin W-L, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006;65:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706655</ArticleId><ArticleId IdType="pubmed">16825955</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Parkkinen L, Al-Sarraj S, et al. . Assessment of alpha-synuclein pathology: a study of the BrainNet Europe consortium. J Neuropathol Exp Neurol 2008;67:125&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">18219257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Braak H, Duda JE, et al. . Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">19909913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28609533</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>317</Volume><Issue>22</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.</ArticleTitle><Pagination><StartPage>2305</StartPage><EndPage>2316</EndPage><MedlinePgn>2305-2316</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2017.6669</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Among cognitively normal individuals, elevated brain amyloid (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be related to risk for later Alzheimer-related cognitive decline.</AbstractText><AbstractText Label="OBJECTIVE">To characterize and quantify the risk for Alzheimer-related cognitive decline among cognitively normal individuals with elevated brain amyloid.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Exploratory analyses were conducted with longitudinal cognitive and biomarker data from 445 cognitively normal individuals in the United States and Canada. Participants were observed from August 23, 2005, to June 7, 2016, for a median of 3.1 years (interquartile range, 2.0-4.2 years; maximum follow-up, 10.3 years) as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI).</AbstractText><AbstractText Label="EXPOSURES">Individuals were classified at baseline as having normal (n&#x2009;=&#x2009;243) or elevated (n&#x2009;=&#x2009;202) brain amyloid using positron emission tomography amyloid imaging or a cerebrospinal fluid assay of amyloid &#x3b2;.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Outcomes included scores on the Preclinical Alzheimer Cognitive Composite (PACC; a sum of 4 baseline standardized z scores, which decreases with worse performance), Mini-Mental State Examination (MMSE; 0 [worst] to 30 [best] points), Clinical Dementia Rating Sum of Boxes (CDR-Sum of Boxes; 0 [best] to 18 [worst] points), and Logical Memory Delayed Recall (0 [worst] to 25 [best] story units).</AbstractText><AbstractText Label="RESULTS">Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women. The mean score for PACC at baseline was 0.00 (2.60); for MMSE, 29.0 (1.2); for CDR-Sum of Boxes, 0.04 (0.14); and for Logical Memory Delayed Recall, 13.1 (3.3). Compared with the group with normal amyloid, those with elevated amyloid had worse mean scores at 4 years on the PACC (mean difference, 1.51 points [95% CI, 0.94-2.10]; P&#x2009;&lt;&#x2009;.001), MMSE (mean difference, 0.56 points [95% CI, 0.32-0.80]; P&#x2009;&lt;&#x2009;.001), and CDR-Sum of Boxes (mean difference, 0.23 points [95% CI, 0.08-0.38]; P&#x2009;=&#x2009;.002). For Logical Memory Delayed Recall, between-group score was not statistically significant at 4 years (mean difference, 0.73 story units [95% CI, -0.02 to 1.48]; P&#x2009;=&#x2009;.056).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Exploratory analyses of a cognitively normal cohort followed up for a median of 3.1 years suggest that elevation in baseline brain amyloid level, compared with normal brain amyloid level, was associated with higher likelihood of cognitive decline, although the findings are of uncertain clinical significance. Further research is needed to assess the clinical importance of these differences and measure longer-term associations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, Department of Neurology, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Chung-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, Department of Neurology, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, University of California-San Francisco7San Francisco VA Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, Department of Neurology, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Jun 13;317(22):2285-2287. doi: 10.1001/jama.2017.6895.</RefSource><PMID Version="1">28609518</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Oct 10;318(14):1392-1393. doi: 10.1001/jama.2017.12951.</RefSource><PMID Version="1">29049580</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures</b>: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28609533</ArticleId><ArticleId IdType="mid">NIHMS918364</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pii">2631529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer&#x2019;s disease? Lancet Neurol. 2004;3(4):246&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer&#x2019;s disease. Neurology. 1988;38(11):1688&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">3054625</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer&#x2019;s disease and its outcome. Lancet Neurol. 2013;12(10):957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Therneau TM, Wiste HJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia. Lancet Neurol. 2016;15(1):56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784263</ArticleId><ArticleId IdType="pubmed">26597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Donohue MC, Mackin RS, et al. Cognitive and functional changes associated with A&#x3b2; pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016;48:172&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710807</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et al. Impact of the Alzheimer&#x2019;s Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659407</ArticleId><ArticleId IdType="pubmed">26194320</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, et al. Amyloid-&#x3b2; imaging with Pittsburgh compound B and florbetapir. J Nucl Med. 2013;54(1):70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale-Revised: Manual. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite. JAMA Neurol. 2014;71(8):961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis I: segmentation and surface reconstruction. Neuroimage. 1999;9(2):179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. 2nd. Tucson, AZ: Neuropsychology Press; 1993.</Citation></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc. 1993;88(421):9&#x2013;25. doi: 10.1080/01621459.1993.10594284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1993.10594284</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike H. Information Theory and an Extension of the Maximum Likelihood Principle. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected Papers of Hirotugu Akaike. New York, NY: Springer; 1998. pp. 199&#x2013;213.</Citation></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1&#x2013;67. doi: 10.18637/jss.v045.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v045.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer&#x2019;s disease. Annu Rev Neurosci. 2014;37:79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">24821312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(13):1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease International. World Alzheimer Report. 2009  http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed May 11, 2017.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28614712</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients.</ArticleTitle><Pagination><StartPage>2244</StartPage><EndPage>2256</EndPage><MedlinePgn>2244-2256</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2017.05.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(17)30713-1</ELocationID><Abstract><AbstractText>Hexanucleotide repeat expansion in the C9ORF72 gene results in production of dipeptide repeat (DPR) proteins that may disrupt pre-mRNA splicing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients. At present, the mechanisms underlying this mis-splicing are not understood. Here, we show that addition of proline-arginine (PR) and glycine-arginine (GR) toxic DPR peptides to nuclear extracts blocks spliceosome assembly and splicing, but not other types of RNA processing. Proteomic and biochemical analyses identified the U2 small nuclear ribonucleoprotein particle (snRNP) as&#xa0;a major interactor of PR and GR peptides. In addition, U2 snRNP, but not other splicing factors, mislocalizes from the nucleus to the cytoplasm both in C9ORF72 patient induced pluripotent stem cell (iPSC)-derived motor neurons and in HeLa cells treated with the toxic peptides. Bioinformatic studies support a specific role for U2-snRNP-dependent mis-splicing in C9ORF72 patient brains. Together, our data indicate that DPR-mediated dysfunction of U2 snRNP could account for as much as &#x223c;44% of the mis-spliced cassette exons in C9ORF72 patient brains.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Shanye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Gonzalez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunz</LastName><ForeName>Ryan C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangopadhyay</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borufka</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gygi</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA. Electronic address: rreed@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM122524</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 GM043375</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM043375</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS079725</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012342">RNA, Small Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017413">Ribonucleoprotein, U2 Small Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C405484">U2 small nuclear RNA</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012342" MajorTopicYN="N">RNA, Small Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017413" MajorTopicYN="N">Ribonucleoprotein, U2 Small Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">DPRs</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">U2 snRNP</Keyword><Keyword MajorTopicYN="N">iPSC-derived motor neurons</Keyword><Keyword MajorTopicYN="N">poly-GR</Keyword><Keyword MajorTopicYN="N">poly-PR</Keyword><Keyword MajorTopicYN="N">pre-mRNA splicing</Keyword><Keyword MajorTopicYN="N">toxic polydipeptide repeats</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28614712</ArticleId><ArticleId IdType="mid">NIHMS913057</ArticleId><ArticleId IdType="pmc">PMC5653973</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.05.056</ArticleId><ArticleId IdType="pii">S2211-1247(17)30713-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, Degroot S, Tapper AR, Sellier C, Charlet-Berguerand N, Karydas A, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta neuropathologica. 2013;126:385&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, Rademakers R, 3rd, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle DJ, Kasim M, Yong J, Lotti F, Lau CK, Mouaikel J, Zhang Z, Han K, Wan L, Dreyfuss G. The SMN complex: an assembly machine for RNPs. Cold Spring Harbor symposia on quantitative biology. 2006;71:313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17381311</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, Manley JL. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Bury JJ, Heath PR, Wyles M, Higginbottom A, Gelsthorpe C, Highley JR, Hautbergue G, Rattray M, Kirby J, et al. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. PloS one. 2015;10:e0127376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4446097</ArticleId><ArticleId IdType="pubmed">26016851</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Walsh MJ, Higginbottom A, Robin Highley J, Dickman MJ, Edbauer D, Ince PG, Wharton SB, Wilson SA, Kirby J, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain : a journal of neurology. 2014;137:2040&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M, Carri MT. Mitochondrial dysfunction in ALS. Progress in neurobiology. 2012;97:54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">21827820</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R, Dufu K, Romney B, Feldt M, Elenko M, Reed R. Functional coupling of RNAP II transcription to spliceosome assembly. Genes &amp; development. 2006;20:1100&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472470</ArticleId><ArticleId IdType="pubmed">16651655</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, Gygi SP, Reed R. SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. Mol Cell. 2007;26:867&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">17588520</ArticleId></ArticleIdList></Reference><Reference><Citation>Das R, Zhou Z, Reed R. Functional association of U2 snRNP with the ATP-independent spliceosomal complex E. Molecular Cell. 2000;5:779&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882114</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2013;linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes &amp; development. 2011;25:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049285</ArticleId><ArticleId IdType="pubmed">21363962</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu XD, Ares M., Jr Context-dependent control of alternative splicing by RNA-binding proteins. Nature reviews. Genetics. 2014;15:689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440546</ArticleId><ArticleId IdType="pubmed">25112293</ArticleId></ArticleIdList></Reference><Reference><Citation>Gama-Carvalho M, M LG-V, F RP, Besse F, Weis J, Voigt A, Schulz JB, De Las Rivas J. Linking amyotrophic lateral sclerosis and spinal muscular atrophy through RNA-transcriptome homeostasis: a genomics perspective. Journal of neurochemistry. 2017;141:12&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054357</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, Sun S, 3rd, Herdy JR, Bieri G, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nature neuroscience. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, Miller TM, Urano F. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Human molecular genetics. 2016;25:1803&#x2013;1813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986334</ArticleId><ArticleId IdType="pubmed">26931465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfir N, Lev-Maor G, Glaich O, Alajem A, Datta A, Sze SK, Meshorer E, Ast G. SF3B1 association with chromatin determines splicing outcomes. Cell reports. 2015;11:618&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892229</ArticleId></ArticleIdList></Reference><Reference><Citation>Krainer AR, Maniatis T, Ruskin B, Green MR. Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro. Cell. 1984;36:993&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">6323033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167:774&#x2013;788. e717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Letunic I, Doerks T, Bork P. SMART: recent updates, new developments and status in 2015. Nucleic acids research. 2015;43:D257&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384020</ArticleId><ArticleId IdType="pubmed">25300481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. The Journal of cell biology. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, McKnight SL. Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell. 2016;167:789&#x2013;802. e712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, Petrucelli L, Miller BL, Almeida S, Gao FB. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlister GC, Huttlin EL, Haas W, Ting L, Jedrychowski MP, Rogers JC, Kuhn K, Pike I, Grothe RA, Blethrow JD, et al. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Analytical chemistry. 2012;84:7469&#x2013;7478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715028</ArticleId><ArticleId IdType="pubmed">22880955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston AE, Desaro P, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature neuroscience. 2015;18:1175&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013;154:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosel-Hillgartner TD, Hung LH, Khrameeva E, Le Querrec P, Gelfand MS, Bindereif A. A novel intra-U1 snRNP cross-regulation mechanism: alternative splicing switch links U1C and U1-70K expression. PLoS genetics. 2013;9:e1003856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798272</ArticleId><ArticleId IdType="pubmed">24146627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruby SW, Chang TH, Abelson J. Four yeast spliceosomal proteins (PRP5, PRP9, PRP11, and PRP21) interact to promote U2 snRNP binding to pre-mRNA. Genes &amp; development. 1993;7:1909&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">8405998</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, Stewart H, Finger E, Volkening K, Seeley WW, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of aging. 2012;33:2950, e2955&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617405</ArticleId><ArticleId IdType="pubmed">22840558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X, Chiang PM, Price DL, Wong PC. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:16325&#x2013;16330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, Wu LC, Ding M, Yu Y, Gall JG, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proceedings of the National Academy of Sciences of the United States of America. 2017;114:E1111&#x2013;E1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, Lu Y, Du X, Nickerson JA, Petrucelli L, Weng Z, et al. Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron. 2015;87:1207&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">19239890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nature structural &amp; molecular biology. 2009;16:1094&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766517</ArticleId><ArticleId IdType="pubmed">19749754</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, Tapia JC, Zhai B, Das R, Lalancette-Hebert M, et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell reports. 2012;2:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483417</ArticleId><ArticleId IdType="pubmed">23022481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Abdallah A, Li Z, Lu Y, Almeida S, Gao FB. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta neuropathologica. 2015;130:525&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S, Yu Y, Reed R. Primary microRNA processing is functionally coupled to RNAP II transcription in vitro. Scientific reports. 2015;5:11992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493704</ArticleId><ArticleId IdType="pubmed">26149087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Das R, Folco EG, Reed R. A model in vitro system for co-transcriptional splicing. Nucleic acids research. 2010;38:7570&#x2013;7578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995048</ArticleId><ArticleId IdType="pubmed">20631007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28628103</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1052</StartPage><EndPage>1061</EndPage><MedlinePgn>1052-1061</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4587</ELocationID><Abstract><AbstractText>A genome-wide survival analysis of 14,406 Alzheimer's disease (AD) cases and 25,849 controls identified eight previously reported AD risk loci and 14 novel loci associated with age at onset. Linkage disequilibrium score regression of 220 cell types implicated the regulation of myeloid gene expression in AD risk. The minor allele of rs1057233 (G), within the previously reported CELF1 AD risk locus, showed association with delayed AD onset and lower expression of SPI1 in monocytes and macrophages. SPI1 encodes PU.1, a transcription factor critical for myeloid cell development and function. AD heritability was enriched within the PU.1 cistrome, implicating a myeloid PU.1 target gene network in AD. Finally, experimentally altered PU.1 levels affected the expression of mouse orthologs of many AD risk genes and the phagocytic activity of mouse microglial cells. Our results suggest that lower SPI1 expression reduces AD risk by regulating myeloid gene expression and cell function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Kuan-Lin</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Medicine and McDonnell Genome Institute, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcora</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3829-4927</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pimenova</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Narzo</LastName><ForeName>Antonio F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Manav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Sheng Chih</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertelsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fairfax</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czajkowski</LastName><ForeName>Jake</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouraki</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachussets, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE -Risk factors and molecular determinants of aging-related diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille - Excellence laboratory Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE -Risk factors and molecular determinants of aging-related diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille - Excellence laboratory Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deming</LastName><ForeName>Yuetiva</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7512-5703</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1942-5845</Identifier><AffiliationInfo><Affiliation>Icelandic Heart Association, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachussetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Hieab H H</ForeName><Initials>HHH</Initials><Identifier Source="ORCID">0000-0003-3687-2508</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Maria Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba&#xf1;ez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2381-7059</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Genomics of Alzheimer's Project</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Psychological Medicine and Clinical Neurosciences, Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escott-Price</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Psychological Medicine and Clinical Neurosciences, Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, and Department of Neurology, Columbia University, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachussetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachussets, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachussetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean Charles</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0829-7817</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE -Risk factors and molecular determinants of aging-related diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille - Excellence laboratory Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachussets, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Psychological Medicine and Clinical Neurosciences, Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE -Risk factors and molecular determinants of aging-related diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille - Excellence laboratory Labex DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Lille, U1167, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borecki</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Genetics, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JSK</Initials><AffiliationInfo><Affiliation>Department of Biology, Brigham Young University, Provo, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, Saint Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York,New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054011</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG049508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_17112</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R25 DA027995</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/P005748/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>201488/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG035083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C064368">proto-oncogene protein Spi-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Financial Interests Statement</b>. I.B. is an employee of Regeneron Pharmaceuticals, Inc. A.M.G. is on the
scientific advisory board for Denali Therapeutics and has served as a consultant
for AbbVie and Cognition Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28628103</ArticleId><ArticleId IdType="mid">NIHMS894538</ArticleId><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="doi">10.1038/nn.4587</ArticleId><ArticleId IdType="pii">nn.4587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study. JAMA Neurol. 2014 doi: 10.1001/jamaneurol.2014.1491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1491</ArticleId><ArticleId IdType="pmc">PMC4314944</ArticleId><ArticleId IdType="pubmed">25199842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, et al. Genome-wide association analysis of age-at-onset in Alzheimer&#x2019;s disease. Mol Psychiatry. 2012;17:1340&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262952</ArticleId><ArticleId IdType="pubmed">22005931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C, et al. Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer&#x2019;s Disease but is not causative. Am J Med Genet. 1995;60:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7485228</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJ, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678314</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Tanaka T. Alzheimer&#x2019;s disease risk genes and the age-at-onset phenotype. Neurobiol Aging. 2013;34:2696 e1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038407</ArticleId><ArticleId IdType="pubmed">23870418</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EL, et al. Evidence that PICALM affects age at onset of Alzheimer&#x2019;s dementia in Down syndrome. Neurobiol Aging. 2013;34:2441 e1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898582</ArticleId><ArticleId IdType="pubmed">23601808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for alzheimer&#x2019;s disease. Neuron. 2013;78:256&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JSK, et al. Alzheimer&#x2019;s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726757</ArticleId><ArticleId IdType="pubmed">18813964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48:245&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767558</ArticleId><ArticleId IdType="pubmed">26854917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, et al. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature. 2015;518:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci. 2015 doi: 10.1038/nn.4126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4126</ArticleId><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344:519&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, et al. Genome-wide association analysis of age-at-onset in Alzheimer&#x2019;s disease. Mol Psychiatry. 2012;17:1340&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262952</ArticleId><ArticleId IdType="pubmed">22005931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium, T. Gte. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet. 2015;47:1228&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714010</ArticleId><ArticleId IdType="pubmed">23453885</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier S, et al. Genome-Wide Haplotype Analysis of Cis Expression Quantitative Trait Loci in Monocytes. PLoS Genet. 2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561129</ArticleId><ArticleId IdType="pubmed">23382694</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343:1246949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron. 2016;89:37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci. 2014;34:11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A. 2016;113:E1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLoS Genet. 2014;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikami K, et al. Association of a functional polymorphism in the 3&#x2032;-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 2011;63:755&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">21360505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, Kellis M. HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham TH, et al. Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. Blood. 2012;119</Citation><ArticleIdList><ArticleId IdType="pubmed">22550342</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat Genet. 2015;47:445&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai K, et al. A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins. Brain Res. 2009;1276:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733343</ArticleId><ArticleId IdType="pubmed">19393635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajari TM, Strasser V, Nimpf J, Schneider WJ. A model for modulation of leptin activity by association with clusterin. FASEB J. 2003;17:1505&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12824284</ArticleId></ArticleIdList></Reference><Reference><Citation>Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014648</ArticleId><ArticleId IdType="pubmed">20935630</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge RJ, et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011;60:2624&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178302</ArticleId><ArticleId IdType="pubmed">21873549</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh JI, Asahina N, Kitano S, Kino Y. A Comprehensive Profile of ChIP-Seq-Based PU.1/Spi1 Target Genes in Microglia. Gene Regul Syst Bio. 2014;8:127&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262374</ArticleId><ArticleId IdType="pubmed">25574134</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel B, et al. The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages. Genes Dev. 2014;28:1562&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102764</ArticleId><ArticleId IdType="pubmed">25030696</ArticleId></ArticleIdList></Reference><Reference><Citation>McKercher SR, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15:5647&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452309</ArticleId><ArticleId IdType="pubmed">8896458</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103:16021&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak KS, Funnell APW, Pearson RCM, Crossley M. PU.1 and haematopoietic cell fate: Dosage matters. International Journal of Cell Biology. 2011 doi: 10.1155/2011/808524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/808524</ArticleId><ArticleId IdType="pmc">PMC3154517</ArticleId><ArticleId IdType="pubmed">21845190</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM, et al. The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia. 2013;61:929&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">23483680</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflammation. 2015;12:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Alp&#xe9;rovitch A, et al. Vascular factors and risk of dementia: Design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598854</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreses-Werringloer U, et al. A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, A&#x3b2; Levels, and Alzheimer&#x2019;s Disease Risk. Cell. 2008;133:1149&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577842</ArticleId><ArticleId IdType="pubmed">18585350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, et al. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 1966;34:553&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">5921755</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham offspring study. Design and preliminary data. Preventive Medicine. 1975;4:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute&#x2019;s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165:1328&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>Beiser A, D&#x2019;Agostino RB, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer&#x2019;s disease in the Framingham Study The Practical Incidence Estimators (PIE) macro. Stat Med. 2000;19:1495&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, et al. Incidence of dementia and probable Alzheimer&#x2019;s disease in a general population: the Framingham Study. Neurology. 1993;43:515&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450993</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer ME, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 1987;60:1023&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3628637</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, et al. Measures of brain morphology and infarction in the framingham heart study: Establishing what is normal. Neurobiol Aging. 2005;26:491&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>Au R, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res. 2004;30:333&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371099</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 2007;6:1106&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28:889&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">24258680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture procedures in patients with Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2009;6:290&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035477</ArticleId><ArticleId IdType="pubmed">19519311</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, et al. Beta Amyloid in Alzheimer&#x2019;s Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. Biol Psychiatry. 2009;65:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63:936&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B-Statistical Methodol. 1972;34:187&#x2013;+.</Citation></Reference><Reference><Citation>Prentice RL, Breslow NE. Retrospective Studies and Failure Time Models. Biometrika. 1978;65:153&#x2013;158.</Citation></Reference><Reference><Citation>van der Net JB, et al. Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies. Eur J Hum Genet. 2008;16:1111&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18382476</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, et al. LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. Exploring long-range genome interactions using the WashU Epigenome Browser. Nat Methods. 2013;10:375&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820286</ArticleId><ArticleId IdType="pubmed">23629413</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffon A, et al. Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res. 2015;43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344487</ArticleId><ArticleId IdType="pubmed">25477382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan CA, et al. ENCODE data at the ENCODE portal. Nucleic Acids Res. 2016;44:D726&#x2013;D732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702836</ArticleId><ArticleId IdType="pubmed">26527727</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell. 2015;58:1028&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475489</ArticleId><ArticleId IdType="pubmed">25982114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003;31:e154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC291882</ArticleId><ArticleId IdType="pubmed">14654707</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28629879</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.</ArticleTitle><Pagination><StartPage>620</StartPage><EndPage>629</EndPage><MedlinePgn>620-629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(17)30122-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(17)30122-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cognitive decline is a debilitating manifestation of disease progression in Parkinson's disease. We aimed to develop a clinical-genetic score to predict global cognitive impairment in patients with the disease.</AbstractText><AbstractText Label="METHODS">In this longitudinal analysis, we built a prediction algorithm for global cognitive impairment (defined as Mini Mental State Examination [MMSE] &#x2264;25) using data from nine cohorts of patients with Parkinson's disease from North America and Europe assessed between 1986 and 2016. Candidate predictors of cognitive decline were selected through a backward eliminated Cox's proportional hazards analysis using the Akaike's information criterion. These were used to compute the multivariable predictor on the basis of data from six cohorts included in a discovery population. Independent replication was attained in patients from a further three independent longitudinal cohorts. The predictive score was rebuilt and retested in 10&#x2008;000 training and test sets randomly generated from the entire study population.</AbstractText><AbstractText Label="FINDINGS">3200 patients with Parkinson's disease who were longitudinally assessed with 27&#x2008;022 study visits between 1986 and 2016 in nine cohorts from North America and Europe were assessed for eligibility. 235 patients with MMSE &#x2264;25 at baseline and 135 whose first study visit occurred more than 12 years from disease onset were excluded. The discovery population comprised 1350 patients (after further exclusion of 334 with missing covariates) from six longitudinal cohorts with 5165 longitudinal visits over 12&#xb7;8 years (median 2&#xb7;8, IQR 1&#xb7;6-4&#xb7;6). Age at onset, baseline MMSE, years of education, motor exam score, sex, depression, and &#x3b2;-glucocerebrosidase (GBA) mutation status were included in the prediction model. The replication population comprised 1132 patients (further excluding 14 patients with missing covariates) from three longitudinal cohorts with 19&#x2008;127 follow-up visits over 8&#xb7;6 years (median 6&#xb7;5, IQR 4&#xb7;1-7&#xb7;2). The cognitive risk score predicted cognitive impairment within 10 years of disease onset with an area under the curve (AUC) of more than 0&#xb7;85 in both the discovery (95% CI 0&#xb7;82-0&#xb7;90) and replication (95% CI 0&#xb7;78-0&#xb7;91) populations. Patients scoring in the highest quartile for cognitive risk score had an increased hazard for global cognitive impairment compared with those in the lowest quartile (hazard ratio 18&#xb7;4 [95% CI 9&#xb7;4-36&#xb7;1]). Dementia or disabling cognitive impairment was predicted with an AUC of 0&#xb7;88 (95% CI 0&#xb7;79-0&#xb7;94) and a negative predictive value of 0&#xb7;92 (95% 0&#xb7;88-0&#xb7;95) at the predefined cutoff of 0&#xb7;196. Performance was stable in 10&#x2008;000 randomly resampled subsets.</AbstractText><AbstractText Label="INTERPRETATION">Our predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis.</AbstractText><AbstractText Label="FUNDING">National Institutes of Health, US Department of Defense.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ganqiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Pierre et Marie Curie Paris 06 UMR S 1127, Sorbonne Universit&#xe9;, Institut du Cerveau et de la Moelle Epini&#xe8;re, Paris, France; U 1127 and Centre d'Investigation Clinique 1422, Institut National de Sant&#xe9; et en Recherche M&#xe9;dicale, Paris, France; U 7225, Centre National de Recherche Scientifique, Paris, France; D&#xe9;partement de Neurologie et de G&#xe9;n&#xe9;tique, Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boot</LastName><ForeName>Brendon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zhixiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Page</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Daly</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Iris E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Medical Genomics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, HZ, Netherlands; German Center for Neurodegenerative diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trisini-Lipsanopoulos</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>Caroline M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Medical Center and Department of Neurology, UCSF School of Medicine, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital and the University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberly</LastName><ForeName>Shirley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbaz</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, Centre for Research in Epidemiology and Population Health, U1018, Epidemiology of ageing and age related diseases, University Paris-Sud, UMRS 1018, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Pierre et Marie Curie Paris 06 UMR S 1127, Sorbonne Universit&#xe9;, Institut du Cerveau et de la Moelle Epini&#xe8;re, Paris, France; U 1127 and Centre d'Investigation Clinique 1422, Institut National de Sant&#xe9; et en Recherche M&#xe9;dicale, Paris, France; U 7225, Centre National de Recherche Scientifique, Paris, France; D&#xe9;partement de Neurologie et de G&#xe9;n&#xe9;tique, Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangone</LastName><ForeName>Graziella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Pierre et Marie Curie Paris 06 UMR S 1127, Sorbonne Universit&#xe9;, Institut du Cerveau et de la Moelle Epini&#xe8;re, Paris, France; U 1127 and Centre d'Investigation Clinique 1422, Institut National de Sant&#xe9; et en Recherche M&#xe9;dicale, Paris, France; U 7225, Centre National de Recherche Scientifique, Paris, France; D&#xe9;partement de Neurologie et de G&#xe9;n&#xe9;tique, Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Voyager Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Program for Regulatory Science and Medicine, Department of Neurology, Georgetown University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cormier-Dequaire</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Pierre et Marie Curie Paris 06 UMR S 1127, Sorbonne Universit&#xe9;, Institut du Cerveau et de la Moelle Epini&#xe8;re, Paris, France; U 1127 and Centre d'Investigation Clinique 1422, Institut National de Sant&#xe9; et en Recherche M&#xe9;dicale, Paris, France; U 7225, Centre National de Recherche Scientifique, Paris, France; D&#xe9;partement de Neurologie et de G&#xe9;n&#xe9;tique, Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Genomics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, HZ, Netherlands; German Center for Neurodegenerative diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinus</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA. Electronic address: cscherzer@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HBS</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>CamPaIGN</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PICNICS</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PROPARK</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PSG</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>DIGPD</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PDBP</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 NS100603</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS050095</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS024778</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0001067</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS082157</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS095736</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS097056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2017 Aug;16(8):576-578. doi: 10.1016/S1474-4422(17)30170-9.</RefSource><PMID Version="1">28629880</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2017 Sep;16(9):683. doi: 10.1016/S1474-4422(17)30254-5.</RefSource><PMID Version="1">28713033</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivinson</LastName><ForeName>Adrian J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trisini-Lipsanopoulos</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>Daly</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sudarsky</LastName><ForeName>Lewis R</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Umeh</LastName><ForeName>Chizoba C</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarzschild</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hung</LastName><ForeName>Albert Y</ForeName><Initials>AY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Alice W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wills</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohur</LastName><ForeName>U Shivraj</ForeName><Initials>US</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>Nicte I</ForeName><Initials>NI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khurana</LastName><ForeName>Vikram</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alora-Palli</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGinnis</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Nutan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gusella</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedley-Whyte</LastName><ForeName>E Tessa</ForeName><Initials>ET</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koenig</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marquis-Sayagues</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okereke</LastName><ForeName>Olivia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stemmer-Rachaminov</LastName><ForeName>Anat</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kloppenburg</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yi</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Haining</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stalberg</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liao</LastName><ForeName>Zhixiang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robbins</LastName><ForeName>Trevor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breen</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummins</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marinus</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elbaz</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallet</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elbaz</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grabli</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klebe</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangone</LastName><ForeName>Graziella</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourdain</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandel</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derkinderen</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesnage</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pico</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ory-Magne</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forlani</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangone</LastName><ForeName>Graziella</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tahiri</LastName><ForeName>Khadija</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcalay</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ascherio</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>Dubois</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewey</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>German</LastName><ForeName>Dwight</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saunders-Pullman</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaillancourt</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petyuk</LastName><ForeName>Vladislav</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>West</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28629879</ArticleId><ArticleId IdType="mid">NIHMS886783</ArticleId><ArticleId IdType="pmc">PMC5761650</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30122-9</ArticleId><ArticleId IdType="pii">S1474-4422(17)30122-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson&#x2019;s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737100</ArticleId><ArticleId IdType="pubmed">10945804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K, van Hilten JJ, Marinus J. Predictors of dementia in Parkinson&#x2019;s disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord. 2014;20(9):980&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25024059</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson&#x2019;s disease: a community-based, prospective study. Neurology. 2001;56(6):730&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274306</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher&#x2019;s mutations accelerate cognitive decline in Parkinson&#x2019;s. Ann Neurol. 2016;80(5):674&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5244667</ArticleId><ArticleId IdType="pubmed">27717005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA-associated Parkinson&#x2019;s disease: The mutation matters. Ann Neurol. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27632223</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5643027</ArticleId><ArticleId IdType="pubmed">28257128</ArticleId></ArticleIdList></Reference><Reference><Citation>Locascio JJ, Eberly S, Liao Z, et al. Association between alpha-synuclein blood transcripts and early, neuroimaging-supported Parkinson&#x2019;s disease. Brain. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643625</ArticleId><ArticleId IdType="pubmed">26220939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson&#x2019;s disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">2215943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina B, Tanner C, Dieuliis D, et al. A longitudinal program for biomarker development in Parkinson&#x2019;s disease: a feasibility study. Mov Disord. 2009;24(14):2081&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19691116</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson&#x2019;s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781007</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson&#x2019;s disease. J Neurol. 2013;260(8):1978&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">23572347</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI) Prog Neurobiol. 2011;95(4):629&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014725</ArticleId><ArticleId IdType="pubmed">21930184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal LS, Drake D, Alcalay RN, et al. The NINDS Parkinson&#x2019;s disease biomarkers program. Mov Disord. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4824671</ArticleId><ArticleId IdType="pubmed">26442452</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788810</ArticleId><ArticleId IdType="pubmed">19933974</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenoven I, Aarsland D, Hurtg H, Chen-Plotkin A. Conversion Between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 Scores in Parkinson&#x2019;s Disease. Movement Disorders. 2014:1809&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371590</ArticleId><ArticleId IdType="pubmed">25381961</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson&#x2019;s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18098298</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson&#x2019;s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry. 2004;75(3):388&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738938</ArticleId><ArticleId IdType="pubmed">14966153</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson&#x2019;s disease rating scale scores to Movement Disorder Society-unified Parkinson&#x2019;s disease rating scale scores. Mov Disord. 2012;27(10):1239&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886777</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbaan D, van Rooden SM, Benit CP, van Zwet EW, Marinus J, van Hilten JJ. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2011;17(8):632&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">21696993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PW, D&#x2019;Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603539</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson&#x2019;s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181006</ArticleId><ArticleId IdType="pubmed">21661055</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson&#x2019;s disease. Mov Disord. 2005;20(10):1255&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041803</ArticleId></ArticleIdList></Reference><Reference><Citation>Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737082</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves G, Lange J, Blennow K, et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">24748671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589197</ArticleId><ArticleId IdType="pubmed">23243071</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts PM, Perez EO. Ethics research compendium. Hauppauge New York: Nova Publishers; 2013.</Citation></Reference><Reference><Citation>Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study G Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72(13):1121&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19020293</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson&#x2019;s disease cohort. Brain. 2007;130(Pt 7):1787&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">17535834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson&#x2019;s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28467028</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov Disord</ISOAbbreviation></Journal><ArticleTitle>Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>864</EndPage><MedlinePgn>853-864</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26987</ELocationID><Abstract><AbstractText Label="BACKGROUND">PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome.</AbstractText><AbstractText Label="OBJECTIVE">We aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for PSP.</AbstractText><AbstractText Label="METHODS">We searched the PubMed, Cochrane, Medline, and PSYCInfo databases for articles published in English since 1996, using postmortem diagnosis or highly specific clinical criteria as the diagnostic standard. Second, we generated retrospective standardized clinical data from patients with autopsy-confirmed PSP and control diseases. On this basis, diagnostic criteria were drafted, optimized in two modified Delphi evaluations, submitted to structured discussions with consensus procedures during a 2-day meeting, and refined in three further Delphi rounds.</AbstractText><AbstractText Label="RESULTS">Defined clinical, imaging, laboratory, and genetic findings serve as mandatory basic features, mandatory exclusion criteria, or context-dependent exclusion criteria. We identified four functional domains (ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP. Within each of these domains, we propose three clinical features that contribute different levels of diagnostic certainty. Specific combinations of these features define the diagnostic criteria, stratified by three degrees of diagnostic certainty (probable PSP, possible PSP, and suggestive of PSP). Clinical clues and imaging findings represent supportive features.</AbstractText><AbstractText Label="CONCLUSIONS">Here, we present new criteria aimed to optimize early, sensitive, and specific clinical diagnosis of PSP on the basis of currently available evidence. &#xa9; 2017 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>&#xa9; 2017 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xf6;glinger</LastName><ForeName>G&#xfc;nter U</ForeName><Initials>GU</Initials><Identifier Source="ORCID">0000-0001-7587-6187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Respondek</LastName><ForeName>Gesine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1668-9925</Identifier><AffiliationInfo><Affiliation>Second Department of Neurology, Attikon University Hospital, University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Carolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Paracelsus-Elena Klinik, Kassel, Germany, and University Medical Center G&#xf6;ttingen, Institute of Neuropathology, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Christer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitwell</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesoya, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank of the Biobank - Hospital Cl&#xed;nic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Wassilios G</ForeName><Initials>WG</Initials><Identifier Source="ORCID">0000-0003-2172-7527</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Institut des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, Institut des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Neurologie, H&#xf4;pital Pellegrin, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pantelyat</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-8185-286X</Identifier><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compta</LastName><ForeName>Yaroslau</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Parkinson's Disease &amp; Movement Disorders Unit, Neurology Service, Hospital Clinic/IDIBAPS/University of Barcelona, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, UPMC Univ Paris 06; and INSERM UMRS_1127, CIC_1422; and CNRS UMR_7225; and AP-HP; and ICM, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement des maladies du syst&#xe8;me nerveux, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colosimo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Santa Maria University Hospital of Terni, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodel</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krismer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzl</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hospital Agatharied, Agatharied, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Palliative Medicine, Munich University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, UCL Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nestor</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Philipps Universit&#xe4;t, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seppi</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eimeren</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Nuclear Medicine and Neurology, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenning</LastName><ForeName>Gregor K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Movement Disorder Society-endorsed PSP Study Group</CollectiveName><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>103838</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC012519</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K-1501</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS089757</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00005/12</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K23 NS088341</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100643</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical diagnostic criteria</Keyword><Keyword MajorTopicYN="N">consensus-based</Keyword><Keyword MajorTopicYN="N">evidence-based</Keyword><Keyword MajorTopicYN="N">progressive supranuclear palsy</Keyword></KeywordList><CoiStatement><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pantelyat</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giese</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colosimo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Christer</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krismer</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Respondek</LastName><ForeName>Gesine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wenning</LastName><ForeName>Gregor K</ForeName><Initials>GK</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xf6;glinger</LastName><ForeName>G&#xfc;nter U</ForeName><Initials>GU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitwell</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash P</ForeName><Initials>KP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seppi</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamelou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nestor</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dodel</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenzl</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Eimeren</LastName><ForeName>Thilo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meissner</LastName><ForeName>Wassilios G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang H</ForeName><Initials>WH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Compta</LastName><ForeName>Yaroslau</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28467028</ArticleId><ArticleId IdType="mid">NIHMS879447</ArticleId><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="doi">10.1002/mds.26987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">14107684</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supra-nuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl 2):II6&#x2013;II15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG. Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25495175</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 1997;120:65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9055798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53:1292&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522887</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord. 2004;19:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14978673</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson&#x2019;s syndrome and PSP-parkinsonism. Brain. 2005;128:1247&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788542</ArticleId></ArticleIdList></Reference><Reference><Citation>Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29:1758&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">25370486</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17:1255&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12465065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto R, Tsuchiya K, Mimura M. Clinical heterogeneity in progressive supranuclear palsy: problems of clinical diagnostic criteria of NINDS-SPSP in a retrospective study of seven Japanese autopsy cases. Neuropathology. 2010;30:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19508347</ArticleId></ArticleIdList></Reference><Reference><Citation>Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013;28:504&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">23436751</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60:615&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073943</ArticleId><ArticleId IdType="pubmed">8648326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz C, Ebersbach G, Respondek G, Giese A, Arzberger T, Hoglinger GU. An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol Commun. 2016;4:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109838</ArticleId><ArticleId IdType="pubmed">27842578</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">20108379</ArticleId></ArticleIdList></Reference><Reference><Citation>Donker Kaat L, Boon AJ, Kamphorst W, Ravid R, Duivenvoorden HJ, van Swieten JC. Frontal presentation in progressive supranuclear palsy. Neurology. 2007;69:723&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709703</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, Kim H, Park JH, et al. Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy. J Clin Neurol. 2010;6:148&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950920</ArticleId><ArticleId IdType="pubmed">20944816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase. 2012;18:478&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">22181323</ArticleId></ArticleIdList></Reference><Reference><Citation>Compta Y, Valldeoriola F, Tolosa E, Rey MJ, Marti MJ, Valls-Sole J. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2007;22:1954&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724746</ArticleId></ArticleIdList></Reference><Reference><Citation>Facheris MF, Maniak S, Scaravilli F, Schule B, Klein C, Pramstaller PP. Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord. 2008;14:517&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">18325816</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007;22:2235&#x2013;2241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005;20:982&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834857</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol. 2014;40:149&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260147</ArticleId><ArticleId IdType="pubmed">23432126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, O&#x2019;Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133:2045&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">20584946</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Katsuse O, Beccano-Kelly DA, et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol. 2006;65:396&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao S, Yokota O, Nanba R, et al. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. J Neurol Sci. 2012;323:147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2009;24:1312&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">19412943</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Mori K, Ito M, Tatsumi S, Mimuro M, Yoshida M. An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement. Neuropathology. 2013;33:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">23320789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord. 2013;19:1149&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">23916652</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Josephs KA, Ogaki K, et al. Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord. 2016;31:653&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861661</ArticleId><ArticleId IdType="pubmed">26841329</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol. 2003;49:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki A, Ueda Y, Komatsuzaki Y, Tsuchiya K, Arai T, Shoji S. Progressive supranuclear palsy presenting with primary progressive aphasia&#x2014;clinicopathological report of an autopsy case. Acta Neuropathol. 2003;105:610&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">12669238</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129:1385&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748312</ArticleId><ArticleId IdType="pubmed">16613895</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol. 2008;21:688&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">18989114</ArticleId></ArticleIdList></Reference><Reference><Citation>Scottish Intercollegiate Guidelines Network. A Guideline Developer&#x2019;s Handbook. Edinburgh, UK: Edinburgh Elliott House; 2008. SIGN 50.</Citation></Reference><Reference><Citation>Respondek G, Kurz C, Arzberger T, et al. Which ante-mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. (submitted)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543934</ArticleId><ArticleId IdType="pubmed">28500752</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Hoglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord. (submitted)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511762</ArticleId><ArticleId IdType="pubmed">28500751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology. 1994;44:2015&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">12722160</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU. Targeting tau therapeutics to PSP: support from new diagnostic criteria and biomarkers. Lancet Neurol. (submitted)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802400</ArticleId><ArticleId IdType="pubmed">28653647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N, Ross Owen A, et al. Genome-wide association study identifies microtubule-associated protein tau (MAPT) and myelin-associated oligodendrocytic basic protein (MOBP) as shared genetic risk factors for corticobasal degeneration and progressive supranuclear palsy. Nat Commun. 2015;6:7247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469997</ArticleId><ArticleId IdType="pubmed">26077951</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70:327&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154081</ArticleId><ArticleId IdType="pubmed">21823158</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 2012;124:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551449</ArticleId><ArticleId IdType="pubmed">22526019</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Meltzer AC, et al. Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti L, V&#xe1;zquez Rodr&#xed;guez P, Hong YT, et al. [18F]AV-1451 positron emission tomography in Alzheimer&#x2019;s disease and progressive supranuclear palsy. Brain. 2017 Jan 24; doi: 10.1093/brain/aww340. pii: aww340. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww340</ArticleId><ArticleId IdType="pmc">PMC5382948</ArticleId><ArticleId IdType="pubmed">28122879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood EM, Falcone D, Suh E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 2013;70:1411&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906581</ArticleId><ArticleId IdType="pubmed">24081456</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Millan J, Serra A, Leigh RJ, Troncoso XG, Macknik SL, Martinez-Conde S. Distinctive features of saccadic intrusions and microsaccades in progressive supranuclear palsy. J Neurosci. 2011;31:4379&#x2013;4387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111217</ArticleId><ArticleId IdType="pubmed">21430139</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28669544</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>308.e6</EndPage><MedlinePgn>297-308.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.05.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30475-0</ELocationID><Abstract><AbstractText>Microglia coordinate various functions in the central nervous system ranging from removing synaptic connections, to maintaining brain homeostasis by monitoring neuronal function, and clearing protein aggregates across the lifespan. Here we investigated whether increased microglial phagocytic activity that clears amyloid can also cause pathological synapse loss. We identified TDP-43, a DNA-RNA binding protein encoded by the Tardbp gene, as a strong regulator of microglial phagocytosis. Mice lacking TDP-43 in microglia exhibit reduced amyloid load in a model of Alzheimer's disease (AD) but at the same time display drastic synapse loss, even in the absence of amyloid. Clinical examination from TDP-43 pathology cases reveal a considerably reduced prevalence of AD and decreased amyloid pathology compared to age-matched healthy controls, confirming our experimental results. Overall, our data suggest that dysfunctional microglia might play a causative role in the pathogenesis of neurodegenerative disorders, critically modulating the early stages of cognitive decline.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 University of Zurich. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paolicelli</LastName><ForeName>Rosa C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren, Switzerland. Electronic address: rosachiara.paolicelli@irem.uzh.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawaid</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brain Research Institute, University of Zurich/ETH, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henstridge</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Center for Cognitive and Neural Systems, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valeri</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlini</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Molecular Cardiology - Vascular Aging &amp; Stroke, University of Zurich, Schlieren, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academic Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS/MDA Center, The Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Cognitive and Neural Systems, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas, Health Science Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren, Switzerland. Electronic address: lawrence.rajendran@irem.uzh.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Aug;13(8):449. doi: 10.1038/nrneurol.2017.103.</RefSource><PMID Version="1">28708134</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s Disease</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">Clearance</Keyword><Keyword MajorTopicYN="N">Frontotemporal Lobar Degeneration</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Phagocytosis</Keyword><Keyword MajorTopicYN="N">Synapse Loss</Keyword><Keyword MajorTopicYN="N">Synaptic Pruning</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Tardbp</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28669544</ArticleId><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.05.037</ArticleId><ArticleId IdType="pii">S0896-6273(17)30475-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold S.E., Toledo J.B., Appleby D.H., Xie S.X., Wang L.S., Baek Y., Wolk D.A., Lee E.B., Miller B.L., Lee V.M., Trojanowski J.Q. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J.&#xa0;Comp. Neurol. 2013;521:4339&#x2013;4355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3872132</ArticleId><ArticleId IdType="pubmed">23881776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali J., Gheinani A.H., Zurbriggen S., Rajendran L. Role of genes linked to sporadic Alzheimer&#x2019;s disease risk in the production of &#x3b2;-amyloid peptides. Proc. Natl. Acad. Sci. USA. 2012;109:15307&#x2013;15311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458335</ArticleId><ArticleId IdType="pubmed">22949636</ArticleId></ArticleIdList></Reference><Reference><Citation>Baralle M., Buratti E., Baralle F.E. The role of TDP-43 in the pathogenesis of ALS and FTLD. Biochem. Soc. Trans. 2013;41:1536&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pubmed">24256250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S., Toledo J.B., Irwin D.J., Raible K.M., Byrne M.D., Lee E.B., Lee V.M., Trojanowski J.Q. A comparison of A&#x3b2; amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathol. 2014;128:543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399383</ArticleId><ArticleId IdType="pubmed">24916271</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimer&#x2019;s disease. J.&#xa0;Neural Transm. Suppl. 1998;53:127&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Toledo J.B., Van Deerlin V.M., Elman L., McCluskey L., Lee V.M., Trojanowski J.Q. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J.&#xa0;Neurol. Sci. 1994;124(Suppl):96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J.&#xa0;Biol. Chem. 2001;276:36337&#x2013;36343.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv. Genet. 2009;66:1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19737636</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang P.M., Ling J., Jeong Y.H., Price D.L., Aja S.M., Wong P.C. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc. Natl. Acad. Sci. USA. 2010;107:16320&#x2013;16324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941284</ArticleId><ArticleId IdType="pubmed">20660762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Lee V.M., Trojanowski J.Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011;17:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole G.M., Bell L., Truong Q.B., Saitoh T. An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann. N Y Acad. Sci. 1992;674:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">1288357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C., Zhang Y.J., Xu Y.F., Dickson D.W., Petrucelli L. TDP-43 in neurodegenerative disorders. Expert Opin. Biol. Ther. 2008;8:969&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855963</ArticleId><ArticleId IdType="pubmed">18549326</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., Gan W.B. ATP mediates rapid microglial response to local brain injury in&#xa0;vivo. Nat. Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Deierborg T. Preparation of primary microglia cultures from postnatal mouse and rat brains. Methods Mol. Biol. 2013;1041:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">23813366</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki N.C., Katzmarski N., Kipnis J., Meyer-Luehmann M. Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathol. 2014;128:333&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4131160</ArticleId><ArticleId IdType="pubmed">25056803</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper D.C., Adachi Y., Sutcliffe B., Humphrey D.M., Elliott C.J., Stepto A., Ludlow Z.N., Vanden Broeck L., Callaerts P., Dermaut B. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum. Mol. Genet. 2013;22:1539&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605831</ArticleId><ArticleId IdType="pubmed">23307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Fa M., Orozco I.J., Francis Y.I., Saeed F., Gong Y., Arancio O. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. J.&#xa0;Vis. Exp. 2010;(41):1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156071</ArticleId><ArticleId IdType="pubmed">20644518</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D., Wilkinson K., Zhao L., Hickman S.E., Means T.K., Puckett L., Farfara D., Kingery N.D., Weiner H.L., El Khoury J. Scara1 deficiency impairs clearance of soluble amyloid-&#x3b2; by mononuclear phagocytes and accelerates Alzheimer&#x2019;s-like disease progression. Nat. Commun. 2013;4:2030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3702268</ArticleId><ArticleId IdType="pubmed">23799536</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J.&#xa0;Mol. Neurosci. 2011;45:486&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207125</ArticleId><ArticleId IdType="pubmed">21811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T., Wieghofer P., Jord&#xe3;o M.J., Prutek F., Hagemeyer N., Frenzel K., Amann L., Staszewski O., Kierdorf K., Krueger M. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 2016;17:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Handley E.E., Pitman K.A., Dawkins E., Young K.M., Clark R.M., Jiang T.C., Turner B.J., Dickson T.C., Blizzard C.A. Synapse Dysfunction of Layer V Pyramidal Neurons Precedes Neurodegeneration in a Mouse Model of TDP-43 Proteinopathies. Cereb Cortex. 2016 Published online August 5, 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">27496536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Beja-Glasser V.F., Nfonoyim B.M., Frouin A., Li S., Ramakrishnan S., Merry K.M., Shi Q., Rosenthal A., Barres B.A. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., Lee V.M. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J.&#xa0;Clin. Invest. 2011;121:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Katsuno M., Niwa J., Takagi S., Ishigaki S., Ikenaka K., Kawai K., Watanabe H., Yamanaka K., Takahashi R. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136:1371&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Murthy S.B., Wilson A.M., Qureshi S.U., Amro M.J., Wheaton M., Simpson E., Harati Y., Strutt A.M., York M.K., Schulz P.E. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph. Lateral Scler. 2010;11:542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage H.A., Hunter S., Matthews F.E., Ince P.G., Hodges J., Hokkanen S.R., Highley J.R., Dening T., Brayne C. TDP-43 pathology in the population: prevalence and associations with dementia and age. J.&#xa0;Alzheimers Dis. 2014;42:641&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">25170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H., Kirchhoff F., Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron. 2013;77:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23312512</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M., Konietzko U., Krebs D.C., Nitsch R.M. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging. 2007;28:1297&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer B.C., Schuck T., Wheeler J.M., Robinson L.C., Trojanowski J.Q., Lee V.M., Schellenberg G.D. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair K.D., Donde A., Ling J.P., Jeong Y.H., Chhabra R., Martin L.J., Wong P.C. Depletion of TDP-43 decreases fibril and plaque &#x3b2;-amyloid and exacerbates neurodegeneration in an Alzheimer&#x2019;s mouse model. Acta Neuropathol. 2016;132:859&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131701</ArticleId><ArticleId IdType="pubmed">27785573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19(R1):R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.Y., Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J.&#xa0;Neural Transm. (Vienna) 2010;117:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J.&#xa0;Biol. Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina D.X., Orr M.E., Oddo S. Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol. Aging. 2014;35:79&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H. Microglial functions and proteases. Mol. Neurobiol. 2003;27:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12777686</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J.&#xa0;Neuropathol. Exp. Neurol. 2012;71:362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Lee E.B., Kremmer E., Flatley A., Xu Y., Forman M.S., Troost D., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in&#xa0;vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R., Jansen W.J., Rabinovici G.D., Knol D.L., van der Flier W.M., van Berckel B.N., Scheltens P., Visser P.J., Verfaillie S.C., Zwan M.D., Amyloid PET Study Group Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Gross C.T. Microglia in development: linking brain wiring to brain environment. Neuron Glia Biol. 2011;7:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22857738</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce D.M., Ghosh R.N., Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer&#x2019;s disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R., 3rd, Lafaille J.J., Hempstead B.L., Littman D.R., Gan W.B. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M., Priller J., Sisodia S.S., Ransohoff R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011;14:1227&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries M., Sastre M. Mechanisms of A&#x3b2; Clearance and Degradation by Glial Cells. Front. Aging Neurosci. 2016;8:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932097</ArticleId><ArticleId IdType="pubmed">27458370</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano G., Appocher C., Scorzeto M., Klima R., Baralle F.E., Megighian A., Feiguin F. Glial TDP-43 regulates axon wrapping, GluRIIA clustering and fly motility by autonomous and non-autonomous mechanisms. Hum. Mol. Genet. 2015;24:6134&#x2013;6145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599672</ArticleId><ArticleId IdType="pubmed">26276811</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer D.P., Lehrman E.K., Kautzman A.G., Koyama R., Mardinly A.R., Yamasaki R., Ransohoff R.M., Greenberg M.E., Barres B.A., Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A., Encinas J.M., Deudero J.J., Chancey J.H., Enikolopov G., Overstreet-Wadiche L.S., Tsirka S.E., Maletic-Savatic M. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7:483&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008496</ArticleId><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9;-Dom&#xe8;nech S., Cruz D.L., Capetillo-Zarate E., Maxfield F.R. The endocytic pathway in microglia during health, aging and Alzheimer&#x2019;s disease. Ageing Res. Rev. 2016;32:89&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127718</ArticleId><ArticleId IdType="pubmed">27421577</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo J.B., Van Deerlin V.M., Lee E.B., Suh E., Baek Y., Robinson J.L., Xie S.X., McBride J., Wood E.M., Schuck T. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement. 2014;10:477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M.E., Stevens B., Sierra A., Wake H., Bessis A., Nimmerjahn A. The role of microglia in the healthy brain. J.&#xa0;Neurosci. 2011;31:16064&#x2013;16069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633221</ArticleId><ArticleId IdType="pubmed">22072657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L., Naval-S&#xe1;nchez M., Adachi Y., Diaper D., Dourlen P., Chapuis J., Kleinberger G., Gistelinck M., Van Broeckhoven C., Lambert J.C. TDP-43 loss-of-function causes neuronal loss due to defective steroid receptor-mediated gene program switching in Drosophila. Cell Rep. 2013;3:160&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">23333275</ArticleId></ArticleIdList></Reference><Reference><Citation>Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J.&#xa0;Neurosci. 2000;20:1657&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772918</ArticleId><ArticleId IdType="pubmed">10684867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakselman S., B&#xe9;chade C., Roumier A., Bernard D., Triller A., Bessis A. Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J.&#xa0;Neurosci. 2008;28:8138&#x2013;8143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670768</ArticleId><ArticleId IdType="pubmed">18685038</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.K., Tripathy K., Restrepo C.R., Ge G., Xu Y., Kwong L.K., Trojanowski J.Q., Lee V.M. An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum. Mol. Genet. 2015;24:7241&#x2013;7254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007600</ArticleId><ArticleId IdType="pubmed">26476406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L.S., Cheng W.C., Shen C.K. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J.&#xa0;Biol. Chem. 2012;287:27335&#x2013;27344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q., Wang H., Hao Z., Fu C., Hu Q., Gao F., Ren H., Chen D., Han J., Ying Z., Wang G. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J. 2016;35:121&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718457</ArticleId><ArticleId IdType="pubmed">26702100</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.F., Zhang Y.J., Lin W.L., Cao X., Stetler C., Dickson D.W., Lewis J., Petrucelli L. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011;6:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wang H., Qiao T., Yang B., Aliaga L., Qiu L., Tan W., Salameh J., McKenna-Yasek D.M., Smith T. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2014;111:E1121&#x2013;E1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying Z., Xia Q., Hao Z., Xu D., Wang M., Wang H., Wang G. TARDBP/TDP-43 regulates autophagy in both MTORC1-dependent and MTORC1-independent manners. Autophagy. 2016;12:707&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836031</ArticleId><ArticleId IdType="pubmed">27050460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28678775</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>547</Volume><Issue>7662</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Cryo-EM structures of tau filaments from Alzheimer's disease.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>190</EndPage><MedlinePgn>185-190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature23002</ELocationID><Abstract><AbstractText>Alzheimer's disease is the most common neurodegenerative disease, and there are no mechanism-based therapies. The disease is defined by the presence of abundant neurofibrillary lesions and neuritic plaques in the cerebral cortex. Neurofibrillary lesions comprise paired helical and straight tau filaments, whereas tau filaments with different morphologies characterize other neurodegenerative diseases. No high-resolution structures of tau filaments are available. Here we present cryo-electron microscopy (cryo-EM) maps at 3.4-3.5&#x2009;&#xc5; resolution and corresponding atomic models of paired helical and straight filaments from the brain of an individual with Alzheimer's disease. Filament cores are made of two identical protofilaments comprising residues 306-378 of tau protein, which adopt a combined cross-&#x3b2;/&#x3b2;-helix structure and define the seed for tau aggregation. Paired helical and straight filaments differ in their inter-protofilament packing, showing that they are ultrastructural polymorphs. These findings demonstrate that cryo-EM allows atomic characterization of amyloid filaments from patient-derived material, and pave the way for investigation of a range of neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Anthony W P</ForeName><Initials>AWP</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shaoda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murshudov</LastName><ForeName>Garib</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R Anthony</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_A025_1012</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600724</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N027892/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Jul 13;547(7662):170-171. doi: 10.1038/nature23094.</RefSource><PMID Version="1">28678777</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Sep;13(9):513. doi: 10.1038/nrneurol.2017.107.</RefSource><PMID Version="1">28731038</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28678775</ArticleId><ArticleId IdType="mid">NIHMS882516</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pii">nature23002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56:343&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7175555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, et al. Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015;41:24&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M. Paired helical filaments in electron microscopy of Alzheimer&#x2019;s disease. Nature. 1963;197:192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. The fine structure of neurofibrillary tangles in Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol. 1963;22:629&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">14069842</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagishita S, Itoh Y, Nan W, Amano N. Reappraisal of the fine structure of Alzheimer&#x2019;s neurofibrillary tangles. Acta Neuropathol. 1981;54:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">7257733</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci U S A. 1991;88:2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85:4884&#x2013;4888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Potential pathways of abnormal Tau and &#x3b1;-synuclein dissemination in sporadic Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Cold Spring Harb Perspect Biol. 2016;8:a023630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088528</ArticleId><ArticleId IdType="pubmed">27580631</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ, et al. Short fibrils constitute the major species of seed-competent Tau in the brains of mice transgenic for human P301S Tau. J Neurosci. 2016;36:762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and &#x3b1;-synuclein in neurodegeneration. Brain. 2017;140:266&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658420</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Goedert M. Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol. 2000;130:271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940231</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med. 2016;213:2635&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Peptide dimer structure in an A&#x3b2;(1-42) fibril visualized with cryo-EM. Proc Natl Acad Sci U S A. 2015;112:11858&#x2013;11863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586870</ArticleId><ArticleId IdType="pubmed">26351699</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin MT, et al. Atomic resolution structure of monomorphic A&#x3b2;42 amyloid fibrils. J Am Chem Soc. 2016;138:9663&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389415</ArticleId><ArticleId IdType="pubmed">27355699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;lti MA, et al. Atomic-resolution structure of a disease-relevant A&#x3b2;(1-42) amyloid fibril. Proc Natl Acad Sci U S A. 2016;113:E4976&#x2013;4984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003276</ArticleId><ArticleId IdType="pubmed">27469165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle MD, et al. Solid-state NMR structure of a pathogenic fibril of full-length human &#x3b1;-synuclein. Nat Struct Mol Biol. 2016;23:409&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034296</ArticleId><ArticleId IdType="pubmed">27018801</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A. 2017;114:574&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017 doi: 10.1016/j.jsb.2017.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2017.02.003</ArticleId><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, et al. Atomic structure and hierarchical assembly of a cross-&#x3b2; amyloid fibril. Proc Natl Acad Sci U S A. 2013;110:5468&#x2013;5473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619355</ArticleId><ArticleId IdType="pubmed">23513222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Novak M, Davison M, Wischik CM. Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer&#x2019;s disease. EMBO J. 1991;10:2725&#x2013;2729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452980</ArticleId><ArticleId IdType="pubmed">1915258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85:4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan A, et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer&#x2019;s disease brain. Acta Neuropathol Commun. 2013;1:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893535</ArticleId><ArticleId IdType="pubmed">24252707</ArticleId></ArticleIdList></Reference><Reference><Citation>Crick FH, Rich A. Structure of polyglycine II. Nature. 1955;176:780&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">13265825</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibow S, et al. The dynamic structure of filamentous tau. Angew Chem Int Ed Engl. 2011;50:11520&#x2013;11524.</Citation><ArticleIdList><ArticleId IdType="pubmed">21990182</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50&#x2019;s selectivity for Alzheimer&#x2019;s disease pathology. J Biol Chem. 1996;271:32789&#x2013;32795.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52:511&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol. 2002;51:525&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11921059</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110:9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A. 2004;101:8342&#x2013;8347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420396</ArticleId><ArticleId IdType="pubmed">15155909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadavath H, et al. Folding of the Tau protein on microtubules. Angew Chem Int Ed Engl. 2015;54:10347&#x2013;10351.</Citation><ArticleIdList><ArticleId IdType="pubmed">26094605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97:5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C, et al. Identification of key amino acids responsible for the distinct aggregation properties of microtubule&#x2010;associated protein 2 and tau. J Neurochem. 2015;135:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049617</ArticleId><ArticleId IdType="pubmed">26134402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry. 1994;33:9511&#x2013;9522.</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron. 2016;92:796&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajava AV, Steven AC. Beta-rolls, beta-helices, and other beta-solenoid proteins. Adv Protein Chem. 2006;73:55&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmer C, et al. Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science. 2008;319:1523&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">18339938</ArticleId></ArticleIdList></Reference><Reference><Citation>Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016;539:227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830791</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann US, et al. Structure-based drug design identifies polythiophenes as antiprion compounds. Sci Transl Med. 2015;7:299ra123.</Citation><ArticleIdList><ArticleId IdType="pubmed">26246168</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;slund A, et al. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem Biol. 2009;4:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886514</ArticleId><ArticleId IdType="pubmed">19624097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb HC, Andr&#xe9;s JI. Tau positron emission tomography imaging. Cold Spring Harb Perspect Biol. 2017;9:a023721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411699</ArticleId><ArticleId IdType="pubmed">27940517</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem. 2015;290:1049&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14:331&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. Gctf: Real-time CTF determination and correction. J Struct Biol. 2016;193:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA, Dodson EJ. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr D. 1997;53:240&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Iverson TM, Alber BE, Kisker C, Ferry JG, Rees DC. A closer look at the active site of gamma-class carbonic anhydrases: high-resolution crystallographic studies of the carbonic anhydrase from Methanosarcina thermophila. Biochemistry. 2000;39:9222&#x2013;9231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. 2010;66:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28683104</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>RNA stores tau reversibly in complex coacervates.</ArticleTitle><Pagination><StartPage>e2002183</StartPage><MedlinePgn>e2002183</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2002183</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pbio.2002183</ELocationID><Abstract><AbstractText>Nonmembrane-bound organelles that behave like liquid droplets are widespread among eukaryotic cells. Their dysregulation appears to be a critical step in several neurodegenerative conditions. Here, we report that tau protein, the primary constituent of Alzheimer neurofibrillary tangles, can form liquid droplets and therefore has the necessary biophysical properties to undergo liquid-liquid phase separation (LLPS) in cells. Consonant with the factors that induce LLPS, tau is an intrinsically disordered protein that complexes with RNA to form droplets. Uniquely, the pool of RNAs to which tau binds in living cells are tRNAs. This phase state of tau is held in an approximately 1:1 charge balance across the protein and the nucleic acid constituents, and can thus be maximal at different RNA:tau mass ratios, depending on the biopolymer constituents involved. This feature is characteristic of complex coacervation. We furthermore show that the LLPS process is directly and sensitively tuned by salt concentration and temperature, implying it is modulated by both electrostatic interactions between the involved protein and nucleic acid constituents, as well as net changes in entropy. Despite the high protein concentration within the complex coacervate phase, tau is locally freely tumbling and capable of diffusing through the droplet interior. In fact, tau in the condensed phase state does not reveal any immediate changes in local protein packing, local conformations and local protein dynamics from that of tau in the dilute solution state. In contrast, the population of aggregation-prone tau as induced by the complexation with heparin is accompanied by large changes in local tau conformations and irreversible aggregation. However, prolonged residency within the droplet state eventually results in the emergence of detectable &#x3b2;-sheet structures according to thioflavin-T assay. These findings suggest that the droplet state can incubate tau and predispose the protein toward the formation of insoluble fibrils.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-3238-2376</Identifier><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yanxian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biomolecular Science and Engineering, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eschmann</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Elmer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Molecular, Cell and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Songi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, California, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056058</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010610</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28683104</ArticleId><ArticleId IdType="pmc">PMC5500003</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.2002183</ArticleId><ArticleId IdType="pii">pbio.2002183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996;383(6600):550&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Letters. 1996;399(3):344&#x2013;9. doi: http://dx.doi.org/10.1016/S0014-5793(96)01386-5
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(96)01386-5</ArticleId><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang D, Zhao J, Qu M, Zhou X, He H, et al. The Proline-Rich Domain and the Microtubule Binding Domain of Protein Tau acting as RNA Binding Domains. Protein &amp; Peptide Letters. 2006;13:679&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders David W, Kaufman Sarah K, DeVos Sarah L, Sharma Apurwa M, Mirbaha H, Li A, et al.
Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron. 2014;82(6):1271&#x2013;88. doi: 10.1016/j.neuron.2014.04.047
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al.
Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biology. 2009;11(7). doi: 10.1038/ncb1901
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee Hyun O, Jawerth L, Maharana S, Jahnel M, Hein Marco Y, et al.
A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162(5):1066&#x2013;77. doi: 10.1016/j.cell.2015.07.047
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.07.047</ArticleId><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke Kathleen A, Janke Abigail M, Rhine Christy L, Fawzi Nicolas L. Residue-by-Residue View of In Vitro FUS Granules that Bind the C-Terminal Domain of RNA Polymerase II. Molecular Cell. 2015;60(2):231&#x2013;41. doi: 10.1016/j.molcel.2015.09.006
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.09.006</ArticleId><ArticleId IdType="pmc">PMC4609301</ArticleId><ArticleId IdType="pubmed">26455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, Brangwynne CP. Spatiotemporal Control of Intracellular Phase Transitions Using Light-Activated optoDroplets. Cell. 2017;168(1&#x2013;2):159&#x2013;71.e14. doi: 10.1016/j.cell.2016.11.054
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.054</ArticleId><ArticleId IdType="pmc">PMC5562165</ArticleId><ArticleId IdType="pubmed">28041848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, et al.
Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149(4):753&#x2013;67. doi: 10.1016/j.cell.2012.04.017
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.04.017</ArticleId><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim Hong J, Mitrea DM, Sarkar M, Freibaum BD, et al.
C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167(3):774&#x2013;88.e17. doi: 10.1016/j.cell.2016.10.002
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, et al.
Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell. 2016;167(3):789&#x2013;802.e12. doi: 10.1016/j.cell.2016.10.003
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.003</ArticleId><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj Anderson P, Kim Hong J, et al.
Phase Separation by Low Complexity Domains Promotes Stress Granule Assembly and Drives Pathological Fibrillization. Cell. 2015;163(1):123&#x2013;33. doi: 10.1016/j.cell.2015.09.015
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al.
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467&#x2013;73. doi: 10.1038/nature11922
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter David SW, Rosen Michael K, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Molecular Cell. 2015;60(2):208&#x2013;19. doi: 10.1016/j.molcel.2015.08.018
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.08.018</ArticleId><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak Chi W, Kosno M, Holehouse Alex S, Padrick Shae B, Mittal A, Ali R, et al.
Sequence Determinants of Intracellular Phase Separation by Complex Coacervation of a Disordered Protein. Molecular Cell. 2016;63(1):72&#x2013;85. doi: 10.1016/j.molcel.2016.05.042
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.05.042</ArticleId><ArticleId IdType="pmc">PMC4973464</ArticleId><ArticleId IdType="pubmed">27392146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jho Y, Yoo HY, Lin Y, Han S, Hwang DS. Molecular and structural basis of low interfacial energy of complex coacervates in water. Advances in Colloid and Interface Science. 2016. 
http://dx.doi.org/10.1016/j.cis.2016.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cis.2016.07.003</ArticleId><ArticleId IdType="pubmed">27499328</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating CD. Aqueous Phase Separation as a Possible Route to Compartmentalization of Biological Molecules. Accounts of Chemical Research. 2012;45(12):2114&#x2013;24. doi: 10.1021/ar200294y
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar200294y</ArticleId><ArticleId IdType="pmc">PMC3525015</ArticleId><ArticleId IdType="pubmed">22330132</ArticleId></ArticleIdList></Reference><Reference><Citation>Priftis D, Megley K, Laugel N, Tirrell M. Complex coacervation of poly(ethylene-imine)/polypeptide aqueous solutions: Thermodynamic and rheological characterization. Journal of Colloid and Interface Science. 2013;398:39&#x2013;50. doi: 10.1016/j.jcis.2013.01.055
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcis.2013.01.055</ArticleId><ArticleId IdType="pubmed">23518303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott Timothy J, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, et al.
Phase Transition of a Disordered Nuage Protein Generates Environmentally Responsive Membraneless Organelles. Molecular Cell. 57(5):936&#x2013;47. doi: 10.1016/j.molcel.2015.01.013
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.01.013</ArticleId><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-Y, Yoo HY, Jho Y, Han S, Hwang DS. Bicontinuous Fluid Structure with Low Cohesive Energy: Molecular Basis for Exceptionally Low Interfacial Tension of Complex Coacervate Fluids. ACS Nano. 2016;10(5):5051&#x2013;62. doi: 10.1021/acsnano.5b07787
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.5b07787</ArticleId><ArticleId IdType="pubmed">27152954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bungenberg de Jong HG. Colloid Science. In: Kruyt HR, editor. II. Amsterdam: Elsevier Publishing Co. Inc; 1949. p. 335&#x2013;432.</Citation></Reference><Reference><Citation>Hwang DS, Zeng H, Srivastava A, Krogstad DV, Tirrell M, Israelachvili JN, et al.
Viscosity and interfacial properties in a mussel-inspired adhesive coacervate. Soft Matter. 2010;6(14):3232&#x2013;6. doi: 10.1039/C002632H
</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C002632H</ArticleId><ArticleId IdType="pmc">PMC3085400</ArticleId><ArticleId IdType="pubmed">21544267</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbeek JT, Voorn MJ. Phase separation in polyelectrolyte solutions; theory of complex coacervation. J Cell Physiol Suppl. 1957;49(Suppl 1):7&#x2013;22; discussion, -6. .</Citation><ArticleIdList><ArticleId IdType="pubmed">13449108</ArticleId></ArticleIdList></Reference><Reference><Citation>Aumiller WM, Pir-Cakmak F, Davis BW, Keating CD. RNA-based coacervates as a model for membraneless organelles: Formation, properties, and interfacial liposome assembly. Langmuir. 2016. 
doi: 10.1021/acs.langmuir.6b02499
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.6b02499</ArticleId><ArticleId IdType="pubmed">27599198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Membraneless organelles: Phasing in and out. Nat Chem. 2016;8(6):528&#x2013;30. doi: 10.1038/nchem.2534
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchem.2534</ArticleId><ArticleId IdType="pubmed">27219695</ArticleId></ArticleIdList></Reference><Reference><Citation>Banani SF, Lee HO, Hyman AA, Rosen MK. Biomolecular condensates: organizers of cellular biochemistry. Nat Rev Mol Cell Biol. 2017;advance online publication. doi: 10.1038/nrm.2017.7
http://www.nature.com/nrm/journal/vaop/ncurrent/abs/nrm.2017.7.html#supplementary-information. </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.7</ArticleId><ArticleId IdType="pmc">PMC7434221</ArticleId><ArticleId IdType="pubmed">28225081</ArticleId></ArticleIdList></Reference><Reference><Citation>Eschmann NA, Georgieva ER, Ganguly P, Borbat PP, Rappaport MD, Akdogan Y, et al.
Signature of an aggregation-prone conformation of tau. Scientific Reports. 2017;7:44739
doi: 10.1038/srep44739
https://www.nature.com/articles/srep44739#supplementary-information. </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44739</ArticleId><ArticleId IdType="pmc">PMC5356194</ArticleId><ArticleId IdType="pubmed">28303942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehmelt L, Halpain S. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 2005;6(1):204
doi: 10.1186/gb-2004-6-1-204
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-6-1-204</ArticleId><ArticleId IdType="pmc">PMC549057</ArticleId><ArticleId IdType="pubmed">15642108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al.
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;8. http://www.nature.com/neuro/journal/v14/n4/abs/nn.2778.html#supplementary-information. doi: 10.1038/nn.2778
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppertz I, Attig J, D&#x2019;Ambrogio A, Easton LE, Sibley CR, Sugimoto Y, et al.
iCLIP: Protein&#x2013;RNA interactions at nucleotide resolution. Methods. 2014;65(3):274&#x2013;87. doi: 10.1016/j.ymeth.2013.10.011
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2013.10.011</ArticleId><ArticleId IdType="pmc">PMC3988997</ArticleId><ArticleId IdType="pubmed">24184352</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedersdorf M, Keene J. Advancing the functional utility of PAR-CLIP by quantifying background binding to mRNAs and lncRNAs. Genome Biology. 2014;15(1):R2
doi: 10.1186/gb-2014-15-1-r2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2014-15-1-r2</ArticleId><ArticleId IdType="pmc">PMC4053780</ArticleId><ArticleId IdType="pubmed">24393468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al.
Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141(1):129&#x2013;41. doi: 10.1016/j.cell.2010.03.009 ; PubMed Central PMCID: PMC2861495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.03.009</ArticleId><ArticleId IdType="pmc">PMC2861495</ArticleId><ArticleId IdType="pubmed">20371350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascano M, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, et al.
FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492(7429):382&#x2013;6. http://www.nature.com/nature/journal/v492/n7429/abs/nature11737.html#supplementary-information. doi: 10.1038/nature11737
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11737</ArticleId><ArticleId IdType="pmc">PMC3528815</ArticleId><ArticleId IdType="pubmed">23235829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, Farazi TA, et al.
RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol. 2011;18(12):1428&#x2013;31. http://www.nature.com/nsmb/journal/v18/n12/abs/nsmb.2163.html#supplementary-information. doi: 10.1038/nsmb.2163
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2163</ArticleId><ArticleId IdType="pmc">PMC3230689</ArticleId><ArticleId IdType="pubmed">22081015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny PJ, Zhou H, Kim M, Skariah G, Khetani RS, Drnevich J, et al.
MOV10 and FMRP regulate AGO2 association with microRNA recognition elements. Cell reports. 2014;9(5):1729&#x2013;41. doi: 10.1016/j.celrep.2014.10.054
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.10.054</ArticleId><ArticleId IdType="pmc">PMC4268400</ArticleId><ArticleId IdType="pubmed">25464849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder SP, Recht MI, Williamson JR. Quantitative analysis of protein-RNA interactions by gel mobility shift. Methods in molecular biology (Clifton, NJ). 2008;488:99&#x2013;115. doi: 10.1007/978-1-60327-475-3_7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60327-475-3_7</ArticleId><ArticleId IdType="pmc">PMC2928675</ArticleId><ArticleId IdType="pubmed">18982286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucconi BE, Ballin JD, Brewer BY, Ross CR, Huang J, Toth EA, et al.
Alternatively Expressed Domains of AU-rich Element RNA-binding Protein 1 (AUF1) Regulate RNA-binding Affinity, RNA-induced Protein Oligomerization, and the Local Conformation of Bound RNA Ligands. Journal of Biological Chemistry. 2010;285(50):39127&#x2013;39. doi: 10.1074/jbc.M110.180182
</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.180182</ArticleId><ArticleId IdType="pmc">PMC2998080</ArticleId><ArticleId IdType="pubmed">20926381</ArticleId></ArticleIdList></Reference><Reference><Citation>Okunola HL, Krainer AR. Cooperative-Binding and Splicing-Repressive Properties of hnRNP A1. Molecular and Cellular Biology. 2009;29(20):5620&#x2013;31. doi: 10.1128/MCB.01678-08
</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01678-08</ArticleId><ArticleId IdType="pmc">PMC2756886</ArticleId><ArticleId IdType="pubmed">19667073</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Berry RW, Binder LI. Modeling Tau Polymerization in Vitro: A Review and Synthesis&#x2020;. Biochemistry. 2003;42(51):15009&#x2013;17. doi: 10.1021/bi035722s
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi035722s</ArticleId><ArticleId IdType="pubmed">14690409</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds MR, Berry RW, Binder LI. Site-Specific Nitration Differentially Influences &#x3c4; Assembly in Vitro. Biochemistry. 2005;44(42):13997&#x2013;4009. doi: 10.1021/bi051028w
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi051028w</ArticleId><ArticleId IdType="pubmed">16229489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortony JH, Hwang DS, Franck JM, Waite JH, Han S. Asymmetric Collapse in Biomimetic Complex Coacervates Revealed by Local Polymer and Water Dynamics. Biomacromolecules. 2013;14(5):1395&#x2013;402. doi: 10.1021/bm4000579
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bm4000579</ArticleId><ArticleId IdType="pmc">PMC4090114</ArticleId><ArticleId IdType="pubmed">23540713</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of &#x3c4; into Filaments in the Presence of Heparin: The Minimal Sequence Required for &#x3c4; - &#x3c4; Interaction. Journal of Neurochemistry. 1996;67(3):1183&#x2013;90. doi: 10.1046/j.1471-4159.1996.67031183.x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67031183.x</ArticleId><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Barghorn S, Biernat J, Mandelkow E-M, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochimica et Biophysica Acta (BBA)&#x2014;Molecular Basis of Disease. 2005;1739(2&#x2013;3):158&#x2013;66. http://dx.doi.org/10.1016/j.bbadis.2004.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.09.010</ArticleId><ArticleId IdType="pubmed">15615635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolde PRt, Frenkel D. Enhancement of Protein Crystal Nucleation by Critical Density Fluctuations. Science. 1997;277(5334):1975</Citation><ArticleIdList><ArticleId IdType="pubmed">9302288</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberkane L, Jasniewski J, Gaiani C, Scher J, Sanchez C. Thermodynamic Characterization of Acacia Gum&#x2212;&#x3b2;-Lactoglobulin Complex Coacervation. Langmuir. 2010;26(15):12523&#x2013;33. doi: 10.1021/la100705d
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/la100705d</ArticleId><ArticleId IdType="pubmed">20586462</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu AY, Melton LD, Jameson GB, Williams MAK, McGillivray DJ. Structural mechanism of complex assemblies: characterisation of beta-lactoglobulin and pectin interactions. Soft Matter. 2015;11(34):6790&#x2013;9. doi: 10.1039/c5sm01378j
</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c5sm01378j</ArticleId><ArticleId IdType="pubmed">26223829</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackburn GM. Nucleic Acids in Chemistry and Biology: Royal Society of Chemistry; 2006.</Citation></Reference><Reference><Citation>Carlstr&#xf6;m D. THE CRYSTAL STRUCTURE OF &#x3b1;-CHITIN (POLY-N-ACETYL-D-GLUCOSAMINE). The Journal of Biophysical and Biochemical Cytology. 1957;3(5):669&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224123</ArticleId><ArticleId IdType="pubmed">13475384</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, Sabry JH, Martone ME, Deerinck TJ, Ellisman MH, Bassell GJ, et al. Translocation of RNA granules in living neurons. Journal of Neuroscience. 1996;16(24):7812&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579227</ArticleId><ArticleId IdType="pubmed">8987809</ArticleId></ArticleIdList></Reference><Reference><Citation>Rook MS, Lu M, Kosik KS. CaMKIIalpha 3' untranslated region-directed mRNA translocation in living neurons: visualization by GFP linkage. J Neurosci. 2000;20(17):6385&#x2013;93. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772957</ArticleId><ArticleId IdType="pubmed">10964944</ArticleId></ArticleIdList></Reference><Reference><Citation>Krichevsky AM, Kosik KS. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron. 2001;32
doi: 10.1016/S0896-6273(01)00508-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00508-6</ArticleId><ArticleId IdType="pubmed">11719208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler JR, Matheny T, Jain S, Abrisch R, Parker R. Distinct stages in stress granule assembly and disassembly. eLife. 2016;5:e18413
doi: 10.7554/eLife.18413
</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.18413</ArticleId><ArticleId IdType="pmc">PMC5014549</ArticleId><ArticleId IdType="pubmed">27602576</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J, Calidas D, Schmidt H, Lu T, Rasoloson D, Seydoux G. Spatial patterning of P granules by RNA-induced phase separation of the intrinsically-disordered protein MEG-3. eLife. 2016;5:e21337
doi: 10.7554/eLife.21337
</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.21337</ArticleId><ArticleId IdType="pmc">PMC5262379</ArticleId><ArticleId IdType="pubmed">27914198</ArticleId></ArticleIdList></Reference><Reference><Citation>Milovanovic D, De Camilli P. Synaptic Vesicle Clusters at Synapses: A Distinct Liquid Phase?
Neuron. 93(5):995&#x2013;1002. doi: 10.1016/j.neuron.2017.02.013
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5347463</ArticleId><ArticleId IdType="pubmed">28279363</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwicker D, Seyboldt R, Weber CA, Hyman AA, Julicher F. Growth and division of active droplets provides a model for protocells. Nat Phys. 2017;13(4):408&#x2013;13. doi: 10.1038/nphys3984
http://www.nature.com/nphys/journal/v13/n4/abs/nphys3984.html#supplementary-information.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nphys3984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Panas MD, Achorn CA, Lyons S, Tisdale S, Hickman T, et al.
G3BP&#x2013;Caprin1&#x2013;USP10 complexes mediate stress granule condensation and associate with 40S subunits. The Journal of Cell Biology. 2016;212(7):845&#x2013;60. doi: 10.1083/jcb.201508028
</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201508028</ArticleId><ArticleId IdType="pmc">PMC4810302</ArticleId><ArticleId IdType="pubmed">27022092</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker R, Sheth U. P bodies and the control of mRNA translation and degradation. Mol Cell. 2007;25
doi: 10.1016/j.molcel.2007.02.011
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2007.02.011</ArticleId><ArticleId IdType="pubmed">17349952</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 126(4):663&#x2013;76. doi: 10.1016/j.cell.2006.07.024
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.024</ArticleId><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al.
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics. 2012;21(15):3500&#x2013;12. doi: 10.1093/hmg/dds161
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds161</ArticleId><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong H, Wang C, Knoferle J, Walker D, Balestra Maureen E, Tong Leslie M, et al.
Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2013;1(3):226&#x2013;34. doi: 10.1016/j.stemcr.2013.08.001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2013.08.001</ArticleId><ArticleId IdType="pmc">PMC3849235</ArticleId><ArticleId IdType="pubmed">24319659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak SK, Huang YA, Iranmanesh S, Vangipuram M, Sundararajan R, Nguyen L, et al.
Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int. 2012;2012:140427. doi: 10.1155/2012/140427 ; PubMed Central PMCID: PMCPMC3339118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/140427</ArticleId><ArticleId IdType="pmc">PMC3339118</ArticleId><ArticleId IdType="pubmed">22567022</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al.
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402&#x2013;14. doi: 10.1016/j.neuron.2013.07.046
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet journal. 2011;17(1):10&#x2013;2.</Citation></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Meth. 2012;9(4):357&#x2013;9. doi: 10.1038/nmeth.1923
http://www.nature.com/nmeth/journal/v9/n4/abs/nmeth.1923.html#supplementary-information. </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184&#x2013;5. doi: 10.1093/bioinformatics/bts356
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts356</ArticleId><ArticleId IdType="pubmed">22743226</ArticleId></ArticleIdList></Reference><Reference><Citation>Althammer S, Gonz&#xe1;lez-Vallinas J, Ballar&#xe9; C, Beato M, Eyras E. Pyicos: a versatile toolkit for the analysis of high-throughput sequencing data. Bioinformatics. 2011;27(24):3333&#x2013;40. doi: 10.1093/bioinformatics/btr570
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr570</ArticleId><ArticleId IdType="pmc">PMC3232367</ArticleId><ArticleId IdType="pubmed">21994224</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig J, Zarnack K, Rot G, Curk T, Kayikci M, Zupan B, et al.
iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol. 2010;17(7):909&#x2013;15. http://www.nature.com/nsmb/journal/v17/n7/abs/nsmb.1838.html#supplementary-information. doi: 10.1038/nsmb.1838
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.1838</ArticleId><ArticleId IdType="pmc">PMC3000544</ArticleId><ArticleId IdType="pubmed">20601959</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, Salzberg S. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biology. 2009;10(3):R25
doi: 10.1186/gb-2009-10-3-r25
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2009-10-3-r25</ArticleId><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Meth. 2012;9(7):671&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasman GD, editor. Handbook of Biochemistry and Molecular Biology. 3rd ed. Cleveland, OH: CRC Press; 1976.</Citation></Reference><Reference><Citation>Jeschke G, Chechik V, Ionita P, Godt A, Zimmermann H, Banham J, et al.
DeerAnalysis2006&#x2014;a comprehensive software package for analyzing pulsed ELDOR data. Applied Magnetic Resonance. 2006;30(3):473&#x2013;98. doi: 10.1007/BF03166213</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03166213</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M, Ko L-w, Easson C, Yen S-H. tau Assembly in Inducible Transfectants Expressing Wild-Type or FTDP-17 tau. The American Journal of Pathology. 2002;161(5):1711&#x2013;22. doi: 10.1016/S0002-9440(10)64448-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64448-3</ArticleId><ArticleId IdType="pmc">PMC1850799</ArticleId><ArticleId IdType="pubmed">12414518</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. The Co-chaperone BAG2 Sweeps PHF Insoluble Tau from the Microtubule. Journal of Neuroscience. 2009;29(7):2151&#x2013;61. doi: 10.1523/JNEUROSCI.4660-08.2009
</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4660-08.2009</ArticleId><ArticleId IdType="pmc">PMC2768429</ArticleId><ArticleId IdType="pubmed">19228967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28692710</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.</ArticleTitle><Pagination><StartPage>1073</StartPage><EndPage>1080</EndPage><MedlinePgn>1073-1080</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.1359</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The utility of plasma total tau level as a prognostic marker for cognitive decline and dementia is not well understood.</AbstractText><AbstractText Label="OBJECTIVES">To determine (1) the association between plasma total tau level, cognitive decline, and risk of mild cognitive impairment (MCI) and dementia; (2) whether this association differs by the presence of elevated brain amyloid &#x3b2; (A&#x3b2;); and (3) whether plasma total tau level is associated with cognitive decline over a short interval of 15 months.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The present analyses included 458 participants who were enrolled in a population-based cohort study between October 2008 and June 2013. All included participants had available plasma total tau levels, A&#x3b2; positron emission tomography imaging, and a complete neuropsychological examine at the same visit, as well as at least 1 follow-up visit.</AbstractText><AbstractText Label="EXPOSURES">Concentration of plasma total tau.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Risk of MCI and dementia; global and domain-specific cognitive decline.</AbstractText><AbstractText Label="RESULTS">Of the 458 participants, 287 (62.7%) were men; mean (SD) age was 80.6 (5.6) years. Among cognitively normal (CN) participants oversampled for elevated brain A&#x3b2;, both the middle (hazard ratio [HR], 2.43; 95% CI, 1.25-4.72) and highest (HR, 2.02; 95% CI, 1.01-4.06) tertiles of plasma total tau level, compared with the lowest, were associated with an increased risk of MCI. Among participants with MCI, higher plasma total tau levels were not significantly associated with risk of dementia (all-cause dementia or Alzheimer disease). Among all participants, higher levels of plasma total tau, examined as a continuous variable, were associated with significant (P&#x2009;&lt;&#x2009;.05) declines in global cognition, memory, attention, and visuospatial ability over a median follow-up of 3.0 years (range, 1.1-4.9 years). In additional analyses restricting the follow-up to 15 months, plasma total tau did not predict decline among CN participants. However, among participants with MCI, higher plasma total tau levels were associated with greater decline in both visuospatial ability (regression coefficient [b]&#x2009;=&#x2009;-0.50 [0.15], P&#x2009;&lt;&#x2009;.001) and global cognition (b&#x2009;=&#x2009;-0.27 [0.10], P&#x2009;=&#x2009;.009) at 15 months. Adjusting for elevated brain A&#x3b2; did not attenuate any association. There was no interaction between plasma total tau level and brain A&#x3b2; for prognosis with any outcome.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These results suggest that elevated plasma total tau levels are associated with cognitive decline, but the results differ based on cognitive status and the duration of follow-up. The association between plasma total tau levels and cognition is independent of elevated brain A&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Clinton E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wennberg</LastName><ForeName>Alexandra M V</ForeName><Initials>AMV</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Airey</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savica</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Mielke served as a paid consultant for Eli Lilly and Lysosomal Therapeutics Inc and receives research support from National Institutes of Health (NIH) grants R01 AG49704, P50 AG44170, and U01 AG06786; Department of Defense grant W81XWH-15-1; and unrestricted research grants from Biogen and Roche. Drs Airey and Dage are employees of Eli Lilly and Company. Drs Machulda and Roberts receive research support from NIH grant U01 AG006786. Dr Knopman served as deputy editor for <i>Neurology</i>; serves on a data safety monitoring board for Lundbeck Pharmaceuticals, and for the Dominantly Inherited Alzheimer Network study; is an investigator in clinical trials sponsored by TauRx Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer&#x2019;s Disease Cooperative Study; and receives research support from NIH grants R01 AG011378, P50 AG016574, U01 AG006786, U01 AG029550, U01 AG032306, and U01 HL096917. Dr Jack has provided paid consulting services for Eli Lilly and Company. He receives research funding from NIH grants R01 AG011378, U01 HL096917, U01 AG024904, RO1 AG041851, R01 AG037551, R01 AG043392, and U01 AG006786 and holds the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr Petersen is paid to serve on scientific advisory boards for Pfizer Inc, Janssen Alzheimer Immunotherapy, Roche Inc, Merck Inc, and Genentech Inc; receives royalties from the publication of <i>Mild Cognitive Impairment</i> (Oxford University Press, 2003); and receives research support from NIH grants P50 AG016574, U01 AG006786, U01 AG024904, and R01 AG011378. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28692710</ArticleId><ArticleId IdType="pmc">PMC5710182</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.1359</ArticleId><ArticleId IdType="pii">2643175</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, et al. . Plasma tau levels in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(2):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu MJ, Yang SY, Horng HE, et al. . Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer&#x2019;s disease. ACS Chem Neurosci. 2013;4(12):1530-1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867966</ArticleId><ArticleId IdType="pubmed">24090201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Xiao S, Liu Y, et al. . The efficacy of plasma biomarkers in early diagnosis of Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2014;29(7):713-719.</Citation><ArticleIdList><ArticleId IdType="pubmed">24318929</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu MJ, Chen YF, Chen TF, et al. . Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer&#x2019;s disease. Hum Brain Mapp. 2014;35(7):3132-3142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6869439</ArticleId><ArticleId IdType="pubmed">24129926</ArticleId></ArticleIdList></Reference><Reference><Citation>Dage JL, Wennberg AM, Airey DC, et al. . Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement. 2016;12(12):1226-1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5148697</ArticleId><ArticleId IdType="pubmed">27436677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Janelidze S, et al. ; ADNI Investigators . Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827-1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The Short Test of Mental Status: correlations with standardized psychometric testing. Arch Neurol. 1991;48(7):725-728.</Citation><ArticleIdList><ArticleId IdType="pubmed">1859300</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L&#x2019;examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Wechsler D. Manual for the Wechsler Memory Scale&#x2013;Revised. San Antonio, TX: The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia, PA: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed New York, NY: Oxford University Press; 2006.</Citation></Reference><Reference><Citation>Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, et al. . Mayo&#x2019;s Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. Clin Neuropsychol. 1992;6(suppl):1-30.</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage. 2005;26(2):600-608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to National Institute on Aging&#x2013;Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765-775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain. 2015;138(pt 5):1370-1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer&#x2019;s disease. Lancet Neurol. 2003;2(10):605-613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28703214</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>547</Volume><Issue>7662</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Stop Alzheimer's before it starts.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>155</EndPage><MedlinePgn>153-155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/547153a</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG046363</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28703214</ArticleId><ArticleId IdType="doi">10.1038/547153a</ArticleId><ArticleId IdType="pii">547153a</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Heart J. 2015 Sep 21;36(36):2425-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26009596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Aug 2;488(7409):96-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2012 Aug 14;7:39</Citation><ArticleIdList><ArticleId IdType="pubmed">22892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2010 Jan;45(1):30-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19853650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Oct;20(10 ):1179-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26055427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 Nov 2;8(363):363ra150</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2016 Sep 1;73(9):1070-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2014 Aug;76(2):185-205</Citation><ArticleIdList><ArticleId IdType="pubmed">24853080</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 Mar;9(2):123-131.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">23411394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Aug 31;537(7618):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Aug 30;367(9):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28671693</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Transcriptomic analysis of purified human cortical microglia reveals age-associated changes.</ArticleTitle><Pagination><StartPage>1162</StartPage><EndPage>1171</EndPage><MedlinePgn>1162-1171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4597</ELocationID><Abstract><AbstractText>Microglia are essential for CNS homeostasis and innate neuroimmune function, and play important roles in neurodegeneration and brain aging. Here we present gene expression profiles of purified microglia isolated at autopsy from the parietal cortex of 39 human subjects with intact cognition. Overall, genes expressed by human microglia were similar to those in mouse, including established microglial genes CX3CR1, P2RY12 and ITGAM (CD11B). However, a number of immune genes, not identified as part of the mouse microglial signature, were abundantly expressed in human microglia, including TLR, Fc&#x3b3; and SIGLEC receptors, as well as TAL1 and IFI16, regulators of proliferation and cell cycle. Age-associated changes in human microglia were enriched for genes involved in cell adhesion, axonal guidance, cell surface receptor expression and actin (dis)assembly. Limited overlap was observed in microglial genes regulated during aging between mice and humans, indicating that human and mouse microglia age differently.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galatro</LastName><ForeName>Thais F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Molecular and Cellular Biology, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtman</LastName><ForeName>Inge R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerario</LastName><ForeName>Antonio M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vainchtein</LastName><ForeName>Ilia D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwer</LastName><ForeName>Nieske</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sola</LastName><ForeName>Paula R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Molecular and Cellular Biology, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veras</LastName><ForeName>Mariana M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-8363-4329</Identifier><AffiliationInfo><Affiliation>Brazilian Aging Brain Study Group, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Tulio F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Center for Studies of Cellular and Molecular Therapy (NAP-NETCEM-NUCEL), University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry Institute, Department of Biochemistry, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Renata E P</ForeName><Initials>REP</Initials><AffiliationInfo><Affiliation>Brazilian Aging Brain Study Group, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wes</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sogayar</LastName><ForeName>Mari C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Center for Studies of Cellular and Molecular Therapy (NAP-NETCEM-NUCEL), University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laman</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Dunnen</LastName><ForeName>Wilfred</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqualucci</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Brazilian Aging Brain Study Group, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oba-Shinjo</LastName><ForeName>Sueli M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Molecular and Cellular Biology, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boddeke</LastName><ForeName>Erik W G M</ForeName><Initials>EWGM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>Suely K N</ForeName><Initials>SKN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Molecular and Cellular Biology, School of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Studies of Cellular and Molecular Therapy (NAP-NETCEM-NUCEL), University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggen</LastName><ForeName>Bart J L</ForeName><Initials>BJL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509295">ITGAM protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28671693</ArticleId><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pii">nn.4597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 2008 Jan;40(1):51-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17994017</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2005 Aug;5(8):1789-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15996224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2016 Dec;17 (12 ):1397-1406</Citation><ArticleIdList><ArticleId IdType="pubmed">27776109</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13794-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20639463</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2002 Nov 15;169(10):5638-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12421943</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2015 Feb 18;85(4):695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">25661180</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2014 Oct;14(10):653-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25234143</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2014 Mar 31;15:92</Citation><ArticleIdList><ArticleId IdType="pubmed">24685233</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e46683</Citation><ArticleIdList><ArticleId IdType="pubmed">23071613</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Rev. 2017 Mar;276(1):80-96</Citation><ArticleIdList><ArticleId IdType="pubmed">28258692</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11756671</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2013 Aug;21(8):413-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23726320</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2014;21(19):2146-55</Citation><ArticleIdList><ArticleId IdType="pubmed">24372213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2013 Jan 1;29(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2016 Nov;22(11):1358-1367</Citation><ArticleIdList><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Dec;16(12):1896-905</Citation><ArticleIdList><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2012 Mar 15;28(6):882-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2010 Feb;17(2):222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20062055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2014 Apr;10(4):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Sep 3;34(36):11929-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2004 Feb 12;20(3):307-15</Citation><ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Aug 12;6:28902</Citation><ArticleIdList><ArticleId IdType="pubmed">27514473</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):357-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19027346</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2010 Oct 8;7(4):532-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20887958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Mar;16(3):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Dec 4;159(6):1312-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 Jan 6;89(1):37-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2015 Jun;21(3):306-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24871624</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2015 Jul 15;195(2):477-87</Citation><ArticleIdList><ArticleId IdType="pubmed">26041540</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2017;1559:333-342</Citation><ArticleIdList><ArticleId IdType="pubmed">28063055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2015 Apr 20;43(7):e47</Citation><ArticleIdList><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2015 Sep 15;31(18):3066-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25979476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jul;18(7):965-77</Citation><ArticleIdList><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2012 Jun 1;28(11):1530-2</Citation><ArticleIdList><ArticleId IdType="pubmed">22539670</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2014 Mar;37(3):125-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24388427</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(4):e60921</Citation><ArticleIdList><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2012 Jan 1;188(1):29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">22079990</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Aug 19;353(6301):aad8670</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2003;122(2):421-36</Citation><ArticleIdList><ArticleId IdType="pubmed">14614907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Dec;18(12):1832-44</Citation><ArticleIdList><ArticleId IdType="pubmed">26571460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2009;4(8):1184-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2015 May 23;3:31</Citation><ArticleIdList><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2012 Sep;33(9):449-58</Citation><ArticleIdList><ArticleId IdType="pubmed">22721918</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2015 Jul 15;759:101-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25814260</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2014 Jan;17(1):131-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2014 Apr 1;30(7):923-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 May 22;78(4):631-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2012 Aug 08;9:190</Citation><ArticleIdList><ArticleId IdType="pubmed">22873355</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Oct 1;106(7):2534-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15928042</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Sep 26;345(6204):1251086</Citation><ArticleIdList><ArticleId IdType="pubmed">25258085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2010 Jan;69(1):70-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20010301</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Jan;35(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">23954174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2007 Jan 15;23(2):257-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17098774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2016 Mar;19(3):504-16</Citation><ArticleIdList><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Aug;36(8):2443.e9-2443.e20</Citation><ArticleIdList><ArticleId IdType="pubmed">26002684</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Jul 3;158(1):15-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Dec 4;159(6):1327-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Nov;10(11):1387-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2013 Jul 25;4(2):385-401</Citation><ArticleIdList><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2017 Jan 10;18(2):391-405</Citation><ArticleIdList><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2016 Jun 29;12 (6):e1005705</Citation><ArticleIdList><ArticleId IdType="pubmed">27355424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28715552</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia: The Age, Gene/Environment Susceptibility-Reykjavik Study.</ArticleTitle><Pagination><StartPage>1105</StartPage><EndPage>1112</EndPage><MedlinePgn>1105-1112</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2017.1397</ELocationID><Abstract><AbstractText Label="IMPORTANCE">With advancing age, an increased visibility of perivascular spaces (PVSs) on magnetic resonance imaging (MRI) is hypothesized to represent impaired drainage of interstitial fluid from the brain and may reflect underlying cerebral small vessel disease (SVD). However, whether large perivascular spaces (L-PVSs) (&gt;3 mm in diameter) visible on MRI are associated with SVD and cognitive deterioration in older individuals is unknown.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether L-PVSs are associated with the progression of the established MRI markers of SVD, cognitive decline, and increased risk of dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The prospective, population-based Age, Gene/Environment Susceptibility-Reykjavik Study assessed L-PVSs at baseline (September 1, 2002, through February 28, 2006) on MRI studies of the brain in 2612 participants. Participants returned for additional MRI from April 1, 2007, through September 30, 2011, and underwent neuropsychological testing at the 2 time points a mean (SD) of 5.2 (0.2) years apart. Data analysis was conducted from August 1, 2016, to May 4, 2017.</AbstractText><AbstractText Label="EXPOSURES">The presence, number, and location of L-PVSs.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident subcortical infarcts, cerebral microbleeds, and progression of white matter hyperintensities detected on MRI; cognitive decline defined as composite score changes between baseline and follow-up in the domains of memory, information processing speed, and executive function; and adjudicated incident dementia cases diagnosed according to international guidelines.</AbstractText><AbstractText Label="RESULTS">Of the 2612 study patients (mean [SD] age, 74.6 [4.8] years; 1542 [59.0%] female), 424 had L-PVSs and 2188 did not. The prevalence of L-PVSs was 16.2% (median number of L-PVSs, 1; range, 1-17). After adjusting for age, sex, and interval between baseline and follow-up scanning, the presence of L-PVSs was significantly associated with an increased risk of incident subcortical infarcts (adjusted risk ratio, 2.54; 95% CI, 1.76-3.68) and microbleeds (adjusted risk ratio, 1.43; 95% CI, 1.18-1.72) and a greater 5-year progression of white matter hyperintensity volume. The presence of L-PVSs was also associated with a steeper decline in information processing speed and more than quadrupled the risk of vascular dementia. All associations persisted when further adjusted for genetic and cerebrovascular risk factors. The associations with cognitive outcomes were independent of educational level, depression, and other SVD MRI markers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Large PVSs are an MRI marker of SVD and associated with the pathogenesis of vascular-related cognitive impairment in older individuals. Large PVSs should be included in assessments of vascular cognitive impairment in the older population and as potential targets for interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intramural Research Program, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigur&#xf0;sson</LastName><ForeName>Sigur&#xf0;ur</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf3;nsson</LastName><ForeName>P&#xe1;lmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiriksdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charidimou</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hemorrhagic Stroke Research Program, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu&#xf0;nason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Intramural Research Program, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059345" MajorTopicYN="Y">Cerebral Small Vessel Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007055" MajorTopicYN="N">Iceland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010841" MajorTopicYN="N">Pia Mater</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013346" MajorTopicYN="N">Subarachnoid Space</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28715552</ArticleId><ArticleId IdType="mid">NIHMS902245</ArticleId><ArticleId IdType="pmc">PMC5695230</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2017.1397</ArticleId><ArticleId IdType="pii">2643984</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. ; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, Berezuk C, McNeely AA, Gao F, McLaurin J, Black SE. Imaging the perivascular space as a potential biomarker of neurovascular and neurodegenerative diseases. Cell Mol Neurobiol. 2016;36(2):289-299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11482437</ArticleId><ArticleId IdType="pubmed">26993511</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int. 2004;45(4):545-552.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186921</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Kida S, Zhang ET. Pathways of fluid drainage from the brain: morphological aspects and immunological significance in rat and man. Brain Pathol. 1992;2(4):277-284.</Citation><ArticleIdList><ArticleId IdType="pubmed">1341963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwee RM, Kwee TC. Virchow-Robin spaces at MR imaging. Radiographics. 2007;27(4):1071-1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu YC, Tzourio C, Soumar&#xe9; A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study. Stroke. 2010;41(11):2483-2490.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864661</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter GM, Doubal FN, Jackson CA, et al. . Enlarged perivascular spaces and cerebral small vessel disease. Int J Stroke. 2015;10(3):376-381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463944</ArticleId><ArticleId IdType="pubmed">23692610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurford R, Charidimou A, Fox Z, Cipolotti L, Jager R, Werring DJ. MRI-visible perivascular spaces: relationship to cognition and small vessel disease MRI markers in ischaemic stroke and TIA. J Neurol Neurosurg Psychiatry. 2014;85(5):522-525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995332</ArticleId><ArticleId IdType="pubmed">24249785</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouhl RP, van Oostenbrugge RJ, Knottnerus IL, Staals JE, Lodder J. Virchow-Robin spaces relate to cerebral small vessel disease severity. J Neurol. 2008;255(5):692-696.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286319</ArticleId></ArticleIdList></Reference><Reference><Citation>Patankar TF, Mitra D, Varma A, Snowden J, Neary D, Jackson A. Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: study in elderly patients with dementia. AJNR Am J Neuroradiol. 2005;26(6):1512-1520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149063</ArticleId><ArticleId IdType="pubmed">15956523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, Berezuk C, McNeely AA, Scott CJ, Gao F, Black SE. Visible Virchow-Robin spaces on magnetic resonance imaging of Alzheimer&#x2019;s disease patients and normal elderly from the Sunnybrook Dementia Study. J Alzheimers Dis. 2015;43(2):415-424.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096616</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry. 2004;75(11):1519-1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738797</ArticleId><ArticleId IdType="pubmed">15489380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakushiji Y, Charidimou A, Hara M, et al. . Topography and associations of perivascular spaces in healthy adults: the Kashima Scan Study. Neurology. 2014;83(23):2116-2123.</Citation><ArticleIdList><ArticleId IdType="pubmed">25361776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu YC, Dufouil C, Soumar&#xe9; A, Mazoyer B, Chabriat H, Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. J Alzheimers Dis. 2010;22(2):663-672.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM, Smith EE, Biessels GJ, et al. ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1) . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714437</ArticleId><ArticleId IdType="pubmed">23867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. J Neurol. 1998;245(2):116-122.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507419</ArticleId></ArticleIdList></Reference><Reference><Citation>Takao M, Koto A, Tanahashi N, Fukuuchi Y, Takagi M, Morinaga S. Pathologic findings of silent, small hyperintense foci in the basal ganglia and thalamus on MRI. Neurology. 1999;52(3):666-668.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu YC, Dufouil C, Mazoyer B, et al. . Frequency and location of dilated Virchow-Robin spaces in elderly people: a population-based 3D MR imaging study. AJNR Am J Neuroradiol. 2011;32(4):709-713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965873</ArticleId><ArticleId IdType="pubmed">21349956</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TB, Launer LJ, Eiriksdottir G, et al. . Age, Gene/Environment Susceptibility&#x2013;Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165(9):1076-1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723948</ArticleId><ArticleId IdType="pubmed">17351290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. . Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry. 2008;79(9):1002-1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11090473</ArticleId><ArticleId IdType="pubmed">18270235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson S, Aspelund T, Forsberg L, et al. . Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik study. Neuroimage. 2012;59(4):3862-3870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712156</ArticleId><ArticleId IdType="pubmed">22119006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Sigurdsson S, Garcia M, et al. . Risk factors associated with incident cerebral microbleeds according to location in older people: the Age, Gene/Environment Susceptibility (AGES)&#x2013;Reykjavik Study. JAMA Neurol. 2015;72(6):682-688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698002</ArticleId><ArticleId IdType="pubmed">25867544</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoire SM, Chaudhary UJ, Brown MM, et al. . The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology. 2009;73(21):1759-1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">19933977</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski JS, Sigurdsson S, Jonsdottir MK, et al. . Cerebral infarcts and cognitive performance: importance of location and number of infarcts. Stroke. 2009;40(3):677-682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244834</ArticleId><ArticleId IdType="pubmed">19131654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer&#x2019;s Disease Diagnostic and Treatment Centers. Neurology. 1992;42(3, pt 1):473-480.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Becker JT, et al. . Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology. 2005;64(9):1539-1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883314</ArticleId></ArticleIdList></Reference><Reference><Citation>Arba F, Quinn TJ, Hankey GJ, et al. . 
Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack [published online August 19, 2016]. Int J Stroke . doi:10.1177/1747493016666091</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1747493016666091</ArticleId><ArticleId IdType="pubmed">27543501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. J Neurol Sci. 2010;299(1-2):66-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Padilla M, Knopman DS. Developmental aspects of the intracerebral microvasculature and perivascular spaces: insights into brain response to late-life diseases. J Neuropathol Exp Neurol. 2011;70(12):1060-1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227674</ArticleId><ArticleId IdType="pubmed">22082663</ArticleId></ArticleIdList></Reference><Reference><Citation>Deramecourt V, Slade JY, Oakley AE, et al. . Staging and natural history of cerebrovascular pathology in dementia. Neurology. 2012;78(14):1043-1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317531</ArticleId><ArticleId IdType="pubmed">22377814</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-&#x3b2; peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. Brain Pathol. 2008;18(2):253-266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Charidimou A, Jaunmuktane Z, Baron JC, et al. . White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology. 2014;82(1):57-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873625</ArticleId><ArticleId IdType="pubmed">24285616</ArticleId></ArticleIdList></Reference><Reference><Citation>Charidimou A, Werring DJ. Cerebral microbleeds and cognition in cerebrovascular disease: an update. J Neurol Sci. 2012;322(1-2):50-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">22717258</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, et al. . Topography of dilated perivascular spaces in subjects from a memory clinic cohort. Neurology. 2013;80(17):1551-1556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662325</ArticleId><ArticleId IdType="pubmed">23553482</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg NM, Kim AE, Gurol ME, et al. . Incidental cerebral microbleeds and cerebral blood flow in elderly individuals. JAMA Neurol. 2015;72(9):1021-1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724412</ArticleId><ArticleId IdType="pubmed">26167811</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veluw SJ, Biessels GJ, Bouvy WH, et al. . Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces. J Cereb Blood Flow Metab. 2016;36(3):576-580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4794108</ArticleId><ArticleId IdType="pubmed">26661250</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Hawkes CA, Kalaria RN, Werring DJ, Carare RO. White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol. 2015;25(1):63-78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028907</ArticleId><ArticleId IdType="pubmed">25521178</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer&#x2019;s disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757469</ArticleId><ArticleId IdType="pubmed">14707310</ArticleId></ArticleIdList></Reference><Reference><Citation>Aribisala BS, Wiseman S, Morris Z, et al. . Circulating inflammatory markers are associated with magnetic resonance imaging-visible perivascular spaces but not directly with white matter hyperintensities. Stroke. 2014;45(2):605-607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906539</ArticleId><ArticleId IdType="pubmed">24399375</ArticleId></ArticleIdList></Reference><Reference><Citation>Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012;78(10):720-727.</Citation><ArticleIdList><ArticleId IdType="pubmed">22357713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28677678</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2017</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits.</ArticleTitle><Pagination><StartPage>16063</StartPage><MedlinePgn>16063</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms16063</ELocationID><Abstract><AbstractText>Hexanucleotide repeat expansions in the C9ORF72 gene are the commonest known genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Expression of repeat transcripts and dipeptide repeat proteins trigger multiple mechanisms of neurotoxicity. How repeat transcripts get exported from the nucleus is unknown. Here, we show that depletion of the nuclear export adaptor SRSF1 prevents neurodegeneration and locomotor deficits in a Drosophila model of C9ORF72-related disease. This intervention suppresses cell death of patient-derived motor neuron and astrocytic-mediated neurotoxicity in co-culture assays. We further demonstrate that either depleting SRSF1 or preventing its interaction with NXF1 specifically inhibits the nuclear export of pathological C9ORF72 transcripts, the production of dipeptide-repeat proteins and alleviates neurotoxicity in Drosophila, patient-derived neurons and neuronal cell models. Taken together, we show that repeat RNA-sequestration of SRSF1 triggers the NXF1-dependent nuclear export of C9ORF72 transcripts retaining expanded hexanucleotide repeats and reveal a novel promising therapeutic target for neuroprotection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hautbergue</LastName><ForeName>Guillaume M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-1621-261X</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelli</LastName><ForeName>Lydia M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraiuolo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Martinez</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2728-6251</Identifier><AffiliationInfo><Affiliation>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higginbottom</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ya-Hui</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Claudia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myszczynska</LastName><ForeName>Monika A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garneret</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Jayanth S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karyka</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stopford</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Emma F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7468-5917</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5052-2101</Identifier><AffiliationInfo><Affiliation>Nationwide Children's Research Institute, Department of Pediatrics, The Ohio State University, 700 Children's Drive, Rm. WA3022, Columbus, Ohio 43205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Nationwide Children's Research Institute, Department of Pediatrics, The Ohio State University, 700 Children's Drive, Rm. WA3022, Columbus, Ohio 43205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Khamisy</LastName><ForeName>Sherif F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Sheffield S10 2TN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vos</LastName><ForeName>Kurt J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzouz</LastName><ForeName>Mimoun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-1154-6629</Identifier><AffiliationInfo><Affiliation>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UP_1501/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M010864/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001492</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K003771/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K008943/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HAUTBERGUE/APR16/846-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K005146/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>309742</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>ISAACS/APR13/818-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M013251/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00015/6</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>294745</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>DEVOS/OCT13/870-792</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105242">ALYREF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C122111">NXF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029543">Nucleocytoplasmic Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000595779">SRSF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>170974-22-8</RegistryNumber><NameOfSubstance UI="D000068103">Serine-Arginine Splicing Factors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029543" MajorTopicYN="N">Nucleocytoplasmic Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068103" MajorTopicYN="N">Serine-Arginine Splicing Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>G.M.H., M.A., A.J.W. and P.J.S. have filed a patent application on the use of SRSF1 antagonists for the treatment of neurodegenerative disorders. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28677678</ArticleId><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="doi">10.1038/ncomms16063</ArticleId><ArticleId IdType="pii">ncomms16063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A. J., Sendtner M. &amp; Shaw P. J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 616&#x2013;630 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M. et al.. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J. et al.. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8, 518&#x2013;530 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22890216</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E. et al.. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M. et al.. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci. 18, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T. et al.. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J. et al.. C9ORF72 GGGGCC expanded repeats produce splicing dysregulation which correlates with disease severity in amyotrophic lateral sclerosis. PLoS ONE 10, e0127376 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4446097</ArticleId><ArticleId IdType="pubmed">26016851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K. et al.. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 125, 413&#x2013;423 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C. J. et al.. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D. et al.. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-B. et al.. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178&#x2013;1186 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J. et al.. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 137, 2040&#x2013;2051 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K. et al.. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K. et al.. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P. E. A. et al.. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S. et al.. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S. et al.. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 74, 180&#x2013;187 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J. G. et al.. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C. et al.. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 35, 1276&#x2013;1297 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan P. M. et al.. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun. 4, 51 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C. P. et al.. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 35, 1656&#x2013;1676 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M. J. et al.. Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. Neuropathol. Appl. Neurobiol. 41, 109&#x2013;134 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329338</ArticleId><ArticleId IdType="pubmed">25319671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer J. D. et al.. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 14, 291&#x2013;301 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd T. W. &amp; Petrucelli L. Insights into the pathogenic mechanisms of chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J. Neurochem. 138, 145&#x2013;162 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27016280</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D. &amp; Haass C. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr. Opin. Neurobiol. 36, 99&#x2013;106 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26555807</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C. P., Smith E. F., Grierson A. J. &amp; De Vos K. J. C9orf72 plays a central role in Rab GTPase-dependent regulation of autophagy. Small GTPases 7, 1&#x2013;10 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997165</ArticleId><ArticleId IdType="pubmed">27768524</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H. et al.. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS. Neuron 87, 1207&#x2013;1214 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock M. et al.. Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathol. Commun. 4, 18 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766718</ArticleId><ArticleId IdType="pubmed">26916632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K. et al.. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B. D. et al.. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A. et al.. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S. et al.. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 6, 20877 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutz F. et al.. REF, an evolutionarily conserved family of hnRNP-like proteins, interacts with TAP/Mex67p and participates in mRNA nuclear export. RNA 6, 638&#x2013;650 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369944</ArticleId><ArticleId IdType="pubmed">10786854</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Gattoni R., Stevenin J. &amp; Steitz J. A. SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol. Cell 11, 837&#x2013;843 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12667464</ArticleId></ArticleIdList></Reference><Reference><Citation>Golovanov A. P., Hautbergue G. M., Tintaru A. M., Lian L.-Y. &amp; Wilson S. A. The solution structure of REF2-I reveals interdomain interactions and regions involved in binding mRNA export factors and RNA. RNA 12, 1933&#x2013;1948 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1624900</ArticleId><ArticleId IdType="pubmed">17000901</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintaru A. M. et al.. Structural and functional analysis of RNA and TAP binding to SF2/ASF. EMBO Rep. 8, 756&#x2013;762 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978082</ArticleId><ArticleId IdType="pubmed">17668007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue G. M., Hung M.-L., Golovanov A. P., Lian L.-Y. &amp; Wilson S. A. Mutually exclusive interactions drive handover of mRNA from export adaptors to TAP. Proc. Natl Acad. Sci. USA 105, 5154&#x2013;5159 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278192</ArticleId><ArticleId IdType="pubmed">18364396</ArticleId></ArticleIdList></Reference><Reference><Citation>Viphakone N. et al.. TREX exposes the RNA-binding domain of Nxf1 to enable mRNA export. Nat. Commun. 3, 1006 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654228</ArticleId><ArticleId IdType="pubmed">22893130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-T. et al.. Chtop is a component of the dynamic TREX mRNA export complex. EMBO J. 32, 473&#x2013;486 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567497</ArticleId><ArticleId IdType="pubmed">23299939</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M. J., Hautbergue G. M. &amp; Wilson S. A. Structure and function of mRNA export adaptors. Biochem. Soc. Trans. 38, 232&#x2013;236 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20074066</ArticleId></ArticleIdList></Reference><Reference><Citation>Longman D., Johnstone I. L. &amp; C&#xe1;ceres J. F. The Ref/Aly proteins are dispensable for mRNA export and development in Caenorhabditis elegans. RNA 9, 881&#x2013;891 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370454</ArticleId><ArticleId IdType="pubmed">12810921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatfield D. &amp; Izaurralde E. REF1/Aly and the additional exon junction complex proteins are dispensable for nuclear mRNA export. J. Cell Biol. 159, 579&#x2013;588 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173090</ArticleId><ArticleId IdType="pubmed">12438415</ArticleId></ArticleIdList></Reference><Reference><Citation>Katahira J., Inoue H., Hurt E. &amp; Yoneda Y. Adaptor Aly and co-adaptor Thoc5 function in the Tap-p15-mediated nuclear export of HSP70 mRNA. EMBO J. 28, 556&#x2013;567 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657587</ArticleId><ArticleId IdType="pubmed">19165146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue G. M. et al.. UIF, a New mRNA export adaptor that works together with REF/ALY, requires FACT for recruitment to mRNA. Curr. Biol. 19, 1918&#x2013;1924 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828547</ArticleId><ArticleId IdType="pubmed">19836239</ArticleId></ArticleIdList></Reference><Reference><Citation>Viphakone N. et al.. Luzp4 defines a new mRNA export pathway in cancer cells. Nucleic Acids Res. 43, 2353&#x2013;2366 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344508</ArticleId><ArticleId IdType="pubmed">25662211</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-McNicoll M. et al.. SR proteins are NXF1 adaptors that link alternative RNA processing to mRNA export. Genes Dev. 30, 553&#x2013;566 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782049</ArticleId><ArticleId IdType="pubmed">26944680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickramasinghe V. O. &amp; Laskey R. A. Control of mammalian gene expression by selective mRNA export. Nat. Rev. Mol. Cell Biol. 16, 431&#x2013;442 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26081607</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath C. G., Viphakone N. &amp; Wilson S. A. The role of TREX in gene expression and disease. Biochem. J. 473, 2911&#x2013;2935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5095910</ArticleId><ArticleId IdType="pubmed">27679854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono F., Ebert J., Lorentzen E. &amp; Conti E. The crystal structure of the exon junction complex reveals how it maintains a stable grip on mRNA. Cell 126, 713&#x2013;725 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16923391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J. et al.. Antisense RNA foci in the motor neurons of. Acta Neuropathol. 130, 63&#x2013;75 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468790</ArticleId><ArticleId IdType="pubmed">25943887</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzl G. et al.. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151&#x2013;156 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K. et al.. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl Acad. Sci. USA 111, 829&#x2013;832 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S. et al.. Recruitment of the human TREX complex to mRNA during splicing. Genes Dev. 19, 1512&#x2013;1517 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1172058</ArticleId><ArticleId IdType="pubmed">15998806</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Yario T. A. &amp; Steitz J. A. A molecular link between SR protein dephosphorylation and mRNA export. Proc. Natl Acad. Sci. USA 101, 9666&#x2013;9670 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470732</ArticleId><ArticleId IdType="pubmed">15210956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartegni L. &amp; Krainer A. R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30, 377&#x2013;384 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Louhichi A., Fourati A. &amp; Reba&#xef; A. IGD: a resource for intronless genes in the human genome. Gene 488, 35&#x2013;40 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21914464</ArticleId></ArticleIdList></Reference><Reference><Citation>Loureiro J. R., Oliveira C. L. &amp; Silveira I. Unstable repeat expansions in neurodegenerative diseases: nucleocytoplasmic transport emerges on the scene. Neurobiol. Aging 39, 174&#x2013;183 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26923414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T. et al.. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA 108, 260&#x2013;265 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd P. K. et al.. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78, 440&#x2013;455 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831531</ArticleId><ArticleId IdType="pubmed">23602499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba&#xf1;ez-Coronel M. et al.. RAN translation in Huntington disease. Neuron 88, 667&#x2013;677 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684947</ArticleId><ArticleId IdType="pubmed">26590344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P. et al.. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 55, 556&#x2013;564 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994817</ArticleId><ArticleId IdType="pubmed">17698009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofola O. A. et al.. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565&#x2013;571 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2215388</ArticleId><ArticleId IdType="pubmed">17698010</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene J. C. et al.. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078&#x2013;4083 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153051</ArticleId><ArticleId IdType="pubmed">12642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan W., Ashburner M. &amp; Hawley R. S. Drosophila Protocols Cold Spring Harbor Laboratory Press. (2000).</Citation></Reference><Reference><Citation>Deglon N., Tseng J. L. &amp; Bensadoun J. C. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson&#x2019;s disease. Human Gene Ther. 11, 179&#x2013;190 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10646649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H., Lieberam I., Porter J. A. &amp; Jessell T. M. Directed differentiation of embryonic stem cells into motor neurons. Cell 110, 385&#x2013;397 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12176325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J. et al.. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13, 134 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412702</ArticleId><ArticleId IdType="pubmed">22708584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling D. &amp; Salvaterra P. M. Robust RT-qPCR data normalization: validation and selection of internal reference genes during post-experimental data analysis. PLoS ONE 6, e17762 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058000</ArticleId><ArticleId IdType="pubmed">21423626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D. et al.. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol. 130, 525&#x2013;535 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranda B., Fan L., Soucy J.-F., Simard L. &amp; Mitchell G. A. Spinal muscular atrophy: clinical validation of a single-tube multiplex real time PCR assay for determination of SMN1 and SMN2 copy numbers. Clin. Biochem. 45, 88&#x2013;91 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22085534</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28728022</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>296.e6</EndPage><MedlinePgn>281-296.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2017.06.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(17)30550-0</ELocationID><Abstract><AbstractText>Progranulin (GRN) and TMEM106B are associated with several common neurodegenerative disorders including frontotemporal lobar degeneration (FTLD). A TMEM106B variant modifies GRN-associated FTLD risk. However, their functional relationship in&#xa0;vivo and the mechanisms underlying the risk modification remain unclear. Here, using transcriptomic and proteomic analyses with Grn<sup>-/-</sup> and Tmem106b<sup>-/-</sup> mice, we show that, while multiple lysosomal enzymes are increased in Grn<sup>-/-</sup> brain at both transcriptional and protein levels, TMEM106B deficiency causes reduction in several lysosomal enzymes. Remarkably, Tmem106b deletion from Grn<sup>-/-</sup> mice normalizes lysosomal protein levels and&#xa0;rescues FTLD-related behavioral abnormalities and retinal degeneration without improving lipofuscin,&#xa0;C1q, and microglial accumulation. Mechanistically, TMEM106B binds vacuolar-ATPase accessory protein 1 (AP1). TMEM106B deficiency reduces vacuolar-ATPase AP1 and V0 subunits, impairing lysosomal acidification and normalizing lysosomal protein levels in Grn<sup>-/-</sup> neurons. Thus, Grn and Tmem106b genes have opposite effects on lysosomal enzyme levels, and their interaction determines the extent of neurodegeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Zoe A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Mengxiao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stagi</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>TuKiet T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA; MS &amp; Proteomics Resource, WM Keck Biotechnology Resource Laboratory, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration &amp; Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, CT 06536, USA. Electronic address: stephen.strittmatter@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074319</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053000</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Progranulin</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">retinal degradation</Keyword><Keyword MajorTopicYN="N">vacuolar ATPase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28728022</ArticleId><ArticleId IdType="mid">NIHMS886902</ArticleId><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.06.026</ArticleId><ArticleId IdType="pii">S0896-6273(17)30550-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Human molecular genetics. 2013;22:685&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch JI, Unger TL, Jain N, Tyler Skrinak R, Charan RA, Chen-Plotkin AS. Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. Hum Mol Genet. 2016;25:2681&#x2013;2697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181637</ArticleId><ArticleId IdType="pubmed">27126638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G. Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem. 2012;287:32298&#x2013;32306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463300</ArticleId><ArticleId IdType="pubmed">22859297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci. 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing research reviews. 2016;32:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112157</ArticleId><ArticleId IdType="pubmed">27197071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotter K, Stransky L, McGuire C, Forgac M. Recent Insights into the Structure, Regulation, and Function of the V-ATPases. Trends Biochem Sci. 2015;40:611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589219</ArticleId><ArticleId IdType="pubmed">26410601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Archives of neurology. 2011;68:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>De Muynck L, Van Damme P. Cellular effects of progranulin in health and disease. J Mol Neurosci. 2011;45:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">21611805</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vugt ME, Riedijk SR, Aalten P, Tibben A, van Swieten JC, Verhey FR. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer&#x2019;s disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16679763</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Baker M, Rademakers R. Common Variant in GRN Is a Genetic Risk Factor for Hippocampal Sclerosis in the Elderly. Neurodegener Dis. 2010;7:170&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859236</ArticleId><ArticleId IdType="pubmed">20197700</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, Jiao J, Zhang Z, Huang EJ, Gao FB, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352&#x2013;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">17912264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127:407&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta neuropathologica. 2014;127:845&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Science of aging knowledge environment: SAGE KE. 2005;2005:re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafler BP, Klein ZA, Jimmy Zhou Z, Strittmatter SM. Progressive retinal degeneration and accumulation of autofluorescent lipopigments in Progranulin deficient mice. Brain Res. 2014;1588:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4254024</ArticleId><ArticleId IdType="pubmed">25234724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68:654&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37:D412&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686466</ArticleId><ArticleId IdType="pubmed">18940858</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian J, Tian QY, Hettinghouse A, Zhao S, Liu H, Wei J, Grunig G, Zhang W, Setchell KD, Sun Y, et al. Progranulin Recruits HSP70 to beta-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease. Ebiomedicine. 2016a;13:212&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5264254</ArticleId><ArticleId IdType="pubmed">27789271</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian J, Zhao S, Tian QY, Liu H, Zhao Y, Chen WC, Grunig G, Torres PA, Wang BC, Zeng B, et al. Association Between Progranulin and Gaucher Disease. Ebiomedicine. 2016b;11:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049935</ArticleId><ArticleId IdType="pubmed">27515686</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing H, Tan MS, Yu JT, Tan L. The Role of PGRN in Alzheimer&#x2019;s Disease. Mol Neurobiol. 2016;53:4189&#x2013;4196.</Citation><ArticleIdList><ArticleId IdType="pubmed">26215834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik S, Cuervo AM. Methods to monitor chaperone-mediated autophagy. Methods in enzymology. 2009;452:297&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300957</ArticleId><ArticleId IdType="pubmed">19200890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki H, Horai R, Iwakura Y, Nishihara M. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behavioural brain research. 2007;185:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">17764761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Capell A, Haass C, Van Broeckhoven C. Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol Neurobiol. 2013;47:337&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538123</ArticleId><ArticleId IdType="pubmed">23239020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. The Journal of biological chemistry. 2012;287:19355&#x2013;19365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F, et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell. 2016;165:921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol. 2012;74:69&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">22335796</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA, Duara R, Carrasquillo MM, Rademakers R, Dickson DW. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol. 2014;128:411&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadal-Nicolas FM, Jimenez-Lopez M, Sobrado-Calvo P, Nieto-Lopez L, Canovas-Martinez I, Salinas-Navarro M, Vidal-Sanz M, Agudo M. Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Investigative ophthalmology &amp; visual science. 2009;50:3860&#x2013;3868.</Citation><ArticleIdList><ArticleId IdType="pubmed">19264888</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR, Wilfred BR, Naj AC, Wang LS, Kukull WA, et al. Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol. 2015;74:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270894</ArticleId><ArticleId IdType="pubmed">25470345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Rademakers R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol. 2016;132:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Leavitt BR. Progranulin in neurodegenerative disease. Trends Neurosci. 2014;37:388&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">24800652</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis. 2012;45:711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, Winden KD, Oldham MC, Martens LH, Zhou P, Farese RV, Jr, et al. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron. 2011;71:1030&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633414</ArticleId><ArticleId IdType="pubmed">21943601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA, Parisi JE, Petersen RC, Graff-Radford NR, Younkin SG, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology. 2012;79:717&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem. 1999;47:719&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">10330448</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder R, Watts GD, Mehta SG, Evert BO, Broich P, Fliessbach K, Pauls K, Hans VH, Kimonis V, Thal DR. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Annals of neurology. 2005;57:457&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15732117</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K, Lichtenthaler SF, Hoogenraad CC, Capell A, Haass C, et al. The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J. 2014;33:450&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37:806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90:1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci. 2014;61:226&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145808</ArticleId><ArticleId IdType="pubmed">25066864</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovic A, Roher AE, Ball MJ. Quantitative analysis of lipofuscin and neurofibrillary tangles in the hippocampal neurons of Alzheimer disease brains. Dementia. 1994;5:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">7951677</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM Alzheimer&#x2019;s Disease Neuroimaging, I. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta neuropathologica. 2017;133:785&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391267</ArticleId><ArticleId IdType="pubmed">28070672</ArticleId></ArticleIdList></Reference><Reference><Citation>Toei M, Saum R, Forgac M. Regulation and isoform function of the V-ATPases. Biochemistry. 2010;49:4715&#x2013;4723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907102</ArticleId><ArticleId IdType="pubmed">20450191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem. 2004;279:13478&#x2013;13487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904802</ArticleId><ArticleId IdType="pubmed">14724290</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC, DeJesus-Hernandez M, Finch NA, Brown PH, Murray ME, et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. 2014;127:397&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944829</ArticleId><ArticleId IdType="pubmed">24385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31:258&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165481</ArticleId><ArticleId IdType="pubmed">12519996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P, et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Science translational medicine. 2017;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J, Martens LH, Seeley WW, et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. The Journal of experimental medicine. 2014;211:1937&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010a;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2010b;24:4639&#x2013;4647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266:17707&#x2013;17712.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Feng Y, Forgac M. Proton conduction and bafilomycin binding by the V0 domain of the coated vesicle V-ATPase. J Biol Chem. 1994;269:23518&#x2013;23523.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J Cell Biol. 2015;210:991&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28720718</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>488</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaam6790</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aam6790</ELocationID><Abstract><AbstractText>Mutations in <i>LRRK2</i>, which encodes leucine-rich repeat kinase 2, are the most common genetic cause of familial and sporadic Parkinson's disease (PD), a degenerative disease of the central nervous system that causes impaired motor function and, in advanced stages, dementia. Dementia is a common symptom of another neurodegenerative disease, Alzheimer's disease, and research suggests that there may be pathophysiological and genetic links between the two diseases. Aggregates of &#x3b2; amyloid [a protein produced through cleavage of amyloid precursor protein (APP)] are seen in both diseases and in PD patients carrying G2019S-mutant LRRK2. Using patient-derived cells, brain tissue, and PD model mice, we found that LRRK2 interacted with and phosphorylated APP at Thr<sup>668</sup> within its intracellular domain (AICD). Phosphorylation of APP at Thr<sup>668</sup> promoted AICD transcriptional activity and correlated with increased nuclear abundance of AICD and decreased abundance of a dopaminergic neuron marker in cultures and brain tissue. The AICD regulates the transcription of genes involved in cytoskeletal dynamics and apoptosis. Overexpression of AICD, but not a phosphodeficient mutant (AICD<sup>T668A</sup>), increased the loss of dopaminergic neurons in older mice expressing LRRK2<sup>G2019S</sup> Moreover, the amount of Thr<sup>668</sup>-phosphorylated APP was substantially greater in postmortem brain tissue and dopaminergic neurons (generated by reprogramming skin cells) from LRRK2<sup>G2019S</sup> patients than in those from healthy individuals. LRRK2 inhibitors reduced the phosphorylation of APP at Thr<sup>668</sup> in the patient-derived dopaminergic neurons and in the midbrains of LRRK2<sup>G2019S</sup> mice. Thus, APP is a substrate of LRRK2, and its phosphorylation promotes AICD function and neurotoxicity in PD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhong-Can</ForeName><Initials>ZC</Initials><Identifier Source="ORCID">0000-0003-2363-4025</Identifier><AffiliationInfo><Affiliation>Neural Stem Cell Research Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-5275-8807</Identifier><AffiliationInfo><Affiliation>Neural Stem Cell Research Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Ling-Ling</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Research Department, National Neuroscience Institute, Singapore General Hospital (SGH) Campus, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Chou</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6181-6247</Identifier><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Analytical Mass Spectrometry Laboratory, Experimental Therapeutics Centre, Agency of Science, Technology and Research (A*STAR), Singapore 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stem Cell and Developmental Biology Group, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National University of Singapore (NUS) Graduate School for Integrative Sciences and Engineering, NUS, Singapore 117456, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neural Stem Cell Research Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angeles</LastName><ForeName>Dario C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Research Department, National Neuroscience Institute, Singapore General Hospital (SGH) Campus, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>Lawrence W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Stem Cell and Developmental Biology Group, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Jian-He</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Analytical Mass Spectrometry Laboratory, Experimental Therapeutics Centre, Agency of Science, Technology and Research (A*STAR), Singapore 138669, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhi-Dong</ForeName><Initials>ZD</Initials><Identifier Source="ORCID">0000-0003-0251-4163</Identifier><AffiliationInfo><Affiliation>Research Department, National Neuroscience Institute, Singapore General Hospital (SGH) Campus, Singapore 169856, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders Program, DUKE-NUS Graduate Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Kah-Leong</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-5440-2588</Identifier><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders Program, DUKE-NUS Graduate Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Yong Loo Lin School of Medicine, NUS, Singapore 117597, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3242-2286</Identifier><AffiliationInfo><Affiliation>Neural Stem Cell Research Laboratory, Research Department, National Neuroscience Institute, Singapore 308433, Singapore. li_zeng@nni.com.sg tan.eng.king@sgh.com.sg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders Program, DUKE-NUS Graduate Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng-King</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0001-9928-4805</Identifier><AffiliationInfo><Affiliation>Research Department, National Neuroscience Institute, Singapore General Hospital (SGH) Campus, Singapore 169856, Singapore. li_zeng@nni.com.sg tan.eng.king@sgh.com.sg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders Program, DUKE-NUS Graduate Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, National Neuroscience Institute, SGH Campus, Singapore 169856, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Oct;32(10):1378-1379. doi: 10.1002/mds.27170.</RefSource><PMID Version="1">28901623</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="Y">Protein Interaction Domains and Motifs</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28720718</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aam6790</ArticleId><ArticleId IdType="pii">10/488/eaam6790</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28742910</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>318</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football.</ArticleTitle><Pagination><StartPage>360</StartPage><EndPage>370</EndPage><MedlinePgn>360-370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2017.8334</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Players of American football may be at increased risk of long-term neurological conditions, particularly chronic traumatic encephalopathy (CTE).</AbstractText><AbstractText Label="OBJECTIVE">To determine the neuropathological and clinical features of deceased football players with CTE.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Case series of 202 football players whose brains were donated for research. Neuropathological evaluations and retrospective telephone clinical assessments (including head trauma history) with informants were performed blinded. Online questionnaires ascertained athletic and military history.</AbstractText><AbstractText Label="EXPOSURES">Participation in American football at any level of play.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Neuropathological diagnoses of neurodegenerative diseases, including CTE, based on defined diagnostic criteria; CTE neuropathological severity (stages I to IV or dichotomized into mild [stages I and II] and severe [stages III and IV]); informant-reported athletic history and, for players who died in 2014 or later, clinical presentation, including behavior, mood, and cognitive symptoms and dementia.</AbstractText><AbstractText Label="RESULTS">Among 202 deceased former football players (median age at death, 66 years [interquartile range, 47-76 years]), CTE was neuropathologically diagnosed in 177 players (87%; median age at death, 67 years [interquartile range, 52-77 years]; mean years of football participation, 15.1 [SD, 5.2]), including 0 of 2 pre-high school, 3 of 14 high school (21%), 48 of 53 college (91%), 9 of 14 semiprofessional (64%), 7 of 8 Canadian Football League (88%), and 110 of 111 National Football League (99%) players. Neuropathological severity of CTE was distributed across the highest level of play, with all 3 former high school players having mild pathology and the majority of former college (27 [56%]), semiprofessional (5 [56%]), and professional (101 [86%]) players having severe pathology. Among 27 participants with mild CTE pathology, 26 (96%) had behavioral or mood symptoms or both, 23 (85%) had cognitive symptoms, and 9 (33%) had signs of dementia. Among 84 participants with severe CTE pathology, 75 (89%) had behavioral or mood symptoms or both, 80 (95%) had cognitive symptoms, and 71 (85%) had signs of dementia.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In a convenience sample of deceased football players who donated their brains for research, a high proportion had neuropathological evidence of CTE, suggesting that CTE may be related to prior participation in football.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mez</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daneshvar</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts3Department of Orthopaedic Surgery, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Patrick T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdolmohammadi</LastName><ForeName>Bobak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victor E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts4VA Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts5Department of Veterans Affairs Medical Center, Bedford, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Bertrand R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts4VA Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts5Department of Veterans Affairs Medical Center, Bedford, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alosco</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowinski</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts6Concussion Legacy Foundation, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHale</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Concussion Legacy Foundation, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cormier</LastName><ForeName>Kerry A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubilus</LastName><ForeName>Caroline A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Brett M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts7Data Coordinating Center, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baugh</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Interfaculty Initiative in Health Policy, Harvard University, Boston, Massachusetts9Division of Sports Medicine, Boston Children's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montenigro</LastName><ForeName>Phillip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaisson</LastName><ForeName>Christine E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts7Data Coordinating Center, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripodis</LastName><ForeName>Yorghos</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts10Department of Biostatistics, Boston University, Boston, Massachusetts11School of Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts4VA Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts12Department of Pathology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weuve</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Boston University, Boston, Massachusetts13Department of Epidemiology, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McClean</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>School of Public Health, Boston University, Boston, Massachusetts14Department of Environmental Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantu</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts6Concussion Legacy Foundation, Waltham, Massachusetts15Department of Neurosurgery, Emerson Hospital, Concord, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lee E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts12Department of Pathology, Boston University School of Medicine, Boston, Massachusetts16Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts17Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts18Department of Biomedical Engineering, Boston University College of Engineering, Boston, Massachusetts19Department of Electrical and Computer Engineering, Boston University College of Engineering, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Douglas I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts20Braintree Rehabilitation Hospital, Braintree, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts21Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts22Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thor D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts4VA Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts5Department of Veterans Affairs Medical Center, Bedford, Massachusetts12Department of Pathology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts4VA Boston Healthcare System, US Department of Veteran Affairs, Boston, Massachusetts5Department of Veterans Affairs Medical Center, Bedford, Massachusetts12Department of Pathology, Boston University School of Medicine, Boston, Massachusetts23Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG046377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057902</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS086659</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Jul 25;318(4):338-340. doi: 10.1001/jama.2017.9353.</RefSource><PMID Version="1">28742889</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2017 Jul 25;358:j3602. doi: 10.1136/bmj.j3602.</RefSource><PMID Version="1">28743696</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Aug 21;548(7668):371. doi: 10.1038/548371a.</RefSource><PMID Version="1">28836609</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Dec 19;318(23):2352. doi: 10.1001/jama.2017.16667.</RefSource><PMID Version="1">29260220</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2017 Dec 19;318(23):2352-2353. doi: 10.1001/jama.2017.16675.</RefSource><PMID Version="1">29260221</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056352" MajorTopicYN="N">Athletes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001265" MajorTopicYN="N">Athletic Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070627" MajorTopicYN="N">Chronic Traumatic Encephalopathy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005538" MajorTopicYN="N">Football</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Nowinski reported that he receives travel reimbursements for various unpaid advisory roles from the NFL Players&#x2019; Association, Major League Lacrosse, World Wrestling Entertainment (WWE), National Collegiate Athletic Association (NCAA), and the Ivy League; receives royalties from the publication of his book <i>Head Games: The Global Concussion Crisis,</i> published by Head Games The Film; served as a consultant for MC10 Inc as recently as 2013; serves as chief executive officer of the Concussion Legacy Foundation; and receives speaking honoraria and travel reimbursements for educational lectures. Ms Baugh reported that she receives research funding through the NCAA and the Harvard Football Players Health Study, which is funded by the NFL Players&#x2019; Association. Dr Cantu reported that he receives compensation from the NFL as senior advisor to its Head, Neck and Spine Committee, from the National Operating Committee on Standards for Athletic Equipment as chair of its Scientific Advisory Committee and from the Concussion Legacy Foundation as cofounder and medical director for some talks given and receives royalties from Houghton Mifflin Harcourt and compensation from expert legal opinion. Dr Stern reported that he has received research funding from the NFL, the NFL Players&#x2019; Association, and Avid Radiopharmaceuticals Inc; is a member of the Mackey-White Committee of the NFL Players&#x2019; Association; is a paid consultant to Amarantus BioScience Holdings Inc, Avanir Pharmaceuticals Inc, and Biogen; and receives royalties for published neuropsychological tests from Psychological Assessment Resources Inc and compensation from expert legal opinion. Dr McKee reported that she has received funding from the NFL and WWE and is a member of the Mackey-White Committee of the NFL Players&#x2019; Association.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28742910</ArticleId><ArticleId IdType="mid">NIHMS939644</ArticleId><ArticleId IdType="pmc">PMC5807097</ArticleId><ArticleId IdType="doi">10.1001/jama.2017.8334</ArticleId><ArticleId IdType="pii">2645104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973;3(3):270-303.</Citation><ArticleIdList><ArticleId IdType="pubmed">4729191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Knabe R, Bovier P, Bouras C. Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol. 1991;82(4):321-326.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759563</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JF, Vowles GH, Nicoll JA, R&#xe9;v&#xe9;sz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 1999;98(2):171-178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10442557</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005;57(1):128-134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987548</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu BI, DeKosky ST, Hamilton RL, et al. . Chronic traumatic encephalopathy in a National Football League player: part II. Neurosurgery. 2006;59(5):1086-1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143242</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. . The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Ross OA, Cormier KA, et al. . Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol. 2015;130(6):877-889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655127</ArticleId><ArticleId IdType="pubmed">26518018</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, et al. ; TBI/CTE group . The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75-86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Daneshvar DH, Baugh CM, et al. . Clinical presentation of chronic traumatic encephalopathy. Neurology. 2013;81(13):1122-1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795597</ArticleId><ArticleId IdType="pubmed">23966253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Solomon TM, Daneshvar DH, et al. . Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther. 2015;7(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601147</ArticleId><ArticleId IdType="pubmed">26455775</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan JD, Bogner J. Initial reliability and validity of the Ohio State University TBI identification method. J Head Trauma Rehabil. 2007;22(6):318-329.</Citation><ArticleIdList><ArticleId IdType="pubmed">18025964</ArticleId></ArticleIdList></Reference><Reference><Citation>Seichepine DR, Stamm JM, Daneshvar DH, et al. . Profile of self-reported problems with executive functioning in college and professional football players. J Neurotrauma. 2013;30(14):1299-1304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713446</ArticleId><ArticleId IdType="pubmed">23421745</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins CA, Daneshvar DH, Picano JD, et al. . Self-reported concussion history: impact of providing a definition of concussion. Open Access J Sports Med. 2014;5:99-103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019619</ArticleId><ArticleId IdType="pubmed">24891816</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JPG, Aizawa H, Ge P, et al. . An improved approach to prepare human brains for research. J Neuropathol Exp Neurol. 1995;54(1):42-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7815079</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JPG, Del Amaya MP, Keller CE. Twenty-first century brain banking: processing brains for research: the Columbia University methods. Acta Neuropathol. 2008;115(5):509-532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292479</ArticleId><ArticleId IdType="pubmed">17985145</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cantu RC, Nowinski CJ, et al. . Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68(7):709-735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Gavett BE, Stern RA, et al. . TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69(9):918-929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)&#x2013;Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999;58(11):1147-1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560657</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. ; National Institute on Aging; Alzheimer&#x2019;s Association . National Institute on Aging&#x2013;Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3)(suppl):417-423.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914880</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. ; Consortium for Frontotemporal Lobar Degeneration . Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Hauw JJ, Bartko JJ, et al. . Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55(1):97-105.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol. 2009;3(1):1-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776269</ArticleId><ArticleId IdType="pubmed">19918325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH. Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol. 2008;67(7):635-648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761710</ArticleId><ArticleId IdType="pubmed">18596549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, et al. . Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry. 1970;33(3):338-357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC493478</ArticleId><ArticleId IdType="pubmed">5431724</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Louis D, Ellison DW. Greenfield&#x2019;s Neuropathology, 2-Volume Set. 8th ed Boca Raton, FL: CRC Press; 2008.</Citation></Reference><Reference><Citation>Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimer&#x2019;s disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport. 1994;5(17):2358-2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533559</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm JM, Bourlas AP, Baugh CM, et al. . Age of first exposure to football and later-life cognitive impairment in former NFL players. Neurology. 2015;84(11):1114-1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371403</ArticleId><ArticleId IdType="pubmed">25632088</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm JM, Koerte IK, Muehlmann M, et al. . Age at first exposure to football is associated with altered corpus callosum white matter microstructure in former professional football players. J Neurotrauma. 2015;32(22):1768-1776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4651044</ArticleId><ArticleId IdType="pubmed">26200068</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenigro PH, Alosco ML, Martin BM, et al. . Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and college football players. J Neurotrauma. 2017;34(2):328-340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5220530</ArticleId><ArticleId IdType="pubmed">27029716</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Chen X-H, Martinez D, et al. . Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol. 2007;208(2):185-192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979356</ArticleId><ArticleId IdType="pubmed">17826768</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Montenigro PH, Alvarez VE, et al. . Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015;130(1):21-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4529056</ArticleId><ArticleId IdType="pubmed">25943889</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Gibbons LE, Dams-O&#x2019;Connor K, et al. . Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 2016;73(9):1062-1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319642</ArticleId><ArticleId IdType="pubmed">27400367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Tripodis Y, Alvarez VE, et al. . Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun. 2016;4(1):112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084333</ArticleId><ArticleId IdType="pubmed">27793189</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S, Schildcrout J, Crane P, Sonnen J, Breitner J, Larson E. Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology. 2009;32(3):229-239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698450</ArticleId><ArticleId IdType="pubmed">19176974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28734653</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.</ArticleTitle><Pagination><StartPage>841</StartPage><EndPage>849</EndPage><MedlinePgn>841-849</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2017.06.2266</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(17)32518-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid-binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid &#x3b2; (A&#x3b2;) biomarker for central nervous system amyloid deposition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of A&#x3b2;38, A&#x3b2;40, and A&#x3b2;42 in human plasma.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A&#x3b2; isoforms have a half-life of approximately 3&#xa0;hours in plasma. A&#x3b2;38 demonstrated faster turnover kinetics compared with A&#x3b2;40 and A&#x3b2;42. Faster fractional turnover of A&#x3b2;42 relative to A&#x3b2;40 and lower A&#x3b2;42 and A&#x3b2;42/A&#x3b2;40 concentrations in amyloid-positive participants were observed.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Blood plasma A&#x3b2;42 shows similar amyloid-associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood-brain transportation mechanism of A&#x3b2;. The stability and sensitivity of plasma A&#x3b2; measurements suggest this may be a useful screening test for central nervous system amyloidosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsey</LastName><ForeName>Kara N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollinger</LastName><ForeName>Jim G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paumier</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078639">amyloid beta-protein (1-38)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Alzheimers Dement. 2017 Oct;13(10):1185. doi: 10.1016/j.jalz.2017.09.004.</RefSource><PMID Version="1">29029683</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid &#x3b2;</Keyword><Keyword MajorTopicYN="N">A&#x3b2;42</Keyword><Keyword MajorTopicYN="N">Human</Keyword><Keyword MajorTopicYN="N">Kinetics</Keyword><Keyword MajorTopicYN="N">Plasma</Keyword><Keyword MajorTopicYN="N">Turnover</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28734653</ArticleId><ArticleId IdType="mid">NIHMS888888</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pii">S1552-5260(17)32518-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8(6):595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, Xiong C, Chott R, Yarasheski K, Sigurdson W, Zhang L, Goate A, Benzinger T, Morris JC, Holtzman D, Bateman RJ. Age and amyloid effects on human CNS amyloid-beta kinetics. Ann Neurol. 2015;78(3):439&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer&#x2019;s disease Centers, 2005&#x2013;2010. J Neuropathol Exp Neurol. 2013;71(4):266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Klunk WE. Early detection of Alzheimer&#x2019;s disease using PiB and FDG PET. Neurobiol Dis. 2014;72(Pt A):117&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226742</ArticleId><ArticleId IdType="pubmed">24825318</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678311</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60(12):1696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer&#x2019;s disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108075</ArticleId><ArticleId IdType="pubmed">21245181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-B synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem. 2013;440(1):56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749773</ArticleId><ArticleId IdType="pubmed">23714261</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, Ovod V, Munsell LY, Mawuenyega KG, Miller-Thomas MM, Moran CJ, Cross DT, III, Derdeyn CP, Bateman RJ. Amyloid-B efflux from the CNS into the plasma. Ann Neurol. 2014;76(6):837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355962</ArticleId><ArticleId IdType="pubmed">25205593</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Grangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;5(3):333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Grwodon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sob&#xf3;w T, Flirski M, K&#x142;oszewska I, Liberski PP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer&#x2019;s disease. Acta Neurobiol Exp (Wars) 2005;65:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15960295</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer&#x2019;s disease: plasma Ab40 and AB42, and genetic variants. Neurobio of Aging. 2011;32(11):S10&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233700</ArticleId><ArticleId IdType="pubmed">22078169</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>